PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP				KEYOMARSI, K; CONTE, D; TOYOFUKU, W; FOX, MP			DEREGULATION OF CYCLIN-E IN BREAST-CANCER	ONCOGENE			English	Article						BREAST CANCER; CELL CYCLE; CYCLIN E; ALTERNATIVE SPLICING	CELL-CYCLE; CANDIDATE ONCOGENE; ESOPHAGEAL CANCER; EXPRESSION; OVEREXPRESSION; PROTEIN; GENE; AMPLIFICATION; FIBROBLASTS; PHASE	Cyclin E, a regulatory subunit of cyclin dependent kinase-2, is thought to be rate limiting for the G1/S transition during the mammalian cell cycle. Previously, we showed severe alterations in cyclin E protein expression in human mammary epithelial cell lines and in surgical material obtained from patients with various malignancies. To understand the functional basis of these alterations we analyse here the regulation of cyclin E in breast cancer cells. We find that while cyclin E protein and its associated kinase activity in normal cells are cell cycle regulated, in tumor cells it remains in an active complex throughout the cell cycle. We also analysed cyclin E for possible deletions which could result in its constitutive function and found two novel truncated variants in its coding region. These variant forms of cyclin E were detected in several normal and tumor cell lines and tissue specimens. However, Western blot analysis indicated that only the multiple isoforms of cyclin E protein were expressed in tumor but not the normal tissue specimen, suggesting post transcriptional regulation of cyclin E. Lastly, in vitro analyses indicated that these truncated variant forms of cyclin E are biochemically active in their ability to phosphorylate histone H1. Collectively these observations suggest the presence of more than one form of cyclin E mRNA in all cells, normal and tumor. Once translated in tumor cells, the protein products of these truncated forms could give rise to a constitutively active form of cyclin E containing complexes.			KEYOMARSI, K (corresponding author), WADSWORTH CTR, DIV MOLEC MED, DIAGNOST ONCOL LAB, ALBANY, NY 12201 USA.		Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849				BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	228	232	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					941	950						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675453				2022-12-28	WOS:A1995RU79800015
J	KNIPPSCHILD, U; KOLZAU, T; DEPPERT, W				KNIPPSCHILD, U; KOLZAU, T; DEPPERT, W			CELL-SPECIFIC TRANSCRIPTIONAL ACTIVATION OF THE MDM2-GENE BY ECTOPICALLY EXPRESSED WILD-TYPE FORM OF A TEMPERATURE-SENSITIVE MUTANT P53	ONCOGENE			English	Article						TEMPERATURE-SENSITIVE MUTANT P53; P53 TRANSCRIPTIONAL ACTIVITY; CELL-SPECIFIC REGULATION OF P53-DEPENDENT TRANSCRIPTION; PHOSPHORYLATION OF P53; P53 TARGET GENES; MDM2-GENE EXPRESSION	TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; AUTOREGULATORY FEEDBACK LOOP; DNA-BINDING; PHOSPHORYLATION SITE; MDM-2 ONCOGENE; GROWTH ARREST; BREAST-CANCER; GENE; CYCLE	The temperature-sensitive mutant p53 tsp53(val135) (tsp53) displays a mutant phenotype at 38 degrees C, but assumes properties of a wild-type (wt) p53 at 32 degrees C. We analysed the cellular responses of two cell lines which ectopically overexpress tsp53, and dramatically differ in their responses to tsp53 expressed at 32 degrees C. Clone 6 (cl6) cells [precrisis rat embryo fibroblasts transformed by tsp53(val135) and an activated ras oncogene at 38 degrees C (Michalovitz et al., 1990. Cell 62, 671-680)] stop to grow and arrest mainly in the G(1) phase of the cell cycle, whereas MethAp53ts cells [BALB/c mouse MethA tumor cells, transfected with the same tsp53 encoding vector as cl6 cells (Otto and Deppert, 1993. Oncogene 8, 2591-2603)] do not growth arrest at 32 degrees C. Both cell lines expressed similar amounts of tsp53, which was mainly cytoplasmic at 38 degrees C and mainly nuclear at 32 degrees C. At 32 degrees C, both cell lines contained similar amounts of waf1/ cip1 mRNA. However, the amount of mdm2 mRNA in MethAp53ts cells was considerably higher compared to that in cl6 cells. The different transcriptional regulation of the mdm2-gene in cl6 and MethAp53ts cells at 32 degrees C indicated that the tsp53 proteins in these cells were functionally different. This assumption was supported by our finding that at 32 degrees C phosphorylation of the tsp53 in these cells was markedly different. We conclude that the cellular environment is an important determinant of p53 function.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARAK Y, 1983, EMBO J, V12, P461; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN JY, 1993, ONCOGENE, V8, P2159; DELPHIN C, 1994, J BIOL CHEM, V249, P29579; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; FAKHARZADEH SS, 1991, EMBO J, V19, P1565; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MARX J, 1993, SCIENCE, V261, P1385, DOI 10.1126/science.8367721; MATLZMAN W, 1984, MOL CELL BIOL, V4, P1689; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OTTO A, 1993, ONCOGENE, V8, P2591; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sambrook J, 1989, J SAMBROOK MOL CLONI; SEGAL PB, 1993, ONCOGENE, V8, P3417; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; THUT CJ, 1994, SCIENCE, V267, P100; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZERRAHN J, 1992, ONCOGENE, V7, P1371	77	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					683	690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651732				2022-12-28	WOS:A1995RQ46900010
J	STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L				STOREY, A; MASSIMI, P; DAWSON, K; BANKS, L			CONDITIONAL IMMORTALIZATION OF PRIMARY-CELLS BY HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND EJ-RAS DEFINES AN E6 ACTIVITY IN G(0)/G(1) PHASE WHICH CAN BE SUBSTITUTED FOR MUTATIONS IN P53	ONCOGENE			English	Article						HPV; CELL CYCLE; CHECKPOINT; P53	RETINOBLASTOMA GENE-PRODUCT; CELLULAR TUMOR-ANTIGEN; DNA-BINDING FUNCTION; PRIMARY MOUSE CELLS; TRANSFORMING ACTIVITY; HUMAN KERATINOCYTES; CERVICAL-CARCINOMA; TRANSCRIPTION FACTOR; ADENOVIRUS E1A; E7 FUNCTIONS	The human papillomavirus (HPV) type 18 E6 gene cooperates with activated Ha-ras to immortalize primary mouse cells in culture. Using a plasmid where HPV18 E6 expression is regulated by the glucocorticoid inducible MMTV LTR, we have generated immortalized cell lines in which the continued expression of E6 was necessary for maintenance of the transformed phenotype. In the absence of exogenously added hormone these cells were found to arrest in G(0)/G(1). Furthermore, we demonstrate that the effects of E6 were essentially p53 independent and therefore define a novel function by which E6 is able to modulate cell proliferation. In addition, when the E6 dependent cells were maintained under conditions of prolonged growth arrest by the removal of E6, revertant cells were isolated which were no longer dependent on E6 expression for continued proliferation. These revertant cells were found to have acquired a mutation in the cellular gene p53, suggesting that certain p53 mutations are dominant over an E6 requirement in this assay.	ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, IMPERIAL CANC RES FUND, SKIN TUMOUR LAB, LONDON E1 2BL, ENGLAND	Barts Health NHS Trust; Royal London Hospital; Cancer Research UK	STOREY, A (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, PADRICIANO 99, I-34012 TRIESTE, ITALY.			Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANSORGE W, 1982, EXP CELL RES, V140, P31, DOI 10.1016/0014-4827(82)90152-5; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KEEN N, 1994, ONCOGENE, V9, P1493; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1987, CANCER CELL, V5, P195; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MOSNER J, 1994, ONCOGENE, V9, P3321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1991, ONCOGENE, V6, P589; PIM D, 1994, ONCOGENE, V9, P1869; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1994, KERATINOCYTE HDB, P439; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS M, 1995, ONCOGENE, V10, P261; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986	76	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					653	661						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651728				2022-12-28	WOS:A1995RQ46900006
J	PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ				PRENDERGAST, GC; KHOSRAVIFAR, R; SOLSKI, PA; KURZAWA, H; LEBOWITZ, PF; DER, CJ			CRITICAL ROLE OF RHO IN CELL-TRANSFORMATION BY ONCOGENIC RAS	ONCOGENE			English	Article						RHO; RAS; CELL TRANSFORMATION; SIGNAL TRANSDUCTION	MAMMALIAN-CELLS; GROWTH-FACTOR; GENE-PRODUCT; PROTEIN; EXPRESSION; GAP; IDENTIFICATION; FARNESYLATION; LOCALIZATION; FIBROBLASTS	We demonstrate that Rho, a regulator of cytoskeletal actin, is necessary for Ras transformation. A dominant inhibitory Rho gene (RhoB(N19)) specifically suppressed Rat1 cell focus formation induced by oncogenic Ras but not by Raf. An activated Rho gene (Rho(V14)) lacked focus formation activity but augmented the focus formation activity of both oncogenes. NIH3T3 cell lines expressing Rho(V14) grew to higher saturation density and displayed reduced serum and anchorage requirements for growth. We concluded that Rho played a role in cell growth regulation and was required for transformation by oncogenic Ras but not Raf. A model for Ras signal transduction proposing separate Rho-dependent and Raf-dependent pathways is discussed.	UNIV PENN,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC; LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	PRENDERGAST, GC (corresponding author), WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1990, MOL GENETICS CANCER, P273; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8232; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJITA H, 1990, EXP CELL RES, V186, P115, DOI 10.1016/0014-4827(90)90217-X; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, LIPID MODIFICATIONS, P335; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARLOW E, 1988, ANTIBODIES LABORATOR; INGBER DE, 1994, INT REV CYTOL, V150, P173; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, UNPUB; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MULLAUER L, 1993, ONCOGENE, V8, P2531; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PERONA R, 1993, ONCOGENE, V8, P1285; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SELF AJ, 1993, ONCOGENE, V8, P665; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	58	273	277	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2289	2296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784077				2022-12-28	WOS:A1995RE54300003
J	MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J				MORISHITA, K; SUZUKAWA, K; TAKI, T; IHLE, JN; YOKOTA, J			EVI-1 ZINC-FINGER PROTEIN WORKS AS A TRANSCRIPTIONAL ACTIVATOR VIA BINDING TO A CONSENSUS SEQUENCE OF GACAAGATAAGATAAN(1-28) CTCATCTTC	ONCOGENE			English	Article						ZINC FINGER PROTEIN; EVI-1; DNA-BINDING; CONSENSUS SEQUENCE; TRANSCRIPTIONAL REGULATION	MYELOID-TRANSFORMING GENE; CYCLIC AMPLIFICATION; CELL-LINES; EXPRESSION; IDENTIFICATION; TRANSLOCATIONS; KILOBASES; SELECTION; COMPLEXES; LEUKEMIAS	Previously, the DNA-binding consensus sequences for domains 1 (GACAAGATAAGATAA) and 2 (GAAGATGAG) of the EVI-1 protein were identified using GST fusion proteins of each domain in binding and amplification reactions, We have utilized full-length EVI-1 protein to confirm these consensus sequences and determine the spacial and orientation requirements for binding, Our data demonstrate that full-length EVI-1 can independently bind the consensus sequences in gel mobility shift assays. In binding and amplification reactions only the domain I consensus sequence (D1-CONS) was obtained with full-length EVI-1 protein. However, by using constructs in which D1-CONS was anchored, products were obtained in which the domain 2 consensus sequence (D2-CONS) was observed with the spacing and orientation of GACAAGATAATATAAN(1-28) CTCATCTTC. Using this consensus sequence we show that EVI-1 can activate transcription from reporter constructs. No transcriptional activation was seen with the reporter construct containing DT-CONS atone while activation was seen with the construct-containing D2-CONS alone. These results indicate that the EVI-1 protein works as a transcriptional activator and the binding of the domain 2 with D2-CONS is essential for its activation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				Suzukawa, Kazumi/0000-0001-9904-3905				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUZUKAWA K, 1994, BLOOD, V84, P2681; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0	26	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1961	1967						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761097				2022-12-28	WOS:A1995QZ92600010
J	BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA				BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA			REPRESSION OF THE CSF-1 RECEPTOR (C-FMS PROTOONCOGENE PRODUCT) BY ANTISENSE TRANSFECTION INDUCES G1-GROWTH ARREST IN L6-ALPHA-1 RAT MYOBLASTS	ONCOGENE			English	Article						D-TYPE CYCLINS; C-FMS; MYOGENESIS	CYCLIN MESSENGER-RNA; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; DNA-REPLICATION; GROWTH-FACTOR; G1 PHASE; S-PHASE	Colony Stimulating Factor (CSF-1) and the CSF-1 receptor (the c-fms product) are expressed during the proliferation of L6 alpha 1 rat myogenic cell line and both are down regulated during the formation of myotubes. In this study, we demonstrated that the expression of c-fms antisense RNA in stably transfected myoblasts repressed the CSF-1 receptor (c-fms protein) and induced a G1-growth arrest. Expression of the cyclin genes, that control passage through the G1 phase and in particular the cyclins identified as genes induced late in G1 by CSF-1 in mouse macrophages was studied in comparative Northern blot analyses of RNAs of subpopulations prepared by centrifugal elutriation of L6 alpha 1 myoblasts and induced Antifms D5 cells expressing c-fms antisense RNA. Repression of the CSF-1 receptor (c-fms product) did not affect cyclins A, B and G expression during the cell cycle. However, D-type cyclins and, at a lesser extend, cyclin E expression were dramatically altered specifically during the late G1 and early S phases, in Antifms D5 cells. These results suggest a role for the CSF-1/c-fms autocrine loop in the control of the proliferation of L6 alpha 1 rat myogenic cell line at the G1/S boundary via the D-type and E cyclins expression.	INST GUSTAVE ROUSSY, EXPTL CANCEROL LAB, CNRS, UA1158, URA126, F-94800 VILLEJUIF, FRANCE; UNIV PARIS 13, BIOL DEV & DIFFERENCIAT LAB, F-93012 BOBIGNY, FRANCE; UNIV PARIS 13, BIOL CELLULAIRE LAB, UFR BIOMED, F-93012 BOBIGNY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite Paris 13; Universite Paris 13								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORYCKI, 1995, IN PRESS EYPT CELL R; BORYCKI AG, 1993, BIOCHIM BIOPHYS ACTA, V1174, P143, DOI 10.1016/0167-4781(93)90108-P; Borycki AG, 1992, GROWTH FACTORS, V6, P209, DOI 10.3109/08977199209021534; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HILLION J, 1984, CANCER RES, V44, P2959; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUTSGI AK, 1991, NATURE, V352, P541; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURMACZ E, 1992, CANCER RES, V52, P4522; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA K, 1993, ONCOGENE, V8, P2113; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YEN A, 1993, J CELL PHYSIOL, V157, P379, DOI 10.1002/jcp.1041570222; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	67	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1799	1811						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753556				2022-12-28	WOS:A1995QX46900013
J	FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G				FORNEROD, M; BOER, J; VANBAAL, S; JAEGLE, M; VONLINDERN, M; MURTI, KG; DAVIS, D; BONTEN, J; BUIJS, A; GROSVELD, G			RELOCATION OF THE CARBOXYTERMINAL PART OF CAN FROM THE NUCLEAR-ENVELOPE TO THE NUCLEUS AS A RESULT OF LEUKEMIA-SPECIFIC CHROMOSOME REARRANGEMENTS	ONCOGENE			English	Article						LEUKEMIA; FUSION PROTEINS; NUCLEOPORINS; TRANSLOCATIONS; CAN PROTOONCOGENE	ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; TRANSLOCATION 6-9; CDNA CLONING; PORE COMPLEX; EXPRESSION; GENE; PROTEIN; FUSION	Fusion genes encoding the 3' part of the can gene are implicated in two types of leukemia, The dek-can fusion gene is present in t(6;9) acute myeloid leukemia and the set-can fusion gene is present in one case of acute undifferentiated leukemia. In order to obtain leads towards the molecular basis of these diseases, we have studied the cellular localization of the DEK-CAN and SET-CAN fusion proteins and their normal counterparts. DEK-CAN and SET-CAN were localized exclusively in the nucleus, and also DEK and SET were found to be nuclear proteins. However, CAN was mainly located at the nuclear and cytoplasmic face of the nuclear envelope. This observation is in accordance with the presence of an amino acid repeat in the C-terminal part of CAN, common to the family of nucleoporins. The C-terminal part also contains a nuclear location domain as shown by deletion analysis. This domain may be important for the presence of CAN at the nucleoplasmic side of the nuclear envelope. The relocation of the carboxyterminal part of CAN due to DEK-CAN and SET-CAN may reinforce a nuclear function of the CAN protein.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; RES INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Erasmus University Rotterdam; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Boer, Judith/A-7546-2010; Fornerod, Maarten/A-7503-2010; von Lindern, Marieke/AAH-2350-2020	Fornerod, Maarten/0000-0002-6166-3030	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADRIAANSEN HJ, 1988, LEUKEMIA, V2, P136; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURT EC, 1989, J CELL SCI, P243; HURT EC, 1990, J CELL BIOL, V111, P2829, DOI 10.1083/jcb.111.6.2829; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MOGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068; MURTI KG, 1985, J ELECTRON MICR TECH, V2, P139, DOI 10.1002/jemt.1060020205; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; ROWLEY JD, 1976, BLOOD, V47, P705; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SIERAKOWSKA H, 1993, CLIN EXP IMMUNOL, V94, P435; SMITH GE, 1993, MOL CELL BIOL, V2, P2156; SOEKARMAN D, 1992, LEUKEMIA, V6, P489; SOEKARMAN D, 1992, BLOOD, V79, P2990; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WEBSTER RE, 1978, EXP CELL RES, V117, P47, DOI 10.1016/0014-4827(78)90426-3; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; YARMUSH ML, 1981, J IMMUNOL, V126, P2240; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P791	40	140	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1739	1748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753551				2022-12-28	WOS:A1995QX46900007
J	TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM				TONG, Q; LI, YS; SMANIK, PA; FITHIAN, LJ; XING, SH; MAZZAFERRI, EL; JHIANG, SM			CHARACTERIZATION OF THE PROMOTER REGION AND OLIGOMERIZATION DOMAIN OF H4 (D10S170), A GENE FREQUENTLY REARRANGED WITH THE RET PROTOONCOGENE	ONCOGENE			English	Article						H4 (D10S170); VET; PROMOTER; OLIGOMERIZATION	THYROID PAPILLARY CARCINOMAS; TYROSINE KINASE; TRANSGENIC MICE; CELL-LINE; PROTOONCOGENE; ACTIVATION; SEQUENCE; CLONING; FUSION; EXPRESSION	PTC-1, the predominant form of PTC oncogene in human papillary thyroid carcinoma, encodes a fusion protein containing the N-terminus of H4 (D10S170) fused 5' to the ret tyrosine kinase domain. Accordingly, the PTC-1 expression is driven by the H4 gene promoter. Our study showed that H4 is expressed in various human tissues, including thyroid. Furthermore, we have localized the transcriptional start sites of H4 to a region 100 to 190 bp upstream of the translation initiation site (ATG) by primer extension assay, and the 114 promoter to a region within 259 bp upstream of the ATG site by luciferase assay. Interestingly, protein sequence analysis indicated a potential coiled-coil domain in the N-terminal region of H4. Indeed, oligomerization was demonstrated by an in vitro assay with recombinant proteins containing this region. As dimerization is considered to be a crucial step for receptor tyrosine kinase activation, we hypothesize that both unscheduled expression of ret tyrosine kinase and constitutive oligomerization of PTC-1 proteins are responsible for PTC-1 transforming activity in thyroid.	OHIO STATE UNIV,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NCI NIH HHS [R29 CA60074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V4, P1519; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P259; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RENOLDS GA, 1984, CELL, V38, P275; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1994, ONCOGENE, V9, P509; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WEINER DB, 1989, NATURE, V239, P230	41	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753554				2022-12-28	WOS:A1995QX46900011
J	FORD, HL; ZAIN, SB				FORD, HL; ZAIN, SB			INTERACTION OF METASTASIS-ASSOCIATED MTS1 PROTEIN WITH NONMUSCLE MYOSIN	ONCOGENE			English	Article						MTS1; METASTASIS; PROTEIN-PROTEIN INTERACTIONS; MOTILITY; MYOSIN	CALCIUM-BINDING PROTEINS; MESSENGER-RNA; HEAVY-CHAIN; MOLECULAR-CLONING; CELLULAR MYOSIN; GENE-PRODUCT; EXPRESSION; CELLS; SEQUENCE; FAMILY	The mts1 gene codes for a 101 amino acid protein which belongs to the subfamily of S100 Ca2+-binding proteins and is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, While the Mts1 protein is putatively involved in cytoskeletal-membrane interactions, its exact physiological role is not known, In order to gain insight into the biological function of Mts1, its expression was monitored throughout mouse embryogenesis as well as in normal adult mouse tissues. In situ hybridizations of mouse embryos showed expression of mts1 mRNA to be highest in trophoblast cells of a day 8 old embryo, In normal adult mouse tissues, immunocytochemistry revealed Mts1 expression in a T-cell specific pattern in both the thymus and spleen, These results indicate that the expression of mts1 is prevalent in motile cell types, and to further elucidate the role of Mts1, gel overlay and GST-fusion protein experiments were performed to identify proteins that interact with the Mts1 protein, Nonmuscle myosin II was found to interact with Mts1, suggesting a role for Mts1 in the process of motility and lending credence to the hypothesis that Mtsl may enhance metastatic potential by increasing the motility of cancerous cells.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA062376, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA11198, R01CA62376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGERER LM, 1987, APPL NEUROBIOLOGY, P42; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DAVIES BR, 1993, ONCOGENE, V8, P999; DELEON M, 1991, J NEUROSCI RES, V29, P155; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; GENBACEV O, 1993, PLACENTA, V14, P463, DOI 10.1016/S0143-4004(05)80466-7; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAKIUCHI S, 1981, FEBS LETT, V126, P203, DOI 10.1016/0014-5793(81)80242-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KORCZAK B, 1991, CELL GROWTH DIFFER, V2, P335; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OVADI J, 1992, CURR TOP CELL REGUL, V33, P105; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; SAHASRABUDHE DM, 1993, J IMMUNOL, V151, P6302; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; TOOTHAKER LE, 1991, BLOOD, V78, P1826; TULCHINSKY E, 1993, ONCOGENE, V8, P79; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WETERMAN MAJ, 1992, CANCER RES, V52, P1291	59	78	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731714				2022-12-28	WOS:A1995QU68100016
J	RIESE, DJ; DIMAIO, D				RIESE, DJ; DIMAIO, D			AN INTACT PDGF SIGNALING PATHWAY IS REQUIRED FOR EFFICIENT GROWTH TRANSFORMATION OF MOUSE C127 CELLS BY THE BOVINE PAPILLOMAVIRUS E5 PROTEIN	ONCOGENE			English	Article						VIRAL ONCOGENE; PDGF RECEPTOR; GROWTH FACTOR RECEPTORS	EARLY REGION TRANSFORMATION; OPEN READING FRAME; FACTOR RECEPTOR; TUMORIGENIC TRANSFORMATION; MORPHOLOGIC TRANSFORMATION; DNA-SYNTHESIS; AMINO-ACIDS; GENE; TYPE-1; VIRUS	The bovine papillomavirus type 1 (BPV) E5 protein is a 44 amino acid, membrane-associated protein that induces growth transformation of cultured rodent and;bovine fibroblasts. In transformed fibroblasts, the BPV E5 protein activates the endogenous platelet-derived growth factor (PDGF) beta receptor, and the introduction of the PDGF beta receptor gene into heterologous cell types normally lacking PDGF beta receptor expression permits transformation by the E5 protein. However, neither the endogenous PDGF beta receptor nor its signaling pathway has been shown to be required for efficient growth transformation of fibroblasts by the BPV E5 gene. Here we have tested whether the endogenous PDGF beta receptor serves as a target for the BPV E5 protein in mouse C127 fibroblasts. We isolated variant C127 cell Lines that displayed reduced DNA synthesis in response to PDGF but a normal response to other mitogens, suggesting that they harbor specific defects in the PDGF signaling pathway. The variant lines also exhibited a specific reduction in the level of DNA synthesis induced by the acute expression of the BPV E5 gene, and a variant cell line containing a reduced level of PDGF beta receptor also displayed reduced stable growth transformation by the BPV E5 and v-sis oncogenes. These results provide genetic support for the model that the PDGF beta receptor signaling pathway is required for efficient growth transformation of C127 cells by the BPV E5 gene.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University			Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [CA37157, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN P, 1988, ONCOGENE, V2, P453; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOTTO GP, 1985, NATURE, V318, P472; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KULKE R, 1991, J VIROL, V65, P4943, DOI 10.1128/JVI.65.9.4943-4949.1991; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PETTI L, 1991, ORIGINS OF HUMAN CANCER, P707; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STETTEN G, 1977, EXP CELL RES, V108, P447, DOI 10.1016/S0014-4827(77)80055-4; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	48	39	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731695				2022-12-28	WOS:A1995QR65100022
J	BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D				BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D			BIOCHEMICAL-CHARACTERIZATION OF 2 ISOFORMS OF FLT4, A VEGF RECEPTOR-RELATED TYROSINE KINASE	ONCOGENE			English	Article						ANGIOGENESIS; ENDOTHELIUM; CYTOPLASMIC SUBSTRATES; FLT1; FLK1; KDR; FLT4; IN SITU HYBRIDIZATION; ONCOGENE; VEGF; TYROSINE KINASE; RECEPTORS	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; FMS PROTEIN; CELL-LINES; EXPRESSION; FAMILY; INVIVO; CDNA	The FLT4 gene encodes a tyrosine kinase receptor related to the two identified receptors for vascular endothelial growth factor (VEGF), FLT1 and FLK1/KDR. Two isoforms of FLT4, differing by their C-terminal ends, have been identified. The long form has 65 additional amino acid residues. We have shown that FLT4 is a highly glycosylated, relatively stable, cell surface associated kinase of approximately 180 kDa. In order to study the signal transduction molecules associated with the FLT4 pathway, and in the absence of a known ligand, we constructed two chimeric molecules (FF4S and FF4L) made of the extracellular region of the CSF1 receptor (Fms gene product) and of the transmembrane and intracellular regions of either form of FLT4. These two chimeric forms were expressed in Rat 2 transfectants. We assayed the ligand-induced capacity of the FF4 short and long forms to sustain growth of Rat 2 cells in semisolid medium. In a soft agar assay, only the long form was able to induce the growth of Rat 2 cells upon ligand treatment. The two forms of FLT4 therefore have different functional capacities. We looked for association and/or phosphorylation of phospholipase C gamma (PLC gamma) and phosphatidylinositol-3'-phosphate (PI3K), after stimulation of the FF4 molecules by CSF1. Finally, we have studied the expression of the Flt4 gene in mouse embryos and in the adult by in situ hybridization. Flt4 transcripts were found at day 12.5 post-coitum and thereafter, including the adult mouse, predominantly in the pericardium, pleural membranes and in the lung.	INSERM,U119,ONCOL LAB,F-13009 MARSEILLE,FRANCE; WELLESLEY COLL HOSP,RES INST,TORONTO,ON,CANADA; INSERM,U119,HEMATOL FONCT & MOLEC LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019; Borg, Jean-Paul/AAX-8096-2020	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Rottapel, Robert/0000-0002-6024-5558; Birnbaum, Daniel/0000-0001-7920-9883				BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO Y, 1990, Technique (Philadelphia), V2, P109; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GALLAND F, 1993, ONCOGENE, V8, P1233; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IHLE J, 1994, ITBC, V19, P222; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KORHONEN J, 1994, ONCOGENE, V9, P395; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1993, NATURE, V367, P576; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHIBUYA M, 1990, ONCOGENE, V5, P519; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STANTON B, 1989, THESIS U MARYLAND BA; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	62	39	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					973	984						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898938				2022-12-28	WOS:A1995QL03800019
J	ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH				ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH			A FUNCTIONAL ASSAY FOR HETEROZYGOUS MUTATIONS IN THE GTPASE-ACTIVATING PROTEIN RELATED DOMAIN OF THE NEUROFIBROMATOSIS TYPE-1 GENE	ONCOGENE			English	Article						NF1; FUNCTIONAL ASSAY IN YEAST FASAY	GAP-RELATED DOMAIN; SACCHAROMYCES-CEREVISIAE; RAS GTPASE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GEL-ELECTROPHORESIS; ADENYLATE-CYCLASE; MAMMALIAN GAP; CDC25 GENE; YEAST; PRODUCT	The GTPase-activating protein related domain of the human neurofibromatosis type 1 protein (NF1GRD) can down-regulate RAS in Saccharomyces cerevisiae, Using a technique termed the FASAY method, for Functional Analysis of Separated Alleles in Yeast, we designed a rapid method for detection of heterozygous NF1GRD loss-of-function mutations, In our method, PCR amplified NF1GRD cDNA is directly cloned into a centromeric vector by homologous recombination in a cdc25 temperature-sensitive mutant strain expressing human Ha-ras. This strain is dependent on the Ha-uas for growth, allowing a simple growth assay for NF1GRD loss-of-function mutations, In a test of our method, two alternatively spliced NF1GRD cDNAs (type I and II) inhibited yeast growth whereas four mutants with amino acid substitutions at highly conserved residues did not, This simple method thus permits the rapid screening for heterozygous germline or somatic NF1GRD mutations, In an initial application of this method, no mutations disrupting NF1GRD function were detected in lymphoblasts from 11 previously untested neurofibromatosis type 1 patients.	MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02129 USA; TOHOKU UNIV, INST DEV AGING & CANC, SENDAI, MIYAGI 980, JAPAN; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,DANA FARBER INST, DEP PEDIAT,DIV HEMATOL ONCOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Tohoku University; University of California System; University of California Santa Barbara; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	ISHIOKA, C (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.		The, Inge/B-8884-2011		PHS HHS [WS 22224] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNARDS A, 1992, DNA CELL BIOL, V11, P727, DOI 10.1089/dna.1992.11.727; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOUTELET F, 1985, EMBO J, V4, P2635, DOI 10.1002/j.1460-2075.1985.tb03981.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; ENG C, 1993, FASEB J, V7, P910, DOI 10.1096/fasebj.7.10.8102106; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GUTMANN DH, 1993, ONCOGENE, V8, P761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KNUNDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LUNBERG KS, 1991, GENE, V108, P1; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; UPADHYAYA M, 1990, J MED GENET, V27, P738, DOI 10.1136/jmg.27.12.738; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	48	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					841	847						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898926				2022-12-28	WOS:A1995QL03800005
J	ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A				ALVES, F; VOGEL, W; MOSSIE, K; MILLAUER, B; HOFLER, H; ULLRICH, A			DISTINCT STRUCTURAL CHARACTERISTICS OF DISCOIDIN-I SUBFAMILY RECEPTOR TYROSINE KINASES AND COMPLEMENTARY EXPRESSION IN HUMAN CANCER	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; DISCOIDIN I MOTIF; SH3 BINDING SITE; TUMOR INVASION	GROWTH-FACTOR RECEPTOR; BINDING; DOMAIN; IDENTIFICATION; MOLECULE; FAMILY; SIGNAL; CELLS; ACID	Mammary carcinoma kinase 10 (MCK-10) and colon carcinoma kinase 2 (CCK-2) constitute a subclass of receptor tyrosine kinases characterized by a discoidin I motif in the extracellular domain and a large cytoplasmic juxtamembrane (JM) region. While the ectodomain structure suggests a common role in cell aggregation, the JM domains of MCK-10 and CCK-2 are structurally most divergent and display features that suggest an involvement in signal generation and definition. MCK-10 occurs in at least three isoforms, which contain alternatively spliced consensus sequences for internalization and SH3 domain interaction. The presence of the 37 amino acid insert affects receptor autophosphorylation and changes ectodomain glycosylation. Proteolytic cleavage within the extracellular domain of MCK-10 generates a membrane-anchored kinase domain and releases a soluble ectodomain fragment including the discoidin I homology domain. CCK-2 and MCK-10 expression was found in connective and epithelial tissues, respectively, which in cancers of epithelial origin results in mutually exclusive expression in stroma and tumor cells, indicating a possible involvement of this class of RTKs in tumor invasion.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY; SUGEN INC, DEPT MOLEC BIOL, REDWOOD CITY, CA 94063 USA; TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, INST ALLGEMEINE & PATHOL ANAT, D-81675 MUNICH, GERMANY	Max Planck Society; Technical University of Munich								ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FENDLY BM, 1990, CANCER RES, V50, P1550; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; LAI C, 1994, ONCOGENE, V9, P877; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEREZ JL, 1994, ONCOGENE, V9, P211; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZERLIN M, 1993, ONCOGENE, V8, P2731; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	211	219	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845687				2022-12-28	WOS:A1995QF64800023
J	FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M				FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M			EFFICIENT CELL-TRANSFORMATION BY THE TPR-MET ONCOPROTEIN IS DEPENDENT UPON TYROSINE-489 IN THE CARBOXY-TERMINUS	ONCOGENE			English	Article						MET; ONCOPROTEIN; CELL TRANSFORMATION; SUBSTRATES; TYROSINE PHOSPHORYLATION	HEPATOCYTE GROWTH-FACTOR; PAPILLARY THYROID CARCINOMAS; GUANINE-NUCLEOTIDE EXCHANGE; SCATTER FACTOR-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; KINASE-ACTIVITY; SH3 DOMAINS	The receptor for hepatocyte growth factor/scatter factor (HGF/SF) was originally identified as an oncogene, Tpr-Met, which consists of the cytoplasmic tyrosine kinase domain of the HGF/SF receptor (Met) fused downstream of sequences encoded by the tpr gene. As a consequence of this rearrangement the Tpr-Met fusion oncoprotein is localized to the cytoplasm and is a constitutively activated kinase. To identify signalling pathways important for Tpr-Met-mediated cell transformation we have generated tyrosine to phenylalanine mutants of Tpr-Met that are compromised in their ability to transform Fischer rat 3T3 (Fr3T3) cells in culture, We show that a single tyrosine residue in the carboxy terminus of Tpr-Met (residue 489) is essential for efficient transformation of Fr3T3 cells by this oncoprotein, Mutation of tyrosine 489 to phenylalanine does not affect the exogenous kinase activity of the Tpr-Met oncoprotein toward casein, but it impairs the ability of the mutant protein to bind to and activate phosphatidylinositol 3 kinase in vivo and completely abolishes the in vivo association with the Grb2 adaptor protein as well as the association and/or phosphorylation of an unknown protein of 110 kDa, These data are consistent with a single tyrosine residue in the Tpr-Met oncoprotein being essential for the activation of several signalling pathways which lead to the transformation of Fr3T3 fibroblasts.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOLEC ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; University of Toronto			Moran, Michael/GYD-3631-2022					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEAR SE, 1989, P NATL ACAD SCI USA, V63, P2959; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; CROWE AJ, 1994, ONCOGENE, V9, P537; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FALETTO DL, 1993, SIGNAL TRANSDUCTION, P108; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HALABAN R, 1992, ONCOGENE, V7, P2195; HARLOW E, 1988, ANTIBODIES LABORATOR; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KAZKAUSKAS A, 1992, MOL CELL BIOL, V12, P2534; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LONGATI P, 1994, ONCOGENE, V9, P49; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	79	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					237	249						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838524				2022-12-28	WOS:A1995QC62400003
J	CIOSSEK, T; MILLAUER, B; ULLRICH, A				CIOSSEK, T; MILLAUER, B; ULLRICH, A			IDENTIFICATION OF ALTERNATIVELY SPLICED MESSENGER-RNAS ENCODING VARIANTS OF MDK1, A NOVEL RECEPTOR TYROSINE KINASE EXPRESSED IN THE MURINE NERVOUS	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; NEURAL DEVELOPMENT	GROWTH-FACTOR RECEPTOR; PROTO-ONCOGENE; W-LOCUS; GENE; MOUSE; FAMILY; MEMBERS; CLONING; CHICKEN; DNA	A novel member of the eck/eph family of receptor tyrosine kinases (RTKs), termed mouse developmental kinase 1 (MDK1), was identified and shown to be closely related to the Eek, Ehk1/Cek7, Ehk2, Cek4/Mek4/hek and Sek/Cek8 subfamily. Northern blot analysis revealed MDK1 mRNA transcripts of 6.8, 5.7, 4.0, 3.2 and 2.6 kb that encode apparent splice variants. Sequence analyses of MDK1 cDNA clones from adult mouse brain predict the existence of at least five isoforms, including two truncated receptor variants lacking the kinase domain. Northern blot and in situ hybridization analysis indicate that in the adult mouse MDK1 RNA expression is restricted to brain, testes and spleen. The distinct patterns of MDK1 gene expression during mouse development suggest an important role in the formation of neuronal structures and possibly other morphogenic processes.	MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Max Planck Society								BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Ito M, 1984, CEREBELLUM NEURAL CO; Jensen D, 1980, HUMAN NERVOUS SYSTEM; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROHEN JW, 1985, FUNKTIONELLE ANATOMI; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sneath PHA., 1973, NUMERICAL TAXONOMY, P230, DOI DOI 10.1111/J.1523-1739.2007.00775.X; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1992, J BIOL CHEM, V267, P1470; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	59	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					97	108						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824284				2022-12-28	WOS:A1995QA98000012
J	KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T				KOIKE, M; ISHINO, K; IKUTA, T; HUH, NH; KUROKI, T			GROWTH ENHANCEMENT OF NORMAL HUMAN KERATINOCYTES BY THE ANTISENSE OLIGONUCLEOTIDE OF RETINOBLASTOMA SUSCEPTIBILITY GENE	ONCOGENE			English	Article						RB; P53; ANTISENSE; KERATINOCYTES	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; P53 GENE; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; CYCLE PROGRESSION; BREAST-CANCER; FACTOR BETA-1	We have found that the growth of normal human keratinocytes, grown in serum-free medium, was significantly stimulated by the antisense oligonucleotide of retinoblastoma susceptibility gene (Rb). Normal human keratinocytes were exposed to phosphorothionate oligonucleotides which were complementary to translation initiation codon of Rb gene. The growth of keratinocytes was enhanced by the antisense, but not the sense, oligonucleotide of Rb gene in a dose-dependent manner from 1 to 10 mu M. The Rb antisense oligonucleotide, however, did not result in any appreciable change in transcription of the gene when examined by reverse-transcription polymerase chain reaction (RT-PCR) analysis or in the protein expression and the phosphorylation pattern when examined by immunoprecipitation and Western blotting.	UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011; HUH, Nam-ho/B-1613-2011; Koike, Manabu/AAP-3107-2021	Kuroki, Toshio/0000-0001-6369-4351; 				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALABRETTA B, 1991, CANCER RES, V51, P4505; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROOK T, 1991, ONCOGENE, V6, P873; Crouch R. J., 1982, NUCLEASES, P211; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1991, EUR J CANCER, V27, P1466, DOI 10.1016/0277-5379(91)90033-A; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; KUROKI T, 1993, JPN J CANCER RES, V84, P1091, DOI 10.1111/j.1349-7006.1993.tb02806.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER CW, 1990, CANCER RES, V50, P7950; MOLES JP, 1993, ONCOGENE, V8, P583; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RINA ZH, 1985, EMBO J, V4, P1251; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEELE C, 1993, CANCER RES, V53, P2330; STOREY A, 1991, NUCLEIC ACIDS RES, V19, P4109, DOI 10.1093/nar/19.15.4109; STRAUSS M, 1992, ONCOGENE, V7, P769; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TSUNENAGA M, 1994, JPN J CANCER RES, V85, P238, DOI 10.1111/j.1349-7006.1994.tb02088.x; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YASUMOTO S, 1992, MOL PATHWAYS KINASES, P35; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					117	122						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824264				2022-12-28	WOS:A1995QA98000014
J	QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI				QIAN, XL; DOUGALL, WC; FEI, ZZ; GREENE, MI			INTERMOLECULAR ASSOCIATION AND TRANS-PHOSPHORYLATION OF DIFFERENT NEU-KINASE FORMS PERMIT SH2-DEPENDENT SIGNALING AND ONCOGENIC TRANSFORMATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR FAMILY; NIH 3T3 CELLS; POINT MUTATION; MONOCLONAL-ANTIBODIES; TRANSMEMBRANE DOMAIN; PDGF RECEPTOR; LIVING CELLS; HUMAN-BREAST	The nea oncogene encodes a 185 kDa receptor tyrosine kinase, A single point mutation (Val664-->Glu) within the p185(neu) transmembrane region results in higher efficiency of receptor dimerization, constitutive activity of tyrosine kinase and cellular transformation, The oncogenic potential of this mutated form of p185(neu) (termed Tneu) can be inactivated by site-directed alteration of a lysine residue in the conserved catalytic domain. In this report, we have utilized the physical and functional interaction of a full-length kinase-deficient neu protein (T757) and truncated kinase-active Tneu forms to determine critical protein domains for Tneu oligomerization and the resultant biological consequences. Analysis of various truncated Tneu mutants confirmed that the transmembrane region was crucial for p185 dimerization. Receptor association facilitates intermolecular phosphorylation of kinase-deficient mutant T757 by truncated kinase-active p185 proteins, and the trans-phosphorylated kinase-deficient T757 was able to associate in vitro with proteins containing SH2 domains. Receptor-receptor interactions resulted in enhanced signal transduction potential and transformation of cell-lines co-expressing different neu-kinase forms. These studies emphasize a novel feature of protein-protein interaction and the functional significance of p185 dimerization, intermolecular phosphorylation and signaling which may result in cellular transformation.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,CTR RECEPTOR BIOL,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; HACK N, 1993, J BIOL CHEM, V268, P26441; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEVEA CM, 1993, RECEPTOR, V3, P293; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MARGOLIS B, 1992, CELL GROWTH DIFFER, V7, P73; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MYERS JN, 1992, RECEPTOR, V2, P1; OTSU M, 1991, CELL, V65, P359; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1992, J BIOL CHEM, V267, P12266; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1993, UNPUB SCIENCE; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SELVA E, 1993, J BIOL CHEM, V268, P2250; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAMOTO T, 1992, J BIOL CHEM, P11337; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	58	34	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824275				2022-12-28	WOS:A1995QA98000025
J	CORBO, L; LEROUX, F; SERGEANT, A				CORBO, L; LEROUX, F; SERGEANT, A			THE EBV EARLY GENE-PRODUCT EB2 TRANSFORMS RODENT CELLS THROUGH A SIGNALING PATHWAY INVOLVING C-MYC	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; LYMPHOCYTE GROWTH TRANSFORMATION; DNA-BINDING; MAX; PROTEINS; TRANSCRIPTION; EXPRESSION; SEQUENCE; ONCOGENE; REQUIRES	Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with several neoplasia. We present evidence here that the protein EB2, an EBV posttranscriptional activator, has transforming properties not only when expressed in established cell lines such as Rat1 or NIH3T3 but also in primary rat fibroblasts (REF). EB2 transformation in Rat1 cells correlates with an increase in the steady-state level of the cellular oncogenic protein c-Myc, and cotransfection of a plasmid expressing Max suppresses the transformation. These results implicate c-Myc in EB2-mediated cell transformation and help define the pathway by which this EBV early protein causes transformation.			CORBO, L (corresponding author), ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.			Le Roux, Frederique/0000-0002-9112-6199				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAICHWALL VR, 1988, ONCOGENE, V2, P416; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORBO L, 1993, EPSTEINBARR VIRUS AS, V225, P51; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hinnebusch A, 1993, CURR OPIN CELL BIOL, V5, P941, DOI 10.1016/0955-0674(93)90073-Y; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOAB I, 1991, J INFECT DIS, V163, P53, DOI 10.1093/infdis/163.1.53; KAROMILAS AE, 1992, SCIENCE, V257, P1685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KIEFF E, 1990, VIROLOGY, P1889; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MARCU KB, 1992, ANN REV BIOCH, V61, P808; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; MIKAELIAN I, 1993, J VIROL, V67, P734; MILLER G, 1990, VIROLOGY, P1921; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PALLESEN G, 1991, BLOOD, V78, P1162; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHIC C, 1982, CELL, V29, P161; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SU IJ, 1991, BLOOD, V77, P799; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WONG KM, 1989, VIROLOGY, V168, P101, DOI 10.1016/0042-6822(89)90408-X; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZENG Y, 1982, INT J CANCER, V29, P193	47	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3299	3304						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936654				2022-12-28	WOS:A1994PM65800023
J	PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G				PLUMMER, SJ; SANTIBANEZKOREF, M; KUROSAKI, T; LIAO, S; NOBLE, B; FAIN, PR; ANTONCULVER, H; CASEY, G			A GERMLINE 2.35-KB DELETION OF P53 GENOMIC DNA CREATING A SPECIFIC LOSS OF THE OLIGOMERIZATION DOMAIN INHERITED IN A LI-FRAUMENI-SYNDROME FAMILY	ONCOGENE			English	Article							CANCER-PRONE FAMILY; MUTANT P53; BREAST-CANCER; WILD-TYPE; SPLICING MUTATION; SUPPRESSOR GENE; PROTEINS; BINDING; PHOSPHORYLATION; TRANSACTIVATION	The primary genetic cancer predisposing event in many Li-Fraumeni syndrome families is a germline mutation in the p53 gene. We describe an extended Li-Fraumeni family with a germline mutation in the p53 gene involving a deletion of exon 10. The mutation is a 2.35 kilobase intragenic deletion encompassing exon 10, which results in the specific loss of the entire p53 oligomerization domain. This mutation segregates with the cancer phenotype. A lymphoblastoid cell line developed from a mutation carrier shows accumulation of mutant p53 protein by immunoblotting. However, tumor tissues from two affected carriers are negative by immunohistochemical staining. A major structural alteration specifically involving the oligomerization domain of a germline p53 gene has not been previously described and occurs in a region rarely mutated in sporadic tumors. The oligomerization domain is dispensable for many wild-type p53 functions, including transactivation, sequence-specific DNA binding, and suppression of oncogenic transformation. However, the domain appears to be required for trancriptional repression, and DNA strand reassociation. The identification of this mutation in an LFS family may yield insights into the importance of the oligomerization domain for suppressor function of the p53 tumor suppressor gene.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; UNIV CALIF IRVINE,DEPT MED,PROGRAM EPIDEMIOL,IRVINE,CA 92717; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Cleveland Clinic Foundation; University of California System; University of California Irvine; Utah System of Higher Education; University of Utah					NCI NIH HHS [CA56554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA056554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BIRCH JM, 1994, CANCER RES, V54, P1298; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1992, CANCER RES, V52, P3234; BRAIN R, 1994, ONCOGENE, V9, P1775; BRUGIERES L, 1993, CANCER RES, V53, P452; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX CA, 1993, ONCOGENE, V8, P1203; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; GARBER JE, 1991, CANCER RES, V51, P6094; HAINAUT P, 1994, ONCOGENE, V9, P299; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIO Y, 1994, ONCOGENE, V9, P1231; JOLLY KW, 1994, ONCOGENE, V9, P97; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; Reed Michael, 1993, Gene Expression, V3, P95; SAMESHIMA Y, 1992, J NATL CANCER I, V48, P5358; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; TARUNINA M, 1993, ONCOGENE, V8, P3165; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	50	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3273	3280						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936651				2022-12-28	WOS:A1994PM65800020
J	MEDCALF, EA; MILNER, J				MEDCALF, EA; MILNER, J			TARGETING AND DEGRADATION OF P53 BY E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 IS PREFERENTIAL FOR THE 1620+ P53 CONFORMATION	ONCOGENE			English	Note							MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; WILD-TYPE; MUTANT CONFORMATION; SUPPRESSOR; PROTEIN; EXPRESSION; TRANSFORMATION; MUTATIONS; DISTINCT	E6-mediated degradation of p53 is believed to play a role in the transformation of cells by high-risk types of human papillomavirus. In order to explore the structural requirements for targeting of p53 we have compared E6-mediated degradation of variant p53 forms expressed in vitro. Complete degradation was observed in samples containing monomers, dimers and higher molecular weight structures of wild-type p53, indicating that E6 targets all quaternary forms of wild-type p53. Wild-type human and murine p53s reactive with PAb 1620 (which recognizes a conformation-dependent epitope) were degraded when incubated with E6. Mutant p53 proteins were variably resistant to E6-mediated degradation, and this correlated with PAb 1620 reactivity. Thus, mutants hp53Val-154, hp53Val-266 and hp53Pro-273 (1620-degrees) were completely resistant to degradation, whereas hp53Ile-247 and hp53Trp-248 (1620+) were degraded. Mutants hp53Leu-273 and mp53Val-135, which are temperature sensitive for conformation, were completely degraded in the 1620+ form but degradation resistant in the 1620-degrees form. Although the PAb 1620+ conformation appeared important for recognition of p53 by E6, the epitope itself is unlikely to be the actual recognition target since the PAb 1620 monoclonal antibody failed to protect against E6-mediated degradation.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge								ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; HUIGBREGTSE J, 1991, EMBO J, V10, P4129; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2847	2851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690928				2022-12-28	WOS:A1993LX34300028
J	DUDLEY, ME; SUNDBERG, JP; ROOPENIAN, DC				DUDLEY, ME; SUNDBERG, JP; ROOPENIAN, DC			MOTIF-PRIMED POLYMERASE CHAIN REACTION-BASED ALLELOTYPE OF SARCOMAS INDUCED BY 3-METHYLCHOLANTHRENE IN INTERSPECIFIC HYBRID MICE	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; GENOME FINGER-PRINTING; PCR; 3-METHYLCHOLANTHRENE	MINOR HISTOCOMPATIBILITY ANTIGENS; MOUSE SKIN; BREAST-CANCER; T-CELLS; TUMORS; CARCINOMAS; AMPLIFICATION; CHROMOSOME-7; RAS; CARCINOGENESIS	Loss of heterozygosity (LOH) occurs commonly in some human tumors and is thought to reflect the selective pressure exerted by tumor suppressor genes. The purpose of this study was to examine the genomic location and relative frequency of LOH of chemically induced tumors in an established mouse model for chemical carcinogenesis. Twenty-four tumors were induced by subcutaneous injection of 3-methylcholanthrene into inter-subspecific hybrid (C57BL/6J x SPRET/Ei)F1 mice. Tumors were diagnosed as poorly differentiated, spindle cell sarcomas. DNA isolated from cell cultures derived from the sarcomas was analysed for LOH using a multi-locus genome scanning technique, motif-primed PCR, followed by conventional simple sequence length polymorphism (SSLP) PCR markers. Ninety-one motif-primed PCR products and seven SSLP markers were evaluated, covering segments of 39 out of 41 chromosomes. LOH was extremely rare; average fractional allelic loss per tumor was less than 0.01 suggesting a remarkable genetic stability of the tumors and that genetic events leading to transformation are only rarely revealed as LOH. However, some regions exhibiting LOH were identified encompassing both known and hypothesized tumor suppressor loci such as Trp53. These data indicate that motif-primed PCR is an efficient method of scanning the genome of interspecific sarcomas for rare mutational events generating LOH during tumor induction. Cell lines derived from the sarcomas promise to be useful for identifying genes whose inactivation causes increased malignancy during tumor progression.			DUDLEY, ME (corresponding author), JACKSON LAB, 600 MAIN ST, BAR HARBOR, ME 04609 USA.				NCI NIH HHS [CA34196] Funding Source: Medline; NIAID NIH HHS [AI28802, AI24544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028802, R29AI024544, R01AI024544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBOR A, 1994, CANCER RES, V54, P4502; BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; BIRKENMEIER EH, 1992, MAMM GENOME, V3, P537, DOI 10.1007/BF00350618; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CAETANOANOLLES G, 1992, MOL GEN GENET, V235, P157, DOI 10.1007/BF00279356; CARBONE G, 1991, INT J CANCER, V47, P619, DOI 10.1002/ijc.2910470423; Coggin J H Jr, 1989, Mol Biother, V1, P223; CORNELISSE CJ, 1992, INT J CANCER, V50, P544, DOI 10.1002/ijc.2910500408; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH W, 1994, GENETICS, V91, P9451; EDWARDS RJ, 1994, CARCINOGENESIS, V15, P829, DOI 10.1093/carcin/15.5.829; FOLEY EJ, 1953, CANCER RES, V13, P835; Gross L, 1943, CANCER RES, V3, P326; HEGI ME, 1994, CANCER RES, V54, P6257; HONMA M, 1994, MUTAT RES, V304, P167, DOI 10.1016/0027-5107(94)90208-9; HOVIG E, 1993, GENOMICS, V17, P66, DOI 10.1006/geno.1993.1284; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KEMP CJ, 1993, CANCER RES, V53, P6022; KLEIN G, 1960, CANCER RES, V20, P1561; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MULLAART E, 1993, NATURE, V365, P469, DOI 10.1038/365469a0; MULLAART E, 1993, GENES CHROMO CANCER, V6, P167; NAGAI H, 1993, CANCER DETECT PREV, V17, P399; NIWA O, 1992, JPN J CANCER RES, V83, P1192, DOI 10.1111/j.1349-7006.1992.tb02744.x; OLD LJ, 1962, ANN NY ACAD SCI, V101, P80, DOI 10.1111/j.1749-6632.1962.tb26446.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PREHN RT, 1957, J NATL CANCER I, V18, P769; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; ROOPENIAN DC, 1984, J IMMUNOL, V132, P1080; ROOPENIAN DC, 1983, J IMMUNOL, V131, P2135; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SATO T, 1990, CANCER RES, V50, P7184; SHU S, 1985, CANCER RES, V45, P1657; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; STEWART HL, 1979, PATHOLOGY TUMOURS LA, V2, P487; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUNDBERG JP, 1991, VET PATHOL, V28, P200, DOI 10.1177/030098589102800303; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELSH J, 1991, NUCLEIC ACIDS RES, V19, P5275, DOI 10.1093/nar/19.19.5275; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	52	4	4	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					517	524						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630636				2022-12-28	WOS:A1995RN53000012
J	BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C				BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C			GAMMA-RADIATION-INDUCED APOPTOSIS IN HUMAN COLORECTAL ADENOMA AND CARCINOMA CELL-LINES CAN OCCUR IN THE ABSENCE OF WILD-TYPE P53	ONCOGENE			English	Note						APOPTOSIS; CELL CYCLE; COLORECTAL; GAMMA RADIATION; G2 ARREST; P53	TUMOR-SUPPRESSOR GENE; THYMOCYTE APOPTOSIS; IONIZING-RADIATION; DNA-DAMAGE; DEATH; IRRADIATION; ACTIVATION; CHECKPOINT; MUTATIONS; CANCER	The tumour suppressor gene p53 codes for a transcription factor which is thought to play a critical role in the induction of G1 cell cycle arrest and programmed cell death (apoptosis) following DNA damage by ionizing radiation, The aim of this investigation was to determine whether a p53 independent radiation-induced apoptosis pathway exists in human colon epithelial cell lines. This report describes the induction, by gamma-radiation, of apoptosis in the colorectal adenoma cell line S/RG/C2, and in the colorectal carcinoma cell line PC/JW, both of which lack wild type p53, In addition, flow cytometry revealed that both cell lines failed to arrest in G1 after radiation. Thus, although loss of wild type p53 may abrogate GI arrest, radiation-induced apoptosis can still occur in human colonic tumour cell lines through a p53 independent mechanism.	UNIV BRISTOL, SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC, COLORECTAL TUMOUR BIOL RES GRP, BRISTOL BS8 1TD, AVON, ENGLAND; BRISTOL ONCOL CTR, BIOPHYS GRP, BRISTOL BS2 8ED, AVON, ENGLAND	University of Bristol; Bristol Haematology & Oncology Centre								ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAKER SJ, 1990, CANCER RES, V50, P7717; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HEERDT BG, 1994, CANCER RES, V54, P3288; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWENTHAL JW, 1985, J IMMUNOL, V135, P1119; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERRITT AJ, 1994, CANCER RES, V54, P614; OCONNOR PM, 1993, CANCER RES, V53, P4776; Okada S, 1970, RAD BIOCH, P247; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, CANCER RES, V49, P1282; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHINOHARA K, 1993, RADIAT RES, V135, P197, DOI 10.2307/3578295; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	38	106	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2391	2396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784088				2022-12-28	WOS:A1995RE54300015
J	KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B				KRIEG, J; OELGESCHLAGER, M; JANKNECHT, R; LUSCHER, B			HIGH-AFFINITY DNA-BINDING OF NATIVE FULL-LENGTH C-MYB AND DIFFERENTIAL PROTEOLYTIC SENSITIVITY OF ITS N-TERMINAL AND C-TERMINAL DOMAINS	ONCOGENE			English	Article						LEUCINE ZIPPER; PHOSPHORYLATION; PROTEIN EXPRESSION; TRANSCRIPTION; VACCINIA VIRUS	HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATION; ONCOGENE PRODUCT; LEUCINE-ZIPPER; PROTEIN; GENE; EXPRESSION; SITES; PHOSPHORYLATION	c-Myb is the prototype of a family of transcription factors characterised by a unique DNA binding domain. Previous analyses have concentrated on truncated versions of c-Myb as it has been very difficult to produce full length c-Myb. To overcome these difficulties we expressed full length c-Myb in HeLa cells using a recombinant vaccinia virus. Partially purified native full length c-Myb bound efficiently and specifically to DNA ,vith a dissociation constant similar to that obtained with bacterially expressed DNA binding domains. No evidence was found for a negative effect of the leucine zipper on DNA binding. Furthermore the DNA binding domain was protease resistant in contrast to the transactivation and negative regulatory domains. Phosphorylation had no apparent effect on this differential protease sensitivity. The increased sensitivity of the C-terminal domain suggests a mote open conformation, which may be relevant in the integration of signals and/or in protein-protein interactions.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School			Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709; Janknecht, Ralf/0000-0003-1741-1562				ANTON IA, 1988, NATURE, V236, P719; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUSSET K, 1993, ONCOGENE, V8, P3211; DUDENDORFF JW, 1992, GENE DEV, V6, P2524; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANEIISHII C, 1995, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MADAN A, 1994, BIOCHEMISTRY-US, V33, P7120, DOI 10.1021/bi00189a015; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	46	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2221	2228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784067				2022-12-28	WOS:A1995RB70300018
J	SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA				SHOU, CC; WURMSER, A; LING, K; BARBACID, M; FEIG, LA			DIFFERENTIAL RESPONSE OF THE RAS EXCHANGE FACTOR, RAS-GRF TO TYROSINE KINASE AND G-PROTEIN MEDIATED SIGNALS	ONCOGENE			English	Article						RAS; EXCHANGE FACTORS; GRF	EPIDERMAL GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GRB2 ADAPTER PROTEIN; T-CELL ACTIVATION; MOLECULAR-CLONING; GUANINE-NUCLEOTIDES; HEMATOPOIETIC-CELLS; MAP KINASE; RECEPTOR; PHOSPHORYLATION	Ras-GRF, a guanine-nucleotide exchange factor that activates Ras p21, was tested for its ability to couple to either tyrosine kinase or heterotrimeric G protein signal transduction pathways. Ras-GRF failed to bind the SH2 and SH3 containing adaptor protein Grb2, either in vitro or in vivo. Furthermore, Ras-GRF did not form a stable complex with activated EGF receptor. However, as has been shown previously (Cen et al., 1994), the presence of Ras-GRF in NIH3T3 cells enhanced the activation of Ras induced by serum stimulation. A similar effect was not observed with PDGF stimulation. Moreover, serum stimulation lead to the hyperphosphorylation of Ras-GRF. Both the serum induced super-activation of Ras, and the hyperphosphorylation of Ras-GRF were blocked by pretreatment of cells with the G(i,o) inhibitor pertussis toxin, but not by pretreatment with the tyrosine kinase inhibitor genistein. These results suggest that Ras-GRF has the capacity to mediate Ras activation initiated by signals using heterotrimeric G proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; BRISTOL MYERS SQUIBB CO,DEPT MOLEC BIOL,PRINCETON,NJ	Tufts University; Bristol-Myers Squibb								ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUSTELLO, 1994, ONCOGENE, V9, P2405; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1994, MOL CELL BIOL, V13, P7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LAMORTE VJ, 1993, J BIOL CHEM, V26, P19411; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1993, MOL BRAIN RES, V19, P124; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	55	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761090				2022-12-28	WOS:A1995QZ92600002
J	VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA				VAIRO, G; VADIVELOO, PK; ROYSTON, AK; ROCKMAN, SP; ROCK, CO; JACKOWSKI, S; HAMILTON, JA			DEREGULATED C-MYC EXPRESSION OVERRIDES IFN-GAMMA-INDUCED MACROPHAGE GROWTH ARREST	ONCOGENE			English	Article						C-MYC; IFN-GAMMA; CAMP; CELL CYCLE; CSF-1; GROWTH ARREST	COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; CELL-CYCLE ARREST; GENE-EXPRESSION; MITOGENIC RESPONSE; SIGNALING PATHWAYS; FACTOR-BETA; FACTOR-I; S-PHASE; INHIBITION	Induction of c-myc gene expression is an essential response to growth promoting agents, including colony-stimulating factor 1 (CSF-1), Down regulation of c-myc expression occurs in response to a variety of negative growth regulators in many cell types, However, for many of these systems the causal link between c-myc down regulation and growth arrest remains to be established. Here we show for CSF-l-dependent BAC1.2F5 mouse macrophages that interferon-gamma (IFN gamma) results in a midlate GI phase decrease of CSF-l-dependent c-myc mRNA and subsequent cell cycle arrest. Introduction of a deregulated c-myc gene into these cells, which prevents the IFN gamma-mediated decrease in c-myc expression, overrides the cell cycle arrest and restores CSF-l-dependent growth in the presence of the cytokine, This result contrasts with the macrophage growth arrest induced by cAMP elevation, which also suppresses c-myc expression, but is not overcome by a deregulated c-myc gene, These results show that inhibition of c-myc expression is an essential component in IFN gamma-mediated cell cycle arrest and demonstrates that distinct mechanisms contribute to IFN gamma- and cAMP-mediated growth arrest in macrophages.	UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, DEPT DIAGNOST HAEMATOL, PARKVILLE, VIC 3050, AUSTRALIA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; St Jude Children's Research Hospital			Jackowski, Suzanne/N-8168-2018; rockman, steve/AAT-5105-2021	Jackowski, Suzanne/0000-0002-6855-1429; Hamilton, John A/0000-0002-9493-9224				ANDERSSON KB, 1993, J CELL PHYSIOL, V157, P61, DOI 10.1002/jcp.1041570108; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMILTON JA, 1989, J CELL PHYSL, V141, P619; HAMILTON JA, 1991, J IMMUNOL, V148, P4028; HARELBELLAN A, 1988, J IMMUNOL, V141, P1012; HARELBELLAN AH, 1987, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZOG PJ, 1988, CLIN IMMUNOL IMMUNOP, V48, P192, DOI 10.1016/0090-1229(88)90083-9; HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KNIGHT KR, 1992, J LEUKOCYTE BIOL, V51, P350, DOI 10.1002/jlb.51.4.350; KREK W, 1995, IN PRESS METHODS ENZ; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; METCALF D, 1984, HEMOPOIETIC COLONIES; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STAEHLI P, 1990, ADV VIRUS RES, V42, P147; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1992, J CELL PHYSIOL, V151, P630, DOI 10.1002/jcp.1041510324; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	57	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1969	1976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761098				2022-12-28	WOS:A1995QZ92600011
J	LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA				LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA			DNA-REPAIR IN THE ENDOGENOUS AND EPISOMAL AMPLIFIED C-MYC ONCOGENE LOCI IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article						DNA REPAIR; C-MYC ONCOGENE; DOUBLE-MINUTE CHROMOSOME	COMPLEMENTATION GROUP-C; HOMOGENEOUSLY STAINING REGIONS; DIHYDROFOLATE-REDUCTASE GENE; HUMAN-COLON CARCINOMA; MATRIX ASSOCIATED DNA; ULTRAVIOLET-LIGHT; DOUBLE MINUTES; TRANSCRIPTION; AMPLIFICATION; FIBROBLASTS	We have studied the repair of u.v.-induced cyclobutane pyrimidine diners (CPDs) in amplified c-myr: oncogene loci in human colon cancer cells to better understand the relationship between chromatin structure, transcription and DNA repair. To assess the variation in DNA repair in the same gene whether located in a chromosomal site or in a extra-chromosomal site, we have quantitated the efficiency of excision repair after u.v. exposure in the endogenous and episomal c-myc genes isolated from COLO320HSR and DM cells. In the HSR cells, c-myc is localized in a homogeneously staining region (HSR), and in the DM cells, the gene is localized in double minute chromosomes (DM). Our results indicate that the repair is less efficient in c-myc amplicons organized as double minute chromosomes than in the endogenous c-myc amplicons, The episomal gene is not repaired with the same efficiency as when it is intrachromosomal. This may reflect differences in chromatin structure. An advantage of this biological system is that the cells possess two different alleles of the c-myc gene, one that is active and another which is inactive. We have studied the relationship between DNA repair and transcriptional activity in the c-myc locus by measuring the efficiency of excision repair after u.v. exposure in the normal and rearranged alleles of the c-myc gene. Surprisingly, the c-myc gene is repaired with similar efficiency in the highly transcribed allele as in the poorly expressed allele. However, u.v. damage is selectively removed from the transcribed strand of the active c-myc allele, but DNA repair is not strand specific in the non-expressed c-myc allele.	NIA, MOLEC GENET LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Bohr, Vilhelm/AAP-5931-2020					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BIANCHI NO, 1991, DNA CELL BIOL, V10, P125, DOI 10.1089/dna.1991.10.125; Biedler JL, 1983, ADV CELL NEUROBIOL, V4, P268; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CLEAVER JE, 1983, J MOL BIOL, V170, P305, DOI 10.1016/S0022-2836(83)80150-8; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DESALUM SB, 1984, CANCER GENET CYTOGEN, V11, P53, DOI 10.1016/0165-4608(84)90098-0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL DL, 1994, PHOTOCHEM PHOTOBIOL, V60, P221, DOI 10.1111/j.1751-1097.1994.tb05094.x; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; QUINN LA, 1979, CANCER RES, V39, P4914; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHIMKE RT, 1982, GENE AMPLIFICATION, P317; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANDEVANTER DR, 1993, GENE CHROMOSOME CANC, V6, P190, DOI 10.1002/gcc.2870060310; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731719				2022-12-28	WOS:A1995QU68100021
J	LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG				LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG			OVEREXPRESSION OF SHC PROTEINS POTENTIATES THE PROLIFERATIVE RESPONSE TO THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND RECRUITMENT OF GRB2/SOS AND GRB2/P140 COMPLEXES TO THE BETA-RECEPTOR SUBUNIT	ONCOGENE			English	Article						GM-CSF; SIGNAL; SHE; GRB2	GUANINE-NUCLEOTIDE EXCHANGE; GM-CSF RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; MOLECULAR-CLONING; CELL-LINE; KINASE; RAS	The high affinity receptor for GM-CSF consists of a unique a subunit and a beta subunit that is shared with receptors for IL-3 and IL-5. Activation of GM-CSF receptor (GMR) triggers two distinct cytoplasmic signalling pathways, JAK2, and Pas, and is sufficient to maintain proliferation of growth factor-dependent cell lines, She proteins are phosphorylated upon activation of GMR and may be involved in the transmission of GM-CSF signals to Pas. To define the role of She proteins in cells stimulated with GM-CSF, we investigated both the network of interactions that involve She after GM-CSF stimulation and the effects of overexpressing She proteins on the proliferative response to GM-CSF. Two cytoplasmic complexes, Grb2/Sos and Grb2/p140 bind through the Grb2 SH2 domain to phosphorylated She, and are thereby recruited to the beta subunit, Both complexes are stable, even in the absence of ligand, and depend on the direct association of p140 and Sos respectively with the SH3 domains of Grb2, p140 is an uncharacterized protein constitutively phosphorylated on tyrosine and, in its Grb2-bonnd form, expressed only in hematopoietic cells, the oligomeric complex formed by phosphorylated beta subunit-phosphorylated Shc-Grb2-SoS-p140 is also induced by IL-3 and L-5 stimulation of growth-factor dependent cell lines, Overexpression of wild-type She proteins in growth factor-dependent cells increases both MAP kinase activation and proliferation in response to GM-CSF, These effects require the association of She with Grb2, Taken together these results indicate that phosphorylation of She proteins is a crucial step in the transmission of GM-CSP proliferative stimuli, since it creates a high affinity binding site for the Grb2/SoS complex, whose function is to activate Ras and, for the Grb2/p140 complex, whose function remains unknown.	DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	LANFRANCONE, L (corresponding author), UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06122 PERUGIA,ITALY.		Pelicci, Giuliana/AAA-8921-2022; Brizzi, Maria Felice/J-7882-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Pawson, Tony J/E-4578-2013	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; CASCIARI, CRISTINA/0000-0002-9170-370X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATZER LN, 1993, NATURE, V363, P85; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LIOUBIN NM, 1994, MOL CELL BIOL, V14, P5682; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; METCALF D, 1993, BLOOD, V82, P3515; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; OKUDA K, 1992, BLOOD, V79, P2880; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SALCINI AE, 1994, IN PRESS ONCOGENE; Sambrook J, 1989, MOL CLONING LABORATO; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONYANG Z, 1994, MOL CELL BIOL, V14, P2777; SORENSEN PHB, 1989, BLOOD, V73, P406; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	44	105	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					907	917						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898932				2022-12-28	WOS:A1995QL03800012
J	WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF				WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF			PRODUCTS OF ALTERNATIVELY SPLICED TRANSCRIPTS OF THE WILMS-TUMOR SUPPRESSOR GENE, WT1, HAVE ALTERED DNA-BINDING SPECIFICITY AND REGULATE TRANSCRIPTION IN DIFFERENT WAYS	ONCOGENE			English	Article						WT1; TRANSCRIPTIONAL FACTOR; ZINC FINGER PROTEIN; ALTERNATIVE SPLICING	ZINC FINGER GENE; EXPRESSION; KRUPPEL; PROTEIN; CELLS; REPRESSION; DOMAINS; GROWTH; LOCUS; E1A	The Wilms' tumor susceptibility gene, wt1, encodes a transcription factor of the zinc finger protein family. Mutations in the WT1 gene product have been detected in both sporadic and familial Wilms' tumors, suggesting that alterations in WT1 may disrupt its normal function as a transcriptional regulator. The transcripts of wt1 are alternatively spliced; however, roles of the alternatively spliced forms have not been defined. The major transcript of wt1 encodes a WT1 protein [WT1(+KTS)+17AA] that contains three amino acids (+KTS) between the third and fourth zinc fingers and a serine-rich, 17 amino acid (+17AA) domain N-terminal to the zinc finger region. We now show that the WT1(+KTS) forms functionally bind to a unique G + C-rich sequence within the PDGF A-chain promoter. We also show that WT1 (+KTS)+17AA functions as a strong transciptional repressor and that +17AA alone fused to the zinc-finger domain of WT1 or to the heterologous DNA binding domain of GAL4 functions independently as a repressor. Deletion of four serine residues within +17AA abolishes the repressor activity of +17AA. These results indicate that wt1 products with +17AA contain an additional dominant repressor domain and that the presence or absence of +KTS determines alternative DNA binding specificity.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Huang, Jeffrey K./AAH-2418-2021; Huang, Jeffrey/J-5248-2017	Huang, Jeffrey K./0000-0003-0996-9451; Huang, Jeffrey/0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL031102, R37HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BASCH I, 1993, EMBO J, V12, P4229; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GESSLER M, 1990, NATURE, V343, P744; GORMAN GM, 1982, MOL CELL BIOL, V8, P1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HSA TT, 1992, SCIENCE, V257, P1946; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN XH, 1992, J BIOL CHEM, V267, P25614; MADDEN SL, 1992, SCIENCE, V253, P1550; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANG ZY, 1993, P NATL ACAD SCI USA, V268, P8896; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	35	82	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					415	422						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845666				2022-12-28	WOS:A1995QF64800001
J	CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K				CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K			IMMEDIATE EFFECTS OF REVERSIBLE HTLV-1 TAX FUNCTION - T-CELL ACTIVATION AND APOPTOSIS	ONCOGENE			English	Article						HTLV-1 TAX; CD3; CD28; ESTROGEN RECEPTOR; T-CELL ACTIVATION; APOPTOSIS	VIRUS TYPE-I; LEUKEMIA-VIRUS; IL-2 RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-EXPRESSION; BINDING DOMAINS; B-CELLS; INTERLEUKIN-2; INDUCTION	The tax protein of Human T-cell leukemia virus type 1 (HTLV-1) is important for the transforming properties of this virus in vitro and is considered to be responsible for the early stages of leukemogenesis in infected hosts. To address the early consequences of HTLV-1 tax function, we have constructed fusion proteins containing tax sequence either aminoterminal (taxER) or carboxyterminal (ERtax) of the hormone binding domain of the human estrogen receptor (ER). Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28). Additional stimulation of the T-cell receptor CD3 complex, led to the upregulation of CD25. B7 was upregulated by concomittent activation of ERtax and CD3 or CD28 pathways, These events were in part reversible upon withdrawal of hormone and inactivation of ERtax. Severe inhibition of proliferation, and apoptosis was observed with cells which had been subjected to short term (3 days) activation of the tax fusion proteins and the CD3 complex, Induction of ERtax activity for longer than 3 days promoted cell death independently of CD3 stimulation. Co-stimulation through the CD28 cell surface molecule did not suppress induction of apoptosis.	GERMAN CANC RES CTR,DEPT TUMOR IMMUNOL,D-69120 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; ALEXIS CARREL MED SCH,MOLEC & CELLULAR IMMUNOVIROL LAB,CNRS,UMR 30,LYON,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centre National de la Recherche Scientifique (CNRS)			Chlichlia, Katerina/Q-3948-2019; Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Chlichlia, Katerina/0000-0003-4952-0675				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094; HATTORI T, 1981, BLOOD, V58, P645; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KELLY K, 1992, ONCOGENE, V7, P1463; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LINSLEY PS, 1993, J IMMUNOL, V150, P3161; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; RUBEN S M, 1990, New Biologist, V2, P894; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHWARTING R, 1989, CLUSTER REPORT CD69, P428; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; TSUDA H, 1984, BRIT J CANCER, V50, P843, DOI 10.1038/bjc.1984.266; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VALLE A, 1990, IMMUNOLOGY, V69, P531; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; YOSHIDA M, 1986, AIDS RES, V2, pS17	61	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					269	277						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838527				2022-12-28	WOS:A1995QC62400006
J	ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD				ESHLEMAN, JR; LANG, EZ; BOWERFIND, GK; PARSONS, R; VOGELSTEIN, B; WILLSON, JKV; VEIGL, ML; SEDWICK, WD; MARKOWITZ, SD			INCREASED MUTATION-RATE AT THE HPRT LOCUS ACCOMPANIES MICROSATELLITE INSTABILITY IN COLON-CANCER	ONCOGENE			English	Article						REPLICATION ERRORS (RER); GENOMIC INSTABILITY; COLON CANCER; HPRT; HPRT (HEREDITARY NONPOLYPOSIS COLON CANCER)	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR; HUMAN-LYMPHOBLASTS; CELLS; CARCINOMA; MECHANISM; CULTURE; HOMOLOG	Hereditary Non-Polyposis Colon Cancer (HNPCC) tumors and some sporadic colon cancers acquire somatic changes in the length of microsatellite sequences, We hypothesized that this 'replication error' (RER) phenotype in these cancers reflects a more general defect which should result in hypermutability of expressed genes. To test this hypothesis mutations of hprt were studied in RER and non-PER tumor cell lines. Increased mutation rates of greater than 100-fold were found in RER compared to non-RER lines. Heterogeneity within the RER group suggests the likely existence of different classes of RER tumors. One non-REP demonstrated a greater than 10-fold increase mutation rate, suggesting that a novel mutator phenotype may exist in some non-PER tumors.	UNIV CLEVELAND HOSP,DEPT PATHOL,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,DEPT MED,CLEVELAND,OH 44106; UNIV CLEVELAND HOSP,IRELAND CANC CTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231	Case Western Reserve University; Johns Hopkins University; Johns Hopkins Medicine				Parsons, Ramon/0000-0002-6656-3514	NCI NIH HHS [CA 54031, R01 CA 57208, R29 CA 51504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA054031, R29CA051504, R01CA057208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; BRONNER CE, 1994, NATURE, V17, P258; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; Glantz S.A., 1981, PRIMER BIOSTATISTICS, V2nd ed.; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Luria SE, 1943, GENETICS, V28, P491; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; WILLSON JKV, 1987, CANCER RES, V47, P2704; WOTRING LL, 1980, CANCER RES, V40, P1458; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994	30	225	237	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					33	37						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824277				2022-12-28	WOS:A1995QA98000005
J	LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL				LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL			IDENTIFICATION OF SOLUBLE AND MEMBRANE-BOUND ISOFORMS OF THE MURINE FLT3 LIGAND GENERATED BY ALTERNATIVE SPLICING OF MESSENGER-RNAS	ONCOGENE			English	Article						FT13 LIGAND; GROWTH FACTOR; GENE LOCATION; TYROSINE KINASE RECEPTOR; HEMATOPOIESIS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; KIT-LIGAND; MOLECULAR-CLONING; HUMAN CSF-1; GENE; MOUSE; TRANSMEMBRANE; ORGANIZATION	We have recently described a novel hematopoietic growth factor, referred to as the flt3 ligand, that stimulates the proliferation of sub-populations of hematopoietic cells that are enriched for stem and progenitor cells, This factor is a transmembrane protein that undergoes proteolytic cleavage to generate a soluble form of the protein. We have isolated additional flt3 ligand isoforms by PCR that contain an extra exon and encode what are predicted to be either a soluble form of the ligand or a longer version of the transmembrane protein. We have also isolated cDNAs from murine T cell libraries that encode an isoform of the flt3 ligand that has an unusual C-terminus, This isoform results from a failure to splice out an intron during mRNA processing. The protein encoded by this cDNA is expressed on the cell surface, where it is biologically active. However, this novel isoform does not appear to give rise to a soluble form of the protein, Regulation of mRNA splicing is likely to control the generation of cell bound or soluble forms of this hematopoietic growth factor, Genetic mapping studies localize the gene encoding the flt3 ligand to the proximal portion of mouse chromosome 7 and to human chromosome 19q13.3.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine	LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Green EL, 1981, GENETICS PROBABILITY, P77; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUANG EJ, 1990, CELL, V5, P225; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LAW CL, 1993, J IMMUNOL, V151, P175; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LU HS, 1991, J BIOL CHEM, V266, P8102; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1991, BLOOD CELL GROWTH FACTORS : THEIR PRESENT AND FUTURE USE IN HEMATOLOGY AND ONCOLOGY, P183; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SIRACUSA LD, 1991, GENETICS, V127, P169; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	32	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					149	157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824267				2022-12-28	WOS:A1995QA98000017
J	TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP				TSUZUKI, T; TAKAHASHI, M; ASAI, N; IWASHITA, T; MATSUYAMA, M; ASAI, JP			SPATIAL AND TEMPORAL EXPRESSION OF THE RET PROTOONCOGENE PRODUCT IN EMBRYONIC, INFANT AND ADULT-RAT TISSUES	ONCOGENE			English	Note						C-RET; RECEPTOR TYROSINE KINASE; RAT EMBRYOGENESIS; NERVOUS SYSTEM; EXCRETORY SYSTEM	PROTOONCOGENE PRODUCTS; SEQUENCE SIMILARITY; TYROSINE KINASE; CADHERIN; NEUROBLASTOMA; MUTATIONS; CLONING; CELLS; CDNA	Immunohistochemical analysis with the anti-Ret antibody was performed to investigate the expression of the c-ret proto-oncogene product (c-Ret protein) in embryonic, infant and adult rat tissues. During embryogenesis, the c-Ret expression became detectable by day 11.5 in the developing peripheral and central nervous systems as well as in the excretory system. In the peripheral nervous system of the trunk, it was expressed at high levels in the enteric neuroblasts and the autonomic and dorsal root ganglia, c-Ret positive cells appeared in the mesenchyme around the foregut and the dorsal aorta at day 11.5 and formed the myenteric plexus of the whole embryonic gut and the sympathetic trunk at later stages respectively. Examination of the cranial region revealed that the c-Ret protein was expressed in neural crest cells migrating from rhombomere 4 at day 11.5 and then became positive in the facial, glossopharyngeal and vagus cranial ganglia at day 12.5-13.5. After day 16.5 of gestation, the c-Ret expression was also observed in the trigeminal ganglion. In the central nervous system, the c-Ret protein was expressed in the neuroepithelial cells of the ventral neural tube (day 11.5-14.5), the motor neurons of the spinal cord (day 18.5) as well as in the embryonic neuroretina (day 18.5). In addition to the nervous system, the c-Ret expression was detected in the nephric duct (day 11.5), the ureteric bud (day 13.5) and the collecting ducts of the kidney (day 16.5). After birth, neurons in the nervous systems mentioned above continued to express the c-Ret protein at variable levels while no c-Ret expression was observed in the kidney of adult rats. Furthermore, the c-Ret expression was found in the acinar cells of the salivary gland, the epithelial cells of the thymus and the follicular dendritic cells of the spleen and lymph node in infant and adult rats. A small number of adrenal chromaffin cells and thyroid C cells also expressed the c-Ret protein. These results demonstrated that the c-Ret protein is expressed in several cell lineages in spatially and temporally controlled manner throughout life of the rat.	NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014	Takahashi, Masahide/0000-0002-2803-2683; Tsuzuki, Toyonori/0000-0002-4855-4366				ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1993, MOL BIOL EVOL, V10, P539; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	21	200	204	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					191	198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824273				2022-12-28	WOS:A1995QA98000022
J	OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ				OLSON, DC; MARECHAL, V; MOMAND, J; CHEN, JD; ROMOCKI, C; LEVINE, AJ			IDENTIFICATION AND CHARACTERIZATION OF MULTIPLE MDM-2 PROTEINS AND MDM-2-P53 PROTEIN COMPLEXES	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; P53 PROTEIN; WILD-TYPE; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; GENE-EXPRESSION; T-ANTIGEN; SV40; PRODUCT	A protein product of the mdm-2 oncogene (p90) has been recently shown to associate with the protein encoded by the tumor-suppressor gene p53. The mdm-2 gene was originally identified as a gene amplified in a spontaneously transformed Balb/c 3T3 cell line (3T3DM). This report describes the characterization of mdm-2 gene products and their interactions with the p53 protein. Polyclonal and monoclonal antibodies were generated against murine and human mdm-2 protein. These antibodies detected the mdm-2 p90 protein and at least four additional polypeptides (p85, p76, p74, p58-p57) in cultured cells. These additional proteins may arise from different spliced mRNA forms of the mdm-2 gene or post-translational modifications of the mdm-2 protein. The monoclonal antibodies distinguished at least three sets of mdm-2 proteins with distinct combinations of epitopes (p90 and p85; p76 and p74; p58-57). One or two of these proteins forms a complex with the p53 protein (p90, p58). These mdm-2 proteins were found to be overexpressed in 3T3DM cells and a subset of these proteins were complexed with p53. In 3T3DM cells, p90, like p53, had a short half-life of approximately 20 min and was localized to the cell nucleus. In resting cells stimulated with serum p90 levels and p90/p53 complex levels increased in the late G1 phase of the cell cycle. The p90 mdm-2 protein could regulate p53 activity in the late G1 phase of the cell cycle.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University			Momand, Jamil/F-8154-2012; marechal, vincent/P-7719-2017		NCI NIH HHS [CA09258-07, P01 CA41086, 5 F32 CA08771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008771, P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JH, 1993, UNPUB; CORDONCARDO C, 1993, UNPUB; ELDEIRY WS, 1992, NAT GENET, V1, P44; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WU X, 1993, UNPUB; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	33	231	235	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2353	2360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689721				2022-12-28	WOS:A1993LT36800005
J	CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ				CHANG, JH; WILSON, LK; MOYERS, JS; ZHANG, K; PARSONS, SJ			INCREASED LEVELS OF P21RAS-GTP AND ENHANCED DNA-SYNTHESIS ACCOMPANY ELEVATED TYROSYL PHOSPHORYLATION OF GAP-ASSOCIATED PROTEINS, P190 AND P62, IN C-SRC OVEREXPRESSORS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; EPIDERMAL GROWTH-FACTOR; RAS P21 GTPASE; SIGNAL TRANSDUCTION; MITOGENIC RESPONSIVENESS; CELLULAR PROTEINS; KINASE; TRANSFORMATION; RECEPTOR; CELLS	While examining the role of pp60c-src in cellular proliferation, we found that overexpression of c-src in C3H10T1/2 murine fibroblasts results in an augmented mitogenic response to epidermal growth factor (EGF) [Luttrell, D.K., Luttrell, L.M. & Parsons, S.J. (1988). Mol. Cell. Biol., 8, 497-501; Wilson, L.K., Luttrell, D.K., Parsons, S.J. (1989). Mol. Cell. Biol., 9, 1536-1544] and enhanced tyrosyl phosphorylation of specific cellular proteins [Wilson, L.K. & Parsons, S.J. (1990). 5, 1471-14801. Here we identify two of these proteins as the GAP (GTPase-activating protein of p21ras)associated proteins, p190 and p62. Evidence is presented to support the notion that, in 10T1/2 fibroblasts, p190 is a preferred substrate of pp6Oc-src, while p62 is preferentially phosphorylated by the EGF receptor. First, the phosphotyrosine content of p190 in quiescent cells is three- to fivefold higher in c-src overexpressors than in control cells and is not altered by growth factor treatment. In contrast, tyrosyl phosphorylation of p62 is undetectable in quiescent cells and transiently observable upon EGF addition. Second, the phosphotyrosine content of p190 in cells overexpressing defective pp60c-src is reduced in comparison with wild-type (wt) c-src overexpressors, while that of p62 is significantly less affected. Further studies revealed that tyrosyl phosphorylation of p190 and p62 is not required for GAP complex formation, as equal amounts of p190 and p62 proteins could be detected in GAP complexes from wt and variant c-src overexpressors both before and after EGF stimulation. However, analysis of GTP-bound p21ras revealed higher basal and EGF-stimulated levels in c-src overexpressors than in control cells. Taken together, these results suggest that one mechanism by which pp60c-src may contribute to early events in the EGF-induced mitogenic pathway in 10T1/2 fibroblasts is by increasing the level of GAP-associated p190 and p62 tyrosyl phosphorylation, which in turn results in higher levels of p21ras-GTP.	UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,INST MOLEC BIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HEIDARAN MA, 1992, ONCOGENE, V7, P147; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MCCORMICK F, 1990, CELL, V56, P5; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PARSONS JT, 1990, TRENDS GENET, V6, P169; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	39	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					959	967						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681161				2022-12-28	WOS:A1993KT22000018
J	LINDBERG, RA; FISCHER, WH; HUNTER, T				LINDBERG, RA; FISCHER, WH; HUNTER, T			CHARACTERIZATION OF A HUMAN PROTEIN THREONINE KINASE ISOLATED BY SCREENING AN EXPRESSION LIBRARY WITH ANTIBODIES TO PHOSPHOTYROSINE	ONCOGENE			English	Article							TYROSINE KINASE; CONSERVED FEATURES; GENE-PRODUCT; CDNA CLONES; IDENTIFICATION; SERINE; PHOSPHORYLATION; FAMILY; AUTOPHOSPHORYLATION; ACID	We have studied the activity and substrate specificity of the catalytic domain of a protein kinase that was isolated in a screen of a human lambdagt11 fibroblast cDNA library with anti-phosphotyrosine antibodies. The sequence of this protein kinase would predict that it is a protein serine/threonine kinase, which at first seemed incongruent with the cloning method. However, recent reports indicate that some protein kinases can phosphorylate both tyrosine and serine/threonine residues. To determine whether this protein kinase, which we call PYT (for phosphotyrosine picked threonine kinase), was a dual-specificity protein kinase we investigated its substrate specificity when expressed in bacteria. The catalytic domain was active as a protein kinase when expressed from any of several promoters and when expressed as a TrpE fusion protein. All experiments that resulted in an active protein kinase, as judged by incorporation of P-32 by metabolic labeling, also resulted in the generation of proteins that were recognized by anti-phosphotyrosine antibodies. Phosphoamino acid analyses of the metabolically labeled proteins that were recognized by the antibodies consistently yielded large amounts of phosphothreonine and only trace amounts of phosphotyrosine. We mapped the phosphorylation sites in the phosphorylated PYT protein and found only phosphothreonine; 90% of the radioactivity mapped to a threonine in the region autophosphorylated by many protein kinases. These data demonstrate that PYT is primarily a protein threonine kinase, but that it can phosphorylate tyrosine to a small extent, making it a potential dual-specificity protein kinase.	SALK INST, PEPTIDE LAB, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	LINDBERG, RA (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; LINDBERG RA, 1988, ONCOGENE, V3, P629; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YANSURA DG, 1990, METHOD ENZYMOL, V185, P161	29	35	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					351	359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678926				2022-12-28	WOS:A1993KN00600014
J	ELKIND, NB; GOLDFINGER, N; ROTTER, V				ELKIND, NB; GOLDFINGER, N; ROTTER, V			SPOT-1, A NOVEL NLS-BINDING PROTEIN THAT INTERACTS WITH P53 THROUGH A DOMAIN ENCODED BY P(CA)(N) REPEATS	ONCOGENE			English	Article						NLS; P(CA)(N) REPEATS; P53; EXPRESSION LIBRARY	NUCLEAR-LOCALIZATION SIGNALS; WILD-TYPE P53; NF-KAPPA-B; CELL-CYCLE; LOCATION SIGNAL; CYTOPLASMIC RETENTION; KARYOPHILIC PROTEINS; COLORECTAL-CANCER; ESCHERICHIA-COLI; HUMAN-DISEASE	Nuclear Localization Signals (NLS) have been found to mediate the import of proteins into the nucleus. Proteins interacting directly with NLS control the subcellular localization of nucleophillic proteins. The p53 protein is spatially regulated throughout the cell cycle and this regulation has been shown to be dependent on the presence of its NLS sequences. We identified three novel cDNA clones that were isolated from an expression library because they encode polypeptides that bind a synthetic peptide containing the major NLS of p53 (NLS I). These clones were found to share a common domain encoded by p(CA)(n) repeats; a simple sequence length polymorphism (SSLP). This is the first report where p(CA)(n) repeats mere found to encode protein. One cDNA clone encodes a fun length, 16 kDa protein, designated spot-1, that is represented in cells predominantly as oligomers. spot-1 interacts with the NLS I of p53 through its p(CA)(n) repeat. Cell fractionation and immunofluorescence analysis demonstrated that spot-1 is a nuclear protein which, in fibroblasts, co-localizes with p53.	WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LI RH, 1992, EXP CELL RES, V202, P355, DOI 10.1016/0014-4827(92)90085-M; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEIER UT, 1992, CELL, V70, P127; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SHAN XY, 1994, J CELL BIOL, V126, P853, DOI 10.1083/jcb.126.4.853; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; ZERRAHN J, 1992, ONCOGENE, V7, P1371	86	13	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					841	851						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675445				2022-12-28	WOS:A1995RU79800004
J	STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A				STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A			GENOMIC STRUCTURE, EXPRESSION AND MUTATIONAL ANALYSIS OF THE P15 (MTS2) GENE	ONCOGENE			English	Note						TUMORGENESIS; CDK INHIBITOR; CELL CYCLE	INHIBITION; KINASES; P21	The P15 gene (MTS2) encodes a cyclin-dependent kinase (CDK) inhibitor with considerable sequence identity and biochemical similarity to the CDK inhibitor p16. It is closely linked to the Pld gene (MTS1) and is homozygously deleted in many tumor cell lines. These features suggest that p15 may be a tumor suppressor. We have determined the genomic structure of P15 and examined its pattern of mRNA expression. In addition, we have shown that ectopic expression of p15 inhibits growth of tumor-derived cell lines. We have also searched for P15 mutations in tumor cell lines and in 9p21-linked melanoma kindreds. Other than the previously described homozygous deletions, no mutations of P15 were found. Collectively, these observations suggest a role for p15 in growth regulation, but a limited role for p15 in tumor progression.	MYRIAD GENET INC, SALT LAKE CITY, UT 84018 USA; UNIV UTAH, MED CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah				albright, lisa/0000-0003-2602-3668				CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P6078; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HORI T, 1987, BLOOD, V70, P1069; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1994, CSH S QUANT BIOL, V59, P38; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LIU Q, 1995, ONCOGENE, V10, P1061; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, IN PRESS CANCER RES; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	34	112	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675459				2022-12-28	WOS:A1995RU79800021
J	MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A				MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A			DIFFERENT STRUCTURAL REQUIREMENTS WITHIN THE SWITCH-II REGION OF THE RAS PROTEIN FOR INTERACTIONS WITH SPECIFIC DOWNSTREAM TARGETS	ONCOGENE			English	Article						RAS; PI-3 KINASE; DOWNSTREAM TARGETS	NUCLEOTIDE-FREE; GTP HYDROLYSIS; P21; DOMAIN; GAP; NEUROFIBROMATOSIS; IDENTIFICATION; ACTIVATION; EXPRESSION; MUTATIONS	Ras proteins function through the formation of specific complexes with Raf-1, B-raf, PI-3 kinase and RalGDS. These interactions all require Ras-GTP with an intact effector binding domain (Switch I region). We have examined the requirements of the Switch II region (amino acids 60-72) for the production of stable interactions between Ras and its downstream effecters. A point mutation at position 65 or 64 combined with additional mutations at either position 65 or 71 rendered nucleotide-free Ras protein unable to stably interact with Ras specific guanine nucleotide exchange factors. Ha-Ras containing point mutations at positions 65 and 71 possessed a twofold higher affinity for B-raf and consequently MEK1. The point mutation at 64, in combination with additional point mutations at either position 65 or 71, resulted in a protein which failed to interact with either PI-3 kinase or neurofibromin, though these Ras mutants effectively bound both Raf-1 and B-raf. An activated form of Ras, Q61L-Ras, associated with all effector proteins independent of the bound guanine nucleotide. Q61L-Ras-GDP was almost as effective as wild type Ras-GMPPNP in the in vitro activation of MEK1 and MAP kinase. Competitive studies with the catalytic domain of neurofibromin, NF1-GRD, demonstrated that its interaction with Ras-GMPPNP is mutually exclusive with both Raf-1 and B-raf. These data suggest that rasGAP and neurofibromin are unable to downregulate Ras-GTP complexed to Raf-1 or B-raf.	CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195; BRISTOL MYERS & SQUIBB RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; AGOURON PHARMACEUT,SAN DIEGO,CA 92191; SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN,DENMARK	Cleveland Clinic Foundation; Bristol-Myers Squibb; Cleveland Clinic Foundation; Pfizer; Merck & Company; Schering Plough Corporation; University of Copenhagen			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAZENET CE, 1994, ONCOGENE, V9, P517; BUSS JE, 1989, BIOCHEM SOC T, V17, P867, DOI 10.1042/bst0170867; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; HALL A, 1986, J BIOL CHEM, V261, P963; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1993, ONCOGENE, V8, P2583; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8693; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOODIE SA, 1994, MOL CELL BIOL, V14, P6944; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1989, GUANINE NUCLEOTIDE B, P165; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	65	65	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					447	454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630628				2022-12-28	WOS:A1995RN53000004
J	FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D				FALASCA, M; SILLETTA, MG; CARVELLI, A; DIFRANCESCO, AL; FUSCO, A; RAMAKRISHNA, V; CORDA, D			SIGNALING PATHWAYS INVOLVED IN THE MITOGENIC ACTION OF LYSOPHOSPHATIDYLINOSITOL	ONCOGENE			English	Article						PHOSPHOLIPASE A(2); LYSOLIPIDS; LYSOPHOSPHATIDIC ACID; GLYCEROPHOSPHOINOSITOLS; THYROID; FRTL5 CELLS	FRTL-5 THYROID-CELLS; GROWTH FACTOR-I; LYMPHOCYTE-T ACTIVATION; GTP-BINDING PROTEINS; MURINE SARCOMA-VIRUS; EPITHELIAL-CELLS; IODIDE EFFLUX; ARACHIDONIC-ACID; PHOSPHOLIPASE-C; PERTUSSIS TOXIN	Lysophosphatidylinositol has been previously shown to stimulate cell proliferation in differentiated and in K-ras transformed thyroid cells. Increased levels of lysophosphatidylinositol, but not lysophosphatidylcholine or lysophosphatidylethanolamine, are present in thyroid as well as in other ras-transformed cell lines. We have now investigated the mechanism of action of this lysolipid by analysing its effects in a differentiated thyroid cell line. Lysophosphatidylinositol did not increase the levels of cAMP, the main stimulator of cell proliferation in the thyroid, whereas it stimulated phosphoinositide breakdown, mobilization of cytosolic Ca2+ and arachidonic acid release, suggesting that it activates both phospholipases C and A(2). None of the effects of lysophosphatidylinositol were prevented by pretreatment of cells with pertussis toxin. Instead, the tyrosine kinase inhibitors, tyrphostins AG18 and AG561, completely blocked its mitogenic action. The effects of lysophosphatidylinositol were distinguishable from those of the well known mitogen lysophosphatidic acid, which affected differently the signalling pathways analysed and was not mitogenic in ras-transformed cells. These results suggest that the mitogenic activity of lysophosphatidylinositol is associated with the activation of phospholipase C and phospholipase A(2) and is relatively specific for ras-transformed cells.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,CELLULAR & MOLEC ENDOCRINOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CHIM,I-88100 CALABRIA,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Universita Mediterranea di Reggio Calabria			Corda, Daniela/K-6385-2016; Falasca, Marco/S-4020-2016	Corda, Daniela/0000-0002-3614-751X; Falasca, Marco/0000-0002-9801-7235; Fusco, Alfredo/0000-0003-3332-5197				ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ALONSO T, 1990, BIOCHEM BIOPH RES CO, V171, P14, DOI 10.1016/0006-291X(90)91349-W; AMBESIIMPIOMBAT.FS, 1989, FRTL5 TODAY; AMBESIIMPIOMBAT.FS, 1980, P NATL ACAD SCI USA, V77, P3455; ASAOKA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1378, DOI 10.1016/0006-291X(91)91046-F; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARAN DT, 1987, ENDOCRINOLOGY, V122, P930; BENTON AM, 1982, BLOOD, V60, P642; BERMAN MI, 1987, ARCH BIOCHEM BIOPHYS, V253, P249, DOI 10.1016/0003-9861(87)90658-8; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIZZARRI C, 1990, P NATL ACAD SCI USA, V87, P4889, DOI 10.1073/pnas.87.12.4889; BIZZARRI C, 1994, EUR J BIOCHEM, V219, P837, DOI 10.1111/j.1432-1033.1994.tb18565.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONE EA, 1986, ENDOCRINOLOGY, V119, P2193, DOI 10.1210/endo-119-5-2193; BURCH RM, 1986, J BIOL CHEM, V261, P1236; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CORDA D, 1985, J BIOL CHEM, V260, P9230; CORDA D, 1989, ADV EXP MED BIOL, V261, P245; CORDA D, 1985, EXP EYE RES, V40, P575, DOI 10.1016/0014-4835(85)90079-X; CORDA D, 1987, ENDOCRINOLOGY, V120, P1152, DOI 10.1210/endo-120-3-1152; Cucchi P., 1992, Acta Medica Romana, V30, P176; DIGIROLAMO M, 1991, ACTA ENDOCRINOL-COP, V125, P192, DOI 10.1530/acta.0.1250192; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; FIELD JB, 1987, BIOCHEM J, V247, P519, DOI 10.1042/bj2470519; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gennis R. B., 1989, BIOMEMBRANE, P235; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JALINK K, 1990, J BIOL CHEM, V265, P12232; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; LORENZET R, 1992, THROMB HAEMOSTASIS, V68, P357; MALAGODI MH, 1974, EUR J PHARMACOL, V27, P25, DOI 10.1016/0014-2999(74)90198-8; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; MARSH D, 1993, BIOMEMBRANE, V1, P1; MARTIN SC, 1992, J MEMBRANE BIOL, V125, P243; MCHOWAT J, 1993, J BIOL CHEM, V268, P15605; METZ SA, 1988, AM J MED, V85, P9, DOI 10.1016/0002-9343(88)90393-2; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; OKAJIMA F, 1988, ENDOCRINOLOGY, V123, P1035, DOI 10.1210/endo-123-2-1035; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO K, 1992, BIOCHEM J, V283, P281, DOI 10.1042/bj2830281; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; SHINITZKY M, 1976, BIOCHIM BIOPHYS ACTA, V433, P133, DOI 10.1016/0005-2736(76)90183-8; SMALLRIDGE RC, 1991, ENDOCRINOLOGY, V129, P542, DOI 10.1210/endo-129-1-542; TAHARA K, 1991, J BIOL CHEM, V266, P440; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TORNQUIST K, 1991, MOL CELL ENDOCRINOL, V79, P147, DOI 10.1016/0303-7207(91)90105-2; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TRAMONTANO D, 1986, ENDOCRINOLOGY, V119, P940, DOI 10.1210/endo-119-2-940; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VALITUTTI S, 1991, CELL SIGNAL, V3, P321, DOI 10.1016/0898-6568(91)90061-X; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; VOGT W, 1963, BIOCHEM PHARMACOL, V12, P415, DOI 10.1016/0006-2952(63)90074-1; WANG WQ, 1992, J CHROMATOGR-BIOMED, V581, P139, DOI 10.1016/0378-4347(92)80457-2; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346	76	47	49	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2113	2124						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784056				2022-12-28	WOS:A1995RB70300006
J	JAMAL, S; ZIFF, EB				JAMAL, S; ZIFF, EB			RAF PHOSPHORYLATES P53 IN-VITRO AND POTENTIATES P53-DEPENDENT TRANSCRIPTIONAL TRANSACTIVATION IN-VIVO	ONCOGENE			English	Article						RAF; P53; TRANSCRIPTION; PHOSPHORYLATION; KINASE; BACULOVIRUS	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE ELEMENT; MAP-KINASE; V-RAF; GENE-EXPRESSION; MOUSE P53; C-FOS; ACTIVATION	Using recombinant baculovirus expressed p53 and Raf proteins, we show that activated Raf-1 kinase can phosphorylate mouse p53 in vitro. We also show that co-expression of vRaf and p53 in NIH3T3 fibroblasts, potentiates the ability of p53 to transactivate a minimal promoter with a p53 cognate DNA binding site. A dominant negative mutant of Raf inhibits the transactivation function of p53 in NIH3T3 fibroblasts. Incubation of Raf-1 kinase with a series of p53 derived synthetic peptides maps the Raf-1 phosphorylation sites to the 27 amino terminal residue region of p53 which coincides with the transactivation domain. Phosphorylation occurs on serines which are phosphorylated in vivo. Our results suggest that the transactivation function of p53 can be regulated by a signaling cascade involving Raf.	NYU,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUSCHER D, 1993, ONCOGENE, V8, P3323; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAISS S, 1990, ONCOGENE, V5, P845; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LISSOOS TW, 1993, J BIOL CHEM, V268, P25132; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; METZ R, 1991, ONCOGENE, V6, P2165; MIHALY A, 1991, BRAIN RES, V547, P309, DOI 10.1016/0006-8993(91)90976-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OLAH Z, 1991, EXP BRAIN RES, V84, P403; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	75	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2095	2101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784054				2022-12-28	WOS:A1995RB70300004
J	PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B				PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B			CHARACTERIZATION OF MEK1 PHOSPHORYLATION BY THE V-MOS PROTEIN	ONCOGENE			English	Note						MOS ONCOGENE; MAP KINASE KINASE; PROTEIN KINASE ACTIVATION; PHOSPHORYLATION SITES	MAP KINASE-KINASE; MAMMALIAN SOMATIC-CELLS; XENOPUS-OOCYTES; IN-VITRO; METAPHASE ARREST; ONCOGENE PRODUCT; 3T3 CELLS; ACTIVATION; MATURATION; INDUCTION	Activation of MAP kinase/Erk Kinase (MEK) via direct phosphorylation by Mos may be crucial for cellular transformation by the activated c-mos or v-mos gene, Recent studies on a number of different protein kinases showed that phosphorylation within a subdomain of the catalytic domain may represent a common mode of activation, In this regard, activation of MEK1 by Raf involves phosphorylation of serine residues 218 and 222, Here we show that recombinant kinase-inactive MEK1 is phosphorylated by v-Mos with equal efficiency at both Ser 218 and Ser 222 in vitro, Tryptic phosphopeptide analysis of glutathione-S-transferase (GST)-MEK1 K97R and its alanine-for-serine mutants indicated that Ser 222 is the preferred phosphorylation site. Wild-type GST-MEK1 was phosphorylated at the same sites but contained a significantly lower amount of doubly phosphorylated species then its K97R kinase-inactive mutant, The ratio of GST-MEK1 species phosphorylated at two serines to those phosphorylated at one serine was similar in auto-phosphorylated and v-Mos-phosphorylated GST-MEK1, Consistent with the in vitro data, phosphopeptide mapping of MEK1 immunoprecipitated from mos transformed cells showed an increased amount of singly phosphorylated phosphopeptide compared to nontransformed cells, MEK1 was found to be more highly activated in NM3T3 cells transformed by an activated c-mos or v-mos gene than in cells growing normally in medium containing serum, Our data indicate that Mos activates MEK1 in vitro as well as in vivo by phosphorylating Ser 222.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU JX, 1990, ONCOGENE, V5, P171; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	35	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1683	1688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731726				2022-12-28	WOS:A1995QU68100028
J	SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H				SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H			FRA-2 PROMOTER CAN RESPOND TO SERUM-STIMULATION THROUGH AP-1 COMPLEXES	ONCOGENE			English	Article						TRANSCRIPTION; AUTOREGULATION; FRA-2; AP-1; SERUM-STIMULATION	C-FOS; ANTISENSE RNA; JUN PROTEINS; GENE FAMILY; CELLS; DNA; EXPRESSION; ONCOGENE; GROWTH; TRANSCRIPTION	fra-2 (fos-related antigen-2) expression is detected at a basal level even in growth-arrested chicken embryo fibroblasts (CEF), but upon serum-stimulation high levels of its transcripts are transiently observed. This induction is delayed and prolonged compared to that of c-fos. Transient expression experiments in CEF using a series of constructs of chicken fra-2 promoter region linked to the CAT reporter gene indicated previously that serum response element (SRE) is not required for full serum inducibility. In this report, we show that constructs in which the CRE-Like sequence and both AP-1 binding sites are disrupted lack serum inducibility, suggesting that either of these enhancers is important in serum induction of fra-2. In growth-arrested CEF, small amounts of Fra-2/c-Jun complex bind to the AP-1 consensus sequences in fra-2 promoter, while a significant part of the enhanced AP-1 binding activity after 60-120 min of serum stimulation is attributable to c-Fos/c-Jun heterodimer. At later times Fra-2/c-Jun again becomes the main complex. Transient expression assays in F9 cells indicated that c-Fos/c-Jun heterodimers have strong stimulatory effects on fra-2 promoter activity, while Fra-2/c-Jun complex has lower transcriptional activity than that of c-Jun homodimer. These results suggest that c-Fos (induced at earlier times) and c-Jun proteins are at least partly responsible for serum-induced expression of fra-2.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Sonobe, Martha/I-2877-2015					CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1993, ONCOGENE, V8, P695; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; VANBEVEREN C, 1983, CELL, V27, P1241; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; YANISCHPERRON C, 1985, GENE, V4, P103; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					689	696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862446				2022-12-28	WOS:A1995QH61200008
J	SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS				SUN, Y; HILDESHEIM, A; LANIER, AEP; CAO, Y; YAO, KT; RAABTRAUB, N; YANG, CS			NO POINT MUTATION BUT DECREASED EXPRESSION OF THE P16/MTS1 TUMOR-SUPPRESSOR GENE IN NASOPHARYNGEAL CARCINOMAS	ONCOGENE			English	Note						NASOPHARYNGEAL CARCINOMA; TUMOR SUPPRESSOR GENE; GENE MUTATION AND EXPRESSION	P53; PROGRESSION; LINKAGE; REGION; PCR; DNA	Nasopharyngeal carcinoma (NPC) is a malignancy which occurs at high incidence in southern China and southeast Asia. The molecular mechanism of this disease, however, is not well understood. Recently, a homozygous deletion and/or loss of heterozygosity on chromosome 9p21-22 was found in several primary NPCs (Huang et al., Cancer Res, 54: 4003-4006, 1994), suggesting that a potential tumor suppressor gene(s) residing in this region may play a role in nasopharyngeal carcinogenesis. Since p16/MTS1, a potential tumor suppressor gene, whose mutations/deletions are frequently found in variety of tumor cells, was mapped to chromosome 9p21, we investigated the possible involvement of this gene in the development of NPC by mutational and Northern blot analysis. SSCP-direct sequencing revealed no point mutations of the p16/MTS-1 gene in any of 42 primary NPC biopsies from three geographical regions nor in two NPC cell lines. We did, however, observe a codon 140(ala-->thr) polymorphism in the gene, which has been previously reported as a point mutation. Furthermore, Northern analysis revealed a decreased expression of the p16/MTS1 gene in two out of two NPC cell lines as compared with immortalized/nontransformed cell lines. These results suggest that down regulation rather than a point mutation of the p16/MTS1 gene may play a role in the genesis of NPC.	NCI, FREDERICK CANC RES & DEV CTR, CELL BIOL SECT, VIRAL CARCINOGENESIS LAB, FREDERICK, MD USA; NCI, ENVIRONM EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; US PHS, INDIAN HLTH SERV, ALASKA AREA NAT HLTH SERV, ANCHORAGE, AK USA; HUNAN MED UNIV, INST HUMAN CANC, CHANGSHA, PEOPLES R CHINA; UNIV N CAROLINA, DEPT MICROBIOL, CHAPEL HILL, NC USA; NATL TAIWAN UNIV, COLL MED, INST MICROBIOL, TAIPEI 10764, TAIWAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Public Health Service; Central South University; University of North Carolina; University of North Carolina Chapel Hill; National Taiwan University								BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HUANG DP, 1994, CANCER RES, V54, P4003; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; MORI T, 1994, CANCER RES, V54, P3396; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1993, ONCOGENE, V8, P791; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, BIOTECHNIQUES, V15, P372; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; SUN Y, 1992, BIOTECHNIQUES, V12, P639; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VANDERRIET P, 1994, CANCER RES, V54, P1156; YA C, 1991, MOL CARCINOGEN, V4, P297, DOI 10.1002/mc.2940040408	23	71	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					785	788						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862458				2022-12-28	WOS:A1995QH61200021
J	TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D				TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D			AUTOCRINE MITOGEN IGEGF COOPERATES WITH C-MYC OR WITH THE HCS LOCUS DURING HEPATOCARCINOGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						LIVER CANCER; TRANSGENIC MICE; EGF; C-MYC; ONCOGENE COOPERATION	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; CHEMICAL CARCINOGENESIS; LIVER NEOPLASIA; TGF-ALPHA; GENE; TUMORS; OVEREXPRESSION; ONCOGENESIS; PANCREAS	Hepatocarcinogenesis is deterministic in transgenic mice expressing in the liver gene construct Alb-DS4 that encodes\autocrine growth factor IgEGF (D Stern et al, (1987), Science 235: 321-324), causing their death within 7.1 months. Hepatic expression of construct AAT-myc encoding murine c-myc causes liver cancer in 44% of the mice at 14.8 months. Cooperation of these genes was evident in CD2F1 transgenics bearing Alb-DS4 plus AAT-myc, in which accelerated hepatocellular carcinoma (HCC) formation caused death of all mice within 4.4 months. Alb-DS4 also cooperates with the Hcs locus, which in C3H/HeJ mice mediates high susceptibility to spontaneous hepatocarcinogenesis, causing accelerated formation of HCC to which mice succumbed at 5.1 months. Thus, genes that predispose to HCC formation cooperate in transgenic mice and their interaction is a key to understand mechanisms that cause liver cancer.	FRAUNHOFER INST TOXICOL & MOLEK BIOL,DEPT CELL BIOL,D-30625 HANNOVER,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Fraunhofer Gesellschaft; Heinrich Pette Institute; University of Hamburg; Transgene SA			Kay, Graham F/A-4130-2011					AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5224; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOFFMANN B, 1990, J CELL PHYSIOL, V142, P149, DOI 10.1002/jcp.1041420118; HOGAN B, 1986, MANIPULATING MOUSE E; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HWANG DL, 1990, REGUL PEPTIDES, V29, P103, DOI 10.1016/0167-0115(90)90073-6; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE GH, 1992, CANCER RES, V52, P5162; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MURAKAMI H, 1993, CANCER RES, V53, P1719; ORIAN JM, 1990, JNCI-J NATL CANCER I, V82, P393, DOI 10.1093/jnci/82.5.393; OSULLIVAN JF, 1991, NATURE, V352, P200, DOI 10.1038/352200a0; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Sambrook J, 1989, MOL CLONING LABORATO; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHULTEHERMANN R, 1985, ARCH TOXICOL, V57, P147, DOI 10.1007/BF00290879; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TAKAGI H, 1992, CANCER RES, V52, P5171; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	34	56	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					765	768						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862454				2022-12-28	WOS:A1995QH61200017
J	HUANG, RP; ADAMSON, ED				HUANG, RP; ADAMSON, ED			A BIOLOGICAL ROLE FOR EGR-1 IN CELL-SURVIVAL FOLLOWING ULTRA-VIOLET IRRADIATION	ONCOGENE			English	Article						ANTISENSE EGR-1; NIH3T3; IMMUNOBLOTTING; OXIDATIVE STRESS; DNA DAMAGE	IONIZING-RADIATION; CANCER MORTALITY; P53 GENE; C-FOS; PROTEIN; UV; ACTIVATION; INDUCTION; ELEMENTS; PROMOTER	The response to ultra-violet (u.v.) irradiation varies among cells, but commonly involves the rapid increase in expression of one or more transcription factors. The specific roles of this increased expression are largely unknown. We show here that in mouse NIH3T3 cells, Egr-1 expression is increased two-fold 10 min after u.v. irradiation, rises to a maximum (eightfold induction) after about 2 h and then declines. The expression of p53 protein is also strongly induced but is maximal between 2 to 4 h before declining. In contrast, the expression of c-Fos, and c-Jun proteins are only slightly affected by u.v. The Egr-1 response is independent of the growth state of the cells but depends on tyrosine kinase and protein kinase C activities. c-Ha-Ras is also involved in the induction of Egr-1 in u.v. irradiated cells. Evidence presented suggests that the mechanism for the response involves oxidative stress rather than DNA damage. We show that Egr-1 functions in the protection of cells against u.v. damage since NIH3T3 cells that constitutively; express antisense Egr-1 and consequently cannot produce an Egr-1 response to u.v., grow at a rate 26% less than similarly irradiated parental cells and 36% less than nonirradiated parental cells. This is the second protective role described for Egr-1.			HUANG, RP (corresponding author), LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [P30-CA30199] Funding Source: Medline; NICHD NIH HHS [HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BLAUSTEIN AR, 1994, P NATL ACAD SCI USA, V91, P1791, DOI 10.1073/pnas.91.5.1791; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; BUSCHER M, 1988, ONCOGENE, V3, P301; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DING RC, 1992, J BIOL CHEM, V267, P12804; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORNACE AJ, 1992, ANN REV GENET, V26, P506; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V86, P901; GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORHAM ED, 1989, CAN J PUBLIC HEALTH, V80, P96; GORHAM ED, 1990, INT J EPIDEMIOL, V19, P820, DOI 10.1093/ije/19.4.820; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUANG RP, 1994, J CELL BIOCHEM, V57, P1; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MERCOLA D, 1992, ONCOGENE, V7, P1793; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RACHAL MJ, 1989, NUCLEIC ACIDS RES, V17, P5135, DOI 10.1093/nar/17.13.5135; RONAI ZA, 1988, ONCOGENE, V2, P201; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SATOH MS, 1992, NATURE, V365, P356; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WILSON RE, 1993, ONCOGENE, V8, P3229; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XANTHOUDAKIS S, 1992, EMBO J, V11, P3233; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	47	63	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					467	475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845671				2022-12-28	WOS:A1995QF64800007
J	LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R				LI, YJ; LAURENTPUIG, P; SALMON, RJ; THOMAS, G; HAMELIN, R			POLYMORPHISMS AND PROBABLE LACK OF MUTATION IN THE WAF1-CIP1 GENE IN COLORECTAL-CANCER	ONCOGENE			English	Note						WAF1-CTP1 GENE; POLYMORPHISM; COLORECTAL	GRADIENT GEL-ELECTROPHORESIS; WILD-TYPE P53; ALLELOTYPE; PROTEIN; APOPTOSIS; INHIBITOR; KINASES; P21	WAF1/CIP1, a gene up-regulated by p53 encodes an inhibitor of cyclin-dependent kinases. Induction of WAF1/CIP1 in cells,vith intact p53 is believed to be instrumental in cell cycle arrest and apoptosis caused by DNA damage. In a model system, WAF1/CIP1 has been shown to have tumor suppressive activity. It is not known however whether WAF1/CIP1 is mutated in human primary tumors. Cells from colorectal cancer have been shown to acquire a series of genetic alterations, including frequent p53 mutations. Thus colorectal tumors, particularly those without identified p53 mutations, are good candidate to search for putative WAF1/CIP1 mutations. DNA extracted from 45 tumors, (including 28 tumors for which p53 mutations had previously been searched for and not found) were PCR amplified for exon 2 of WAF1/CIP1. A search for point mutations was performed in each amplified product using a denaturing gradient gel electrophoresis (DGGE) technique which enables the efficient screening of codons 9 to 139 (i.e. 80% of the WAF1/CIP1 coding sequence). TWO different DNA variants were identified and shown to be present in constitutional DNAs of the corresponding patients. The first variant, a C to A transversion at codon 31, changes a serine for an arginine and was detected in eight tumors (18% of the cases). The second variant, detected in a single case (2%) is a silent A to T transversion at the third base of codon 91. DNA extracted from 70 unrelated members from the Centre d'Etude du Polymorphisme Humain (CEPH) was screened for these polymorphisms. The ser/arg polymorphism of codon 31 was detected in seven cases (10%) thus suggesting that it is not associated with a marked colorectal cancer predisposition. The polymorphism on codon 91 was not detected. Two additional variants (arginine to histidine at position 67 and threonine to methionine at position 80) were observed once each in the CEPH family members. Somatic mutation of the WAF1/CIP1 gene was not observed, indicating that, unless there are hot spots for mutations outside the screened region, this gene is not a frequent site of point mutation in colorectal cancer.	INST CURIE,GENET TUMEURS LAB,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			laurent-puig, pierre/B-2226-2013; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMELIN R, 1993, ONCOGENE, V8, P2213; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORITA R, 1991, CANCER RES, V51, P820; MOYRET C, 1994, ONCOGENE, V9, P1739; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SATO T, 1991, CANCER RES, V51, P5118; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	26	92	95	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					599	601						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845685				2022-12-28	WOS:A1995QF64800021
J	HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				HIGASHITSUJI, H; ARII, S; FURUTANI, M; IMAMURA, M; KANEKO, Y; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			ENHANCED EXPRESSION OF MULTIPLE PROTEIN-TYROSINE PHOSPHATASES IN THE REGENERATING MOUSE-LIVER - ISOLATION OF PTP-RL10, A NOVEL CYTOPLASMIC-TYPE PHOSPHATASE WITH SEQUENCE HOMOLOGY TO CYTOSKELETAL PROTEIN-4.1	ONCOGENE			English	Note						PARTIAL HEPATECTOMY; LIVER REGENERATION; PROTEIN TYROSINE PHOSPHATASE; PTP-RL10, EZRIN; BAND 4.1	IMMEDIATE-EARLY GENE; MOLECULAR-CLONING; CDNA SEQUENCE; RECEPTOR; FAMILY; IDENTIFICATION; GROWTH; MEMBER; EZRIN; BAND-4.1	To elucidate the role that protein tyrosine phosphatases (PTPs) may play in liver regeneration, PTPs expressed in the mouse liver after partial hepatectomy (PH) were investigated by a PCR-based cloning method, Sequencing of 115 cDNA clones identified 10 different sequences including MPTP (T cell PTP), PTP-1B, PTP-P19, mR-PTP mu, R-PTP alpha, PTP NE-3 (PTP-P1), R-PTP-kappa and the murine homologue of human LAR, The remaining two sequences, PTP-RL9 and PTP-RL10, encoded novel PTPs. PTP-RL10 cDNA contained an open reading frame of 1176 amino acids with no apparent membrane-spanning region. The amino-terminal region had sequence homology to those of human erythrocyte protein 4.1 and ezrin, cytoskeletal proteins. In the regenerating liver, the levels of five PTP gene mRNAs (MPTP, PTP-P19, R-PTP alpha, LAR homologue, and PTP-RL9) increased within 6h, decreased to the normal level by 24h, and increased again at 48 to 72 h after PH, The levels of PTP-1B and R-PTP-kappa mRNAs peaked within 6 h, decreased gradually, and returned to the normal level by 168 h after PH, In contrast, the levels of two PTP mRNAs (mR-PTP mu and PTP-RL10) peaked at 48 to 72 h, and returned to the normal level by 168 h after PH, No expression of PTP NE-3 was detected in the liver by Northern blotting, The differential expression of multiple PTPs during the prereplicative and post-replicative stages of liver regeneration suggests that PTPs are involved in the regulation of growth and differentiation of liver cells.	KYOTO UNIV,FAC MED,DEPT SURG 1,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT CLIN MOLEC BIOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University								BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOEHM T, 1993, ONCOGENE, V8, P1385; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUCHER NLR, 1963, INT REV CYTOL, V15, P245, DOI 10.1016/S0074-7696(08)61119-5; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; CORREAS I, 1986, J BIOL CHEM, V261, P3362; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FAUSTO N, 1989, LAB INVEST, V60, P4; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GRISHAM JW, 1962, CANCER RES, V22, P842; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HERTOG JD, 1992, BIOCHEM BIOPH RES CO, V184, P1241; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PAN MG, 1993, J BIOL CHEM, V268, P19284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STREULI M, 1988, J EXP MED, V168, P1553; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON KM, 1993, NEURON, V11, P387, DOI 10.1016/0896-6273(93)90193-U; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YI TL, 1991, BLOOD, V78, P2222; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					407	414						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838537				2022-12-28	WOS:A1995QC62400021
J	KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B				KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B			A NEW CYTOKINE (IK) DOWN-REGULATING HLA CLASS-II - MONOCLONAL-ANTIBODIES, CLONING AND CHROMOSOME LOCALIZATION	ONCOGENE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL-LINES; EXPRESSION; DNA; ANTIGENS; GAMMA; GENE; INTERFERON; MOLECULES; SEQUENCE	The role of HLA class II Antigens in the control of the immune response is determined not only by the genetic polymorphism of these molecules, but also by their density on the cell surface. It is therefore essential to identify the signals that modulate HLA Class II gene activity in normal and neoplastic cells. We have purified a cytokine (IK factor, 19 kDa) secreted by the leukemic cell line K562 and several cancer cells, which inhibits HLA Class II antigen induction by IFN-gamma. We produced specific mAbs which antagonize the biological effect of IK in colon carcinoma Cole 205 cells induced to express HLA-DR molecules by IFN-gamma. Moreover, in Cole 205, HLA-DR can also be induced by the protein synthesis inhibitor Cycloheximide (0.1 mu g ml(-1)) and addition of IK factor almost completely abolishes HLA class II expression. We have also performed the cloning and the sequencing of a specific cDNA. This probe recognizes a 2.1 Kb mRNA in different eel types. The nucleotide sequence exhibits no homologies with known cytokines. IK gene localization shows that it maps on chromosome 2p15-p14. The transient transfection of the cDNA in COS cells induces the secretion of a biologically active 19 kDa protein which is recognized in Western blot by 1C5B11 blocking mAb. This paper reports the characterization of a new cytokine downregulating HLA class II Antigens, whose analysis will help to better understand HLA class II gene regulation and the mechanism of escape from immunorecognition in cancer cells,	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U332,F-75014 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	KRIEF, P (corresponding author), HOP PAUL BROUSSE,INSERM,U268,114 AVE PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE.		Krief, Patricia/M-6073-2014; Plaisance, Stephane/ABI-6307-2020; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009	Krief, Patricia/0000-0001-5106-466X; Plaisance, Stephane/0000-0002-1651-241X; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Assier, Eric/0000-0001-8366-1645; Boucheix, Claude/0000-0003-4184-7008				BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOUCHEIX C, 1986, METHOD ENZYMOL, V121, P580; CHENG JH, 1993, BIOCHEM J, V294, P589, DOI 10.1042/bj2940589; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOHERTY PC, 1985, ADV CANCER RES, V42, P1; DOUKAS J, 1990, J IMMUNOL, V145, P1088; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; GUERRASIO A, 1981, BLOOD CELLS, V7, P165; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; JANEWAY CA, 1984, IMMUNOL TODAY, V5, P99, DOI 10.1016/0167-5699(84)90043-4; KOELER G, 1975, NATURE, V256, P495; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; KRIEF P, 1988, VIRAL HEPATITIS LIVE, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLER RI, 1985, J IMMUNOL, V135, P2914; LEVESQUE JP, 1991, BIOTECHNIQUES, V11, P313; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCK MFR, 1991, HUMAN GENET, V86, P350; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; POVEY S, 1989, CYTOGENET CELL GENET, V51, P91, DOI 10.1159/000132782; RADKA SF, 1986, HUM IMMUNOL, V16, P390, DOI 10.1016/0198-8859(86)90065-0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TABILIO A, 1983, CANCER RES, V43, P4569; UCER U, 1985, INT J CANCER, V36, P103, DOI 10.1002/ijc.2910360116; VIRELIZIER JL, 1984, EUR J IMMUNOL, V14, P106, DOI 10.1002/eji.1830140120; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	34	37	39	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3449	3456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970704				2022-12-28	WOS:A1994PT39200006
J	OTTERSON, GA; KRATZKE, RA; COXON, A; KIM, YW; KAYE, FJ				OTTERSON, GA; KRATZKE, RA; COXON, A; KIM, YW; KAYE, FJ			ABSENCE OF P16(INK4) PROTEIN IS RESTRICTED TO THE SUBSET OF LUNG-CANCER LINES THAT RETAINS WILDTYPE RB	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION; EXPRESSION; INACTIVATION; SUPPRESSION; CARCINOMA; BINDING; GROWTH	Cell cycle dependent phosphorylation of the RB tumor suppressor protein is mediated by a family of G1 cyclin dependent kinases (cdks) and cyclins including the activated cdk4:cyclin D complex. The identification of a cdk4 inhibitor, p16(INK4), as a target for mutations in cultured tumor lines and primary tumors suggested that RB activity may be affected in these cells. We have examined 88 lung cancer lines for p16(INK4) protein expression and have observed a striking inverse correlation between the presence of p16(INK4) and wildtype RB. We demonstrated that only 6/55 (11%) of small cell lung cancer (SCLC) samples had absent p16(INK4) protein, and all 6 belonged to the rare subset of SCLC with wildtype RB expression. Conversely of 48 SCLC samples with absent or mutant RB, all showed detectable levels of p16(INK4) protein. In contrast, we observed that 23/33 (70%) of non-SCLC samples had loss of p16(INK4). Twenty-two of 26 non-SCLC lines with wildtype RB had absent p16(INK4) while 6 of 7 non-SCLC lines with absent or mutant RB had detectable p16(INK4). The inverse correlation of RB and p16(INK4) expression and the absence of p16(INK4) inactivation in RB (-/-) SCLC lines (0/48) confirms a common p16(INK4)/RB growth suppressor pathway in human cancers and provides evidence that p16(INK4), and not an adjacent gene on chromosome 9p, is a specific target for mutational events.	NCI,NAVY ONCOL BRANCH,BETHESDA,MD 20889; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20889	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA			kaye, frederic/E-2437-2011					BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORI T, 1994, CANCER RES, V54, P3396; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOKAWA K, 1993, ONCOGENE, V8, P2175; OTTERSON GA, 1993, ONCOGENE, V8, P949; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1988, ONCOGENE, V3, P471	31	373	382	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3375	3378						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936665				2022-12-28	WOS:A1994PM65800034
J	RASCLE, A; GHYSDAEL, J; SAMARUT, J				RASCLE, A; GHYSDAEL, J; SAMARUT, J			C-ERBA, BUT NOT V-ERBA, COMPETES WITH A PUTATIVE ERYTHROID REPRESSOR FOR BINDING TO THE CARBONIC-ANHYDRASE-II PROMOTER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; BETA-GLOBIN GENE; ACID RECEPTORS; RESPONSE ELEMENT; NUCLEAR RECEPTORS; VITAMIN-D; TRANSCRIPTION; PROTEIN; CELLS	The carbonic anhydrase II (CAII) gene is the only known gene identified as direct target for v-ErbA-mediated repression in avian erythroleukemic cells transformed by Avian Erythroblastosis Virus (AEV). This gene is transcriptionally activated by thyroid hormone (T3) in normal erythrocytic cells. In this work we have analysed the molecular basis of the transcriptional control of the CAII gene by c-ErbA and v-ErbA. We show that several domains in the promoter control hormonal regulation of transcription. One domain proximal to the TATA box mediates T3 response but contains no identified binding site for c-ErbA. An other domain termed PAL2 is approximately 600 bp upstream the transcription initiation site and contains a c-ErbA binding site. We show that when it is associated to a heterologous promoter this site mediates transcriptional repression in erythrocytic cells but not in HeLa cells. Moreover, this site binds a nuclear erythrocyte-specific factor that we called NFX, which is different from c-ErbA. Heterodimers between c-ErbA and the 9-cis retinoic acid receptor (RXR) compete with NFX for binding to PAL2. In contrast, v-ErbA alone or in association with RXR is a very poor competitor and is unable to chase NFX out of the PAL2 site. We propose that NFX is a transcription repressor whose activity is inhibited by c-ErbA but not v-ErbA. This mechanism might contribute to the overall regulation of the carbonic anhydrase II promoter. These data illustrate another possible mechanism through which v-ErbA might antagonize the function of c-ErbA in controlling gene expression.	ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR49,F-69364 LYON 07,FRANCE; CTR UNIV ORSAY,INST CURIE,BIOL SECT,F-91405 ORSAY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Samarut, Jacques/AAD-2587-2019; GHYSDAEL, Jacques/F-3377-2013; Rascle, Anne/AAC-1904-2019	Rascle, Anne/0000-0001-7464-8545				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CRENON I, 1993, ONCOGENE, V8, P867; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EMERSON BM, 1987, P NATL ACAD SCI USA, V84, P4786, DOI 10.1073/pnas.84.14.4786; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HARDING PP, 1992, J BIOL CHEM, V267, P14145; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HERMANN T, 1993, ONCOGENE, V8, P55; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIEBER MR, 1987, J CELL BIOL, V105, P1055, DOI 10.1083/jcb.105.3.1055; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PAIN B, 1990, New Biologist, V2, P284; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	54	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2853	2867						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916146				2022-12-28	WOS:A1994PG82200011
J	HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS				HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS			THE HOX11 HOMEOBOX-CONTAINING GENE OF HUMAN LEUKEMIA IMMORTALIZES MURINE HEMATOPOIETIC PRECURSORS	ONCOGENE			English	Article							T-CELL LEUKEMIA; STEM-CELLS; BONE-MARROW; MYELOID-LEUKEMIA; DIFFERENTIATION; EXPRESSION; GROWTH; LINES; MICE; INTERLEUKIN-6	The t(10;14) chromosomal translocation of T-cell acute lymphoblastic leukemia joins the T-cell receptor delta gene to a region upstream of a diverged homeobox-containing gene called HOX11. To better understand the pathogenetic role of HOX11 in leukemogenesis, post 5-fluorouracil-treated murine bone marrow cells were infected with a replication-defective retrovirus bearing the gene. Constitutive expression of HOX11 in hematopoietic precursors yielded cell lines at high frequency consisting of immature cells belonging to the myeloid lineage. HOX11-transformed cell lines displayed a strict dependence on IL-3 for their survival and proliferation in culture and were not leukemogenic. The results support the hypothesis that the transforming capacity of HOX11 derives from its ability to alter the expression of genes regulating hematopoietic differentiation and that secondary mutations promoting cell survival or stimulating proliferation are required for progression to malignancy. The findings further suggest that the oncogenic activity of HOX11 might not be restricted to T-cell leukemias in humans.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4N 3M5, ON, CANADA; UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA	University of Toronto; University of Ottawa; University of Ottawa	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK MED CTR, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Hawley, Robert/0000-0003-3512-5818				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; DUHRSEN U, 1990, BLOOD, V75, P190; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GOODWIN RG, 1991, CYTOKINE HDB, P191; GREEN SM, 1989, ONCOGENE, V4, P737; HARLOW E, 1988, ANTIBODIES LABORATOR; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HAWLEY RG, 1993, CLIN EXP METASTAS, V11, P213, DOI 10.1007/BF00114979; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY RG, 1993, IN PRESS J EXP MED, V178; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER JR, 1989, J IMMUNOL, V143, P4025; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEE JC, 1981, P NATL ACAD SCI-BIOL, V78, P7712, DOI 10.1073/pnas.78.12.7712; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER BA, 1985, J IMMUNOL, V134, P3286; MING L, 1992, ONCOGENE, V7, P1325; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, J EXP MED, V166, P12, DOI 10.1084/jem.166.1.12; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; ZHANG N, 1993, IN PRESS ONCOGENE, V8	61	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					1	12						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905617				2022-12-28	WOS:A1994MW24700001
J	BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L				BLAGOSKLONNY, MV; TORETSKY, J; NECKERS, L			GELDANAMYCIN SELECTIVELY DESTABILIZES AND CONFORMATIONALLY ALTERS MUTATED P53	ONCOGENE			English	Article						BENZOQUINONE ANSAMYCINS; GELDANAMYCIN; MUTATED P53; PROTEIN STABILITY	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; MUTANT P53; ACTIVATING MUTATIONS; BINDING-SITE; DNA-DAMAGE; COS CELLS; WILD-TYPE; GENE; TRANSFORMATION	Mutated p53 proteins interfere in the function of wild type p53 and may also serve as a dominant oncogene, The vast majority of p53 mutations result in a protein of altered conformation and prolonged half-life. We sought to examine whether geldanamycin, a drug capable of destabilizing several oncogene and proto-oncogene products, could alter the stability and DNA binding characteristics of several mutated p53 proteins, Brief exposure to GA destabilized the p53 protein of several breast, prostate and leukemic cell lines harboring mutated p53 alleles, resulting in a significant reduction in p53 steady state level and half-life. In contrast to its effects on mutated p53, GA altered neither steady state level nor inducibility of the wild type protein. In addition to its effects on protein stability, GA also altered the conformation of mutated p53, so that it was no longer detectable with a mutant conformation-specific antibody. Finally, mutated p53 protein isolated from GA-treated cells regained partial ability to bind a wild type-specific p53 DNA consensus sequence, These data indicate the feasability of pharmacologic intervention for altering the mutated p53 phenotype.	NCI,CLIN PHARMACOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AVILA MA, 1994, CANCER RES, V54, P2424; BARTEK J, 1990, ONCOGENE, V5, P893; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1991, CELL, V70, P153; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; NEGRINI M, 1994, CANCER RES, V54, P1818; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRICE BD, 1993, ONCOGENE, V8, P3055; RYAN JJ, 1994, LEUKEMIA RES, V18, P617, DOI 10.1016/0145-2126(94)90043-4; SHUE G, 1994, J BIOL CHEM, V269, P2702; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; UEHARA Y, 1989, CANCER RES, V49, P780; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1992, ONCOGENE, V7, P1645	52	181	184	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					933	939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675452				2022-12-28	WOS:A1995RU79800014
J	GOUBIN, F; DUCOMMUN, B				GOUBIN, F; DUCOMMUN, B			IDENTIFICATION OF BINDING DOMAINS ON THE P21(CIP1) CYCLIN-DEPENDENT KINASE INHIBITOR	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE INHIBITORS; P21CIP1; CDK2; PCNA	CELL NUCLEAR ANTIGEN; CONTROL GENE CDC2; SCANNING MUTAGENESIS; PROTEIN; SEQUENCE; SUC1; P21	Members of the recently discovered family of cyclin-dependent kinases inhibitors (CKIs) appear to play an essential regulatory role in the control of cell proliferation. To investigate the molecular basis of the interaction between these proteins and the cyclin-dependent kinases (CDKs), we performed a systematic mutagenesis of the CKI family member p21Cip1 using the alanine-scanning strategy. We have examined the interaction between in vitro translated human cdk2, cyclins A and D1, purified proliferating cell nuclear antigen (PCNA) and a set of human p21Cip1 mutants fused to glutathione S-transferase. Independent domains that are required for the interaction with cdk2 and with PCNA have been identified. The cdk2 binding domain is located in the N-terminal part of the protein, between residues 45 and 60, a region that is fully conserved in the p27Kip1 inhibitor. A PCNA binding region was localised to the C-terminus of the protein, between residues 142 and 163. These findings define protein motifs that are highly conserved between members of the CKI family and that are likely to play an essential function in the regulation of the G1/S transition.	UNIV TOULOUSE 3, PHARMACOL & TOXICOL FONDAMENTALES LAB, CNRS, F-31077 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				BRAMBILLA P, 1992, SPR COLD HARB S QUAN, V56, P515; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOWNES CS, 1994, BIOESSAYS, V16, P75, DOI 10.1002/bies.950160112; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784076				2022-12-28	WOS:A1995RE54300002
J	WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH				WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH			P53-MEDIATED TRANSCRIPTIONAL ACTIVITY INCREASES IN DIFFERENTIATING EPIDERMAL-KERATINOCYTES IN ASSOCIATION WITH DECREASED P53 PROTEIN	ONCOGENE			English	Article						P53; EPIDERMIS; DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; WAF1; MDM-2	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE T-ANTIGEN; DNA-BINDING; MONOCLONAL-ANTIBODIES; MALIGNANT PROGRESSION; ACTIVATING MUTATIONS; CELL-DIFFERENTIATION; EPITHELIAL-CELLS; GROWTH-FACTOR	The regulation of p53 protein synthesis and p53-mediated gene transactivation mere evaluated in cultured mouse keratinocytes maintained as basal cells or induced to differentiate by Ca2+>0.1 mM. p53 protein half-life, p53 protein synthesis and the level of p53 mRNA decreased during terminal differentiation, as detected by immunoprecipitation ,vith a panel of p53-specific antibodies and Northern blotting. Thus differentiating keratinocytes have lower levels of p53 protein. This decline is not observed following growth arrest alone, or in papilloma cell lines which do not terminally differentiate in response to Ca2+. In contrast, the ability of endogenous p53 to transactivate transcription from the PGI, CAT plasmid increased during differentiation in vitro. This change in activity cannot be explained by changes in p53 conformation or nuclear localization. Consistent with these findings, mRNA for the p53-mediated genes WAF1 and mdm-2 increased with Ca2+-induced differentiation in a time dependent manner, suggesting activation of p53 contributes to the differentiated phenotype. However, p53-null mice exhibit histologically normal skin and epidermal keratinocytes from these mice express the appropriate markers of differentiation and suppression of DNA synthesis in vitro when the [Ca2+] is >0.1 mM. The observation that proliferating cells have higher levels of p53 protein which is less active for its function than differentiated cell types could have a consequence for the selection of p53 gene mutations during carcinogenesis, depending upon the stage of differentiation of the tumor cell type.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	WEINBERG, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BLDG 37,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009					ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOND JA, 1994, ONCOGENE, V9, P1885; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BURNS PA, 1991, ONCOGENE, V6, P2363; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOTTO GP, 1988, MOL CARCINOGEN, V1, P171, DOI 10.1002/mc.2940010305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, P NATL ACAD SCI US; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAINAUT P, 1993, CANCER RES, V53, P4469; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTLEY JA, 1985, CANCER RES, V45, P4864; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINJILAL S, 1993, CANCER RES, V53, P2961; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REISS M, 1993, CANCER RES, V53, P899; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SPANDAU DF, 1994, ONCOGENE, V9, P1861; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG WC, 1994, CANCER RES, V54, P5584; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; YUSPA SH, 1985, METHODS SKIN RES, P213; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, CANCER RES, V54, P4448	90	102	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2271	2279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784075				2022-12-28	WOS:A1995RE54300001
J	DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A				DESAINTES, C; HALLEZ, S; DETREMMERIE, O; BURNY, A			WILD-TYPE P53 DOWN-REGULATES TRANSCRIPTION FROM ONCOGENIC HUMAN PAPILLOMAVIRUS PROMOTERS THROUGH THE EPITHELIAL SPECIFIC ENHANCER	ONCOGENE			English	Article						HPV; P53; TBP; TRANSCRIPTION; EPITHELIAL ENHANCER	CARCINOMA CELL-LINES; OPEN READING FRAMES; NUCLEAR FACTOR-I; HUMAN KERATINOCYTES; GENE-EXPRESSION; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; BINDING PROTEIN; E6 ONCOPROTEIN; TUMOR-ANTIGEN	High-risk Human Papillomavirus (HPV) E6 and E7 immortalizing oncoproteins are expressed from promoter tightly regulated by an epithelial specific enhancer. To determine if the p53 tumour suppressor protein can modulate the transcription of these genes, we performed co-transfection experiments with plasmids containing the HPV type 16 or 18 long control regions linked to the chloramphenicol acetyl transferase gene, along with p53 expression vectors. Wild-type, but not mutant, murine or human p53 expression vectors reduced the activity of reporter constructs when co-transfected into HeLa or C33 cell lines. Mutations within the HPV TATA boxes did not significantly alter the levels of p53 repression, suggesting a TATA-independent mechanism. Deletion analyses mapped the p53-responsive domain to the constitutive 230 base pair epithelial specific enhancer. In addition, the enhancer could confer p53-mediated repression when placed upstream of a heterologous promoter.	FREE UNIV BRUSSELS,CHIM BIOL LAB,B-1640 RHODE ST GENESE,BELGIUM									AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CRIPE T P, 1990, New Biologist, V2, P450; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CRUM CP, 1988, J VIROL, V62, P84, DOI 10.1128/JVI.62.1.84-90.1988; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MOMMAND J, 1992, CELL, V69, P1237; MUNGER K, 1989, J VIROL, V63, P4417; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICK.A, 1986, EMBO J, V5, P2285; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THIERRY F, 1991, NEW BIOL, V3, P90; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; THIERRY F, 1987, CANCER CELL, V5, P23; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	64	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2155	2161						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784059				2022-12-28	WOS:A1995RB70300010
J	MARSTON, NJ; JENKINS, JR; VOUSDEN, KH				MARSTON, NJ; JENKINS, JR; VOUSDEN, KH			OLIGOMERIZATION OF FULL-LENGTH P53 CONTRIBUTES TO THE INTERACTION WITH MDM2 BUT NOT HPV E6	ONCOGENE			English	Article						P53; HPV E6; MDM2	HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; WILD-TYPE; DNA-BINDING; MUTANT P53; PROTEIN; CONFORMATION; DEGRADATION; ONCOPROTEIN; EXPRESSION	The tumour suppressor protein p53 normally functions as a tetramer in a defined conformational state. Mutations within p53 which contribute to cancer development frequently induce a conformational shift in the protein which correlates with loss of wild type growth suppressor functions. Both the cell encoded mdm2 protein and the human papillomavirus oncoprotein E6 can regulate p53 function and we have examined the interaction of these proteins with p53. The E6/p53 association is sensitive to conformational alterations in the p53 protein, although oligomerisation is not necessary for this interaction to occur. Analysis of C-terminal p53 truncations has indicated that the region between residues 327 and 347 may play a role in E6 binding. Since monomeric forms of p53 retain transcriptional and transformation suppressor activities, our results indicate that E6 targets p53 proteins which retain these wild type functions. Conversely, the interaction of p53 with mdm2 is not dependent on the conformation of the p53 protein but is significantly impaired by loss of quaternary structure. It is possible that mdm2 plays a role in mediating activities of p53 which, unlike transcriptional activation, depend on oligomerisation.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; MARIE CURIE RES INST, CELL PROLIFERAT LAB, SURREY RH8 0TL, ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, LANCET, V79, P817; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1994, ONCOGENE, V9, P299; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	54	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1709	1715						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753547				2022-12-28	WOS:A1995QX46900003
J	BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G				BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G			TRANSLOCATION (12-22) (P13-Q11) IN MYELOPROLIFERATIVE DISORDERS RESULTS IN FUSION OF THE ETS-LIKE TEL GENE ON 12P13 TO THE MN1 GENE ON 22Q11	ONCOGENE			English	Article						TRANSLOCATION; TEL; MN1; MYELOID LEUKEMIA; CHROMOSOME 12P	ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID-LEUKEMIA; CHROMOSOMAL REARRANGEMENT; SUBSTRATE RECOGNITION; PROTEIN; IDENTIFICATION; ACTIVATION; BREAKPOINT; KINASES; DOMAIN	In myeloid and lymphoid leukemias recurrent chromosomal aberrations can be detected in chromosome region 12p13, We characterized the genes involved in t(12;22) (p13;q11) in two patients with myeloid leukemia and one with myelodysplastic syndrome (MDS). MN1, a gene on chromosome 22q11 was shown to be fused to TEL, a member of the family of ETS transcription factors on chromosome 12p13. The translocation results in transcription of the reciprocal fusion mRNAs, MN1-TEL and TEL-MN1, of which MN1-TEL is likely to encode an aberrant transcription factor containing the ETS DNA-binding domain of TEL. In addition to fusion of TEL to the PDGF beta receptor in t(5;12) in chronic myelomonocytic leukemia (CMML), our data suggest that the involvement of this protein in myeloid leukemogenesis could be dual; its isolated protein-protein dimerization and DNA-binding domains may be crucial for the oncogenic activation of functionally different fusion proteins.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38101 USA; ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS	St Jude Children's Research Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Radboud University Nijmegen			van Kessel, Ad Geurts/A-2810-2010; Riegman, Peter/GLS-0041-2022		NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRIAANSEN HJ, 1992, THESIS ERASMUS U ROT, P123; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CALLEN DF, 1991, CANCER GENET CYTOGEN, V51, P255, DOI 10.1016/0165-4608(91)90138-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DELATTRE O, 1992, NATURE, V359, P1962; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; ENGEL E, 1977, NEW ENGL J MED, V296, P1295; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAGEMEIJER A, 1981, CANCER GENET CYTOGEN, V3, P109, DOI 10.1016/0165-4608(81)90065-0; HAGEMEIJER A, 1979, CYTOGENET CELL GENET, V23, P208, DOI 10.1159/000131327; HAGEMEIJER A, 1993, GENE CHROMOSOME CANC, V8, P237, DOI 10.1002/gcc.2870080406; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHANSSON B, 1990, CANCER GENET CYTOGEN, V48, P119, DOI 10.1016/0165-4608(90)90224-X; KASHIMURA M, 1993, CANCER GENET CYTOGEN, V65, P81, DOI 10.1016/0165-4608(93)90066-U; KRANCE RA, 1992, LEUKEMIA, V6, P251; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mertens F., 1991, CATALOG CHROMOSOME A; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAIMONDI SC, 1986, BLOOD, V68, P69; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDERBLIJPHILIPSEN M, 1977, HUM GENET, V39, P229, DOI 10.1007/BF00287017; VANDERPLAS DC, 1995, LEUKEMIA, V8, P2041; VANKESSEL AG, 1994, CANCER GENET CYTOGEN, V72, P105, DOI 10.1016/0165-4608(94)90124-4; VANKESSEL AHMG, 1981, CYTOGENET CELL GENET, V30, P83; VERMA RS, 1979, CYTOGENET CELL GENET, V23, P274, DOI 10.1159/000131338; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	43	242	249	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731705				2022-12-28	WOS:A1995QU68100006
J	KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK				KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK			THE DCC GENE SUPPRESSES THE MALIGNANT PHENOTYPE OF TRANSFORMED HUMAN EPITHELIAL-CELLS	ONCOGENE			English	Article						DCC; TUMOR SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS; CELL TRANSFORMATION	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; ADHESION MOLECULES; FREQUENT LOSS; EXPRESSION; PROGRESSION; CARCINOMA; CANCER; HPV-18; P53	Loss of heterozygosity and loss of expression of the deleted in colon cancer (DCC) gene is frequently observed in a number of different cancer types. To determine if the DCC gene plays a direct role in tumor suppression, wild-type full-length or truncated DCC cDNA constructs were transfected into nitrosomethylurea (NMU) transformed tumorigenic HPV-immortalized human epithelial cells that had allelic loss and reduced expression of DCC. Full-length DCC suppressed tumorigenicity whereas truncated DCC did not. Tumorigenic reversion of initially suppressed transfectants was associated,vith loss of DCC expression and loss or rearrangement of transfected DCC sequences. These results provide the first direct evidence that DCC is a tumor suppressor gene.	JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [T32CA009657, P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42792, CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLANTON RA, 1991, AM J PATHOL, V138, P673; BROOKS JD, 1993, J UROLOGY, V150, P1278, DOI 10.1016/S0022-5347(17)35760-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1992, J CELL BIOCHEM, P137; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG Y, 1992, CANCER RES, V52, P6525; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KIM MS, 1993, ANTICANCER RES, V13, P1405; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIYAKE K, 1993, BLOOD, V82, P927; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NARAYANAN R, 1992, ONCOGENE, V7, P553; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sambrook J, 1989, MOL CLONING LABORATO; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUCK PH, 1989, GEO IMMIGR LJ, V3, P1; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	44	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1581	1586						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731713				2022-12-28	WOS:A1995QU68100014
J	MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D				MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D			CELL-CYCLE ARREST BY TYROSINE KINASE ABL INVOLVES ALTERED EARLY MITOGENIC RESPONSE	ONCOGENE			English	Article						ABL TRYOSINE KINASE; CELL CYCLE; ESTROGEN RECEPTOR; MITOGENIC RESPONSE; GROWTH INHIBITION	C-ABL; V-ABL; SIGNAL-TRANSDUCTION; FUSION PROTEINS; FOS PROTEINS; GENE-PRODUCT; TRANSFORMATION; LEUKEMIA; BINDING; LOCALIZATION	Activated forms of the nuclear and cytoplasmic tyrosine kinase c-Abl are completely cytoplasmic and oncogenic, The overexpression of c-AbI, and in certain fibroblast cell lines even of v-Abl, leads to a cell cycle arrest revealing an alternative Abl function, To facilitate the analysis of this growth inhibitory function we have taken advantage of regulable Abl-estrogen receptor (ABL:ER) fusion proteins, Oncogenic in the presence of estrogen, they are reversibly switched to inhibit cell proliferation upon removal of hormone, Using this system, we demonstrate that inhibition is effected by Abl derivatives which we have previously shown to be hypo-phosphorylated and to have low kinase activity. Since an almost exclusively cytoplasmic ABL:ER protein is fully growth inhibitory, relevant interactions may occur in the cytoplasm. We identify the cell cycle arrest as an early G1 or G0-like block. Interestingly, growth inhibition correlates with an altered expression pattern of early serum response genes; c-Jun mRNA and c-Fos protein levels are elevated in Abl-blocked cells. In view of the two functional modes of overexpressed Abl proteins, one can speculate that normal c-Abl may be involved in relaying growth regulatory signals from the membrane to the nucleus.	UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				Jackson, Peter/0000-0002-1742-2539				AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENNETT RL, 1992, DEVELOPMENT, V116, P953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DHUT S, 1991, ONCOGENE, V6, P1459; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WICK M, 1994, J CELL SCI, V107, P227; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	36	36	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731683				2022-12-28	WOS:A1995QR65100009
J	ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH				ZIMONJIC, DB; ALIMANDI, M; MIKI, T; POPESCU, NC; KRAUS, MH			LOCALIZATION OF THE HUMAN HER4/ERBB-4 GENE TO CHROMOSOME-2	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE; ERBB FAMILY; GENE MAPPING; FISH	FACTOR RECEPTOR FAMILY; FRAGILE SITES; TRANSLOCATION (2-13)(Q37-Q14); ALVEOLAR RHABDOMYOSARCOMA; NERVOUS-SYSTEM; ONCOGENE; MEMBER; HER4/P180(ERBB4); EXPRESSION; HEREGULIN	The HER4/erbB-4 gene has been isolated as the fourth member of the human EGFR subfamily of tyrosine kinases and has been reported to encode a receptor for NDF/heregulin. In the present study we determined the chromosomal location of the HER4/erbB-4 gene within the human genome. Using human cDNA probes in fluorescence in situ hybridization (FISH), we mapped the HER4/erbB-4 gene to human chromosome 2q33.3-34. This finding established that also the HER4/erbB-4 gene is located in close vicinity of homeobox and collagen gene loci, as is the case for the related EGFR, erbB-2/neu and erbB-3. Aberrations of this chromosomal region associated with T cell leukemias and lymphomas as well as alveolar rhabdomyosarcomas raise the possibility that HER4/erbB-4 might be activated in these tumour types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zimonjic, Drazen/AAX-7513-2020	Alimandi, Maurizio/0000-0002-1409-6803				CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRAIGHOLMES AP, 1987, HUM GENET, V76, P134, DOI 10.1007/BF00284909; DANIEL A, 1984, AM J MED GENET, V18, P483, DOI 10.1002/ajmg.1320180318; Di Fiore P P, 1992, Cancer Treat Res, V61, P139; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAI JL, 1987, CANCER GENET CYTOGEN, V25, P371, DOI 10.1016/0165-4608(87)90201-9; LIZARDNACOL S, 1987, CANCER GENET CYTOGEN, V25, P373, DOI 10.1016/0165-4608(87)90202-0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCKUSICK VA, 1993, J MED GENET, V30, P1, DOI 10.1136/jmg.30.1.1; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; RABIN M, 1986, P NATL ACAD SCI USA, V83, P9104, DOI 10.1073/pnas.83.23.9104; RETIEF E, 1985, HUM GENET, V69, P304, DOI 10.1007/BF00291646; SEIDAL T, 1982, ACTA PATH MICRO IM A, V90, P345; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; TILLER GE, 1994, GENOMICS, V20, P275, DOI 10.1006/geno.1994.1164; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wang-Wuu S, 1988, Cancer Res, V48, P983; WEIL D, 1988, AM J HUM GENET, V42, P435; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XU J, 1994, CANCER GENET CYTOGEN, V74, P1, DOI 10.1016/0165-4608(94)90020-5; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	27	31	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1235	1237						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700649				2022-12-28	WOS:A1995QN35300026
J	COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W				COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W			TRANSCRIPTIONAL REGULATION OF THE JUNB PROMOTER - ANALYSIS OF STAT-MEDIATED SIGNAL-TRANSDUCTION	ONCOGENE			English	Article						JUNB; STAT; IL-6; IFN-GAMMA; SIGNAL TRANSDUCTION	DNA-BINDING; C-JUN; GENE-EXPRESSION; PROTEIN-KINASE; LEUCINE ZIPPER; NUCLEAR FACTOR; INTERLEUKIN-6; ACTIVATION; PHOSPHORYLATION; ELEMENTS	The product of the junB gene is a member of the AP-1 family of transcription factors that activate transcription by binding to TPA-responsive elements (TREs) within the promoters of target genes, Components of AP-1 are immediate-early genes whose expression is upregulated by a plethora of extracellular stimuli and are important in mediating cellular proliferation and differentiation, Such stimuli include the pleiotropic cytokine interleukin-6 (IL-6) which plays a role in immune and inflammatory responses and ciliary neurotrophic factor (CNTF) which enhances survival and differentiation of neurons and glia. We have analysed expression from junB promoter-CAT reporter constructs in HepG2 cells and found that a region between -196 and -91 can mediate response to IL-6 and CNTF and was able to confer responsiveness to a heterologous promoter, We further show by gel retardation analysis that distinct nuclear factors induced by IL-6 specifically bind to this interleukin-6 response element (IRE). This region contains both a putative ETS- and a STAT-transcription factor binding site, We show by mutational analysis and supershift data that the IL-6 induced complex indeed contains the transcription factor APRF/Stat3 that is both necessary and sufficient for activation, Interestingly this site does not appear to bind Stat1 itself, as shown by supershift analysis and a lack of response to IFN-gamma both at the DNA-binding and transcriptional level, Furthermore, we demonstrate that the junB IRE-binding activity induced by IL-6 requires tyrosine kinase activity, whereas induced transactivation of IRE-constructs additionally occurs through an H7-sensitive pathway that is p21ras-independent, implicating serine/threonine kinases in the transactivation of IRE-binding factors.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV GRONINGEN,DEPT GENET,9750 AA HAREN,NETHERLANDS	RWTH Aachen University; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3357; BOHMANN D, 1988, SCIENCE, V238, P1386; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LAMPH WW, 1988, NATURE, V334, P592; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SADOWSKI HB, 1993, SCIENCE, V261, P1738; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YIN TG, 1994, J BIOL CHEM, V269, P3731; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	60	109	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					985	994						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898939				2022-12-28	WOS:A1995QL03800020
J	DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V				DELLARAGIONE, F; RUSSO, GL; OLIVA, A; MASTROPIETRO, S; MANCINI, A; BORRELLI, A; CASERO, RA; IOLASCON, A; ZAPPIA, V			5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND P16(INK4) DEFICIENCY IN MULTIPLE TUMOR-CELL LINES	ONCOGENE			English	Article						5'-METHYLTHIOADENOSINE PHOSPHORYLASE; P16(INK4) GENE; TUMOR SUPPRESSOR GENE; HUMAN CANCERS; 9P21 CHROMOSOME	METHYLTHIOADENOSINE PHOSPHORYLASE; HUMAN GLIOMAS; CHROMOSOME-9; MALIGNANCY; DELETIONS; ABSENCE; ENZYME; GENE	5'-Deoxy-5'-methylthioadenosine phosphorylase (MTA-Pase) gene is localized at the 9p21 region linked to the recently identified putative tumor suppressor gene, p16(INK4), which appears implicated in the control of cell division cycle, The phosphorylase is a housekeeping enzyme involved in the purine and amino acid metabolism whose activity is evidentiable in all the normal tissues, Chromosomal deletions encompassing both MTAPase and p16(INK4) genes cause the total absence of the enzymatic activity only in malignant cells, thus resulting in defined metabolic differences between malignant and normal cells, MTAPase deficiency was investigated by direct radiochemical assay method and by immunochemical techniques in 35 different human malignant cell lines established from several tumor types, The enzyme-deficient cells derived from breast, lung, ovary and liver cancer, malignant melanomas, malignant gliomas and liposarcomas, Two of the MTAPase-deficient cell preparations (from a liver carcinoma and from a melanoma) are primary cultures thus directly representing the original cancer genotypes, Several of the MTAPase-negative cells were studied for p16(INK4) gene deletions and for p16(INK4) protein deficiency, In all the examined samples a full correlation exists between the lack of MTAPase and that of p16(INK4). A similar result was obtained analysing extracts of Vero cell line, which is a fibroblast MTAPase-negative cell line established from the kidney of a normal adult monkey, Conversely, Cos cells, which also are fibroblasts derived from monkey kidney, show both MTAPase and p16(INK4) protein, These results: (i) demonstrate that the phosphorylase deficiency is distributed among almost all the most important human cancers; (ii) confirm and extend the tumor types were p16(INK4) gene inactivation is observable and (iii) suggest that deletions at 9p21 (in humans) or at syntenic chromosomes (in other species) might represent a general mechanism of p16(INK4) gene loss of function and possibly, in turn, of cancer development and/or progression.	UNIV NAPLES 2,SCH MED,DEPT PEDIAT,NAPLES,ITALY; G PASCALE FDN,INST STUDY & TREATMENT TUMORS,NAPLES,ITALY; JOHNS HOPKINS UNIV,SCH MED,ONCOL CTR LABS,BALTIMORE,MD 21231	Universita della Campania Vanvitelli; IRCCS Fondazione Pascale; Johns Hopkins University	DELLARAGIONE, F (corresponding author), UNIV NAPLES 2,SCH MED,INST BIOCHEM MACROMOLEC,NAPLES,ITALY.		Iolascon, Achille/A-4461-2014; RUSSO, GIAN LUIGI/GQB-0962-2022	Casero, Robert/0000-0001-5653-3306; Borrelli, Antonella/0000-0002-4439-6882; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Della Ragione, Fulvio/0000-0002-0592-4283				BACKLUND PS, 1982, J BIOL CHEM, V257, P4196; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1994, SCIENCE, V265, P414; CARRERA CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2665, DOI 10.1073/pnas.81.9.2665; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; DELLARAGIONE F, 1986, J BIOL CHEM, V261, P2324; DELLARAGIONE F, 1990, J BIOL CHEM, V265, P6241; DELLARAGIONE F, 1992, BIOCHEM J, V281, P533, DOI 10.1042/bj2810533; DELLARAGIONE F, 1993, ADV EXP MED BIOL, V348, P31; DELLARAGIONE F, 1989, PHYSL POLYAMINES, P231; DELLARAGIONE F, 1981, J CHROMATOGR, V226, P2243; HEGI M, 1994, 59 COLD SPR HARB LAB, P85; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JONASSON J, 1977, J CELL SCI, V24, P217; KAMATANI N, 1981, P NATL ACAD SCI-BIOL, V78, P1219, DOI 10.1073/pnas.78.2.1219; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P344, DOI 10.1126/science.8153613; NOBORI T, 1991, CANCER RES, V51, P3193; NOBORI T, 1992, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V358, P753; OLOPADE OI, 1992, CANCER RES, V52, P2523; SAIKI RK, 1988, SCIENCE, V238, P487; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRAWEEK ST, 1988, BLOOD, V71, P1568; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; WORSHAM MJ, 1993, GENE CHROMOSOME CANC, V6, P58, DOI 10.1002/gcc.2870060111	29	50	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					827	833						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898924				2022-12-28	WOS:A1995QL03800003
J	MURRELL, AM; GREEN, AR				MURRELL, AM; GREEN, AR			REGULATION OF LINEAGE RESTRICTED HEMATOPOIETIC TRANSCRIPTION FACTORS IN CELL HYBRIDS	ONCOGENE			English	Article						SCL/TAL1; GATA-1; GATA-2; GATA-3; CELL HYBRIDS	GATA-BINDING PROTEINS; SCL GENE-PRODUCT; LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC-CELLS; DNA METHYLATION; MESSENGER-RNA; OCTAMER MOTIF; GLOBIN GENES; EXPRESSION	SCL, GATA-1, GATA-2 and GATA-3 encode lineage restricted haemopoietic transcription factors. We have previously shown that SCL, GATA-1 and GATA-2 are expressed in multipotent progenitors prior to lineage commitment, but are down-regulated during granulocyte/monocyte differentiation. The phenomenon of gene extinction in cell hybrids may reveal negative regulatory mechanisms operating during normal differentiation. We have therefore analysed the regulation of SCL, GATA-1, GATA-2 and GATA-3 in cell hybrids formed by the fusion of cell lines representing different haemopoietic lineages. Expression of GATA-3 was extinguished in both human and murine erythroid x T cell hybrids, an observation which suggests that erythroid cells contain factors capable of repressing GATA-3 expression. By contrast expression of SCL, GATA-1 and GATA-2 was not extinguished in erythroid x T or in erythroid x B cell hybrids. These data suggest that T cells and B cells do not contain trams-acting factors capable of down-regulating expression of SCL, GATA-1 or GATA-2 and therefore raise the possibility that a 'hit and run' mechanism may repress these genes during normal haemopoiesis, HpaII sites within the SCL promoter were unmethylated in erythroid cells but methylated in T cells. Erythroid x T and erythroid x B cell hybrids both methylated and unmethylated SCL thus implicating a heritable cis-acting mechanism in the regulation of the SCL gene in lymphoid cell lines. These results provide the first analysis of SCL and GATA gene regulation in stable cell hybrids.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge				Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKROYD J, 1987, ONCOGENE, V1, P347; ALBERTS B, 1990, NATURE, V344, P193, DOI 10.1038/344193a0; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BAUMANN H, 1985, MOL GEN GENET, V201, P505, DOI 10.1007/BF00331347; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOSHART M, 1993, TRENDS GENET, V9, P240, DOI 10.1016/0168-9525(93)90088-Y; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1993, SCIENCE, V262, P56; CROSS MA, 1994, ONCOGENE, V9, P3013; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEISSEROTH A, 1975, P NATL ACAD SCI USA, V72, P1102, DOI 10.1073/pnas.72.3.1102; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P21; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, INT J CELL CLONING, V10, P269, DOI 10.1002/stem.5530100504; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HWANG LY, 1993, ONCOGENE, V8, P3043; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KIM KJ, 1979, J IMMUNOL, V122, P549; LESHKOWITZ D, 1991, MOL CELL BIOL, V11, P1547, DOI 10.1128/MCB.11.3.1547; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOUTHON MA, 1993, BLOOD, V81, P647; NITSCH D, 1993, GENE DEV, V7, P308, DOI 10.1101/gad.7.2.308; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1985, P NATL ACAD SCI USA, V82, P780, DOI 10.1073/pnas.82.3.780; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PYATI J, 1980, P NATL ACAD SCI-BIOL, V77, P3435, DOI 10.1073/pnas.77.6.3435; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHEN LY, 1993, MOL CELL BIOL, V13, P3530, DOI 10.1128/MCB.13.6.3530; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSAI FY, 1993, BLOOD, V82, pA86; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P195; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORTON RG, 1979, METHOD ENZYMOL, P322; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZANG CC, 1992, P NATL ACAD SCI USA, V89, P7511; ZON LI, 1991, J BIOL CHEM, V266, P22948; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZON LI, 1993, BLOOD, V81, P3234	76	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					631	639						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862440				2022-12-28	WOS:A1995QH61200002
J	VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS				VOELKERDING, KV; STEFFEN, DW; ZAIDI, SHE; MALTER, JS			POSTTRANSCRIPTIONAL REGULATION OF THE P53 TUMOR-SUPPRESSOR GENE DURING GROWTH-INDUCTION OF HUMAN PERIPHERAL-BLOOD MONONUCLEAR-CELLS	ONCOGENE			English	Article						P53; POSTTRANSCRIPTIONAL REGULATION	MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; C-FOS; PHORBOL ESTER; PROTEIN; EXPRESSION; MYC; ACTIVATION; STABILITY; DIFFERENTIATION	Regulation of p53 gene expression at the posttranscriptional level was investigated during growth induction of human peripheral blood mononuclear cells (PBMCs). Freshly isolated PBMCs, which are in the G(0) phase of the cell cycle, were shown to express low levels of p53 mRNA that was rapidly degraded with a half life of Ih. The rapid decay of p53 mRNA in quiescent PBMCs was dependent on global protein synthesis as treatment with cycloheximide resulted in stabilization of the p53 message. PBMCs were stimulated to enter the cell cycle by treatment with a combination of the mitogenic lectin phytohemagglutinin (PHA) and phorbol ester (TPA). Progressive stabilization of the p53 message occurred in PBMCs during growth induction. By 24 h of incubation in the presence of PHA and TPA, the half life of p53 mRNA was 6 h and p53 mRNA steady state levels were increased 4.5 to 5.0-fold. p53 protein was not detected in quiescent PBMCs, but was readily detected in PBMCs stimulated for 24 h with PHA and TPA. Stabilization of p53 mRNA was observed in PBMCs treated with either PHA or TPA, but to a lesser degree than when PKA and TPA were used as co-stimulants. These results indicate that differential degradation of p53 messenger RNA occurs in quiescent vs mitogen stimulated PBMCs and suggest that post-transcriptional regulation importantly contributes to increased p53 mRNA steady state levels as PBMCs enter the cell cycle.	UNIV WISCONSIN,CTR COMPREHENS CANC,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison	VOELKERDING, KV (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53792, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045213] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK45213] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN A, 1992, IMMUNOLOGY, V76, P465; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1988, ONCOGENE RES, V3, P155; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINZLER KW, 1992, CELL, V70, P523; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3172; MERCER WE, 1985, EXP CELL RES, V100, P31; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OSIPOVICH OA, 1992, ONCOGENE, V7, P549; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Peltz Stuart W., 1992, Current Opinion in Cell Biology, V4, P979, DOI 10.1016/0955-0674(92)90129-Z; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	32	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845676				2022-12-28	WOS:A1995QF64800012
J	KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A				KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A			PHOSPHORYLATION OF E2F-1 BY CYCLIN A-CDK2	ONCOGENE			English	Article						E2F; CYCLIN DEPENDENT KINASE; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; CDC2 KINASE; DEPENDENT REGULATION; SUSCEPTIBILITY GENE; RB PROTEIN; S-PHASE; CDK2	Transcription factor E2F-1 has a putative consensus sequence for phosphorylation by cyclin dependent kinase (Ser-Pro-X-Lys/Arg). Therefore, we studied the phosphorylation of E2F-1 in vivo and in vitro and its biological functions. E2F-1 was prepared by immunoprecipitation with anti-E2F-1 antibody from IMR32 lysates and was effectively phosphorylated by human cyclin A-cdk2 which was expressed in insect cells using baculovirus system. GST-EZF-1 was phosphorylated by cyclin A-cdk2 more efficiently than by cyclin E-cdk2. Cyclin D1-cdk4 phosphorylated PRE but scarcely phosphorylated GST-E2F-1 or H1 histone. The 60 kd protein precipitated with anti-E2F-1 antibody was phosphorylated in vivo. Phospho-peptide mapping indicated that its cleavage profile was identical with that of E2F-1 phosphorylated by cyclin A-cdk2 in vitro. This 60 kd protein, which is likely to be E2F-1, was not phosphorylated during the GO and early G1 phase, Phosphorylation of E2F-1 began from the S phase while phosphorylation of pRB started nearly at G1/S. The in vivo phosphorylation of E2F-1 was inhibited by butyrolactone I, a cyclin-dependent kinase inhibitor (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). The binding of E2F-1 to E2 promoter was found to be reduced by phosphorylation of E2F-1 by cyclin A-cdk2, suggesting that phosphorylation of E2F-1 may induce shut off of gene expression at the transcriptional level. These results suggest that E2F-1 is phosphorylated by cyclin A-cdkZ in the S phase in vivo as well as in vitro and that its phosphorylation by cyclin A-cdkZ may modulate its activity.	KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJYUKU KU,TOKYO 160,JAPAN; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Keio University; Vanderbilt University; National Cancer Center - Japan	KITAGAWA, M (corresponding author), MERCK RES LABS,BANYU TSUKUBA RES INST COLLABORAT,OKUBO 3,TSUKUBA,IBARAKI 30033,JAPAN.		Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V66, P1217; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; GIRARD F, 1993, CELL, V67, P1169; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUBER HE, 1993, P NATL ACAD SCI USA, V99, P3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORI N, 1990, ONCOGENE, V5, P1713; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171	53	116	119	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					229	236						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838523				2022-12-28	WOS:A1995QC62400002
J	ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG				ROBB, L; RASKO, JEJ; BATH, ML; STRASSER, A; BEGLEY, CG			SCL, A GENE FREQUENTLY ACTIVATED IN HUMAN T-CELL LEUKEMIA, DOES NOT INDUCE LYMPHOMAS IN TRANSGENIC MICE	ONCOGENE			English	Note						TAL1; CD2 ENHANCER; TRANSGENE	LOOP-HELIX GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING MOTIF; C-MYC; TAL-1 GENE; N-MYC; TRANSLOCATION; LOCUS; OVEREXPRESSION; HEMATOPOIESIS	The scl gene is implicated in human T cell acute lymphoblastic leukaemia (T-ALL) through its involvement in the t(1;14)(p32;q11) chromosomal translocation and, more frequently, as a result of a tumour-specific interstitial deletion on chromosome 1. The consequence of both these chromosomal alterations is overexpression of scl in the leukaemic cells. Despite the strong inference of a role in human T-ALL, scl has not yet been demonstrated to be causally involved in neoplastic transformation. We attempted to do this by generating transgenic mice in which scl expression was directed to the T cell lineage using the CD2 enhancer and the strong SR alpha viral promoter (CD2-scl mice). Three transgenic lines, an of which expressed the scl transgene at a high level, were bred and analysed. No alterations in T cell development were seen in the mice. Unexpectedly CD2-scl mice did not develop tumours, nor did the transgene enhance tumourigenesis by Moloney murine leukaemia virus. These findings throw into question the mechanism by which aberrant scl expression contributes to T cell leukaemogenesis.			ROBB, L (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.		Strasser, Andreas/C-7581-2013; Rasko, John EJ/F-5754-2013	Strasser, Andreas/0000-0002-5020-4891; rasko, John/0000-0003-2975-807X	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCH P, 1992, ONCOGENE, V7, P2389; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HATANO M, 1992, BLOOD S, V80, pA355; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALLIANPUR AR, 1994, BLOOD, V83, P1200; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SOLOMON E, 1991, SCIENCE, V254, P1135; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKABE Y, 1988, MOL CELL BIOL, V8, P466; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VISVADER J, 1991, ONCOGENE, V6, P195; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	42	40	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824274				2022-12-28	WOS:A1995QA98000024
J	BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J				BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J			DISRUPTION OF I-KAPPA-B-ALPHA REGULATION BY ANTISENSE RNA EXPRESSION LEADS TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE BCL-3; REL ONCOGENE; P65 SUBUNIT; GENE; INHIBITOR; FAMILY	NF-kappa B transcription factors regulate the expression of a variety of genes involved in immune regulation and cell growth. In most cell types NF-kappa B proteins are localized in an inactive form in the cytoplasm coupled to the inhibitory I kappa B proteins. Viruses, cytokines, lipopolysaccharides and other stimulating agents promote the dissociation of the cytosolic NF-kappa B/I kappa B complexes, via phosphorylation and degradation of I kappa B, resulting in the translocation of DNA binding, NF-kappa B complexes to the nucleus. To further understand the association of I kappa B with cell growth regulation, the effect of ectopic expression of sense and antisense I kappa B genes was examined in NIH3T3 cells. Overexpression of I kappa B alpha antisense RNA but not I kappa B gamma antisense RNA decreased the steady state levels of I kappa B alpha protein, altered NF-kappa B DNA binding and gene activity and, most importantly, induced malignant transformation as measured by saturation density, growth in soft agar and tumorigenicity in nude mice. In contrast, overexpression of I kappa B alpha resulted in decreased saturation density, a battened cellular morphology and decreased NF-kappa B dependent reporter gene activity. These results indicate that overexpression of an I kappa B alpha antisense RNA may disrupt the NF-kappa B/I kappa B autoregulatory loop, leading to cellular transformation. Our results raise the interesting possibility that I kappa B alpha represents a potential tumor suppressor activity.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University								Ausubel FM, 1988, MOL REPROD DEV; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PEPIN N, 1994, IN PRESS VIROLOGY; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rossi John J., 1993, Methods (Orlando), V5, P1, DOI 10.1006/meth.1993.1001; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WEINBERG RA, 1989, CANCER RES, V49, P3713	49	80	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936641				2022-12-28	WOS:A1994PM65800010
J	YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G				YOUNG, J; BUTTENSHAW, R; BUTTERWORTH, L; WARD, M; SEARLE, J; LEGGETT, B; CHENEVIXTRENCH, G			ASSOCIATION OF THE SS GENOTYPE OF THE L-MYC GENE AND LOSS OF 18Q SEQUENCES WITH A WORSE CLINICAL PROGNOSIS IN COLORECTAL CANCERS	ONCOGENE			English	Article							FRAGMENT-LENGTH-POLYMORPHISM; HUMAN-BREAST-CANCER; LUNG-CANCER; METASTASIS; HETEROZYGOSITY; CARCINOMAS; FREQUENCY; TUMORS; COLON; LOCUS	L-myc is a nuclear oncogene which is sometimes activated late in tumourigenesis. Digestion of DNA with EcoRI reveals a simple restriction fragment length polymorphism (RFLP) located in the second intron of L-myc, with allele sizes 10 kb (L-allele) and 6.6 kb (S-allele). Some studies have suggested that the presence of the S-allele in the constitutional DNA of a patient with cancer is associated with a higher risk of metastasis in lung, breast and renal cell carcinomas. The aims of this study were to determine if the S-allele was significantly associated with metastasis and also with inactivation of tumour suppressor genes in colorectal cancer. One hundred and twenty-four Caucasian colorectal cancer patients were studied for L-myc genotype, and a subgroup of these (108) had their tumours examined for allele loss at multiple loci on nine chromosomal arms (1p, 1q, 5q, 8p, 14q, 17p, 17q, 18q, 22q) and for mutations in the 12th codon of K-ras. The percentage of individuals with the SS genotype was 19% (4/21) Dukes Stage A, 19% (10/54) Dukes B, 25% (8/32) Dukes C and 40% (8/20) Dukes D. The trend observed here is significant (P<0.05, Wilcoxon Rank Sum Test). Also, the SS genotype was significantly more common in individuals whose tumours showed allelic loss on 18q (P<0.01, Fishers Exact Test). This work suggests that the S-allele of L-myc, or a gene in linkage disequilibrium with it, may modify the development of colorectal cancer.	UNIV QUEENSLAND,SCH MED,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; ROYAL BRISBANE HOSP,DEPT PATHOL,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA	University of Queensland; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute	YOUNG, J (corresponding author), GLAXO GASTROENTEROL LAB,CLIN RES CTR,BANCROFT CTR,300 HERSTON RD,BRISBANE,QLD 4029,AUSTRALIA.		Young, Joanne P/H-7774-2014; Young, Joanne P/B-9981-2011; Leggett, Barbara A/D-3579-2011	Leggett, Barbara/0000-0003-2062-7380; Chenevix-Trench, Georgia/0000-0002-1878-2587				BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BIECHE I, 1990, HUM GENET, V85, P101; CHAMPEME MH, 1992, INT J CANCER, V50, P6, DOI 10.1002/ijc.2910500103; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHENEVIXTRENCH G, 1989, BRIT J CANCER, V60, P872, DOI 10.1038/bjc.1989.382; DEPHINO RA, 1987, GENE DEV, V1, P1311; IKEDA I, 1988, JPN J CANCER RES, V79, P674, DOI 10.1111/j.1349-7006.1988.tb02220.x; ISHIZAKI K, 1990, J NATL CANCER I, V82, P238, DOI 10.1093/jnci/82.3.238; KAKEHI Y, 1989, INT J CANCER, V43, P391, DOI 10.1002/ijc.2910430307; KATO M, 1990, INT J CANCER, V45, P47, DOI 10.1002/ijc.2910450110; KAWASHIMA K, 1988, P NATL ACAD SCI USA, V85, P2353, DOI 10.1073/pnas.85.7.2353; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAWASHIMA K, 1987, P JPN ACAD B-PHYS, V63, P300, DOI 10.2183/pjab.63.300; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SARANATH D, 1990, BRIT J CANCER, V61, P530, DOI 10.1038/bjc.1990.119; TAMAI S, 1990, INT J CANCER, V46, P411, DOI 10.1002/ijc.2910460314; TAYLOR JA, 1993, INT J CANCER, V54, P927, DOI 10.1002/ijc.2910540610; TEFRE T, 1990, BRIT J CANCER, V61, P809, DOI 10.1038/bjc.1990.182; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; YOUNG J, 1992, CANCER RES, V52, P285	29	34	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1053	1056						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7907781				2022-12-28	WOS:A1994NC04800007
J	LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T				LIU, XQ; BRODEUR, SR; GISH, G; SONGYANG, Z; CANTLEY, LC; LAUDANO, AP; PAWSON, T			REGULATION OF C-SRC TYROSINE KINASE-ACTIVITY BY THE SRC SH2 DOMAIN	ONCOGENE			English	Article							PHOSPHORYLATED CELLULAR PROTEINS; GROWTH-FACTOR RECEPTORS; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING	The protein-tyrosine kinase activity of pp60c-src (c-Src) is inhibited by phosphorylation of tyr527, within the c-Src c-terminal tail. Genetic and biochemical data have suggested that this negative regulation requires an intact Src homology 2 (SH2) domain. Since SH2 domains recognize phosphotyrosine, it is possible that these two noncatalytic domains associate, and thereby repress c-Src kinase activity. Consistent with this model, an isolated Src SH2 domain expressed in bacteria as a GST fusion protein bound in vitro to a synthetic phosphotyrosine-containing peptide modeled on the C-terminal 13 residues of the c-Src tail. Binding was absolutely dependent on phosphorylation of tyr527 in the tail peptide, and was modified by both the length and sequence of the peptide. Competition experiments indicated only a moderate binding affinity between the Src SH2 domain and the phosphorylated tail. A distinct phosphotyrosine-containing peptide previously identified as binding the Src SH2 domain with high affinity stimulated c-Src tyrosine kinase activity in vitro, possibly by competing with the endogenous tail phosphorylation site for binding to the SH2 domain. Indeed, this activation was competitively inhibited by purified bacterial Src SH2 domain. These data provide direct evidence that the c-Src tail has an intrinsic affinity for the Src SH2 domain, and suggest that such an interaction in the intact molecule contributes to maintaining c-Src in an inactive form.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03825; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University System Of New Hampshire; University of New Hampshire; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto			Gish, Gerald D/C-7228-2017; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CH, 1987, CELL, V40, P83; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HU P, 1992, MOL CELL BIOL, V981, P990; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1987, ONCOGENE, V1, P181; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VEILLETTE A, 1992, ONCOGENE, V7, P971; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	42	199	208	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1119	1126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683128				2022-12-28	WOS:A1993KY32800002
J	BIA, B; COWELL, JK				BIA, B; COWELL, JK			INDEPENDENT CONSTITUTIONAL GERMLINE MUTATIONS OCCURRING IN THE RB1 GENE IN COUSINS WITH BILATERAL RETINOBLASTOMA	ONCOGENE			English	Note						RB1 GENE; MUTATIONS	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; LOW-PENETRANCE; MECHANISMS; PEDIGREES	The inheritance of a genetic susceptibility to the development of retinoblastoma generally follows an autosomal mode of inheritance with high penetrance. Rare families, however, show evidence of incomplete penetrance where individuals can transmit the mutant gene without being affected themselves. In these families formal proof of this dogma requires the identification of the predisposing mutation. In this study we have identified the mutations in cousins with bilateral (hereditary) disease. Using SSCP and DNA sequencing, different constitutional mutations were detected in the affected cousins in this pedigree. One cousin carries a C-->T mutation in exon 8 generating a stop codon directly which was also present in his affected mother whereas the other cousin carries an 8 base pair deletion in exon 20. Neither half of the family carried the same mutation as the other. The mother of the patient with the 8 bp deletion carried neither of the mutations. Thus, we have demonstrated that the retinoblastomas in this family have developed as a result of independent, sporadic genetic events which occurred coincidentally in the same extended family rather than being due to a common mutation which manifests as incompletely penetrant, These observations have important implications for genetic counselling in this type of family.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,HEMATOL ONCOL UNIT,LONDON WC1,ENGLAND					Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MATSUNAGA E, 1978, AM J HUM GENET, V30, P406; MUNIER FL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1507, DOI 10.1001/archopht.1993.01090110073028; NAUMOVA A, 1994, AM J HUM GENET, V54, P264; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; VOGEL F, 1979, HUM GENET, V52, P1; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	20	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					977	979						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675457				2022-12-28	WOS:A1995RU79800019
J	MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA				MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA			ALTERED EXPRESSION OF THE P50 SUBUNIT OF THE NF-KAPPA-B TRANSCRIPTION FACTOR COMPLEX IN NON-SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Note						NF-KAPPA-B; P50 SUBUNIT; NSCLC; ALTERATION	ADHESION MOLECULE-1; PROTEIN SUBUNITS; GENE-EXPRESSION; INDUCTION	Recent studies have implicated a role for the p50 subunit of the NF-kappa B transcription factor complex in tumorigenesis, Therefore, we investigated the expression of the p50 subunit of the NF-kappa B transcription factor complex in paired normal and non-small cell lung carcinoma (NSCLC) tissues. Here we show that nine of 11 (81.8%) fresh NSCLC tissues expressed from two- to 20-fold higher levels of the p50 subunit than normal lung tissue. Thirteen NSCLC cell lines also exhibited high levels of p50. Alterations in the normal NF-kappa B/rel pathway of regulation may play a role in the genesis of NSCLC.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,THORAC MOLEC ONCOL SECT,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R37CA045187, R01CA045187, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; GRUMONT RJ, 1994, MOL CELL BIOL, V14, P8460, DOI 10.1128/MCB.14.12.8460; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; SATO H, 1993, ONCOGENE, V8, P395; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1986, CELL, V46, P921; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; THAKUR S, 1994, ONCOGENE, V9, P2335; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	26	120	125	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675461				2022-12-28	WOS:A1995RU79800023
J	KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC				KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC			INCREASED INCIDENCE OF P53 MUTATIONS IS ASSOCIATED WITH HEPATIC METASTASIS IN COLORECTAL NEOPLASTIC PROGRESSION	ONCOGENE			English	Article						P53; COLON; HEPATIC METASTASIS	GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; ALLELIC LOSS; CARCINOMA; CANCER; TUMORS; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION; DELETIONS	Within a panel of 15 colon carcinoma cell lines we have characterized the p53 gene status using immunocytochemistry (ICC), SSCP and direct sequence analysis. Extension of this analysis to the use of ICC on 104 colonic lesions, representative of different stages of colonic neoplastic progression, showed an absence of detectable p53 nuclear staining in preneoplastic polyp lesions (20 cases) with staining of 52% (25/48) of primary colon carcinomas and 81% (29/36) of hepatic metastases, suggestive of an increased incidence of p53 mutations in late stage lesions of colonic cancer. To address this issue more directly, we analysed 18 primary colon carcinomas and hepatic metastases excised coincidentally from the same patients. In ICC, p53 nuclear staining was recorded in matching lesions from eight individuals where direct sequencing revealed identical mutations in each case. In four individuals no ICC staining was detected in either lesion and molecular analysis revealed wild type sequence in exons 4-9. In six individuals p53 nuclear staining was observed in the hepatic metastases of patients but not the primary lesion. Molecular analysis revealed point mutation events in hepatic metastases from these patients which were not detected in the primary tumor. The point mutations identified in colon carcinomas were predominantly transition events (83%) located in previously characterized codon hotspot regions. These results demonstrate an increased incidence of p53 mutations associated with secondary lesions of colorectal tumors suggestive of a role for p53 in the establishment of colorectal hepatic metastases.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,CANC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA044704, R23CA042944, T32CA009580, R01CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704, CA42944, T32 CA 09580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIGNATELLI M, 1992, INT J CANCER, V50, P638; PURDIE CA, 1991, AM J PATHOL, V138, P807; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; SHIRASAWA S, 1991, CANCER RES, V51, P2874; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	24	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					647	652						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651727				2022-12-28	WOS:A1995RQ46900005
J	NUNOUE, K; OHASHI, K; OKANO, I; MIZUNO, K				NUNOUE, K; OHASHI, K; OKANO, I; MIZUNO, K			LIMK-1 AND LIMK-2, 2 MEMBERS OF A LIM MOTIF-CONTAINING PROTEIN-KINASE FAMILY	ONCOGENE			English	Article						PROTEIN KINASE; LIMK; LIM-KINASE; LIM; LIM MOTIF; ZINC FINGER	CYSTEINE-RICH PROTEIN; ZINC-FINGER MOTIF; CONSERVED FEATURES; INSULIN GENE; DOMAIN; HOMEODOMAIN; ACTIVATION; RECEPTOR; ELEGANS; TTG-1	We previously isolated human cDNA encoding LIM-kinase (LIMK), a putative protein kinase which contains two repeats of the LIM motif at the N-terminus and a protein kinase consensus sequence at the C-terminus. Using as a probe a cDNA fragment of human LIMK, we isolated from a rat brain cDNA library cDNA clones encoding two distinct protein kinases (termed LIMK-1 and LIMK-2) related to human LIMK. LIMK-1 shares with human LIMK 95% of the total 647 amino acids and is probably a rat equivalent of human LIMK. LIMK-2 has an overall sequence and a domain structure similar to that of human LIMK and rat LIMK-1, but overall identity is 50-51% at the amino acid level, Like human LIMK, the protein kinase domains of rat LIMK-1 and -2 contain a characteristic sequence DLNSHN in subdomain VIB and a highly basic insert between subdomain VII and VIII. LIMK-1 and -2 are therefore closely related but distinct members of a novel LIM-containing protein kinase subfamily. Several forms of LIMK-2 transcripts encoding proteins that are N-terminally modified and/or C-terminally truncated are generated by alternative splicing or alternative initiation. Northern blot analysis revealed the expression of LIMK-1 mRNA predominantly in the brain and the expression of LIMK-2 mRNA in various tissues in the rat. Antibody raised against LIMK-1 specifically immunoprecipitated and identified in Rat2 fibroblast cells a 72 kDa protein, which has no detectable autophosphorylating activity but is capable of phosphorylating serine and threonine residues of myelin basic protein, by in vitro kinase reaction. As the LIMK family kinases have unique structural features, they are likely to have specific functions in previously uncharacterized signaling pathways.	KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; RES DEV CORP JAPAN, PRESTO, INHERITANCE & VARIAT GRP, TOKYO, JAPAN	Kyushu University; Japan Science & Technology Agency (JST)			Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X				BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; OHASHI K, 1994, ONCOGENE, V9, P699; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; PERZALVARDO GC, 1994, NAT STRUCT BIOL, V1, P388; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	36	83	91	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					701	710						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651734				2022-12-28	WOS:A1995RQ46900012
J	MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC				MONTANER, S; RAMOS, A; PERONA, R; ESTEVE, P; CARNERO, A; LACAL, JC			OVEREXPRESSION OF PKC-XI IN NIH3T3 CELLS DOES NOT INDUCE CELL-TRANSFORMATION NOR TUMORIGENICITY AND DOES NOT ALTER NF-KAPPA-B ACTIVITY	ONCOGENE			English	Article						PKC-XI; CELL TRANSFORMATION; NF-KAPPA-B	PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; RAT FIBROBLASTS; ZETA-ISOFORM; ACTIVATION; GROWTH; ONCOGENE; BINDING; EPSILON	Signal transduction is the major mechanism by which cells communicate among themselves through extracellular stimuli. Among the different Structural components involved in signal transduction, protein kinases are one of the key elements in the process. Protein kinase C is a multimember family of kinases which has been involved in the regulation of diverse cellular functions. Regulation of cell growth in fibroblasts has been reported to be one of such functions, In particular the PKC zeta isoenzyme has been postulated to be transforming to NIH3T3 cells (Berra et al., 1993) and to serve as an effector for Ras proteins through the regulation of the NF kappa B transcription factor (Dominguez et al., 1993) and direct interaction (Diaz-Meco et al., 1994). We have investigated the effects of overexpressing the mouse wild-type PKC zeta in NIH3T3 cells. When compared to the parental NIH3T3 cells, we have found (1) no significant effect on cell morphology; (2) no difference in growth properties in the absence of serum or in the presence of individual growth factors such as insulin, phorbol esters or PDGF; (3) no growth in soft agar nor tumorigenic activity in nude mice. In addition cells stably overexpressing the PKC zeta kinase did not interfere or amplify the induction of NF kappa B activity by tumor necrosis factor alfa (TNF-alpha) nor altered NF kappa B activity in transient expression of cells treated with TNF-alpha. Thus, mammalian PKC zeta is most likely not directly involved in the regulation of cell proliferation in fibroblasts nor affects directly or indirectly the activation of NF kappa B.	CSIC,INST INVEST BIOMED,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EXTON JH, 1990, J BIOL CHEM, V265, P1; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LACAL JC, 1994, ONCOL REP, V1, P667; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; SINGHAL RL, 1994, CANCER RES, V54, P5574; TOKER A, 1994, J BIOL CHEM, V269, P32358; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	36	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2213	2220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784066				2022-12-28	WOS:A1995RB70300017
J	LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L				LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L			FIBROBLAST GROWTH-FACTOR RECEPTOR-1 REGULATION OF SRC FAMILY KINASES	ONCOGENE			English	Article						FGF RECEPTOR; SRC FAMILY KINASES; REGULATION	PROTEIN-TYROSINE KINASE; B-TYPE RECEPTOR; SIGNAL-TRANSDUCTION; C-SRC; PDGF RECEPTOR; SH2 DOMAIN; PHOSPHOLIPASE C-GAMMA-1; BETA-RECEPTOR; CDNA CLONING; PHOSPHORYLATION	Fibroblast growth factors (FGFs) induce proliferation and differentiation of a wide variety of cells by stimulation of cell surface expressed high affinity-binding receptor tyrosine kinases. Members of the Src family of cytoplasmic tyrosine kinases are substrates for certain growth factor receptors, We have examined interactions between FGF receptor-1 (FGFR-1) and Src, Fyn and Yes. In lung capillary endothelial cells and murine fibroblasts, bFGF stimulation led to increased autophosphorylation of Src family members, In contrast, in porcine aortic endothelial cells (FGFR-1/PAE) and lung fibroblasts from chinese hamster (CCL 39), activation of FGFR caused reduced autophosphorylation of Src and Fyn. In neither case could complex-formation between Src members and FGFR be seen, Analysis of a panel of mutated FGFR-1 expressed in PAE cells showed that FGFR-1/Y766F mediated an increased autophosphorylation of Src members and upregulation of their kinase activities, Y766 in FGFR-1 has been shown to serve as a binding site for phospholipase C-gamma, which regulates Ca2+ fluxes and protein kinase C (PKC) activity. The negative effect on Src kinase activity upon FGFR stimulation was mimicked by activation of PKC in FGFR-1/PAE or CCL 39 cells using phorbol 12-myristate 13-acetate (PMA) and Src was phosphorylated in vitro by purified recombinant PKC alpha. Moreover, inhibition of PBC attenuated the bFGF induced decrease in autophosphorylation of Src family members, These data indicate a negative regulatory role for PRC on Src kinase activity in certain cell types.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	LANDGREN, E (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, UPPSALA BRANCH, BOX 595, S-75124 UPPSALA, SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANDINO L, 1990, ONCOGENE, V5, P721; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOU JZ, 1993, PROTEIN SCI, V2, P86; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STABEL S, 1991, METHOD ENZYMOL, V200, P670; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; ZHAN X, 1994, J BIOL CHEM, V269, P20221	51	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2027	2035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761103				2022-12-28	WOS:A1995QZ92600017
J	SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB				SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB			C-FOS IS A POSITIVE REGULATOR OF CARCINOGEN ENHANCEMENT OF ADENOVIRUS TRANSFORMATION	ONCOGENE			English	Article						IMMEDIATE-EARLY RESPONSE GENES; INDUCIBLE EXPRESSION VECTORS; C-FOS ANTISENSE RNA; VIRAL TRANSFORMATION; AP-1 BINDING; NUCLEAR RUN-ON	EMBRYO FIBROBLAST CELLS; DNA-DAMAGING AGENTS; HOST-RANGE MUTANT; TYPE-5 ADENOVIRUS; METHYL METHANESULFONATE; GROWTH-ARREST; JUN-B; IONIZING-RADIATION; GENOTOXIC-STRESS; GENE-EXPRESSION	The early gene expression changes mediating carcinogen enhancement of viral transformation (GET) remain to be elucidated. A model cell culture system has been developed that is now permitting a molecular analysis of GET. Pretreatment of cloned rat embryo fibroblast (CREF) cells with methyl methanesulfonate (MMS) prior to infection with the cold-sensitive host-range type 5 adenovirus mutant, H5hr1, results in a dose-dependent increase in viral transformation, The present study investigates the role of immediate-early response genes, specifically c-fos, in the CET process, MMS pretreatment, alone or in combination with infection with H5hr1 temporally and differentially increases c-fos, c-jun, jun-B, jun-D and c-myc steady-state mRNA levels, Maximum induction occurs with c-fos and c-jun 8 to 12 h posttreatment and the magnitude of response is generally greatest in CREF cells pretreated with MMS and then infected with H5hr1. Enhancement in RNA levels is observed in the presence of cycloheximide indicating that ongoing protein synthesis is not required for induction of c-fos, c-jun, jun-B or c-myc expression, Nuclear run-on analysis indicates an enhancement in transcriptional rates for c-fos, c-jun, jun-B and c-myc in CREF cells treated with MMS or MMS plus infection with H5hr1. A requirement for elevated c-fos in the early stages of CET is indicated by the ability of c-fos antisense oligonucleotides to prevent the CET process, Direct evidence implicating early increases in c-fos as a mediator of the CET process is demonstrated by stably expressing mouse mammary tumor virus promoter-regulated human sense and antisense c-fos genes in CREF cells, Induction of c-fos sense expression by dexamethasone (DEX) in the absence of MMS treatment results in enhanced c-fos mRNA, Fos protein, AP-1 DNA-binding activity and H5hr1-induced transformation and GET. Induction of c-fos expression by DEX in stable c-fos-sense CREF constructs also results in elevated levels of c-jun, jun-B and c-myc mRNA and protein. Conversely, induction of c-fos antisense expression prevents the increase in c-fos mRNA, Fos protein and AP-I DNA-binding activity and eliminates GET. In the antisense-c-fos constructs, increases in c-jun, jun-B and c-myc mRNA and protein normally induced by MMS also are not apparent, Thus, induction or inhibition in c-fos expression affects the level of expression of additional immediate-early response genes, including c-jun, jun-B and c-myc. These results demonstrate a pivotal role for the early induction of c-fos and possibly c-fos responsive genes, in the CET process.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA043208, R01CA035675, R29CA060639] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA43208, R29 CA60639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Casto B C, 1973, Prog Med Virol, V16, P1; CATLING AD, 1993, ONCOGENE, V8, P1875; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1987, ONCOGENE, V2, P79; Curran T, 1988, ONCOGENE HDB, P307; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1983, CANCER INVEST, V1, P495, DOI 10.3109/07357908309020275; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FISHER PB, 1981, CARCINOGENS IND ENV, P113; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAUGEN A, 1990, HDB EXPT PHARM, V94, P249; HERMO H, 1987, CARCINOGENESIS, V8, P967, DOI 10.1093/carcin/8.7.967; HERMO H, 1988, CANCER RES, V48, P3050; HERMO H, 1985, MOL BASIS CANCER A, P489; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PRICE BD, 1994, CANCER RES, V54, P896; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEN R, 1995, IN PRESS P NATL ACAD; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SU ZZ, 1989, MOL CARCINOGEN, V2, P252, DOI 10.1002/mc.2940020505; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1990, MOL CARCINOGEN, V3, P141, DOI 10.1002/mc.2940030307; SU ZZ, 1994, ONCOGENE, V9, P1123; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, MOL CARCINOGEN, V8, P155, DOI 10.1002/mc.2940080306; SU ZZ, 1993, CANCER RES, V53, P1929; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TISHLER RB, 1993, CANCER RES, V53, P2212; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zur Hausen H, 1987, Appl Pathol, V5, P19; [No title captured]	86	3	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2037	2049						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761104				2022-12-28	WOS:A1995QZ92600018
J	BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW				BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW			PROMOTERS CONTAINING ATF-BINDING SITES ARE DE-REGULATED IN CELLS THAT EXPRESS THE EWS/ATF1 ONCOGENE	ONCOGENE			English	Article						ONCOGENES; TRANSCRIPTION, CAMP	TRANSCRIPTION FACTOR CREB; MULTIPLE SEQUENCE ELEMENTS; C-FOS PROMOTER; CYCLIC-AMP; MALIGNANT-MELANOMA; RESPONSE ELEMENT; SOMATOSTATIN GENE; PROTEIN-KINASE; FRTL5 CELLS; SOFT PARTS	Chromosomal translocations that fuse the N-terminal region of the Ewings sarcoma oncogene (EWS) to the C-terminal region (including the DNA-binding domain) of the cellular transcription factor ATF1 are associated with a tumour type termed malignant melanoma of soft parts (MMSP). It is envisioned that transformation by the EWS/ATF1 fusion protein results from aberrant transcriptional regulation of genes that are normally regulated by ATF1. To examine this hypothesis we have expressed exogenous EWS-ATF1 in JEG3 cells and tested its ability to activate several promoters that contain binding sites for ATF1. We show that EWS-ATF1 is a strong constitutive activator of some promoters tested but represses others. Significantly, the ability of particular promoters to be activated by EWS/ATF1 in JEG3 cells correlates with promoter activity in two MMSP-derived cell lines (SU-CCS-1 and DTC1). Our results therefore provide evidence that endogenous EWS/ATF1 can de-regulate transcription and that this capacity may contribute to transformation in MMSP.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV SO CALIF,CHILDRENS HOSP,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIGNANI F, 1994, BLOOD, V83, P10; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBER B, 1994, ONCOGENE, V9, P1295; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; JONES C, 1991, MOL CELL BIOL, V11, P4297, DOI 10.1128/MCB.11.9.4297; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LADANYI M, 1994, CANCER RES, V54, P2837; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MACARTHUR H, 1984, J VIROL, V483, P84; MAO XH, 1994, J BIOL CHEM, V269, P18216; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V5, P1163; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	77	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1749	1756						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753552				2022-12-28	WOS:A1995QX46900008
J	LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M				LEDENT, C; MARCOTTE, A; DUMONT, JE; VASSART, G; PARMENTIER, M			DIFFERENTIATED CARCINOMAS DEVELOP AS A CONSEQUENCE OF THE THYROID-SPECIFIC EXPRESSION OF A THYROGLOBULIN-HUMAN PAPILLOMAVIRUS TYPE-16 E7 TRANSGENE	ONCOGENE			English	Article						RETINOBLASTOMA SUSCEPTIBILITY; GENE PRODUCT; THYROID TUMORS; TRANSGENIC MODEL	TISSUE-SPECIFIC EXPRESSION; MICE; GENE; PROTEIN; TUMORIGENESIS; ONCOGENES; CLONING; COEXPRESSION; THYROTROPIN; FRAGMENTS	The oncogenic properties of the high risk human papillomaviruses (HPV) E7 protein are attributed to its interaction with the retinoblastoma susceptibility gene product RB1 and other related proteins, We report here the generation of a transgenic model expressing the E7 oncogene of HPV16 in thyroid follicular cells, under control of the bovine thyroglobulin gene promoter. Transgenics develop differentiated and functionally regulated thyroid goitres, due to thyroid cell proliferation and accumulation of colloid, On the background of this colloid goitre, the mice develop foci of more actively proliferating cells that become invasive and ultimately tend to loose their differentiation, Old mice display secondary tumour nodules that mimic the various histological aspects of the human differentiated thyroid cancers: the follicular and papillary carcinomas, The development of totally undifferentiated carcinoma is in contrast exceptional, We conclude that RB1, and/or related proteins, are responsible for the strict negative control of proliferation that characterizes the thyroid cell of the adult, Inactivation of these proteins results in a continuous growth of the thyroid, without affecting its differentiation, function and regulation, Given the high frequency of progression to highly malignant phenotypes, the retinoblastoma susceptibility and related genes are good candidates as targets for mutations or deletions in early steps of human thyroid carcinogenesis. The search for such mutations in human thyroid cancers will test if this hypothesis holds true.	FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	LEDENT, C (corresponding author), FREE UNIV BRUSSELS,IRIBHN,CAMPUS ERASME,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				AASLAND R, 1988, BRIT J CANCER, V57, P358, DOI 10.1038/bjc.1988.82; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; CORDONCARDO C, 1994, AM J PATHOL, V144, P500; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIGGE J, 1991, AM J PATHOL, V139, P1213; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HEDINGER C, 1988, INT HISTOLOGICAL CLA; HOGAN B, 1986, MANIPULATING MOUSE E; HOLM R, 1994, J PATHOL, V172, P267, DOI 10.1002/path.1711720307; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDENT C, 1994, EUR J ENDOCRINOL, V130, P8, DOI 10.1530/eje.0.1300008; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; MACMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MAYOL X, 1993, ONCOGENE, V8, P2561; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PONTA H, 1994, BBA-REV CANCER, V1198, P1, DOI 10.1016/0304-419X(94)90002-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH P, 1989, THYROID TUMORS MOL B; STUDER H, 1986, SIMPLE NODULAR SPORA; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WYLLIE FS, 1989, BRIT J CANCER, V60, P561, DOI 10.1038/bjc.1989.313; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	47	46	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1789	1797						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753555				2022-12-28	WOS:A1995QX46900012
J	AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S				AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S			MOLECULAR-CLONING AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN PLATELET-DERIVED GROWTH-FACTOR-ALPHA RECEPTOR GENE PROMOTER	ONCOGENE			English	Note						PDGF; RECEPTOR; CAMP; GENE; RETINOIC ACID; TRANSCRIPTION	DEVELOPMENTAL EXPRESSION; PDGF RECEPTOR; TRANSCRIPTION FACTOR; RETINOIC ACID; CELLS; TISSUE; BETA; EMBRYOGENESIS; ESTABLISHES; SEQUENCE	Expression of the platelet-derived growth factor alpha receptor (PDGF alpha R) is strictly regulated during mammalian development and tumorigenesis. The molecular mechanisms involved in the specific regulation of PDGF alpha R expression are unknown, but transcriptional regulation of the PDGF alpha R gene is most likely to be involved, This study describes the molecular cloning of the non-coding exon 1 and approximately 2 kb of 5' flanking region of the human PDGF alpha R gene, This 5' flanking region is a functional promoter of the PDGF alpha R gene as concluded from its capacity to drive luciferase reporter gene expression in an orientation dependent way, Analysis of 5' promoter deletion mutants revealed that the region from -441 to +118, relative to the transcription initiation site, is sufficient to establish high level promoter activity, In addition, the morphogen retinoic acid, alone or in combination with dibutyryl cAMP, gives a 22-fold induction of PDGF alpha R gene promoter activity in human teratocarcinoma cells, This effect is mediated through specific transcription factor binding within the -52/+118 region of the PDGF alpha R gene.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	AFINK, GB (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL,TOERNOOIVELD 1,6525 ED NIJMEGEN,NETHERLANDS.		Afink, Gijs/AAB-2832-2021; Afink, Gijs/A-2025-2009	Afink, Gijs/0000-0002-2155-725X				BOWENPOPE DF, 1991, TRENDS GENET, V7, P413, DOI 10.1016/0168-9525(91)90222-C; CHAUDHRY A, 1992, CANCER RES, V52, P1006; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DO MS, 1992, ONCOGENE, V7, P1567; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; HAMPE A, 1989, ONCOGENE RES, V4, P9; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KUMABE T, 1992, ONCOGENE, V7, P627; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; MOSSELMAN S, 1989, FEBS LETT, V247, P154, DOI 10.1016/0014-5793(89)81260-8; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISTER M, 1991, J BIOL CHEM, V266, P16755; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; RAINES EW, 1991, PEPTIDE GROWTH FACTO, V1, P173; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Sambrook J, 1989, MOL CLONING LABORATO; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WATSON AJ, 1992, MOL REPROD DEV, V31, P87, DOI 10.1002/mrd.1080310202; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	43	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731723				2022-12-28	WOS:A1995QU68100025
J	KATOH, M; HIRAI, M; SUGIMURA, T; TERADA, M				KATOH, M; HIRAI, M; SUGIMURA, T; TERADA, M			CLONING AND CHARACTERIZATION OF MST, A NOVEL (PUTATIVE) SERINE THREONINE KINASE WITH SH3 DOMAIN	ONCOGENE			English	Note						SERINE THREONINE KINASE; SH3 DOMAIN; LEUCINE ZIPPER DOMAIN	RECEPTOR TYROSINE KINASE; EXPRESSION CLONING; MESSENGER-RNAS; GENE; PROTEINS; FAMILY; ZIPPER; WELL	Protein kinases play a key role in cell growth regulation. We have isolated a cDNA fragment of the MST gene from the MKN28 gastric cancer cell line cDNA pool by degenerate polymerase chain reaction. MST-cDNAs were cloned from the human brain cDNA library. Nucleotide sequence analysis indicated that the MST gene encodes a novel putative non-receptor type of serine/threonine kinase with Src homology 3 (SH3) domain, two leucine zipper domains and proline rich domain. The deduced amino acid sequence corresponding to a part of kinase domain and leucine zipper domains of MST (amino acid codons 244-461) is almost identical to the published partial amino acid sequence of MLK2. MST is the first non-receptor type of serine/threonine kinase containing SH3 domain, leucine zipper domain and proline rich domain other than PTK1/Sprk. The MST gene was moderately expressed in brain, skeletal muscle and testis as a 3.8 kb mRNA, and the MST gene has been mapped to human chromosome 19q13.1-q13.2.	NATL CANC CTR, RES INST, DIV GENET, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, GRAD SCH SCI, DEPT ANTHROPOL, BUNKYO KU, TOKYO 113, JAPAN	National Cancer Center - Japan; University of Tokyo								DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; GALLO KA, 1994, J CELL BIOCH S1, V50, P278; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; KATOH M, 1993, JPN J CANCER RES, V84, P117, DOI 10.1111/j.1349-7006.1993.tb02843.x; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KATOH M, 1993, GASTROENTEROL JPN, V28, P739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ST, 1993, ONCOGENE, V8, P3403; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANHEECKEREN W, 1992, NUCLEIC ACIDS RES, V14, P3721; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	21	51	55	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1447	1451						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731697				2022-12-28	WOS:A1995QR65100024
J	ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H				ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H			IMMORTALIZATION OF HUMAN-CELLS BY MUTANT AND CHIMERIC PRIMATE POLYOMAVIRUS T-ANTIGEN GENES	ONCOGENE			English	Article						TRANSFORMATION; IMMORTALIZATION; POLYOMAVIRUSES; T-ANTIGEN; SV40; JCV; BKV	SV40-TRANSFORMED HUMAN-FIBROBLASTS; PAPILLOMAVIRUS TYPE-16 DNA; MOUSE EMBRYO FIBROBLASTS; VIRUS 40 GENE; SIMIAN VIRUS-40; JC-VIRUS; MALIGNANT TRANSFORMATION; CELLULAR SENESCENCE; VIRAL-DNA; 3' END	Human fibroblasts were morphologically transformed with wild type and mutant SV40 T-antigens (T-Ags) and with SV40/JCV and SV40/BKV chimeric T-Ags. The transformants were then assayed for the attainment of immortal cell growth. Several observations relating T-Ag and T-Ag domains to immortalization were made. Approximately 10% of SV40-transformants became immortal. Transformants generated by transfection or infection of cells with C-terminal T-Ag deletion mutants of SV40 did not immortalize. SV40/JCV and SV40/BKV chimeric T-Ags, containing C-terminal sequences from JCV or BKV, immortalized cells more efficiently than did the intact SV40 T-Ag, suggesting that the C-termini of the JCV and BKV T-Ags contain an enhanced immortalization function. However, chimeras in which the N-terminal or proximal-central portions of T-Ag were composed of JCV sequences failed to immortalize but did induce transformation, Constructs in which the JCV T-Ag Rb binding domain was replaced with SV40 sequences transformed human cells, but again the cells failed to immortalize. Transformants and immortalized cell lines produced by some SV40/JCV chimeras, contained p53 which was unbound by T-Ag. This occurred under conditions where p53 from SV40 and SV40/BKV transformants was bound to T-Ag. This may reflect the reduced stability of the SV40/JCV T-Ags.	UNIV UTAH,DEPT CELLULAR VIRAL & MOLEC BIOL,DEPT PATHOL,SALT LAKE CITY,UT 84132; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	ONEILL, FJ (corresponding author), VET AFFAIRS MED CTR,RES SERV,SALT LAKE CITY,UT 84148, USA.				NATIONAL CANCER INSTITUTE [R01CA044970] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE CN, 1979, J VIROL, V30, P683, DOI 10.1128/JVI.30.3.683-691.1979; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; CRISTOFALO VJ, 1985, GERONTOLOGIST, V25, P577, DOI 10.1093/geront/25.6.577; DEFENDI V, 1982, J CELL PHYSL S, V2, P131; DEPPERT W, 1989, VECTORS TOOLS STUDY, P399; DURST M, 1987, ONCOGENE, V1, P251; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIRARDI AJ, 1965, J CELL COMP PHYSL, V165, P69; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GROSSI MP, 1982, J GEN VIROL, V63, P393, DOI 10.1099/0022-1317-63-2-393; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAO CH, 1993, J VIROL, V67, P1987, DOI 10.1128/JVI.67.4.1987-1995.1993; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUHAR SG, 1991, ONCOGENE, V6, P1499; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MANIATIS T, 1982, MOL CLONING LAB MANU; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MONIER R, 1986, PAPOVAVIRIDAE; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; ONEILL FJ, 1980, J VIROL, V35, P233, DOI 10.1128/JVI.35.1.233-245.1980; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1986, VIROLOGY, V154, P344, DOI 10.1016/0042-6822(86)90460-5; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1981, VIROLOGY, V112, P800, DOI 10.1016/0042-6822(81)90330-5; PATER A, 1980, J VIROL, V36, P480, DOI 10.1128/JVI.36.2.480-487.1980; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P201; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMA.L, 1991, J VIROL, V65, P2843; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1990, CANCER CELL-MON REV, V2, P360; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TOOZE J, 1981, COLD SPRING HARBOR L; TROWBRIDGE PW, 1993, VIROLOGY, V196, P458, DOI 10.1006/viro.1993.1502; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VANHEUVERSWYN H, 1979, J VIROL, V67, P1817; WALKER DL, 1986, POLYOMAVIRUSES; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	66	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1131	1139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700639				2022-12-28	WOS:A1995QN35300014
J	HALL, AR; MILNER, J				HALL, AR; MILNER, J			STRUCTURAL AND KINETIC-ANALYSIS OF P53-DNA COMPLEXES AND COMPARISON OF HUMAN AND MURINE P53	ONCOGENE			English	Article						P53-DNA INTERACTION; KINETICS; P53 CONFORMATION	TUMOR SUPPRESSOR PROTEIN; WILD-TYPE; DNA-BINDING; MUTANT CONFORMATION; SIMIAN VIRUS-40; SEQUENCE; DOMAIN; SITE	Sequence-specific DNA binding by p53 is dependent upon protein conformation. The 1620(+) form correlates with wild type p53 suppressor function and is a prerequisite for binding to the DNA consensus p53-CON in vitro. It has been reported that murine p53 changes conformation on interaction with high affinity DNA target sequences and in the present Study we have analysed p53-DNA complexes using conformation-specific monoclonal antibodies against p53. For murine p53 (mp53) we show (i) the 1620(+) form is retained and stabilised in complex,vith DNA, and (ii) the complexes are dissociated by the PAb1620 monoclonal antibody. In contrast, PAb1620 did not detect nor dissociate human p53-DNA complexes nor did it interfere with complex formation. In competition experiments murine p53 replaced human p53 (hp53) in p53-DNA complexes and this correlated with the greater lability observed for hp53-DNA complexes at a given temperature. Mixed human-murine p53 oligomers were competent for DNA binding,vith an estimated affinity around 5x10(-10)M, similar to that observed for either human or murine p53 alone, The potential significance of these observations is discussed in relation p53 function in vivo.			HALL, AR (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	33	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					561	567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845681				2022-12-28	WOS:A1995QF64800017
J	MA, QF; HERSCHMAN, HR				MA, QF; HERSCHMAN, HR			THE YEAST HOMOLOG YTIS11, OF THE MAMMALIAN TIS11 GENE FAMILY IS A NONESSENTIAL, GLUCOSE REPRESSIBLE GENE	ONCOGENE			English	Article						TIS11; IMMEDIATE-EARLY GENE; YEAST; PRIMARY RESPONSE GENE	PRIMARY RESPONSE GENE; TETRADECANOYL PHORBOL ACETATE; SWISS 3T3 CELLS; SCHIZOSACCHAROMYCES-POMBE; GROWTH-FACTORS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MIG1 REPRESSOR; PROTEINS; CDNA	The murine TIS11 primary response gene is rapidly and transiently induced in response to many extracellular signals, A CX(8)CX(5)CX(3)H sequence is present twice in the TIS11 protein, in two additional murine proteins, TIS11B and TIS11D, that share regions of strong sequence conservation with THS11, and in a Drosophila homologue (DTIS11). Although immunolocalization of TIS11 protein to the nucleus and zinc binding have lead to the speculation that the TIS11 family proteins are transcription factors, no function for these proteins has yet been clearly determined. We have now identified a TIS11 homologue, YTIS11, from Saccharomyces cerevisiae. The Ytis11p protein conserves both the two putative zinc finger CX(8)CX(5)CX(3)H sequences and the spacing between them, as web as additional amino acids in this region. The amino terminal 169 amino acid portion of Ytis11p protein, which contains a large number of acidic amino acids, can serve as transactivator when fused to the Ga14 DNA-binding domain. Expression of the YTIS11 gene is not induced in response to DNA damaging agents, heat shock, sporulation conditions, or mating factor. However, YTIS11 expression is subjected to rapid glucose repression. Disruption of the YTIS11 gene in the M12B strain of Saccharomyces cerevisiae does not effect viability, growth in rich or synthetic medium, mating, or spore formation. However, YTIS11 gene disruption causes an alteration in metabolism that is reflected by a pH color change when cells are grown on YP plates supplemented with 2% glucose. Overexpression of murine TIS11 or TIS11B proteins dramatically attenuates the growth of both ytis11 and wild-type yeast.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,US DOE,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					PHS HHS [M24797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOUTRY M, 1977, BIOCHIM BIOPHYS ACTA, V464, P602, DOI 10.1016/0005-2736(77)90034-7; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CONWAY EJ, 1950, BIOCHEM J, V47, P360, DOI 10.1042/bj0470360; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FOURY F, 1975, J BIOL CHEM, V250, P2354; FOURY F, 1977, J BIOL CHEM, V252, P4577; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NIE XF, 1994, IN PRESS GENE; ROSE MD, 1990, COLD SPRING HARBOR L; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIGLER K, 1980, FOLIA MICROBIOL, V25, P311, DOI 10.1007/BF02876611; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V79, P3454; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WESTERBEEKMARRE.CA, 1988, EUR J BIOCHEM, V174, P611	33	37	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					487	494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845673				2022-12-28	WOS:A1995QF64800009
J	TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S				TAYLOR, JP; POMERANTZ, RJ; OAKES, JW; KHALILI, K; AMINI, S			A CNS-ENRICHED FACTOR THAT BINDS TO NF-KAPPA-B AND IS REQUIRED FOR INTERACTION WITH HIV-1 TAT	ONCOGENE			English	Note						TAT; HIV-1; NF-KAPPA-B; TRANSCRIPTION FACTOR; TAR	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; INDEPENDENT ACTIVATION; TRANSCRIPTION FACTOR; KAPOSIS-SARCOMA; NASCENT RNA; PROTEIN; TYPE-1; CELLS	The Human Immunodeficiency Virus type 1 (HIV-1) Tat protein is a potent activator of transcription directed by the long terminal repeat (LTR), an essential step in the life-cycle of HIV-1. While interaction of Tat with an RNA element encoded by downstream LTR sequences (termed TAR) is commonly considered essential to activation, numerous recent reports have implicated upstream transcription elements within the LTR as participants in mediating this activation. We have recently demonstrated that Tat activation occurs independent of the TAR element in certain cells derived from the central nervous system (CNS), and that this activation is mediated by the kappa B domain of the LTR. Further, CNS-derived cells were found to contain kappa B-binding activity capable of both interacting with Tat and activating LTR transcription in vitro, The present study demonstrates that the kappa B-binding transcription factor derived from CNS cells consists of a component indistinguishable from prototypical Nuclear Factor-kappa B (NEF-kappa B) (in size, mobility on native gel, kinetics of activation and cognate binding sequence) as well as a supershifting component that is dissociable under certain conditions. The supershifting activity is found to stabilize binding of the presumed NF-kappa B to DNA. Further, only the form of NF-kappa B which is associated with this supershifting activity is capable of binding Tat. We hypothesize a model in which Tat utilizes this interaction to activate HIV-1 through the NF-kappa B domain of the LTR in circumstances where TAR is absent. This model has implications with respect to the ability of Tat to alter cellular gene expression and perhaps contribute to the array of problems seen in HIV-1 infection such as altered immune status, CNS toxicity, and the formation of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272, R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI28272, AI31836] Funding Source: Medline; NINDS NIH HHS [P01 NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CUPP C, 1993, ONCOGENE, V8, P2231; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HUANG LM, 1993, J VIROL, V67, P6937, DOI 10.1128/JVI.67.12.6937-6944.1993; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM CM, 1992, ONCOGENE, V7, P1525; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; TAYLOR JP, 1993, VIROLOGY, V195, P780, DOI 10.1006/viro.1993.1430; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0	39	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					395	400						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838536				2022-12-28	WOS:A1995QC62400019
J	JIANG, HP; LIN, J; SU, ZZ; COLLART, FR; HUBERMAN, E; FISHER, PB				JIANG, HP; LIN, J; SU, ZZ; COLLART, FR; HUBERMAN, E; FISHER, PB			INDUCTION OF DIFFERENTIATION IN HUMAN PROMYELOCYTIC HL-60 LEUKEMIA-CELLS ACTIVATES P21, WAF1/CIP1, EXPRESSION IN THE ABSENCE OF P53	ONCOGENE			English	Article							PROTEIN KINASE-C; GLIOBLASTOMA-MULTIFORME CELLS; CYCLIN-DEPENDENT KINASES; MYELOID-LEUKEMIA; LINE HL-60; TERMINAL DIFFERENTIATION; TRANSFORMED PHENOTYPE; ANTIGENIC PHENOTYPE; GENE-EXPRESSION; RESISTANT	The melanoma differentiation associated gene, mda-6, which is identical to the P53-inducible gene WAF1/CIP1, encodes an M(r) 21,000 protein (p21) that can directly inhibit cell growth by repressing cyclin dependent kinases, mda-6 was identified using subtraction hybridization by virtue of its enhanced expression in human melanoma cells induced to terminally differentiate by treatment with human fibroblast interferon and the anti-leukemic compound mezerein (Jiang and Fisher, 1993). In the present study, we demonstrate that mda-6 (WAF1/CIP1) is an immediate early response gene induced during differentiation of the promyelocytic HL-60 leukemia cell line along the granulocytic or macrophage/monocyte pathway. mda-6 gene expression in HL-60 cells is induced within 1 to 3 h during differentiation along the macrophage/monocyte pathway evoked by 12-0-tetradecanoyl phorbol-13-acetate (TPA) or 1,25-dihydroxyvitamin D3 (Vit D3) or the granulocytic pathway produced by retinoic acid (RA) or dimethylsulfoxide (DMSO). Immunoprecipitation analyses using an anti-p21 antibody indicate a temporal induction of p21 protein following treatment with TPA, DMSO or RA. A relationship between rapid induction of mda-6 gene expression and differentiation is indicated by a delay in this expression in an HL-60 cell variant resistant to TPA-induced growth arrest and differentiation. A similar delay in mda 6 gene expression is not observed in Vit D3 treated TPA-resistant variant cells that are also sensitive to induction of monocytic differentiation. Since HL-60 cells have a null-p53 phenotype, these results demonstrate that p21 induction occurs during initiation of terminal differentiation in a p53-independent manner. In this context, p21 may play a more global role in growth control and differentiation than originally envisioned.	COLUMBIA UNIV, COLL PHYSICIANS & SURGEONS,INST CANC RES, CTR COMPREHENS CANC ,DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYSICIANS & SURGEONS,INST CANC RES, CTR COMPREHENS CANC,DEPT UROL, NEW YORK, NY 10032 USA; ARGONNE NATL LAB, CTR MECHANIST BIOL & BIOTECHNOL, ARGONNE, IL 60439 USA	Columbia University; Columbia University; United States Department of Energy (DOE); Argonne National Laboratory				Collart, Frank/0000-0001-6942-4483	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208] Funding Source: NIH RePORTER; NCI NIH HHS [CA43208, CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANDERSON NL, 1985, CANCER RES, V45, P4955; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1984, CANCER RES, V44, P5550; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1991, SERONO SYM, V82, P201; FOON KA, 1982, BLOOD, V60, P1; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GALLAGHER R, 1979, BLOOD, V54, P713; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOMMA Y, 1988, CANCER RES, V48, P2744; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; JIANG H, 1994, IN PRESS MOL CELL DI, V2; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LI Y, 1994, ONCOGENE, V9, P2261; LIN J, 1994, INT J ONCOL, V5, P5; LOTAN R, 1993, RETINOIDS ONCOLOGY, P43; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MICHIELI P, 1994, CANCER RES, V54, P3391; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MURAO S, 1983, CANCER RES, V43, P4989; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TANAKA H, 1982, BIOCHEM J, V204, P713, DOI 10.1042/bj2040713; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	50	622	635	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3397	3406						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936668				2022-12-28	WOS:A1994PM65800037
J	MATIN, A; HUNG, MC				MATIN, A; HUNG, MC			THE RETINOBLASTOMA GENE-PRODUCT, RB, REPRESSES NEU EXPRESSION THROUGH 2 REGIONS WITHIN THE NEU REGULATORY SEQUENCE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; CELL-CYCLE; SUSCEPTIBILITY GENE; OVARIAN-CANCER; DNA-BINDING; ENCODED PROTEIN; MAMMALIAN-CELLS; POINT MUTATION; C-ERBB-2 GENE	The neu oncogene is frequently overexpressed in breast, ovarian and lung cancers, and its overexpression correlates with poor disease prognosis. The exact mechanism of deregulation of neu expression is not well understood. Our previous studies indicate that the tumor suppressor retinoblastoma gene product, Rb, represses transcription of neu through the GTG enhancer (-243 to -234 relative to initiation of translation site of rat neu). We carried out further deletion analysis of the regulatory sequences of neu and found that Rb also represses neu close to transcription initiation sites (-172 to -79). Bal 31 deletions downstream of nucleotide -172 show that the sequence TCGAGGAA (-172 to -165) is important for efficient transcription from the neu promoter and also for repression by Rb. Rb mutants with mutations in the large T/E1a binding domain repress transcription from transcription initiation sites but not the GTG enhancer, suggesting that Rb modulates different regions of the regulatory sequence of neu by different pathways. The net effect of the Rb mutants is to repress not only transcription but also the transforming activity of activated neu in focus-forming assays. Thus, one mechanism whereby Rb may act as a tumor suppressor is to repress transcription of the strongly transforming nea oncogene.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [NCI CA58880, NCI CA16672, NCI CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, P30CA016672, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEMILIA J, 1989, ONCOGENE, V4, P1233; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERN JA, 1990, CANCER RES, V50, P5184; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER SJ, 1994, IN PRESS INT J ONCOL; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PARK JB, 1989, CANCER RES, V49, P6005; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSSELL KS, 1992, CANCER RES, V52, P6624; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; VIJVER M, 1987, MOL CELL BIOL, V7, P2019; WANG NP, 1993, ONCOGENE, V8, P279; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINER DB, 1990, CANCER RES, V50, P421; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE MRA, 1992, ONCOGENE, V7, P677; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1991, ONCOGENE, V6, P1991; ZHANG X, 1989, ONCOGENE, V4, P985; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	68	17	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1333	1339						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908732				2022-12-28	WOS:A1994NH40100004
J	ZHANG, N; GONG, ZZ; MINDEN, M; LU, M				ZHANG, N; GONG, ZZ; MINDEN, M; LU, M			THE HOX-11 (TCL-3) HOMEOBOX PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN THAT UNDERGOES CELL CYCLE-DEPENDENT REGULATION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ACUTE LYMPHOBLASTIC-LEUKEMIA; E2F TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; G1-SPECIFIC CYCLINS; BINDING PROTEIN; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; YEAST	Molecular analysis of the t(10;14) chromosomal translocation found in pediatric patients with T-cell acute lymphoblastic leukemia has led to the identification of the HOX-11 (TCL-3) protooncogene. The HOX-11 cDNA contains an open reading frame encoding a homeoprotein with features of DNA-binding. The majority of the t(10;14) chromosomal translocation breakpoints have been mapped to the 5' end of the HOX-11 gene, supporting the notion that deregulation of the HOX-11 gene by the t(10;14) chromosomal translocation contributed importantly to leukemia formation. To further define the role of the HOX-11 homeoprotein, we have prepared rabbit antiserum against a trpE-HOX-11 fusion protein. The purified anti-HOX-11 IgG immunoprecipitated a protein with apparent relative molecular mass of 40 kD. Biochemical fractionation demonstrated that the protein is localized in the nucleus. Furthermore, the HOX-11 RNA and protein appeared to be modulated during the cell cycle, with the highest level of expression at G(1)/S phase boundary. Taken together, these data suggest that the HOX-11 gene product may function as a transcription factor for G(1) progression in the cell cycle.	UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA; UNIV TORONTO, ONTARIO CANC INST, TORONTO M4X 1K9, ON, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ON, CANADA	University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1992, NATURE, V355, P393, DOI 10.1038/355393a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GEHRING WJ, 1992, TRENDS BIOCHEM SCI, V17, P277, DOI 10.1016/0968-0004(92)90434-B; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MING L, 1992, ONCOGENE, V7, P1325; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	41	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3265	3270						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	7902555				2022-12-28	WOS:A1993MG78200009
J	PODHIPLEUX, N; WILLMAN, CL				PODHIPLEUX, N; WILLMAN, CL			ISOLATION AND CHARACTERIZATION OF THE MURINE C-FGR GENOMIC LOCUS - EXONS IB-XII	ONCOGENE			English	Note						FGR; GENOMIC ORGANIZATION; SRC FAMILY MEMBER; PROTOONCOGENE	PROTEIN-TYROSINE KINASE; ONCOGENE; EXPRESSION; CELLS; SRC; IDENTIFICATION; PROTOONCOGENE; LYMPHOCYTES; ACTIVATION; GENE	The c-fgr proto-oncogene is a member of the src family of intracellular protein tyrosine kinases. C-fgr is selectively expressed in hematopoietic cells, particularly in monocytes, neutrophils and natural killer cells. Although c-fgr is presumed to play a role in signal transduction, its normal function has not been completely elucidated. In contrast to all other members of the src family, the presumed murine and human c-fgr homologues have a low degree of homology in their amino terminal domains which likely mediate the association of c-fgr proteins with signalling complexes and other targets; murine and human c-fgr proteins exhibit other functional differences as well. In contrast to human C-FGR, the murine C-FGR genomic locus has not been characterized. We have now isolated and mapped three overlapping phage clones spanning 33 kb of the murine C-FGR genomic locus. Contained within these clones are 18 kb of DNA containing the C-FGR coding exons (exons IT-XII), one 5' untranslated region exon (exon Tb) located 1.7 kb upstream of exon II, 6.5 kb of DNA upstream of exon Ib, and 6.7 kb of DNA downstream of the polyadenylation site in exon XII. From exons Ib-XII, the exon-intron organization, exon-intron junctions and intron lengths of the murine and human C-FGR genomic loci are quite similar; with the exception of exon II, the exon lengths are also quite similar. Although these studies suggest that the murine and human C-FGR genes are in fact homologues, the organization of these genes upstream of exon Ib is quite divergent.	UNIV NEW MEXICO,SCH MED,CTR CANC,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT CELL BIOL,ALBUQUERQUE,NM 87131	University of New Mexico; University of New Mexico					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043042] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK/CA-43042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HATAKEYAMA S, 1994, P NATL ACAD SCI USA, V91, P3458, DOI 10.1073/pnas.91.8.3458; INOUE K, 1990, MOL CELL BIOL, V11, P6279; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KING FJ, 1990, ONCOGENE, V5, P338; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; LINK DC, 1992, ONCOGENE, V7, P877; LINK DC, 1995, BLOOD, V85, P472; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; PATEL M, 1990, ONCOGENE, V5, P201; POTTER JW, 1994, UNPUB; POTTER JW, 1994, J CELL BIOL B, V18, P287; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; WILLMAN CL, 1991, BLOOD, V77, P6; WILLMAN CL, 1992, J CELL BIOCHEM, V16, P219; YI TL, 1989, ONCOGENE, V4, P1081	23	0	0	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					781	784						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651742				2022-12-28	WOS:A1995RQ46900021
J	BALSALOBRE, A; JOLICOEUR, P				BALSALOBRE, A; JOLICOEUR, P			FOS PROTEINS CAN ACT AS NEGATIVE REGULATORS OF CELL-GROWTH INDEPENDENTLY OF THE FOS TRANSFORMING PATHWAY	ONCOGENE			English	Article						FOS; CELL CYCLE; CELL GROWTH	D-TYPE CYCLINS; RETINOBLASTOMA GENE-PRODUCT; C-FOS; DIFFERENTIAL EXPRESSION; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; ANTISENSE RNA; V-FOS; PHOSPHORYLATION; JUN	The proto-oncogene c-fos is known to be an important positive regulator of cell growth and notably of the G0/G1 transition. However, we observed that v-fos or c-fos-transformed rat-1 fibroblasts paradoxically had a low growth rate as compared to control untransformed rat-1 cells. We determined that this slow growth mainly reflects an increase of the G1 phase of the cell cycle (up to fourfold). In addition, the G0-->S progression of serum-starved fos-expressing rat-1 cells refed with serum was found to be also delayed as compared to rat-1 cells. The delayed G0-->S progression in fos-expressing cells was accompanied by the inappropriate levels or kinetics of expression of several cell cycle-regulated genes (cyclin D1, cdc2, cdk2, cdk4 and rb). Furthermore, a clear uncoupling of the pRb hyperphosphorylation with the entry into S phase was found in these fos-expressing rat-1 cells. Interestingly, the effect of the Fos proteins on the cell cycle was independent of the fos transforming pathway, indicating that the effector genes for Fos proteins are likely to be different for each process. In conclusion, our results indicate that Fos proteins may act as negative regulators of cell growth in some cell types, independently of the fos transforming pathway.	CLIN RES INST MONTREAL,MOLEC BIOL LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA; MCGILL UNIV,DEPT EXPTL MED,MONTREAL,PQ H3G 1A4,CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILED SJ, 1992, P NATL ACAD SCI USA, V89, P9306; FISHER C, 1991, DEVELOPMENT, V111, P253; GARRIDO C, 1993, ONCOGENE, V8, P2713; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holt J, 1992, Cancer Treat Res, V63, P301; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; IBA H, 1988, ONCOGENE RES, V2, P121; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOLICOEUR P, 1992, J VIROL, V66, P3904, DOI 10.1128/JVI.66.6.3904-3908.1992; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER AD, 1984, CELL, V36, P51; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; MULLER R, 1983, EMBO J, V2, P679, DOI 10.1002/j.1460-2075.1983.tb01484.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OGRYZKO VV, 1994, J VIROL, V68, P3724, DOI 10.1128/JVI.68.6.3724-3732.1994; PARDEE A B, 1992, Current Opinion in Cell Biology, V4, P186, DOI 10.1016/0955-0674(92)90031-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEAR WS, 1993, P NATL ACAD SCI USA, V98, P8392; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; VANBEVEREN C, 1983, CELL, V32, P124; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	57	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					455	465						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630629				2022-12-28	WOS:A1995RN53000005
J	HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W				HENNIG, G; BEHRENS, J; TRUSS, M; FRISCH, S; REICHMANN, E; BIRCHMEIER, W			PROGRESSION OF CARCINOMA-CELLS IS ASSOCIATED WITH ALTERATIONS IN CHROMATIN STRUCTURE AND FACTOR-BINDING AT THE E-CADHERIN PROMOTER IN-VIVO	ONCOGENE			English	Article						E-CADHERIN PROMOTER; CARCINOMA PROGRESSION; IN VIVO FOOTPRINTING; GENE REGULATION; CHROMATIN STRUCTURE; DNA METHYLATION	LIGATION MEDIATED PCR; GENE-EXPRESSION; HYPERSENSITIVE SITES; ADHESION MOLECULE; DNA INTERACTIONS; INVIVO PROTEIN; METHYLATION; ACTIVATION; ENHANCER; IDENTIFICATION	E-cadherin has been identified as a tumor (invasion) suppressor gene, which is mutated in 50% of diffuse-type human gastric carcinomas. In other carcinomas, the expression of E-cadherin is down-regulated in the poorly differentiated cells such as from breast, bladder, lung and colon. We have here examined the in vivo properties of the genomic E-cadherin promoter in well and poorly differentiated carcinoma cell lines in order to gain insights into the mechanisms of E-cadherin downregulation in tumors. In vivo footprinting analysis revealed that positive regulatory elements of the E-cadherin promoter (a GC-rich region, the CCAAT-box and a palindromic element) are specifically bound by transcription factors in E-cadherin-expressing but not in non-expressing cells. The tested cell systems include more than a dozen carcinomas cell lines as well as mammary epithelial cells where E-cadherin expression can be switched off by activation of a Fos-estrogen receptor fusion protein and rhabdomyosarcoma cells where E-cadherin expression was induced by transfection with E1A. Mapping of DNase I hypersensitive sites showed that the chromatin structure in the promoter region is loosened in expressing but condensed in nonexpressing cells. Furthermore, the endogenous E-cadherin promoter is specifically methylated at CpG sites in the undifferentiated cells. We also show that the in vivo properties of the promoter in E-cadherin-negative carcinoma cells are similar as in mesenchymal cells, i.e. fibroblasts or sarcoma cells. These data suggest that silencing of the E-cadherin promoter during epithelial-mensenchymal transition and tumor progression is due to a loss of factor binding in vivo and to chromatin rearrangement in the regulatory region.	MAX DELBRUCK CENTRUM MOLEK MED,D-13125 BERLIN,GERMANY; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Sanford Burnham Prebys Medical Discovery Institute; Swiss Institute Experimental Cancer Research								BECKER KF, 1994, CANCER RES, V54, P3845; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bienz Mariann, 1992, Current Opinion in Cell Biology, V4, P955, DOI 10.1016/0955-0674(92)90124-U; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRABANT G, 1994, CANCER RES, V53, P4987; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DORUDI S, 1993, AM J PATHOL, V142, P981; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LACRONIQUE V, 1992, NUCLEIC ACIDS RES, V20, P5669, DOI 10.1093/nar/20.21.5669; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SALUZ HP, 1987, LABORATORY GUIDE GEN; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SORKIN BC, 1993, P NATL ACAD SCI USA, V90, P11356, DOI 10.1073/pnas.90.23.11356; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1994, CURR OPIN CELL BIOL, V5, P806; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VALLES AM, 1991, CELL MOTILITY FACTOR, P17; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WU C, 1978, J CELL BIOL, V79, P113	54	137	141	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					475	484						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630631				2022-12-28	WOS:A1995RN53000007
J	SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G				SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G			RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS	ONCOGENE			English	Note						EBV; RB; P53; B-CELL; EBNA	EPSTEIN-BARR-VIRUS; ENCODED NUCLEAR ANTIGEN; TUMOR-SUPPRESSOR GENES; RETINOBLASTOMA PROTEIN; TRANSFORMATION INVITRO; GROWTH TRANSFORMATION; BURKITTS-LYMPHOMA; LYMPHOCYTES-B; ANTIBODIES; DIFFERENTIATION	Using immunofluorescence technique we have analysed the Rb, p53, EBNA-2 and EBNA-5 expression pattern in EBV infected human B-cells and established lymphoblastoid cell lines (LCL-s). Resting B-cells showed only a faint Rb and no p53 immunostaining. The expression of both Rb and p53 increased after EBV infection. The change was first detectable 6 h after infection. The frequency of brilliantly Rb positive cells increased more than p53 positives. EBNA-2 and EBNA-5 first detectable 12 h after infection. The frequency of EBNA positive cells in the freshly infected cultures was concordant with the proportion of CD23 and PCNA positives, but remained consistently below the frequency of Rb and p53 positive cells. Double immunofluorescence staining showed that all EBNA-5 positive cells were strongly Rb and p53 positive. LCL-s did not stain for p53, whereas the Rb staining was maintained at a high level. The EBNA-5 staining pattern changed from brilliant almost homogeneous nuclear staining in the freshly infected B-cells, to a nonhomogeneous pattern with a small number of strongly fluorescent nuclear bodies in established LCL-s. There was no change in the EBNA-2 staining pattern. Our findings indicate that the immortalization of B-cells by EBV may initially involve a high expression of EBNA-5, p53 and Rb, but only cells with low p53 and focal expression of EBNA-5 in nuclear bodies have the selective advantage required to grow into immortalized lines.	KAROLINSKA INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	SZEKELY, L (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Szekely, Laszlo/0000-0001-6144-6573	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA14054-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1992, J VIROL, V66, P7555, DOI 10.1128/JVI.66.12.7555-7559.1992; DILLNER J, 1988, INT J CANCER, V42, P721, DOI 10.1002/ijc.2910420516; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JIANG WQ, 1991, EXP CELL RES, V197, P314, DOI 10.1016/0014-4827(91)90438-Z; JIANG WQ, 1991, J CELL SCI, V99, P497; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817	32	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753563				2022-12-28	WOS:A1995QX46900021
J	PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM				PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM			THE MOTOGENIC AND MITOGENIC RESPONSES TO HGF ARE AMPLIFIED BY THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						MET ONCOGENE; HEPATOCYTE GROWTH FACTOR; SCATTER FACTOR; SHC; CELL MOTILITY	HEPATOCYTE GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SCATTER FACTOR-RECEPTOR; C-MET PROTOONCOGENE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; RAS PROTEINS; GRB2	The receptor of Hepatocyte Growth Factor-Scatter Factor (HGF) is a tyrosine kinase which regulates cell motility and growth. After ligand-induced tyrosine phosphorylation, the HGF receptor associates with the Shc adaptor, via the SH2 domain. Site-directed mutagenesis of the HGF receptor indicates that phosphotyrosines y(1349)VHV and (YVNV)-V-1356 can work as docking sites for Shc. The K-d of this interaction, measured in real time using synthetic phosphopeptides and recombinant She on a BIAcore biosensor, is 150 nm for both sites. After stimulation of the HGF receptor, Shc is phosphorylated on (YVNV)-V-317, generating an high affinity binding site for Gr62 (K-d = 15 nM). This duplicates the high affinity binding site for Grb2 present on the HGF receptor ((YVNV)-V-1356). Thus HGF stimulation can trigger the Ras pathway by recruiting Gr62 both directly through the receptor, and indirectly, through Site. Overexpression of wild-type She, but not of the Y-317 --> F mutant, enhances cell migration and growth in response to HGF. These data show that Shc is a relevant substrate of the HGF receptor, and works as an 'amplifier' of the motogenic as well as of the mitogenic response.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Turin; University of Perugia; Ludwig Institute for Cancer Research			Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017; Giordano, Silvia/J-9858-2018; Lanfrancone, Luisa/AAC-8671-2019; BARDELLI, Alberto/J-9721-2018	Pelicci, Giuliana/0000-0003-0986-8255; Giordano, Silvia/0000-0003-1854-1086; Lanfrancone, Luisa/0000-0002-4523-3815; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Salcini, Anna Elisabetta/0000-0001-5828-2512				ALBINI A, 1987, CANCER RES, V47, P3239; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHERARDI E, 1991, CANCER CELLS, V31, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU C, 1992, ONCOGENE, V7, P181; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OBERMEIER A, 1993, J BIOL CHEM, V267, P22963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1993, CELL, V71, P1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	55	186	197	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731718				2022-12-28	WOS:A1995QU68100020
J	MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y				MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y			ERBB-3 MEDIATES DIFFERENTIAL MITOGENIC EFFECTS OF NDF HEREGULIN ISOFORMS ON MOUSE KERATINOCYTES	ONCOGENE			English	Article						EGF FAMILY; TYROSINE KINASE; GROWTH FACTOR; SIGNAL TRANSDUCTION; ONCOGENE	FACTOR RECEPTOR FAMILY; GROWTH-FACTOR; HUMAN-BREAST; SIGNAL TRANSDUCTION; TYROSINE KINASE; MAMMARY-TUMORS; NERVOUS-SYSTEM; LIGAND; CELLS; EXPRESSION	The family of Neu differentiation factors (NDFs, or heregulins) includes a dozen secreted glycoproteins, whose receptor binding domain displays two variants, alpha and beta, and they bind to two receptor tyrosine kinases, ErbB3 and ErbB-4. Certain isoforms were reported to induce growth-arrest and differentiation of mammary tumor cells, while other breast cancer cell lines responded mitogenically, The present study addressed the biologic effects of various NDF isoforms on normal EGF-dependent epithelial cells, Balb/MK keratinocytes, that can undergo either proliferation or differentiation, We found that beta isoforms of NDF induced a mitogenic effect, that was significantly smaller than the maximal response to EGF, By contrast with NDF-beta, NDF-alpha isoforms exerted almost no mitogenic effect, but they were sufficient to maintain keratinocytes in culture, Consistent with their higher mitogenic potency, NDF-beta isoforms bound to Balb/MK cells with higher affinity (K-d=2.2 nM) than alpha isoforms, however both groups shared their receptor, that we identified as ErbB-3. No transcript of ErbB-4 was detectable in the keratinocytes, but these cells express multiple NDF mRNAs and also ErbB-2, We conclude that different isoforms of NDF induce distinct growth regulatory effects on cultured keratinocytes, through direct interaction with ErbB-3.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Amgen; Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1993, CANCER RES, V53, P5251; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; FALCO JP, 1988, ONCOGENE, V2, P573; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORRURTREGER A, 1992, P NATL ACAD SCI USA, P1746; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAFRAN A, 1990, ONCOGENE, V5, P635; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STANCOVSKI I, 1993, REGULATORY MECHANISM, P161; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V1, P59; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	49	76	77	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1403	1411						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731691				2022-12-28	WOS:A1995QR65100018
J	SQUIRE, JA; THORNER, PS; WEITZMAN, S; MAGGI, JD; DIRKS, P; DOYLE, J; HALE, M; GODBOUT, R				SQUIRE, JA; THORNER, PS; WEITZMAN, S; MAGGI, JD; DIRKS, P; DOYLE, J; HALE, M; GODBOUT, R			COAMPLIFICATION OF MYCN AND A DEAD BOX GENE (DDX1) IN PRIMARY NEUROBLASTOMA	ONCOGENE			English	Article						GENE AMPLIFICATION; NEUROBLASTOMA; MYCN; RNA HELICASE; PROGNOSIS	HUMAN NEURO-BLASTOMA; N-MYC; CELL-LINES; HUMAN SARCOMAS; DNA-SEQUENCES; EXPRESSION; ONCOGENE; PROTEIN; REGION; FAMILY	DEAD box proteins are putative RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share eight conserved amino acid motifs, including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif. Recently, we have shown that the novel DDX1 gene containing a DEAD box motif maps to the same chromosome band as MYCN at 2p24 and is co-amplified with MYCN in retinoblastoma cell lines. Here, we show that the DDX1 gene is co-amplified with the MYCN gene in 2 of three neuroblastoma cell lines and that DDX1 RNA levels correlate with DDX1 gene copy number. Since amplification of MYCN is an indicator of poor prognosis in neuroblastoma, it was of interest to determine whether co-amplification with DDX1 occurred in clinical samples of neuroblastoma and whether such a finding carried any additional prognostic significance, We determined the gene copy number of DDX1 in 32 neuroblastoma patient samples (representative of all stages): 13 were MYCN amplified and 19 had normal copy numbers of the MYCN gene. Of the 13 neuroblastomas that were MYCN amplified, seven were also DDX1 amplified, Of the 19 that were not MYCN amplified, none were DDX1 amplified. This is the first example of a gene that is co-amplified with MYCN at a high frequency in neuroblastoma. While there was a trend towards a worse clinical outcome with co-amplification, the numbers were too small to reach significance.	UNIV ALBERTA, CROSS CANC INST, DEPT ONCOL, EDMONTON, AB T6G 1Z2, CANADA; HOSP SICK CHILDREN, DEPT PATHOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT PEDIAT, DIV ONCOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT SURG, DIV NEUROSURG, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA	University of Alberta; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Godbout, Roseline/I-4639-2016; Squire, Jeremy/A-9352-2012	Godbout, Roseline/0000-0002-4779-9265; Squire, Jeremy/0000-0002-9863-468X				AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMLER LC, 1992, ONCOGENE, V7, P807; Biedler JL, 1983, ADV CELL NEUROBIOL, V4, P268; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; COHN SL, 1991, PROG CLIN BIOL RES, V366, P21; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; GODBOUT R, 1992, GENE, V123, P195; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KHATIB ZA, 1993, CANCER RES, V53, P5535; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maniatis T, 1989, MOL CLONING; MONTGOMERY KT, 1988, ADV NEUROBLASTOMA RE, V2, P71; REIFENBERGER G, 1994, CANCER RES, V54, P4299; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SH, 1991, ADV NEUROBLASTOMA RE, V3, P71; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHILOH Y, 1986, CANCER RES, V46, P5297; SHIMADA H, 1984, J NATL CANCER I, V73, P406; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TONIN PN, 1989, ONCOGENE, V4, P1117; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522	42	86	89	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1417	1422						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731693				2022-12-28	WOS:A1995QR65100020
J	WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL				WONG, KK; HARDIN, JD; BOAST, S; COOPER, CL; MERRELL, KT; DOYLE, TG; GOFF, SP; CALAME, KL			A ROLE FOR C-ABL IN C-MYC REGULATION	ONCOGENE			English	Article						C-ABL; C-MYC; TRANSCRIPTION TYROSINE KINASE; ABL(ML) MOUSE	NF-KAPPA-B; TYROSINE KINASE; CELL-CYCLE; V-ABL; MESSENGER-RNA; GENE; BINDING; TRANSFORMATION; PROTEIN; PROMOTER	c-Abl, a nonreceptor tyrosine kinase, appears to play a role in cell cycle progression, cell proliferation and differentiation. Mice homozygous for a mutation in c-abl (abl(ml)), show pleiotropic abnormalities, including neonatal death, developmental defects, susceptibility to infection and dehydration (Schwartzberg et al., 1991). However, the exact substrates of c-Abl and the signal transduction pathways it might initiate are not known. We have examined how c-Abl affects c-myc expression by studying abl(ml) mice. Quantitative riboprobe analyses demonstrated that in the heart, liver, thymus, brain, testes, intestines and lung, there were no differences in the-steady-state level of c-myc RNA between the abl(ml) mice and Littermate controls. However, in adrenal glands, kidneys and splenic B cells, c-myc RNA levels were decreased approximately 50% compared to littermate controls. Induction of c-myc mRNA following activation of splenic B cells with LPS is also defective in abl(ml) splenocytes. Finally, me show that c-Abl can directly transactivate c-myc transcription. These results suggest that c-Abl is involved in the normal transcription regulation of c-myc in selected tissues and that decreased c-myc RNA could be one cause of abnormalities in the abl(ml) mice.	COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUYAO MP, 1990, CURR TOP MICROBIOL, V166, P211; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDIN JD, 1994, UNPUB; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MONROE JG, 1983, J IMMUNOL, V130, P626; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN R, 1993, ONCOGENES TUMOR SUPP, P167; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	47	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					705	711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862448				2022-12-28	WOS:A1995QH61200010
J	ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN				ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN			NOVEL REPLICATION INHIBITORY FUNCTION OF THE DEVELOPMENTAL REGULATOR TRANSCRIPTION REPRESSOR PROTEIN WT1 ENCODED BY THE WILMS-TUMOR GENE	ONCOGENE			English	Article							ZINC FINGER PROTEIN; SIMIAN-VIRUS 40; SV40 T-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; DNA-BINDING DOMAIN; FACTOR-A-CHAIN; TRANSCRIPTIONAL ACTIVATOR; CELL-GROWTH; EGR FAMILY; SV40-TRANSFORMED CELLS	The tumor suppressor/developmental regulator protein WT1 encoded by the Wilms' tumor gene is a zinc finger-containing transcription factor which binds to the G + C-rich motif 5'-GCGGGGGCG-3' and represses transcription. Alternatively spliced variants of WT1 (termed + KTS) having an insertion in the zinc finger region are defective for binding to and hence for repression of transcription from promoters containing this motif. Due to the known interactions of two other tumor suppressor proteins with the simian virus 40 (SV40) oncoprotein large tumor antigen (TAg) [which in one case (p53) results in inhibition of the replication initiation activity of TAg], and because of the presence of G+C-rich sequences in the SV40 origin region, we tested the effect of WT1 on TAg- and SV40 origin-dependent DNA replication. WT1 and its alternatively spliced variants were found to be potent inhibitors of replication. Inhibition of replication by WT1 required portions of the N-terminal transcription repression domain and the C-terminal DNA binding domain, while other WT1 sequences needed for transcriptional regulation were dispensable. WT1 neither inhibited the synthesis of TAg nor formed a stable complex with it. Studies of the requirement of cis-active origin sequences in vivo and protein-DNA interactions in vitro indicated that WT1 and its alternatively spliced variants might inhibit replication by their novel binding to the GC box promoter motifs of the SV40 21 bp repeat replication-auxiliary sequence.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute					NCI NIH HHS [CA 52009, CA 47983] Funding Source: Medline; NCRR NIH HHS [S07 RR 05369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANT S, 1992, METHOD ENZYMOL, V216, P20; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOANG AT, 1992, MOL CELL BIOL, V12, P3087, DOI 10.1128/MCB.12.7.3087; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE NG, 1991, ONCOGENE, V6, P1161; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEVINS JR, 1992, SCIENCE, V258, P424; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Roswell D. F., 1978, METHOD ENZYMOL, V57, P409, DOI [10.1016/0076-6879(78)57038-9, DOI 10.1016/0076-6879(78)57038-9]; Sambrook J, 1989, MOL CLONING LABORATO; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SZYMANSKI P, 1990, J VIROL, V64, P1360, DOI 10.1128/JVI.64.3.1360-1365.1990; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG ZY, 1992, J BIOL CHEM, V267, P21999; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	12	12	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3113	3126						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936634				2022-12-28	WOS:A1994PM65800003
J	HUANG, AP; WRIGHT, JA				HUANG, AP; WRIGHT, JA			FIBROBLAST GROWTH-FACTOR MEDIATED ALTERATIONS IN DRUG-RESISTANCE, AND EVIDENCE OF GENE AMPLIFICATION	ONCOGENE			English	Article							DIHYDROFOLATE-REDUCTASE GENE; RIBONUCLEOTIDE REDUCTASE; CELL-LINES; DNA AMPLIFICATION; TUMOR PROGRESSION; AUTOCRINE GROWTH; FACTOR RECEPTOR; 3T3 CELLS; CAD GENE; TRANSFORMATION	We have investigated the drug resistance and gene amplification potential of NIH3T3 cells transfected with sequences coding for K-FGF, a known oncogene product, or bFGF, a non-oncogene member of the fibroblast growth factor family. Resistance to methotrexate, N-(phosphonacetyl)-L-aspartate and hydroxyurea was observed with K-fgf transfectants, due to amplification of dihydrofolate reductase, CAD or ribonucleotide reductase R2 genes, respectively. In keeping with the increase in gene amplification frequency, cells transfected with the K-fgf gene also exhibited a marked increase in CAD gene amplification rate, as determined by fluctuation analysis in the presence of N-(phosphonacetyl)-L-asparate. Cells transfected with bFGF encoding cDNA also exhibited a significant elevation in N-(phosphonacetyl)-L-aspartate resistance, and CAD gene amplification. Treatment with suramin, which interferes with the interaction of fibroblast growth factors with their cell surface receptors, did not decrease the drug resistance properties of K-fgf transfected cells. These observations with suramin and the findings with bFGF, which lacks a conventional signal sequence for secretion, suggests that the growth factor-mediated effects on drug resistance and gene amplification occur through an intracellular as opposed to autocrine mode of action. The finding that aberrant growth factor expression regulates gene amplification opens up new possibilities for investigating intracellular mechanisms relevant to this process and also describes new functions for the altered expression of K-FGF and bFGF, which are relevant to mechanisms of malignant progression.	UNIV MANITOBA, MANITOBA INST CELL BIOL, 100 OLIVIA ST, WINNIPEG R3E 0V9, MB, CANADA	University of Manitoba								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BLAM SB, 1988, ONCOGENE, V3, P129; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; Brigstock DR, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104815; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CILLO C, 1987, CANCER RES, V47, P2604; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DAMEN JE, 1991, BIOCHIM BIOPHYS ACTA, V1097, P103, DOI 10.1016/0925-4439(91)90092-N; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DREWS RE, 1992, MOL CELL BIOL, V12, P198, DOI 10.1128/MCB.12.1.198; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EGAN SE, 1991, ENVIRON HEALTH PERSP, V93, P91, DOI 10.2307/3431175; EGAN SE, 1990, ANTICANCER RES, V10, P1341; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDS RG, 1981, J CELL PHYSIOL, V106, P309, DOI 10.1002/jcp.1041060218; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; HUANG SS, 1988, J BIOL CHEM, V263, P12608; Issandou M, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000289; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LAROCCA RV, 1990, CANCER CELL-MON REV, V2, P106; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; NOWELL PC, 1986, CANCER RES, V46, P2203; OTTO E, 1989, J BIOL CHEM, V264, P3390; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RODECK U, 1991, CANCER CELL-MON REV, V3, P308; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SHIGESADA K, 1985, MOL CELL BIOL, V5, P1735, DOI 10.1128/MCB.5.7.1735; STARK GR, 1990, GENE REARRANGEMENT F, P99; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	67	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					491	499						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7904743				2022-12-28	WOS:A1994MW24800016
J	HUSSAIN, SP; AGUILAR, F; CERUTTI, P				HUSSAIN, SP; AGUILAR, F; CERUTTI, P			MUTAGENESIS OF CODON-248 OF THE HUMAN P53 TUMOR-SUPPRESSOR GENE BY N-ETHYL-N-NITROSOUREA	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; GENOTYPIC ANALYSIS; DNA-POLYMERASE; NITRIC-OXIDE; MUTATIONS; SEQUENCES; REPAIR; DAMAGE; INVIVO; SITES	Base pair mutations in the p53 tumor suppressor gene are among the most frequently observed genetic changes in human malignancies. Several mutational hotspots have been identified and tumor- and tissue-specific differences have been observed. We studied the mutability of hotspot codon 248, CGG, in human fibroblasts in response to the alkylating agent N-ethyl-N-nitrosourea (ENU) by MspI RFLP/PCR analysis. Alkylating agents are implicated as etiological agents in carcinogenesis in the gut and other tissues in the human. ENU induced preferentially G to A transitions in the non-transcribed strand. The predominant mutation involving the G-residue of the CpG dinudeotide was observed with an absolute frequency of 4 x 10(-7). The corresponding C to T transition in the first position of codon 248 was observed at several fold lower frequency suggesting more efficient excision repair of the transcribed strand. The G to A transition in the third position of codon 248 occurred at low frequency. Our results are compatible with a role for aliphatic alkylating agents in human tumors with codon 248 mutations since almost all mutations reported in this codon are transitions in the CpG-dinucleotide.	SWISS INST EXPTL CANC RES, DEPT CARCINOGENESIS, CH-1066 LAUSANNE, SWITZERLAND	Swiss Institute Experimental Cancer Research				Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1993, IN PRESS METHODS T B, V1; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTSCH H, 1990, MUTAT RES, V238, P255, DOI 10.1016/0165-1110(90)90017-6; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HANAWALT PC, 1989, GENOME, V31, P605, DOI 10.1139/g89-113; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; RECIO L, 1990, MUTAGENESIS, V5, P505, DOI 10.1093/mutage/5.5.505; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; Singer B., 1983, MOL BIOL MUTAGENS CA; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; ZIJLSTRA J, 1990, PROG CLIN BIOL RES, V347, P187	24	40	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					13	18						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905619				2022-12-28	WOS:A1994MW24700002
J	KOMADA, M; KITAMURA, N				KOMADA, M; KITAMURA, N			THE CELL-DISSOCIATION AND MOTILITY TRIGGERED BY SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR ARE MEDIATED THROUGH THE CYTOPLASMIC DOMAIN OF THE C-MET RECEPTOR	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; HUMAN-FIBROBLASTS; EPITHELIAL-CELLS; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; CHIMERIC RECEPTOR; MOLECULAR-CLONING; RAT HEPATOCYTES; HEPATOPOIETIN-A	Scatter factor (SF), which dissociates epithelial cell colonies into individual cells and stimulates the migration of epithelial cells, is identical to hepatocyte growth factor (HGF), a mitogen for melanocytes, endothelial cells and epithelial cells, including hepatocytes. It was previously shown by cDNA transfection that the mitogenic effect of SF/HGF is mediated by activation of the tyrosine phosphorylation of the c-Met receptor (the c-met protooncogene product). In this study, we constructed a cDNA encoding a chimeric receptor composed of the extracellular domain of the epidermal growth factor (EGF) receptor and the transmembrane and cytoplasmic domains of the c-Met receptor. We transfected the cDNA into the B16-F1 mouse melanoma cell line to investigate whether the cell dissociation and motility were mediated through this chimeric receptor following ligand stimulation. The chimeric receptor cDNA was expressed in the transfected cells and the protein product was transported to the cell surface in the correct transmembrane orientation. EGF treatment of the chimeric receptor-expressing cells markedly enhanced tyrosine phosphorylation of the chimeric receptor and led to scattered morphology and enhanced motility. This scattered morphology was inhibited by a tyrosine kinase inhibitor. Based on these results, we concluded that the cell dissociation and motility triggered by SF/HGF were mediated through the cytoplasmic domain of the c-Met receptor by activation of its tyrosine kinase. Thus, it is likely that the different biological effects of SF/HGF are mediated by different intracellular signal cascades.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; BARDELLI A, 1992, ONCOGENE, V7, P1973; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHAN AML, 1988, ONCOGENE, V2, P593; DAS M, 1978, P NATL ACAD SCI USA, V75, P2644, DOI 10.1073/pnas.75.6.2644; DEMOUZON SH, 1992, J CELL PHYSL, V150, P180; FIDLER IJ, 1975, CANCER RES, V35, P218; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KING AC, 1982, J BIOL CHEM, V257, P3053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1989, CANCER RES, V49, P3314	65	57	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2381	2390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689722				2022-12-28	WOS:A1993LT36800008
J	ANGUS, J; THOMSON, F; MURPHY, K; BAKER, E; SUTHERLAND, GR; PARSONS, PG; STURM, RA				ANGUS, J; THOMSON, F; MURPHY, K; BAKER, E; SUTHERLAND, GR; PARSONS, PG; STURM, RA			THE BRN-2 GENE REGULATES THE MELANOCYTIC PHENOTYPE AND TUMORIGENIC POTENTIAL OF HUMAN-MELANOMA CELLS	ONCOGENE			English	Article						BRN-2; POU DOMAIN; MELANOMA; ANTISENSE RNA; MICROPHTHALMIA; ICAM-1	HUMAN-MALIGNANT MELANOMA; OCTAMER-BINDING-PROTEINS; CENTRAL-NERVOUS-SYSTEM; POU-DOMAIN; DIFFERENTIATING AGENTS; TRANSCRIPTION FACTORS; ADHESION MOLECULES; DNA-BINDING; SCID MOUSE; EXPRESSION	The Oct transcription factors N-Oct-3 and N-Oct-5 are differentially expressed in normal melanocytes, melanoma tumors and cell lines. We have cloned the human brn-2 gene and have shown that it encodes both the N-Oct-3 and N-Oct-5 octamer binding activities detected in melanoma cells. The brn-2 genomic locus has been mapped to chromosome 6q16 and although chromosomal aberrations are common in this region in melanoma, no deletion or rearrangement of the brn-2 gene in melanoma cell lines was observed. Sequencing of the entire gene showed that there are no intervening sequences within the open reading frame. Antisense RNA-mediated inhibition of brn-2 gene expression in melanoma cells was associated with a change in morphology and loss of melanocytic and neural crest markers, including the melanocyte transcription factor microphthalmia and the TYRP pigmentation genes. In addition, loss of brn-2 in these cells resulted in the complete loss of ability to form tumors in SCID and nu/nu mice. These results suggest roles for brn-2 in the determination of the melanocytic lineage and in the tumorigenic phenotype of melanoma.	UNIV QUEENSLAND, CTR MOLEC & CELLULAR BIOL, ST LUCIA, QLD 4072, AUSTRALIA; QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, HERSTON, QLD 4029, AUSTRALIA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOLEC GENET, ADELAIDE, SA 5006, AUSTRALIA	University of Queensland; QIMR Berghofer Medical Research Institute; Womens & Childrens Hospital Australia			Sturm, Richard A/C-9943-2009; Sutherland, Grant Robert/D-2606-2012; Parsons, Peter G/H-8163-2015	Sturm, Richard A/0000-0003-1301-0294; Parsons, Peter G/0000-0002-0473-3346				AVRAHAM KB, 1993, GENOMICS, V18, P131, DOI 10.1006/geno.1993.1436; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BHAT KM, 1994, DEVELOPMENT, V120, P1483; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHAR BR, 1994, DEVELOPMENT, V120, P1929; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MILLIKIN D, 1991, CANCER RES, V51, P5449; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NAKAJIMA T, 1982, CANCER, V50, P912, DOI 10.1002/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U; PARMITER AH, 1993, J INVEST DERMATOL, V100, pS254, DOI 10.1038/jid.1993.46; QIN XF, 1994, EMBO J, V13, P5967, DOI 10.1002/j.1460-2075.1994.tb06942.x; RESNICOFF M, 1994, CANCER RES, V54, P4848; RON D, 1992, BIOTECHNIQUES, V13, P866; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHREIBER E, 1992, CANCER RES, V52, P6121; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; TAKAHASHI H, 1990, PIGM CELL RES, V3, P223, DOI 10.1111/j.1600-0749.1990.tb00294.x; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; THOMSON JAF, 1994, INT J CANCER, V58, P285, DOI 10.1002/ijc.2910580223; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANDUINEN CM, 1994, CANCER-AM CANCER SOC, V73, P2131, DOI 10.1002/1097-0142(19940415)73:8<2131::AID-CNCR2820730818>3.0.CO;2-1; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WANG SL, 1993, P NATL ACAD SCI USA, V90, P10385, DOI 10.1073/pnas.90.21.10385; WELCH DR, 1994, ONCOGENE, V9, P255; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; YANG XH, 1993, GENE DEV, V7, P504, DOI 10.1101/gad.7.3.504; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	61	66	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					691	700						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651733				2022-12-28	WOS:A1995RQ46900011
J	SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY				SANCHEZPRIETO, R; LLEONART, M; CAJAL, SRY			LACK OF CORRELATION BETWEEN P53 PROTEIN LEVEL AND SENSITIVITY TO DNA-DAMAGING AGENTS IN KERATINOCYTES CARRYING ADENOVIRUS E1A MUTANTS	ONCOGENE			English	Article						ONCOGENES; ADENOVIRUS E1A; E1A MUTANTS; DRUG RESISTANCE; APOPTOSIS; P53	WILD-TYPE P53; CELL-DEATH; TUMOR-SUPPRESSOR; APOPTOSIS; TRANSFORMATION; INDUCTION; GENE; EXPRESSION; CHECKPOINT; ONCOGENE	p53 tumor suppressor protein is required for efficient execution of apoptosis after DNA-damage in many cell systems. Since the oncogene E1a confers susceptibility to DNA-damaging agents and stabilizes p53 protein, we investigate whether the sensitivity to anticancer drugs of E1a-expressing cells was mediated by binding to a specific set of cellular proteins (p60, p105, p107 and p300) and related to the induction of apoptosis and the level of p53 protein. We studied the effect of cisplatin (CDDP), doxorubicin (DOX) and ionizing radiation (RX) on murine keratinocytes (PAM 212) transfected by the wild type E1a oncogene or several E1a mutants which bind to different subsets of cellular proteins. Keratinocytes transfected with the mutant d1787N (which binds to p60, p105, p107 and p300) showed a lethality in response to CDDP (10 mu g ml(-1)) fourfold higher than controls and threefold higher in response to DOX and radiation (5 grays). The sensitivity of keratinocytes carrying the mutant NTd1598 (binding to p105, p107 and p60) to DNA-damaging agents was similar to that of control keratinocytes, while mutant d1992/947 (binding only to p300) were resistant to CDDP and RX but sensitive to DOX. Apoptosis (after 24 h) studied by DNA fragmentation and flow cytometry was only observed in cells carrying the wild type E1a or the mutant d1787N. After treatment with DNA-damaging agents, p53 protein expression increased in all the cell lines and no rE1ation to sensitivity to anticancer agents or induction of apoptosis was observed. From these results, we conclude that cell sensitivity to cisplatin and ionizing radiation induced by the E1a oncogene requires binding to p105, p107 and p300 cellular proteins, while sensitivity to Doxorubicin requires binding only to p300. Interestingly, p53 protein levels were related to the binding to the p300 protein. The high levels of p53 after CDDP and DOX in the mutant d1922/947, which are only sensitive to DOX, suggest that E1a oncogene products may induce sensitivity to DNA-damaging agents by p53-related and unrelated pathways.	CLIN PUERTA DE HIERRO,DEPT PATHOL,E-28035 MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Prieto, Ricardo/AAZ-7221-2021; Ramon y Cajal, Santiago/H-4955-2016; Sanchez-Prieto, Ricardo/AAY-4271-2021	Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lleonart Pajarin, Matilde/0000-0002-6196-7405				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAJAL SRY, 1994, AM J PATHOL, V145, P846; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS CA, 1993, CANCER RES, V53, P1735; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FLORINCHRISTENS.M, 1993, EXP CELL RES, V207, P57; FREEDMAN CA, 1980, PHARMACOLOGY, V20, P133; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWE SW, 1994, J EXP MED, V266, P807; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; RAFF MC, 1993, SCIENCE, V262, P694; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	46	49	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					675	682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651731				2022-12-28	WOS:A1995RQ46900009
J	WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D				WOLF, DA; HERMEKING, H; ALBERT, T; HERZINGER, T; KIND, P; EICK, D			A COMPLEX BETWEEN E2F AND THE PRB-RELATED PROTEIN P130 IS SPECIFICALLY TARGETED BY THE SIMIAN-VIRUS-40 LARGE T-ANTIGEN DURING CELL-TRANSFORMATION	ONCOGENE			English	Article						TRANSFORMATION; E2F; P130; SV40 LARGE T ANTIGEN; CELL CYCLE	RETINOBLASTOMA SUSCEPTIBILITY GENE; TRANSCRIPTION FACTOR E2F; CYCLIN-A; VIRAL ONCOPROTEINS; BINDING PROTEIN; PRODUCT; RB; INHIBITION; EXPRESSION; KINASE	The p130 protein is a recently cloned member of the retinoblastoma protein family. We show here that transformation of NIH3T3-L1 fibroblasts (L1 cells) by the simian virus 40 large T antigen (LTAg) depends on the disruption of DNA binding complexes between transcription factor E2F and p130. LTAg binds to the pocket region of p130 in vivo and disrupts the E2F-p130 complexes. E2F-p130 complexes are present only in quiescent L1 cells and disappear at the G1/S phase boundary concomitantly to induction of DNA synthesis and expression of the E2F-regulated cdc2 gene. p130 is a substrate of cyclin-dependent kinase 2 (Cdk2) in vitro and associates with a Cdk in vivo which is activated upon serum stimulation in late G1. Overexpression of p130 inhibits cdc2 promoter activity and entry of quiescent L1 cells into S phase. The results demonstrate that p130 is a negative regulator of cell cycle progression which is specifically targeted by LTAg during cell transformation.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070; Albert, Thomas Karl/0000-0002-2488-0706				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEW J, 1992, J BIOL CHEM, V267, P25922; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NEVINS JR, 1992, SCIENCE, V258, P424; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JW, 1994, SCIENCE, V246, P1467; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF DA, 1991, BRIT J CANCER, V64, P47, DOI 10.1038/bjc.1991.237; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; YEUNG RS, 1993, ONCOGENE, V8, P3465; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2067	2078						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784051				2022-12-28	WOS:A1995RB70300001
J	MUNN, KE; WALKER, RA; VARLEY, JM				MUNN, KE; WALKER, RA; VARLEY, JM			FREQUENT ALTERATIONS OF CHROMOSOME-1 IN DUCTAL CARCINOMA IN-SITU OF THE BREAST	ONCOGENE			English	Note						DCIA; BREAST; CHROMOSOME 1; MICRODISSECTION	INTRADUCTAL CARCINOMA; FOLLOW-UP; CANCER; GENE; HETEROZYGOSITY; DISTINCT; DELETION; REGIONS; BIOPSY; INSITU	Ductal carcinoma in situ (DCIS) of the breast is commonly described as a premalignant lesion, Using PCR to amplify DNA from areas of tumour cells which have been microdissected from fixed material, we have studied the involvement of chromosome 1 in 19 cases of DCIS, A series of microsatellite repeat polymorphisms has been used to define regions of allelic imbalance and this has confirmed the involvement in DCIS of six of the regions previously implicated in studies of invasive breast tumours. This suggests that these regions may harbour tumour suppressor genes, the inactivation of which is important for the early stages of breast tumour development. Analysis of separate ducts from within the same tumour has revealed-that the same genetic alterations are not necessarily present throughout the lesion. In addition we have found that in three cases where frank invasive carcinoma is also present, similar alterations can be detected in the in situ and invasive component.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT CANC GENET,CRC,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV LEICESTER,DEPT PATHOL,LEICESTER LE2 7LX,LEICS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Leicester								BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; BIECHE I, 1993, CANCER RES, V53, P1990; BIECHE I, 1990, HUM GENET, V85, P101; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COXMATISE T, 1994, NAT GENET, V6, P384; CROPP CS, 1993, CANCER RES, V53, P5617; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FRYKBERG ER, 1994, ADV SURG, V26, P29; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; KLEIN KG, 1994, CANCER GENET CYTOGEN, V73, P109, DOI 10.1016/0165-4608(94)90194-5; KUGOH HM, 1990, ONCOGENE, V5, P1637; MERLO GR, 1989, CANCER RES, V49, P6966; MITCHELL ELD, 1990, GENE CHROMOSOME CANC, V2, P278, DOI 10.1002/gcc.2870020405; NIELSEN KV, 1989, ACTA ONCOL, V28, P919, DOI 10.3109/02841868909092332; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Sambrook J., 1989, MOL CLONING; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VERBEEK AL, 1984, LANCET, P1222; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	26	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1653	1657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731721				2022-12-28	WOS:A1995QU68100023
J	AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M				AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M			A RECIPROCAL TRANSLOCATION (1-15) (36.2-Q24) IN A NEUROBLASTOMA CELL-LINE IS ACCOMPANIED BY DNA DUPLICATION AND MAY SIGNAL THE SITE OF A PUTATIVE TUMOR SUPPRESSOR-GENE	ONCOGENE			English	Article						D1S1160/D1S244; PEDIATRIC YEAST ARTIFICIAL CHROMOSOME (YAC); FLUORESCENCE IN SITU HYBRIDIZATION (FISH)	HUMAN NEURO-BLASTOMA; YEAST ARTIFICIAL CHROMOSOMES; N-MYC AMPLIFICATION; HUMAN GENOME; SHORT ARM; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; ABNORMALITIES; DEFINITION	Cytogenetic analyses and molecular deletion studies of human neuroblastomas have indicated the chromosomal bands 1p36.1-1p36.2 as a location of genetic information which may be involved in tumorigenesis. To define this putative neuroblastoma locus in more detail we have analysed cell lines with alterations of distal Ip, Here we show, by fluorescence in situ hybridization (FISH), that cell line NGP has a reciprocal 1;15 translocation. Loci D1S214/D1S96 could be shown to map telomeric/distal, D1S228 centromeric/proximal to the break, We have identified yeast artificial chromosomes (YACs) that cover the break and map to D1S160 and D1S244. This chromosomal position is within the smallest region of overlap (SRO) found in neuroblastoma tumors (Weith et al., 1989; Caron et al., 1993; Schleiermacher ct al., 1994) and within the region of a constitutional interstitial deletion of a neuroblastoma patient (Biegel et al., 1993). Mapping studies with FISH revealed that the translocation is associated with duplication of DNA. It appears, as if the subchromosomal region we describe here is a good candidate for harboring the postulated neuroblastoma suppressor-gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE		AMLER, LC (corresponding author), GERMAN CANC RES CTR,DEPT CYTOGENET,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARILLOT E, 1992, NUCLEIC ACIDS RES, V19, P6241; BARKER PE, 1993, ONCOGENE, V8, P3353; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUNT JD, 1990, GENE CHROMOSOME CANC, V2, P137, DOI 10.1002/gcc.2870020210; LAHTI MJ, 1994, NAT GENET, V7, P370; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUREYS G, IN PRESS ONCOGENE; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; PIETSCH T, 1988, ANTICANCER RES, V8, P1329; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; Sambrook J, 1989, J SAMBROOK MOL CLONI; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHAFER BW, 1993, GENOMICS, V17, P249, DOI 10.1006/geno.1993.1315; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1982, J IMMUNOL, V128, P983; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WADA RK, 1988, ADV NEUROBLASTOMA RE, V2, P57; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0	45	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1095	1101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700634				2022-12-28	WOS:A1995QN35300009
J	DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR				DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR			STRESS-ACTIVATED PROTEIN-KINASES BIND DIRECTLY TO THE DELTA-DOMAIN OF C-JUN IN RESTING CELLS - IMPLICATIONS FOR REPRESSION OF C-JUN FUNCTION	ONCOGENE			English	Article						JUN; AP-1; KINASE; SAPK	GLYCOGEN-SYNTHASE KINASE-3; TUMOR-NECROSIS-FACTOR; DNA-BINDING; V-JUN; PHOSPHORYLATION; TRANSCRIPTION; AP-1; INVITRO; FOS	The transactivating function of the c-Jun proto-oncogene component of the AP-1 transcription factor is acutely regulated by a wide variety of cellular signals via modulation of phosphorylation of two serines (63 and 73). The viral oncoprotein, v-Jun, while containing homologous serines, is not phosphorylated in cells. A novel family of stress-activated protein kinases (SAPKs), also termed Jun N-terminal domain kinases (JNKs), are responsible for mediating S63/73 phosphorylation in response to a variety of cellular stimuli including tumor necrosis factor-alpha, heat stress and u.v. light. The p54 alpha(1), alpha(2), p54 beta and p46 beta SAPKs are shown to bind directly to c-Jun but not to v-Jun, with an absolute requirement for c-Jun amino acids 31-47, a region deleted in v-Jun. Inactive SAPKs tightly bind c-Jun in resting cells and may be a manifestation of the 'delta' inhibitor, a previously described repressor of c-Jun function.	ONTARIO CANC INST,DIV CELL & MOLEC BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; MASSACHUSETTS GEN HOSP E,DIABET RES LABS,MED SERV,BOSTON,MA 02129	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alabama System; University of Alabama Birmingham; Beatson Institute			Woodgett, Jim/F-1087-2010; Gillespie, David/R-4771-2019	Woodgett, Jim/0000-0003-3731-5797; Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline; NIGMS NIH HHS [GM 46577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; DEGROOT RP, 1993, ONCOGENE, V8, P841; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEFFLER WK, 1994, NUCLEIC ACIDS RES, V22, P1305, DOI 10.1093/nar/22.7.1305; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; YAN MH, 1994, NATURE, V372, P798	35	108	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898927				2022-12-28	WOS:A1995QL03800006
J	DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ				DIB, A; ADELAIDE, J; CHAFFANET, M; IMBERT, A; LEPASLIER, D; JACQUEMIER, J; GAUDRAY, P; THEILLET, C; BIRNBAUM, D; PEBUSQUE, MJ			CHARACTERIZATION OF THE REGION OF THE SHORT ARM OF CHROMOSOME-8 AMPLIFIED IN BREAST-CARCINOMA	ONCOGENE			English	Article						AMPLIFICATION; BREAST CANCER; CHROMOSOME 8; MAPPING; ONCOGENE; YEAST ARTIFICIAL CHROMOSOMES	POLYMERASE CHAIN-REACTION; HUMAN GENOME; LINKAGE MAP; DNA AMPLIFICATION; HUMAN-TUMORS; PLAT GENES; CANCER; RECEPTOR; LIBRARY; CLONING	Chromosomal region 8p11.2-p12 is consistently amplified in human breast cancer, We have constructed a 2.8 Mb YAC contig of this region, centered on the human Fibroblast Growth Factor Receptor 1 (FGRF1) locus and encompassing the Adrenergic beta 3 Receptor (ADRB3) focus. A smaller centromeric YAC contig spanning 1.4 Mb was also assembled, and included the Ankyrin 1 (ANK1) and Tissue-type Plasminogen Activator (FLAT) genes, Results from mapping of the contigs showed physical linkage of the ADRB3 and FGFR1 genes, which were colocalized within the same YAC clone and separated by about 900 kb, FGFR1 being in centromeric position, It also showed physical linkage of ANK1 and FLAT genes, which appear to be separated by a maximum of 700 kb. In parallel, several loci were mapped according to their amplification status in a large panel of breast tumor samples. The overall amplification pattern suggested a continuous amplicon with a core around FGFR1. Data from both the detailed physical map and the amplification status allowed to establish the following gene order, from telomere to centromere: ADRB3-D8S105-FGFR1-ANK1-PLAT-POLB. The precise localization and YAC cloning of the core of the amplicon will allow to isolate a putative oncogene involved in mammary carcinogenesis.	INSERM,U119,MOLEC ONCOL LAB,F-13009 MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE; IGMM,CNRS,URA 9942,MONTPELLIER,FRANCE; LGMCH,CNRS,URA 1462,NICE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Theillet, Charles/O-7634-2018; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017	ADELAIDE, José JA/0000-0003-4364-9857; Birnbaum, Daniel/0000-0001-7920-9883; Theillet, Charles/0000-0001-5555-2759; CHAFFANET, Max/0000-0002-2344-1488; Le Paslier, Denis/0000-0003-4335-9956				ADELAIDE J, 1994, GENE CHROMOSOME CANC, V11, P66, DOI 10.1002/gcc.2870110111; ADNANE J, 1991, ONCOGENE, V6, P659; ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BRADFORD CR, 1991, GENE CHROMOSOME CANC, V3, P272, DOI 10.1002/gcc.2870030406; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROWNSTEIN BH, 1989, SCIENCE, V244, P1348, DOI 10.1126/science.2544027; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1993, GENOMICS, V15, P530, DOI 10.1006/geno.1993.1105; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; IMBERT A, 1994, CYTOGENET CELL GENET, V67, P175, DOI 10.1159/000133817; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KERANGUEVEN F, 1995, IN PRESS ONCOGENE; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LAMBERT S, 1990, P NATL ACAD SCI US, V87; LI X, 1994, GENOMICS, V19, P470, DOI 10.1006/geno.1994.1096; MARICS I, 1989, ONCOGENE, V4, P335; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; OCHMAN H, 1988, GENETICS, V120, P621; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAINTRUF C, 1991, CANCER GENET CYTOGEN, V52, P27, DOI 10.1016/0165-4608(91)90050-5; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; SZEPETOWSKI P, 1992, ONCOGENE, V7, P2513; THEILLET C, 1989, ONCOGENE, V4, P915; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TUTIC M, 1990, EUR J BIOCHEM, V188, P523, DOI 10.1111/j.1432-1033.1990.tb15431.x; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIEGANT J, 1991, GENOMICS, V10, P345, DOI 10.1016/0888-7543(91)90318-9; Wood S, 1993, Cytogenet Cell Genet, V64, P134; 1991, CYTOGENET CELL GENET, V58, P1	53	43	45	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					995	1001						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898940				2022-12-28	WOS:A1995QL03800021
J	DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC				DENBAKKER, MA; RIEGMAN, PHJ; HEKMAN, RACP; BOERSMA, W; JANSSEN, PJA; VANDERKWAST, TH; ZWARTHOFF, EC			THE PRODUCT OF THE NF2 TUMOR-SUPPRESSOR GENE LOCALIZES NEAR THE PLASMA-MEMBRANE AND IS HIGHLY EXPRESSED IN MUSCLE-CELLS	ONCOGENE			English	Article						NF2; TUMOR SUPPRESSOR GENE; CYTOSKELETON; MUSCLE CELLS	BILATERAL ACOUSTIC NEUROFIBROMATOSIS; TYPE-2 NEUROFIBROMATOSIS; UNITED-KINGDOM; RADIXIN; EZRIN; TALIN; CYTOSKELETON; CONFIRMATION; FAMILY; MOESIN	Neurofibromatosis type 2 (NF2) is a disease resulting in the formation of schwannomas of the eighth cranial nerve, and other central nervous system tumours. A tumour suppressor gene has been found to be responsible for this disorder. The 595 amino acid NF2 protein shows a great deal of homology to a superfamily of membrane organizing proteins. To generate antibodies against the NF2 protein four synthetic peptides (SP) were injected in rabbits. COS cells transfected with an NF2 cDNA construct in an expression vector were used for immunocytochemical staining experiments; lysates of transfected COS cells were used for Western blotting experiments, as were lysates of E. coli cultures transformed with an NF2 cDNA construct subcloned in a prokaryotic expression vector. In western blots all sera detected a band indicating the appropriate molecular weight in lysates of transfected COS cells and E. coli. Immunocytochemical staining experiments indicate that the NF2 protein localizes in or near the cell membrane. Immunohistochemical staining of human tissue sections demonstrated the presence of the NF2 protein in muscle-, and Schwann cells. These results support the hypothesis that the NF2 protein functions as a membrane organizing element.	TNO, MBL, DEPT IMMUNOL, 2280 HV RIJSWIJK, NETHERLANDS	Netherlands Organization Applied Science Research	DENBAKKER, MA (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PATHOL, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Riegman, Peter/GLS-0041-2022	Van der Kwast, Theodorus/0000-0001-8640-5786				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CLAUDIO JO, 1994, HUM MOL GENET, V3, P185; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; GUTMANN DH, 1993, ARCH NEUROL-CHICAGO, V50, P1185, DOI 10.1001/archneur.1993.00540110065007; HARA T, 1994, CANCER RES, V54, P330; HAWKES R, 1986, METHOD ENZYMOL, V121, P484; IRVING RM, 1994, HUM MOL GENET, V3, P347, DOI 10.1093/hmg/3.2.347; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KUPFER MIK, 1989, ARCH OPHTHALMOL-CHIC, V107, P541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDAU K, 1993, BRIT J OPHTHALMOL, V77, P646, DOI 10.1136/bjo.77.10.646; LOWLY DR, 1993, CIBA F S, V176, P67; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MULVIHILL JJ, 1990, ANN INTERN MED, V113, P39, DOI 10.7326/0003-4819-113-1-39; PAKKANEN R, 1988, J CELL BIOCHEM, V38, P65, DOI 10.1002/jcb.240380107; PYKETT MJ, 1994, HUM MOL GENET, V3, P559, DOI 10.1093/hmg/3.4.559; RAGGE NK, 1993, BRIT J OPHTHALMOL, V77, P662, DOI 10.1136/bjo.77.10.662; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; RICCARDI V M, 1989, Neurofibromatosis, V2, P284; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SATO N, 1992, J CELL SCI, V103, P131; STERNBERGER LA, 1979, J HISTOCHEM CYTOCHEM, V27, P1424, DOI 10.1177/27.11.92498; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; WEBB MAP, 1986, NEW ENGL J MED, V315, P1553; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J	40	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					757	763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862453				2022-12-28	WOS:A1995QH61200016
J	SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM				SAPI, E; FLICK, MB; GILMOREHEBERT, M; RODOV, S; KACINSKI, BM			TRANSCRIPTIONAL REGULATION OF THE C-FMS (CSF-1R) PROTOONCOGENE IN HUMAN BREAST-CARCINOMA CELLS BY GLUCOCORTICOIDS	ONCOGENE			English	Article						C-FMS; PROTOONCOGENE; GLUCOCORTICOIDS; BREAST NEOPLASMS; TRANSCRIPTIONAL REGULATION RU486	COLONY-STIMULATING FACTOR; GENE-EXPRESSION; RECEPTOR GENE; MESSENGER-RNA; GROWTH-FACTOR; V-FMS; ADENOCARCINOMAS; MONOCYTES; INVITRO; PRODUCT	Expression of the macrophage colony stimulating factor CSF-1 and its receptor, the c-fms proto-oncogene, has been observed in macrophages, trophoblast and in a variety of neoplasms of epithelial origin including those of the breast. We have reported earlier (Oncogene, 1991, 6: 941-952) that c-fms transcript and protein expression were dramatically increased in several breast carcinoma cell lines by glucocorticoids which are essential humoral regulators of normal mammary epithelial cell differentiation. In this communication, we demonstrate that levels of c-fms transcript and protein increased significantly within the first few hours of glucocorticoid treatment, and that these increases were completely abolished by pretreatment of cells with mifepristone (RU486). We also demonstrate that such early increases in c-fms transcript levels could not be attributed to prolongation of transcript half-life. Both promoters of the c-fms gene were found to exhibit some basal activity in breast carcinoma cell lines and both were stimulated 2-3-fold by glucocorticoids. However the first promoter was shown to be responsible for more than 95% of the observed c-fms transcription. Sequence upstream of both promoters was found to contain potential 'glucocorticoid response elements' (GREs), and in each case, elimination of the GRE closest to the promoter abolished glucocorticoid stimulation. Our observations suggest that one mechanism by which glucocorticoids regulate the proliferation and differentiation of neoplastic mammary epithelial cells is through their regulation of transcription of the gene for the receptor of a ubiquitous cytokine, CSF-1.	YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NATIONAL CANCER INSTITUTE [R01CA047292] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-47292] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKKER GH, 1987, CANCER TREAT REP, V71, P1021; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BRUCKNER A, 1992, CANCER RES, V52, P3043; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHAMBERS SK, 1994, STEROIDS, V59, P514, DOI 10.1016/0039-128X(94)90069-8; COPE CL, 1972, ADRENAL STEROIDS DIS; COUSSENS L, 1986, NATURE, V320, P180; DAITER E, 1992, J CLIN ENDOCR METAB, V74, P850, DOI 10.1210/jc.74.4.850; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAGNE D, 1985, J STEROID BIOCHEM, V23, P247, DOI 10.1016/0022-4731(85)90401-7; GAILLARD RC, 1985, J CLIN ENDOCR METAB, V61, P1009, DOI 10.1210/jcem-61-6-1009; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GUSELLA GL, 1990, J IMMUNOL, V111, P3571; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEISTERKAMP N, 1983, VIROLOGY, V126, P248, DOI 10.1016/0042-6822(83)90476-2; HORIGUCHI J, 1988, BIOCHEM BIOPH RES CO, V157, P395, DOI 10.1016/S0006-291X(88)80060-3; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KLIJN JGM, 1989, CANCER RES, V49, P2851; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANDELONDE T, 1987, HORMONAL MANIPULATIO; Maniatis T., 1982, MOL CLONING; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBERTS WM, 1992, BLOOD, V79, P586; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P666; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WEBER B, 1989, MOL CELL BIOL, V9, P768; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	49	53	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					529	542						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845678				2022-12-28	WOS:A1995QF64800014
J	PLET, A; EICK, D; BLANCHARD, JM				PLET, A; EICK, D; BLANCHARD, JM			ELONGATION AND PREMATURE TERMINATION OF TRANSCRIPTS INITIATED FROM C-FOS AND C-MYC PROMOTERS SHOW DISSIMILAR PATTERNS	ONCOGENE			English	Article						IN VIVO FOOTPRINT; C-FOS AND C-MYC; PROTOONCOGENES; INTRAGENIC BLOCK; ELONGATION	RNA POLYMERASE-II; SEQUENCE REQUIREMENTS; DROSOPHILA-MELANOGASTER; TRANS-ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION; MESSENGER-RNA; INVIVO; BLOCK; CELLS	RNA polymerase II seems to be prone to stop at intrinsic pause sites, thus introducing a further potential level of regulation. It was recently shown that RNA polymerase Lf was held at the P2 promoter of c-myc gene. We confirmed the presence of engaged polymerases in the murine fibroblastic Ltk(-) and pre-B lymphoid 70Z3 cell lines. High resolution run-on analysis and in vivo permanganate-dependent footprinting showed that this holds true for the c-fos gene in unstimulated cells where a strong block to transcription elongation was evidenced. In contrast to what was observed in the c-myc gene, an even more intense signal was observed in run-on experiments downstream to the promoter, on a c-fos oligonucleotide including position +385 where an in vitro transcription arrest site was previously mapped. Genomic footprinting of DNA from intact cells and isolated nuclei confirmed the involvement of several thymidines belonging to a T-rich stretch in a melted region which was not detected upon polymerase release. In order to observe a short abortive c-fos transcript accumulating in vivo we resorted to microinjection of c-fos templates in Xenopus oocytes where transcripts were stable.	UNIV MONTPELLIER 2,MONTPELLIER 1,FRANCE; FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY	Universite de Montpellier	PLET, A (corresponding author), INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,BP 5051,1919 ROUTE MENDE,MONTPELLIER 1,FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BONNIEU A, 1989, ONCOGENE, V4, P881; BURTON ZF, 1986, EMBO J, V5, P2923, DOI 10.1002/j.1460-2075.1986.tb04588.x; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MIRKOVITCH J, 1992, MOL BIOL CELL, V3, P1085, DOI 10.1091/mbc.3.10.1085; MORGAN GT, 1984, NUCLEIC ACIDS RES, V12, P6043, DOI 10.1093/nar/12.15.6043; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; PLET A, 1992, ONCOGENE, V7, P1847; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SALDITTGEORGIEF.M, 1980, CELL, V19, P69; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SZENTIRMAY MN, 1993, EMBO J, V12, P4677, DOI 10.1002/j.1460-2075.1993.tb06156.x; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	44	72	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					319	328						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838531				2022-12-28	WOS:A1995QC62400011
J	GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M				GILLARDON, F; ESCHENFELDER, C; UHLMANN, E; HARTSCHUH, W; ZIMMERMANN, M			DIFFERENTIAL REGULATION OF C-FOS, FOSB, C-JUN, JUNB, BCL-2 AND BAX EXPRESSION IN RAT SKIN FOLLOWING SINGLE OR CHRONIC ULTRAVIOLET-IRRADIATION AND IN-VIVO MODULATION BY ANTISENSE OLIGODEOXYNUCLEOTIDE SUPERFUSION	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; SUNBURN CELL; FOLLICULAR LYMPHOMA; GENE-EXPRESSION; PROTO-ONCOGENE; MESSENGER-RNA; VIRUS TYPE-1; DNA; APOPTOSIS; MOUSE	Single ultraviolet (u.v.) irradiation of mammalian cells in culture evokes the transcriptional activation of various proto-oncogenes, among them members of the fos/jun family which are known to play an important role in cell proliferation and differentiation. u.v. exposure of mammalian skin results in growth arrest and cell death followed by hyperproliferation of epidermal cells. To obtain information in vivo about a possible relationship between u.v.-induced proto-oncogene expression and cellular alterations, me have analysed the expression of c-fos, fosB, c-jun, junB, bcl-2 and bdx in rat epidermis after single and chronic u.v. irradiation. We present data demonstrating that the transcripts of these genes are constitutively expressed in the epidermis and that expression is differentially modulated by u.v. exposure, Single u.v. irradiation causes a rapid and sustained increase in c-jun, junB and c-fos mRNA and a decline in bcl-2 transcripts, whereas expression of bax remained unchanged. c-Fos and c-Jun immunoreactivity was localized throughout the epidermal cell layers 1.5 h after single irradiation, but restricted to basal cells at 48 h suggesting an involvement in both u.v.-induced apoptosis and hyperproliferation. 48 h after chronic exposure a significantly higher induction and a totally different pattern of epidermal proto-oncogene expression was detectable which may be associated with malignancy. Superfusion of rat skin with c-fos antisense oligodeoxynucleotides inhibited the increase in c-Fos immunolabeled epidermal cells 1.5 h after single u.v. irradiation demonstrating that antisense oligodeoxynucleotides are capable of penetrating mammalian skin and modulating the u.v. response in vivo. However, suppression of the early c-Fos activation did not significantly affect the formation of sunburn cells in the u.v.-exposed epidermis. Thus, c-Fos does not seem to play a major role in u.v.-induced apoptosis or other members of the fos/jun family may compensate for a loss in c-Fos.	HOECHST AG, GEN PHARMA RES G838, D-65926 FRANKFURT, GERMANY; UNIV HEIDELBERG, HAUT KLIN, D-69115 HEIDELBERG, GERMANY	Sanofi-Aventis; Ruprecht Karls University Heidelberg	GILLARDON, F (corresponding author), UNIV HEIDELBERG, INST PHYSIOL 2, INF 326, D-69120 HEIDELBERG, GERMANY.			Eschenfelder, Christoph/0000-0003-2766-2488				BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BHALLA K, 1992, BLOOD, V80, P2883; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BRUNET S, 1990, J PHOTOCH PHOTOBIO B, V6, P431, DOI 10.1016/1011-1344(90)85116-E; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNO K, 1981, PHOTOCHEM PHOTOBIOL, V34, P203; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dilworth D D, 1992, PCR Methods Appl, V1, P279; DONAWHO CK, 1991, CANCER METAST REV, V10, P177, DOI 10.1007/BF00049413; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; Ferre F, 1992, PCR Methods Appl, V2, P1; FISHER C, 1991, DEVELOPMENT, V111, P253; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GARMYN M, 1991, LAB INVEST, V65, P471; GILLARDON F, 1991, NEUROSCI LETT, V124, P144, DOI 10.1016/0304-3940(91)90080-D; GRASSILLI E, 1992, BIOCHEM BIOPH RES CO, V188, P1261, DOI 10.1016/0006-291X(92)91367-Y; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANADA K, 1991, J INVEST DERMATOL, V96, P838, DOI 10.1111/1523-1747.ep12474538; HERDEGEN T, 1991, J COMP NEUROL, V312, P1; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; IYER RP, 1990, J ORG CHEM, V55, P4693, DOI 10.1021/jo00302a039; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MAI S, 1989, J CELL SCI, V94, P609; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; MATTEUCCI MD, 1981, J AM CHEM SOC, V103, P3185, DOI 10.1021/ja00401a041; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; OLSEN WM, 1990, J INVEST DERMATOL, V94, P101, DOI 10.1111/1523-1747.ep12873961; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARRISH JA, 1979, DERMATOLOGY GENERAL, P957; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SAKAI M, 1989, CANCER RES, V49, P5633; Sambrook J, 1989, MOL CLONING LABORATO; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UHLMANN E, 1990, CHEM REV, V90, P544; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Weedon D, 1979, Am J Dermatopathol, V1, P133; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	59	71	72	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3219	3225						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936645				2022-12-28	WOS:A1994PM65800014
J	MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ				MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ			EVIDENCE THAT P53 AND BCL-2 ARE REGULATORS OF A COMMON CELL-DEATH PATHWAY IMPORTANT FOR IN-VIVO LYMPHOMAGENESIS	ONCOGENE			English	Article							WILD-TYPE P53; THYMOCYTE APOPTOSIS; LYMPHOID-TISSUES; BURKITT-LYMPHOMA; PROTEIN; MUTATIONS; GENE; ONCOGENES; HYPERPLASIA; PROGRESSION	Multistep lymphomagenesis involves the deregulation of oncogenes and inactivation of tumor suppressor genes resulting in altered rates of proliferation as well as apoptotic cell death in tumor cells. The contribution of bcl-2 and p53 to the regulation of cell death during lymphomagenesis is assessed using bcl-2-1g, p53 'knockout' (p53 KO), and p53 KO/bcl-2 hybrid mice. PCR-SSCP and DNA sequence analysis demonstrated that p53 somatic mutations are uncommon in lymphomas arising in bcl-2-Ig transgenic mice. Reduction in tumor latency was not observed in p53 KO/bcl-2 hybrid mice compared to p53 KO mice. Furthermore, overexpressed bcl-2 suppressed wild-type p53 associated apoptosis following gamma-radiation. These findings indicate that bcl-2 and p53 serve a suppressor and effector function, respectively, of a common cell death pathway. These findings also suggest that p53 somatic mutations provide no selective advantage during in vivo multistep lymphomagenesis in the context of bcl-2 gene deregulation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL RADIOTHERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DIV PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA062597, R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA54897] Funding Source: Medline; NCRR NIH HHS [RR5511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASTER JC, 1992, AM J PATHOL, V141, P291; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIMPENS J, 1991, ONCOGENE, V6, P2271; LOCOCO F, 1993, BLOOD, V82, P2289; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCDONNELL TJ, 1993, TRANSGENE, V1, P47; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORI N, 1992, BRIT J HAEMATOL, V81, P235, DOI 10.1111/j.1365-2141.1992.tb08213.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SANDER CA, 1993, BLOOD, V82, P1994; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	78	81	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3107	3112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936633				2022-12-28	WOS:A1994PM65800002
J	CHEN, YY; GILL, GN				CHEN, YY; GILL, GN			POSITIVE AND NEGATIVE REGULATORY ELEMENTS IN THE HUMAN ERBB-2 GENE PROMOTER	ONCOGENE			English	Article							FACTOR RECEPTOR PROMOTER; HUMAN-BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; C-ERBB-2 PROTOONCOGENE; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; THYROID-HORMONE; PROTO-ONCOGENE; DNA	Analysis of the proximal promoter of the human erbB-2 gene identified a 100 bp region that enhanced activity of the proximal TATA box 200-fold. DNase I footprinting mapped three Sp1 binding sites within this 100 bp region but only one of these sites was of high affinity and strongly correlated to Sp1-dependent activity in who. This Sp1 site overlapped the distal of two similar palindromic sequences. The proximal palindrome did not bind Sp1 but overlaps the CAAT box. When placed in the context of a heterologous promoter, the palindrome functioned as a positive response element. However, removal of the 5' half of the proximal palindrome increased promoter activity indicating that it functions as an inhibitory element within the erbB-2 context. Using electrophoretic mobility shift assays, a nuclear protein was detected that bound to either the 5' or 3' half of the palindrome but not to both. Analysis of the function of mutant sequences revealed maximal activity when both halves of the palindrome were intact with decreased but significant activity persisting when the 3' half of the palindrome was disrupted. Disruption of the 5' half of the palindrome impaired activity to a greater extent. These studies indicate erbB-2 promoter activity is positively regulated by Sp1 and negatively regulated in a position-dependent context by a protein that binds to a palindromic sequence.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NIDDK NIH HHS [DK 13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1990, ONCOGENE, V5, P237; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PRADHY LC, 1982, CELL, V28, P865; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TAL M, 1987, MOL CELL BIOL, V7, P2587; WHITE MRA, 1992, ONCOGENE, V7, P677; XU J, 1993, J BIOL CHEM, V268, P16065; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	32	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2269	2276						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913545				2022-12-28	WOS:A1994NX62900019
J	MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW				MCINTOSH, GG; ANDERSON, JJ; MILTON, I; STEWARD, M; PARR, AH; THOMAS, MD; HENRY, JA; ANGUS, B; LENNARD, TWJ; HORNE, CHW			DETERMINATION OF THE PROGNOSTIC VALUE OF CYCLIN D1 OVEREXPRESSION IN BREAST-CANCER	ONCOGENE			English	Article						CYCLIN D1; MONOCLONAL ANTIBODY; IMMUNOHISTOCHEMISTRY; BREAST CANCER; PROGNOSIS	CELL-CYCLE; GENE AMPLIFICATION; DNA-REPLICATION; EXPRESSION; ONCOGENE; RETINOBLASTOMA; PROGRESSION; CARCINOMAS; SURVIVAL; C-ERBB-2	Cyclin D1 plays a critical role in the timing of the initiation of DNA synthesis in the normal cell cycle of mammalian cells, Deregulated expression of this protein has been seen in a variety of tumours either as a result of gene amplification or chromosomal translocation, in breast cancer and B cell malignancies respectively. In order to determine the role this putative oncoprotein plays in breast cancer, we have applied a new monoclonal antibody, recently produced in our laboratory, in an imnunohistochemical study of 93 primary breast carcinomas. We show that approximately 28% of the cases displayed enhanced expression of the cyclin D1 protein. Furthermore, either cyclin D1, cyclin D3, or both, were expressed in 69% of cases, suggesting that overexpression of any one member of this family may relieve cancer cells of their mitogenic stimulatory requirement. In addition, we show that those patients whose breast cancers co-express cyclin D1 with either epidermal growth factor receptor (EGFR) or the retinoblastoma protein (pRB) have a significantly poorer prognosis in comparison to those expressing cyclin D1 alone. Our observations indicate that, in a subset of breast cancers, aberrant cyclin D1 expression is a contributory factor to tumorigenesis and in association with EGFR or pRB expression, identify those tumours which may require more aggressive therapy.	NOVOCASTRA LABS, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT SURG, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	MCINTOSH, GG (corresponding author), UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, DEPT PATHOL, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.		Angus, Brian/L-9246-2019	Angus, Brian/0000-0003-3598-7784				ADNANE J, 1989, ONCOGENE, V4, P1389; AJCHENBAUM F, 1992, J CELL BIOL, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CARTER MJ, 1993, NUCLEIC ACIDS RES, V21, P1044, DOI 10.1093/nar/21.4.1044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; HARPER JW, 1993, CELL, V75, P805; HASTRICH D, 1992, J PATHOL S, V167, pA143; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KCOH KS, 1994, BIOCHEM BIOPH RES CO, V204, P91; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, ONCOGENE, V6, P439; LI Y, 1994, ONCOGENE, V9, P2261; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; Maniatis T, 1989, MOL CLONING; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCINTOSH EM, 1993, MUTAT RES, V289, P61, DOI 10.1016/0027-5107(93)90131-X; MORGAN JM, 1994, J PATHOL, V174, P301, DOI 10.1002/path.1711740410; MORISAKI T, 1994, CANCER RES, V54, P1113; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NANXIN L, 1994, ONCOGENE, V9, P3457; PALMERO I, 1993, ONCOGENE, V8, P1049; PEPPER DS, 1994, BIOCHIM BIOPHYS ACTA, V1198, P215; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SURMACZ E, 1992, CANCER RES, V52, P4522; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1989, ONCOGENE, V4, P915; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; WRIGHT C, 1989, CANCER RES, V49, P2087; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZHANG SY, 1994, AM J CLIN PATHOL, V102, P695, DOI 10.1093/ajcp/102.5.695	52	212	215	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675447				2022-12-28	WOS:A1995RU79800009
J	SUEN, KL; BUSTELO, XR; BARBACID, M				SUEN, KL; BUSTELO, XR; BARBACID, M			LACK OF EVIDENCE FOR THE ACTIVATION OF THE RAS RAF MITOGENIC PATHWAY BY 14-3-3-PROTEINS IN MAMMALIAN-CELLS	ONCOGENE			English	Article						RAS PROTEINS; RAF KINASE; MEK; MAP KINASE; SIGNAL TRANSDUCTION	TYROSINE 3-MONOOXYGENASE; KINASE-C; TRANSFORMATION; IDENTIFICATION; FAMILY; DNA	We have isolated cDNA clones encoding the rodent 14-3-3 zeta and epsilon isoforms by screening bacteriophage expression libraries vith a probe derived from the carboxy-terminus of the Vav oncoprotein. These isoforms, however, did not recognize the full length Vav protein under physiological conditions. In agreement with previous studies (see D Morrison, Science 266, 56-57, 1994), these 14-3-3 proteins bound very efficiently to Raf. The interaction between 14-3-3 zeta and Raf involves the central region of 14-3-3 zeta which includes a motif related to annexins. 14-3-3 zeta binds to Raf independently of Ras and forms stable ternary complexes with these two molecules. In contrast to published reports, we have observed that the catalytic activity of Raf was not activated in Raf/14-3-3 zeta immunocomplexes. Likewise, purified preparations of 14-3-3 zeta had no effect on the kinase activity of Raf immunoprecipitates. In addition, Ras activated Raf regardless of whether it was bound or not to 14-3-3 zeta. Finally, overexpression of 14-3-3 zeta cDNA clones in NIH3T3 cells did not result in detectable morphologic transformation even when co-transfected with plasmids encoding Raf and/or Ras proteins. These observations argue against a critical regulatory role of the 14-3-3 proteins in the Raf mitogenic pathway.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DU XP, 1994, J BIOL CHEM, V269, P18287; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LOEB LA, 1986, J BIOL CHEM, V262, P10467; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V239, P853; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAHASHI N, 1991, J MOL BIOL, V217, P125; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X	39	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675443				2022-12-28	WOS:A1995RU79800002
J	BERBERICH, SJ; POSTEL, EH				BERBERICH, SJ; POSTEL, EH			PUF/NM23-H2/NDPK-B TRANSACTIVATES A HUMAN C-MYC PROMOTER-CAT GENE VIA A FUNCTIONAL NUCLEASE HYPERSENSITIVE ELEMENT	ONCOGENE			English	Article						PUF; NM23; NDPK; C-MYC; NUCLEASE HYPERSENSITIVE METASTASIS	NUCLEOSIDE DIPHOSPHATE KINASE; REGULATORY ELEMENTS; CHROMATIN STRUCTURE; TUMOR-METASTASIS; LEUKEMIA-CELLS; RNA LEVELS; TRANSCRIPTION; BINDING; RIBONUCLEOPROTEIN; DIFFERENTIATION	We have isolated the transacting factor PuF that, through its interaction with a nuclease hypersensitive element (NHE) located upstream of the c-myc gene, transactivates the human c-myc gene in vitro (Postel et al., 1989). PuF was recently identified as being encoded by the nonmetastatic 23-H2 (nm23-H2)/nucleoside diphosphate kinase-B (NDPK-B) gene (Postel ct al., 1993). In addition to its ability to transactivate the c-myc gene in vitro, PuF/NDPK-B catalyzes the shuttling of gamma-phosphates between nucleoside triphosphates and diphosphates (Gilles et al., 1991; Postel and Ferrone, 1994) and has been postulated to suppress tumor metastasis (Stahl et al., 1991). Here we have extended our studies of PuF and c-myc transcription by testing whether PuF affects c-myc transcription using a transient transfection assay. A plasmid containing the human c-myc promoter-NHE region was cloned upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene. When cotransfected with a PuF expression vector, CAT activity was elevated 3-4 fold relative to transfections containing the myc-CAT plasmid. In contrast, a myc-CAT reporter plasmid in which the NHE element was deleted showed no increase in CAT activity when cotransfected with the PuF expression vector. From these results we conclude that PuF transactivates the c-myc gene via the nuclease hypersensitive element.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	BERBERICH, SJ (corresponding author), WRIGHT STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, DAYTON, OH 45435 USA.				NCI NIH HHS [R01CA5584] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSO LE, 1985, CANCER RES, V45, P5035; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAHL JA, 1991, CANCER RES, V51, P445; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	31	133	133	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2343	2347						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784082				2022-12-28	WOS:A1995RE54300009
J	RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH				RASHEED, BKA; MCLENDON, RE; FRIEDMAN, HS; FRIEDMAN, AH; FUCHS, HE; BIGNER, DD; BIGNER, SH			CHROMOSOME-10 DELETION MAPPING IN HUMAN GLIOMAS - A COMMON DELETION REGION IN 10Q25	ONCOGENE			English	Note						GLIOBLASTOMA; CHROMOSOME 10; LOSS OF HETEROZYGOSITY	FACTOR RECEPTOR GENE; MALIGNANT GLIOMAS; GLIOBLASTOMA-MULTIFORME; HUMAN ASTROCYTOMAS; GLIAL ORIGIN; HETEROZYGOSITY; AMPLIFICATION; MUTATIONS; TUMOR; OLIGODENDROGLIOMAS	The high incidence of loss of chromosome 10 alleles in glioblastoma multiforme suggests the presence on this chromosome of a tumor suppressor gene that is important in glioma tumorigenesis and progression. Our initial deletion mapping studies using restriction fragment length polymorphism markers indicated a common deletion region in 10q24-qter. In an attempt to localize the deleted region further, we screened a panel of 117 gliomas for loss of heterozygosity for chromosome 10 loci using 10 microsatellite markers. Seventeen tumors showed partial loss of a copy of chromosome 10 and;were further analysed using 28 additional microsatellite markers. Of these, 10 had terminal deletion in the q arm, three had deletions in both p and q arms, two contained interstitial deletion in 10q and two carried deletions in 10p. In the 15 tumors with deletions in 10q, the minimal overlapping deletion region was in distal 10q between markers D10S587 and D10S216. Loci D10S587 and D10S216 are approximately mapped to a 5 cM region in 10q25.1.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,PREUSS LAB BRAIN TUMOR RES,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Duke University; Duke University; Duke University					NATIONAL CANCER INSTITUTE [R37CA043722, R01CA043722] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1988, CANCER RES, V48, P405; BURGER PC, 1991, SURGICAL PATHOLOGY N; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HE J, 1994, CANCER RES, V54, P5804; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MIYAKOSHI J, 1990, CANCER RES, V50, P278; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P348, DOI 10.1002/gcc.2870050411; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; REIFENBERGER G, 1993, CANCER RES, V53, P2736; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; VONDEIMLING A, 1992, CANCER RES, V52, P4277; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	24	197	205	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2243	2246						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784070				2022-12-28	WOS:A1995RB70300021
J	LIU, M; PELLING, JC				LIU, M; PELLING, JC			UV-B/A IRRADIATION OF MOUSE KERATINOCYTES RESULTS IN P53-MEDIATED WAF1/CIP1 EXPRESSION	ONCOGENE			English	Article						UV IRRADIATION; P53; WAF1/CIP1; KERATINOCYTE; SKIN CANCER	P53 MUTATIONS; ATAXIA-TELANGIECTASIA; SKIN-CANCER; DNA-DAMAGE; WILD-TYPE; CELL; RADIATION; PROTEIN; INDUCTION; ULTRAVIOLET	The tumor suppressor gene p53 is involved in controlling cell cycle checkpoint or triggering apoptosis. p53 may accomplish these roles by acting as a sequence-specific transcription factor, One of the downstream targets of p53 transcription control is the WAF1/CIP1 gene, whose gene product p21 interacts with several cyclins and cyclin-dependent kinases, resulting in inhibition of these kinases. Tn our previous studies, we have shown that the p53 protein level in mouse keratinocytes was elevated following UV-B/A irradiation. In this paper we further investigated the consequences of increased p53 protein level by characterizing p53 DNA-binding level and WAF1/CIP1 gene expression in UV-B/A-irradiated mouse keratinocytes. Consistent with the increased level of p53 protein, both p53 DNA-binding level and steady-state level of WAFI/CIP1 mRNA were elevated. We have demonstrated that the induction of WAF1/CIP1 mRNA was mediated by p53, since no WAF1/CIP1 induction was observed in p53-deficient cells upon W-B exposure. These observations suggest an important role for the tumor suppressor gene p53 in the response of keratinocytes to the biologically relevant W-BIA irradiation and in suppressing UV-induced skin cancer.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA040847, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727-07, CA40847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOL MOL; BEER JZ, 1993, PHOTOCHEM PHOTOBIOL, V58, P676, DOI 10.1111/j.1751-1097.1993.tb04951.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINALY CA, 1989, CELL, V57, P1083; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HERRLICH P, 1984, ADV ENZYME REGUL, V25, P485; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON BE, 1984, PHYSL PATHOPHYSIOLOG, V8, P2414; KANJILAL S, 1993, CANCER RES, V53, P2961; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOONE MD, 1986, J INVEST DERMATOL, V87, P343, DOI 10.1111/1523-1747.ep12524440; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOGANZO JF, 1994, MOL CELL DIFF, V2, P23; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHIELI P, 1994, CANCER RES, V54, P3391; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1993, ONCOGENE, V8, P3055; Romerdahl C A, 1989, Cancer Commun, V1, P209; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; URBACH F, 1984, TOPICS PHOTOMEDICINE, P67; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1994, CANCER RES, V54, P4448; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	48	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1955	1960						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761096				2022-12-28	WOS:A1995QZ92600009
J	BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER				BLYTH, K; TERRY, A; OHARA, M; BAXTER, EW; CAMPBELL, M; STEWART, M; DONEHOWER, LA; ONIONS, DE; NEIL, JC; CAMERON, ER			SYNERGY BETWEEN A HUMAN C-MYC TRANSGENE AND P53 NULL GENOTYPE IN MURINE THYMIC LYMPHOMAS - CONTRASTING EFFECTS OF HOMOZYGOUS AND HETEROZYGOUS P53 LOSS	ONCOGENE			English	Article						MYC; P53; LYMPHOMA	WILD-TYPE; P53-DEFICIENT MICE; CELL-LINE; APOPTOSIS; MUTATIONS; COOPERATION; EXPRESSION; ONCOGENE; LEUKEMIA; TUMORS	Activation of the c-myc oncogene and functional loss of the p53 tumour suppressor gene are among the most frequently recorded genetic lesions in neoplasia but their combined effect has not previously been investigated. By breeding together mice transgenic for human c-myc (CD2-myc) and mice carrying an inactive p53 allele (p53(-/-)) we found that these genetic lesions act synergistically in vivo, Offspring carrying the CD2-myc transgene and the homozygous p53 null mutation (p53(-/-)/CD2-myc) were viable but developed thymic lymphomas with dramatically increased frequency and reduced latency compared to both parental groups. The tumour phenotype was similar to that previously recorded for CD2-myc mice (predominantly CD3+, CD4+8+) but tumour clonal complexity and metastasis was significantly greater in the p53(-/-)/CD2-myc mice, In contrast, no significant increase in tumour incidence was seen in p53(+/-)/CD2-myc vs p53(+/+)/CD2-myc mice over a 6 month observation period, However, the loss of wild type p53 in a proportion of tumour cells in p53(+/-)/CD2-myc lymphomas suggests that wild type allele loss can occur as a late progression step rather than an initiating step in these tumours, We suggest that p53 loss of function may collaborate with the CD2-myc transgene at more than one stage in thymic lymphoma development.	UNIV GLASGOW, SCH VET, DEPT VET PATHOL, GLASGOW G61 1QH, LANARK, SCOTLAND; UNIV GLASGOW, SCH VET, DEPT VET ANIM HUSBANDRY, GLASGOW G61 1QH, LANARK, SCOTLAND; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	University of Glasgow; University of Glasgow; Baylor College of Medicine				Blyth, Karen/0000-0002-9304-439X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARTEK J, 1991, ONCOGENE, V6, P1699; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORN W, 1988, J IMMUNOL, V140, P3228; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FARRUGIA MM, 1994, BLOOD, V83, P191; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HAUPT Y, 1993, ONCOGENE, V8, P3161; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEWART M, 1993, INT J CANCER, V53, P1023; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	41	94	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1717	1723						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753548				2022-12-28	WOS:A1995QX46900004
J	HAUPT, Y; ROWAN, S; OREN, M				HAUPT, Y; ROWAN, S; OREN, M			P53-MEDIATED APOPTOSIS IN HELA-CELLS CAN BE OVERCOME BY EXCESS PRB	ONCOGENE			English	Article						P53; APOPTOSIS; PRB; TUNEL; TUMOR SUPPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; CYCLE CONTROL; GROWTH SUPPRESSION; PROTEIN; DEATH; IDENTIFICATION	Studies on DNA tumor viruses have suggested a link between p53 and pRB in the control of cell growth and apoptosis. We examined the role of pRB in the control of p53-mediated apoptosis in HeLa cells, in which the activities of p53 and members of the pRB family are very low, Transient overexpression of wild type (wt) p53 in HeLa cells induced apoptotic cell death. Importantly, coexpression of functional pRB resulted in significant protection of HeLa cells from p53-mediated apoptosis, without interfering with the transcriptional activity of wt p53. These results suggest that pRB, and possibly other pRB-related proteins, play a major role in the decision of whether cells respond to activated p53 by undergoing growth arrest or apoptosis. Our findings demonstrate a direct link between these two tumor suppressors in the control of cell growth and cell death.			HAUPT, Y (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743	NCI NIH HHS [R01 CA 4009] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1991, NATURE, V349, P802; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1994, CANCER BIOL, V5, P1; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRATTON MR, 1990, ONCOGENE, V5, P1297; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; VOUDSEN KH, 1993, ONCOGENE, V8, P1697; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1993, PROGRAMMED CELL DEAT, P187; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	79	157	158	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1563	1571						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731711				2022-12-28	WOS:A1995QU68100012
J	SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D				SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D			FIBROBLAST GROWTH-FACTOR RECEPTORS DISPLAY BOTH COMMON AND DISTINCT SIGNALING PATHWAYS	ONCOGENE			English	Article						FGF RECEPTORS SIGNALING; PROLIFERATION; LIGAND DEPENDENT TRANSFORMATION; TYROSINE PHOSPHORYLATION; KGF; AFGF	HIGH-AFFINITY RECEPTOR; FGF RECEPTOR; EXPRESSION PATTERN; TYROSINE KINASE; FACTOR FAMILY; CDNA CLONING; GENE FAMILY; BINDING; HEPARIN; MOUSE	We compared the mitogenic and signaling pathways of three Fibroblast Growth Factor Receptors (FGFRs), FGFR1, KGFR and FGFR4 in the same cell line. Each receptor was expressed in L6E9 rat myoblasts that do not normally express detectable levels of FGFRs and clones that express comparable levels of each receptor were selected. Our results show that FGFs induce an effective survival and growth of FGFR1 and KGFR expressing cells. In addition, these cells exhibit a morphology that is reminiscent of that of malignantly transformed cells and display anchorage independent growth in a ligand dependent manner. Unlike KGFR and FGFR1, FGFR4 mediates a less effective growth, and cells overexpressing this receptor do not undergo any morphological changes nor do they display an anchorage independent growth in response to FGFs, All three receptors exhibit both quantitative and qualitative differences in their ability to induce tyrosine phosphorylation of cellular substrates, Both FGFR1 and KGFR induce strong phosphorylation of phospholipase C-gamma and a 90 kDa protein, while FGFR4 induces a relatively weak phosphorylation of phospholipase C-gamma and completely fails to induce phosphorylation of the 90 kDa. The three receptors also induce phosphorylation of the mitogen activated protein kinases (MAPK) but the effect of FGFR1 is far stronger than that of the other two receptors, Since FGFR4 is expressed in myoblasts in vivo, we examined whether this receptor can function in the differentiation pathway of myoblasts. Contrary to its weak mitogenic activity, FGFR4 effectively mediates the inhibition of myogenic differentiation in L6E9 cells and also suppresses the expression of the myogenic regulatory protein myogenin, Taken together, our results suggest that the signaling mechanism of FGFR4 differs from that of FGFR1 and KGFR, and that the primary role of FGFR4 in myoblasts may be the maintenance of their non differentiated state.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Technion Israel Institute of Technology								ARNAUD PC, 1991, ONCOGENE, V6, P979; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GINARD BN, 1978, CELL, V15, P855; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOUHARA H, 1994, ONCOGENE, V9, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, P NATL ACAD SCI USA, V89, P3315, DOI 10.1073/pnas.89.8.3315; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STARK KL, 1991, DEVELOPMENT, V113, P641; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	64	118	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1553	1561						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731710				2022-12-28	WOS:A1995QU68100011
J	IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A				IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A			INDUCTION OF PLATELET-DERIVED GROWTH-FACTOR B/C-SIS BY THE V-ERBA ONCOGENE IN GLIAL-CELLS	ONCOGENE			English	Article						ERBA ONCOGENE; PDGF B/C-SIS; GLIAL CELLS; THYROID HORMONE RECEPTOR; AUTOCRINE STIMULATION	THYROID-HORMONE RECEPTOR; HUMAN-MALIGNANT GLIOMA; CENTRAL-NERVOUS-SYSTEM; C-ERBA; OLIGODENDROCYTE DEVELOPMENT; GENE-EXPRESSION; AB HETERODIMER; MESSENGER-RNA; PDGF-A; PROTEIN	The v-erbA oncogene codes for a mutated form of the thyroid hormone receptor TRlc-eubA-alpha, Thyroid hormone (triiodothyronine, T3) regulates glial functions such as myelination and both astrocytes and oligodendrocytes have been shown to express thyroid hormone receptors (TRs). To study putative effects of v-erbA on glial precursors, we have expressed it in a glial clonal cell line established from early embryonal mouse brain, We have found that v-erbA increases cell survival in serum-free conditions. Moreover, v-erbA-expressing cells show a substantial growth in the presence of insulin or IGF-I, whereas normal and TR/c-erbA-over-expressing cells progressively degenerate. By Northern blotting, immuno-fluorescence, immunoprecipitation, and neutralization experiments, we show that v-erbA actions are mediated by an increase in the levels of PDGF B/c-sis mRNA and protein. We used anti-PDGF receptor and antiphosphotyrosine antibodies to show the constitutive activation of PDGF receptors in B3.1+v-erbA cells, and neutralizing anti-PDGF antibodies to demonstrate that v-erbA enhances the secretion of active PDGF into the culture medium. Our data indicate that v-erbA induces PDGF B/c-sis, a factor involved in the generation df gliomas, the most common central nervous system tumor in humans.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; UNIV MAINZ,DIV HAMATOL ONKOL,INNERE MED KLIN 3,D-55131 MAINZ,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Johannes Gutenberg University of Mainz			Munoz, Alberto/O-6393-2014; , Susana/AAA-9282-2019; Bernal, Juan/J-6086-2014	Munoz, Alberto/0000-0003-3890-4251; Bernal, Juan/0000-0002-5867-4951; Llanos, Susana/0000-0002-8555-9326; Iglesias, Teresa/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1989, GENE DEV, V5, P2033; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GANDRILLON O, 1994, ONCOGENE, V9, P749; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HERMANSON M, 1992, CANCER RES, V52, P3213; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; IGLESIAS T, 1994, ENDOCR REV, V5, P697; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LENS PF, 1986, MOL CELL BIOL, V6, P3537, DOI 10.1128/MCB.6.10.3537; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1986, CANCER RES, V46, P332; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NISTER M, 1991, J BIOL CHEM, V266, P16755; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PAIN B, 1990, New Biologist, V2, P284; PASTOR R, 1994, ONCOGENE, V9, P1081; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; PRESS RD, 1989, CANCER RES, V49, P2914; PUYMIRAT J, 1986, NEUROSCI LETT, V68, P299, DOI 10.1016/0304-3940(86)90506-9; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RICHARDSON W D, 1991, Current Biology, V1, P162, DOI 10.1016/0960-9822(91)90220-Q; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTPHAL M, 1988, CANCER LETT, V38, P283, DOI 10.1016/0304-3835(88)90020-1; YUSTA B, 1988, ENDOCRINOLOGY, V122, P2278, DOI 10.1210/endo-122-5-2278; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	55	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1103	1110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700635				2022-12-28	WOS:A1995QN35300010
J	ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE				ANTELMAN, D; MACHEMER, T; HUYGHE, BG; SHEPARD, HM; MANEVAL, D; JOHNSON, DE			INHIBITION OF TUMOR-CELL PROLIFERATION IN-VITRO AND IN-VIVO BY EXOGENOUS P110(RB), THE RETINOBLASTOMA TUMOR-SUPPRESSOR PROTEIN	ONCOGENE			English	Article						RETINOBLASTOMA; TUMOR SUPPRESSOR; PROTEIN THERAPY	BLADDER-CARCINOMA CELLS; RB GENE SUPPRESSES; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; ALTERED EXPRESSION; CANCER-CELLS; LUNG-CANCER; TAT PROTEIN; G1 PHASE; PRODUCT	Reconstitution of retinoblastoma gene (RE) deficient tumor cells with RE generally leads to growth suppression in vitro and/or reduced tumorigenicity in nude mice. An alternate approach to gene replacement is the delivery of the RE gene product (p110(RB)) into cells lacking its expression. In this report we demonstrate that exogenously added p110(RB) is taken up by and localized to the nucleus of cultured cells and has growth suppression properties similar to endogenous RE. RE-negative (RB(neg)) tumor cells are preferentially growth inhibited while most RE-positive (RB(pos)) tumor cells and normal cells are much less sensitive. We have extended these studies to relevant nude mouse xenograft models for human lung cancer. Local or systemic administration of p110(RB) inhibits armor growth in treated animals. These results represent the first use of a tumor suppressor protein as a potential cancer therapeutic.			ANTELMAN, D (corresponding author), CANJI INC,3030 SCI PK RD,SUITE 310,SAN DIEGO,CA 92121, USA.							AURUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BAILYES EM, 1982, BIOCHEM J, V203, P245, DOI 10.1042/bj2030245; BANERJEE A, 1992, CANCER RES, V52, P6297; BODYCOTE J, 1986, P NATL ACAD SCI USA, V83, P4749, DOI 10.1073/pnas.83.13.4749; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1990, MOL CELL BIOL, V9, P1628; CASEY G, 1991, ONCOGENE, V6, P1791; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KORNBLAU SM, 1994, CANCER RES, V54, P242; KORNBLAU SM, 1992, CANCER RES, V52, P4587; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; NEVINS JR, 1992, SCIENCE, V258, P424; OLDHAM KG, 1971, ANAL BIOCHEM, V44, P143, DOI 10.1016/0003-2697(71)90355-1; OOKAWA K, 1993, ONCOGENE, V8, P2175; PEREZ F, 1992, J CELL SCI, V102, P717; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIMIZU E, 1994, ONCOGENE, V9, P2441; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WANG NP, 1993, ONCOGENE, V8, P279; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; YONEMURA Y, 1993, INT J ONCOL, V3, P71; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	51	18	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					697	704						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862447				2022-12-28	WOS:A1995QH61200009
J	KHANDJIAN, EW				KHANDJIAN, EW			HEAT-TREATMENT INDUCES DEPHOSPHORYLATION OF PRB AND DISSOCIATION OF T-ANTIGEN PRB COMPLEX DURING TRANSFORMING INFECTION WITH SV40	ONCOGENE			English	Article						HEAT SHOCK; RETINOBLASTOMA; S-PHASE; T-ANTIGEN PRB COMPLEX; HSP71; PROLIFERATION	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; LARGE-TUMOR-ANTIGEN; MOUSE KIDNEY-CELLS; SIMIAN VIRUS-40; SHOCK PROTEINS; SUSCEPTIBILITY GENE; NUCLEAR COLOCALIZATION; IMMUNOLOGICAL EVIDENCE; TRANSCRIPTION FACTOR	The effects of heat treatment on key cell cycle regulatory molecules is currently unknown. Using primary mouse kidney cell cultures induced to re-enter S-phase by transforming infection with SV40, the effects of thermal treatment on the phosphorylation state of the Retinoblastoma gene product (pRb) and on its ability to bind T-antigen were examined. Time course analysis showed no detectable inhibition of cellular protein and T-antigen synthesis up to 180 min treatment at 42.5 degrees C, while a gradual disappearance of the phosphorylated forms of pRb was observed after 90 min. Dephosphorylation of pRb was shown to correlate with inhibition of SV40-induced DNA synthesis. Also, large T-antigen/pRb protein complex was affected since a gradual dissociation of the hypophosphorylated pRb from large T-antigen was observed concomitant to the inhibition of DNA synthesis. The effects of heat treatment were found to be reversible after shifting the cultures to 37 degrees C. Cells were shown to resume DNA synthesis concomitant to the reappearance of the phosphorylated forms of pRb and rebinding of the hypophosphorylated form to large T-antigen within 6-8 h after recovery at 37 degrees C. In addition, no evidence for a bona fide hsp71/large T-antigen protein complex was seen under the experimental conditions used. The data strongly suggest that inhibition of DNA synthesis by heat treatment might involve either an increase in phosphatase activity or the inhibition of a pRb kinase activity.	UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY,PQ,CANADA	Laval University	KHANDJIAN, EW (corresponding author), HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY,PQ G1L 3L5,CANADA.							ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ANGELIDIS CE, 1988, EUR J BIOCHEM, V172, P27, DOI 10.1111/j.1432-1033.1988.tb13851.x; ANGHILERI LJ, 1986, HYPERTHERMIA CANCER, V1; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CURRIE RW, 1991, BIOCHEM CELL BIOL, V69, P375, DOI 10.1139/o91-057; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EHRHART JC, 1988, ONCOGENE, V3, P595; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORTIN CA, 1994, MOL CELL BIOL, V72, P239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLOVER CVC, 1982, P NATL ACAD SCI-BIOL, V79, P1781, DOI 10.1073/pnas.79.6.1781; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; ISSELS RD, 1988, RECENT RESULTS CANCE, V107; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LASZLO A, 1992, CELL PROLIFERAT, V25, P59, DOI 10.1111/j.1365-2184.1992.tb01482.x; LATHANGUE NB, 1987, BIOSCIENCE REP, V7, P475, DOI 10.1007/BF01116504; LEE WH, 1991, COLD SH Q B, V56, P211; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; NIHEI T, 1993, CANCER LETT, V73, P181, DOI 10.1016/0304-3835(93)90262-8; NOVER L., 1991, HEAT SHOCK RESPONSE; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROTI JLR, 1992, CELL PROLIFERAT, V25, P89, DOI 10.1111/j.1365-2184.1992.tb01483.x; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STREFFER C, 1987, RECENT RESULTS CANCE, V104; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; STURZBECHER HW, 1988, ONCOGENE, V1, P201; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WHITE E, 1988, J VIROL, V62, P4153, DOI 10.1128/JVI.62.11.4153-4166.1988; WHITSON RH, 1992, J CELL BIOCHEM, V48, P305, DOI 10.1002/jcb.240480311; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	71	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					359	367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838534				2022-12-28	WOS:A1995QC62400015
J	KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			PARENTAL ORIGIN OF 11P15 DELETIONS IN HUMAN LUNG-CANCER	ONCOGENE			English	Note							SHORT ARM; WILMS-TUMOR; CHROMOSOME-11; GENES; CARCINOGENESIS; ABNORMALITIES; RELAXATION; CARCINOMAS; ALLELE	Frequent occurrence of 11p deletions has been reported for diverse types of human cancers including lung cancers and Wilms' tumors. In contrast to the well documented identification of preferential retention of the paternal allele in Wihms' tumors, no data have hitherto been available for cancers of adults. Taking advantage of the paternal allele-specific expression of IGF2 in the normal lung, we examined 79 lung cancer cases to investigate allelic loss at 11p15 and the parental origin of the retained alleles. While 11 of 36 (31%) informative lung cancer cases exhibited 11p15 deletions, only seven of these (64%) retained the paternal allele in tumors (P = 0.274), showing a contrast to the strong paternal bias in childhood tumors. Our strategy eliminates the need for parental DNAs for the determination and should be applicable to other adulthood tumors carrying 11P deletions such as breast and bladder cancers.	AICHI CANC CTR, RES INST, CHEMOTHERAPY LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 2, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEE JH, 1989, CANCER RES, V49, P1220; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MINNA JD, 1991, BRIS MYER C, V12, P63; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEILLET C, 1986, CANCER RES, V46, P4776; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILKINS RJ, 1988, LANCET, V1, P329	19	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3063	3065						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916149				2022-12-28	WOS:A1994PG82200038
J	PIETRAS, RJ; FENDLY, BM; CHAZIN, VR; PEGRAM, MD; HOWELL, SB; SLAMON, DJ				PIETRAS, RJ; FENDLY, BM; CHAZIN, VR; PEGRAM, MD; HOWELL, SB; SLAMON, DJ			ANTIBODY TO HER-2/NEU RECEPTOR BLOCKS DNA-REPAIR AFTER CISPLATIN IN HUMAN BREAST AND OVARIAN-CANCER CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; NEU ONCOGENE; TUMOR-CELLS; CARCINOMA-CELLS; PROTO-ONCOGENE; EXPRESSION; GENE; OVEREXPRESSION; C-ERBB-2	Approximately 30% of human breast and ovarian cancers have amplification and/or overexpression of HER-2/neu gene which encodes a cell surface growth-factor receptor. Overexpression of this receptor, P185(HER-2/neu), is associated with poor outcome and may predict clinical response to chemotherapy. Antibodies to HER-2/neu receptor have a cytostatic effect in suppressing growth of cells with overexpression of p185(HER-2/neu). To elicit a cytocidal effect, therapy with antireceptor antibody was used in combination with the DNA-damaging drug, cisplatin, and this combined treatment produced a synergistic decrease in cell growth. In addition, antibody mediated an increased sensitivity to cisplatin in drug-resistant ovarian carcinoma cells containing multiple copies of HER-2/neu gene. To evaluate the mechanism for this synergy, unscheduled DNA synthesis was measured in cancer cells using incorporation of [H-3]thymidine and autoradiography, and formation and repair of cisplatin-induced DNA adducts was also measured. Treatment with cisplatin led to a marked, dose-dependent increase in unscheduled DNA synthesis which was significantly reduced by combined treatment with antireceptor antibody in HER-2/neu-overexpressing cells. Therapy with antibody to HER-2/neu receptor also led to a 35-40% reduction in repair of cisplatin-DNA adducts after cisplatin exposure and, as a result, promoted drug-induced killing in target cells. This phenomenon which we term receptor-enhanced chemosensitivity may provide a rationale for more selective targeting and exploitation of overexpressed growth factor receptors in canter cells, thus leading to new strategies for clinical intervention.	GENENTECH INC,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92093	Roche Holding; Genentech; University of California System; University of California San Diego	PIETRAS, RJ (corresponding author), UNIV CALIF LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.			Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [CA01714-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; ALLRED DC, 1992, J CLIN ONCOL, V10, P599, DOI 10.1200/JCO.1992.10.4.599; ANDREWS PA, 1988, CANCER RES, V48, P68; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P15, DOI 10.1016/0002-9378(91)90615-X; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; BUTTERWORTH BE, 1987, MUTAT RES, V189, P113, DOI 10.1016/0165-1218(87)90017-6; CAMPBELL RC, 1967, STATISTICS BIOL; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CHRISTEN R D, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P430; CHRISTEN RD, 1990, J CLIN INVEST, V86, P1632, DOI 10.1172/JCI114885; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DESANTES K, 1992, CANCER RES, V52, P1916; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DISAIA PJ, 1972, AM J OBSTET GYNECOL, V114, P979, DOI 10.1016/0002-9378(72)90109-3; DOMINICI C, 1989, J CLIN ONCOL, V7, P100, DOI 10.1200/JCO.1989.7.1.100; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; DREBIN JA, 1988, ONCOGENE, V2, P387; FENDLY BM, 1990, CANCER RES, V50, P1550; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; ISONISHI S, 1991, CANCER RES, V51, P5903; JENSEN L, 1988, MOL CELL BIOL, V8, P3964, DOI 10.1128/MCB.8.9.3964; JONES JC, 1991, J BIOL CHEM, V266, P7101; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KINZEL V, 1990, CANCER RES, V50, P7932; KLIJN JGM, 1992, P AN M AM SOC CLIN, V11, P53; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LEMOINE NR, 1990, ONCOGENE, V5, P237; Lofts F J, 1992, Cancer Treat Res, V61, P161; MARTIN M, 1992, J CLIN ONCOL, V10, P433, DOI 10.1200/JCO.1992.10.3.433; MASUDA H, 1988, CANCER RES, V48, P5713; MASUI H, 1984, CANCER RES, V44, P1002; MCCLAY EF, 1990, GYNECOL ONCOL, V36, P1, DOI 10.1016/0090-8258(90)90099-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONTINE TJ, 1988, CANCER RES, V48, P6017; MROCZKOWSKI B, 1984, NATURE, V309, P270, DOI 10.1038/309270a0; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERA MF, 1981, CHEM-BIOL INTERACT, V37, P245, DOI 10.1016/0009-2797(81)90181-2; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIETRAS R J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P547; PIETRAS RJ, 1991, J CELL BIOL, V115, P416; PRESS MF, 1993, CANCER RES, V53, P4960; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SCANLON KJ, 1989, ANTICANCER RES, V9, P1301; SCANLON KJ, 1988, P NATL ACAD SCI USA, V85, P650, DOI 10.1073/pnas.85.3.650; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SKLAR MD, 1988, CANCER RES, V48, P793; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TROSKO JE, 1974, EXP CELL RES, V88, P47, DOI 10.1016/0014-4827(74)90616-8; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; WILLIAMS GM, 1977, CANCER RES, V37, P1845; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, CANCER RES, V46, P414; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	76	407	462	1	21	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1829	1838						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	7911565				2022-12-28	WOS:A1994NR68500004
J	MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG				MAGLIONE, D; GUERRIERO, V; VIGLIETTO, G; FERRARO, MG; APRELIKOVA, O; ALITALO, K; DELVECCHIO, S; LEI, KJ; CHOU, JY; PERSICO, MG			2 ALTERNATIVE MESSENGER-RNAS CODING FOR THE ANGIOGENIC FACTOR, PLACENTA GROWTH-FACTOR (PIGF), ARE TRANSCRIBED FROM A SINGLE GENE OF CHROMOSOME-14	ONCOGENE			English	Article							ENDOTHELIAL-CELL MITOGEN; VASCULAR-PERMEABILITY FACTOR; FACTOR-A-CHAIN; ACID; CDNA; HYBRIDIZATION; SEQUENCES; INDUCTION	We have previously reported on the identification of a cDNA (placenta growth factor, PIGF) coding for a novel angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor (VPF/VEGF). Biochemical and functional characterization of PIGF derived from transfected COS-1 celts revealed that it is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. Here, we report the isolation and characterization of the PIGF gene located on chromosome 14. At least two different mRNAs are produced from this single-copy gene in different cell lines and tissues. Sequence comparison of the polypeptides encoded by the two different isolated cDNAs indicates that they are identical except for the insertion of a highly basic 21 amino acid stretch at the carboxyl end of the protein. RNA expression analysis of several tissues, tumors and cell tines indicates differential distribution of the two PlGF mRNAs. Finally, preliminary results indicate that the PlGF gene has been conserved in evolution, since the human PlGF cDNA hybridizes to sequences present in the genomic DNA of Drosophila, Xenopus, chicken and mouse.	CNR,INT INST GENET & BIOPHYS,VIA G MARCONI 12,I-80125 NAPLES,ITALY; SIFI SPA,I-95020 LAVINAIO,ITALY; UNIV HELSINKI,DEPT PATHOL,SF-00290 HELSINKI 29,FINLAND; FDN G PASCALE,IST NAZL STUDIO CURA TUMORI,I-80131 NAPLES,ITALY; NICHHD,HUMAN GENET LAB,BETHESDA,MD 20892	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Helsinki; IRCCS Fondazione Pascale; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Alitalo, Kari K/J-5013-2014; Viglietto, Giuseppe/AAC-2852-2019; Del Vecchio, Silvana/F-4972-2012	Alitalo, Kari K/0000-0002-7331-0902; Viglietto, Giuseppe/0000-0003-2327-7515; DEL VECCHIO, Silvana/0000-0002-5466-1213				AUSPRUNK D, 1977, MICROVASC RES, V14, P52; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONO R, 1991, AM J HUM GENET, V49, P555; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7913; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; LEI KJ, 1992, MOL ENDOCRINOL, V6, P703, DOI 10.1210/me.6.5.703; LERACH H, 1977, BIOCHEMISTRY-US, V16, P4743; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1992, IN PRESS GROWTH FACT; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PLOUZEK CA, 1991, ENDOCRINOLOGY, V129, P950, DOI 10.1210/endo-129-2-950; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; ROCCHI M, 1986, HUMAN GEET, V74; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TISHER E, 1991, J BIOL CHEM, V266, P11974; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTERMARK B, 1991, CANCER RES, V51, P5087	35	276	314	0	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681160				2022-12-28	WOS:A1993KT22000014
J	LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF				LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF			THE TUMOR-SUPPRESSOR GENE WT1 INHIBITS RAS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article						WT1; TUMOR SUPPRESSORS; RAS-TRANSFORMATION	WILMS-TUMOR; HUMAN CHROMOSOME-11; PROMOTER ACTIVITY; NUDE MICE; CELL-LINE; GROWTH; PRODUCT; EXPRESSION; ONCOGENE; KIDNEY	Wilms' tumor belongs to a small group of pediatric neoplasms that have served as paradigms of human cancers in which recessive mutations play a primary role in tumorigenesis. WT1 is a candidate tumor suppressor gene that is mutationally inactivated in a proportion of both familial and sporadic Wilms' tumors. Recent studies demonstrated that WT1 can partially suppress growth of a Wilms' tumor cell line in vitro and in vivo. We investigated the ability of WT1 to inhibit the expression of the transformed phenotype in non-Wilms' tumor cells. The expression of WT1 cDNA in ras-transformed NIH3T3 cells yielded large, flat cells that exhibited complete contact-inhibition. These morphologic changes were associated with decreased proliferation, suppression of clonogenicity in soft agar and inhibition of tumor growth in nude mice. Moreover, expression of WT1 in non-transformed NIH3T3 cells resulted in similar morphologic changes and profound resistance to transformation by an activated uas oncogene. These studies suggest that tumor inhibition by WT1 in these cells may be achieved by interference with the ras-mediated signalling pathway.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; MASSACHUSETTS GEN HOSP, CTR CANC, GENET MOLEC LAB, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059998, R01CA037887, R23CA037887] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA59998, CA37887] Funding Source: Medline; NHLBI NIH HHS [HL42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAREL JC, 1989, J IMMUNOL, V143, P923; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHANG KS, 1993, BLOOD, V82, pA191; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Favaloro J, 1980, Methods Enzymol, V65, P718; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HUANG RP, 1994, ONCOGENE, V9, P1367; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KIVINEN L, 1993, ONCOGENE, V8, P2703; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	44	56	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					743	750						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651738				2022-12-28	WOS:A1995RQ46900016
J	MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y				MONTE, D; COUTTE, L; BAERT, JL; ANGELI, I; STEHELIN, D; DELAUNOIT, Y			MOLECULAR CHARACTERIZATION OF THE ETS-RELATED HUMAN TRANSCRIPTION FACTOR ER81	ONCOGENE			English	Note						ER81; TRANSCRIPTION FACTOR; ETS GENE; ALTERNATIVE SPLICING	GENE FAMILY; BINDING-PROTEIN; ONCOGENE FAMILY; C-ETS-1 PROTEIN; MESSENGER-RNAS; MEMBER; PEA3; ACTIVATION; EVOLUTION; DOMAIN	The PEA3 group is a homogeneous group of the ets transcription factor family and is composed df three known members, PEA3, ERM and ER81, which, on the amino acid (AA) level, are more than 95% identical within the DNA-binding domain (the Ets domain), more than 85% within a 32 AA domain (the acidic domain) localized in the amino-terminus and almost 50% identical overall. By screening a human kidney cDNA library with a specific probe obtained from mouse ER81 we isolated two clones of 1.6 and 1.5 kb in length encoding a 458 AA open reading frame. When compared to mouse ER81, the present human ER81 lacks the last 13 AA of the acidic domain and the 5 AA contiguous to the carboxy-terminal part of the acidic domain. Of the 458 AA of the human ER81 protein, 97% are identical to mouse ER81. Gel shift analysis indicates that the full-length human ER81 protein is able to bind specifically to an oligonucleotide containing the binding sites recognized by most of the Ets proteins. By transient expression in RK13 mammalian cells, human ER81 protein transactivated a reporter plasmid containing Ets binding sites, indicating that this molecule is a bonafide transcriptional activator, while by expression in Cos-1 transfected cells, we detected the presence of human ER81 protein in the nucleus using immunocytochemistry. In human tissues, ER81 mRNA is very highly expressed in brain, highly expressed in testis, lung and heart, moderately in spleen, small intestine, pancreas and colon, weakly in liver, prostate and thymus, very weakly in skeletal muscle, kidney and ovary and not in placenta and peripheral blood leukocytes. Analysis of human solid or haematopoietic tumour cell lines showed that most of them did not express ER81 detectably. Database searches revealed that ETV1 mRNA is highly similar to human ER81 described here, although it contains the full-length acidic domain present in mouse ER81. By screening a genomic DNA library, we characterized the intron-exon junction within the acidic domain of human ER81 and we showed that this junction corresponds to the site where the remaining AA of the acidic domain of ETV1 or mouse ER81 are inserted.	INST PASTEUR,CNRS,URA 1160,UNITE ONCOL MOLEC,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				coutte, laurent/0000-0002-0031-4742; monte, didier/0000-0002-0613-6203				ALBAGLI O, 1994, ONCOGENE, V9, P3259; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CREPIEUX P, 1995, IN PRESS CRITICAL RE; Crepieux Pascale, 1993, Gene Expression, V3, P215; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LIANG H, 1994, STRUCT BIOL, V1, P871; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; MONTE D, 1994, ONCOGENE, V9, P1397; MONTE D, 1995, IN PRESS ANN ENDOCRI; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; POGNONEC P, 1989, ONCOGENE, V4, P691; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOGANATHAN T, 1992, EUR J BIOCHEM, V207, P195, DOI 10.1111/j.1432-1033.1992.tb17037.x; ZHAO HF, 1991, J BIOL CHEM, V266, P583	29	88	89	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					771	779						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651741				2022-12-28	WOS:A1995RQ46900020
J	QUELLE, DE; ASHMUN, RA; HANNON, GJ; REHBERGER, PA; TRONO, D; RICHTER, KH; WALKER, C; BEACH, D; SHERR, CJ; SERRANO, M				QUELLE, DE; ASHMUN, RA; HANNON, GJ; REHBERGER, PA; TRONO, D; RICHTER, KH; WALKER, C; BEACH, D; SHERR, CJ; SERRANO, M			CLONING AND CHARACTERIZATION OF MURINE P16(INK4A) AND P15(INK4B) GENES	ONCOGENE			English	Article						P16(INK4A); P15(INK4B); CDK; MEL CELLS; D CYCLINS; PRB	CELL-CYCLE PROGRESSION; FACTOR-I RECEPTOR; MOUSE CHROMOSOME-4; RAT CHROMOSOME-5; G(1); DNA; D1; TRANSFORMATION; OVEREXPRESSION; FIBROBLASTS	Progression through the G1 phase of the cell cycle is regulated in part by the D-type cyclin-dependent kinases, cdk4 and cdk6. Genes encoding two specific inhibitors of these kinases, human p16((INK4A/MTSI)) and p15((INK4B/MTS2)), map to a region of common cytogenetic abnormalities on chromosome 9p21. The murine cognates of these genes were isolated and identified as mouse p16(INK4a) and p15(INK4b) based on their homology to their human counterparts and their selective transcriptional induction by SV40T-antigen and TGF-beta, respectively. Both genes map to position C3-C6 on mouse chromosome 4, in a region syntenic with human chromosome 9p. Amplification of polyadenylated mRNA by polymerase chain reactions revealed no expression of mouse p16(INK4a) in many normal tissues, whereas p15(INK4b) was expressed ubiquitously. Like human p16(INK4a), mouse p16(INK4a) binds specifically to cdk4 and cdk6 in vitro and inhibits the phosphorylation of the retinoblastoma protein, pRb, by each of these cyclin D-dependent kinases. In mouse MEL erythroleukemia cells, p16(INK4a) associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. Expression vectors encoding human or mouse p16(INK4a) caused G1 phase arrest in NIH3T3 fibroblasts, and cyclin D1- and cdk4-dependent pRb kinase activities were inhibited in the p16(INK4a)-arrested cells.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA; GERMAN CANC RES CTR, DEPT BIOCHEM TISSUE SPECIF REGULAT, D-69120 HEIDELBERG, GERMANY; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, SMITHVILLE, TX 78957 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Helmholtz Association; German Cancer Research Center (DKFZ); University of Texas System; UTMD Anderson Cancer Center			Hannon, Gregory/AAB-3568-2019; Sherr, Charles J/N-8074-2018; Serrano, Manuel/H-2634-2015	Sherr, Charles J/0000-0002-5516-6206; Serrano, Manuel/0000-0001-7177-9312; Quelle, Dawn/0000-0001-8776-0122	NATIONAL CANCER INSTITUTE [R35CA047064, R01CA063613] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63613, CA-47064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT CM, 1993, MAMM GENOME, V4, pS58, DOI 10.1007/BF00360830; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERZOG CR, 1994, CANCER RES, V54, P4007; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISLAM MQ, 1989, J CELL SCI, V92, P147; JIANG W, 1993, ONCOGENE, V8, P3447; JON J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KHATIB ZA, 1993, CANCER RES, V53, P5535; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KNAPEK DF, 1995, IN PRESS CANCER RES; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LITZKAS P, 1984, MOL CELL BIOL, V4, P2549, DOI 10.1128/MCB.4.11.2549; LOOK AT, 1984, J CLIN INVEST, V73, P1617, DOI 10.1172/JCI111368; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, IN PRESS P NATL ACAD; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PINCS J, 1993, TRENDS BIOCHEM SCI, V18, P195; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; SZPIRER C, 1990, GENOMICS, V6, P679, DOI 10.1016/0888-7543(90)90504-N; TAM SW, 1994, ONCOGENE, V9, P2663; TAM SW, 1994, CANCER RES, V54, P5816; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WASHIMI O, 1995, CANCER RES, V55, P514; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	70	227	240	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					635	645						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651726				2022-12-28	WOS:A1995RQ46900004
J	CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B				CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B			DIFFERENTIAL-EFFECTS BY MAD AND MAX ON TRANSFORMATION BY CELLULAR AND VIRAL ONCOPROTEINS	ONCOGENE			English	Article						RAS; C-MYC; ELA; P53; HPV16	C-MYC; DNA-BINDING; PHOSPHORYLATION SITES; RAS COTRANSFORMATION; EMBRYONIC LETHALITY; NEOPLASTIC-CELLS; PROTEIN; ONCOGENES; GROWTH; GENES	c-Myc is an essential component of the regulatory mechanisms controlling cell growth. Max is the obligatory partner of c-Myc for all its biological functions analysed to date. Recently two Max interacting proteins, Mad and Mxi1, have been identified. It has been suggested that these two proteins modulate c-Myc function, in the simplest model by competing with c-Myc for the interaction with Max. We have analysed different aspects of Mad function in comparison to Max, Native Mad/Max heterodimers bound specifically to a c-Myc/Max consensus DNA binding site. Furthermore Mad inhibited efficiently c-Myc, mutant p53, adenovirus Ela, or human papilloma virus type 16 transformation of rat embryo cells in cooperation with activated Ha-Ras, Myc transformed clones showed an increased cell cycle time and a reduced immortalization frequency after cotransfection with either mad or max. In contrast to Mad, Max did not inhibit E1a/Ha-Ras cotransformation but repressed c-Myc/Ha-Ras transformation efficiently. Mad Delta N, an N-terminal deletion mutant of Mad, was as efficient in repressing c-Myc/Ha-Ras cotransformation as full length Mad but showed little inhibitory activity when assayed on E1a/Ha-Ras. Unlike wt Mad, Mad Delta N had little effect on cell growth. Our data suggest that Mad affects cell growth at least in part by a c-Myc independent mechanism.	HANNOVER MED SCH, INST MOLEK BIOL, D-30623 HANNOVER, GERMANY; UNIV VIENNA, INST TUMORBIOL, A-1090 VIENNA, AUSTRIA	Hannover Medical School; University of Vienna			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGLIATI T, 1993, ONCOGENE, V8, P1263; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EDELHOFF S, 1994, ONCOGENE, V9, P665; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	57	64	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					587	596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630643				2022-12-28	WOS:A1995RN53000020
J	PRESS, RD; WISNER, TW; EWERT, DL				PRESS, RD; WISNER, TW; EWERT, DL			INDUCTION OF B-CELL LYMPHOMAS BY OVEREXPRESSION OF A MYB ONCOGENE TRUNCATED AT EITHER TERMINUS	ONCOGENE			English	Article						LYMPHOMA; MYB; ONCOGENE; B CELL	AVIAN-LEUKOSIS VIRUS; C-MYB; DNA-BINDING; MONOCLONAL-ANTIBODIES; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION; CHICKEN; DIFFERENTIATION	The c-myb oncogene encodes a nuclear transcriptional transactivator that is often terminally truncated in hematopoietic tumors. To directly assess the tumorigenic activity of full length and terminally-truncated variants of c-myb, we have overexpressed several structurally-altered forms of myb within an avian retroviral vector and have shown that overexpression of truncated (but not full length) myb transforms both myeloid cells in vitro and mesenchymal cells in vivo. In vivo infection with these truncated myb viruses is now shown to induce metastatic B cell lymphomas in a significant minority of animals. Evaluation of the lymphomas revealed two distinct mechanisms of myb-induced tumorigenesis. In most of the lymphomas, proviral DNA inserted into the endogenous chicken c-myb gene and promoted the expression of a 5'-truncated myb transcript encoding an amino terminal truncated protein. In comparison, some animals infected with a virus encoding a carboxyl (C) terminal truncated myb (T-myb) developed non-insertional B cell lymphomas that directly expressed the provirally-encoded T-myb gene. The lymphomagenic T-myb protein lacks 214 C terminal amino acids including all of the myb transcription inhibition domain, This novel lymphomagenic activity for a C terminal truncated myb suggests that a loss of regulatory sequences at either end of c-myb is sufficient to create a B cell-specific transforming gene.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	PRESS, RD (corresponding author), OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201, USA.			Press, Richard/0000-0002-2103-5144	NATIONAL CANCER INSTITUTE [R01CA057516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57516] Funding Source: Medline; NINDS NIH HHS [NS-01551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V210, P249; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; ONG GLS, 1984, SCIENCE, V226, P1077; PINK JR, 1983, HYBRIDOMA, V2, P287, DOI 10.1089/hyb.1983.2.287; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; VELLARD M, 1991, ONCOGENE, V6, P505; VEROMAA T, 1988, HYBRIDOMA, V7, P41, DOI 10.1089/hyb.1988.7.41; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010	37	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					525	535						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630637				2022-12-28	WOS:A1995RN53000013
J	GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR				GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR			CLONING AND DEVELOPMENTAL EXPRESSION ANALYSIS OF THE MURINE C-MER TYROSINE KINASE	ONCOGENE			English	Article						TYROSINE; KINASE; RECEPTOR; EXPRESSION; ONCOGENE; DEVELOPMENT	EMBRYONIC STEM-CELLS; YOLK-SAC; RECEPTOR; INVITRO; ONCOGENE; CLEAVAGE; CULTURE	We have cloned the putative mouse homologue of the human c-mer receptor tyrosine kinase proto-oncogene. Comparison of the mouse and human c-mer amino acid sequences reveals an overall identity of 88%, Similar to the human, the extracellular region of the murine c-mev protein possesses two amino terminal immunoglobulinlike domains and two membrane proximal fibronectin type III domains, which places it in the Axl family of tyrosine kinases, Our analysis of the Axl family identifies eight different regions of amino acid consensus that have residues characteristic of this and no other tyrosine kinase family; six of the eight are within tyrosine kinase subdomains. The homology within the Axl family is highest between c-mer and c-eyk, the chicken proto-oncogene of the tumor virus gene product v-eyk, Northern analysis of adult tissues suggests that the mouse c-mev, although expressed in many tissues, has an expression pattern unique among Axl family members. In normal adult hematopoietic cells c-mer seems to be expressed predominantly if not exclusively in the monocytic lineage, Mouse c-mer is expressed during most, if not all, stages of embryological development beginning in the morula and blastocyst and progressing through the yolk sac and fetal liver stages. This early and consistent expression of c-mer was confirmed during in vitro differentiation of embryonic stem cells, The embryonic expression profile of c-mer suggests that this tyrosine kinase may play an important function in the developing mouse.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT IMMUNOL & MICROBIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Stanford, William/0000-0002-5813-8016; Dawson, Thomas/0000-0003-3878-1722	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4351701] Funding Source: Medline; NIGMS NIH HHS [GM07040] Funding Source: Medline; PHS HHS [A107273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BISHOP JM, 1988, LEUKEMIA, V2, P199; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOZAK M, 1986, CELL, V144, P283; KUNG HJ, 1990, DEV BIOLOGICALS, V72, P139; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SNODGRASS HR, 1992, J CELL BIOCHEM, V49, P225, DOI 10.1002/jcb.240490304; SNODGRASS HR, 1993, PERIPHERAL BLOOD STE, P65; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; TYAN ML, 1968, J IMMUNOL, V101, P446; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILES MV, 1991, DEVELOPMENT, V111, P259; 1991, GCG SOFTWARE PACKAGE	38	113	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2349	2359						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784083				2022-12-28	WOS:A1995RE54300010
J	ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T				ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T			LOSS OF FAS/APO-1 RECEPTOR ACCELERATES LYMPHOMAGENESIS IN E-MU L-MYC TRANSGENIC MICE BUT NOT IN ANIMALS INFECTED WITH MOMULV	ONCOGENE			English	Note						HOMEOSTASIS; FAS/APO-1; APOPTOSIS; TRANSGENIC MICE; TUMOR PROGRESSION	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; C-MYC; N-MYC; LEUKEMIA-VIRUS; FAS ANTIGEN; LPR MICE; SYSTEMIC AUTOIMMUNITY; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING	The Fas/Apo-1 receptor is an integral membrane protein that transduces apoptotic signals upon binding to its natural ligand or to specific antibodies. Loss of Fas/Apo-1 receptor leads in (lpr;lpr) mice to a nonmalignant accumulation of abnormal T-cells very probably due to the lack of induction of apoptosis in peripheral T-cells. It has been reported that soluble forms of Fas/Apo-1 receptor that may interfere with apoptotic signaling occur in patients suffering from various forms of lymphoid neoplasms. Therefore, we wished to investigate whether the loss of proper homeostatic regulation through Fas/Apo-1 receptor mediated apoptosis could influence the process of lymphomagenesis, To this end, we performed two experiments (i) we infected (lpr,lpr) animals with Moloney Murine Leukemia Virus (MoMuLV) that causes T-cell lymphoma in mice and (ii) we crossed (lpr,lpr) animals with E mu L-myc transgenic mice that are prone to develop T- and B-cell lymphoma due to deregulated expression of the L-myc transgene by the immunoglobulin enhancer E mu. We find that infection with MoMuLV did not accelerate the formation of lymphoid neoplasms in (lpr,lpr) mice when compared to infected normal animals. However, E mu L-myc/(lpr,lpr) animals that constitutively express the L-myc transgene in the lymphoid lineage clearly show accelerated formation of T- and B-cell lymphoma when compared to normal E mu L-myc transgenics. These data demonstrate that in cooperation with particular oncogenes impairment of Fas/Apo-1 receptor function can indeed affect and modulate the process of tumor formation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV MARBURG,INST EXPTL IMMUNOL,D-35037 MARBURG,GERMANY	Philipps University Marburg; Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; KNIPPING E, 1995, IN PRESS BLOOD; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOLLER P, 1993, BLOOD, V81, P2067; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; OEHM A, 1992, J BIOL CHEM, V267, P10709; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	33	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2397	2401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784089				2022-12-28	WOS:A1995RE54300016
J	HIRANO, Y; YAMATO, K; TSUCHIDA, N				HIRANO, Y; YAMATO, K; TSUCHIDA, N			A TEMPERATURE-SENSITIVE MUTANT OF THE HUMAN P53, VAL138, ARRESTS RAT-CELL GROWTH WITHOUT INDUCED EXPRESSION OF CIP1/WAF1/SDI1 AFTER TEMPERATURE SHIFT-DOWN	ONCOGENE			English	Article						TEMPERATURE-SENSITIVE MUTANTS; P53; TUMOR SUPPRESSOR GENE; CIP1/WAF1/SDI1	WILD-TYPE P53; MAMMALIAN-CELLS; GENE; PROTEIN; TRANSFORMATION; SUPPRESSOR; DNA; CARCINOMA; ONCOGENE; SEQUENCE	To investigate functions of wild type p53 in human cells, we introduced a (Ala-->Val) mutation at the 138th codon of the human p53 (Val138), which corresponds to the Val135 mutation of the temperature sensitive mouse p53, The human Val138 mutant showed temperature-sensitive transformation of rat embryo fibroblasts (REFs) in collaboration assay with activated vas, and arrested cell proliferation of transformed clones in G1 at 32.5 degrees C. Transient CAT assay for transcriptional activation in human Saos2 cells revealed activity equivalent to that of wild type at 32.5 degrees C but undetectable at 37.5 degrees C. These results suggest that the human Val138 mutant also exhibited the wild type phenotype at the permissive temperature as is for the mouse Val135 mutant, although we observed differences between the two mutants such as in transactivational activities in CV-1 and HeLa cells, Further, the role of cip1/waf1/sdi1 in the cell growth arrest of the Val138/ras-transformed REFs and Val138-introduced Saos2 cells was studied by northern hybridization analysis, Although rapid induction of cip1/waf1/sdi1 mRNA was observed in the Saos2 cells, no detectable induction of mRNAs for cip1/waf1/sdi1 and gadd45 was observed in the transformed REFs upon temperature shift-down, while mdm2 mRNA was enhanced, suggesting that the p53 gene could arrest cell growth by a mechanism other than that,vith induced expression of the gene for p21 cdk-cyclin inhibitor.	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1994, CANCER RES, V54, P3391; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEY G, 1952, CANCER RES, V12, P246; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRANO Y, IN PRES ORAL ONCOL E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKEDA M, 1989, RECENT PROGR LIFE SC, P119; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P52; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOMAND J, 1992, CELL, V69, P1233; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAKAI E, 1992, ONCOGENE, V7, P927; Sambrook J, 1989, MOL CLONING LABORATO; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	50	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1879	1885						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761089				2022-12-28	WOS:A1995QZ92600001
J	SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A				SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A			THE INTERACTIONS OF E2F WITH PRB AND WITH P107 ARE REGULATED VIA THE PHOSPHORYLATION OF QRB AND P107 BY A CYCLIN-DEPENDENT KINASE	ONCOGENE			English	Article						PRB; P107; E2F; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; MAMMALIAN FIBROBLASTS; CELL-PROLIFERATION; CDC2 KINASE; PROTEIN; RB; CDK2; COMPLEX; IDENTIFICATION	It has been postulated that the product (pRB) of the retinoblastoma gene dissociates from the E2F-pRB complex upon phosphorylation by cyclin-dependent kinase(s) (cdk). However, there is no direct evidence for the regulation of formation of the E2F-pRB complex via phosphorylation by purified cdk, Therefore,we investigated the regulation of formation of this complex by phosphorylation using pRB and purified cyclin A-cdk2, cyclin E-cdk2 or cyclin D1-cdk4. Purified pRB was incubated with nuclear extracts prepared from pRB-defective cells and then subjected to gel mobility shift assays, We confirmed that unphosphorylated pRB associated with various types of E2F but pRB has been phosphorylated by cyclin A-cdk2 did not. We found that E2F-pRB complexes were disrupted as a consequence of phosphorylation by cyclin A-cdk2, and the levels of the free forms of E2Fs increased. We also found that not only the E2F-pRB complexes but also the E2F-p107 complexes were disrupted upon phosphorylation by cyclin A-cdk2. Furthermore, E2F-pRB complexes were disrupted through phosphorylation by cyclin D1-cdk4 and cyclin E-cdk2, as web as by cyclin A-cdk2. These results clearly demonstrate that the phosphorylation of pRB and p107 by cdks regulates the formation of complexes between E2F and pRB or p107.	BANYU TSUKUBA RES INST,MERCK RES LABS,TSUKUBA,IBARAKI 30033,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Merck & Company; National Cancer Center - Japan			Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1995, ONCOGENE, V10, P229; KITAGAWA M, 1993, ONCOGENE, V8, P2425; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI N, 1990, ONCOGENE, V5, P1713; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	39	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1691	1698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753545				2022-12-28	WOS:A1995QX46900001
J	BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F				BUTZ, K; SHAHABEDDIN, L; GEISEN, C; SPITKOVSKY, D; ULLMANN, A; HOPPESEYLER, F			FUNCTIONAL P53 PROTEIN IN HUMAN PAPILLOMAVIRUS-POSITIVE CANCER-CELLS	ONCOGENE			English	Article						TUMOR VIRUS; TUMOR SUPPRESSOR GENES; P21; P53; HPV	WILD-TYPE P53; DNA-DAMAGE; ONCOGENE EXPRESSION; IONIZING-RADIATION; CELLULAR-RESPONSE; MUTANT P53; TRANSCRIPTION; BINDING; E6; SEQUENCES	There is accumulating evidence that the p53 protein contributes to tumor suppression by stimulating the transcription of specific cellular genes, such as the cell cycle control gene WAF1/ClP1. p53-mediated transcriptional activation is inhibited in cotransfection assays by overexpressed E6 protein from cancer-associated human papillomavirus (HPV) types, pointing at a possible molecular mechanism by which these viruses contribute to malignant cell, transformation. Here we analysed the transcriptional transactivation function of endogenous p53 protein in a series of cervical cancer cell lines, which express the E6 gene from integrated viral sequences. Transient and stable transfection analyses employing p53-responsive reporter constructs indicated that HPV-positive cervical cancer cells contained transactivating p53 protein, Treatment of HPV-positive cells with genotoxic agents, such as mitomycin C, cisplatin, or u.v. irradiation, resulted in an increase of nuclear p53 protein levels and enhanced binding of p53 to a p53-recognition site. These effects were accompanied by an increase of WAF1/ClP1 mRNA levels. In several HPV-positive cell lines, these molecular events were linked to a cell cycle arrest in G(1). In contrast, cancer cells containing mutant p53 genes did not contain transactivating endogenous p53 protein and lacked the p53-mediated response to DNA damaging agents. These results indicate that the tumorigenic phenotype of HPV-positive cancer cell lines does not necessarily correlate with a lack of basal or DNA damage induced p53 activities and that therefore the presence of high risk HPV sequences is not functionally equivalent to the loss of p53 function through somatic mutations of the p53 gene.	DEUTSCH KREBSFORSCHUNGSZENTRUM, PROJEKTGRP ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)				Hoppe-Seyler, Felix/0000-0002-1864-300X				ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BOHM S, 1993, INT J CANCER, V55, P791, DOI 10.1002/ijc.2910550517; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU ZM, 1994, ONCOGENE, V9, P629; HARPER JW, 1993, CELL, V75, P805; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; HOPPESEYLER F, 1992, NUCLEIC ACIDS RES, V20, P6701, DOI 10.1093/nar/20.24.6701; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARK DJ, 1994, ONCOGENE, V9, P205; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REUTER S, 1991, J VIROL, V65, P5564, DOI 10.1128/JVI.65.10.5564-5568.1991; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE C, 1985, AM J PATHOL, V119, P361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	65	164	166	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					927	936						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898934				2022-12-28	WOS:A1995QL03800014
J	KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D				KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D			LOSS OF HETEROZYGOSITY AND LINKAGE ANALYSIS IN BREAST-CARCINOMA - INDICATION FOR A PUTATIVE 3RD SUSCEPTIBILITY GENE ON THE SHORT ARM OF CHROMOSOME-8	ONCOGENE			English	Note						BREAST CANCER; CHROMOSOME 8; DELETIONS; TUMOR SUPPRESSOR GENES; MICROSATELLITES; LINKAGE ANALYSIS	TUMOR-SUPPRESSOR GENES; FAMILIAL BREAST; OVARIAN-CANCER; COLORECTAL-CANCER; ALLELIC LOSS; DELETION; POLYMORPHISMS; ALLELOTYPE	We have analysed losses of heterozygosity (LOH) at eight markers from the p12-p22 region of human chromosome 8 in a panel of 113 breast tumors. LOH were detected in almost half of the tumors. The most frequently deleted region included microsatellite (CA)n repeats markers D8S258, D8S133 and D8S259, located at 8p12-p22, while markers NEFL and LPL appeared less frequently altered. In parallel, linkage analysis was performed using the same informative markers, to test for the involvement of chromosome 8p loci in familial breast cancer. Positive cumulative multipoint lod score of 2.51 at Theta=0.0 was obtained with markers NEFL and D8S259. These results suggest that region 8p12-p22 carries at least one tumor suppressor gene involved in sporadic and perhaps also in familial breast cancer.	INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; INSERM,U155,PARIS,FRANCE; INSERM,U119,MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; CTR RENE HUGUENIN,ST CLOUD,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Rene Huguenin Hospital; UNICANCER; Institut Paoli-Calmette (IPC)				Eisinger, Francois/0000-0002-8794-0681				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIECHE I, 1992, B CANCER, V79, P1115; BOVA GS, 1993, CANCER RES, V53, P3869; BOWCOCK AM, 1993, BREAST CANCER RES TR, V28, P121, DOI 10.1007/BF00666425; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; CROPP CS, 1994, CANCER RES, V54, P2548; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DEVILEE P, 1991, ONCOGENE, V6, P1705; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LALLE P, 1994, ONCOGENE, V9, P437; LATHROP GM, 1984, P NATL ACAD SCI USA, V81, P3343; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; SOBOL H, 1992, HUM GENET, V89, P381; STEICHENGERSDOR.E, 1994, AM J HUM GENET, V55, P870; THEILLET C, 1989, ONCOGENE, V4, P915; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1990, AM J HUM GENET S, V47, pA204; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YAREMKO L, 1994, GENE CHROMOSOME CANC, V10, P1	54	126	128	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1023	1026						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898921				2022-12-28	WOS:A1995QL03800026
J	CHEN, PC; LIN, HH; WEISSMAN, BE				CHEN, PC; LIN, HH; WEISSMAN, BE			A FUNCTIONAL-ANALYSIS OF TUMOR-SUPPRESSOR ACTIVITY FOR PERIPHERAL NEUROEPITHELIOMAS BY MONOCHROMOSOME TRANSFER	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENES; MICROCELL HYBRIDIZATION; PNET	NORMAL HUMAN CHROMOSOME-11; DINUCLEOTIDE REPEAT POLYMORPHISMS; HUMAN NEUROBLASTOMA-CELLS; POLYMERASE CHAIN-REACTION; HUMAN CANCER; TUMORIGENICITY; LINE; GROWTH; AMPLIFICATION; EXPRESSION	The microcell hybridization technique provides a powerful method for the identification and characterization of tumor suppressor genes. By introducing chromosomes from a normal human cell into a tumor cell, several studies have presented functional evidence for the presence of tumor suppressor activity. In order to map the location(s) of functional tumor suppressor gene(s) for peripheral neuroepithelioma (PNET) cells, we have used the microcell hybridization technique to transfer three individual human chromosomes into three different PNET cell lines, A673, SK-N-MC and TC32. We could not isolate microcell hybrids from one of the cell lines as the transferred chromosome tended to fragment upon transfer. Introduction of chromosome 13 into the remaining two cell lines caused a marked inhibition of in vitro and in vivo growth. Chromosome 11 appeared to harbor a functional tumor suppressor gene while transfer of chromosome 17 caused a suppression of growth in culture, presumably due to the presence of the p53 tumor suppressor gene. Thus, each cell line showed a different response to the introduction off normal genetic information suggesting diverse genetic abnormalities among these tumors of similar histological or origin.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CYTOGENET LAB,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANERJEE A, 1992, CANCER RES, V52, P6297; BENEDICT WF, 1984, CANCER RES, V44, P3471; BIEDLER JL, 1973, CANCER RES, V33, P2643; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAHILL TC, 1990, PRENATAL DIAG, V10, P795, DOI 10.1002/pd.1970101206; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EGE T, 1974, EXP CELL RES, V87, P378, DOI 10.1016/0014-4827(74)90494-7; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIARD DJ, 1974, J NATL CANCER I, V51, P1417; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRIFFIN CA, 1988, CANCER RES, V48, P175; HALL JM, 1992, AM J HUM GENET, V50, P1235; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1992, ONCOGENE, V7, P2013; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PASQUALE SR, 1988, CANCER RES, V48, P2715; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCHOTT DR, 1994, CANCER RES, V54, P1393; SHIMIZU M, 1990, ONCOGENE, V5, P185; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V21, P185; YAMADA H, 1990, ONCOGENE, V5, P1141; YANDELL DW, 1989, AM J HUM GENET, V45, P547	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					577	586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845683				2022-12-28	WOS:A1995QF64800019
J	MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ				MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ			THE DOMAIN OF P53 REQUIRED FOR BINDING HPV-16 E6 IS SEPARABLE FROM THE DEGRADATION DOMAIN	ONCOGENE			English	Article						PAPILLOMAVIRUS E6 PROTEIN; P53; TRANSCRIPTIONAL ACTIVATION	HUMAN PAPILLOMAVIRUS TYPE-16; SV40 LARGE T; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; DNA-BINDING; PROTEIN; ONCOPROTEIN; TRANSACTIVATION; SEQUENCES	The E6 proteins of specific cancer-associated human papillomaviruses (HPVs) complex with and mediate degradation of the cellular anti-oncogene p53 in vitro. A critical property of p53 is its ability to stimulate transcription from promoters containing its recognition sequence. HPV E6, mutant p53 proteins, and several DNA tumor virus oncogenes inhibit the transcriptional activity of wild-type p53. In this report, the structural requirements for the interaction between HPV 16 E6 and p53 were examined both in vivo and in vitro. p53-stimulated transcription was efficiently inhibited by wild-type HPV 16 E6 and E6 mutants competent for p53 binding and degradation. A series of p53 deletions and hybrid proteins with heterologous DNA binding, dimerization and transactivation domains were analysed for transcriptional interaction with HPV 16 E6 to determine the domains of p53 required for transcriptional inhibition. These chimeric proteins were also analysed for E6 binding and E6-mediated degradation in vitro. In both assays, complex formation with E6 was mediated through the amino-terminal 345 amino acids of p53 without a specific requirement for its C-terminus. Hybrid proteins containing residues 161-345 of p53 also bound E6, but this segment of p53 was not susceptible to E6 induced proteolysis. A second region of p53, within its N-terminal 160 aa, is required for E6 induced degradation of complexed p53. Taken together, these results suggest that the complex formation between E6 and p53 is not mediated through the C-terminus of p53 and that binding and degradation are separable.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	MANSUR, CP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA.			Mansur, Claire/0000-0002-2470-3443; Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA044174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA44174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1994, ONCOGENE, V9, P1225; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DIMAIO D, 1991, ADV CANCER RES, V56, P133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					457	465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845670				2022-12-28	WOS:A1995QF64800006
J	LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA				LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA			DIRECT RELATIONSHIP BETWEEN THE EXPRESSION OF TUMOR-SUPPRESSOR H19 MESSENGER-RNA AND C-MOS PROTOONCOGENE DURING MYOGENESIS	ONCOGENE			English	Article						H19; C-MOS; MYOGENESIS; GENE; EXPRESSION	SOMATIC-CELL EXPRESSION; MYOSIN LIGHT CHAIN-1; MURINE SARCOMA-VIRUS; SKELETAL-MUSCLE; MESSENGER-RNA; ALPHA-ACTIN; MOUSE; GENE; CDNA; DIFFERENTIATION	We have cloned and sequenced an almost complete c-DNA and the entire genomic sequence of rat the H19 gene, which is developmentally regulated in skeletal muscle, The data base comparison revealed a 92% homology with mouse gene H19. However the rat H19 ORFs do not display significant homology with the H19 ORFs from other species, In contrast to the mouse, the rat H19 mRNA is not easily detectable in fetal rat skeletal fibers. Its level increases after birth (up to 12 to 18 days) and remains stable thereafter. The pattern of H19 mRNA expression in rat muscle in vivo is very similar to the c-mos gene expression in this tissue, suggesting an interrelationship between H19 and c-mos products during muscle differentiation. Indeed, our results indicate that overexpression of c-mos protein in the muscle cell line C2C12 induces a concomitant increase of H19 mRNA expression. Furthermore, repression of c-mos protein expression by anti-sense RNAs extinguishes H19 mRNA expression and inhibits the differentiation process. These data suggest a relationship between c-mos and H19 expression and, in addition, the involvement of both gene products in the process of myogenesis.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,F-94805 VILLEJUIF,FRANCE; CTR PERRIN,RADIOTHERAPIE SERV,F-53011 CLERMONT FERRAND,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	LEIBOVITCH, MP (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P447; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; KURATA N, 1989, EMBO J, V8, P457, DOI 10.1002/j.1460-2075.1989.tb03398.x; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIBOVITCH SA, 1989, ONCOGENE RES, V4, P157; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEIBOVITCH SA, 1993, ONCOGENE, V8, P2361; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; LI CCH, 1993, ONCOGENE, V8, P1685; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OKAZAKI K, 1992, EMBO J, V11, P2443; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSUI LV, 1993, INT J ONCOL, V2, P493; VOGEL M, 1987, DEV BIOL, V119, P481, DOI 10.1016/0012-1606(87)90051-0; WILES MV, 1988, DEVELOPMENT, V104, P403; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					251	260						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838525				2022-12-28	WOS:A1995QC62400004
J	HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C				HAGUE, A; MOORGHEN, M; HICKS, D; CHAPMAN, M; PARASKEVA, C			BCL-2 EXPRESSION IN HUMAN COLORECTAL ADENOMAS AND CARCINOMAS	ONCOGENE			English	Note							PROGRAMMED CELL-DEATH; DNA FRAGMENTATION; APOPTOSIS; PROTEIN; LINES; CANCER; NEUROBLASTOMA; PROTOONCOGENE; RESISTANCE; PROSTATE	As BCL-2 oncoprotein has been implicated as a survival factor in a number of tissues, we examined colorectal tumour specimens and cell lines for BCL-2 expression. BCL-2 protein was expressed in 19/22 adenocarcinomas and 12/13 adenomas. 6/9 carcinoma cell lines and 7/8 adenoma cell lines were also BCL-2 positive. BCL-2 expression was retained in metastases to the regional lymph nodes (3/3 specimens) and in the cell line SW620, derived from a lymph node metastasis. These studies suggest a role for BCL-2 in promoting cell survival of benign and malignant colorectal tumours and that BCL-2 deregulation may be a relatively early event in colorectal carcinogenesis. The retention of BCL-2 expression in the carcinomas and lymph node metastases may explain the resistance of colorectal tumours to chemotherapeutic treatment.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol								COLOMBEL M, 1993, AM J PATHOL, V143, P390; FEARON ER, 1990, SCIENCE, V247, P47; FISHER TC, 1993, CANCER RES, V53, P3321; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HANADA M, 1993, CANCER RES, V53, P4978; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IKEGAKI N, 1994, CANCER RES, V54, P6; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1992, CANCER RES, V52, P5407; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; REED JC, 1991, CANCER RES, V51, P6529; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1992, INT J CANCER, V52, P785, DOI 10.1002/ijc.2910520519	25	184	185	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3367	3370						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936663				2022-12-28	WOS:A1994PM65800032
J	MANO, H; SATO, K; YAZAKI, Y; HIRAI, H				MANO, H; SATO, K; YAZAKI, Y; HIRAI, H			TEC PROTEIN-TYROSINE KINASE DIRECTLY ASSOCIATES WITH LYN PROTEIN-TYROSINE KINASE THROUGH ITS N-TERMINAL UNIQUE DOMAIN	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; SH3 DOMAINS; AMINO-ACIDS; GENE	Most of non-receptor-type protein-tyrosine kinases share common structures, such as N-terminal unique domains, Src homology region (SH)-2 domains, SH-3 domains and kinase domains. Although vast effort has brought some information about the in vivo roles of SH-2, -3 and kinase domains, little is still understood about the function of N-terminal unique domain. By utilizing the glutathione S-transferase (GST)-fusion system, we have investigated the role of N-terminal unique domain of the Tec protein-tyrosine kinase in a mouse IL-3-dependent myeloid cell line. We could reveal that the C-terminal half of the Tec N-terminal unique domain (NTec2 region) can bind to a set of tyrosine-phosphorylated cellular proteins in vitro in an IL-3-dependent manner. Surprisingly, p56/53(Lyn) constitutively binds to the NTec2 region. Among the NTec2-bound Lyn proteins, only-the p56 form seems to be inducibly tyrosine-phosphorylated in response to IL-3. Binding domain of Lyn to the NTec2 region was localized to its SH-3 domain. Tec was also shown to make a stable complex with Lyn in vivo. This is the first report demonstrating the direct association between distinct cytoplasmic protein-tyrosine kinases, especially through N-terminal unique domain.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo	MANO, H (corresponding author), JICHI MED SCH,DEPT MOLEC BIOL,3311-1 YAKUSHIJI,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATZAV S, 1989, ONCOGENE, V4, P1129; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MACAULEY A, 1993, ONCOGENE, V8, P117; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J, 1989, MOL CLONING LABORATO; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	35	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3205	3211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936643				2022-12-28	WOS:A1994PM65800012
J	KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H				KUROKAWA, M; OGAWA, S; TANAKA, T; MITANI, K; YAZAKI, Y; WITTE, ON; HIRAI, H			THE AML1 EVI-1 FUSION PROTEIN IN THE T(3-21) TRANSLOCATION EXHIBITS TRANSFORMING ACTIVITY ON RAT1 FIBROBLASTS WITH DEPENDENCE ON THE EVI-1 SEQUENCE	ONCOGENE			English	Article						AMLI/EVI-1; TRANSFORMATION; FIBROBLAST; API ACTIVATION; C-JUN	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; ZINC FINGER PROTEIN; C-JUN; TRANSCRIPTION FACTOR; MESSENGER-RNA; PHILADELPHIA-CHROMOSOME; PRE-B; T(15-17) TRANSLOCATION	The t(3;21) (q26;q22) chromosomal translocation associated with blastic crisis of chronic myelogenous leukemia (CML) results in the formation of a chimeric protein fusing the amino-terminal DNA-binding domain encoded by the AML1 gene to the carboxyl-terminal-encoding portion of the Evi-1 gene. In order to evaluate transforming activity of this protein, AML1/Evi-1 was introduced into Rat1 fibroblasts, Cells expressing the fusion product formed macroscopic colonies in soft agar, indicating that AML1/Evi-1 is a transforming gene. It was also demonstrated that introduction of AML1/Evi-1 into the Rat1 clones harboring BCR/ABL also conferred enhanced capacity for anchorage independent growth, Analyses of deletion mutants of AML1/Evi-1 revealed that removal of the second zinc finger domain within the Evi-1 sequence totally abrogated the ability of AML1/Evi-1 to transform Rat1 cells. We showed that the transforming effect is correlated with the AP-1 activation induced by AML1/Evi-1. Furthermore, me demonstrated that c-jan is transcriptionally activated in Rat1 cells transformed by AML1/Evi-1, suggesting that c-jun expression is under control of AML1/Evi-1. These results indicate that the oncogenic effect of the t(3;21) translocation is caused by the generation of a chimeric transcriptional factor and that AML1/Evi-1 could perform a pivotal role in leukemic progression of CML.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of Tokyo; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			Tanaka, Tomoyuki U/A-4775-2008					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN Z, 1991, CANCER GENET CYTOGEN, V57, P153, DOI 10.1016/0165-4608(91)90146-L; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE T, 1988, AM J HEMATOL, V27, P56, DOI 10.1002/ajh.2830270113; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KANTARJIAN HM, 1993, BLOOD, V82, P691; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, BLOOD, V81, P883; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUBIN CM, 1990, BLOOD, V76, P2594; RUBIN CM, 1987, BLOOD, V70, P1338; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHNEIDER NR, 1991, ANN GENET-PARIS, V34, P256; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONOBE MH, 1991, ONCOGENE, V6, P1531; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	76	51	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					833	840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675444				2022-12-28	WOS:A1995RU79800003
J	LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ				LI, XR; ADAM, G; CUI, HM; SANDSTEDT, B; OHLSSON, R; EKSTROM, TJ			EXPRESSION, PROMOTER USAGE AND PARENTAL IMPRINTING STATUS OF INSULIN-LIKE GROWTH-FACTOR-II (IGF2) IN HUMAN HEPATOBLASTOMA - UNCOUPLING OF IGF2 AND H19 IMPRINTING	ONCOGENE			English	Article						IGF2; H19; HEPATOBLASTOMA; PARENTAL IMPRINTING; PROMOTER; METHYLATION	BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; GENE; RELAXATION; ALLELE; RNA	We have studied the promoter utilization and parental imprinting status of human IGF2 in three genetically informative hepatoblastomas from patients ranging in age from 9 months to 3 years, In all three cases, there is a downregulation of promoter P1 in the tumor tissues while the P2 and P3 promoters are upregulated compared to the normal liver, One of the three patients displayed loss of imprinting (LOI) of IGF2 in the tumor tissue, We also investigated the expression of the H19 gene in all three cases and the methylation pattern in H19 from the patient with LOI of IGF2. The expression of H19 was greatly reduced in all tumors. Monoallelic H19 expression however, was retained even in the case which showed LOI of IGF2. Unlike the situation in Wilms' tumor, no differences in the methylation pattern between the normal liver and tumor tissues were observed in the H19 promoter or 3' region, using HpaII analysis. We show here, that in contrast to the situation in Wilms' tumor, H19 expression is not a prerequisite for maintaining a monoallelic IGF2 expression.	KAROLINSKA HOSP,DEPT CLIN NEUROSCI,EXPTL ALCOHOL & DRUG ADDICT RES SECT,S-17176 STOCKHOLM,SWEDEN; UNIV UPPSALA,DEPT ANIM DEV & GENET,S-75236 UPPSALA,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,DIV PEDIAT,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Uppsala University; Karolinska Institutet; Karolinska University Hospital			Cui, Hengmi/A-2598-2008; Ekström, Tomas/B-7764-2013					BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRICE AL, 1989, DEVELOPMENT, V106, P543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIES SM, 1993, CANCER RES, V53, P4781; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RECHLER MM, 1990, INSULIN LIKE GROWTH, P263; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCHNEID H, 1993, ENDOCRINOLOGY, V132, P1145, DOI 10.1210/en.132.3.1145; SHAFFORD EA, 1994, EUR J CANCER, V30A, P1050, DOI 10.1016/0959-8049(94)90453-7; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1993, ADV EXP MED BIOL, V343, P63; SUSSENBACH JS, 1991, ADV EXP MED BIOL, V293, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WALSH C, 1995, CANCER RES, V55, P1111; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	37	91	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					221	229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624139				2022-12-28	WOS:A1995RK95700002
J	KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B				KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B			LIGAND-INDEPENDENT ACTIVATION OF TYROSINE KINASE IN FIBROBLAST GROWTH-FACTOR RECEPTOR-1 BY FUSION WITH BETA-GALACTOSIDASE	ONCOGENE			English	Article						FIBROBLAST GROWTH FACTOR RECEPTOR 1; TETRAMERIZATION; TYROSINE KINASE; TRANSFORMATION	FGF RECEPTOR; POINT MUTATION; MITOGENIC ACTIVITY; CODING SEQUENCE; CELLS; EXPRESSION; GENE; IDENTIFICATION; BINDING; CANCER	To examine the biological role of fibroblast growth factor receptor 1 (FGFR1) oligomerization far its signal transduction, we construct an expression vector encoding a FGFR1-beta-galactosidase fusion protein, This vector is designed to fuse the 3'-portion of FGPR1 to beta-galactosidase. Transfection of this vector into FGFR-negative rat L6 myoblast cells results in ligand-indpendent inhibition of differentiation into myocytes, suggesting that FGFR1 within this fusion protein is constitutively activated, This can be confirmed by demonstrating that this fusion protein exhibits the tyrosine kinase activity and phaspholipase C-gamma I is tyrosine-phosphorylated even in the absence of ligand stimuli, Since the transfected cells also exhibit the enzyme activity of beta-galactosidase which is known to be active only in a tetramer form, this constitutive activation can be elicited by tetramerization of FGFR1, Furthermore, deletion of a region corresponding to C terminal 10 amino acids important for tetramerization of beta-galactosidase from this expression vector abolishes the constitutively active nature of FGFR1 with simultaneous loss of P-galactosidase activity, Transfection of non-deleted expression vector into NIH3T3 cells results in acquisition of focus-forming activity while a deleted form of expression vector fails to show this activity even in the presence of basic FGF, These results would suggest that tetramerization of FGFR1 can produce a constitutively active form responsible for transformation of NIH3T3 cells.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN	Osaka University			Kishimoto, Tadamitsu/C-8470-2009					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; FOWLER AV, 1966, SCIENCE, V25, P1027; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KOUHARA H, 1994, ONCOGENE, V9, P455; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; MARICS I, 1989, ONCOGENE, V4, P335; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAMBROOK L, 1989, MOL CLONING, V16, P66; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2315	2322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784079				2022-12-28	WOS:A1995RE54300006
J	XIE, YM; LI, KY; HUNG, MC				XIE, YM; LI, KY; HUNG, MC			TYROSINE PHOSPHORYLATION OF SHC PROTEINS AND FORMATION OF SHC/GRB2 COMPLEX CORRELATE TO THE TRANSFORMATION OF NIH3T3 CELLS MEDIATED BY THE POINT-MUTATION ACTIVATED NEU	ONCOGENE			English	Note						SHC; GRB2; P185(NEU); TYROSINE PHOSPHORYLATION; TRANSFORMATION	GROWTH-FACTOR RECEPTOR; ONCOGENIC ACTIVATION; SIGNAL TRANSDUCTION; 3T3 CELLS; GENE; KINASE; DOMAIN	PLC-gamma, ras-GAP and She have been proposed to be in vivo substrates for the nea-encoded p185(neu) receptor tyrosine kinases. We compared the tyrosine phosphorylation levels of PLC-gamma, ras-GAP and She in two NIH3T3 derived cell lines, transformed B104-1-1 and non-transformed DHFR/G8 cells in which point-mutation activated and normal rat nea genes were transfected and expressed, respectively. We found that tyrosine phosphorylation of She and formation of Shc/ Grb2 complex were more significant in B104-1-1 cells than in DHFR/G8 cells, while no obvious difference could be detected for the tyrosine phosphorylation levels of ras-GAP and PLC-gamma between these two cell lines. Furthermore, we observed that association with She was severely impaired by deletion of most of the major autophosphorylation sites of the point-mutated neu. The truncated nea product, however, fully retained its ability to transform NIH3T3 cells, induce She tyrosine phosphorylation and Shc/Grb2 complex formation. Our results suggest that tyrosine phosphorylation of She which allows formation of Shc/Grb2 complex may play an important role for cell transformation induced by the point mutation-activated neu, and that stable binding to mutant p185(neu) may not be necessary for She to mediate this signaling pathway.	UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JANES PW, 1994, ONCOGENE, V9, P3601; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1993, MOL CARCINOGEN, V7, P44, DOI 10.1002/mc.2940070108; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2409	2413						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784091				2022-12-28	WOS:A1995RE54300018
J	GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T				GRAY, DA; INAZAWA, J; GUPTA, K; WONG, A; UEDA, R; TAKAHASHI, T			ELEVATED EXPRESSION OF UNPH, A PROTOONCOGENE AT 3P21.3, IN HUMAN LUNG-TUMORS	ONCOGENE			English	Article						UBIQUITIN PROTEASE; 3P21; LUNG CANCER	CANCER CELL-LINES; TRE ONCOGENE; GENE FAMILY; DELETION; REGION; HETEROZYGOSITY; CHROMOSOME-17; HYBRIDIZATION; CLONING; MARKERS	The murine Unp proto-oncogene encodes a nuclear ubiquitin protease whose overexpression leads to oncogenic transformation of NIH3T3 cells. We have cloned cDNAs originating from the human homolog of this gene, designated herein as Unph (Unp, human), and have used these cDNAs to map the gene to 3p21.3, a region frequently rearranged in human tumor cells. Unph mRNA levels are consistently elevated in small cell tumors and adenocarcinomas of the lung, suggesting a possible causative role for the gene in the neoplastic process.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8M5,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIGYO KU,KYOTO 602,JAPAN; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	University of Ottawa; University of Ottawa; Kyoto Prefectural University of Medicine; Aichi Cancer Center	GRAY, DA (corresponding author), OTTAWA REG CANC CTR,501 SMYTH RD,OTTAWA,ON K1H 8L6,CANADA.		Takahashi, Takashi/I-7262-2014; /U-3554-2018	Takahashi, Takashi/0000-0003-0615-7001; /0000-0002-8634-4984				ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BAKER RT, 1992, J BIOL CHEM, V267, P23364; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V553, P205; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; HIDA T, 1993, JPN J CLIN ONCOL, V23, P14; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YUN K, 1993, CANCER RES, V53, P5166	27	95	101	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2179	2183						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784062				2022-12-28	WOS:A1995RB70300013
J	ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M				ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M			STABILIZATION OF CYCLIN-E AND CDK2 MESSENGER-RNAS AT G1/S TRANSITION IN RAT-1A CELLS EMERGING FROM THE G0 STATE	ONCOGENE			English	Article						IMMEDIATE-EARLY GENES; DELAYED-EARLY GENES; DELTA-FOSB; FOSB CELL CYCLE; CELL PROLIFERATION	IMMEDIATE-EARLY GENES; CULTURED MOUSE CELLS; 3T3 CELLS; MESSENGER-RNA; C-FOS; SHORT FORM; EXPRESSION; PROTEIN; JUN; FIBROBLASTS	mRNAs for cyclin E and Cdk2 have a role in the commitment to DNA replication in the cell cycle, and are induced in Rat-1A cells by serum stimulation. Cyclin E and cdk2 genes are transcribed in quiescent cells, but their transcripts rapidly turn over and levels are kept low. The rate of transcription of the cdk2 gene is slightly increased after serum stimulation, while that of cyclin E is fairly constant. At the G1/S transition of serum-stimulated cells, transient stabilization of the two types of mRNAs occurs, an event which may lead to induction of each mRNA. Artificial expression of an immediate-early protein Delta FosB results in proliferation of quiescent Rat-1A cells, and this is accompanied by an efficient induction of cyclin E and cdk2 mRNAs. In Delta FosB-expressing cells, two types of mRNAs are stabilized to the same extent seen in serum-stimulated cells. The expression of cyclin E and cdk2 genes is upregulated by stabilization of their transcripts, at least in part. We propose that Delta FosB may have a role in regulation of progression of the cell cycle in serum-stimulated Rat-1A cells by triggering stabilization of mRNAs for cyclin E and Cdk2.	KYUSHU UNIV 69, MED INST BIOREGULAT, DEPT BIOCHEM, FUKUOKA 812, JAPAN	Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FINANCSEK I, 1982, GENE, V18, P115; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVARY K, 1991, NEW BIOL, V3, P870; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MILLER AD, 1984, CELL, V36, P51; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; NATHANS D, 1991, ORIGINS OF HUMAN CANCER, P353; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAMURA K, 1993, ONCOGENE, V8, P2113; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIMMEL A, 1994, ONCOGENE, V9, P995; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1343	1351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731685				2022-12-28	WOS:A1995QR65100011
J	DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL				DEVRIESSMITS, AMM; PRONK, GJ; MEDEMA, JP; BURGERING, BMT; BOS, JL			SHC ASSOCIATES WITH AN UNPHOSPHORYLATED FORM OF THE P21RAS GUANINE-NUCLEOTIDE EXCHANGE FACTOR MSOS	ONCOGENE			English	Article						EGF RECEPTOR; INSULIN RECEPTOR; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; INSULIN-RECEPTOR SUBSTRATE-1; SIGNAL-REGULATED KINASE-2; TYROSINE KINASES; MITOGENIC SIGNAL; RAS; PROTEIN; GRB2; ACTIVATION; PHOSPHORYLATION	Association of the p21ras guanine nucleotide exchange factor mSOS with tyrosine-phosphorylated She has been implicated in the activation of p21ras, In addition, after growth factor stimulation mSOS becomes phosphorylated as indicated by the appearance of a form of mSOS with reduced electrophoretic mobility. This phosphorylation is delayed with respect to Shc-Grb2-mSOS complex formation and activation of p21ras. To investigate the role of mSOS phosphorylation in further detail we have investigated the effect of phosphorylation on mSOS complex formation and p21ras activation, We found that She is associated with the unphosphorylated, faster migrating form of mSOS. Furthermore, although there is a correlation between the amount of complexes formed and the activation of p21ras, there is no such a correlation between mSOS phosphorylation and p21ras activation. In addition, inhibition of mSOS phosphorylation did not affect complex formation of mSOS with tyrosine phosphorylated She. Also, induction of mSOS phosphorylation prior to complex formation did not affect EGF-induced association of mSOS with She significantly, and She still associated predominantly with the faster migrating form of mSOS. From these results we conclude that the unphosphorylated form of mSOS is associated with She and that perhaps a phosphorylation-dephosphorylation step is part of the mSOS activation-inactivation cycle.	UNIV UTRECHT,PHYSIOL CHEM LAB,3508 TA UTRECHT,NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEYER MG, 1994, MOL CELL BIOL, V14, P3577; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOBE K, 1993, J BIOL CHEM, V268, P11167; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	30	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					919	925						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898933				2022-12-28	WOS:A1995QL03800013
J	MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J				MORRIS, C; BENJES, S; HAATAJA, L; LEDBETTER, DH; HEISTERKAMP, N; GROFFEN, J			SPATIAL-ORGANIZATION OF ABR AND CRK GENES ON HUMAN-CHROMOSOME BAND 17P13.3	ONCOGENE			English	Note						ABR GENE; CRK GENE; CHROMOSOME; 17P13.3; D17S34	GUANINE-NUCLEOTIDE EXCHANGE; INTERPHASE CELL-NUCLEI; MILLER-DIEKER SYNDROME; HYPERVARIABLE RFLP; DNA-SEQUENCES; ONCOGENE; PROTEIN; P53; LOCALIZATION; HOMOLOGY	Deletion of part or all of chromosome 17p is among the most frequent chromosome abnormalities in human cancer. We show that the CRK and ABR genes are close to a marker on chromosome 17p13.3, D17S34, which is frequently deleted in different tumours, and demonstrate that CRK is centromeric to ABR. CRK and ABR may be involved in cancer themselves, or otherwise may function as points of reference for further experiments to clone genes from chromosome 17p which may play a role in cancer.	CHILDRENS HOSP LOS ANGELES,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90027; CHRISTCHURCH HOSP,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Children's Hospital Los Angeles; Christchurch Hospital New Zealand; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Morris, Christine/G-1690-2011; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; BIEGEL JA, 1992, CANCER RES, V52, P3391; CHAN AML, 1994, ONCOGENE, V9, P1057; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5925, DOI 10.1093/nar/18.19.5925; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; FIORETOS T, 1993, ONCOGENE, V8, P2853; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; NISHIDA N, 1993, CANCER RES, V53, P368; PRESTI JC, 1991, CANCER RES, V51, P5405; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; RON D, 1991, NEW BIOL, V3, P372; SAXENA A, 1992, CANCER RES, V52, P6716; TAN EC, 1993, J BIOL CHEM, V268, P27291; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; TSAO SW, 1991, ANTICANCER RES, V11, P1975; UMBRICHT CB, 1994, GENOMICS, V20, P249, DOI 10.1006/geno.1994.1161; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	36	17	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1009	1011						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898918				2022-12-28	WOS:A1995QL03800023
J	SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M				SHAULIAN, E; HAVIV, I; SHAUL, Y; OREN, M			TRANSCRIPTIONAL REPRESSION BY THE C-TERMINAL DOMAIN OF P53	ONCOGENE			English	Article						P53; TRANSCRIPTION; TRANSACTIVATION	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENES; TATA-BINDING PROTEIN; DNA-BINDING; RESPONSIVE ELEMENT; ACTIVATION DOMAIN; SEQUENCE; TRANSFORMATION; INHIBITION	We have previously shown that monomeric p53 can transactivate target genes in vivo and that C-terminal fragments of p53 are oncogenic. To further elaborate these findings a series of C-terminal truncations of p53 was generated. The transactivation capacity and the ability of the truncated p53 to suppress oncogene-mediated transformation were studied. We found that p53 truncated at amino acid 303 (p53wtdl303) can still function in both assays, though less efficiently than full length wild type (wt) p53. Transforming C-terminal fragments inhibited transactivation induced by full length wt p53. Surprisingly, they also inhibited transactivation by wtdl303, with which they do not share e any overlapping sequences. Furthermore, the C-terminal fragments repressed the transactivation domains of several viral and cellular transcriptional activators. These data raise the possibility that the C-terminal domain of p53 may compete with the p53 transactivation domain for a common basal transcription factor.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Haviv, Izhak/E-3782-2015	Haviv, Izhak/0000-0002-0837-5005	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, IN PRESS GENE DEV; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1944, SCIENCE, V265, P386; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; HUPP TR, 1994, IN PRESS COLD SPRING, V59; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	80	73	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					671	680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862444				2022-12-28	WOS:A1995QH61200006
J	VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL				VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL			A NOVEL INTRACELLULAR EPITHELIAL-CELL TYROSINE KINASE IS EXPRESSED IN THE SKIN AND GASTROINTESTINAL-TRACT	ONCOGENE			English	Article						INTESTINE; SKIN; TYROSINE KINASE; EPITHELIA	SH3 DOMAINS; TERMINAL DIFFERENTIATION; SIGNAL TRANSDUCTION; GENE-EXPRESSION; PROTEIN-KINASE; STEM-CELLS; MOUSE; FAMILY; RAS; DROSOPHILA	A portion of the catalytic domain of a novel tyrosine kinase was cloned from mouse intestinal crypt cells, in a screen designed to identify kinases that may play a role in the regeneration of the intestinal epithelium (E Siyanova, MS Serfas, IA Mazo and AL Tyner, Oncogene 9, 2053-2057). We have cloned a cDNA encoding this kinase, termed sik for src-related intestinal kinase. The sik cDNA encodes a 451 amino acid protein that shares 80% identity with the recently cloned human tyrosine kinase, brk. Sequences found in src family kinases, such as SH2 and SH3 domains and a putative regulatory tyrosine at the carboxy terminus are found in the sik kinase. In contrast, sik lacks a myristylation site. The protein encoded by the sik cDNA has tyrosine kinase activity when expressed in E. coli, We have determined that sik is expressed only in epithelial tissues, including the skin and lining of the alimentary canal, and using in situ hybridization we show that expression of sik mRNA is restricted to the cell layers immediately above the proliferative cell zone in these epithelia, The sik mRNA is first detected at day 15.5 of gestation in the mouse embryo, where it is expressed in the newly forming granular layer of the skin. The restricted expression of sik to differentiating cells of rapidly renewing epithelia suggests that sik may play a specialized role in these tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; AMGEN INC, AMGEN CTR, DEPT MOLEC BIOL, THOUSAND OAKS, CA 91320 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Amgen				Tyner, Angela/0000-0001-7448-8625; Vasioukhin, Valeri/0000-0002-6730-0281	NIDDK NIH HHS [R01 DK044525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FISHER C, 1987, CURR TOP DEV BIOL, V22, P209; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMOS JA, 1971, J CELL BIOL, V50, P255, DOI 10.1083/jcb.50.1.255; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1988, ONCOGENE, V3, P629; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUGH R, 1991, MOUSE ITS REPRODUCTI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	76	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838533				2022-12-28	WOS:A1995QC62400014
J	RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF				RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF			STRAND-SPECIFIC REMOVAL OF CYCLOBUTANE PYRIMIDINE DIMERS FROM THE P53 GENE IN THE EPIDERMIS OF UVB-IRRADIATED HAIRLESS MICE	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; DNA-REPAIR; ULTRAVIOLET RADIATION; TRANSCRIBED STRAND; ACTIVE GENES; DHFR GENE; MUTATIONS; MOUSE; SKIN	Removal of UVB-induced cyclobutane pyrimidine dimers (CPD) from each of the two strands of the transcriptionally active p53 tumor suppressor gene and the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was determined in the epidermis of the hairless mouse using the CPD-specific enzyme T4 endonuclease V. Mice were exposed to a single dose of UVB (2 kJ/m(2)) and kept in darkness for up to 24 h. About 80% of the CPD were removed from the transcribed strand of the p53 and HPRT genes within 24 h. Most rapid removal was observed during the first 4 h. Tn contrast, very little removal of CPD from the nontranscribed strand of the p53 and the HPRT genes was observed in 24 h. The same low level of repair was observed in the inactive cmos proto-oncogene. The efficient repair of the transcribed strand compared to the nontranscribed strand of transcriptionally active genes in the epidermis of the hairless mouse resembles the repair of CPD in cultured rodent cells. Moreover, the selective removal of CPD from the transcribed strand of the p53 gene correlates well with the known strand bias of u.v.-induced mutations at dipyrimidine sites in the p53 gene of u.v.- induced mouse skin tumors.	LEIDEN UNIV,MGC,DEPT RADIAT GENET & CHEM MUTAGENESIS,2333 AL LEIDEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS; INTERUNIV RES INST RADIOPATHOL & RADIAT,JA COHEN INST,LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Netherlands National Institute for Public Health & the Environment								BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P3782; BRUNET S, 1989, MUTAT RES, V219, P217, DOI 10.1016/0921-8734(89)90003-9; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EVANS MK, 1993, CANCER RES, V53, P5377; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GATTONI S, 1982, MOL CELL BIOL, V2, P42, DOI 10.1128/MCB.2.1.42; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KANJILAL S, 1993, CANCER RES, V53, P2961; KONECKI DS, 1982, NUCLEIC ACIDS RES, V81, P2147; KRESS S, 1992, CANCER RES, V52, P6400; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; NEKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; RADY P, 1992, CANCER RES, V52, P3804; RUVEN HJT, 1993, CANCER RES, V53, P1642; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	32	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3427	3432						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970701				2022-12-28	WOS:A1994PT39200003
J	BRUNET, A; PAGES, G; POUYSSEGUR, J				BRUNET, A; PAGES, G; POUYSSEGUR, J			CONSTITUTIVELY ACTIVE MUTANTS OF MAP KINASE KINASE (MEK1) INDUCE GROWTH FACTOR-RELAXATION AND ONCOGENICITY WHEN EXPRESSED IN FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE; HAMSTER FIBROBLASTS; SIGNALING PATHWAYS; NA+/H+ ANTIPORTER; ACTIVATION; CELLS; RAS; PHOSPHATASE; CASCADE; PHOSPHORYLATION	The Mitogen Activated Protein Kinase (MAPK) module operates downstream of Pas to convey cell surface signals to the nucleus via the nuclear translocation of p42/p44 MAPKs. We have previously established that MAPK activation is obligatory and must persist in the G1 phase to allow resting fibroblasts to exit from G0 (Pages et al., Proc. Natl. Acad. Sci.1993, 90, 8319-8323). It remained to be established whether MAPK activation was sufficient to trigger cell proliferation. To this aim, we generated and expressed in Chinese hamster lung fibroblasts, constitutively active mutants of hamster MAP kinase kinase (MAPKK). Three mutants: S218D, S222D and S218D/S222D in which we substituted the Raf1/MAPKKK-dependent regulatory phosphorylation sites by aspartic acid residues, displayed increased basal activity when expressed in fibroblasts. Two of them, S218D and S218D/S222D which have a basal activity higher than serum-stimulated wild type-MAPKK (respectively 2- and 5-fold), induced activation of p42 MAPK in growth factor-deprived cells. Interestingly, only these two mutants led to a growth factor-independent state as judged by early gene transcription (activation of the fos promoter), increased sensitivity to growth factors for reinitiation of DNA synthesis, autonomous cell cycling and rapid tumor formation in nude mice. Therefore we conclude that the downstream elements of the growth factor signalling cascade, MAPKK-MAPK, are both necessary and sufficient to promote growth factor signals and autonomous cell cycling in fibroblasts.	UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Pages, Gilles/N-7135-2017					ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBOIS MF, 1994, IN PRESS EMBO J; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELLIS L, 1986, COLD SPRING HARB SYM, V51, P773, DOI 10.1101/SQB.1986.051.01.090; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOTOH Y, 1994, ONCOGENE, V9, P1891; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGECARTER CA, 1993, SCIENCE, V260, P318; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MORDRET G, 1993, BIOL CELL, V79, P193, DOI 10.1016/0248-4900(93)90138-5; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; POYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589	57	226	229	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3379	3387						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936666				2022-12-28	WOS:A1994PM65800035
J	SOANS, C; HOLASH, JA; PASQUALE, EB				SOANS, C; HOLASH, JA; PASQUALE, EB			CHARACTERIZATION OF THE EXPRESSION OF THE CEK8 RECEPTOR-TYPE TYROSINE KINASE DURING DEVELOPMENT AND IN TUMOR-CELL LINES	ONCOGENE			English	Article							NERVOUS-SYSTEM; EPH GENE; PROTEIN; FAMILY; CHICKEN; IDENTIFICATION; HINDBRAIN; MEMBERS; ENCODES; CLONING	Cek8 is a receptor-type tyrosine kinase gene that was identified by screening a 10 day chicken embryo library with a DNA probe corresponding to the related kinase Cek4 (Sajjadi and Pasquale, 1993). Here we report the characterization of the Cek8 protein and its expression in embryonic tissues and tumor cell lines. The 120 kd Cek8 protein is detected early in embryogenesis, is developmentally regulated and preferentially, but not exclusively, expressed in neural tissues. In the stage 24 chick embryo, Cek8 immunoreactivity is prominent in the spinal cord and spinal nerves. At embryonic day 6, Cek8 expression becomes concentrated to the ventral portion of the spinal nerves, suggesting a role in axonogenesis of specific subsets of neurons. Cek8 is expressed in nearly all of the tumor cell lines examined, including cell lines derived from tumors of the central nervous system. Although the phosphorylation on tyrosine of Cek8 during development is moderate or undetectable, Cek8 is substantially phosphorylated on tyrosine (and thus presumably activated) in many of the transformed cell lines. Because of its high frequency of expression in tumor cell lines, Cek8 differs from previously investigated Eph-related kinases. However, as we show, Cek8 is not unique among the Eph-related kinases: another member of the Eph subclass, Cek5, has similar patterns of expression and phosphorylation in tumor cells. Based on its binding to a variety of lectin columns, Cek8 contains complex N-linked oligosaccharides. Cross-linking of Cek8 molecules on the cell surface with wheat germ agglutinin caused their rapid phosphorylation on tyrosine. Autophosphorylation on tyrosine is typically the first step in the activation of a receptor tyrosine kinase by a ligand.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56721] Funding Source: Medline; NICHD NIH HHS [HD-26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BISHOP JM, 1991, CELL, V64, P234; BOHME B, 1993, ONCOGENE, V8, P2857; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HARLOW E, 1988, ANTIBODIES LABORATOR; Hazan R., 1993, Molecular Biology of the Cell, V4, p9A; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SUGII S, 1982, CARBOHYD RES, V99, P99, DOI 10.1016/S0008-6215(00)80982-9; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	34	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3353	3361						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936661				2022-12-28	WOS:A1994PM65800030
J	ENGELKE, U; SMARDA, J; LIPSICK, JS				ENGELKE, U; SMARDA, J; LIPSICK, JS			BYPASS OF TPA-INDUCED DIFFERENTIATION AND CELL-CYCLE ARREST BY THE C-MYB DNA-BINDING DOMAIN	ONCOGENE			English	Article						MYB; CELL CYCLE; TPA	TRANSFORMATION; TRUNCATION; GENE; ACTIVATION; EXPRESSION; ONCOGENE; PROTEIN	Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with phorbol ester (TPA). This differentiation occurs during both the G(1) and the G(2) phases of the cell cycle and is accompanied by cell cycle arrest. The introduction of a protein consisting of the three repeats (3R) of the c-Myb DNA-binding domain permits the by-pass of this phorbol ester-induced differentiation and cell cycle arrest. In particular, monoblasts which express the 3R protein progress through both the G(1)/S and G(2)/M transitions in the presence of phorbol ester. However, the 3R protein contains no detectable transcriptional activation domain. These results demonstrate that the c-Myb DNA-binding domain can regulate the cell cycle without functioning as a direct transcriptional activator.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; MASARYK UNIV,FAC SCI,DEPT MOLEC BIOL & GENET,CS-61137 BRNO,CZECH REPUBLIC	Stanford University; Masaryk University Brno					FOGARTY INTERNATIONAL CENTER [R03TW000291] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00291] Funding Source: Medline; NCI NIH HHS [R01 CA43592] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; GARCIA A, 1991, ONCOGENE, V6, P265; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1993, GENE, V137, P145; SMARDA J, 1994, ONCOGENE, V9, P237; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587	21	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					735	741						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651737				2022-12-28	WOS:A1995RQ46900015
J	ROLLEY, N; BUTCHER, S; MILNER, J				ROLLEY, N; BUTCHER, S; MILNER, J			SPECIFIC DNA-BINDING BY DIFFERENT CLASSES OF HUMAN P53 MUTANTS	ONCOGENE			English	Article						P53; DNA BINDING; STRUCTURAL MUTANTS; DNA CONTACT MUTANTS	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; PROTEIN; CONFORMATION; APOPTOSIS; GENE; TRANSCRIPTION; P53-PROTEIN; COMPLEXES; INHIBITOR	The p53 protein is a multifunctional transcription factor which orchestrates cellular responses to DNA damage, so helping to conserve genomic stability. It may also regulate genes involved in intercellular signalling, such as thrombospondin, a negative regulator of angiogenesis and metastatic spread. Activation of p53 target genes requires sequence-specific DNA binding, a function which maps to the central core of the protein. Missense point mutations within this domain inactivate p53 tumour suppressor function and involve either (i) DNA contact residues, or (ii) residues important for conformational structure. Using in vitro techniques we have analysed seven DNA contact mutants and 17 structural mutants known to occur in cancer. We show that DNA contact mutants can be carried into specific DNA interaction when co-expressed with wild type protein. For structural mutants, 9/17 retained DNA binding capacity and, with one exception, DNA binding correlated with conformational flexibility of the mutant protein. The exception was Asp(281), which appeared essential for DNA interaction, probably due to its ability to form salt bridges with DNA contact residues Arg(273) and Arg(280). We suggest that different classes of p53 mutant may prove amenable to different strategies for restoration of wild type tumour suppressor function as means of anti-cancer therapy.	UNIV YORK,DEPT BIOL,YORKSHIRE CANC RES CAMPAIGN P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHIBA I, 1990, ONCOGENE, V5, P1603; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1992, CELL, V75, P817; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HAINAUT P, 1993, CANCER RES, V53, P4463; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARPER JW, 1993, CELL, V75, P805; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEDCALF EA, 1991, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOMAND J, 1992, CELL, V69, P1273; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; ROLLEY N, 1994, ONCOGENE, V9, P3067; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V6, P1143; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	59	92	94	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					763	770						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651740				2022-12-28	WOS:A1995RQ46900019
J	BAKER, SJ; REDDY, EP				BAKER, SJ; REDDY, EP			B-CELL DIFFERENTIATION - ROLE OF E2A AND PAX5/BSAP TRANSCRIPTION FACTORS	ONCOGENE			English	Review						B-CELL DIFFERENTIATION; E2A; PAX5; BSAP	DNA-BINDING PROTEINS; HEAVY-CHAIN ENHANCER; LOOP-HELIX PROTEINS; LYMPHOCYTES-PRE-B; IMMUNOGLOBULIN ENHANCER; GENE-TRANSCRIPTION; NUCLEAR-LOCALIZATION; V(D)J RECOMBINATION; SWITCH REGIONS; CIRCULAR DNA	Transcriptional regulation of lineage specific genes has the ability to dictate both the proliferative and differentiative potentials of a pulipotent precursor cell. The E2A and Pax5/BSAP genes encode transcription factors which bind to B cell specific promoters and enhancers and guide the development of immature, but committed cells into mature B lymphocytes which express and secrete immunoglobulins. In vitro analysis has consistently suggested that these proteins regulate distinct classes of genes during B cell differentiation; however, recent targeted gene disruption and transgene expression in mice has indicated that these genes may actually be components of a single regulatory mechanism which is essential for both B lymphocyte differentiation and proliferation.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011					ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALESSANDRINI A, 1991, MOL CELL BIOL, V11, P2096, DOI 10.1128/MCB.11.4.2096; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BARBERIS A, 1989, GENE DEV, V3, P663, DOI 10.1101/gad.3.5.663; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DORN A, 1989, MOL CELL BIOL, V9, P312, DOI 10.1128/MCB.9.1.312; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GOLAY JT, 1987, IMMUNOLOGY, V62, P279; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; JACOBS Y, 1994, MOL CELL BIOL, V14, P4087, DOI 10.1128/MCB.14.6.4087; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KASHIWAMURA SI, 1990, J IMMUNOL, V145, P337; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; LIAO F, 1994, J IMMUNOL, V152, P2904; LIAO F, 1992, J IMMUNOL, V148, P2909; LIEBERSON R, 1991, NUC ACIDS RES, V19, P165; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849, DOI 10.1128/MCB.8.4.1849; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEURATH MF, 1994, J IMMUNOL, V153, P730; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKABE T, 1992, EUR J IMMUNOL, V22, P31, DOI 10.1002/eji.1830220106; PEREZMUTUL J, 1988, NUCLEIC ACIDS RES, V16, P6085, DOI 10.1093/nar/16.13.6085; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SAISANIT S, 1995, MOL CELL BIOL, V15, P1513; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2788, DOI 10.1073/pnas.88.7.2788; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; SU LK, 1990, MOL CELL BIOL, V10, P2619, DOI 10.1128/MCB.10.6.2619; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANAKA M, 1993, CELL, V60, P275; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; XIN XQ, 1993, J IMMUNOL, V151, P5398; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	101	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					413	426						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630627				2022-12-28	WOS:A1995RN53000001
J	ZENKLUSEN, JC; WEITZEL, JN; BALL, HG; CONTI, CJ				ZENKLUSEN, JC; WEITZEL, JN; BALL, HG; CONTI, CJ			ALLELIC LOSS AT 7Q31.1 IN HUMAN PRIMARY OVARIAN CARCINOMAS SUGGESTS THE EXISTENCE OF A TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; OVARY; CHROMOSOME 7	MALIGNANT-TUMORS; FREQUENT LOSS; CANCER; CHROMOSOME-17; HETEROZYGOSITY; ALLELOTYPE; DELETION; MUTATION; P53	We studied loss of heterozygosity (LOH) in chromosome 7q in order to determine the location of a putative tumor suppressor gene (TSG) in human epithelial ovarian carcinomas. Samples were obtained from 26 primary ovarian carcinomas at the time of staging laparotomy. Paired normal and tumoral DNAs were used as templates for polymerase chain reaction amplification of a set of 14 (C-A)(n) microsatellite repeats on 7q21-qter. All the cases studied presented LOH at one or more loci on 7q. Seventy-three percent LON (in 14 of 19 informative cases) were detected in D7S522 at 7q31.1. The percentages of LOH were normally distributed around microsatellite D7S522 determining a smallest common deleted region of 1 cM. The high incidence of LOH in primary ovarian carcinomas suggests that a TSG relevant to the development of ovarian cancers is present at 7q31.1, confirming our previous functional evidence for a TSG in this region.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT OBSTET GYNECOL, DIV GYNECOL ONCOL, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR,SCH MED,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA	University of Texas System; UTMD Anderson Cancer Center; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University					NCI NIH HHS [K08 CA01574, CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001574, R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; ATKIN NB, 1991, CANCER GENET CYTOGEN, V52, P113, DOI 10.1016/0165-4608(91)90061-X; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V1, pCH2; CLIBY W, 1993, CANCER RES, V53, P2393; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; EHLEN T, 1990, ONCOGENE, V5, P219; FIGO cancer committee, 1986, GYNECOL ONCOL, V25, P383; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; GALLION HH, 1990, GYNECOL ONCOL, V38, P473, DOI 10.1016/0090-8258(90)90094-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KERE J, 1989, BLOOD, V73, P230; KIBBELAAR RE, 1993, BLOOD, V82, P904; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; LEE JH, 1990, CANCER RES, V50, P2724; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; MILNER BJ, 1993, CANCER RES, V53, P2128; MORI N, 1989, CANCER RES, V49, P5130; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PHILLIPS N, 1993, INT J CANCER, V54, P85, DOI 10.1002/ijc.2910540115; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1991, CANCER RES, V51, P5118; TENERIELLO MG, 1993, CANCER RES, V53, P3103; VACHERLAVENU MC, 1993, B CANCER, V80, P135; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; ZAR JH, 1991, BIOSTAT ANAL, pCH6; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	42	93	95	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					359	363						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624150				2022-12-28	WOS:A1995RK95700016
J	PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM				PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM			COMBINED ORAL CARCINOGENICITY OF HPV-16 AND BENZO(A)PYRENE - AN IN-VITRO MULTISTEP CARCINOGENESIS MODEL	ONCOGENE			English	Article						ORAL CANCER; HPV; BENZO(A)PYRENE; MULTISTEP CARCINOGENESIS; TUMOR SUPPRESSOR	PRIMARY HUMAN KERATINOCYTES; HUMAN PAPILLOMAVIRUS; INSITU HYBRIDIZATION; CERVICAL-CARCINOMA; CELLULAR-RESPONSE; ACTIVATED RAS; DNA DAMAGE; CELLS; TRANSFORMATION; EXPRESSION	We previously immortalized normal human oral keratinocytes by transfection with recombinant HPV-16 DNA and subsequently exposed the cells to benzo(a)pyrene for 7 days. The exposure to benzo(a)pyrene modified the immortalized cells: the modified cells (HOK-16B-BaP) proliferated in an ordinary culture medium containing physiological calcium level (1.5 mM), but demonstrated only enhanced proliferation capacity without tumor formation in nude mice and failed to show in vitro anchorage-independency. In this study, we further modified the HOK-16B-BaP cells by subculturing the cells in a medium containing benzo(a)pyrene for 6 months. The cells were further modified with a chronic benzo(a)pyrene exposure and were termed HOK-16B-BaP-T cells (1) demonstrated a malignant phenotype in organotypic 'raft' culture, (2) showed in vitro anchorage-independency, (3) developed tumors in nude mice when injected subcutaneously, (4) contained a significantly higher copy number of intact and integrated HPV-16 DNA; (5) contained higher level of HPV-16 E6/E7 messages and E7 protein, (6) were more resistant to transforming growth factor-beta 1 and (7) secreted higher level of vascular endothelial growth factor with molecular weight of 56 kd than parental HOK-16B-BaP cells. However, the levels of p53 and ras proteins and the levels of p53, c-myc and c-fos transcripts in the HOK-16B-BaP-T cells were not different from those in the HOK-16B-BaP cells. The highly conserved coding regions of the p53, c-Ha-ras1, and c-Ki-ras2 genes of the tumor cells were not mutated. These data indicate that the HPV-immortalized human oral keratinocytes can convert to tumorigenic cells by chronic exposure to benzo(a)pyrene. The tumorigenic conversion seems to be associated with (1) the overexpression of viral oncogenes such as E6 and E7 genes, (2) the higher resistance of cells to transforming growth factor-beta(1) and (3) the high secretion of 56 kd vascular endothelial growth factor from the cells.	UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	PARK, NH (corresponding author), UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90024 USA.		Min, Byung-Moo/F-2854-2012		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAEK JH, 1994, INT J ONCOL, V5, P1023; BIREK C, 1993, AM J PATHOL, V142, P917; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CURRAN T, 1984, CELL, V36, P259; DILUCA D, 1990, J DENT RES, V69, P51; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FIELD JK, 1990, ANTICANCER RES, V10, P1; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, CANCER RES, V53, P4811; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MIN BM, 1991, IN VITRO CELL DEV B, V27, P128; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCULLY C, 1988, ORAL SURG ORAL MED O, V65, P526, DOI 10.1016/0030-4220(88)90134-X; SHAH KV, 1990, PAPILLOMAVIRUSES HUM, P73; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODS KV, 1993, J ORAL PATHOL MED, V22, P101, DOI 10.1111/j.1600-0714.1993.tb01038.x; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZURHANSEN H, 1986, LANCET, V3, P489	43	79	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2145	2153						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784058				2022-12-28	WOS:A1995RB70300009
J	WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR				WONG, YH; CHAN, JSC; YUNG, LY; BOURNE, HR			MUTANT ALPHA-SUBUNIT OF G(Z) TRANSFORMS SWISS 3T3 CELLS	ONCOGENE			English	Article						G PROTEINS; NEOPLASTIC TRANSFORMATION; CYCLIC AMP	NUCLEOTIDE-BINDING PROTEIN; CYCLIC-AMP ACCUMULATION; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; ADENYLYL-CYCLASE; INHIBITION; ONCOGENES; RECEPTOR; MITOGENESIS; ACTIVATION	Many hormones and neurotransmitters induce cell proliferation by regulating signaling pathways controlled by heterotimeric G proteins. Mutations that activate the alpha subunits of G(s) and G(i2) produce the gsp and gip2 oncogenes that are found in certain human endocrine tumors. Similar mutations have conferred on other G alpha subunits the ability to promote neoplastic transformation in cultured mammalian cells, G(z), a G protein whose normal signaling function is poorly understood, shares with G(i2) the ability to inhibit adenylyl cyclase. We asked whether mutationally activated alpha(z) can stimulate cell proliferation in a cell line in which stimulation adenylyl cyclase is mitogenic, Swiss 3T3 cells, Stable expression of alpha(z)-Q205L in Swiss 3T3 cells induced focus formation, a faster growth rate with a higher saturation density, anchorage-independent growth in soft agar, and increased [H-3]thymidine incorporation in the absence of growth factors. alpha(z)-Q205L produced a similar but less extensively transformed phenotype in NIH3T3 cells-increased saturation density in culture, a smaller number of foci and few colonies in soft agar. Stimulation of thymidine incorporation by alpha(z)-Q205L in Swiss 3T3 cells was increased by co-treatment with cholera toxin, a stimulator of adenylyl cyclase. Taken together, our results indicate that a(z) stimulates one or more mitogenic pathways in Swiss 3T3 cells, and that effectiveness of these mitogenic pathways does not require reducing the concentration of cellular cAMP.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; HONG KONG UNIV SCI & TECHNOL,DEPT BIOL,KOWLOON,HONG KONG	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hong Kong University of Science & Technology								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUI Z, 1991, J BIOL CHEM, V266, P20276; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; FAURE M, 1994, J BIOL CHEM, V269, P7852; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VOYNOYASENETSKA.TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1993, J PHARMACOL EXP THER, V267, P1002; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1994, METHOD ENZYMOL, V238, P81; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1; ZIGMAN JM, 1994, ENDOCRINOLOGY, V135, P31, DOI 10.1210/en.135.1.31	31	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1927	1933						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761094				2022-12-28	WOS:A1995QZ92600006
J	RENZING, J; LANE, DP				RENZING, J; LANE, DP			P53-DEPENDENT GROWTH ARREST FOLLOWING CALCIUM PHOSPHATE-MEDIATED TRANSFECTION OF MURINE FIBROBLASTS	ONCOGENE			English	Note						P53; GROWTH ARREST; CALCIUM PHOSPHATE TRANSFECTION	P53 PROTEIN; DNA; INDUCTION; UV	A variety of genotoxic agents can induce an accumulation of p53 protein in the nuclei of mammalian cells and lead to either growth arrest or apoptosis in a p53-dependent manner. Recently, the induction of the p53 pathway has also been reported for non-genotoxic agents such as heat shock and hypoxia, rendering it likely that p53 activity might be triggered by a wider range of cellular stress factors. Here we report the effect of calcium phosphate-mediated transfection, a technique commonly used in studies of transient gene expression in mammalian cells, on fibroblasts containing wild-type p53. Incubation with a calcium phosphate precipitate results in a transient growth arrest in the presence or absence of plasmid DNA. The effect is accompanied by a rise in p53 protein levels and increased transcription of a p53-dependent reporter construct and is not observed in fibroblasts derived from p53 knockout mice.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOVER R, 1994, J CELL SCI, V107, P1181; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALL PA, 1993, ONCOGENE, V8, P203; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANIATIS T, 1990, MOL CLONING; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	16	84	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1865	1868						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753562				2022-12-28	WOS:A1995QX46900020
J	OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B				OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B			THE CLONING OF GRB10 REVEALS A NEW FAMILY OF SH2 DOMAIN PROTEINS	ONCOGENE			English	Article						SH2 DOMAIN; EGF; GRB1O; GRB7; MIG1O; GROWTH FACTOR RECEPTOR	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; CAENORHABDITIS-ELEGANS; EXPRESSION CLONING; SIGNALING PROTEINS; ADAPTER PROTEIN; BINDING-SITE; HUMAN-BREAST; RAS	SH2 domains function to bind proteins containing phosphotyrosine and are components of proteins that are important signal transducers for tyrosine kinases. We have cloned SH2 domain proteins by screening bacterial expression libraries with the tyrosine phosphorylated carboxyterminus of the epidermal growth factor (EGF) receptor. Here we report the identification of a new SH2 domain protein, Grb10, Grb10 is highly related to Grb7, an SH2 domain protein that we have previously identified, In addition to an SH2 domain, Grb7 and Grb10 have a central domain with similarity to a putative C, elegans gene likely to be involved in neuronal migration. At least three forms of Grb10 exist in fibroblasts apparently due to alternate translational start sites, Grb10 undergoes serine but not tyrosine phosphorylation after EGF treatment resulting in a shift mobility in a large fraction of Grb10 molecules, However Grb10 appears to bind poorly to EGF-Receptor and the true binding partner for the Grb10 SH2 domain is unclear, Grb10 maps to mouse chromosome 11 very close to the EGF-Receptor which is remarkably similar to Grb7 that maps near the EGF-Receptor related HER2 receptor, The finding of multiple family members with evolutionarily conserved domains indicates that these SH2 domain proteins are likely to have an important, although as of yet, unidentified function.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	New York University; New York University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA58586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUCHBERG AM, 1993, MAMM GENOME, V4, pS164, DOI 10.1007/BF00360837; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DIETRICH W, 1992, GENETICS, V131, P423; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Green E.L., 1981, MOUSE BIOMEDICAL RES, P91; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	136	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731717				2022-12-28	WOS:A1995QU68100019
J	CHUNG, SW; WONG, PMC				CHUNG, SW; WONG, PMC			THE BIOLOGY OF ABL DURING HEMATOPOIETIC STEM-CELL DIFFERENTIATION AND DEVELOPMENT	ONCOGENE			English	Review							MURINE LEUKEMIA-VIRUS; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ABELSON TYROSINE KINASE; IMMATURE LYMPHOID-CELLS; P210 BCR ABL; C-ABL; HEMATOPOIETIC-CELLS; V-ABL; PHILADELPHIA-CHROMOSOME		TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	CHUNG, SW (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT BIOCHEM, 3307 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BELL JC, 1987, NATURE, V325, P552, DOI 10.1038/325552a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENNETT RL, 1992, DEVELOPMENT, V116, P953; BERGOLD PJ, 1987, VIROLOGY, V158, P320, DOI 10.1016/0042-6822(87)90204-2; BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; BESMER P, 1983, NATURE, V303, P825, DOI 10.1038/303825a0; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1994, IN PRESS ONCOGENE, V9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; DANIEL R, 1994, IN PRESS ONCOGENE; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DYALLSMITH D, 1988, ONCOGENE RES, V2, P403; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; EVANS CA, 1993, CANCER RES, V53, P1735; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GISHIZKY ML, 1991, ONCOGENE, V6, P1299; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERMINE O, 1991, BLOOD, V78, P2253; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LOTEM J, 1991, BLOOD, V78, P953; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARK JK, 1990, SCIENCE, V248, P378; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PECH N, 1993, BLOOD, V82, P1502; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PREVOT BM, 1986, MOL CELL BIOL, V6, P4133; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAMBALDI A, 1987, BLOOD, V69, P1409; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROVERA G, 1987, ONCOGENE, V1, P29; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCOTT KS, 1990, P NATL ACAD SCI USA, V87, P6502; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHORE SK, 1994, J BIOL CHEM, V269, P5413; SIRARD C, 1994, BLOOD, V83, P1575; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WONG PMC, 1987, EXP HEMATOL, V15, P280; WONG PMC, 1988, EXP HEMATOL, V16, P5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	105	14	20	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1261	1268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731675				2022-12-28	WOS:A1995QR65100001
J	PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A				PEEPER, DS; KEBLUSEK, P; HELIN, K; TOEBES, M; VANDEREB, AJ; ZANTEMA, A			PHOSPHORYLATION OF A SPECIFIC CDK SITE IN E2F-1 AFFECTS ITS ELECTROPHORETIC MOBILITY AND PROMOTES PRB-BINDING IN-VITRO	ONCOGENE			English	Article						E2F; PRB; CYCLIN; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS E1A PROTEINS; CELL-CYCLE; COMPLEX-FORMATION; TRANS-ACTIVATION; S-PHASE; EXPRESSION; P107; RB	The E2F transcription factor family participates in growth control presumably through transcriptional activation of genes that promote entry into S phase. E2F activity is believed to be controlled across the cell cycle by association with various cellular proteins, including the product of the retinoblastoma gene (pRB). We find that E2F-1 proteins are heterogeneously phosphorylated in insect cells, as a result of which they migrate as a doublet on SDS-polyacrylamide gels. This electrophoretic shift is shown to be dependent upon specific phosphorylation of E2F-1 on serine-375 (S375), near the pRB-binding site. Phosphorylation on S375 also occurs in human cells. E2F-1 was most efficiently phosphorylated on this residue by cyclin A/cdc2 kinase, and to a lesser extent by cyclin A/cdk2, irrespective of the presence of the pRB-related p107 protein. Phosphorylation of E2F-1 on S375 greatly enhanced its affinity of PRE in vitro. These results suggest a novel way of regulating E2F-1 activity, namely by cell-cycle-dependent phosphorylation of this transcription factor.	LEIDEN UNIV, DEPT MOLEC CARCINOGENESIS, SYLVIUS LAB, 2333 AL LEIDEN, NETHERLANDS; MASSACHUSETTS GEN HOSP E, CTR CANC, BOSTON, MA 02129 USA	Leiden University; Leiden University - Excl LUMC			Helin, Kristian/K-2526-2019; Peeper, Daniel/AAA-2430-2020; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PEEPER DS, 1992, VIROLOGY, V190, P733, DOI 10.1016/0042-6822(92)90911-8; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Summers MD, 1987, TEXAS AGR EXPT STATI; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	60	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					39	48						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824278				2022-12-28	WOS:A1995QA98000006
J	LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T				LAROSE, L; GISH, G; SHOELSON, S; PAWSON, T			IDENTIFICATION OF RESIDUES IN THE BETA PLATELET-DERIVED GROWTH-FACTOR RECEPTOR THAT CONFER SPECIFICITY FOR BINDING TO PHOSPHOLIPASE C-GAMMA-1	ONCOGENE			English	Article							PDGF RECEPTOR; V-SRC; TYROSINE KINASES; CDNA CLONING; SH2 DOMAINS; PHOSPHOTYROSINE; PROTEINS; PHOSPHORYLATION; SITE; GAP	The SH2 domains of cytoplasmic signaling proteins bind to autophosphorylated growth factor receptors by direct recognition of specific phosphotyrosine-containing sites. To identify the phosphotyrosine involved in association of phospholipase C (PLC)-gamma1 with the beta platelet-derived growth factor receptor (PDGFR), and to investigate which contiguous residues confer specificity for PLC-gamma1, phosphotyrosine-containing glutathione S-transferase (GST) fusion proteins possessing different regions of the beta-PDGFR were incubated with lysates of Rat-2 cells that overexpress PLC-gamma1. The phosphorylated C-terminal tail of the PDGFR bound PLC-gamma1, but did not associate with phosphatidylinositol (PI) 3'-kinase or GTPase-activating protein (GAP). High-affinity binding of PLC-gamma1 was dependent on phosphorylation of Tyr-1021. Creation of a new phosphorylation site by replacing Asp-1018 with tyrosine did not restore binding of PLC-gamma1 in the absence of Tyr-1021, indicating that the location of the phosphorylated tyrosine is important for PLC-gamma1 binding. Substitution of the proline at the +3 position relative to Tyr-1021 with methionine (Y1021IIP-->Y1021IIM) in the phosphorylated PDGFR tail did not alter PLC-gamma1 association, but conferred binding activity towards PI 3'-kinase, indicating that this residue is critical in discriminating between PLC-gamma1 and PI 3'-kinase. Progressive conversion of the three residues C-terminal to Tyr-1021 to the consensus for PI 3'-kinase binding (YMDM) allowed PI 3'-kinase association, but did not block PLC-gamma1 binding, suggesting that additional residues other than the three residues immediately following the phosphotyrosine may contribute to the association of PLC-gamma1 with the PDGFR. These results indicate that phosphorylation at Tyr-1021 in the tail of the PDGFR creates a specific binding site for PLC-gamma1. Proline at the +3 position relative to Tyr-1021 is crucial in conferring specificity for binding to PLC-gamma1.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X5,ON,CANADA; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,JOSLEN DIABET CTR,DIV RES,BOSTON,MA 02115	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; ECK M, 1993, IN PRESS CELL; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMPS MP, 1988, ONCOGENE, V2, P305; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1993, IN PRESS P NATL ACAD; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SONGYANG Z, 1993, CELL, V72, P1; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	32	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2493	2499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689724				2022-12-28	WOS:A1993LT36800021
J	MAISONPIERRE, PC; GOLDFARB, M; YANCOPOULOS, GD; GAO, GX				MAISONPIERRE, PC; GOLDFARB, M; YANCOPOULOS, GD; GAO, GX			DISTINCT RAT GENES WITH RELATED PROFILES OF EXPRESSION DEFINE A TIE RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Article							CLONING; DOMAINS; MOUSE	We have isolated rat cDNAs that encode two related receptor-like tyrosine kinases. One of these receptors, TIE-1, is the rat homolog of a recently described human receptor-like kinase termed TIE (Partanen et al., 1992). The related TIE-2 receptor has the same organization of amino acid sequence motifis characteristic of TIE-1: two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin III-like repeats in the extracellular region and a short kinase insert sequence and C-terminal tail in the intracellular region. The amino acid sequences of the intracellular and extracellular regions of TIE-1 and TIE-2 are 79% and 32% identical respectively. Both tie genes are broadly expressed in embryonic, neonatal and adult tissues, accounted for largely by their coexpression in endothelial cells. The tie-2 gene is also uniquely expressed in several additional embryonic tissues, including the lens epithelium and the heart epicardium.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University	MAISONPIERRE, PC (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							DUMONT DJ, 1992, ONCOGENE, V7, P1471; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1991, DEVELOPMENT, V112, P397; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; STARK KL, 1991, DEVELOPMENT, V113, P641; STRUELI M, 1988, J EXP MED, V168, P1523; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	19	127	144	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1631	1637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684830				2022-12-28	WOS:A1993LE06400027
J	GALDEMARD, C; BRISON, O; LAVIALLE, C				GALDEMARD, C; BRISON, O; LAVIALLE, C			THE PROTOONCOGENE FGF-3 IS CONSTITUTIVELY EXPRESSED IN TUMORIGENIC, BUT NOT IN NONTUMORIGENIC, CLONES OF A HUMAN COLON-CARCINOMA CELL-LINE	ONCOGENE			English	Article						FGF-3/INT-2; DIFFERENTIAL TRANSCRIPTION; COLON CARCINOMA; MYC AMPLIFICATION	GROWTH-FACTOR FAMILY; C-MYC AMPLIFICATION; HUMAN-BREAST TUMORS; INT-2 GENE; MESSENGER-RNA; HUMAN CANCER; MOUSE; PHENOTYPE; MEMBER; ACID	The human colon carcinoma cell line, SW613-S, is composed of cells with a high-level amplification of the MYC proto-oncogene that are tumorigenic in nude mice and of cells with a low-level amplification of MYC that are not tumorigenic. Transcripts from FGF-3, a member of the fibroblast growth factor gene family, accumulate in cells from tumorigenic clones, but are undetectable in those from non-tumorigenic clones. Nuclear run-on analyses indicate that this differential FGF-3 expression is regulated at the level of transcription initiation. Determination of the structure of the FGF-3 transcripts indicates that they are generated by splicing of the three exons and termination at the single polyadenylation site predicted from the genomic sequence. Their size heterogeneity is due to multiple initiation sites spanning a 700 base-pair long promoter region. FGF-3 is activated in tumors induced in nude mice by MYC-transfected cells from non-tumorigenic clones. However, in most of the cell lines established from these tumors, FGF-3 expression tends to be lost upon in vitro propagation. Thus, in these transfectant cell lines, the presence of exogenous MYC gene copies is not sufficient to activate FGF-3 expression and in vivo growth is also required.	INST GUSTAVE ROUSSY,GENET ONCOL LAB,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Lavialle, Christian/O-2329-2019; Lavialle, Christian/B-3775-2009					ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BROOKES S, 1989, ONCOGENE, V4, P429; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHERIF D, 1989, CHROMOSOMA, V97, P327, DOI 10.1007/BF00371974; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GOLDFARB M, 1991, ONCOGENE, V6, P65; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMONERIE T, 1995, EXP CELL RES, V216, P342, DOI 10.1006/excr.1995.1043; LAVIALLE C, 1988, ONCOGENE, V3, P335; LAVIALLE C, 1990, ONCOGENE, V5, P245; LAVIALLE C, 1989, ANTICANCER RES, V9, P1265; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LISCIA DS, 1989, ONCOGENE, V4, P1219; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MODJTAHEDI N, 1992, INT J CANCER, V52, P483, DOI 10.1002/ijc.2910520325; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MODJTAHEDI N, 1992, EXP CELL RES, V201, P74, DOI 10.1016/0014-4827(92)90349-D; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURAKAMI A, 1993, NUCLEIC ACIDS RES, V21, P5351, DOI 10.1093/nar/21.23.5351; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; Sambrook J, 1989, MOL CLONING LABORATO; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; THEILLET C, 1989, ONCOGENE, V4, P915; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; ZHANG GH, 1994, CELL GROWTH DIFFER, V5, P349	46	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784081				2022-12-28	WOS:A1995RE54300008
J	BOGENMANN, E; TORRES, M; MATSUSHIMA, H				BOGENMANN, E; TORRES, M; MATSUSHIMA, H			CONSTITUTIVE N-MYC GENE-EXPRESSION INHIBITS TRKA MEDIATED NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						N-MYC; TRKA; DIFFERENTIATION; NEURONAL CELLS; CELL CYCLE	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROBLASTOMA CELL-LINE; AFFINITY NGF RECEPTOR; CLASS-I GENE; PC12 CELLS; NEUROTROPHIC FACTOR; C-MYC; MONOCLONAL-ANTIBODIES; MESSENGER-RNA	The effect of constitutively expressed N-myc gene on nerve growth factor (NGF) induced neuronal differentiation was investigated, B104, a rat central nervous system-derived cell line and its N-myc gene expressing derivative lines (C6, C7) (Bernards et al., 1986), were stably transfected with the trkA proto-oncogene and independent clones for each cell line were analysed. NGF induced phosphorylation of the trkA receptor, activated a cascade of cellular intermediaries such as phospholipase C gamma 1 and ERK proteins, and stimulated c-fos gene transcription in all trk-A-expressing clones. NGF-mediated neuronal differentiation was observed solely in trkA-expressing B104-derived clones and was characterized by reduced cell growth, activation of NGF-regulated genes, and downregulation of the endogenous low-affinity NGF receptor gene (gp75(NGFR)). NO such phenotypical changes occurred in trkA-expressing C6 or C7-derived clones following NGF treatment. These results are consistent with the hypothesis that constitutive expression of N-myc inhibits exit from cell cycle and blocks neuronal cell differentiation.	UNIV SO CALIF,SCH PHARM,LOS ANGELES,CA 90089; CALTECH,DIV BIOL 14775,PASADENA,CA 91125; JIKEI UNIV,SCH MED,DEPT PEDIAT,MINATO KU,TOKYO 105,JAPAN	University of Southern California; California Institute of Technology; Jikei University	BOGENMANN, E (corresponding author), CHILDRENS HOSP LOS ANGELES,RES INST,DIV HEMATOL ONCOL,4650 SUNSET BLVD,LOS ANGELES,CA 90027, USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARDO CC, 1991, CELL, V66, P173; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; EAGER KB, 1991, ONCOGENE, V6, P819; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ERNFORS P, 1988, NEURON, V1, P983, DOI 10.1016/0896-6273(88)90155-9; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROSS N, 1990, CANCER RES, V50, P7532; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1993, J NEUROSCI, V13, P2919; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MACLEOD AR, 1981, EUR J BIOCHEM, V119, P353, DOI 10.1111/j.1432-1033.1981.tb05615.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MILLER FD, 1991, J CELL BIOL, V112, P303, DOI 10.1083/jcb.112.2.303; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1982, ANN INTERN MED, V97, P873, DOI 10.7326/0003-4819-97-6-873; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUGIO K, 1991, CANCER, V67, P1384, DOI 10.1002/1097-0142(19910301)67:5<1384::AID-CNCR2820670518>3.0.CO;2-7; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANN REV CELL BIOL, V100, P251; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WHITESELL L, 1991, MOL CELL BIOL, V11, P1360, DOI 10.1128/MCB.11.3.1360; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZANCA DM, 1989, MOL CELL BIOL, V9, P24; ZANCA DM, 1986, NATURE, V319, P743	82	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1915	1925						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761093				2022-12-28	WOS:A1995QZ92600005
J	TASHIRO, S; TAKEMOTO, Y; HANDA, H; ISHII, S				TASHIRO, S; TAKEMOTO, Y; HANDA, H; ISHII, S			CELL-TYPE-SPECIFIC TRANSACTIVATION BY THE B-MYB GENE-PRODUCT - REQUIREMENT OF THE PUTATIVE COFACTOR BINDING TO THE C-TERMINAL CONSERVED DOMAIN	ONCOGENE			English	Article						B-MYB; TRANSACTIVATOR; CELL TYPE SPECIFICITY	NUCLEOTIDE-SEQUENCE; V-MYB; EXPRESSION; TRANSACTIVATION; TRANSFORMATION; PROLIFERATION; PROTOONCOGENE; ONCOGENE; LEUKEMIA; PROTEIN	The myb gene family has three members, c-myb, A-myb and B-myb. We have examined the trans-activating capacity of the B-myb gene product (B-Myb) in various types of cells. B-Myb functions as a transcriptional activator in CV-1 and HeLa cells, but not in NIH3T3 cells, indicating that B-Myb is a cell type-specific transcriptional activator. Deletion analyses of B-Myb have demonstrated that the region conserved between three members of the myb gene family (CR for conserved region) is necessary for trans-activation by B-Myb. An in vivo competition assay suggests that regulatory factor(s) that binds to the CR of B-Myb is required for transactivation. Analyses using an affinity resin show that multiple proteins bind to the CR of B-Myb and that the CR-binding proteins in CV-1 and HeLa cells are different from those in NIH3T3 cells. These results suggest that the CR-binding cofactor(s) is critical for the cell type-specific trans-activation by B-Myb.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; TOKYO INST TECHNOL,FAC LIFE SCI & TECHNOL,DEPT BIOSYST,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	RIKEN; Tokyo Institute of Technology			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ARSURA M, 1992, BLOOD, V79, P2708; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAM EWF, 1992, ONCOGENE, V7, P1885; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TIJAN R, 1994, CELL, V77, P5; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	44	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1699	1707						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753546				2022-12-28	WOS:A1995QX46900002
J	DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW				DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW			DEREGULATION OF C-ABL MEDIATED CELL-GROWTH AFTER RETROVIRAL TRANSFER AND EXPRESSION OF ANTISENSE SEQUENCES	ONCOGENE			English	Article						C-ABL; ANTISENSE; CELL CYCLE	HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE; BINDING; GENE; PROTEIN; CYCLE; ACTIVATION; ONCOGENE	To determine the role of c-abl during cell growth, we constructed a retrovirus vector alpha A, capable of expressing an antisense RNA directed against the abl mRNA, Based on v-abl-mediated 3T3 transformation assay, we showed that the number of transformed foci was reduced 50-94% when alpha A-infected 3T3 cells were superinfected with A-MuLV, Up to a 100% of inhibition could be observed when the time of infection was lengthened. Introduction of the antisense sequence into NM3T3 cells resulted in reduction of growth rate. These cells entered into S phase from G1 phase of the cell cycle earlier in time than untransduced cells, Thus c-abl serves as a checkpoint during G1/S transition in the cell cycle, and its reduction resulted in deregulation of cell growth.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; SUNY DOWNSTATE MED CTR,MORSE INST MOLEC GENET,DEPT IMMUNOL & MICROBIOL,BROOKLYN,NY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASKARAN R, 1993, P NATL ACAD SCI USA, V98, P11167; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1994, ONCOGENE, V9, P3527; CHUNG SW, 1995, IN PRESS ONCOGENE; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TYBULEWICZ VLJ, 1991, CELL, V65, P1097; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	26	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731715				2022-12-28	WOS:A1995QU68100017
J	PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV				PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV			B-RAF PROTEIN ISOFORMS INTERACT WITH AND PHOSPHORYLATE MEK-1 ON SERINE RESIDUE-218 AND RESIDUE-222	ONCOGENE			English	Note						B-RAF; C-RMIL; MEK-1; MAP KINASE CASCADE; SERINE THREONINE KINASES	KINASE; PROTOONCOGENE; COMPLEX; CELLS	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases, Tt encodes multiple protein isoforms resulting from alternative splicing of two exons located upstream of the kinase domain, Recent studies suggested that B-Raf could be the intermediate molecule between Ras and Mek-1 (MAP Kinase Kinase) in signalling pathways specific of neural cells. However, there has been no evidence for a direct interaction between B-Raf and Mek-1, We report here that different B-Raf isoforms can be co-immunoprecipitated with anti-Mek-1 antisera in COS-1 cells and that the kinase activity of B-Raf is not required for its interaction with Mek-1. We also show that all B-Raf isoforms tested phosphorylate Mek-1 in a time-dependent manner, whereas kinase defective mutants fail to do so. Finally, we demonstrate that the constitutively activated S218D, S222D and S218D/S222D mutants of Mek-1 interact similarly with B-Raf. However, only the S218D and S222D mutants, and not the S218D/S222D double mutant, can be phosphorylated by B-Raf isoforms. Therefore, serine residues 218 and 222, previously shown to regulate Mek-1 activity, appear to be the major phosphorylation sites by B-Raf in vitro.	CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,UNITE MIXTE RECH 146,F-91405 ORSAY,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Eychene, Alain/M-8838-2017; Pages, Gilles/N-7135-2017	EYCHENE, Alain/0000-0002-6818-7225				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRUNET A, 1994, ONCOGENE, V9, P3379; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1647	1651						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731720				2022-12-28	WOS:A1995QU68100022
J	AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G				AHOMADEGBE, JC; BARROIS, M; FOGEL, S; LEBIHAN, ML; DOUCRASY, S; DUVILLARD, P; ARMAND, JP; RIOU, G			HIGH-INCIDENCE OF P53 ALTERATIONS (MUTATION, DELETION, OVEREXPRESSION) IN HEAD AND NECK PRIMARY TUMORS AND METASTASES - ABSENCE OF CORRELATION WITH CLINICAL OUTCOME - FREQUENT PROTEIN OVEREXPRESSION IN NORMAL EPITHELIUM AND IN EARLY NONINVASIVE LESIONS	ONCOGENE			English	Article						P53 ALTERATIONS; HEAD AND NECK METASTASES; PROGNOSIS	SQUAMOUS-CELL CARCINOMA; SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; OVER-EXPRESSION; CANCER PATIENTS; POOR-PROGNOSIS; BREAST-CANCER; TP53 GENE; ACCUMULATION; CARCINOGENESIS	We have analysed 78 head and neck carcinomas (50 node metastases and 28 primary tumors including 13 matched specimens) in 65 patients for p53 alterations. Mutations were found in 54 (69%) tumors. Of the 53 mutations within exons, 40 (76%) were missense, five (9%) nonsense and eight (15%) microdeletions or microinsertions. Twenty-five (47%) mutations were transitions mostly G-->A (40%) and 20 (38%) were transversions, mostly G-->T (25%), thus confirming the role of tobacco carcinogens in the induction of these mutations. The incidence of mutations was not different in primary tumors (68%) and node metastases (70%) indicating that this gene alteration was not related to the metastatic dissemination, For eight patients, mutations were observed in matched primary tumors and metastases, indicating clonal dissemination of tumor cells in most of these carcinomas. There was a good correlation between mutation and protein overexpression (Fisher's exact test P < 10(-4)). Immunostaining was also observed in basal cells from normal epithelium and in early lesions adjacent to the primary tumor in 11/15 (73%) specimens irrespective of the presence of mutation in the corresponding tumors. These data confirm that p53 overexpression is an early event in the multistep process of epithelial cell carcinogenesis. Loss of heterozygosity for the TP53 locus was detected in 54% of tumors but no association was found with mutation (Fisher's exact test P = 0.14). No mdm-2 amplification was detected in any tumors. No correlation was found between mutation and clinical parameters, the 5-year survival rates were not different (log rank test P = 0.39) in patients with and without mutation. In conclusion, we have shown that p53 gene mutations and deletions and protein overexpression are frequent in the most aggressive head and neck carcinomas but are not associated with disease progression. The presence of protein in normal mucosa and in non-invasive lesions may constitute a biomarker for early stages of carcinogenesis.	INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT ANATOMOPATHOL,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT MED,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy								ADAMSON R, 1994, ONCOGENE, V9, P2077; ANWAR K, 1993, INT J CANCER, V53, P952; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BENNETT WP, 1992, CANCER RES, V52, P6092; BENNETT WP, 1993, CANCER RES, V53, P4817; BOURHIS J, 1994, INT J CANCER, V57, P458, DOI 10.1002/ijc.2910570403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1993, CANCER RES, V53, P3667; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHUNG KY, 1993, CANCER RES, V53, P1676; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DENG G, 1994, CANCER RES, V54, P499; DOLCETTI R, 1992, INT J CANCER, V52, P178, DOI 10.1002/ijc.2910520204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; Hill C., 1993, EVOLUTION MORTALITE; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEES M, 1993, CANCER RES, V53, P4189; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PUISIEUX A, 1991, CANCER RES, V51, P6185; RICHARD JM, 1987, LARYNGOSCOPE, V97, P97; RIOU G, 1993, J NATL CANCER I, V85, P1765, DOI 10.1093/jnci/85.21.1765; RIOU G, 1995, IN PRESS MOL CARCINO; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SHENG ZM, 1990, BRIT J CANCER, V62, P398, DOI 10.1038/bjc.1990.306; SHIN DM, 1994, CANCER RES, V54, P321; SLOOTWEG PJ, 1994, ORAL ONCOL, V30B, P138; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG LD, 1993, CANCER RES, V53, P1783; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	57	216	219	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1217	1227						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700647				2022-12-28	WOS:A1995QN35300024
J	GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF				GAWLER, DJ; ZHANG, LJ; REEDIJK, M; TUNG, PS; MORAN, MF			CALB - A 43 AMINO-ACID CALCIUM-DEPENDENT MEMBRANE PHOSPHOLIPID-BINDING DOMAIN IN P120 RAS GTPASE-ACTIVATING PROTEIN	ONCOGENE			English	Article						RAS; SRC; CALCIUM; CALB; C2; RAS-GAP	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; TYROSINE KINASE; MYRISTYLATION SIGNAL; SYNAPTOTAGMIN P65; REGULATORY DOMAIN; PLASMA-MEMBRANE; GENE-PRODUCT; EGF RECEPTOR	CaLB was originally observed as a conserved sequence motif in various calcium-responsive signalling proteins and also in p120 Ras GTPase activating protein (p120(GAP)) (Clark et al. Cell 65: 1043-1051, 1991). Here we show the 43 residue CaLB motif in p120(GAP) is a functional protein domain that when expressed as a fusion protein in vitro confers Ca2+-dependent interactions with cellular membranes and phosphatidylserine and phosphatidylinositol vesicles. p120(GAP), but not a mutant lacking the CaLB domain, associates with the particulate fraction of cells in response to elevated intracellular Ca2+ suggesting that p120(GAP) may be regulated in part by calcium signals. Addition of the p120(GAP) CaLB domain was able to restore transforming activity and particulate localization to an otherwise transformation-defective and cytosolic mutant v-Src tyrosine kinase. The CaLB domain appears to be a prevalent protein module that may affect the molecular interactions and subcellular localization of signalling proteins.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto			Moran, Michael/GYD-3631-2022					ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; JOHNSTONE SA, 1993, BIOCHEM J, V294, P801, DOI 10.1042/bj2940801; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUO JH, 1993, J BIOL CHEM, V268, P3715; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERIN MS, 1991, J BIOL CHEM, V266, P615; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STONE JC, 1991, METHOD ENZYMOL, V200, P673; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	42	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					817	825						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898923				2022-12-28	WOS:A1995QL03800002
J	HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M				HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M			ALTERATIONS IN TELOMERIC REPEAT LENGTH IN LUNG-CANCER ARE ASSOCIATED WITH LOSS OF HETEROZYGOSITY IN P53 AND RB	ONCOGENE			English	Article						LUNG CANCER; TELOMERE; P53; RB; IMMORTALITY; 1P32	CELLULAR SENESCENCE; RETINOBLASTOMA GENE; HUMAN FIBROBLASTS; L-MYC; MUTATIONS; POLYMORPHISM; TUMOR; DNA; IMMORTALIZATION; ADENOCARCINOMA	In the two-stage model of controlling cellular senescence in cultured human fibro blasts, retinoblastoma (Rb) and p53 proteins may be key factors regulating the mortality stage 1 mechanism. In addition, the critical loss of telomeric DNA due to the end-replication problem may result in the mortality stage 2 mechanism, Cells which acquire telomerase activity can overcome the M2 mechanism by stabilizing telomere length and thus become immortal (telomere hypothesis). At present it is known whether cellular immortality is a prerequisite for all human cancers, To investigate this question and the applicability of the two-stage model to human cancers, we analysed the relationship between alterations of telomere length and other genetic changes in lung cancer. Among 60 primary lung cancer tissues, telomere length alterations were observed in 16 tumors (26.7%) including 14 with short and two with elongated telomeres. Ten of them revealed allelic loss of both p53 and Rb genes, and remaining six showed no abnormalities in both genes. We propose that inactivation of both p53 and Rb genes may promote cell divisions causing telomere shortening in lung cancer as in the two-stage model, while there may be another pathway to overcome both M1 and M2 mechanisms, especially for adenocarcinoma.	HIROSHIMA UNIV,SCH MED,DEPT PATHOL 2,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT GEN MED,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University	HIYAMA, K (corresponding author), HIROSHIMA UNIV,SCH MED,DEPT INTERNAL MED 2,HIROSHIMA 734,JAPAN.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BERGH JCS, 1990, AM REV RESPIR DIS, V142, pS20, DOI 10.1164/ajrccm/142.6_Pt_2.S20; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOND JA, 1994, ONCOGENE, V9, P1885; BRANDT B, 1992, AM J HUM GENET, V51, P1450; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; CORNELIS RS, 1994, CANCER RES, V54, P4200; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAY JP, 1993, ENVIRON MOL MUTAGEN, V22, P245, DOI 10.1002/em.2850220411; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hermanek P, 1987, TNM CLASSIFICATION M, P69; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA K, 1993, CHEST, V104, P1606, DOI 10.1378/chest.104.5.1606; HIYOSHI H, 1992, JPN J CANCER RES, V83, P101, DOI 10.1111/j.1349-7006.1992.tb02358.x; HORIO Y, 1993, CANCER RES, V53, P1; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAYE FJ, 1990, AM REV RESPIR DIS, V142, pS44, DOI 10.1164/ajrccm/142.6_Pt_2.S44; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; SACHSE R, 1994, ONCOGENE, V9, P39; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SHIROTANI Y, 1994, LUNG CANCER-J IASLC, V11, P29, DOI 10.1016/0169-5002(94)90280-1; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TAKAHASHI N, 1990, MUTAT RES, V234, P61, DOI 10.1016/0165-1161(90)90032-J; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	56	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					937	944						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898935				2022-12-28	WOS:A1995QL03800015
J	FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM				FERRACINI, R; DIRENZO, MF; SCOTLANDI, K; BALDINI, N; OLIVERO, M; LOLLINI, P; CREMONA, O; CAMPANACCI, M; COMOGLIO, PM			THE MET/HGF RECEPTOR IS OVER-EXPRESSED IN HUMAN OSTEOSARCOMAS AND IS ACTIVATED BY EITHER A PARACRINE OR AN AUTOCRINE CIRCUIT	ONCOGENE			English	Article						OSTEOSARCOMA; GROWTH FACTORS; TYROSINE KINASE RECEPTOR	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN MET PROTOONCOGENE; FACTOR SCATTER FACTOR; SINGLE CHAIN FORM; C-MET; EPITHELIAL-CELLS; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; HEPATOPOIETIN-A	The c-MET oncogene encodes the receptor for the Hepatocyte Growth Factor/Scatter Factor (HGF), a cytokine that stimulates the invasive growth of normal and neoplastic cells. The Met/HGF receptor is expressed by epithelial cells and its ligand by cells of mesenchymal origin. Receptor-ligand interaction occurs via a paracrine circuit. We studied the expression of the Met/HGF receptor and of its ligand in mesenchymal human tumours by examining 39 clinical samples of bone tumours. The Met/HGF receptor was not detectable in the majority of bone tumours, as expected from their mesenchymal origin. Notably, the receptor was overexpressed in 60% of the osteosarcomas examined. In 12 osteosarcoma cell lines the Met/HGF receptor was overexpressed, phosphorylated by HGF stimulation and fully functional, HGF was detected in two out of seven clinical specimens of osteosarcoma. The ligand and the receptor are co-expressed in two clonal osteosarcoma cell lines. In these lines the Met/HGF receptor was constitutively phosphorylated; phosphorylation was suppressed by suramin treatment, a known blocker of autocrine loops. These data suggest that activation of the Met/HGF receptor by a paracrine or an autocrine mechanism might play a role in the particularly aggressive behaviour of osteosarcomas.	UNIV SASSARI, SCH MED, IST ISTOL & EMBRIOL, I-07100 SASSARI, ITALY; UNIV TURIN, SCH MED, IRCC, TURIN, ITALY; UNIV TURIN, SCH MED, DEPT MED SCI, TURIN, ITALY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; UNIV BOLOGNA, SCH MED, INST CANC, BOLOGNA, ITALY	University of Sassari; University of Turin; University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	FERRACINI, R (corresponding author), SALUZZO GEN HOSP, SALUZZO, ITALY.		olivero, martina/J-4811-2018; Cremona, Ottavio/AAB-8793-2019; Baldini, Nicola/J-4806-2016; Ferracini, Riccardo/AAL-4622-2020; DI RENZO, Maria Flavia/B-6091-2012; Lollini, Pier Luigi/A-7644-2008; Scotlandi, Katia/J-9009-2016	olivero, martina/0000-0002-6815-3498; Cremona, Ottavio/0000-0001-9462-1040; Baldini, Nicola/0000-0003-2228-3833; DI RENZO, Maria Flavia/0000-0002-5093-3373; Lollini, Pier Luigi/0000-0003-1702-4108; Scotlandi, Katia/0000-0001-6114-9499; Comoglio, Paolo/0000-0002-7056-5328				ARAKI N, 1991, CLIN ORTHOP RELAT R, V270, P271; ASHIHARA T, 1986, ACTA HISTOCHEM CYTOC, V19, P51, DOI 10.1267/ahc.19.51; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Campanacci M., 1990, BONE SOFT TISSUE TUM, V2nd, P455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGLIANO A, 1991, BONE, V12, P365, DOI 10.1016/8756-3282(91)90024-D; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ENNEKING WF, 1991, CLIN MUSCULOSKELETAL, P411; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1993, IT J MINERAL ELECTRO, V3, P199; GALIMI F, 1994, UNPUB J CELL BIOL; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOHJI K, 1994, JPN J CANCER RES, V85, P152, DOI 10.1111/j.1349-7006.1994.tb02076.x; GOORIN AM, 1981, SURG CLIN N AM, V61, P1379; GRANO M, 1994, J BONE MINER RES, V9, P1013; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KANDA H, 1993, ONCOGENE, V8, P3047; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU C, 1992, ONCOGENE, V7, P181; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MILLER CW, 1990, CANCER RES, V50, P7950; MIURA Y, 1993, CLIN ORTHOP RELAT R, V300, P225; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA S, 1994, CYTOKINE, V6, P285, DOI 10.1016/1043-4666(94)90025-6; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCOTLANDI K, 1992, ANN ONCOL, V3, pS29, DOI 10.1093/annonc/3.suppl_2.S29; SCOTLANDI K, 1993, INT J ONCOL, V3, P963; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEBBI CK, 1988, PEDIATR ANN, V17, P285, DOI 10.3928/0090-4481-19880401-08; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WU JX, 1990, ONCOGENE, V5, P989; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZHEN Z, 1994, ONCOGENE, V9, P1691	77	255	265	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					739	749						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862451				2022-12-28	WOS:A1995QH61200014
J	DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE				DREBIN, JA; HARTZELL, SW; GRIFFIN, C; CAMPBELL, MJ; NIEDERHUBER, JE			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE HUMAN HOMOLOG OF A B-LYMPHOCYTE SPECIFIC PROTEIN-TYROSINE KINASE (BLK)	ONCOGENE			English	Article						BLK; PROTEIN TYROSINE KINASE; B LYMPHOCYTE	CELL ANTIGEN RECEPTOR; TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR; TRANSFORMING PROTEIN; CONSERVED FEATURES; BINDING SITE; SH3 DOMAINS; SRC FAMILY; PHOSPHORYLATION; CARCINOMA	A cDNA encoding the human homologue of the murine protein tyrosine kinase, blk, has been cloned from a human B-lymphocyte cDNA library by cross-species hybridization using the murine blk cDNA as a probe. The sequence of the 2608 bp human blk cDNA clone contains an open reading frame encoding a predicted 505 amino acid protein with SH3, SH2 and catalytic domains that contain consensus sequences of the src protein tyrosine kinase family. Comparison of human and murine blk sequences indicated that they share 86% amino acid identity, the most conserved region being the catalytic domain (93% identity). Like the murine blk gene, human blk is expressed only in B lymphocytes. The human blk gene was mapped to chromosome 8 at p22-23.	STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT SURG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA	Stanford University; Stanford University; Johns Hopkins University; Johns Hopkins University					NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00373] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CARLOCK LR, 1986, SOMAT CELL MOLEC GEN, V12, P163, DOI 10.1007/BF01560663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; EMI M, 1993, J BIOL CHEM, V268, P2120; FAGAN K, 1988, HUM GENET, V79, P365; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FONG D, 1992, HUM GENET, V89, P10, DOI 10.1007/BF00207033; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HICKMAN D, 1994, BICH J, P441; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIN JJ, 1992, J IMMUNOL, V149, P1548; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACOSKA JA, 1994, CANCER RES, V54, P3824; Marshall CJ, 1985, RNA TUMOR VIRUSES MO, P487; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1990, ONCOGENE, V5, P1437; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SHECHTER I, 1994, GENOMICS, V20, P116, DOI 10.1006/geno.1994.1135; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WONG WW, 1985, P NATL ACAD SCI USA, V82, P7711, DOI 10.1073/pnas.82.22.7711; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	59	16	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					477	486						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845672				2022-12-28	WOS:A1995QF64800008
J	KIESS, M; GILL, RM; HAMEL, PA				KIESS, M; GILL, RM; HAMEL, PA			EXPRESSION OF THE POSITIVE REGULATOR OF CELL-CYCLE PROGRESSION, CYCLIN D3, IS INDUCED DURING DIFFERENTIATION OF MYOBLASTS INTO QUIESCENT MYOTUBES	ONCOGENE			English	Article						CYCLINS; MYOBLAST DIFFERENTIATION; CELL CYCLE; KINASES	RETINOBLASTOMA PROTEIN; CANDIDATE ONCOGENE; PUTATIVE ONCOGENE; DEPENDENT KINASE; DNA-REPLICATION; PRAD1/CYCLIN D1; MYOGENIN GENE; G1 PHASE; MUSCLE; FIBROBLASTS	L(6) cells are committed skeletal muscle precursors which can be induced to differentiate into multinucleated, terminally differentiated myotubes. Upon differentiation, these immature skeletal myotubes enter a quiescent state and are unable to reenter the cell cycle. We have examined expression of a series of genes involved in regulation of progression through the G(1)/S boundary in undifferentiated L(6) cells and during terminal differentiation of L(6) myoblasts. While no change in the level of cyclin D1 transcript and a transient increase in cyclin D2 transcript were observed, a large increase in cyclin D3 expression was found. Immunohistochemistry demonstrated strong staining for cyclin D3 protein in the nuclei of the multinucleated myotubes from 4 independent myoblast cell lines; L(6), L(8), G(8) and C2C12. Immunoprecipitation confirmed a greater than 20-fold increase in the levels of cyclin D3 protein in the differentiated L(6) myotubes as well as its association with a number of proteins. Western assays demonstrated, further, that cyclin D3 was complexed with the cyclin dependent-kinases, cdk2 and cdk4, in differentiated L(6) cells. However, while kinase activity specific for a GST-pRB fusion protein was seen for cyclin D3-containing complexes isolated from undifferentiated cells, the high levels of cyclin D3 in the differentiated myotubes had no associated kinase activity. These data demonstrate that cyclin D3 may also have a function in terminally differentiated, quiescent cells. The lack of cyclin D3-associated kinase activity and its association with a number of different proteins suggest that cyclin D3 may regulate the function of other proteins by direct interaction with these factors.	UNIV TORONTO, DEPT CELLULAR & MOLEC PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDO T, 1989, CELLULAR MOL BIOL MU; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MONTARRAS D, 1991, NEW BIOL, V3, P592; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, 9TH ANN M ONC FRED, P7; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAFFE D, 1973, COLD SPRING HARB SYM, V37, P543, DOI 10.1101/SQB.1973.037.01.065; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	58	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					159	166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824268				2022-12-28	WOS:A1995QA98000018
J	DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM				DARBON, JM; DEVAULT, A; TAVIAUX, S; FESQUET, D; MARTINEZ, AM; GALAS, S; CAVADORE, JC; DOREE, M; BLANCHARD, JM			CLONING, EXPRESSION AND SUBCELLULAR-LOCALIZATION OF THE HUMAN HOMOLOG OF P40(MO15) CATALYTIC SUBUNIT OF CDK-ACTIVATING KINASE	ONCOGENE			English	Article							MATURATION-PROMOTING FACTOR; CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; CELL-CYCLE; TYROSINE KINASE; FISSION YEAST; NEGATIVE REGULATION; CDC25 PROTEIN; S-PHASE; PHOSPHORYLATION	Transitions of the cell cycle are controlled by cyclin-dependent protein kinases (cdks) whose phosphorylation on the Thr residue included in the conserved sequence YTHEVV dramatically increases the activity. A kinase responsible for this specific phosphorylation, called CAK for cdk-activating kinase, has been recently purified from starfish and Xenopus oocytes and shown to contain the MO15 gene product as a catalytic subunit. In the present paper, we have cloned the human homolog of Xenopus p40(MO15) by probing a HeLa cell cDNA library with degenerate oligonucleotides deduced from Xenopus and starfish MO15 sequences. Human and Xenopus MO15 displayed a strong homology showing 86% identity with regard to amino acid sequences. Northern blot analysis of RNA extracts from a series of human tissues as well as from cultured rodent fibroblasts revealed a unique 1.4 kb MO15 mRNA. No variation in the amount of MO15 transcript or protein was found along the entire course of the fibroblast cell cycle. Fluorescence in situ hybridization on human lymphocyte metaphases showed two distinct chromosomal locations of human MO15 gene at 5q12-q13 and 2q22-q24. By using gene tagging and mammalian cell transfection, we demonstrate that the KRKR motif located at the carboxy terminal end of MO15 is required for nuclear targeting of the protein. Mutation of KRKR to NGER retains MO15 in the cytoplasmic compartment, whilst the wild-type protein is detected exclusively in the nucleus. Interestingly, we demonstrate that the nuclear targeting of MO15 is necessary to confer the protein its CAK activity. In contrast to the wild-type, the NLS-mutated MO15 expressed in Xenopus oocytes is unable to generate CAK as long as the nuclear envelope is not broken. The nuclear localization of both the MO15 gene product and CAK activity may imply that cdks activation primarily occurs in the cell nucleus.	CNRS, UMR 9942, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS)	DARBON, JM (corresponding author), CNRS, INSERM, U249, UPR 9008, BP 5051, F-34033 MONTPELLIER, FRANCE.		Fesquet, didier/M-9750-2019; Fesquet, Didier/A-1490-2009; martinez, Anne-marie/R-2751-2017	Fesquet, didier/0000-0001-5657-9689; martinez, Anne-marie/0000-0001-8562-7627				BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CLARKE PR, 1991, J CELL SCI, V100, P409; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVAULT A, 1992, J CELL BIOL, V118, P1109, DOI 10.1083/jcb.118.5.1109; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS NL, 1990, NUCLEIC ACIDS RES, V18, P3015, DOI 10.1093/nar/18.10.3015; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Hunt T, 1991, Semin Cell Biol, V2, P213; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOSAK M, 1984, NUCLEIC ACIDS RES, V12, P857; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LABBE JC, 1994, IN PRESS EMBO J; LASKEY RA, 1993, CELL, V74, P585, DOI 10.1016/0092-8674(93)90505-K; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LORCA T, 1992, J CELL SCI, V102, P55; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ONOE S, 1993, BIOMED RES-TOKYO, V14, P441, DOI 10.2220/biomedres.14.441; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0	60	48	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3127	3138						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936635				2022-12-28	WOS:A1994PM65800004
J	BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H				BRAUNINGER, A; KARN, T; STREBHARDT, K; RUBSAMENWAIGMANN, H			CHARACTERIZATION OF THE HUMAN CSK LOCUS	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; RECEPTOR GENE; SEQUENCE; PHOSPHORYLATION; PP60C-SRC; PROTOONCOGENE; EXPRESSION; ONCOGENES; CLONING; DOMAINS	The CSK-gene encodes an intracellular protein-tyrosine kinase (PTK). In contrast to members of the src-family, an autophosphorylation site corresponding to Tyr416, as well as the equivalent of the regulatory Tyr527 in p60c-src are missing in the amino acid sequence deduced from the gene. CSK phosphorylates other members of the src-family of tyrosine kinases at their regulatory carboxy-terminus. By regulating the activity of these kinases, CSK may play an important role in cell growth and development. Here we describe the structure of the human CSK gene. The entire coding region spans a genomic distance of only 4.9 kb. It encompasses 12 exons ranging between 66 and 220 bp in size. The introns between coding exons vary between 76 and 920 bp in length. An exon coding for the 5'-untranslated region of CSK is separated from the first coding exon by an intron of more than 6400 bp. Based on comparisons of sequence homologies within the catalytic domains, the intracellular PTKs are divided into the src-family, the fes/fer- and the abl/arg-group. The genomic structure of four members of the SRC-family revealed nearly identical exon/intron boundaries within the catalytic domain of this family. They differ from those described for FES. Comparing the genomic structure of CSK with the exon/intron organisation of both, it is obvious that the exon/intron boundaries are in common either with those of the SRC-type or the FES boundaries. This intermediate exon/intron structure of CSK between FES and the SRC-family agrees with the position of CSK in a phylogenetic tree based on sequence homology within the kinase domain.	CHEMOTHERAPEUT FORSCHUNGSINST,GEORG SPEYER HAUS,PAUL EHRLICH STR 42-44,W-6000 FRANKFURT 70,GERMANY	Octapharma			karn, t/C-7452-2013; Karn, Thomas/AAE-7723-2019; Strebhardt, Klaus/E-8765-2011	karn, t/0000-0002-3264-6573; Karn, Thomas/0000-0002-3264-6573; Strebhardt, Klaus/0000-0003-2173-9763				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ANDRE C, 1992, ONCOGENE, V7, P685; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HRADETZKY D, 1992, GENE, V113, P275, DOI 10.1016/0378-1119(92)90407-G; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATEL M, 1990, ONCOGENE, V5, P201; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	37	23	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1365	1369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683131				2022-12-28	WOS:A1993KY32800030
J	ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH				ZANDER, NF; COOL, DE; DILTZ, CD; ROHRSCHNEIDER, LR; KREBS, EG; FISCHER, EH			SUPPRESSION OF V-FMS-INDUCED TRANSFORMATION BY OVEREXPRESSION OF A TRUNCATED T-CELL PROTEIN TYROSINE PHOSPHATASE	ONCOGENE			English	Article							FELINE SARCOMA-VIRUS; MCDONOUGH STRAIN; GROWTH-FACTOR; EXPRESSION; RECEPTOR; ACTIVATION; BINDING; CLONING; ANTIGEN; KINASE	Rat 2 cells stably transformed by murine v-fms (pB5 cells) were infected with retroviruses containing a human cDNA encoding either a full-length human T-cell protein tyrosine phosphatase (TC.PTP) or a truncated form (DELTAC11.PTP) in which an 11-kDa carboxy-terminal extension had been removed. This segment is responsible for enzyme localization and regulation. Clonal cell lines were isolated following G418 selection and their transforming properties analysed; pB5 cells containing the vector alone or TC.PTP remained transformed. These cells grew readily in soft agar, formed tumors in nude mice and were morphologically indistinguishable from the parental pB5 cells. In contrast, cells expressing DELTAC11.PTP showed dramatic changes in cell morphology, loss of anchorage-independent growth in soft agar and reduced or lack of tumor formation in nude mice. Both increases and decreases in tyrosine phosphorylation of specific proteins in the cells overexpressing the truncated enzyme were detected. These results indicate that coexpression of the deregulated, soluble tyrosine phosphatase with a constitutively active, oncogenic receptor tyrosine kinase leads to the suppression of the transformed phenotype.	UNIV WASHINGTON,DEPT BIOCHEM,SJ 70,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT PHARMACOL,SL 15,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								ALEXANDER D R, 1990, New Biologist, V2, P1049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; BROWNSHIMER S, 1992, CANCER RES, V52, P1234; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LYMAN SD, 1987, MOL CELL BIOL, V7, P3287, DOI 10.1128/MCB.7.9.3287; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHERR CJ, 1991, SEMIN HEMATOL, V28, P143; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORDTHOMAS T, 1992, J CELL BIOL, V117, P401; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	34	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1175	1182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683129				2022-12-28	WOS:A1993KY32800008
J	FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP				FOURNIER, E; DUBREUIL, P; BIRNBAUM, D; BORG, JP			MUTATION AT TYROSINE RESIDUE-1337 ABROGATES LIGAND-DEPENDENT TRANSFORMING CAPACITY OF THE FLT4 RECEPTOR	ONCOGENE			English	Article						ENDOTHELIUM; FLT4; PHOSPHORYLATION; RECEPTOR; SH2 DOMAIN; SHC	ENDOTHELIAL GROWTH-FACTOR; SH3 DOMAINS; SIGNAL TRANSDUCTION; KINASE; EXPRESSION; CELLS; VEGF; MOLECULES; BINDING	In humans, the FLT4 gene encodes two isoforms of a tyrosine kinase receptor, which differ in their carboxy terminal regions. As compared to the short form, the long form has an additional stretch of 65 amino acids containing three tyrosine residues (Y1333, Y1337 and Y1363). Once expressed in fibroblast cells, only the long form is able to elicit both anchorage-independent growth in a soft agar assay and tumors in nude mice, and thus appears endowed,vith a potential ligand-dependent transforming capacity. Replacement of tyrosine 1337 by phenylalanine abrogates the transforming capacity of the long form. This residue was identified as a potential autophosphorylation site, and a docking site for a substrate important in the signal transduction specific of the long FLT4 isoform. We demonstrate that the GRB2 and SHC cytoplasmic substrates are involved in FLT4 signal transduction. SHC interaction could be crucial to FLT4-mediated transforming activity associated with the long isoform. Finally, trancripts for the two forms are detected in tissues positive for FLT4 gene expression.	INSERM, U119, ONCOL MOLEC LAB, F-13009 MARSEILLE, FRANCE; INSERM, U119, HEMATOL FONCTIONNELLE & MOLEC LAB, F-13009 MARSEILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			dubreuil, patrice/F-5346-2011; Borg, Jean-Paul/AAX-8096-2020; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Dubreuil, Patrice/0000-0003-1155-1150				APRELIKOVA O, 1992, CANCER RES, V52, P746; BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORG JP, 1995, ONCOGENE, V10, P973; BORG JP, 1995, IN PRESS MOL ANAL MA; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BROWN LF, 1993, AM J PATHOL, V143, P1255; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CASTERAN N, 1994, CELL MOL BIOL, V40, P443; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; GALLAND F, 1993, ONCOGENE, V8, P1233; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HATVA E, 1995, AM J PATHOL, V146, P368; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PARK JE, 1994, J BIOL CHEM, V269, P25646; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	52	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					921	931						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675451				2022-12-28	WOS:A1995RU79800013
J	MAYOL, X; GARRIGA, J; GRANA, X				MAYOL, X; GARRIGA, J; GRANA, X			CELL CYCLE-DEPENDENT PHOSPHORYLATION OF THE RETINOBLASTOMA-RELATED PROTEIN P130	ONCOGENE			English	Article						P130; RETINOBLASTOMA PROTEIN; CELL CYCLE; PHOSPHORYLATION; T98G CELLS; CYCLINS; CDKS	GENE-PRODUCT; INHIBITION; P107; E2F; TRANSACTIVATION; BINDING; CLONING; MEMBER; FAMILY	The retinoblastoma-related protein p130 is a putative negative regulator of cell proliferation in mammalian cells. In this study, p130 is exist in multiple phosphorylated forms in human cells. In glioblastoma T98G cells synchronized by serum deprivation, specific phosphorylated forms of p130 are found at different times after serum re-stimulation. Two phosphorylated forms of p130 only found in serum-arrested T98G cells and in early G(1) phase associate with the adenovirus oncoprotein E1A in vitro. One of these two forms corresponds to the in vivo E1A-associated p130 in 293 cells, which express endogenous E1A protein. Moreover, p130 undergoes an abrupt shift to a unique phosphorylated form in mid G(1) which is the only p130 form found during the remaining phases of the cell cycle. This phosphorylated form possesses an associated histone H1 kinase activity that is most active in late S phase and G(2)/M. The cell cycle-dependent expression pattern of cyclins in T98G cells is compatible with cyclin D1/CDK complexes driving the shift to this phosphorylated p130 form in mid G(1). These results suggest that the putative growth inhibitory function of p130 is regulated by phosphorylation of this protein. They also suggest that differential phosphorylation of p130 during the cell cycle plays distinct roles in the regulation of p130 function.			MAYOL, X (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Mayol, Xavier/C-1391-2012	Mayol, Xavier/0000-0001-7288-195X; Grana, Xavier/0000-0001-7134-0473				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERMANN CH, 1991, J VIROL, V65, P5848; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; KITAGAWA M, 1995, ONCOGENE, V10, P229; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MAYOL X, 1993, ONCOGENE, V8, P2561; NEVINS JR, 1994, CURR OPIN GENE DEV, V4, P1130; PEEPER DS, 1995, ONCOGENE, V10, P39; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	40	135	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					801	808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651744				2022-12-28	WOS:A1995RQ46900024
J	TEODORO, JG; SHORE, GC; BRANTON, PE				TEODORO, JG; SHORE, GC; BRANTON, PE			ADENOVIRUS E1A PROTEINS INDUCE APOPTOSIS BY BOTH P53-DEPENDENT AND P53-INDEPENDENT MECHANISMS	ONCOGENE			English	Article						APOPTOSIS; P53; ADENOVIRUS; E1A; E1B	E2F TRANSCRIPTION FACTOR; REGION 1A PROTEINS; RAT-KIDNEY CELLS; CELLULAR PROTEINS; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; TUMOR-ANTIGENS; INFECTED-CELLS; GENE-PRODUCT; DNA-BINDING	E1A of human adenovirus type 5 (Ad5) encodes proteins of 289 and 243 residues (289R and 243R) which differ only by the 46 amino acid CR3 region known to activate expression of certain cellular and early viral genes. E1A proteins also induce DNA synthesis and cell transformation, but as well can stimulate apoptosis. Two adenovirus E1B products act to protect cells from E1A-induced cell death, including a 19 kDa protein which is functionally similar to the cellular Bcl-2 suppressor of apoptosis, and a 55 kDa species which binds to and inhibits p53. Previous studies suggested that E1A-induced cell death occurs via a p53-dependent mechanism requiring regions of E1A proteins linked to induction of DNA synthesis and cell transformation. We report here that the 289R E1A protein induces apoptosis in cell lines lacking p53, whereas the 243R product was dependent upon p53. We also show that this p53-independent process involves the expression of one or more additional viral proteins which are presumably synthesized in response to transactivation by 289R. Thus E1A proteins induce cell death by both p53-dependent and p53-independent mechanisms involving separate E1A functions.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA	McGill University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839				Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BABISS LE, 1985, MOL CELL BIOL, V5, P2552, DOI 10.1128/MCB.5.10.2552; BACCHETTI S, 1993, INT J ONCOL, V3, P781; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BARBEAU D, 1994, ONCOGENE, V9, P359; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMONT DJ, 1989, J VIROL, V63, P987, DOI 10.1128/JVI.63.2.987-991.1989; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOROWITZ MS, 1990, VIROLOGY, P1679; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; PILDER S, 1986, MOL CELL BIOL, V6, P470, DOI 10.1128/MCB.6.2.470; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; SEARLE J, 1975, J PATHOL, V116, P129, DOI 10.1002/path.1711160302; SHENK T, 1991, ADV CANCER RES, V57, P47; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	80	138	145	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					467	474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630630				2022-12-28	WOS:A1995RN53000006
J	GRANA, X; REDDY, EP				GRANA, X; REDDY, EP			CELL-CYCLE CONTROL IN MAMMALIAN-CELLS - ROLE OF CYCLINS, CYCLIN-DEPENDENT KINASES (GDKS), GROWTH SUPPRESSOR GENES AND CYCLIN-DEPENDENT KINASE INHIBITORS (CKIS)	ONCOGENE			English	Review						CELL CYCLE; CYCLINS; CDC2; CYCLIN DEPENDENT KINASES (CDKS); CYCLIN-DEPENDENT KINASE INHIBITORS (CKIS); RETINOBLASTOMA GENE FAMILY; P53	PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; NITROGEN-MUSTARD; DNA-REPLICATION; CDC28 MUTATION; TGF-BETA; CDK2; P53	All eukaryotic cells possess similar mechanisms to regulate the progression of the cell cycle, However, higher eukaryotes have evolved to respond to a large array of positive and negative signals with an intracellular or extracellular origin, These signals are eventually integrated by a conserved protein engine consisting of holoenzymes with kinase activity, which trigger crucial transitions during the cell cycle, In this review, the mechanisms by which the mammalian cell cycle engine integrates intracellular and extracellular signals of different nature are discussed.			GRANA, X (corresponding author), TEMPLE UNIV,SCH DENT,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011	Grana, Xavier/0000-0001-7134-0473	NCI NIH HHS [CA 65779, CA 52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065779, P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAN SJ, 1995, CANCER RES, V55, P1649; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAPIDOT LY, 1992, P NATL ACAD SCI USA, V89, P579; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAEKELAE TP, 1994, NATURE, V371, P254, DOI 10.1038/371254A0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, UNPUB; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OKUDA T, 1992, ONCOGENE, V7, P2249; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PAULES RS, 1995, CANCER RES, V55, P1763; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POWELL SN, 1995, CANCER RES, V55, P1643; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, ONCOGENE, V9, P2663; TAMURA K, 1993, ONCOGENE, V8, P2113; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU LT, 1994, ONCOGENE, V9, P2089; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	139	1064	1108	1	68	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					211	219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624138				2022-12-28	WOS:A1995RK95700001
J	INOUE, H; TAVOLONI, N; HANAFUSA, H				INOUE, H; TAVOLONI, N; HANAFUSA, H			SUPPRESSION OF V-SRC TRANSFORMATION IN PRIMARY RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article						TYROSINE KINASE; FIBRONECTIN; FIBRONECTIN RECEPTOR; CELL FUSION; ANCHORAGE INDEPENDENT GROWTH; PAXILLIN	HUMAN PAPILLOMAVIRUS TYPE-16; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; CELL-TRANSFORMATION; SURFACE PROTEIN; FOCAL ADHESIONS; ONCOGENE; GENES; IDENTIFICATION; HYBRIDS	To understand the mechanism for resistance of primary cultures of rat embryo fibroblasts (REFs) to oncogene-induced transformation, we studied the transforming ability of a recombinant retrovirus, ZSV, containing v-src and neo genes in REFs and in the rat cell line F2408. The susceptibility of REFs to p60(v-src) transformation was markedly reduced when compared with that of F2408 cells, despite high levels of expression of functional p60(v-src) tyrosine kinase in the two systems, In hybrid cells obtained by somatic cell fusion between F2408 cells transformed by v-src and uninfected REFs, the transformed phenotype was suppressed despite persistent expression of p60(v-src) tyrosine kinase, On the other hand, hybrid cells between v-src transformed F2408 cells and uninfected F2408 cells retained the transformed phenotypes, These results indicate that primary cells possess an intracellular function(s) that cause suppression of the transformed phenotype induced by the v-src gene, In ZSV-infected REFs, tyrosine phosphorylation of cellular proteins, including p125 focal adhesion kinase, p70 paxillin and p130 was similar to that in the ZSV-infected F2408 cells, indicating that tyrosine phosphorylation of these proteins is not sufficient for the expression of transformed phenotype, On the other hand, cellular fibronectin and one of integrin receptors were downregulated in the ZSV-transformed F2408 cells but not in ZSV-infected REFs, suggesting that fibronectin and/or its receptor might play a role in suppressing v-src transformation in primary rat cells.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA44356] Funding Source: Medline; NIDDK NIH HHS [DK24346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2417; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILMER TM, 1985, MOL CELL BIOL, V5, P1707, DOI 10.1128/MCB.5.7.1707; HARRIS H, 1988, CANCER RES, V48, P3302; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; INOUE H, 1983, VIROLOGY, V125, P242, DOI 10.1016/0042-6822(83)90078-8; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; INOUE H, 1993, VIROLOGY, V195, P757, DOI 10.1006/viro.1993.1426; INOUE H, 1991, J MED VIROL, V35, P246, DOI 10.1002/jmv.1890350407; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MIYASAKA M, 1991, J VIROL, V65, P479, DOI 10.1128/JVI.65.1.479-482.1991; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; NODA M, 1987, ONCOGENES CANCER, P261; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STEEL DM, 1989, J CELL SCI, V93, P515; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WILLINGHAM MC, 1977, CELL, V10, P375, DOI 10.1016/0092-8674(77)90024-1; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	46	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					231	238						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624140				2022-12-28	WOS:A1995RK95700003
J	LABRECQUE, S; MATLASHEWSKI, GJ				LABRECQUE, S; MATLASHEWSKI, GJ			VIABILITY OF WILD-TYPE P53-CONTAINING AND P53-DEFICIENT TUMOR-CELLS FOLLOWING ANTICANCER TREATMENT - THE USE OF HUMAN PAPILLOMAVIRUS E6 TO TARGET P53	ONCOGENE			English	Note						P53; CELL VIABILITY; ANTICANCER TREATMENT	TRANSFORMED-CELLS; ACTIVATED RAS; EARLY GENES; CANCER; IDENTIFICATION; TRANSCRIPTION; PROTEINS	One of the mechanisms in which anticancer therapies function is to induce cell death by apoptosis. In this regard, the biological activity of p53 may be critical since the presence of p53 appears to play a role in apoptosis following genotoxic stress. In experimental systems using in vitro transformed primary cells, there is a direct correlation between the presence of p53 and apoptosis. For example, E1A/ras-transformed primary mouse fibroblasts are less viable and undergo apoptosis following genotoxic stress if these cells contain a wild type p53. In comparison, similarly transformed cells which are p53-deficient are more viable and will not undergo apoptosis under these conditions. Although these are important observations, it remains to be established whether there exists a similar relationship between the presence of wild type p53 and loss of cell viability following therapy in human tumour cells. One way to address this question is to target wild type p53 in human tumour cells using human papillomavirus E6 which mediates the degradation of wild type p53 through the ubiquitin pathway. In this manner, E6 engineered p53-deficient and parental p53-containing human tumour cells provides an appropriate experimental system in which to determine whether wild type p53 in tumour cells has influence on cell viability following genotoxic anticancer treatments, In the present study, the wild type p53 protein in human fibrosarcoma HT1080 cells were targeted with HPV-18 E6 and the viability of these cells in response to treatment with adriamycin, u.v.-irradiation and gamma-irradiation was examined. Data is presented which shows that p53-containing and p53-deficient cells were equally sensitive to these treatments, These data argue that the wild type p53 in these tumour cells does not cause these cells to be less viable when treated with anticancer agents or u.v.-irradiation, Therefore, the status of p53 alone in tumour cells may not be an indicator of response to anticancer treatments.	MCGILL UNIV, INST PARASITOL, ST ANNE DE BELLEVUE, PQ H9X 3V9, CANADA; MCGILL CANC CTR, MONTREAL, PQ, CANADA	McGill University; McGill University								CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GU ZM, 1994, ONCOGENE, V9, P629; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARX J, 1993, SCIENCE, V262, P1645, DOI 10.1126/science.8259507; MATLASHEWSKI G, 1989, ANTICANCER RES, V9, P1447; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MIYASHITA T, 1995, CELL, V80, P293; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STOREY A, 1994, KERATINOCYTE HDB, P439; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	30	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					387	392						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624152				2022-12-28	WOS:A1995RK95700019
J	BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G				BOLINO, A; SCHUFFENECKER, I; LUO, Y; SERI, M; SILENGO, M; TOCCO, T; CHABRIER, G; HOUDENT, C; MURAT, A; SCHLUMBERGER, M; TOURNIAIRE, J; LENOIR, GM; ROMEO, G			RET MUTATIONS IN EXON-13 AND EXON-14 OF FMTC PATIENTS	ONCOGENE			English	Note						FAMILIAL MEDULLARY THYROID CARCINOMA; RET PROTOONCOGENE; MUTATIONS; SINGLE STRAND CONFORMATION POLYMORPHISM	ENDOCRINE NEOPLASIA TYPE-2A; CHROMOSOME 10Q11.2; PROTOONCOGENE; GENE; LINKAGE; REGION; MEN2A; LOCUS; MAP; 2A	RET is a receptor tyrosine kinase gene which is responsible for three different inherited cancer syndromes namely multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC) as web as for Hirschsprung disease (HSCR), a congenital disorder affecting the intestinal motility. Germ-line mutations in the RET exons 10 and 11 were demonstrated in the majority of the MEN 2A and FMTC patients, On the other hand, one codon of RET exon 16 is preferentially changed in MEN 2B patients, Recently, a germ-line mutation in the exon 13 was described in one FMTC family as well as in four sporadic MTCs. In the present study, we observed the same exon 13 mutation in two FMTC families. In addition, we identified a previously unreported substitution of RET exon 14 in two unrelated FMTC families. Both mutations segregate with the disease in these four FMTC families and involve the tyrosine kinase domain of RET. Haplotype analysis using polymorphic markers tightly Linked to the RET gene indicates that in each pedigree the mutation arose as an independent event.	IST GIANNINA GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; UNIV TURIN,IST SCI PEDIAT,I-10100 TURIN,ITALY; HOP HAUTE PIERRE,SERV MED INTERNE,STRASBOURG,FRANCE; HOP BOIS GUILLAUME,SERV ENDOCRINOL,ROUEN,FRANCE; HOP HOTEL DIEU,SERV ENDOCRINOL,NANTES,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,PARIS,FRANCE; HOP ANTIQUAILLE,SERV ENDOCRINOL,LYON,FRANCE	University of Genoa; IRCCS Istituto Giannina Gaslini; CHU Lyon; University of Turin; CHU Strasbourg; CHU de Rouen; Nantes Universite; CHU de Nantes; UNICANCER; Gustave Roussy; CHU Lyon			Bolino, Alessandra/O-2933-2013; Seri, Marco/A-4339-2014	Silengo, Margherita/0000-0002-6255-1532; Seri, Marco/0000-0003-2425-2176; Bolino, Alessandra/0000-0002-8980-4878				BROOKSWILSON AR, 1990, NUCLEIC ACIDS RES, V18, P16; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, J ENDOCRINOL INVEST, V17, P201; CECCHERINI I, 1994, ONCOGENE, V9, P1; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1994, IN PRESS ONCOGENE; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LAIRMORE TC, 1991, GENOMICS, V9, P181, DOI 10.1016/0888-7543(91)90237-9; LOVE DR, 1993, HUM MOL GENET, V2, P491, DOI 10.1093/hmg/2.4.491-a; MCMAHON R, 1994, HUM MOL GENET, V3, P643, DOI 10.1093/hmg/3.4.643; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA Y, 1989, GENOMICS, V5, P199, DOI 10.1016/0888-7543(89)90046-3; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; PASINI B, 1995, IN PRESS NATURE GENE; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, NUCLEIC ACIDS RES, V18, P7472, DOI 10.1093/nar/18.24.7472-a	23	227	234	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2415	2419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784092				2022-12-28	WOS:A1995RE54300019
J	SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P				SPITKOVSKY, D; STEINER, P; GOPALKRISHNAN, RV; EILERS, M; JANSENDURR, P			THE ROLE OF P53 IN COORDINATED REGULATION OF CYCLIN D1 AND P21 GENE-EXPRESSION BY THE ADENOVIRUS E1A AND E1B ONCOGENES	ONCOGENE			English	Note						ADENOVIRUS E1A; ADENOVIRUS EIB; CYCLIN D1; P53; P2L(WAF-1); CIP-1	CELL-CYCLE; PROTEIN; TRANSFORMATION; MUTANT; PHOSPHORYLATION; LOCALIZATION; FIBROBLASTS; INHIBITION; PRODUCTS; G(1)	Expression of the cyclin D1 gene is induced when quiescent fibroblasts are stimulated to reenter the cell cycle by addition of growth factors. Moderate ectopic expression of cyclin D1 in early G1 facilitates progression through G1, When transiently overexpressed at the G1/S boundary, cyclin D1 prevents S phase entry, suggesting a dual role for this protein in cellular growth control. It was shown that the retinoblastoma protein (pRB) can activate cyclin D1 gene expression; furthermore, there is evidence that expression of the cyclin D1 gene is down-regulated by the SV40 large T and adenovirus E1A genes, both of which were shown to target pRB, We now report that in diploid human fibroblasts functional inactivation of pRB by adenovirus E1A is not sufficient for efficient repression Of cyclin D1 gene expression, since the E1B gene product, in addition to E1A, is required for repression of the cyclin D1 gene. Since E1B was shown to target p53, we investigated the role of p53 for expression of the cyclin D1 gene. In a cell line with temperature-sensitive p53, cyclin D1 is moderately expressed at the restrictive temperature. Induction of p53 function by temperature shift leads to an increase of cyclin D1 mRNA and protein, parallel to the activation of p21(WAF-1/CIP1) gene expression in this system, When the capability of adenovirus gene products to affect expression of either gene was analysed, we found that infection of Ad5 drastically reduced cyclin D1 and p21(WAF-1/CIP1) gene expression in cells where p53 function is limiting. Under these conditions E1A and E1B cooperate to reduce the cyclin D1 level, while p21(WAF-1)/(CIP1) expression was found insensitive to E1A expression. In cells containing elevated p53 function, modulation of gene expression by E1B was severely compromised; under these conditions, expression of E1A reduced expression of cyclin D1 without affecting p21(WAF-1/CIP1). The data suggest that E1A and E1B cooperate to inhibit expression of cyclin D1 and identify the cyclin D1 gene as a new downstream target for p53.	DEUTSCH KREBSFORSCHUNGSZENTRUM,ABT 620,D-69120 HEIDELBERG,GERMANY; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Eilers, Martin/0000-0002-0376-6533				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUPPI K, 1994, ONCOGENE, V9, P3017; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P2547; KATO J, 1993, GENE DEV, V7, P331; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULZE A, 1994, ONCOGENE, V9, P3475; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; TAM SW, 1994, ONCOGENE, V9, P2663; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	30	29	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2421	2425						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784093				2022-12-28	WOS:A1995RE54300020
J	BIESECKER, LG; GIANNOLA, DM; EMERSON, SG				BIESECKER, LG; GIANNOLA, DM; EMERSON, SG			IDENTIFICATION OF ALTERNATIVE EXONS, INCLUDING A NOVEL EXON, IN THE TYROSINE KINASE RECEPTOR GENE ETK2/TYRO3 THAT EXPLAIN DIFFERENCES IN 5' CDNA SEQUENCES	ONCOGENE			English	Note						RECEPTOR; PROTEIN TYROSINE KINASE; BRAIN	CELLS	Protein tyrosine kinase transmembrane receptors trigger signal transduction cascades upon ligand binding, resulting in cellular proliferation, differentiation, differentiation inhibition or apoptosis depending upon the cell target. The ETK2/TYRO3 receptor is a tyrosine kinase expressed in embryonic stem cells, brain and testis that has recently been cloned by several groups. Analysis of cDNA clones isolated from several tissues shows 2 isoforms of the Etk2/tyro3 gene product that result from usage of alternative exons near the 5' end of the gene. In addition, our data suggest that a third alternative exon is positioned between these two alternative exons. This novel exon encodes yet another isoform that predicts a unique amino-terminal protein sequence, The alternative exons (exons 2A, 2B and 2C), predict three isoforms with different initiation codons, signal sequences and lengths. The existence of these multiple isoforms may be important for protein processing, translocation, or function.	UNIV PENN,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania	BIESECKER, LG (corresponding author), NIH,NATL CTR HUMAN GENOME RES,GENET DIS RES LAB,BETHESDA,MD 20892, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008414] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline; NICHD NIH HHS [HD28820] Funding Source: Medline; NIDDK NIH HHS [DK08414] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRIBSKOV M, 1992, SEQUENCE ANAL PRIMER; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; SCHLESSINGER J, 1991, NEURON, V9, P383; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAYLOR ICA, 1995, IN PRESS J BIOL CHEM; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	17	19	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2239	2242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784069				2022-12-28	WOS:A1995RB70300020
J	SU, LC; MUKHERJEE, AB; MUKHERJEE, BB				SU, LC; MUKHERJEE, AB; MUKHERJEE, BB			EXPRESSION OF ANTISENSE OSTEOPONTIN RNA INHIBITS TUMOR PROMOTER-INDUCED NEOPLASTIC TRANSFORMATION OF MOUSE JB6 EPIDERMAL-CELLS	ONCOGENE			English	Article						OSTEOPONTIN; ANTISENSE OPN; TUMOR PROMOTION	RAT-KIDNEY CELLS; SECRETED PHOSPHOPROTEIN; BONE SIALOPROTEIN; MESSENGER-RNA; PHYSIOLOGICAL-PROPERTIES; NONPHOSPHORYLATED FORMS; BINDING-PROPERTIES; MAMMALIAN-CELLS; PROTEINS; TUMORIGENICITY	Elevated expression of osteopontin (OPN), a secreted adhesive phosphoglycoprotein, is frequently associated with many transformed cell lines of epithelial and stromal origin. Moreover, several clonal lines of preneoplastic JB6 cells derived from Balb/c mouse epidermal cultures (Colburn et al., 1978, 1979), upon treatment with 12-O-tetradecanoyl phorbol-13-acetate (TPA), become irreversibly oncogenic and concomitantly synthesize OPN at elevated levels (Smith and Denhardt, 1989). In the present study we sought to determine whether OPN expression facilitates transformation of such preneoplastic (initiated) cells. We transfected TPA-promotable JB6 c141.5a cells with an expression vector containing mouse OPN cDNA in antisense orientation under transcriptional control of dexamethasone-inducible MMTV-LTR promoter. Four stably transfected clones, which expressed drastically reduced levels of OPN in the presence of both dexamethasone and TPA, were characterized. We found that (a) more than 20 copies of OPN antisense cDNA were stably incorporated into the genome of cells from two of these clones that were examined by Southern blot analysis; (b) dexamethasone-induced expression of antisense OPN RNA prevented augmented OPN expression at both mRNA and protein levels following TPA treatment; and (c) cells from all four clones failed to form colonies in soft agar medium containing both dexamethasone and TPA. Taken together, these data demonstrate that inhibition of elevated OPN expression blocks TPA-induced anchorage-independent growth of JB6 c141.5a cells, suggesting the possibility that OPN overproduction is causally related to transformation of preneoplastic cells.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA; NICHHD,HUMAN GENET BRANCH,DEV GENET SECT,BETHESDA,MD 20892	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BEHREND EI, 1994, CANCER RES, V54, P832; BENINATI S, 1994, J BIOCHEM-TOKYO, V115, P675, DOI 10.1093/oxfordjournals.jbchem.a124395; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; CHACKALAPARAMPI.I, 1985, J VIROL, V53, P841; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHEN Y, 1992, J BIOL CHEM, V267, P24871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLBURN NH, 1978, CANCER RES, V38, P624; COLBURN NH, 1979, NATURE, V282, P589; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARDNER HAR, 1994, ONCOGENE, V9, P2321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; NOSE K, 1990, CELL GROWTH DIFFER, V1, P511; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1991, BIOCHEM BIOPH RES CO, V177, P1205, DOI 10.1016/0006-291X(91)90669-X; REINHOLT FP, 1990, P NATL ACAD SCI USA, V77, P4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1988, CANCER RES, V48, P5770; SINGH K, 1990, J BIOL CHEM, V265, P18696; SINGH K, 1993, J BIOCHEM-TOKYO, V114, P702, DOI 10.1093/oxfordjournals.jbchem.a124240; SINGH K, 1992, J BIOL CHEM, V267, P23847; SMITH BM, 1986, CANCER RES, V46, P701; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126	39	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2163	2169						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784060				2022-12-28	WOS:A1995RB70300011
J	DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL				DESOUZA, AT; HANKINS, GR; WASHINGTON, MK; FINE, RL; ORTON, TC; JIRTLE, RL			FREQUENT LOSS OF HETEROZYGOSITY ON 6Q AT THE MANNOSE 6-PHOSPHATE/INSULIN-LIKE GROWTH-FACTOR-II RECEPTOR LOCUS IN HUMAN HEPATOCELLULAR TUMORS	ONCOGENE			English	Article						LOSS OF HETEROZYGOSITY; MGP/IGFII RECEPTOR; HEPATOCELLULAR CARCINOMA	FACTOR TYPE-2 RECEPTOR; HUMAN BREAST-CANCER; P53 GENE-MUTATIONS; FACTOR-BETA-1 PRECURSOR; 6-PHOSPHATE RECEPTORS; COLORECTAL CANCERS; SUPPRESSOR GENES; WILMS TUMOR; FACTOR-BETA; CARCINOMA	The mannose 6-phosphate/insulin-like growth factor III receptor (M6P/IGFIIr) is required for the activation of transforming growth factor beta, and previously we have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs). Therefore, we have postulated that loss of the M6P/IGFIIr gene may be mechanistically involved in liver carcinogenesis. Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of the M6P/IGFIIr gene to screen non-cirrhotic, hepatitis virus negative patients with hepatocellular tumors for LOH. Twenty-two of 36 (61%) patients were informative (heterozygous), and 14/22 (64%) liver tumors had LOH; 11/16 (69%) carcinomas, 1/3 (33%) fibrolamellar tumors and 2/3 (67%) adenomas. This is the first report of LOH at the M6P/IGFIIr locus in human hepatocellular tumors, and the presence of LOH in adenomas suggests that allelic loss may be an early event in the etiology of HCCs. These results support the hypothesis that the M6P/IGFIIr gene may function as a tumor suppressor gene in the liver.	DUKE UNIV,MED CTR,DEPT RADIAT ONCOL,DURHAM,NC 27710; ZENECA PHARMACEUT,DEPT SAFETY MED,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University; Duke University; Duke University					NCI NIH HHS [CA25951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DEVILEE P, 1991, ONCOGENE, V6, P1705; DRAGAN YP, 1992, CARCINOGENESIS, V5, P739; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; HEDRUM A, 1994, BIO-TECHNOL, V7, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEE JH, 1990, CANCER RES, V50, P2724; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOUIS DN, 1992, AM J PATHOL, V141, P777; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORITA R, 1991, CANCER RES, V51, P5817; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOSE H, 1993, CANCER, V72, P355, DOI 10.1002/1097-0142(19930715)72:2<355::AID-CNCR2820720208>3.0.CO;2-W; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SAITO S, 1992, CANCER RES, V52, P5812; SANGER F, 1987, P NATL ACAD SCI USA, V74, P5463; SIMON D, 1990, CANCER GENET CYTOGEN, V45, P255, DOI 10.1016/0165-4608(90)90091-N; SLAGLE BL, 1991, CANCER RES, V51, P49; SMITH M, 1986, AM J HUM GENET, V39, P654; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUE SR, 1994, IN PRESS ANN SURGERY; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1993, TRENDS GENET, V4, P138; WALKER GJ, 1991, CANCER RES, V51, P4367; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	64	192	194	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1725	1729						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753549				2022-12-28	WOS:A1995QX46900005
J	BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC				BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC			2 SERUM RESPONSE ELEMENTS MEDIATE TRANSCRIPTIONAL REPRESSION OF HUMAN SMOOTH-MUSCLE ALPHA-ACTIN PROMOTER IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article						ALPHA-ACTIN PROMOTER; SRES; RAS-ONCOGENE; REPRESSION	C-FOS; FIBROBLAST CELLS; GENE-EXPRESSION; ACTIVATION; CDNA; ONCOGENES; PROTEIN; YY1; TUMORIGENICITY; SUPPRESSION	The mechanism by which activated uas expression leads to repression genes specific actin filament proteins not understood, However, these changes associated with loss of organized actin filaments, are necessary to maintain the transformed phenotype. The human smooth muscle (sm) alpha-actin promoter is repressed in ras-transformed fibroblast cells and derepressed in revertant cell lines. In this study, we demonstrate that two serum response elements (SREs) present in the alpha-actin promoter are required for transcriptional repression in ras-transformed cells and the two SREs act synergistically to repress heterologous promoters in a ras-transformation dependent manner, Serum response factor (SRF), which can bind to the sm alpha-actin SREs, restores alpha-actin promoter activity in ras-transformed cells. c-Fos, c-Jun and YY1 also repress alpha-actin promoter through SREs, suggesting that these transcription factors may play a role in repressing alpha-actin promoter in uas-transformed cells.	SCHERING PLOUGH CORP, RES INST, DEPT TUMOR BIOL, KENILWORTH, NJ 07033 USA; MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Merck & Company; Schering Plough Corporation; Massachusetts Institute of Technology (MIT)			Kim, Jae-Hong/B-2530-2009; Chang, Wen/AAA-5076-2021	Kim, Jae-Hong/0000-0002-8019-0208; Chang, Wen/0000-0003-3369-083X	NCI NIH HHS [R01CA40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CARROLL SL, 1986, J BIOL CHEM, V261, P8955; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; KUMAR CC, 1991, EXP BIOL M, P47; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIN BH, 1990, J BIOL CHEM, V265, P16667; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; POLLACK R, 1984, ADV VIRAL ONCOL, V4, P3; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; REDDY S, 1990, J BIOL CHEM, V265, P1683; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Treisman R, 1990, Semin Cancer Biol, V1, P47; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	39	31	35	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1361	1370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731687				2022-12-28	WOS:A1995QR65100013
J	LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N				LAUREYS, G; SPELEMAN, F; VERSTEEG, R; VANDERDRIFT, P; CHAN, A; LEROY, J; FRANCKE, U; OPDENAKKER, G; VANROY, N			CONSTITUTIONAL TRANSLOCATION T(1-17)(P36.31-P36.13-Q11.2Q12.1) IN A NEUROBLASTOMA PATIENT. ESTABLISHMENT OF SOMATIC-CELL HYBRIDS AND IDENTIFICATION OF PND/A12M2 ON CHROMOSOME-1 AND NF1/SCYA7 ON CHROMOSOME-17 AS BREAKPOINT FLANKING SINGLE-COPY MARKERS	ONCOGENE			English	Article						NEUROBLASTOMA; SOMATIC CELL HYBRIDS; PRONATRIODILATIN; MONOCYTE CHEMOTACTIC PROTEIN; ADENOVIRUS INTEGRATION SITE; NEUROFIBROMATOSIS; SUPPRESSOR GENE	TUMOR-NECROSIS-FACTOR; CUTANEOUS MALIGNANT-MELANOMA; SHORT ARM; LINKAGE MAP; RNA GENES; N-MYC; REGION; 1P36; CANCER; EXPRESSION	Cytogenetic and molecular studies in neuroblastoma suggest the presence of a tumor suppressor gene at the distal band p36 of human chromosome 1, We described a constitutional translocation t(1;17)(p36;q12-q21), involving the critical region 1p36, in a patient with neuroblastoma, and hypothesized that the translocation predisposed the patient to tumor development, Here we report the molecular delineation of the translocation breakpoints, Somatic cell hybrids were generated by fusion of the patient's fibroblasts with the thymidine kinase deficient hamster cell line, a3, In hybrid cell lines which retained the human derivative chromosomes, the position of chromosome 1p and 17q DNA probes respective to the translocation breakpoints was determined by fluorescence in situ hybridization and Southern blot analysis, The chromosome Ip breakpoint was localized within a repetitive region encoding t-RNA genes, with 12A-2 (PND) as most distal and pHE2.6 (A12M2) as most proximal single-copy breakpoint flanking markers, For the chromosome 17 breakpoint, the proximal and distal flanking markers were identified as 7G4 (NF1) and cMCP-3 (SCYA7), respectively, In this study, cMCP-3 (SCYA7), encoding the human monocyte chemotactic protein-3, was mapped between NF1 and ERBB2, As a pivotal step towards breakpoint cloning, at present these flanking markers optimally delineate the breakpoint regions of both chromosomes 1 and 17 at the molecular level.	STATE UNIV GHENT HOSP, DEPT MED GENET, B-9000 GHENT, BELGIUM; STATE UNIV GHENT HOSP, DEPT PEDIAT, B-9000 GHENT, BELGIUM; UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1105 AZ AMSTERDAM, NETHERLANDS; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, STANFORD, CA 94305 USA; CATHOLIC UNIV LEUVEN, REGA INST MED RES, LOUVAIN, BELGIUM	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Howard Hughes Medical Institute; Stanford University; KU Leuven	LAUREYS, G (corresponding author), STATE UNIV GHENT HOSP, DEPT PEDIAT ONCOL, B-9000 GHENT, BELGIUM.		Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Versteeg, Rogier/AAQ-1765-2020; laureys, genevieve/AAG-2390-2021	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Versteeg, Rogier/0000-0001-7172-0388				BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BARKER PE, 1993, ONCOGENE, V8, P3353; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOYD E, 1989, HUM GENET, V81, P153, DOI 10.1007/BF00293892; BRODEUR GM, 1981, CANCER RES, V41, P4678; BUCKLAND RA, 1992, CYTOGENET CELL GENET, V61, P1, DOI 10.1159/000133358; CARON H, 1994, AM J HUM GENET, V55, P341; CHENG NC, 1995, ONCOGENE, V10, P291; CORSARO CM, 1978, SOMAT CELL GENET, V4, P541, DOI 10.1007/BF01542925; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ELLMEIER W, 1992, EMBO J, V11, P2563, DOI 10.1002/j.1460-2075.1992.tb05321.x; FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888-7543(87)90034-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUNTAIN JW, 1989, AM J HUM GENET, V44, P58; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GILBERT F, 1984, CANCER RES, V44, P5444; GOILLOT E, 1992, CANCER RES, V52, P3194; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JORDE LB, 1993, AM J HUM GENET, V53, P1038; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1966, CANCER, V19, P1032, DOI 10.1002/1097-0142(196607)19:7<1032::AID-CNCR2820190719>3.0.CO;2-7; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LEISTER I, 1990, CANCER RES, V50, P7232; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LENGAUER C, 1992, CANCER RES, V52, P2590; LINDGREN V, 1985, MOL CELL BIOL, V5, P2172, DOI 10.1128/MCB.5.9.2172; LINDGREN V, 1985, NATURE, V314, P115, DOI 10.1038/314115a0; LUND E, 1983, MOL CELL BIOL, V3, P2211, DOI 10.1128/MCB.3.12.2211; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MCBRIDE OW, 1989, GENOMICS, V5, P561, DOI 10.1016/0888-7543(89)90024-4; MCDOUGALL JK, 1971, J GEN VIROL, V12, P43, DOI 10.1099/0022-1317-12-1-43; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; OCONNELL P, 1993, GENOMICS, V15, P38, DOI 10.1006/geno.1993.1007; OPDENAKKER G, 1994, GENOMICS, V21, P403, DOI 10.1006/geno.1994.1283; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PONZONI M, 1992, CANCER RES, V52, P931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROSEN ST, 1987, LAB INVEST, V56, P302; Sambrook J, 1989, MOL CLONING LABORATO; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SOLOMON E, 1991, CYTOGENET CELL GENET, V58, P1, DOI 10.1159/000133157; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TANAKA K, 1993, ONCOGENE, V8, P2253; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WAYE JS, 1986, NUCLEIC ACIDS RES, V14, P6915, DOI 10.1093/nar/14.17.6915; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WESTERVELD A, 1971, NATURE-NEW BIOL, V234, P20, DOI 10.1038/newbio234020a0; WITZLEBEN CL, 1974, CANCER-AM CANCER SOC, V34, P786, DOI 10.1002/1097-0142(197409)34:3<786::AID-CNCR2820340339>3.0.CO;2-9	66	46	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1087	1093						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700633				2022-12-28	WOS:A1995QN35300008
J	LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA				LESSNICK, SL; BRAUN, BS; DENNY, CT; MAY, WA			MULTIPLE DOMAINS MEDIATE TRANSFORMATION BY THE EWINGS-SARCOMA EWS/FLI-1 FUSION GENE	ONCOGENE			English	Article						EWINGS SARCOMA; EWS/FLI-1; ETS PROTEINS; CHIMERIC TRANSCRIPTION FACTOR	CHIMERIC TRANSCRIPTION FACTOR; DNA-BINDING DOMAIN; TRANSACTIVATION DOMAIN; PRE-B; ACTIVATION; TRANSLOCATION; PROTEINS; FAMILY; FLI-1; LIPOSARCOMA	The (11;22) chromosomal translocation found in Ewing's sarcoma and related tumors fuses the amino terminus of the EWS protein to the DNA-binding domain of the FLI-1 transcription factor. In contrast to normal FLI-1, the EWS/FLI-1 fusion transforms NIH3T3 cells and this activity requires both EWS and FLI-1 sequences. Reporter gene assays showed that the portion of EWS fused to FLI-1 encodes a strong transcriptional activation domain. To determine whether this function is necessary for transformation by EWS/FLI-1, deletion analysis of EWS was performed. We found that the EWS domain could be functionally subdivided into two regions: (i) an amino terminal domain (domain A) which transforms efficiently when fused to FLI-1 but has little transactivation activity in a model system and (ii) a distal region (domain B) which transactivates efficiently but transforms less efficiently when fused to FLI-1. Replacement of the EWS domain with known heterologous transcriptional activation domains yielded chimeric FLI-1 fusions that in some instances could transform NM3T3 cells. Finally we demonstrate that EWS/FLI-1 and related FLI-1 chimeras are able to cooperate,vith another transcription factor to activate a model reporter gene. These results further demonstrate that EWS/FLI-1 is an aberrant transcription factor and suggest that the EWS domain mediates important protein-protein interactions with other factors resulting in the transcriptional modulation of target genes.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,GWYNNE HAZEN CHERRY MEM LABS,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [P01CA012800, R01CA050443] Funding Source: NIH RePORTER; NCI NIH HHS [CA12800, CA50443] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS J, 1992, BLOOD, V80, P2953; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYE JA, 1992, GENE DEV, V67, P975; OHNO T, 1993, CANCER RES, V53, P5859; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAO VN, 1993, ONCOGENE, V8, P2167; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WU YL, 1990, NUCLEIC ACIDS RES, V18, P1919, DOI 10.1093/nar/18.7.1919; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	36	152	161	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					423	431						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845667				2022-12-28	WOS:A1995QF64800002
J	CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A				CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A			2 DISTINCT PROTEIN ISOFORMS ARE ENCODED BY NTK, A CSK-RELATED TYROSINE PROTEIN-KINASE GENE	ONCOGENE			English	Article							SRC FAMILY KINASES; RECEPTOR; P56LCK; AUTOPHOSPHORYLATION; PHOSPHORYLATES; ASSOCIATION; ACTIVATION; EXPRESSION; P50(CSK); P56(LCK)	Recently, we and others have cloned cDNAs encoding a second member of the Csk family of inhibitory tyrosine protein kinases, which we have termed Ntk. Intriguingly, the mouse ntk cDNA sequences published by two independent groups differed by the presence or absence of a 136 nucleotide-insert near their 5' ends. In this report, we demonstrate that this 136 nucleotide-sequence likely corresponds to a complete exon in the ntk gene (termed exon 2), and that the two types of cDNAs/transcripts are produced by alternative splicing. Using ribonuclease protection assays, it was also established that brain and lymphoid organs, as well as most hemopoietic cells, predominantly expressed ntk transcripts lacking exon 2. In contrast, selected hemopoietic cell lines, such as the immature myeloid cell lines 32D cl3(G) and WEHI-3B, exclusively possessed exon 2-bearing RNAs. Interestingly, exon 2 introduced a novel in-frame upstream AUG in the ntk transcript, which is in the appropriate context for translation initiation. Evidence was obtained that this AUG is utilized in vivo, and that it extends the amino-terminal sequence of Ntk by 40 amino acids. Indeed, while exon 2-deficient ntk RNAs were translated into a 52 kilodalton (kDa) polypeptide (p52(ntk)), those bearing exon 2 produced a 56 kDa protein (p56(ntk)). Furthermore, p56(ntk), but not p52(ntk), was recognized by an antiserum directed against the novel amino-terminal sequence encoded by exon 2. Additional biochemical characterizations showed that p52(ntk) and p56(ntk) were localized to the cytoplasm, and that they partially accumulated in the detergent-insoluble cellular fraction. This last finding suggested that the Ntk proteins can associate with the cytoskeleton. Finally, through linkage analysis of two multilocus crosses, the ntk gene was mapped to Chromosome 10 in the mouse. Taken together, these data showed that ntk, a csk-related tyrosine protein kinase gene, encodes two protein isoforms expressed in distinct cell types. Moreover, they raised the possibility that Ntk may be involved in the regulation of Src-Like enzymes in detergent-insoluble cellular compartments.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; UNIV QUEBEC,INST ARMAND FRAPPIER,CTR RECH IMMUNOL,LAVAL H7V 1B7,PQ,CANADA; NIAID,BETHESDA,MD 20892; ALEXION PHARMACEUT INC,NEW HAVEN,CT 06511; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,PQ,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; University of Quebec; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Coligan JKA, 1991, CURRENT PROTOCOLS IM; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Gosselin Pierre, 1993, Molecular Immunology, V30, P1185, DOI 10.1016/0161-5890(93)90137-Z; Green EL, 1981, GENETICS PROBABILITY, P77; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAKE LE, 1994, IN PRESS GENOMICS; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEMIEUX S, 1991, CELL IMMUNOL, V134, P191, DOI 10.1016/0008-8749(91)90342-9; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAKANO S, 1994, ONCOGENE, V9, P1155; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	41	35	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3437	3448						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970703				2022-12-28	WOS:A1994PT39200005
J	SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA				SHEIKH, MS; LI, XS; CHEN, JC; SHAO, ZM; ORDONEZ, JV; FONTANA, JA			MECHANISMS OF REGULATION OF WAF1 CIP1 GENE-EXPRESSION IN HUMAN BREAST-CARCINOMA - ROLE OF P53-DEPENDENT AND INDEPENDENT SIGNAL-TRANSDUCTION PATHWAYS	ONCOGENE			English	Article							DNA-DAMAGING AGENTS; P53 PROTEIN EXPRESSION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVITY; CANCER CELLS; GROWTH; BINDING; SUPPRESSION; MUTATIONS; CYCLE	WAF1/Cip1 was recently identified as the wild-type p53 target that appears to mediate the tumor suppressing effects of p53. We investigated the mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma (HBC) cells. Our results demonstrate that the HBC cells harboring wild-type p53 express 26-33-fold higher WAF1/Cip1 mRNA levels than the cells harboring mutant p53. The DNA damaging agent etoposide induced p53 accumulation only in cells harboring wild-type p53 yet it induced WAF1/Cip1 gene expression in cells carrying wild-type or mutant p53, suggesting the involvement of p53-dependent and independent signaling pathways in the regulation of WAF1/Cip1 gene expression. Serum starvation-induced growth arrest although not altering the endogenous p53 levels or its ability to transactivate the reporter gene, induced WAF1/Cip1 gene expression in cells carrying wild-type as well as mutant p53. These results further implicated the involvement of p53-independent signal transduction pathways in WAF1/Cip1 gene regulation. Our data also suggest that WAF1/Cip1 gene expression is tightly associated with cell cycle progression in cells containing either wild-type or mutant p53. WAF1/Cip1 expression was transiently induced in response to serum treatment and declined as the cells passed through the S-phase of the cell cycle. We thus provide evidence that the mechanisms of WAF1/Cip1 gene regulation involve p53-dependent and independent signaling pathways in HBC.	UNIV MARYLAND,SCH MED,DEPT MED,DIV ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,BALTIMORE,MD 21201; VET ADM MED CTR,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Fontana, Joseph/0000-0003-3829-3358	NATIONAL CANCER INSTITUTE [R01CA063335] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63335] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MCGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SHEIKH MS, 1993, ANTICANCER RES, V13, P1387; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1993, J CELL PHYSIOL, V155, P556, DOI 10.1002/jcp.1041550314; TISHLER RB, 1993, CANCER RES, V53, P2212; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V7, P1126; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	38	246	248	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3407	3415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970699				2022-12-28	WOS:A1994PT39200001
J	COX, AD; BRTVA, TR; LOWE, DG; DER, CJ				COX, AD; BRTVA, TR; LOWE, DG; DER, CJ			R-RAS INDUCES MALIGNANT, BUT NOT MORPHOLOGIC, TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article							C-MYC; PROTEIN-KINASE; EXPRESSION; ONCOGENES; GROWTH; BCL-2; GENE; ACTIVATION; PRODUCT; GTPASES	Although previous studies have not identified transforming properties of the Ras-related protein R-Ras, two recent observations have prompted our further evaluation of R-Ras function. First, we observed that mutant forms of the closely related R-Ras2/TC21 protein (similar to 70% identity) exhibited the same potent transforming activity as oncogenic Ras proteins. Second, R-Ras association with Bcl-2 suggested a possible role for R-Ras in apoptotic growth control. Therefore, we have performed a detailed analysis of R-Ras transforming potential in NIH3T3 cells. Whereas expression of a mutant R-Ras protein (38V; analogous to the 12V activating Ras mutation) did not induce morphologic transformation of NIH3T3 cells, R-Ras(38V)-expressing cells proliferated in low serum, formed colonies in soft agar, and formed progressive tumors in nude mice. Like Ras-transformed cells, R-Ras(38V)-transformed cells exhibited constitutively activated mitogen activated protein kinases. Furthermore, R-Ras(38V) stimulated transcriptional activation of Ras-responsive promoter elements, and this activity (and transformation) was blocked by Raf dominant negative proteins, Finally, whereas co-expression of Bcl-2 did not cause significant alteration in wild type or mutant R-Ras transforming activity, coexpression of v-Myc and R-Ras(38V) induced a striking morphologic transformation of NIH3T3 cells. Taken together, these observations suggest that aberrant R-Ras function may stimulate malignant transformation, in the absence of morphologic transformation, via up-regulation of part of the Ras signal transduction pathway.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Roche Holding; Genentech	COX, AD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA61951, CA52070, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R29CA061951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COX AD, 1994, METHOD ENZYMOL, V238, P277; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SELF AJ, 1993, ONCOGENE, V8, P655; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	36	114	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3281	3288						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936652				2022-12-28	WOS:A1994PM65800021
J	SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH				SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH			INTEGRATED HEPATITIS-B VIRUS-X AND 3' TRUNCATED PRES/S-SEQUENCES DERIVED FROM HUMAN HEPATOMAS ENCODE FUNCTIONALLY ACTIVE TRANSACTIVATORS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; CELLULAR FLANKING SEQUENCES; LONG TERMINAL REPEAT; NF-KAPPA-B; TRANS-ACTIVATION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA INTEGRATION; VIRAL ENHANCERS; LIVER-CANCER	The hepatitis B virus (HBV) frequently integrates into hepatocellular genomic DNA during viral infection. Transcriptional transactivators encoded by integrated HBV X and 3' truncated preS/S sequences are known to stimulate gene expression from homologous and heterologous promoters. Here we demonstrate that 21 of 26 (81%) hepatocellular carcinoma tissues/cell lines contain coding sequences for at least one of the two known transactivators. Pour integrated X and three preS/S transactivator sequences contained in five isolates from three hepatoma primary tissues or cell lines were used as examples to prove functionality of the encoded transactivators, In one case, where both X and preS/S sequences were present, dissection of X and preS/S transactivator sequences showed independent functionality. The investigation of X- and preS/S-specific RNA and protein expression revealed the existence of. carboxyterminally truncated viral-cellular fusion proteins that were able to stimulate gene expression from the c-fos proto-oncogene promoter five- to ten-fold. These results demonstrate that structurally intact HBV transactivator sequences are integrated in the majority of HBV-associated HCCs/hepatoma cell lines. In all tested examples integrated DNAs had retained functionality as transactivators. This data thereby support indirectly the hypothesis of a possible involvement of HBV transactivators in liver cell proliferation and hepatocarcinogenesis.	MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,D-82152 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81366 MUNICH,GERMANY	Max Planck Society; University of Munich								ARII M, 1992, ONCOGENE, V7, P397; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BUDKOWSKA A, 1986, J MED VIROL, V20, P111, DOI 10.1002/jmv.1890200204; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO KB, 1986, VIROLOGY, V154, P405, DOI 10.1016/0042-6822(86)90467-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FAUSTO N, 1989, LAB INVEST, V60, P4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEITELSON MA, 1989, GASTROENTEROLOGY, V98, P1071; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GERBES AL, 1993, J HEPATOL, V19, P312, DOI 10.1016/S0168-8278(05)80587-2; GEY GO, 1952, CANCER RES, V12, P264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KAM W, 1982, VIRAL HEPATITIS, P809; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOCH S, 1984, NUCLEIC ACIDS RES, V17, P6871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MATSUMOTO H, 1988, INT J CANCER, V42, P1, DOI 10.1002/ijc.2910420102; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; MIZUSAWA H, 1985, P NATL ACAD SCI USA, V82, P208, DOI 10.1073/pnas.82.1.208; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; OGATA N, 1990, HEPATOLOGY, V11, P1017, DOI 10.1002/hep.1840110617; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUADE K, 1992, J GEN VIROL, V73, P179, DOI 10.1099/0022-1317-73-1-179; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SLAGLE BL, 1991, CANCER RES, V51, P49; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAGINUMA K, 1985, P NATL ACAD SCI USA, V82, P4458, DOI 10.1073/pnas.82.13.4458; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V192, P111, DOI 10.1006/bbrc.1993.1388; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V197, P1209, DOI 10.1006/bbrc.1993.2605; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	74	104	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3335	3344						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936659				2022-12-28	WOS:A1994PM65800028
J	LI, Y; JENKINS, CW; NICHOLS, MA; XIONG, Y				LI, Y; JENKINS, CW; NICHOLS, MA; XIONG, Y			CELL-CYCLE EXPRESSION AND P53 REGULATION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P21	ONCOGENE			English	Article							DIRECTED PROTEIN-KINASE; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; GENE AMPLIFICATION; MESSENGER-RNA; CANCER; MUTATIONS; TRANSFORMATION	In normal human fibroblast cells, the primary cell cycle regulators, the cyclin-dependent kinases (CDKs), exist predominantly in multiple quarternary complexes, each consisting of a CDK, a cyclin, proliferating cell nuclear antigen (PCNA) and p21. p21 encodes a universal inhibitor of cyclin-dependent kinases, Here we show that the level of p21 mRNA and the interaction of p21 protein with cyclin-CDK enzymes are regulated during the cell cycle. When normal human fibroblast IMR90 cells were released from serum starvation, p21 mRNA reached its highest level immediately following serum stimulation, began to decrease at the G1/S boundary, fell to its lowest level during S phase, and accumulated again as cells exited from S phase. p21 protein associates with each cyclin-CDK complex in a cell cycle dependent manner. Cyclin A-CDK2-p21-PCNA and Cyclin B1-CDC2-p21-PCNA complexes are assembled in early S and G2 phase, respectively, indicating that p21 and/or PCNA regulates the enzymatic activity of each kinase at the time of their functioning. Cyclin D1-CDK4-p21-PCNA complexes, on the other hand, persist throughout the cell cycle, suggesting that cyclin D1-CDK4 quarternary complexes may play a role in monitoring an event(s) that may occur at any time, rather than at a specific stage of the cell cycle. The level of p21 mRNA in early passage Li-Fraumeni cells that are heterozygous for p53 mutation remained similar to that in normal fibroblasts, but was undetectable in immortalized Li-Fraumeni cells homozygous for mutant p53. This finding provides a plausible molecular explanation for the loss of genetic stability associated with cells homozygous, but not heterozygous, for p53 mutation.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, PROGRAM MOLEC BIOL & BIOTECHNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KUSUBATA M, 1992, J BIOL CHEM, V267, P20937; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, J NATL CANCER I, V43, P1365; LITTLE JB, 1987, CELL, V70, P923; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	54	376	390	7	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2261	2268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913544				2022-12-28	WOS:A1994NX62900018
J	QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI				QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI			KINASE-DEFICIENT NEU PROTEINS SUPPRESS EPIDERMAL GROWTH-FACTOR RECEPTOR FUNCTION AND ABOLISH CELL-TRANSFORMATION	ONCOGENE			English	Article							ATP-BINDING-SITE; NIH 3T3 CELLS; INSULIN-RECEPTOR; POINT MUTATION; HUMAN-BREAST; INTERMOLECULAR AUTOPHOSPHORYLATION; ONCOGENE; HETERODIMERIZATION; PHOSPHORYLATION; EXPRESSION	p185(c-neu) and epidermal growth factor receptor (EGFR) associate into an active heterodimer, and overexpression of these two receptors leads to a transformed phenotype. However, the association of EGFR and kinase-deficient Neu proteins (point mutant N757 or cytoplasmic domain deletion mutant N691stop) results in a defective or inactive heterodimeric complex. In this report we explore the biological consequences of heterodimerization between EGFR and wild-type (WT) or kinase-deficient mutant Neu proteins in living cells. We show that co-expression of EGFR and kinase-deficient Neu proteins abolished the synergistic transformation and tumorigenicity. Moreover, the normal responses of EGFR to ligand were significantly suppressed, e.g., loss of EGF-dependent transformation, reduced rate of receptor endocytosis and turnover, diminished DNA synthesis, and decreased EGF binding affinity. These results provide the first evidence that kinase-deficient Neu proteins suppress normal EGFR function and display a dominant negative mutant phenotype. Together with the stimulatory effects observed in cells forming active heterodimers, these studies provide a role for heterodimerization of EGFR and Neu/c-erbB2 in interreceptor activation and synergistic signaling which may be responsible for the transition from normal receptor function into oncogenesis.			QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DECKER SJ, 1989, J BIOL CHEM, V264, P9204; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORNILOVA ES, 1992, ONCOGENE, V7, P511; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOOLENAAR BF, 1990, J CELL BIOL, V110, P491; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN X, 1994, IN PRESS P NATL ACAD; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	41	76	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1507	1514						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908733				2022-12-28	WOS:A1994NH40100026
J	CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR				CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR			INTESTINAL CRYPT CELLS CONTAIN HIGHER LEVELS OF CYTOSKELETAL-ASSOCIATED PP60C-SRC PROTEIN TYROSINE KINASE-ACTIVITY THAN DO DIFFERENTIATED ENTEROCYTES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN-COLON CARCINOMA; GAP JUNCTION PROTEIN; ISOLATED MICROVILLUS CYTOSKELETON; INSOLUBLE CELLULAR MATRIX; EXPRESSED RAT FIBROBLASTS; CHICK-EMBRYO DEVELOPMENT; MIDDLE TUMOR-ANTIGEN; HERBIMYCIN-A; MORPHOLOGICAL TRANSFORMATION	Undifferentiated crypt cells from chicken small intestine contain 15-fold higher levels of tyrosine-phosphorylated proteins than do differentiated enterocytes located at the villus apex. The tyrosine kinase activity and the tyrosine-phosphorylated proteins are associated with the Triton-insoluble cytoskeleton. To determine whether: (1) pp60c-src is an active tyrosine kinase in crypt cell cytoskeletons and (2) cytoskeletal-associated pp60c-src activity decreases as crypt cells differentiate, we isolated pp60c-src from subcellular fractions of cells along the crypt-villus axis of chicken small intestine and measured its protein kinase activity. We observed that pp60c-src activity in crypt cytoskeleton was higher (on average, fourfold as measured by enolase phosphorylation or sevenfold as measured by autophosphorylation) than that in cytoskeletons from differentiated enterocytes. Moreover, nearly 70% of pp60c-src activity in crypt cells, like that of pp60v-src, pp60c-src mutants with elevated kinase, activity or pp60v-src from activated platelets, localized to the cellular cytoskeleton. In contrast, less than 20% of pp60c-src activity in differentiated enterocytes, like that of kinase-inactive pp60v-src or pp60c-src from fibroblasts or resting platelets, associated with the cytoskeleton. Furthermore, in crypt cells, unlike differentiated enterocytes, cytoskeletal-associated pp60c-src appeared to have higher specific protein tyrosine kinase activity than did soluble pp60c-src. The data suggest that a kinase-active form of pp60c-src located in the cytoskeleton of crypt cells may be responsible for phosphorylating proteins on tyrosine and regulating growth and differentiation of the cells.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Salk Institute	CARTWRIGHT, CA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,MED SCH LAB,SURGE BLDG,P304,STANFORD,CA 94305, USA.				NCI NIH HHS [CA-13884] Funding Source: Medline; NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA013884, R01CA013884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BREIMER ME, 1981, EXP CELL RES, V135, P1, DOI 10.1016/0014-4827(81)90293-7; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; FATH KR, 1990, DEVELOPMENT, V109, P449; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KMIECK TE, 1987, CELL, V49, P75; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MURAKAMI Y, 1988, CANCER RES, V48, P1587; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SUZUKAKETSUCHIY.K, 1989, J ANTIBIIOT, V12, P1831; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WEISER MM, 1986, INT REV CYTOL, V101, P1, DOI 10.1016/S0074-7696(08)60245-4; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	54	58	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1033	1039						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681158				2022-12-28	WOS:A1993KT22000027
J	KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K				KAECH, S; SCHNIERLE, B; WYSS, A; BALLMERHOFER, K			MYRISTYLATION AND AMINO-TERMINAL PHOSPHORYLATION ARE REQUIRED FOR ACTIVATION OF PP60(C-SRC) DURING MITOSIS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CYANOGEN-BROMIDE CLEAVAGE; MIDDLE-T-ANTIGEN; SRC FAMILY; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; PP60C-SRC; P60C-SRC; RECEPTOR; MUTATION	pp60c-src, a cellular tyrosine kinase homologous to the retroviral v-src oncogene, becomes transiently activated during mitosis. Activation is accompanied by phosphorylation of three sites in the amino-terminal regulatory domain of the protein, threonine 34, threonine 46 and serine 72. These sites can be phosphorylated in vitro by a cell cycle-regulated kinase, p34cdc2, yet this does not result in increased kinase activity of pp60c-src. pp60c-src is negatively regulated by phosphorylation at tyrosine 527, and it has been shown that this site is transiently dephosphorylated in mitotic cells. The importance of tyrosine 527 in the regulation of pp60c-src is also emphasized by the fact that oncogenic mutants of pp60src lacking tyrosine 527 are constitutively active during the entire cell cycle. Here we report that a non-myristylated mutant of pp60c-src is not activated and only partially phosphorylated at the amino terminus in mitotic cells. Additional mutants lacking one (TTAc-src), two (AASc-src) and three (AAAc-src) cdc2 phosphorylation sites had slightly higher kinase activity than wild-type pp60c-src in interphase cells and were not activated during mitosis. However, all four mutant proteins were still transiently dephosphorylated at tyrosine 527 during mitosis, suggesting that myristylation and amino-terminal phosphorylation may be necessary but are clearly not sufficient for mitosis-specific activation.	FRIEDRICH MIESCHER INST, BOX 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research			Schnierle, Barbara/AAG-8108-2019	Kaech Petrie, Stefanie/0000-0002-6246-6434; Ballmer-Hofer, Kurt/0000-0002-3800-9129				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EISEMAN E, 1992, NATURE, V355, P78; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shaw A, 1991, CURR OPIN CELL BIOL, V3, P862, DOI 10.1016/0955-0674(91)90061-3; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453	45	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1993	8	3					575	581						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	7679790				2022-12-28	WOS:A1993KN00800007
J	COOK, JL; RE, R; GIARDINA, JF; FONTENOT, FE; CHENG, DY; ALAM, J				COOK, JL; RE, R; GIARDINA, JF; FONTENOT, FE; CHENG, DY; ALAM, J			DISTANCE CONSTRAINTS AND STEREOSPECIFIC ALIGNMENT REQUIREMENTS CHARACTERISTIC OF P53 DNA-BINDING CONSENSUS SEQUENCE HOMOLOGIES	ONCOGENE			English	Article						P53; TRANSCRIPTIONAL REGULATION; STEM CELL; LEUKEMIA GENE; CONSENSUS SEQUENCE	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVITY; REPORTER GENE; PROTEIN; PROMOTER; EXPRESSION; MUTATIONS; MUTANTS; SITES; MODULATION	We present evidence in favor of the position that some mutant p53 proteins retain the ability to trans-activate downstream genes through p53 DNA-binding consensus sequence (CS) homologies. We tested one cell line possessing high levels of mutant p53 and found that this mutant p53 is highly active in trans-activating one CS homology, moderately active in trans-activating a second sequence and inactive in modulating a third sequence. We tested a second cell line, also possessing high levels of mutant p53 and found the same pattern of activation. In addition we find that inter-motif distance [represented by N in RRRCWWGYYY(N)RRRCWWGYYY] is very important in determining the relative binding affinity of a given CS homology for wild-type or mutant p53. Our studies suggest that stereospecific alignment of the DNA-binding motifs within the CS may favor binding of wildtype p53 while misalignment may favor binding of mutant p53. Furthermore, we find that the maximum distances at which p53 DNA-binding CS homologies are functionally active vary for different sequences. Introduction of as few as 200 bp between one CS homology and the downstream TATA box can eliminate a 45-fold p53-mediated trans-activation. We present evidence that the composition of the DNA which flanks a p53 DNA-binding consensus sequence may also modulate trans-activation.			COOK, JL (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DIV RES,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X				ALAM J, 1992, J BIOL CHEM, V267, P21894; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BARBEE RW, 1993, BIOCHEM BIOPH RES CO, V190, P70, DOI 10.1006/bbrc.1993.1012; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MIYASHITA T, 1994, CANCER RES, V54, P3131; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RIVAS CI, 1992, BLOOD, V79, P1982; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZHANG W, 1993, CANCER RES, V53, P4772; ZHANG W, 1993, ONCOGENE, V8, P2555	49	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					723	733						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651736				2022-12-28	WOS:A1995RQ46900014
J	KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF				KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF			NATURE OF G1/S CELL-CYCLE CHECKPOINT DEFECT IN ATAXIA-TELANGIECTASIA	ONCOGENE			English	Article						ATAXIA-TELANGIECTASIA; CELL CYCLE; P53; CYCLIN-DEPENDENT-KINASE; P53/WAF1; RETINOBLASTOMA PROTEIN	IONIZING-RADIATION; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; P53 PROTEIN; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; CDK2 ACTIVITY; EXPRESSION; INDUCTION	We have previously demonstrated that cells from patients with ataxia-telangiectasia (A-T) fail to show initial delay at several cell cycle checkpoints post-irradiation. In addition a defect in the induction of p53 by ionizing radiation was evident. We demonstrate here that the radiation signal transduction pathway operating through p53, its target gene WAF1, cyclin-dependent kinases and the retinoblastoma (Rb) protein is defective in A-T cells. The defective p53 induction after ionizing radiation, observed previously in A-T cells, was also reflected at the functional level using p53-DNA binding activity, transactivation and transfection with wild type p53. Correction of the defect at the G1/S checkpoint was observed when wild type p53 was constitutively expressed in A-T cells. Exposure of control cells to radiation gave rise to p53 induction and as a consequence increased expression of WAF1 mRNA and protein, but A-T cells were defective in this response. As expected the WAF1 response in irradiated control cells resulted in an inhibition of cyclin-dependent kinase activity including cyclin E-cdk2, which plays an important role in the transition from G1 to S phase. No inhibition of cyclin-dependent kinase activity was observed in A-T cells correlating with the delayed WAF1 response. On the contrary an enhancement of cyclin-dependent kinase activity was seen in A-T cells post-irradiation. An accumulation of the hypophosphorylated form of Rb protein occurred in irradiated control cells compatible with the G1/S phase delay observed in these cells after exposure to radiation. In unirradiated A-T cells the amount of Rb protein was much higher compared to controls and it was mainly in the hyperphosphorylated (functionally inactive) form. In addition, accumulation of the hypophosphorylated form of Rb in A-T cells postirradiation was defective, consistent with the lack of cell cycle arrest. Thus the failure of the G1/S checkpoint in A-T cells after exposure to ionizing radiation is consistent with a defective radiation signal transduction pathway operating through p53.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BANCROFT CTR, BRISBANE, QLD 4029, AUSTRALIA; MED SCH HERSTON, DEPT PATHOL, QUEENSLAND CANC FUND RES UNIT, HERSTON, QLD 4006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT SURG, HERSTON, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014; Yan, Jun/F-1224-2010	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381; Yan, Jun/0000-0001-9617-0335				BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN P, 1983, THESIS U QUEENSLAND; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAN SJ, 1994, CANCER RES, V54, P5824; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1994, CANCER RES, V54, P1412; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LAVIN MF, 1992, CELL BIOL, V77, P235; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MICHIELI P, 1994, CANCER RES, V54, P3391; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NEVINS JR, 1992, SCIENCE, V258, P424; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1993, ONCOGENE, V8, P3055; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	110	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651723				2022-12-28	WOS:A1995RQ46900001
J	MACHIDE, M; MANO, H; TODOKORO, K				MACHIDE, M; MANO, H; TODOKORO, K			INTERLEUKIN-3 AND ERYTHROPOIETIN INDUCE ASSOCIATION OF VAV WITH TEC KINASE THROUGH TEC HOMOLOGY DOMAIN	ONCOGENE			English	Article						TEC KINASE; VAV; ERYTHROPOIETIN; IL3; SIGNAL TRANSDUCTION	TYROSINE-PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; SH2 DOMAIN; RECEPTOR; GRB2; ACTIVATION; GENE; RAS	Although hematopoietic cytokine receptors lack tyrosine kinase domains, the binding of their ligands to the receptors induce rapid tyrosine phosphorylation of various cellular target proteins. The specific tyrosine kinases which phosphorylate these substrates, however, have not been identified, other than that JAK kinases which phosphorylate STAT proteins and the receptors. We found that the c-vav proto-oncogene product, Vav, is rapidly and transiently tyrosine-phosphorylated in response to erythropoietin and IL3 stimulations and that Tec kinase is also transiently activated by these cytokines. Immunoprecipitation experiments demonstrated that Tec kinase binds to Vav upon these cytokine stimulations and that Grb2 constitutively associates with Vav. In vitro binding assays showed that erythropoietin and IL3 stimulation induce the specific binding of Vav to Tec kinase through Tec homology domains. We therefore concluded that Tec kinase is one of the key enzymes in Epo and IL3 receptor-mediated signaling pathways and that Vav plays an important role in the cytokine receptor-mediated signal transduction.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,DEPT ZOOL,SAKYO KU,KYOTO,JAPAN; JICHI MED SCH,DEPT MOLEC BIOL,MINAMI KAWACHI,TOCHIGI,JAPAN	RIKEN; Kyoto University; Jichi Medical University								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GOLDWASSER E, 1990, PEPTIDE GROWTH FACTO, V1, P747; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P688; KURAMOCHI S, 1991, BIOCHEM BIOPH RES CO, V181, P1103, DOI 10.1016/0006-291X(91)92052-L; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; QUELLE FW, 1991, J BIOL CHEM, V266, P609; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN HY, 1994, J BIOL CHEM, V269, P19633; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1989, GENE, V67, P31; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TODOKORO K, 1994, BIOCHEM BIOPH RES CO, V202, P1912; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	57	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					619	625						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651724				2022-12-28	WOS:A1995RQ46900002
J	ZAKUT, R; GIVOL, D				ZAKUT, R; GIVOL, D			THE TUMOR SUPPRESSION FUNCTION OF P21(WAF) IS CONTAINED IN ITS N-TERMINAL HALF (HALF-WAF)	ONCOGENE			English	Note						WAF-1; P53; TUMOR SUPPRESSOR; N-TERMINAL HALF; GENE THERAPY	CYCLIN-DEPENDENT KINASES; P53; GENE	The Waf-1 encoded protein, p21, mediates p53 suppression of tumor cell growth. Overexpression of p21 in the H1299 tumor cell line suppresses colony formation similar to that resulted;from p53 overexpression. In an effort to localize the tumor suppression function within the structure of p21 we utilized vectors constructed with systematic truncations of p21 and tested their efficiency in suppressing tumor cell growth. We demonstrate that the N-terminal half of the p21 molecule (residues 1-80 and 1-89) shows better tumor cell growth suppression than the entire p21 molecule whereas the C-terminal half of p21 does not show this effect, These results may have implications for gene therapy of cancer.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY SW, 1994, CANCER RES, V154, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HALEVY O, 1995, SCIENCE, V267, P1024; HARPER JW, 1993, CELL, V75, P805; JIANG HP, 1994, ONCOGENE, V9, P3397; MICHIELI P, 1994, CANCER RES, V54, P3391; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1018; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCOTT WL, 1994, SCIENCE, V266, P807; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TOYOSHIMA H, 1994, CELL, V79, P67; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V36, P701	21	41	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					393	395						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624153				2022-12-28	WOS:A1995RK95700020
J	TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB				TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB			ABROGATION OF P53 FUNCTION BY TRANSFECTION OF HPV16 E6 GENE ENHANCES THE RESISTANCE OF HUMAN-DIPLOID FIBROBLASTS TO IONIZING-RADIATION	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENES; RADIOSENSITIVITY; HUMAN PAPILLOMAVIRUS 16; P5A; RETINOBLASTOMA	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; SV40 T-ANTIGEN; ATAXIA-TELANGIECTASIA; SKIN FIBROBLASTS; HUMAN KERATINOCYTES; NORMAL INDIVIDUALS; TRANSFORMED-CELLS; CELLULAR PROTEIN; DNA-DAMAGE	In order to examine the role of p53 expression on the sensitivity of cells to radiation-induced reproductive failure, we examined the radiosensitivity of a human diploid fibroblast cell strain (AG1521) before and after transfection with the E6 or E6/E7 genes of human papillomavirus 16 (HPV16)(3). HPV E6 binds to p53, promoting its degradation and abrogating wild-type p53 function. AG1521 cells transfected with either E6 or E6/E7 showed no radiation induction of either p53 or WAF1/Cip1. The radioresistance of these cells were significantly increased; the D-0 of the survival curves rose from 130 +/- 4 cGy for wild type (neo-transfected) cells to 178-192 cGy for three subclones transfected with E6 alone, and 151-218 cGy for eight subclones transfected with E6/E7. The change in radiosensitivity took place before the process of cellular immortalization and transformation produced by transfection with these genes. Thus, the effect on radiosensitivity appears to be an early effect of the loss of p53 function in nontransformed cells, perhaps related to the loss of the G(1) checkpoint and of the capacity for programmed death amongst radiation damaged cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BARBOSA MS, 1989, ONCOGENE, V4, P1529; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI CY, 1995, INT J ONCOL, V6, P233; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1988, INT J RADIAT BIOL, V54, P899, DOI 10.1080/09553008814552311; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, J VIROL, V63, P4417; NAGASAWA H, 1987, J INVEST DERMATOL, V88, P149, DOI 10.1111/1523-1747.ep12525294; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARRIS CN, 1990, CANCER LETT, V55, P171, DOI 10.1016/0304-3835(90)90029-W; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	109	112	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784090				2022-12-28	WOS:A1995RE54300017
J	BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M				BAZAR, L; HARRIS, V; SUNITHA, I; HARTMANN, D; AVIGAN, M			A TRANSACTIVATOR OF C-MYC IS COORDINATELY REGULATED WITH THE PROTOONCOGENE DURING CELLULAR GROWTH	ONCOGENE			English	Article						C-MYC REGULATOR; FUSE BINDING PROTEIN; GROWTH RESPONSE GENE	HEMATOPOIETIC-CELLS; LEUKEMIA-CELLS; HL60 CELLS; 3T3 CELLS; EXPRESSION; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; RNA; GENES	A recently cloned nuclear protein, which binds a far upstream element (FUSE) of the human c-myc protooncogene, stimulates promoter driven expression in undifferentiated cells. In concert with a loss of c-myc expression, both FUSE binding protein (FBP) mRNA and protein levels disappeared in HL60 cells after PMA-induced differentiation, due to a drop in the rate of transcription that was measured by nuclear runoff. During the differentiation of these cells, the brief half-lives of FBP mRNA (3 h) and protein (1.5 h) did not change, allowing for the rapid down-regulation of nuclear protein levels, as detected by immunohistochemical staining. Like c-myc, FBP is expressed in proliferating cells from a variety of lineages, but not in quiescent cells. When T cells and fibroblasts were stimulated to transit from G0 into the cell cycle, there was a dramatic rise of both FBP mRNA and DNA sequence specific nuclear FBP binding activity, which correlated with the appearance of c-myc mRNA. In contrast to the transient expression of many other immediate early growth response genes, both FBP and c-myc expression were sustained for more than 24 h. In fibroblasts, the coordinate expression of FBP and c-myc throughout all phases of the cell cycle is consistent with FBP's role as a growth-dependent regulator of c-myc expression.	GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT MED, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NCI NIH HHS [CA54818] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BECKER B, 1994, BIOTECHNIQUES, V17, P630; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELANO P, 1989, BIOTECHNIQUES, V7, P942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANOVA M, 1993, ANN NY ACAD SCI, V698, P174, DOI 10.1111/j.1749-6632.1993.tb17206.x; DIAMOND LW, 1980, CANCER RES, V40, P703; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1988, J BIOL CHEM, V263, P4828; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANDBERG G, 1991, ACTA ONCOL, V30, P917, DOI 10.3109/02841869109088244; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; MARCUKB, 1992, ANNU REV BIOCHEM, V61, P809; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2229	2238						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784068				2022-12-28	WOS:A1995RB70300019
J	FINCHAM, VJ; WYKE, JA; FRAME, MC				FINCHAM, VJ; WYKE, JA; FRAME, MC			V-SRC-INDUCED DEGRADATION OF FOCAL ADHESION KINASE DURING MORPHOLOGICAL TRANSFORMATION OF CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Note						V-SRC; MORPHOLOGICAL TRANSFORMATION; FOCAL ADHESION KINASE	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHORYLATION; PAXILLIN; PP125FAK	Morphological transformation of cells by the v-Src tyrosine kinase is incompletely understood, However, it is independent of nuclear functions and probably involves phosphorylation of targets associated with the cytoskeleton and focal adhesions, structures which tether the cytoskeleton to the points of cell attachment. v-Src activity both stimulates tyrosine phosphorylation of a tyrosine kinase present in focal adhesions (focal adhesion kinase or pp125(FAK)) and disrupts focal adhesions, leading to cell rounding and detachment. However, pp125(FAK) is also phosphorylated on tyrosine as a result of integrin stimulation which induces quite different biological consequences including the organisation of focal adhesions when cells spread on fibronectin (reviewed in Schaller and Parsons, 1993). To address this paradox, we examined changes in pp125(FAK) during activation and shut-off of temperature sensitive mutant v-Src proteins that induce varying degrees of transformation in chick embryo fibroblasts. An efficiently transforming v-Src mutant initially stimulated pp125(FAK) tyrosine phosphorylation, but induced subsequent pp125(FAK) degradation prior to the onset of cell rounding and detachment. v-Src mutants which are impaired in their ability to induce morphological transformation were much less efficient at inducing degradation of pp125(FAK). Moreover, cell spreading during restitution of normal morphology did not require detectable tyrosine phosphorylation of pp125(FAK), or its potential substrate paxillin, suggesting that pp125(FAK) may function more in the turnover of focal adhesions than in their assembly.			FINCHAM, VJ (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN G61 1BD,SCOTLAND.							BADER JP, 1972, J VIROL, V10, P267, DOI 10.1128/JVI.10.2.267-276.1972; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CATLING AD, 1994, J VIROL, V68, P4392, DOI 10.1128/JVI.68.7.4392-4399.1994; CATLING AD, 1993, ONCOGENE, V8, P1875; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTTBURDEN T, 1989, J CELL PHYSIOL, V141, P267, DOI 10.1002/jcp.1041410206; TURNER CE, 1993, J CELL SCI, V105, P637; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	25	80	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2247	2252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784071				2022-12-28	WOS:A1995RB70300022
J	LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA				LORENZI, MV; LONG, JE; MIKI, T; AARONSON, SA			EXPRESSION CLONING, DEVELOPMENTAL EXPRESSION AND CHROMOSOMAL LOCALIZATION OF FIBROBLAST GROWTH FACTOR-VIII	ONCOGENE			English	Note						GROWTH FACTORS; FGF-8; AIGF; EXPRESSION CLONING	CDNA CLONING; FACTOR-I; FAMILY; GENE; PROTEIN; TRANSFORMATION; RECEPTORS; SEQUENCE; MEMBER; CELLS	A mouse testis cDNA library in lambda pCEV27 eukaryotic expression vector was transfected in NIH3T3 fibroblasts and several transformed foci were identified. A plasmid with high-titered focus forming activity was rescued from one of these transformants. Structural analysis of this cDNA predicted a protein identical to androgen induced growth factor (AIGF), recently identified as the eighth member of the fibroblast growth factor (FGF) family, A 1.6 kiIobasepair transcript of the FGF-8 gene was detected in testis but not in other adult tissues analysed. During development, expression of FGF-8 was restricted to embryonic days 9 through 13 suggesting that the growth factor plays a role during a discrete stage of mouse embryogenesis, An exon-containing genomic clone of human FGF-8 was isolated and structural comparisons indicated that the gene structure of this region is highly conserved among the FGF genes. Using a panel of human-rodent somatic cell hybrids, the FGF-8 gene was localized to human chromosome 10.	MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BROOKES S, 1989, ONCOGENE, V24, P429; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KOUHARA H, 1994, ONCOGENE, V9, P455; MARICS I, 1989, ONCOGENE, V4, P335; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERGIA A, 1989, BIOCHEM BIOPH RES CO, V164, P1121, DOI 10.1016/0006-291X(89)91785-3; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLANEY BP, 1992, ENDOCRINOLOGY, V131, P2928, DOI 10.1210/en.131.6.2928; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YU YL, 1992, J EXP MED, V175, P1073, DOI 10.1084/jem.175.4.1073; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	29	46	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761105				2022-12-28	WOS:A1995QZ92600019
J	SHIRAISHI, M; SEKIYA, T				SHIRAISHI, M; SEKIYA, T			MUTATIONS IN AN ALU REPEATED SEQUENCE ASSOCIATED WITH THE DXS43 LOCUS IN HUMAN SMALL-CELL LUNG CANCERS	ONCOGENE			English	Note						HUMAN SMALL CELL LUNG CANCER; X CHROMOSOME; ALU REPEATED SEQUENCE; POINT MUTATION	CARCINOMAS; GENE; DNA	Point mutations in an Alu repeated sequence associated with the DXS43 locus were identified in two out of 10 human small cell lung cancers. Since these aberrations were identified in DNA from both metastatic lesions and primary lesions from the same patient, they would appear to have occurred at a relatively early stage. Although this sequence is not apparently associated with known genes, these tumor-specific mutations occurred at an early stage may play an important role in tumorigenesis.			SHIRAISHI, M (corresponding author), NATL CANC CTR, RES INST, DIV ONCOGENE, CHUO KU, 1-1 TSUKIJI 5 CHOME, TOKYO 104, JAPAN.							AUSTIN GE, 1993, LEUKEMIA, V7, P1445; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; IIZUKA M, 1995, INPRESS GENES CHROMO; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 1989, JPN J CANCER RES, V80, P924, DOI 10.1111/j.1349-7006.1989.tb01627.x	8	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1453	1454						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731698				2022-12-28	WOS:A1995QR65100025
J	NAKAJIMA, T; OHI, N; ARAI, T; NOZAKI, N; KIKUCHI, A; ODA, K				NAKAJIMA, T; OHI, N; ARAI, T; NOZAKI, N; KIKUCHI, A; ODA, K			ADENOVIRUS E1A-INDUCED APOPTOSIS ELICITS A STEEP DECREASE IN THE TOPOISOMERASE II-ALPHA LEVEL DURING THE LATENT PHASE	ONCOGENE			English	Article						ADENOVIRUS E1A; APOPTOSIS; TOPOISOMERASE II-ALPHA	HUMAN PAPILLOMAVIRUS TYPE-16; PROGRAMMED CELL-DEATH; P53 TUMOR-SUPPRESSOR; DNA TOPOISOMERASES; INDUCE APOPTOSIS; E6 ONCOPROTEIN; E1A PROTEINS; LP+ LOCUS; GENE; EXPRESSION	The human KB derivative cell line MA1, established by introduction of the adenovirus E1A 12S cDNA linked to the hormone-inducible promoter, elicits apoptosis upon treatment with dexamethasone. The cell lines partially refractory to apoptosis were established by introducing the expression plasmid for the adenovirus E1B 19k protein to MA1 cells. After induction of E1A in MA1 cells by dexamethasone, the level of p53 increased to about 10-fold within 24 h, and morphological changes characteristics of apoptosis began to be observed within 48h. Most of cells were killed at 72 h releasing apoptotic bodies. The level of topoisomerase II alpha began to decrease steeply within 36 h, preceding the onset of DNA degradation while its mRNA level unchanged throughout the apoptotic process, E1B 19k protected the decrease in topoisomerase II alpha as well as DNA fragmentation depending on its expression levels. Topoisomerase II alpha is induced specifically at G2/M, and computer search revealed the presence of cyclin B type destruction box in topoisomerase II alpha. These results strongly suggest that E1A or E1A stabilized p53 induces apoptosis by targeting topoisomerase II alpha to the ubiquitination pathway and E1B 19k alleviates its action,	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	Tokyo University of Science; Tokyo University of Science								ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EBERT SN, 1994, J VIROL, V68, P1010, DOI 10.1128/JVI.68.2.1010-1020.1994; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HSIANG YH, 1988, CANCER RES, V48, P3230; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V13, P4129; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MANSER T, 1984, P NATL ACAD SCI-BIOL, V81, P2470, DOI 10.1073/pnas.81.8.2470; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAKAI E, 1992, ONCOGENE, V7, P927; Sambrook J, 1989, MOL CLONING LABORATO; SCHAACK J, 1990, J VIROL, V64, P78, DOI 10.1128/JVI.64.1.78-85.1990; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WALKER PR, 1991, CANCER RES, V51, P1078; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	66	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					651	662						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862442				2022-12-28	WOS:A1995QH61200004
J	HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J				HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J			MODULATION BY COPPER OF P53 CONFORMATION AND SEQUENCE-SPECIFIC DNA-BINDING - ROLE FOR CU(II) CU(I) REDOX MECHANISM	ONCOGENE			English	Article						P53; REGULATION; REDOX; COPPER; DNA BINDING	TUMOR-SUPPRESSOR P53; GENE-EXPRESSION; WILD-TYPE; MALTOSE-BINDING; METAL-IONS; PROTEIN; FORMS; HYDROQUINONE; COMPLEXES; OXIDATION	The tumor suppressor protein p53 is a metal-binding transcription factor whose conformation and function are altered by mutation in cancers. Using murine p53 translated in vitro, we report here that concentrations of copper within the physiological range (< 30 mu M) alter the conformation of wild-type p53 and inhibit sequence-specific DNA-binding. Direct binding of copper to p53 in the form of Cu(I) was demonstrated by Electron Spin Resonance using a purified recombinant protein containing residues 1-343 of murine wild-type p53 fused to E. coli maltose binding protein. Moreover, protection against the effect of Cu(II) sulfate was achieved by the Cu(I)-specific chelator bathocuproinedisulfonic acid but not by scavengers of reactive oxygen species, suggesting that alteration of p53 by copper depends upon a Cu(II)/Cu(I) redox mechanism, but does not require the production of reactive oxygen species. Thus copper at physiological concentrations can interact with wild-type p53 and affect its DNA-binding capacity.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	HAINAUT, P (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davies, Michael J/H-4939-2011; Hainaut, Pierre/B-6018-2012; Davies, Michael/GWV-2527-2022; Davies, Michael/AGX-9184-2022	Davies, Michael J/0000-0002-5196-6919; Hainaut, Pierre/0000-0002-1303-1610; Davies, Michael/0000-0002-5196-6919				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CANTOR KP, 1966, P NATL ACAD SCI USA, V55, P642, DOI 10.1073/pnas.55.3.642; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; Goodman BA, 1970, ADV INORG CHEM RAD, V13, P135, DOI DOI 10.1016/S0065-2792(08)60336-2; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Jameson R. F, 1981, MET IONS BIOL SYST, V12, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LI YB, 1993, CARCINOGENESIS, V14, P1303, DOI 10.1093/carcin/14.7.1303; LI YB, 1993, ARCH BIOCHEM BIOPHYS, V300, P346, DOI 10.1006/abbi.1993.1047; MARGALIOTH EJ, 1983, CANCER, V52, P868, DOI 10.1002/1097-0142(19830901)52:5<868::AID-CNCR2820520521>3.0.CO;2-K; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, MET IONS BIOL SYST, V25, P105; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POSWILLO DE, 1971, NATURE, V231, P447, DOI 10.1038/231447a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SRINIVASAN R, 1993, CANCER RES, V53, P5361; WACKER WEC, 1959, J BIOL CHEM, V234, P3257; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575	38	84	84	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824276				2022-12-28	WOS:A1995QA98000004
J	KAMPS, MP; WRIGHT, DD				KAMPS, MP; WRIGHT, DD			ONCOPROTEIN E2A-PBX1 IMMORTALIZES A MYELOID PROGENITOR IN PRIMARY MARROW CULTURES WITHOUT ABROGATING ITS FACTOR-DEPENDENCE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; GROWTH-FACTOR-INDEPENDENCE; HOMEOBOX GENE; PRE-B; CHROMOSOMAL TRANSLOCATIONS; TRANSGENIC MICE; PROTEIN; EXPRESSION	E2A-PBX1 is a chimeric homeobox oncogene formed by the t(1;19) translocation of human pre-B cell acute lymphoblastic leukemia (ALL). Tn a previous study, we found that retroviral expression of E2A-Phx1 in the marrow of reconstituted mice induced the formation of acute myeloid leukemia (AML) in vivo. Here, we report that E2A-Pbx1 can also immortalize myeloid progenitors in vitro, and that the outgrowth of immortalized myeloblasts is evident only in the presence of the myeloid lymphokine, granulocyte-macrophage colony stimulating factor (GM-CSF). When cultured in the presence of GM-CSP, responsive myeloblasts from normal marrow exhibit concurrent proliferation and differentiation, and undergo terminal differentiation into non-mitotic neutrophils and macrophages within 4 weeks. Infection of identical cultures with a retrovirus encoding E2A-Pbx1 produces a rapid outgrowth of myeloid progenitors that express high levels of E2A-Pbx1 protein. A small fraction of myeloblasts in each population exhibited limited differentiation to neutrophils, and all populations of myeloblasts retained a strict dependence on GM-CSF for both survival and proliferation. This data suggests that the function of E2A-Pbx1 in leukemias is to strongly retard differentiation without affecting growth-factor dependence.			KAMPS, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA 56876-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, COLD SPRING HARB SYM, V56, P109; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1984, BLOOD, V63, P721; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUBE ID, 1991, BLOOD, V78, P2996; ERICKSON P, 1992, BLOOD, V80, P1825; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MOUTHON MA, 1993, BLOOD, V81, P647; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OVAL J, 1992, LEUKEMIA, V6, P446; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; READING CL, 1993, BLOOD, V81, P3083; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; VOGT M, 1987, ONCOGENE RES, V2, P49; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WRIGHT CVE, 1989, TRENDS BIOCHEM SCI, V14, P52, DOI 10.1016/0968-0004(89)90043-1	39	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3159	3166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936638				2022-12-28	WOS:A1994PM65800007
J	GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J				GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J			C-ERBA-ALPHA/T3R AND RARS CONTROL COMMITMENT OF HEMATOPOIETIC SELF-RENEWING PROGENITOR CELLS TO APOPTOSIS OR DIFFERENTIATION AND ARE ANTAGONIZED BY THE V-ERBA ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; B-CELLS; DEATH; BCL-2; INVITRO	In AEV-transformed erythroleukemic cells the v-erbA gene product is likely to antagonize the function of triiodothyronine (T3) and retinoic acid (RA) receptors and thereby to block cell differentiation. We have thus investigated the effects of T3 and RA on normal early erythrocytic progenitor cells. Here we show: (1) that either RA or T3 play an essential role during the early commitment to erythrocytic differentiation, (2) that both T3 and RA induce death by apoptosis and a strong inhibition of self-renewal in progenitor cells grown in the absence of differentiation-inducing agents and (3) that the v-erbA oncogene renders erythrocytic progenitor cells insensitive to apoptosis and to self-renewal inhibition induced by RA or T3. The behaviour of a nontransforming mutant of v-evbA suggests that this v-erbA-induced protection is related to its transforming potential.	UNIV JOSEPH FOURIER,CERMO,BIOL DIFFERNTIAT EPITHELIALE LAB 621,F-38041 GRENOBLE,FRANCE; MICHIGAN STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,E LANSING,MI 48824	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Michigan State University	GANDRILLON, O (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE.		Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORREA PN, 1992, INT J CELL CLONING, V10, P286, DOI 10.1002/stem.5530100506; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS CA, 1993, CANCER RES, V53, P1735; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERRE F, 1989, NUCLEIC ACIDS RES, V17, P2141, DOI 10.1093/nar/17.5.2141; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOURY MJ, 1992, EXP HEMATOL, V20, P391; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; POPOVIC WJ, 1977, J CLIN INVEST, V60, P907, DOI 10.1172/JCI108845; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Robbins J., 1986, THYROID HORMONE META, P3; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VISANI G, 1992, BRIT J HAEMATOL, V81, P444, DOI 10.1111/j.1365-2141.1992.tb08254.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; ZHOU HR, 1991, J IMMUNOL METHODS, V138, P211, DOI 10.1016/0022-1759(91)90169-G	48	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					749	758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7906409				2022-12-28	WOS:A1994MW55100009
J	THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS				THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS			INDUCTION OF TUMOR-FORMATION AND CELL-TRANSFORMATION BY POLYOMA MIDDLE T-ANTIGEN IN THE ABSENCE OF SRC	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; RAT-CELLS; ONCOGENIC TRANSFORMATION; YES PROTEIN; VIRUS; PP60C-SRC; ASSOCIATION; EXPRESSION; BINDING; MICE	In polyomavirus-transformed cells, middle T antigen binds to and activates the protein tyrosine kinase, Src. To determine whether this interaction is critical for middle T transformation, we examined the ability of middle T to transform cells that lack endogenous Src (because of a targeted disruption of both Src alleles). Infection of newborn or 2-week-old Src-negative mice with a retrovirus encoding middle T led to the induction of visceral hemangiomas that were indistinguishable from tumors in wild-type mice with respect to their morphology, frequency or latency period. In addition, middle T was able to induce foci formation on cell monolayers and colony formation in soft agar in Src-negative immortalized fibroblasts. These results indicated that Src is not essential for middle T-induced transformation of the cells targeted in these assays. To examine the protein tyrosine kinases that interact with middle T in the absence of Src, we compared the level of middle T phosphorylation in immune complex kinase assays from Src-negative and Src-positive cell lysates, and identified the middle T-associated kinases in these cells. In Src-positive cell lysates, there was a similar level of middle T phosphorylation in Src and Yes immunoprecipitates, suggesting that middle T can bind to Src and Yes to a similar extent in this cell type. Fyn immunoprecipitates displayed fourfold lower levels of middle T phosphorylation than that detected in the Src and Yes immunoprecipitates. In Src-negative cells, the level of middle T phosphorylation in Yes and Fyn immunoprecipitates was not significantly different from that detected in the Src-positive cells, suggesting that the absence of Src does not lead to a compensating increase in the proportion of middle T associated with these kinases. The level of middle T-associated phosphatidylinositol 3'-kinase was also examined since this kinase is known to interact with middle T-kinase complexes. Phosphatidylinositol 3'-kinase activity associated with middle T was reduced 30-60% in Src-negative cells, suggesting that Src contributes at least one-third of the total middle T associated in wild-type cells. Taken together, these results indicate that Src is not required for middle T-induced hemangiomas in mice or for focus induction in immortalized fibroblasts, and that the residual level of Yes, Fyn and phosphatidylinositol kinase activity associated with middle T in Src-negative cells may compensate for the absence of Src.	UNIV PENN, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST MOLEC GENET, HOUSTON, TX 77030 USA; UNIV ZURICH, DEPT PATHOL, INST NEUROPATHOL, CH-8006 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, VIENNA, AUSTRIA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION, P17; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAPTIS L, 1985, MOL CELL BIOL, V6, P1545; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1988, CELL, V52, P121; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; ZHAO YH, 1990, ONCOGENE, V5, P1629	42	37	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2521	2529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689725				2022-12-28	WOS:A1993LT36800024
J	FUJII, M; IDE, T; WADHWA, R; TAHARA, H; KAUL, SC; MITSUI, Y; OGATA, T; OISHI, M; AYUSAWA, D				FUJII, M; IDE, T; WADHWA, R; TAHARA, H; KAUL, SC; MITSUI, Y; OGATA, T; OISHI, M; AYUSAWA, D			INHIBITORS OF CGMP-DEPENDENT PROTEIN-KINASE BLOCK SENESCENCE INDUCED BY INACTIVATION OF T-ANTIGEN IN SV40-TRANSFORMED IMMORTAL HUMAN FIBROBLASTS	ONCOGENE			English	Article						CGMP DEPENDENT PROTEIN KINASE; INHIBITION; T ANTIGEN; SENESCENCE; MORTALIN	HUMAN-DIPLOID FIBROBLASTS; LARGE-TUMOR-ANTIGEN; INDEFINITE DIVISION; SIMIAN VIRUS-40; SELECTIVE INHIBITOR; CELLULAR SENESCENCE; GENETIC-ANALYSIS; HUMAN-CELLS; POTENT; MOUSE	Immortal human fibroblasts isolated following transfection with thermolabile simian virus 40 T antigen lost division potential upon shift up in temperature due to heat inactivation of the antigen. Such cells showed a concomitant change in the distribution of a mortality marker, mortalin, from a juxtanuclear cap like distribution of immortal cells to a uniform cytosolic distribution of mortal cells. We made an attempt to modulate the above inducible system of cellular senescence using various protein kinase inhibitors. Among the indolocarbazole type inhibitors tested, only KT5823, defined as a specific inhibitor of cGMP-dependent protein kinase, blocked the loss of division potential as determined by cell growth and colony forming ability. This inhibitor also prevented the above change in mortalin distribution due to temperature shift. In addition, the isoquinoline sulfonamide derivatives H8, H9, H88 and H89, all shown to inhibit cGMP-dependent protein kinase, suppressed the senescence. Inhibitors specific to other types of protein kinases, protein phosphatases or tyrosine kinases tested had no effect. Since there was no difference between the effective and non-effective inhibitors in their effects on cell cycle progression, cell cycle arrest by itself cannot account for the above phenomenon. These results suggest that a signaling pathway possibly mediated by cGMP-dependent protein kinase is involved in the induction of cellular senescence.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; HIROSHIMA UNIV, SCH MED, DEPT CELLULAR & MOLEC BIOL, HIROSHIMA 734, JAPAN; AGCY IND SCI & TECHNOL, NATL INST BIOSCI & HUMAN TECHNOL, TSUKUBA, IBARAKI 305, JAPAN; NATL INST HLTH, SHINJUKU KU, TOKYO 162, JAPAN	University of Tokyo; Hiroshima University; National Institute of Advanced Industrial Science & Technology (AIST)			Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IDE T, 1983, EXP CELL RES, V143, P343, DOI 10.1016/0014-4827(83)90060-5; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KASE H, 1988, BIOL ACTINOMYCETES 8, P159; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RANDA RL, 1989, MOL CELL BIOL, V9, P3093; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WADHWA R, 1993, J BIOL CHEM, V268, P22239; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1995, EXP CELL RES, V216, P101, DOI 10.1006/excr.1995.1013; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WYATT TA, 1991, J BIOL CHEM, V266, P21274; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	45	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					627	634						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651725				2022-12-28	WOS:A1995RQ46900003
J	POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK				POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK			EVIDENCE FOR UV INDUCTION OF CDKN2 MUTATIONS IN MELANOMA CELL-LINES	ONCOGENE			English	Article						CDKN2 GENE; DIPYRIMIDINE; MELANOMA; TANDEM MUTATION; UV RADIATION	FAMILIAL MELANOMA; P53 MUTATIONS; STRAND BIAS; GENE; SKIN; SPECIFICITY; REPAIR; LOCUS; ASSIGNMENT; HOTSPOTS	The CDKN2 gene, encoding the cyclin dependent kinase inhibitor p16, is a tumour suppressor gene involved in melanoma and maps to chromosome band 9p22. Mutations or interstitial deletions of this gene have been found both in the germline of familial melanoma cases and somatically in melanoma cell lines. Previous mutation analyses of melanoma cell lines have indicated a high frequency of C:G to T:A transitions, with all of these mutations occurring at dipyrimidine sites. Including three melanoma cell lines carrying tandem CC to TT mutations, the spectrum of mutations so far reported indicates a possible role for u.v. radiation in the mutagenesis of this gene in some tumours. To further examine this hypothesis we have characterised mutations of the CDKN2 gene in 30 melanoma cell lines. Nineteen lines carried complete or partial homozygous deletions of the gene. Of the remaining cell lines, eight were shown by direct sequencing of PCR products from exon 1 and exon 2 to carry a total of nine different mutations of CDKN2. Two cell lines carried tandem CC to TT mutations and a high rate of C:G to T:A transitions was observed. This study provides further evidence for the role of u.v. light in the genesis of melanoma, with one target being the CDKN2 tumour suppressor gene.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES LABS,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			Parsons, Peter G/H-8163-2015; hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	Parsons, Peter G/0000-0002-0473-3346; hayward, nicholas k/0000-0003-4760-1033; Pollock, Pamela/0000-0001-8420-1026				AIRNS P, 1994, SCIENCE, V265, P415; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHENG JQ, 1994, CANCER RES, V54, P5547; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRANKLIN WA, 1985, NUCLEIC ACIDS RES, V13, P5317, DOI 10.1093/nar/13.14.5317; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GRUIS NA, 1993, MELANOMA RES, V3, P271; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1995, SCIENCE, V267, P16, DOI 10.1126/science.267.5194.16; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LIU QY, 1995, ONCOGENE, V10, P619; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MORI T, 1994, CANCER RES, V54, P3396; MURTY VVVS, 1992, GENOMICS, V13, P227, DOI 10.1016/0888-7543(92)90228-K; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1964, NATURE, V368, P753; OHTA M, 1994, CANCER RES, V54, P5269; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	39	109	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					663	668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651729				2022-12-28	WOS:A1995RQ46900007
J	KIM, HA; ROSENBAUM, T; MARCHIONNI, MA; RATNER, N; DECLUE, JE				KIM, HA; ROSENBAUM, T; MARCHIONNI, MA; RATNER, N; DECLUE, JE			SCHWANN-CELLS FROM NEUROFIBROMIN DEFICIENT MICE EXHIBIT ACTIVATION OF P21(RAS), INHIBITION OF CELL-PROLIFERATION AND MORPHOLOGICAL-CHANGES	ONCOGENE			English	Article						NEUROFIBROMATOSIS TYPE 1 (NF1); NF1-TRANSGENIC MOUSE; GLIAL GROWTH FACTOR (GGF); DORSAL ROOT GANGLIA (DRG); SCHWANNOMA	TYPE-1 GENE-PRODUCT; GROWTH-FACTOR; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CATALYTIC DOMAIN; PROTEIN PRODUCT; RAS PROTEINS; PC12 CELLS; NF1 GENE; DIFFERENTIATION; IDENTIFICATION	Schwann cells are thought to be abnormal in type 1 neurofibromatosis (NF1) and to contribute to the formation of benign and malignant tumors in this disease. To test the role of the NF1 gene product neurofibromin as a Ras-GTPase activating protein in Schwann cells, and to study the effect of the loss of neurofibromin on Schwann cell. proliferation, we isolated Schwann cells from mice with targeted disruption of NET. The properties of these neurofibromin deficient cells were strikingly similar to those of v-ras expressing rat Schwann cells with normal levels of neurofibromin. The similarities included: growth inhibition, noted as a decrease in cell division in response to glial growth factor 2 (GGF2) and of neuronal contact; morphological changes such as the appearance of elaborated processes; and elevated levels of Ras-GTP, Furthermore, Ras-GTP levels in the neurofibromin deficient Schwann cells were consistently elevated in response to GGFZ treatment. In contrast to these results, introduction of v-ras into a Schwannoma cell line (RN22) led to cell transformation. We conclude that neurofibromin functions as a major regulator of Ras-GTP in Schwann cells; however, mutation in NF1 by itself is unlikely to explain the hyperplasia observed in Schwann cell tumors in NF1 disease.	UNIV CINCINNATI,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,CINCINNATI,OH 45267; CAMBRIDGE NEUROSCI,CAMBRIDGE,MA 02139; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				RATNER, NANCY/0000-0001-5030-9354	NCI NIH HHS [CA59268] Funding Source: Medline; NINDS NIH HHS [NS 28840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARON P, 1991, ACTA NEUROPATHOL, V81, P491, DOI 10.1007/BF00310128; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1990, EMBO J, V12, P1923; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1983, DEV REGENERATING VER, P71; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; Davis FA, 1940, ARCH OPHTHALMOL-CHIC, V23, P957, DOI 10.1001/archopht.1940.00860131081007; Davis FA, 1940, ARCH OPHTHALMOL-CHIC, V23, P735, DOI 10.1001/archopht.1940.00860130827006; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOTHI NA, 1993, DEV NEUROSCI-BASEL, V15, P10, DOI 10.1159/000111311; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; GIBBS JB, 1985, TIBS, P355; GOLUBIC M, 1992, ONCOGENE, V7, P2151; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P1300; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; HANSSON HA, 1988, SCAND J PLAST RECONS, V22, P7, DOI 10.3109/02844318809097929; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; Kleitman N, 1991, CULTURING NERVE CELL, P337; KRASNOSELSKY A, 1994, J NEUROSCI, V14, P7284; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEBLANC AC, 1992, MOL BRAIN RES, V12, P31, DOI 10.1016/0169-328X(92)90065-J; LEMKE GE, 1984, J NEUROSCI, V4, P75; LEVI ADO, 1994, IN PRESS J NERUROSCI; LONARDO F, 1990, New Biologist, V2, P992; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MUROYA K, 1992, ONCOGENE, V7, P277; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; ORRURTREGER A, 1952, P NATL ACAD SCI USA, P1746; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELTONEN J, 1984, ACTA NEUROPATHOL, V63, P269, DOI 10.1007/BF00687332; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; PLEASURE D, 1985, DEV NEUROSCI-BASEL, V7, P364, DOI 10.1159/000112303; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; RAFF MC, 1978, NATURE, V273, P672, DOI 10.1038/273672a0; RATNER N, 1986, J CELL BIOL, V103, P159, DOI 10.1083/jcb.103.1.159; RATNER N, 1985, J CELL BIOL, V101, P744, DOI 10.1083/jcb.101.3.744; RATNER N, 1990, ANN NEUROL, V27, P298, DOI 10.1002/ana.410270312; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHUBERT D, 1979, NATURE, V249, P224; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SOBUE G, 1984, SCIENCE, V224, P72, DOI 10.1126/science.6322307; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBSTER HF, 1984, PERIPHERAL NEUROPATH, P243; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	77	120	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					325	335						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624147				2022-12-28	WOS:A1995RK95700013
J	JONES, DE; CUI, DM; MILLER, DM				JONES, DE; CUI, DM; MILLER, DM			EXPRESSION OF BETA-GALACTOSIDASE UNDER THE CONTROL OF THE HUMAN C-MYC PROMOTER IN TRANSGENIC MICE IS INHIBITED BY MITHRAMYCIN	ONCOGENE			English	Article						C-MYC; TRANSCRIPTION; TRANSGENIC; MITHRAMYCIN	RNA STABILITY INVITRO; TRANSCRIPTIONAL ACTIVITY; GENE; BINDING; CELLS; ONCOGENE; PROTEIN; INVIVO; MAX	In order to assess the functional contribution of the human c-myc promoter region in the expression of the c-myc gene, transgenic mouse lines containing a bacterial lac Z gene encoding beta-galactosidase under the control of the human c-myc protooncogene promoter were generated. Transgenic mouse embryos heterozygous for the human c-myc Z transgene demonstrate high amounts of beta-galactosidase activity as early as day 11 of embryogenesis by histochemical staining of whole embryos using 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) as substrate, localizing specifically to early spinal cord tissue. beta-galactosidase activity can be demonstrated by histochemical staining in brain tissue of day 14 embryos, localizing mainly to the prefrontal cortex region, while relative amounts of beta-galactosidase in spinal cord tissue are reduced. Determination of specific activity of beta-galactosidase using resorufin-beta galactopyranoside as substrate in homogenates of whole embryos heterozygous for the human c-myc/lac Z transgene demonstrates significantly elevated beta-galactosidase activity over control embryos in day 11 and day 14 embryos. Surprisingly, cell homogenates of brain tissue from adult G(1) generation mice heterozygous for the human c-myc/lac Z transgene demonstrate greater than 10-foId higher specific activity of beta-galactosidase over normal control brain tissue. Specific inhibition of the c-myc/lac Z transgene was also demonstrated in developing embryos using mithramycin given at a dose of 150 mu g kg(-1) d(-1) intraperitoneal to pregnant females on days 7-13 of gestation. Both histochemical staining of beta-galactosidase and specific activity assays of day 14 embryos demonstrated significantly lower levels of beta-galactosidase than untreated controls. These results are unique since we are able to detect expression of beta-galactosidase in developing embryonic central nervous system tissue along with adult brain tissue of animals carrying the human c-myc Z transgene and we are able to specifically inhibit expression of the transgene using mithramycin administered in utero.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOCHEM & MOLEC GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, BOLDEN LAB, BIRMINGHAM, AL 35294 USA; VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA-42664, CA-42337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042664, R01CA042337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAMPBELL VW, 1994, AM J MED SCI, V307, P167, DOI 10.1097/00000441-199403000-00002; CHANG Y, 1991, ONCOGENE, V6, P1979; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAVENU A, 1994, ONCOGENE, V9, P527; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; MORELLO D, 1993, ONCOGENE, V8, P1921; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; RAY R, 1990, AM J MED SCI, V300, P203, DOI 10.1097/00000441-199010000-00001; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; Sambrook J, 1989, MOL CLONING LABORATO; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7	28	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784080				2022-12-28	WOS:A1995RE54300007
J	DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP				DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP			TTF, A GENE ENCODING A NOVEL SMALL G-PROTEIN, FUSES TO THE LYMPHOMA-ASSOCIATED LAZ3 GENE BY T(3-4) CHROMOSOMAL TRANSLOCATION	ONCOGENE			English	Article						LAZ3 BCL6 GENE; LYMPHOMA; TRANSLOCATION (3-4); SMALL G PROTEIN; LAZ3 FUSION GENE	GTP-BINDING-PROTEIN; NON-HODGKINS-LYMPHOMA; RAS GENE; BURKITTS-LYMPHOMA; FAMILY; EXPRESSION; CLONING; CDNAS; PURIFICATION; BREAKPOINT	We have previously shown that the LAZ3/BCL6 gene encoding a potential transcription factor, is disrupted in B-diffuse large cell non-Hodgkin's lymphomas (NHL) with 3q27 chromosomal abnormalities involving the immunoglobulin (IG) genes. However, LAZ3 rearrangement also occurs in NHL bearing 3q27 translocations without involvement of the IG genes: for example the VAL cell line exhibits t(3;4)(q27;p11). In the present work we have used a RT-PCR method to detect and to sequence the LAZ3 mRNA products from the VAL cell line. We report that the consequence of the t(3;4) is the expression of a chimeric transcript of LAZ3 with a new gene encoding a small G-like protein, termed TTF (Translocation Three Four). Nucleotide sequence analysis of a 1.4 kb cDNA predicts that the TTF gene encodes a protein of 191 amino-acids similar to members of the RAS superfamily including HRAS (27% identical), RAB1A (30% identical) and RHO proteins: the human RAC1, RHOB and CDC42Hs proteins (respectively 43, 44 and 45% identical) and the yeast RHO2 protein (44% identical). Unlike most other small G proteins which are expressed ubiquitously, TTF was transcribed only in hemopoietic cells as a 2.2 kb transcript. TTF may define a new subgroup of RHO-like proteins.	INST RECH CANC LILLE, INSERM, U124, F-59045 LILLE, FRANCE; CTR HENRI BECQUEREL, F-76038 ROUEN, FRANCE; CTR REG TRANSFUS SANGUINE, DEPT CYTOGENET, F-76232 BOIS GUILLAUME, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASTARD C, 1992, BLOOD, V79, P2527; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1993, HDB EXPT PHARM, V108, P159; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FUKUHARA S, 1979, CANCER RES, V39, P3119; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MIKI T, 1994, BLOOD, V83, P26; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	42	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2171	2178						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784061				2022-12-28	WOS:A1995RB70300012
J	HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I				HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I			HUMAN ERG IS A PROTOONCOGENE WITH MITOGENIC AND TRANSFORMING ACTIVITY	ONCOGENE			English	Article						ETS; TRANSCRIPTION FACTORS; TUMOR; CHROMOSOME 21; CHROMOSOME TRANSLOCATION	ETS-RELATED GENE; DNA-BINDING; TRANSCRIPTION FACTOR; LEUKEMIA-VIRUS; DOWN-SYNDROME; C-ETS-1 PROTOONCOGENE; FLI-1 GENE; FAMILY; EXPRESSION; SEQUENCE	The ETS related gene, ERG, is one of 20 or more genes belonging to the ETS family of transcription factors, Translocation of the ERG gene t(21;22) results in the chimeric fusion transcript seen in approximately 10% of Ewings sarcomas, In addition, recent studies have shown that a reciprocal translocation t(21;16) of ERG gives rise to two aberrant transcripts seen in some forms of acute myeloid leukaemia. ln vitro studies have linked the up regulation of ERG expression with stromal cell independence in erythroleukemic clones and shown that the ERG related genes ETS1 and ETS2 have mitogenic and transforming activity when overexpressed in NIH3T3 cells, Interestingly ERGB/FLI-1, which is also involved in Ewings sarcoma translocations and shares a very high sequence identity with ERG has been reported to be unable to transform NIH3T3 cells, In this study we investigate the effects of overexpression of ERG on cell proliferation, factor dependence, growth in soft agar and tumorigenesis in nude mice, An ERG expression construct with the human ERG2 cDNA driven by the sheep metallothionein la promoter (sMTERG) was transfected into NIH3T3 cells. Clonal cell lines overexpressing ERG were established. The cell lines became morphologically altered, grew in low serum and serum free media and gave rise to colonies in soft agar suspension. Furthermore, we demonstrate that after subcutaneous injection these clones grow as solid tumors in nude mice, These data demonstrate that c-ERG is a proto-oncogene capable of transforming NM3T3 cells. Therefore, overexpression or inappropriate expression of ERG may contribute to oncogenesis.	MONASH UNIV, MONASH MED CTR, INST REPROD & DEV, MOLEC EMBRYOL & BIRTH DEFECTS LAB, CLAYTON, VIC 3168, AUSTRALIA	Monash University			Hart, Adam/C-1196-2011; Kola, Ismail/C-5254-2013; Hertzog, Paul/I-7053-2013	Hart, Adam/0000-0001-8129-3877; Hertzog, Paul/0000-0002-1373-8472				ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; ISELIUS L, 1990, HUM GENET, V85, P477; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1989, REPROD FERT DEVELOP, V1, P81, DOI 10.1071/RD9890081; KORENBERG JR, 1990, AM J HUM GENET, V47, P236; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; Maniatis T., 1982, MOL CLONING; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V56, P1175; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROBISON LL, 1992, LEUKEMIA, V6, P5; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; TYMMS M, 1995, IN VITRO TRANSCRIPTI, P31; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	50	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731694				2022-12-28	WOS:A1995QR65100021
J	BUCKLE, RS; MECHALI, M				BUCKLE, RS; MECHALI, M			ANALYSIS OF C-MYC AND MAX BINDING TO THE C-MYC PROMOTER - EVIDENCE THAT AUTOSUPPRESSION OCCURS VIA AN INDIRECT MECHANISM	ONCOGENE			English	Note						C-MYC/MAX; AUTOSUPPRESSION; DNA BINDING PROTEINS; XENOPUS; DNA REPLICATION	DNA-BINDING; REPLICATION ORIGIN; PROTEIN; GENE; SEQUENCE; AUTOREGULATION; TRANSCRIPTION; ONCOPROTEIN; ASSOCIATION; ACTIVATION	c-myc negatively autoregulates its expression at the level of transcriptional initiation, although the precise mechanism remains debated. While conclusive evidence for c-Myc binding in its own promoter has not been found, it has been proposed that c-Myc binds to a site upstream of the human c-myc gene which may also be a component of a replication origin (Ariga et al., 1989). In an attempt to clarify this issue, sequences flanking the c-myc gene were screened for c-Myc or Max binding sites using a novel procedure to facilitate the detection of DNA binding dependent upon long distance interactions or DNA secondary structure, Since the sequence specificity of DNA binding proteins may also be mediated by interaction with other proteins or by protein modification, this affinity capture assay was used in conjunction with nuclear extracts, potentially allowing the selection of novel in vivo DNA binding spcificities. Using conditions that gave strong binding to an internal control sequence, c-Myc or Max binding elements were not detected in genomic sequences extending 5.4 kb upstream of the Xenopus c-myc gene. Identical results were obtained using both purified proteins and a variety of nuclear extracts, suggesting c-myc autosuppression most likely involves an indirect pathway.	INST JACQUES MONOD,MOLEC EMBRYOL UNIT,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cleveland J L, 1988, Oncogene Res, V3, P357; CROUCH DH, 1990, ONCOGENE, V5, P683; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V5, P1475; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HALZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6612; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P85; KITAURA H, 1991, FEBS LETT, V290, P147, DOI 10.1016/0014-5793(91)81246-5; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4916; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	40	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1249	1255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700652				2022-12-28	WOS:A1995QN35300029
J	WHITEHEAD, I; KIRK, H; KAY, R				WHITEHEAD, I; KIRK, H; KAY, R			RETROVIRAL TRANSDUCTION AND ONCOGENIC SELECTION OF A CDNA-ENCODING DBS, A HOMOLOG OF THE DBL GUANINE-NUCLEOTIDE EXCHANGE FACTOR	ONCOGENE			English	Article						GUANINE NUCLEOTIDE EXCHANGE FACTOR; DBL ONCOGENE; RETROVIRAL VECTOR	VAV PROTOONCOGENE; MOLECULAR-CLONING; SH3 DOMAINS; PROTEIN; RAS; GENE; EXPRESSION; PRODUCT; REGION; CELLS	A retroviral vector was used to transfer a large library of cDNAs from the 32D murine hemopoietic cell line to NIH3T3 fibroblasts, for the purpose of Selecting cDNAs that induce oncogenic transformation. One highly transformed colony arising in the infected NIH3T3 cell culture contained a provirus with a 1900 bp cDNA insert. After recovery and reincorporation into a retroviral vector, this cDNA induced rapid morphological transformation add proliferation when expressed in NIH3T3 or C3H10T1/2 fibroblast cell lines. The transforming cDNA encoded a protein, designated Dbs, which had a region of high sequence similarity to the Dbl proto-oncogene. This region included motifs characteristic of the CDC24 family of guanine nucleotide exchange factors, and an adjacent pleckstrin homology domain. Dbs was distinguished from Dbl by an N-terminal extension and the presence of an SH3 domain at its C terminus. Deletions of the Dbs-encoding; cDNA demonstrated that transformation of NIH3T3 cells required intact exchange factor and pleckstrin homology domains, but dial not require the SH3 domain. In contrast to Dbl, the N-terminal sequences of Dbs did hot suppress its transforming activity. The Dbs gene was expressed at low levels in several murine hemopoietic cell lines and in thymus and spleen, and at higher levels in other tissues, particularly in brain. Dbs may be one of a large family of exchange factors which provide cell-type specific pathways for regulating proliferation via the activation of Ras-like proteins.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V5Z 4E6,CANADA; BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA	University of British Columbia; British Columbia Cancer Agency								ADAMS JM, 1992, ONCOGENE, V7, P611; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOLDSCHMIDTCLER.PJ, 1992, CURR BIOL, V2, P669; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HESITERKAMP N, 1993, J BIOL CHEM, V268, P16903; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1989, ONCOGENE, V4, P1067; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1993, NUCLEIC ACIDS RES, V11, P2427; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TOKSOZ D, 1994, ONCOGENE, V9, P621; TRAHEY M, 1968, SCIENCE, V242, P1697; VOGELI G, 1985, ANAL BIOCHEM, V151, P442, DOI 10.1016/0003-2697(85)90202-7; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116	57	75	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					713	721						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862449				2022-12-28	WOS:A1995QH61200011
J	DAS, GC; SHIVAKUMAR, CV; TODD, SD				DAS, GC; SHIVAKUMAR, CV; TODD, SD			CELL-SPECIFIC MODULATION OF THE PAPOVAVIRUS PROMOTERS BY TUMOR-SUPPRESSOR PROTEIN P53 IN THE ABSENCE OF LARGE T-ANTIGEN	ONCOGENE			English	Article						P53; TUMOR-SUPPRESSOR PROTEIN; PAPOVAVIRUS PROMOTERS; TRANSACTIVATION; GENE REGULATION BY P53	WILD-TYPE P53; EMBRYONAL CARCINOMA-CELLS; POLYOMAVIRUS BK INVITRO; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; SV40-TRANSFORMED CELLS; IDENTIFICATION; SEQUENCES; INDUCTION; ENHANCER	The oncoproteins from several DNA tumor viruses form a complex with p53 and inactivate its function. Wild-type p53 is a transcription factor and can regulate eukaryotic promoters both positively and negatively. To elucidate the basis of the opposing functions and to understand whether and how oncoprotein synthesis in papovaviruses is regulated by p53, we studied modulation of the early promoters of SV40, polyomavirus and BK virus in the absence of the interfering effect of viral large T antigens. We here show that murine p53 can regulate the viral promoters either positively or negatively depending on the cell type. A temperature-sensitive mutant p53, 135 Val, at 37 degrees C also showed a cell-specific effect. These results suggest that promoter activation by p53 is not solely determined by p53 binding site, but host factors modulate p53's transactivation function. A TATA-less polyomavirus Late promoter was also repressed in HeLa cells and the level of repression was much less in the presence of active early promoter. As p53 and 135 Val were overexpressed to similar extent in different transfected cell Lines, variation in transactivation function is not due to the difference in the level of expressed protein. Our observations thus suggest that p53 interactions with cellular factors in addition to the TATA binding protein (TBP) are important for activator and repressor functions of p53. Well-defined viral promoters could thus provide us with an important tool for the identification and characterization of cellular factors that modulate p53-binding dependent gene regulation in animal cells.			DAS, GC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC BIOL,POB 2003,TYLER,TX 75710, USA.				NCI NIH HHS [CA 47611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABORTY T, 1989, MOL CELL BIOL, V9, P3821, DOI 10.1128/MCB.9.9.3821; CHAKRABORTY T, 1991, J GEN VIROL, V72, P1935, DOI 10.1099/0022-1317-72-8-1935; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DASGUPTA S, 1993, J GEN VIROL, V74, P597, DOI 10.1099/0022-1317-74-4-597; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEYERLE KL, 1987, J VIROL, V62, P3378; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1049; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1991, SCIENCE, V256, P827; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MEITZ JA, 1992, EMBO J, V11, P5013; MICHALOVITZ D, 1990, CURR OPIN CELL BIOL, V3, P282; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1992, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMBROOK J, 1993, MOL CLONING LABORATO; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P10277; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEGHAL PB, 1993, ONCOGENE, V8, P3417; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1994, J GEN VIROL, V75, P1281, DOI 10.1099/0022-1317-75-6-1281; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSENG RW, 1988, J VIROL, V62, P2896, DOI 10.1128/JVI.62.8.2896-2902.1988; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZAMBETTI ZP, 1992, GENE DEV, V6, P1131	58	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					449	455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845669				2022-12-28	WOS:A1995QF64800005
J	BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS				BLAYDES, JP; SCHLUMBERGER, M; WYNFORDTHOMAS, D; WYLLIE, FS			INTERACTION BETWEEN P53 AND TGF-BETA-1 IN CONTROL OF EPITHELIAL-CELL PROLIFERATION	ONCOGENE			English	Article						P53; TGF-BETA; RAS; THYROID; IMMORTALIZATION	TRANSFORMING GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; FACTOR-BETA; MURINE KERATINOCYTES; MUTANT P53; TGF-BETA; LARGE-T; RAS ONCOGENE; EXPRESSION; CARCINOMA	Although loss of sensitivity to transforming growth factor beta (TGF beta) may be a key step in the escape of epithelial tumours from normal growth control, the intracellular signals determining responsiveness remain controversial, particularly the role of p53. We have investigated this question using thyroid epithelial lines as a model. We analysed (i) human thyroid cancer cell lines having either wild-type (wt) or mutant p53; (ii) rat thyroid lines derived by spontaneous immortalisation following introduction of mutant H-ras, which exhibit high levels of wt p53 but loss of p53-mediated cell-cycle control. Loss of response to TGF beta 1 was found in all human lines bearing mutant p53, and in the majority of the functionally equivalent rat lines, consistent with a role of wt p53 in mediating response, However, introduction of a dominant negative p53 mutant into TGF beta 1 responsive human lines containing wt p53 did not reduce responsiveness, demonstrating that p53 function is not necessary for TGF beta 1 response. On the other hand, expression of a temperature-sensitive (ts) p53 gene in a partially-responsive rat line demonstrated a highly significant modulation of TGF beta response, which fell from 65% inhibition of H-3-thymidine labelling index at 32.5 degrees C (wt p53 conformation) to only 14% at 37.5 degrees C (mutant conformation), The results suggest that p53 and TGF beta generate separate but interacting inhibitory signals, i.e. that p53 modulates but does not mediate TGF beta response. This conclusion explains previous conflicting data and is consistent with current models of cell cycle control by multiple inhibitors of cyclin-dependent kinases.	UNIV WALES COLL MED,DEPT PATHOL,THYROID TUMOUR BIOL RES GRP,CANC RES CAMPAIGN,CARDIFF CF4 4XN,S GLAM,WALES; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Cardiff University; UNICANCER; Gustave Roussy			Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ANTONINI P, 1993, CANCER GENET CYTOGEN, V67, P117, DOI 10.1016/0165-4608(93)90163-G; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BRASH DE, 1987, MOL CELL BIOL, V7, P2031, DOI 10.1128/MCB.7.5.2031; BURNS JS, 1989, BRIT J CANCER, V59, P755, DOI 10.1038/bjc.1989.158; BURNS JS, 1992, MOL CARCINOGEN, V6, P129, DOI 10.1002/mc.2940060208; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACDONALD RJ, 1987, GUIDE MOL CLONING TE, P219; MANNING AM, 1991, ONCOGENE, V6, P1471; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; ONG G, 1991, ONCOGENE, V6, P761; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REISS M, 1990, CANCER RES, V50, P6641; REISS M, 1993, CANCER RES, V53, P899; REISS M, 1989, J INVEST DERMATOL, V93, P136, DOI 10.1111/1523-1747.ep12277384; SHIPLEY GD, 1986, CANCER RES, V43, P5915; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WILLIAMS NW, 1989, EXP CELL RES, V184, P316, DOI 10.1016/0014-4827(89)90331-5; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; WYLLIE FS, IN PRESS ONCOGENE; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	52	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					307	317						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838530				2022-12-28	WOS:A1995QC62400010
J	KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R				KIESS, M; SCHARM, B; AGUZZI, A; HAJNAL, A; KLEMENZ, R; SCHWARTEWALDHOFF, I; SCHAFER, R			EXPRESSION OF RIL, A NOVEL LIM DOMAIN GENE, IS DOWN-REGULATED IN HRAS-TRANSFORMED CELLS AND RESTORED IN PHENOTYPIC REVERTANTS	ONCOGENE			English	Article						GENETIC SUPPRESSION; CELLULAR TRANSFORMATION; ZINC FINGER PROTEIN; IN SITU HYBRIDIZATION	CYSTEINE-RICH PROTEIN; RAT EMBRYONIC FIBROBLASTS; MESSENGER-RNA; INTESTINAL PROTEIN; TRANSGENIC MICE; LYSYL OXIDASE; DNA-BINDING; SUPPRESSION; ELEGANS; MOTIF	Several candidate genes involved in the maintenance of normal growth control (H-rev) were identified by differential expression cloning on the assumption that they are expressed in phenotypically normal rat cells and repressed in closely related H-ras transformed cells. Previously the genes coding for lysyl oxidase (H-rev142) and for an 18K-protein of unknown function (H-rev107) were recovered as cDNAs by subtraction cloning. Here we describe the identification and expression pattern of ril, a novel member of the heterogeneous group of genes encoding proteins with LIM/double zinc finger domains. The ril gene is expressed in normal fibroblasts and downregulated in H-uas-transformed derivatives. Expression is restored in several independent phenotypic revertants derived from H-ras transformed cells. The predicted protein product of ril harbors a single LIM domain but lacks a homeodomain. The ril gene is highly conserved during evolution and is transcribed in various normal cell lines. Northern blot analysis and in situ hybridization studies showed that ril is expressed in meiotic spermatocytes, in somites of developing mice, and in a side variety of tissues of adult mice.	UNIV ZURICH,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich				Aguzzi, Adriano/0000-0002-0344-6708; Schafer, Reinhold/0000-0001-7952-2124				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALTZ R, 1992, PLANT CELL, V4, P1465, DOI 10.1105/tpc.4.12.1465; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4371; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; HENDERSON C, 1990, J HISTOTECHNOL, V12, P123; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLAUER L, 1993, ONCOGENE, V8, P2531; NALIK P, 1989, MOL CELL ENDOCRINOL, V62, P235, DOI 10.1016/0303-7207(89)90010-5; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; SCHWARTEWALDHOF.I, 1994, ONCOGENE, V9, P899; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TURNER CE, 1994, J CELL SCI, V107, P1583; WANG XK, 1992, J BIOL CHEM, V267, P9176; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	56	74	79	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					61	68						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824279				2022-12-28	WOS:A1995QA98000008
J	SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW				SLACK, RS; CRAIG, J; COSTA, S; MCBURNEY, MW			ADENOVIRUS 5 E1A INDUCED-DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS REQUIRES BINDING TO P300	ONCOGENE			English	Article						E1A MUTATIONS; ENDODERM; RETINOIC ACID; RETINOBLASTOMA PROTEIN	F9 TERATOCARCINOMA CELLS; REGION 1A PROTEINS; MOUSE PGK-1 GENE; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; DNA-SYNTHESIS; TRANSFORMATION; POLYPEPTIDES; EXPRESSION; REPRESSION	We transfected P19 embryonal carcinoma (EC) cells with genes encoding the adenovirus 5 E1A products. Expression of either the 12S or 13S transcripts yielded P19 cells either incapable of proliferating or able to proliferate but having lost the characteristics of the EC cell parent. The proliferating clones of E1A expressing P19 cells were incapable of differentiating in response to retinoic acid or dimethyl sulfoxide, no longer expressed the SSEA-1 surface antigen characteristic of EC cells, and did express cytokeratin 55, a marker of epithelial tissues. We used a number of 12S E1A constructs carrying deletions in the first exon and found that the effects on P19 cell growth and differentiated properties were lost with alterations affecting either the N terminal 25 amino acids or the CR1 region of the E1A protein. Both regions are required to bind the cellular p300 protein that we showed is present in P19 cells. We conclude that binding of E1A to the p300 protein in P19 cells results in the loss of EC cell characteristics.	UNIV OTTAWA, DEPT MED, OTTAWA, ON K1H 8M5, CANADA	University of Ottawa				Slack, Ruth/0000-0002-1552-2835				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOCCO JL, 1993, ONCOGENE, V8, P2977; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DYSON N, 1992, CANCER SURV, V12, P161; EAGEN C, 1988, MOL CELL BIOL, V8, P3955; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRIS JF, 1984, J IMMUNOL, V132, P2502; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1988, VIROLOGY, V163, P494; JELMSA TN, 1989, VIROLOGY, V171, P120; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCBURNEY MW, 1994, UNPUB; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SLACK RS, 1993, ONCOGENE, V8, P1585; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; ULFENDAHL PJ, 1987, EMBO J, V6, P2037, DOI 10.1002/j.1460-2075.1987.tb02468.x; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	43	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824272				2022-12-28	WOS:A1995QA98000003
J	MORRISON, BW; LEDER, P				MORRISON, BW; LEDER, P			NEU AND RAS INITIATE MURINE MAMMARY-TUMORS THAT SHARE GENETIC-MARKERS GENERALLY ABSENT IN C-MYC AND INT-2-INITIATED TUMORS	ONCOGENE			English	Article							TRANSGENIC MICE; BREAST-CANCER; RETINOIC ACID; HA-RAS; MOUSE; ONCOGENE; SEQUENCE; PROTEIN; CELLS; TUMORIGENESIS	We have previously shown that each of four activated oncogenes (c-myc, nea, ras, and int-2) can serve as transgenic initiators of morphologically distinct adenocarcinomas of the murine mammary gland. Since abnormalities of these oncogenes are found frequently in human breast cancers, such differences are of particular interest. Thus, the distinctiveness of each murine tumor type might reflect a relationship between a specific oncogene and a susceptible target cell or might reflect distinctive changes brought about by the idiosyncratic action of each oncogene. We have identified six genes (two of them novel) expressed in tumors initiated by nea, but usually absent from tumors initiated by c-myc. The expression of these genes (kappa-casein, transferrin, cellular retinol binding protein I (CRBPI), WDNM1, and the two novel ones) cannot be induced in c-myc-initiated tumors by the introduction of an activated nea oncogene nor can their expression be inhibited in nea-initiated tumors by the introduction of c-myc. Therefore, these genes appear to represent markers of a cell type preferentially transformed by neu. Further analysis reveals that the six markers are also expressed by ras-initiated mammary tumors, but not by int-2 initiated tumors suggesting that neu/ras-initiated tumors share a common cellular lineage and/or a common signal transduction pathway. Interestingly, one of the novel marker genes (Mat-8) appears to encode a cell-surface chloride channel and the other, a secreted protein with homologies to glycosyl hydrolases, both of which might be useful for the diagnosis and treatment of specific mammary tumors.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute					NCI NIH HHS [K11 CA01578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRES AC, 1994, ONCOGENE, V9, P1461; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1993, CANCER SURV, V16, P97; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; CHEN LH, 1987, J BIOL CHEM, V262, P17247; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEAR TN, 1988, CANCER RES, V48, P5203; DEAR TN, 1991, BIOCHEM BIOPH RES CO, V176, P247, DOI 10.1016/0006-291X(91)90916-U; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAKALA BE, 1993, J BIOL CHEM, V28, P25803; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MORRISON BW, 1994, HEMATOL ONCOL CLIN N, V8, P15, DOI 10.1016/S0889-8588(18)30185-0; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; NYIRKOS P, 1990, BIOCHEM J, V268, P265; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; ROSEN PP, 1991, BREAST DISEASES, P245; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGATTO O, 1993, ONCOGENE, V8, P2105; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; THOMPSON MD, 1985, DNA-J MOLEC CELL BIO, V4, P263, DOI 10.1089/dna.1985.4.263; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	50	206	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3417	3426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970700				2022-12-28	WOS:A1994PT39200002
J	MARQUARDT, B; FRITH, D; STABEL, S				MARQUARDT, B; FRITH, D; STABEL, S			SIGNALING FROM TPA TO MAP KINASE REQUIRES PROTEIN-KINASE-C, RAF AND MEK - RECONSTITUTION OF THE SIGNALING PATHWAY IN-VITRO	ONCOGENE			English	Article							PHORBOL ESTER; GROWTH-FACTORS; ONCOGENIC P21(RAS); RAT-1 FIBROBLASTS; THREONINE KINASE; IN-VITRO; ACTIVATION; PHOSPHORYLATION; CELLS; TYROSINE	The phorbol ester PMA/TPA (phorbol 12-myristate 13-acetate) is a potent tumor promoter which mimicks distinct intracellular signalling events triggered by activated growth factor receptors, e.g. the activation of MAP kinases. The largest known family of TPA-binding proteins comprise members of the protein kinase C (PKC) family although other TPA-binding proteins outside the PKC family have recently been identified. In this report we addressed the mechanism and the pathway by which TPA induces the activation Of MAPkinases. Using recombinant proteins and in vitro phosphorylation reactions we identified the components in the signal transduction pathway from TPA to MAPkinase and we show that the activation of MAPkinase by TPA requires the presence of protein kinase C, c-raf and the MAPkinase activator MEK. We also find that the activation of raf autophosphorylation in vitro correlates with the ability of Raf to signal to MAPkinase. Thus the activation of Raf by PKC apparently can trigger the same signalling pathway as oncogenic Raf or Raf activation by vas in combination with tyrosine phosphorylation.	MAX PLANCK GESELL,MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,LONDON SW7 2AY,ENGLAND	Max Planck Society; Imperial College London								ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADEREM A, 1992, PROTEIN KINASE C CUR, P255; AHMED S, 1993, J BIOL CHEM, V268, P10709; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHUNG DL, 1992, P NATL ACAD SCI USA, V89, P1993, DOI 10.1073/pnas.89.5.1993; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PFEIFER AMA, 1989, P NATL ACAD SCI USA, V86, P10075, DOI 10.1073/pnas.86.24.10075; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SOZERI O, 1992, ONCOGENE, V7, P2259; Stabel S., 1993, INTRACELLULAR MESSEN, P167; STABEL S, 1993, METH NEUROSCI, V18, P154; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TOBE K, 1991, J BIOL CHEM, V266, P24793; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARNER LC, 1993, ONCOGENE, V8, P3249; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	56	162	162	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3213	3218						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936644				2022-12-28	WOS:A1994PM65800013
J	MOSNER, J; DEPPERT, W				MOSNER, J; DEPPERT, W			P53 AND MDM2 ARE EXPRESSED INDEPENDENTLY DURING CELLULAR PROLIFERATION	ONCOGENE			English	Article							WILD-TYPE P53; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; A MOUSE CELLS; DNA-REPLICATION; CYCLE CONTROL; GROWTH-REGULATION; NUCLEAR ANTIGEN; NORMAL 3T3; GENE	We analysed p53 expression during proliferation of serum stimulated Swiss mouse 3T3 cells and of concanavalin A stimulated mouse spleen lymphocytes and correlated it to rate of DNA synthesis and to expression of PCNA. We also analysed mdm2 gene expression, as rising p53 levels during proliferation might require MDM2 protein expression to functionally antagonize p53 mediated growth inhibition. p53 protein synthesis closely paralleled DNA synthesis and PCNA expression, suggesting a direct involvement of p53 in cellular DNA synthesis. mdm2 expression in 3T3 cells could not be correlated with p53 expression and DNA synthesis and was not detected at all in stimulated lymphocytes. We conclude that p53 and mdm2 expression during proliferation are not functionally related and that mdm2 expression is not required for proliferation.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASERGA R, 1991, J CELL SCI, V98, P433; BOYUM A, 1968, SCAND J CLIN LAB INV, V97, P76; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PERRY ME, 1993, CURR OPIN CELL BIOL, V5, P1378; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SHOHAT O, 1987, ONCOGENE, V1, P277; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STURZBECHER HW, 1994, ONCOL REP, V1, P301; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	39	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3321	3328						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936657				2022-12-28	WOS:A1994PM65800026
J	MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK				MURTY, VVVS; LI, RG; HOULDSWORTH, J; BRONSON, DL; REUTER, VE; BOSL, GJ; CHAGANTI, RSK			FREQUENT ALLELIC DELETIONS AND LOSS OF EXPRESSION CHARACTERIZE THE DCC GENE IN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							SUPPRESSOR GENE; CYTOGENETIC ANALYSIS; HETEROZYGOSITY; CHROMOSOME-18; CARCINOMAS; CANCER; 18Q21	The DCC tumor suppressor gene has been shown to be frequently deleted or its expression reduced or absent in colorectal, gastro-intestinal, pancreatic, prostatic, and breast carcinomas, and glioblastomas. By allelotype analysis using the DCC-flanking polymorphic marker D18S5 we have previously shown that allelic deletions at 18q21 occur in 40% of male germ cell tumors (Murty et al., 1994). In order to further understand the role of DCC gene in germ cell tumorigenesis, we evaluated deletions by loss of heterozygosity (LOH) and mRNA expression by RT-PCR in tumor tissues and cell lines. Analysis of 61 paired normal-tumor DNAs using the probes D18S5, JOSH 4.4 (a polymorphism within the DCC locus) and a (CA)(n) polymorphism in an intron of DCC revealed that 45% of GCTs had allelic deletions. In addition, two homozygous deletions were found in the DCC gene among 91 (61 used in the LOH analysis and an additional 30) tumor DNAs when screened with the cDNA probes (pDCC 1,65, pDCC 1.9 and pDCC 1.0). By RT-PCR analysis of four normal testes, nine GCT cell lines and 14 tumor tissues, DCC gene expression was detected in all four normal testes, while four (45%) GCT cell lines and one (7%) tumor specimen showed lack of expression. In addition, DCC expression was highly reduced in three (21%) tumor tissues. The high frequency of LOH at 18q21 was characteristic of seminomas as well as all subsets of non-seminomas in primary as well as metastatic states. Frequent allelic loss in all histologic subsets, homozygous deletions, and loss of expression of DCC suggest that suppression of this gene's function is an early event in GCT development.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; UNIV MINNESOTA,DEPT UROL SURG,MINNEAPOLIS,MN 55455	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Minnesota System; University of Minnesota Twin Cities	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NCI NIH HHS [CA-08748, CA-05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHAGANTI RSK, 1994, LANCET, V343, P1130, DOI 10.1016/S0140-6736(94)90235-6; CHAGANTI RSK, 1993, UROL CLIN N AM, V20, P55; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DAVIES PO, 1993, DEV BIOL, V3, P179; DEVILEE P, 1991, ONCOGENE, V6, P311; EDELMAN GM, 1988, BIOCHEMISTRY-US, V27, P3533, DOI 10.1021/bi00410a001; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; HOHNE MW, 1992, CANCER RES, V52, P2616; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PORFIRI E, 1993, BLOOD, V81, P2696; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; SCHECK AC, 1993, CANCER RES, V53, P5605; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099	20	46	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3227	3231						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936646				2022-12-28	WOS:A1994PM65800015
J	WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL				WU, K; SALAS, PJI; YEE, L; FREGIEN, N; CARRAWAY, KL			TISSUE AND TUMOR EXPRESSION OF A CELL-SURFACE GLYCOPROTEIN COMPLEX CONTAINING AN INTEGRAL MEMBRANE GLYCOPROTEIN ACTIVATOR OF P185(NEU)	ONCOGENE			English	Article							MAMMARY ADENOCARCINOMA CELLS; GROWTH FACTOR-ALPHA; EGF RECEPTOR; DIFFERENTIATION FACTOR; SIGNAL TRANSDUCTION; SIALOMUCIN COMPLEX; NEU ONCOGENE; TRANSFORMATION; HEREGULIN; PRECURSOR	Ascites 13762 rat mammary adenocarcinoma cells contain an abundant heterodimeric cell surface glycoprotein complex. It is composed of a transmembrane subunit and a sialomucin subunit and is the product of a single gene. The transmembrane subunit has two EGF-like domains and activates the proto-oncogene receptor kinase p185(neu). Southern blot comparisons of the ascites tumor and rat liver demonstrated the presence of the gene encoding the complex in normal tissues and showed an amplification of about fivefold in the ascites tumor. Polymerase chain reaction assays showed the presence of mRNA for the complex in rat brain and lung, but not in liver, pancreas, placenta,intestine, kidney, ovary and uterus. Northern blot analyses showed that the 9 kb transcript for the complex is expressed at an approximately 500-fold higher level in the ascites cells than in rat brain. Immunocytochemical studies using antiserum directed against the transmembrane subunit showed its presence in bronchial epithelium, brain ependymal and neurons of four day old animals and in the endoderm and neuronal cells of embryos. Similar immunocytochemical studies showed the presence of the transmembrane subunit in some human breast tumors. These results suggest that the gene encoding this complex is regulated in a tissue-specific manner, is overexpressed in some tumors and may play a role in tumor progesssion.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; MT SINAI MED CTR,MIAMI BEACH,FL 33140	University of Miami; University of Miami; Mount Sinai Medical Center			Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NCI NIH HHS [CA 52498, CA 14395] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498, P30CA014395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BUCK RL, 1979, ARCH BIOCHEM BIOPHYS, V198, P12, DOI 10.1016/0003-9861(79)90390-4; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1992, J CELL SCI, V103, P299; CODINGTON JF, 1983, BIOMEMBRANE, V11, P207; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Favaloro J, 1980, Methods Enzymol, V65, P718; GOSPODAROWICZ D, 1976, ANNU REV BIOCHEM, V45, P531, DOI 10.1146/annurev.bi.45.070176.002531; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HUGGINS JW, 1980, CANCER RES, V40, P1873; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Maniatis T., 1982, MOL CLONING; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MERCOLA M, 1988, DEVELOPMENT, V102, P451; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WU K, 1994, J BIOL CHEM, V269, P11950; YU DH, 1991, ONCOGENE, V6, P1991	42	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3139	3147						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936636				2022-12-28	WOS:A1994PM65800005
J	TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA				TRIMBLE, MS; XIN, JH; GUY, CT; MULLER, WJ; HASSELL, JA			PEA3 IS OVEREXPRESSED IN MOUSE METASTATIC MAMMARY ADENOCARCINOMAS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; DNA-BINDING DOMAIN; NEU ONCOGENE; POLYOMAVIRUS ENHANCER; GENE FAMILY; PROTOONCOGENE; EXPRESSION; PROMOTER; AP-1; ACTIVATION	Transgenic mice bearing the rat neu proto-oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter develop focal mammary adenocarcinomas after long latency that are metastatic to the lung in a high percentage of the tumor-bearing animals. Because expression of the neu gene in the mammary epithelium precedes the occurrence of tumors, it appears that another genetic event in addition to neu transgene expression is required for tumorigenesis. We have investigated the expression of PEA3, a new member of the ets oncogene family of transcriptional regulatory factors, in neu-induced mammary tumors to learn whether PEA3 plays a role in tumor progression in this organ. We observed high levels of PEA3 RNA in neu-induced tumors, but little, if any, PEA3 RNA in the surrounding mammary epithelium. Moreover, mammary tumors that had metastasized to the lung also overexpressed the PEA3 gene, whereas normal lung tissue did not. Similar results were obtained after analyses of other transgenic mouse lines bearing metastatic mammary tumors induced by polyomavirus middle T antigen. These findings suggest that enhanced expression of PEA3 may be required to facilitate mammary tumor progression and metastasis.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ASANO M, 1990, J VIROL, V64, P5927, DOI 10.1128/JVI.64.12.5927-5938.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; NERLOV C, 1991, ONCOGENE, V6, P1583; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; Sambrook J, 1989, MOL CLONING LABORATO; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	28	100	101	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3037	3042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692372				2022-12-28	WOS:A1993MC09300018
J	PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A				PERI, KG; GERVAIS, FG; WEIL, R; DAVIDSON, D; GISH, GD; VEILLETTE, A			INTERACTIONS OF THE SH2 DOMAIN OF LYMPHOCYTE-SPECIFIC TYROSINE PROTEIN-KINASE P56(LCK) WITH PHOSPHOTYROSINE-CONTAINING PROTEINS	ONCOGENE			English	Article								We have previously demonstrated that the non-catalytic Src homology 2 (SH2) domain is required for both positive and negative regulation of the catalytic function of the lymphocyte-specific tyrosine protein kinase p56lck. Indeed, the ability of activated p56lck molecules (tyrosine 505 to phenylalanine 505 mutants) to enhance T-cell receptor (TCR)-induced tyrosine protein phosphorylation is dramatically reduced by deletion of the SH2 domain. Paradoxically, removal of the SH2 sequence also results in constitutive elevation of the catalytic function of wild-type Lck polypeptides, rendering them capable of oncogenic transformation of rodent fibroblasts. As SH2 sequences can mediate binding to phosphotyrosine-containing peptides, the ability of the Lck SH2 domain to interact with tyrosine-phosphorylated proteins was tested. We found that the SH2 sequence of p56lck can bind several of the TCR-regulated tyrosine phosphorylation substrates in vitro. One of the substrates, an 80-kilodalton (kDa) phosphoprotein (p80) showed the tightest binding to the SH2 domain of Lck. Additionally, it was observed that the SH2 domain of Lck can bind a synthetic peptide containing the phosphorylated carboxy-terminal tyrosine 505 of p56lck. Indirect evidence indicating that the SH2 region interacts with the tyrosine-phosphorylated carboxy terminus of Lck in vivo was also obtained. As deletion of the SH2 domain or mutation of tyrosine 505 results in p56lck activation in vivo, it is conceivable that interactions between these two regions impose a conformation that is unfavorable to phosphorylation of intracellular substrates. Collectively, these findings suggest that the SH2 domain modulates the catalytic function of Lck through complex interactions with phosphotyrosine-containing proteins.	MCGILL UNIV, MCGILL CANC CTR,ROOM 715B,MCINTYRE MED SCI BLDG, 3655 DRUMMOND ST, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV MED ONCOL, MONTREAL H3G 1A4, QUEBEC, CANADA	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Gish, Gerald D/C-7228-2017	Weil, Robert/0000-0001-5235-0932				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGERTON M, 1992, J IMMUNOL, V149, P1847; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2765	2772						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690927				2022-12-28	WOS:A1993LX34300018
J	BETTICHER, DC; THATCHER, N; ALTERMATT, HJ; HOBAN, P; RYDER, WDJ; HEIGHWAY, J				BETTICHER, DC; THATCHER, N; ALTERMATT, HJ; HOBAN, P; RYDER, WDJ; HEIGHWAY, J			ALTERNATE SPLICING PRODUCES A NOVEL CYCLIN D1 TRANSCRIPT	ONCOGENE			English	Article						CCND1; CYCLIN D1; SPLICING; POLYMORPHISM	MESSENGER-RNA; RETINOBLASTOMA PROTEIN; FIBROBLASTS; GENE; DNA	Using Northern blotting and PCR analysis of cDNA derived from a range of cell lines and tissues, alternate splicing of the cyclin D1 gene (CCND1) mRNA has been demonstrated, The variant transcript shows no splicing at the downstream exon 4 boundary, encoding a protein with an altered carboxy-terminal domain, Investigation of mRNA extracted from mononuclear cells, lung tumour and normal tissue suggests that both transcripts are invariably expressed. However, splicing to produce the two forms of mRNA is modulated, in the heterozygote, by a frequent A/G polymorphism located within the splice donor region of exon 4. Preliminary analysis of patients with resectable non-small cell lung cancer suggests that genotype is associated with shortened event free survival and greater risk of local relapse.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT CANC GENET, MANCHESTER M20 9BX, LANCS, ENGLAND; UNIV HOSP BERN, INST PATHOL, BERN, SWITZERLAND; CHRISTIE HOSP NHS TRUST, CANC RES CAMPAIGN, DEPT MED ONCOL, BERN, SWITZERLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Bern; University Hospital of Bern			Betticher, Daniel C/G-5849-2013					AKIYAMA N, 1994, CANCER RES, V54, P377; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; COX DR, 1972, J R STAT SOC B, V34, P187; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOBSEN KS, 1990, NUCLEIC ACIDS RES, V18, P3669, DOI 10.1093/nar/18.12.3669; JARES P, 1994, CANCER RES, V54, P4813; Kay R, 1983, Stat Med, V2, P41, DOI 10.1002/sim.4780020106; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nelson W., 1969, J QUAL TECHNOL, V1, P27, DOI DOI 10.1080/00224065.1969.11980344; OHNO K, 1988, J BIOL CHEM, V263, P18563; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; VIDAUD M, 1989, P NATL ACAD SCI USA, V86, P1041, DOI 10.1073/pnas.86.3.1041; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; 1987, MANUAL STAGING CANCE; 1981, HISTOLOGICAL TYPING	39	368	375	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					1005	1011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675441				2022-12-28	WOS:A1995RU79800024
J	CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S				CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S			TELOMERASE ACTIVITY IN NORMAL AND MALIGNANT MURINE TISSUES	ONCOGENE			English	Article						TELOMERASE; MAMMARY TUMORIGENESIS; MOUSE TISSUES; PROLIFERATIVE LIFE-SPAN	HUMAN FIBROBLASTS; SENESCENCE; IDENTIFICATION; CELLS; MOUSE; MICE	Telomere shortening may contribute to the limited lifespan of somatic cells and telomerase, the enzyme that elongates telomeric DNA and maintains telomere length, may be essential for unlimited cell proliferation irt vivo and in vitro. Telomerase is not expressed in most human somatic cells but is a nearly ubiquitous tumour marker, being activated in malignant cells from many cancers, Inhibition of telomerase may lead to telomere shortening and eventually limit the proliferative capacity of malignant cells and hence be of therapeutic value, With the intent of characterizing an animal model for inhibition studies, we investigated telomerase activity during mammary tumorigenesis in transgenic mice overexpressing the neu gene, We detected activity in primary mammary tumours and lung metastases but also in normal mammary glands and other organs, Activity Tvas elevated in tumors versus normal tissues and was enhanced by short-term culturing of normal cells, Telomerase activity was also present in somatic tissues from the non-transgenic parental strain and the outbred Mus spretus strain, As we recently detected telomerase activity in normal human hemopoietic tissues, mouse models of tumorigenesis may provide useful experimental systems for assessing the outcome of in vivo inhibition of telomerase in both malignant and normal cells.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8N 3Z5,CANADA; GERON CORP,MENLO PK,CA 94025	McMaster University; McMaster University; Geron Corporation			Chadeneau, Corinne/AAT-6790-2021	Chadeneau, Corinne/0000-0001-8808-1738				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BACCHETTI S, 1995, IN PRESS INT J ONC, V7; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; COUNTER CM, 1995, BLOOD, V9, P2315; COUNTER CM, 1994, EMBO J, V91, P2900; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIRTE HW, 1994, CANCER, V74, P900, DOI 10.1002/1097-0142(19940801)74:3<900::AID-CNCR2820740317>3.0.CO;2-N; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NILSSON P, 1994, ONCOGENE, V9, P3043; NOWELL PC, 1986, CANCER RES, V46, P2203; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	133	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675448				2022-12-28	WOS:A1995RU79800010
J	ZHANG, YH; CHELLAPPAN, SP				ZHANG, YH; CHELLAPPAN, SP			CLONING AND CHARACTERIZATION OF HUMAN DP2, A NOVEL DIMERIZATION PARTNER OF E2F	ONCOGENE			English	Article						E2F; RB; DP1; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; DNA-BINDING; GROWTH SUPPRESSION; COMPLEX-FORMATION; S-PHASE; RB; TRANSACTIVATION	The transcription factor E2F consists of a family of proteins that bind to the sequence TTTCGCGC and regulate the expression of various cellular and viral promoters. E2F binds to DNA as homodimers or as heterodimers in association with a protein, DP1 (for dimerization partner 1). E2F-DP1 heterodimers bind more efficiently than homodimers to DNA, retinoblastoma gene product as well as the adenovirus E4 protein and DP1 can stimulate transcription from E2F sites in a synergistic fashion. Here we describe the cloning and characterization of a novel human DP gene, DP2, whose product dimerizes efficiently with E2F. Unlike DP1, there appear to be multiple transcripts for DP2 and their distribution appears to vary in different tissues and cell lines. DP2 binds to E2F as detected by in vitro reconstitution assays and an E2F-DP2 heterodimer can bind to DNA in gel-retardation assays. We believe that DP2 also plays a major role in modulating the function of E2F in cell cycle regulation and oncogenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University					NCI NIH HHS [CA 63136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1994, EMBO J, V12, P4317; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JORDAN KL, 1994, ONCOGENE, V9, P1177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; SAMBROOK J, 1989, LABORATORY MANUAL; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITHIES O, 1981, CELL, V26, P345, DOI 10.1016/0092-8674(81)90203-8; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	62	93	95	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2085	2093						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784053				2022-12-28	WOS:A1995RB70300003
J	KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J				KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J			MDM2 PROTEIN CONFERS THE RESISTANCE OF A HUMAN GLIOBLASTOMA CELL-LINE TO CISPLATIN-INDUCED APOPTOSIS	ONCOGENE			English	Article						MDM2; CISPLATIN; P53; GLIOMA AND APOPTOSIS	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; DNA-DAMAGING AGENTS; CANCER-CHEMOTHERAPY; ANTICANCER AGENTS; GENE; INDUCTION; EXPRESSION; ACTIVATION; GROWTH	Induction of apoptosis in tumor cells is an important mechanism of chemotherapy-induced cell death. The tumor-suppressor gene p53 is required for the efficient activation of apoptosis following chemotherapy. However,, the molecular mechanism regulating p53-associated apoptosis remains controversial. In this study, we show that the expression of both wild-type p53 and MDM2 (murine double minute 2) proteins was induced when cisdiamminedichloroplatinum (cisplatin) caused apoptosis in human glioblastoma U87-MG cells, which expressed neither wild-type p53 nor MDM2 protein prior to treatment, Overexpression of MDM2 in U87-MG cells transfected with human mdm2 expression vector conferred the resistance of tumor cell to cisplatin-induced apoptosis, In contrast, the treatment with mdm2 antisense oligonucleotide targeted against mdm2 mRNA increased the susceptibility of tumor cells to apoptosis. Changes in expression level of MDM2 protein, however, did not affect the expression of wild-type p53 protein. These findings suggest that MDM2 protein may act as a negative regulator of cisplatin-induced apoptosis, and moreover, may play an important role in the development of resistance to cisplatin in human tumors.	NATL UTANO HOSP,DEPT CLIN RES CTR,KYOTO,JAPAN; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO,JAPAN		KONDO, S (corresponding author), CLEVELAND CLIN FDN,CTR CANC,CTR BRAIN TUMOR,DEPT NEUROSURG,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COTTER TG, 1992, ANTICANCER RES, V12, P773; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIWARA T, 1994, CANCER RES, V54, P2287; HARPER JW, 1993, CELL, V75, P805; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KONDO S, 1994, BRIT J CANCER, V69, P627, DOI 10.1038/bjc.1994.123; KONDO S, 1994, CANCER RES, V54, P2928; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	124	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2001	2006						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761100				2022-12-28	WOS:A1995QZ92600014
J	DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J				DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J			DIFFERENTIAL REGULATION OF MAX AND ROLE OF C-MYC DURING ERYTHROID AND MYELOMONOCYTIC DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Note						C-MYC; MAX; K562 CELLS; DIFFERENTIATION	MURINE ERYTHROLEUKEMIA-CELLS; MYELOID-LEUKEMIA CELLS; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE AUTOREGULATION; GROWTH-INHIBITION; PHORBOL ESTER; LINE K562; ONCOGENE; PROTEIN	The protein Max binds to c-Myc and the heterodimer c-Myc/Max seems to be the active form in vivo. While the expression of c-myc is extensively regulated, no major changes in max expression have been reported so far with respect to differentiation, We have studied the expression of c-Myc and Max during in vitro differentiation of the bipotent human myeloid leukemia K562 cell line, This cell model system allowed us to compare c-Myc and Max expression during differentiation along erythroid (induced by 1-beta-D-arabinofuranosyl-cytosine) and myelomonocytic lineages (induced by 12-0-tetradecanoylphorbol-13-acetate). We found that c-myc expression decreased as a result of both differentiating treatments, The expression level of max remained unchanged during myelomonocytic differentiation, In contrast, max mRNA and protein were dramatically down-regulated during erythroid differentiation of K562 cells, thus demonstrating that max gene is subjected to regulation during differentiation, We also studied the expression of the other two described members of the c-Myc network: mxi1 and mad. mxi1 expression increased during erythroid differentiation but was strongly downregulated during myelomonocytic differentiation of K562, mad was constitutively expressed during K562 erythroid differentiation and slightly increased during induction of the myelomonocytic pathway, We have obtained K562 sublines stably transfected with a zinc-inducible c-myc gene, In these clones the overexpression of c-Myc did not interfere with TPA-induced myelomonocytic differentiation. In contrast, erythroid differentiation was significantly inhibited upon c-myc induction despite the downregulation of endogeneous max expression, These results suggest a differential role for c-Myc in the human myeloid cell differentiation depending on the cell lineage.	UNIV CANTABRIA,FAC MED,DEPT BIOL MOLEC,E-39011 SANTANDER,SPAIN	Universidad de Cantabria			Leon, Javier/K-4615-2014; Canelles, Matilde/AAB-1011-2019; Delgado, M. Dolores/K-9056-2014	Canelles, Matilde/0000-0003-2973-609X; Delgado, M. Dolores/0000-0003-4682-4040; Leon, Javier/0000-0001-5803-0112				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleveland J L, 1988, Oncogene Res, V3, P357; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOFFMANLIEBERMA.B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, BLOOD REV, V2, P121, DOI 10.1016/0268-960X(88)90034-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAMBROOK F, 1989, MOL CLONING LABORATO; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; TONINI GP, 1987, CANCER RES, V47, P4544; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	42	62	64	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731722				2022-12-28	WOS:A1995QU68100024
J	MULLER, E; SCHEIDTMANN, KH				MULLER, E; SCHEIDTMANN, KH			PURIFICATION AND CHARACTERIZATION OF A PROTEIN-KINASE WHICH IS ACTIVATED BY SV40 LARGE T-ANTIGEN AND PHOSPHORYLATES THE TUMOR-SUPPRESSOR PROTEIN P53	ONCOGENE			English	Article						T-ANTIGEN; LT-ACTIVATED KINASE; P53 PHOSPHORYLATION; CELL CYCLE; TRANSFORMATION	WILD-TYPE P53; CELL-CYCLE CONTROL; DNA-REPLICATION; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; 3T3 CELLS; SITE; TRANSFORMATION; BINDING	In SV40-transformed or infected rat cells phosphorylation of the tumor suppressor protein p53 is enhanced due to activation of kinases. At least three different kinases can be co-precipitated with p53-large T (LT) immune complexes, casein kinase II representing the major activity, a cyclin dependent kinase (Cdk), and a kinase which appears to be specifically activated by LT (E Muller, B Boldyreff and KH Scheidtmann, Oncogene 8: 2193-2205, 1993). In this paper we describe the purification and identification of the LT-activated kinase that phosphorylates a site adjacent to the Cdk site in rat p53. To monitor the activity a synthetic peptide was used containing glutamic acid at the position of Ser-313, thus mimicking a phosphorylated Cdk site, With a combination of Mono Q chromatography and subsequent affinity chromatographies with p13(suc1) and a p53-fragment as ligands a 42 kDa protein kinase was purified to near homogeneity from SV40-transformed rat cells, This kinase phosphorylated both the peptide substrate and the native rat p53, Interestingly, phosphorylation of the specific site seemed to depend on prior phosphorylation of the Cdk site. On the other hand, the kinase seemed to be activated by LT, as the activity towards the peptide substrate was significantly higher in extracts from wildtype LT-transformed cells than from normal or mutant LT-transformed cells, This activation was not restricted to rat cells but occurred in SV40-transformed mouse and infected monkey cells as well, Phosphorylation of the specific site by LT-activated kinase was not dependent on the presence of LT in vitro suggesting that activation of the LT-activated kinase is probably indirect rather than through direct interaction with LT. Cell cycle studies revealed that the LT-activated kinase is cell cycle regulated, since its activity was not detectable in M phase but increased during G1 phase after which it remained relatively constant.	UNIV BONN, INST GENET, DEPT MOLEC GENET, D-53117 BONN, GERMANY	University of Bonn								BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FISCELLA M, 1993, ONCOGENE, V8, P1519; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MULLER E, 1993, ONCOGENE, V8, P2193; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; OROURKE RW, 1990, ONCOGENE, V5, P1829; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU JS, 1994, J BIOL CHEM, V269, P14341; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	74	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1175	1185						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700642				2022-12-28	WOS:A1995QN35300019
J	FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y				FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y			ISOLATION OF A CANDIDATE TUMOR-SUPPRESSOR GENE ON CHROMOSOME 8P21.3-P22 THAT IS HOMOLOGOUS TO AN EXTRACELLULAR DOMAIN OF THE PDGF RECEPTOR-BETA GENE	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; PDGF RECEPTOR BETA; COLORECTAL CANCER; HEPATOCELLULAR CARCINOMA	GROWTH-FACTOR PDGF; CELL-LINES; IDENTIFICATION; DELETION; MUTATIONS; CANCER; FAMILY; LOCUS; CARCINOMAS; EXPRESSION	We have isolated a candidate tumor suppressor gene from a 600-kb region on chromosome 8p21.3-p22 that is commonly deleted in sporadic hepatocellular carcinomas (HCC), colorectal cancers (CRC), and non-small cell lung cancers (NSCLC). As this gene encodes a protein of 375 amino acids that bears significant sequence similarity to the extracellular (ligand-binding domain of platelet-derived growth factor receptor beta, we have designated it PRLTS (PDGF-receptor beta-like tumor suppressor). Structural rearrangement involving this gene was found in a sporadic NSCLC. In addition, somatic missense and frame-shift mutations were found in two HCCs and one CRC. These findings indicate that inactivation of the PRLTS gene may play a significant role in development of some carcinomas.	CANC INST,DEPT BIOCHEM,TOKYO 170,JAPAN; CANC INST,DEPT PATHOL,TOKYO 170,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Osaka University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGQVIST MHJ, 1992, PHYTOCHEM ANALYSIS, V3, P215, DOI 10.1002/pca.2800030503; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAMP A, 1994, SCIENCE, V264, P436; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SHIBUYA M, 1988, CANCER RES, V48, P1930; SMITS A, 1992, AM J PATHOL, V140, P639; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	34	112	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					891	895						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898930				2022-12-28	WOS:A1995QL03800010
J	SCHUCHARDT, A; SRINIVAS, S; PACHNIS, V; COSTANTINI, F				SCHUCHARDT, A; SRINIVAS, S; PACHNIS, V; COSTANTINI, F			ISOLATION AND CHARACTERIZATION OF A CHICKEN HOMOLOG OF THE C-RET PROTOONCOGENE	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; RET; EVOLUTION; PROTOONCOGENE; EMBRYOGENESIS; NERVOUS SYSTEM; HIRSCHSPRUNGS DISEASE	CELL-ADHESION MOLECULE; PROTEIN-TYROSINE KINASE; TRANSGENIC MICE; SEQUENCE SIMILARITY; TRANSFORMING GENE; MESSENGER-RNAS; CDNA CLONING; EGF RECEPTOR; EXPRESSION; CADHERIN	The c-ret proto-oncogene encodes a receptor tyrosine kinase that plays important roles in human disease and in normal mammalian development. Mutations in the human RET gene are associated with multiple endocrine neoplasia syndromes and Hirschsprung's disease in humans, while targeted mutagenesis of murine c-ret resulted in severe developmental abnormalities affecting the excretory and peripheral nervous systems. To examine the evolutionary conservation of the ret protein sequence and its developmental expression pattern, we isolated and sequenced cDNA clones of chicken c-ret and examined its expression in chick embryos and adult tissues. The cytoplasmic domains of chicken and human ret were relatively well conserved (91% similar), but the extracellular domains were more divergent (68% similar), although the conservation of cysteine residues in this region suggests a conserved secondary structure. As in mouse and human, chicken c-ret encodes two protein isoforms, The number and sizes of the transcripts were similar to those in human and mouse cells, and during chick embryogenesis, c-ret mRNA was observed in many of the same sites as in the mouse, including the Wolffian duct and ureteric bud, the enteric, dorsal root, sympathetic and facioacoustic ganglia, and the ventral spinal cord. Evolutionary differences in expression were observed in the trigeminal ganglion, the ventral roots of the spinal cord, the mesenchymal cells of the branchial arches and the adult testes. The results are discussed with regard to the role of the ret receptor in normal development and disease.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; NATL INST MED RES,GENE STRUCT & EXPRESS LAB,LONDON NW7 1AA,ENGLAND	Columbia University; MRC National Institute for Medical Research				Srinivas, Shankar/0000-0001-5726-7791; Pachnis, Vassilis/0000-0001-9733-7686	NCI NIH HHS [CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHEN J, 1991, ONCOGENE, V6, P157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; IWAMOTO T, 1990, ONCOGENE, V5, P535; IWAMOTO T, 1993, ONCOGENE, V8, P1087; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE JJ, 1992, DEVELOPMENT, V115, P277; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROMEO G, 1994, NATURE, V367, P367; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SASAKI E, 1993, GENE, V128, P257, DOI 10.1016/0378-1119(93)90571-J; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITE MF, 1991, J BIOENERG BIOMEMBR, V23, P63; WILKS AF, 1993, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; 1991, PROGRAM MANUAL GCG P	54	43	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					641	649						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862441				2022-12-28	WOS:A1995QH61200003
J	WANG, Y; FARMER, G; SOUSSI, T; PRIVES, C				WANG, Y; FARMER, G; SOUSSI, T; PRIVES, C			XENOPUS-LAEVIS P53 PROTEIN - SEQUENCE-SPECIFIC DNA-BINDING, TRANSCRIPTIONAL REGULATION AND OLIGOMERIZATION ARE EVOLUTIONARILY CONSERVED	ONCOGENE			English	Note						P53; XENOPUS; DNA BINDING; OLIGOMERIZATION	MUTANT P53; WILD-TYPE; GENE; MUTATIONS; SITE; TRANSFORMATION; COMPLEXES	The well conserved human and murine p53 proteins are tetramers that can activate transcription from templates bearing p53 binding sites. Since the normal function of mammalian p53 is necessary for preserving the stability of genome, we examined the properties of purified Xenopus p53 (Xp53) to determine whether it shares similar biochemical activities. Xp53 was shown to bind specifically to sites containing the p53 consensus sequence derived for human p53. Moreover, Xp53 transactivates reporter genes containing a human p53 response element in vivo. Finally, Xp53 can be crosslinked into tetramers in a manner similar to human p53. However, Xp53 forms hetero-oligomers with human or murine p53 only very ineffectively, in contrast to the efficient hetero-oligomer formation that occurs between human and murine p53 polypeptides. Taken together, our data indicate that sequence specific DNA binding, transcriptional regulation and oligomerization of p53 are common properties of vertebrate p53 proteins, and thus they are likely to be required for the biological activity of the protein.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293	NCI NIH HHS [CA 58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058316, R01CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOEVER M, 1993, ONCOGENE, V9, P109; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kay BK, 1991, METHODS CELL BIOL, V36; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Reed Michael, 1993, Gene Expression, V3, P95; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACHANG F, 1993, DEV BIOL, V159, P163	30	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					779	784						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862457				2022-12-28	WOS:A1995QH61200020
J	ADNANE, J; ROBBINS, PD				ADNANE, J; ROBBINS, PD			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REGULATES MYC-MEDIATED TRANSCRIPTION	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; MYC; TRANSCRIPTION	APOPTOTIC CELL-DEATH; VIRUS-40 LARGE-T; C-MYC; DNA-BINDING; MOLECULAR-CLONING; FACTOR E2F; PROTEIN; MAX; DOMAIN; ACTIVATION	The protein product of the retinoblastoma tumor suppressor gene (RE) has been demonstrated to bind c-Myc protein (Myc) in vitro. To determine whether RE regulates Myc transcriptional activity in vivo, GAL4-Myc chimeric expression plasmids were generated and cotransfected with a RE expression plasmid and a GAL4-dependent reporter plasmid. RE stimulated GAL4-Myc-mediated transcription, dependent upon a domain(s) in the amino-terminus of Myc. The stimulation of Myc-mediated transcription by RE was cell-type specific and was inhibited by SV40 T-antigen, but not by a T-antigen mutant defective in RE-binding. Moreover, RE mutants containing mutations in domain B of RE pocket were significantly reduced in their ability to stimulate GAL4-Myc mediated transcription. To determine whether RE and Myc interact in vivo either directly or indirectly, a two hybrid system was used where GAL4-Rb and Myc-VP16 expression constructs were cotransfected with a GAL4-dependent reporter plasmid. A significant increase of GAL4-dependent transcription was observed, dependent upon the presence of both GAL4-Rb and Myc-VP16 fusion proteins, Mutational analysis of the Myc-VP16 chimeric proteins suggests that the amino-terminus of Myc is essential for the interaction with RE. These results demonstrate that RE can regulate Myc-mediated transcription in vivo in a cell-type specific manner through protein-protein interactions.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENEDICT WF, 1988, CANCER, V62, P1691, DOI 10.1002/1097-0142(19881015)62:1+<1691::AID-CNCR2820621306>3.0.CO;2-5; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHENG J, 1990, BLOOD, V75, P730; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCHER B, 1990, I MYC GENES DEV, V4, P2025; MAYOL X, 1993, ONCOGENE, V8, P2561; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SRINIVASAN A, 1989, J VIROL, P5459; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	62	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					381	387						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838535				2022-12-28	WOS:A1995QC62400017
J	CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R				CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R			DELETION MAPPING IN NEUROBLASTOMA CELL-LINES SUGGESTS 2 DISTINCT TUMOR-SUPPRESSOR GENES IN THE 1P35-36-REGION, ONLY ONE OF WHICH IS ASSOCIATED WITH N-MYC AMPLIFICATION	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENES; N-MYC; CHROMOSOME 1	NEURO-BLASTOMA; EMBRYONIC LETHALITY; HUMAN CHROMOSOME-1; SHORT ARM; HETEROZYGOSITY; EXPRESSION; DNA; TUMORIGENICITY; MORPHOLOGY; ONCOGENE	Neuroblastoma is characterized by deletions of the short arm of chromosome 1 (1p) and amplification of the N-myc oncogene, We have made somatic cell hybrids of two human neuroblastoma cell lines, one with and one without N-myc expression and amplification, The expression of the amplified N-myc gene is completely switched off in the hybrids, This suggests that N-myc expression results from loss of a repressor function, As N-myc amplification is associated with loss of heterozygosity (LOH) of 1p36, we analysed 1p deletions in 16 neuroblastoma cell lines, The seven cell lines without N-myc amplification have no deletions or relatively small deletions, with an SRO on 1p36.23-33. This suggests that a tumor suppressor gene maps in this region, All nine cell lines with N-myc amplification have larger deletions, with an SRO from 1p35-36.1 to the telomere, This suggests that a second tumor suppressor gene which is associated with N-myc amplification maps more proximally, Fine mapping of 1p36 deletions in the two cell lines of the fusion experiment suggests that the distal locus is not a repressor of N-myc expression, but the more proximal locus could be a candidate for this function.	UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1100 DE AMSTERDAM, NETHERLANDS; STATE UNIV GHENT, DEPT MED GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Ghent University			speleman, frank/AAR-5184-2020; Versteeg, Rogier/AAQ-1765-2020	speleman, frank/0000-0002-6628-8559; Versteeg, Rogier/0000-0001-7172-0388				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GRADY EF, 1987, CANCER RES, V47, P2931; HELSON L, 1980, HUMAN CANCER ITS CHA, P86; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUTHIER V, 1992, HUM MOL GENET, V1, P63; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1994, ADV NEUROBLASTOMA RE, V4, P3; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	41	127	129	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					291	297						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838528				2022-12-28	WOS:A1995QC62400008
J	LYMAN, SD; JAMES, L; ZAPPONE, J; SLEATH, PR; BECKMANN, MP; BIRD, T				LYMAN, SD; JAMES, L; ZAPPONE, J; SLEATH, PR; BECKMANN, MP; BIRD, T			CHARACTERIZATION OF THE PROTEIN ENCODED BY THE FLT3 (FLK2) RECEPTOR-LIKE TYROSINE KINASE GENE	ONCOGENE			English	Article							SITE-SPECIFIC MUTAGENESIS; CELL-SURFACE EXPRESSION; GROWTH-FACTOR; PHENOTYPIC SELECTION; ONCOGENE PRODUCT; PDGF RECEPTOR; W-LOCUS; FMS; IDENTIFICATION; LOCALIZATION	We have developed rabbit polyclonal antibodies to the C-terminus of the flt3-encoded protein, which is a member of the receptor tyrosine kinase family. Immunoprecipitation using this antiserum brings down two protein bands, a major band of 143 kDa and a less abundant, more diffuse, band of 158 kDa. Pulse-chase analysis of flt3 protein from transfected COS-7 cells shows that the larger band is derived from the smaller one and presumably represents maturation of the protein from a glycosylated high-mannose form to a complex carbohydrate form. N-glycosidase F digestion confirmed the presence of N-linked carbohydrates, and cell-surface labeling of flt3-transfected cells indicated that the 158-kDa glycoprotein is the species found on the cell surface. A mutated form of the flt3 protein that was defective in its glycosylational processing was identified. Western blotting of the immunoprecipitated flt3 protein showed that it is heavily phosphorylated on tyrosine, and that this phosphorylation probably occurs in the absence of ligand. In this regard, the flt3 protein resembles the c-erbB2 protein, which is also highly phosphorylated in the absence of ligand. These data suggest that the flt3 receptor regulates the growth and differentiation of cells via an as yet unknown ligand.	IMMUNEX RES & DEV CORP,DEPT HYBRIDOMA,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROTEIN CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101		LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,51 UNIV ST,SEATTLE,WA 98101, USA.							CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1986, MOL IMMUNOL, V23, P935, DOI 10.1016/0161-5890(86)90123-9; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONARDO F, 1990, New Biologist, V2, P992; LYMAN SD, 1989, ONCOGENE RES, V4, P149; LYMAN SD, 1992, J AM SOC PED HEM ONC, V14, P1; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SATOH H, 1987, JPN J CANCER RES, V78, P772; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1992, PROG GROWTH FACTOR R, V3, P235; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	31	102	109	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					815	822						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681159				2022-12-28	WOS:A1993KT22000001
J	PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG				PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG			CONSTITUTIVE PHOSPHORYLATION OF SHC PROTEINS IN HUMAN TUMORS	ONCOGENE			English	Article						SHC PHOSPHORYLATION; HUMAN TUMORS	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; ADAPTER PROTEIN; SEVENLESS GENE; V-SRC; RAS; GRB2; IDENTIFICATION	The She gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. She proteins are ubiquitously expressed and are downstream targets and effecters of activated tyrosine kinases (TK). We investigated tyrosine-phosphorylation of She proteins in normal and transformed cells. In tumor cells with known TK gene alterations She proteins were constitutively phosphorylated and complexed with the activated TK. No constitutive She phosphorylation was found in primary cell cultures and normal tissues, In 14 of 27 tumor cell lines with no reported TK alterations, She proteins were constitutively phosphorylated and formed stable complexes with novel tyrosine-phosphorylated polypeptides. Ten distinct She-associated phosphoproteins were identified with molecular weights ranging from 30 to 200 kDa. In a subset of carcinoma cell lines, phosphorylated She proteins complexed with a p175 phosphoprotein that was identified as the constitutively activated EGFR. In one glioblastoma cell line, a Shc-associated p190 was identified as the activated PDGFR. In 13 of 14 acute leukemia samples phosphorylated She proteins were constitutively complexed with a p140 phosphoprotein. Some of the She-associated phosphoproteins (EGFR, PDGFR, erbB-2, Met, bcr-abl, H4-ret) bound both the Shc- and Grb2-SH2 domains in vitro; others (p175; p70-p80) only the Shc-SH2 domain and yet others (p140) only the Grb2-SH3 domains. These results indicate that She proteins are common substrates of constitutively activated TKs and that the analysis of She phosphorylation allow the identification of tumors with constitutive TK activation.	UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06100 PERUGIA,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; IST NAZL TUMORI,MILAN,ITALY; IST REGINA ELENA,ROME,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY; EUROPEAN INST ONCOL,MILAN,ITALY	University of Perugia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; IRCCS European Institute of Oncology (IEO)			Borrello, Maria Grazia/C-3161-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017; Di Fiore, Pier Paolo/K-2130-2012; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Di Fiore, Pier Paolo/0000-0002-2252-0950; Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512; Segatto, Oreste/0000-0003-2561-1142				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER LN, 1993, NATURE, V363, P85; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DAMEN JE, 1993, BLOOD, V82, P2996; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DILWORTH S, 1994, NATURE, V267, P87; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAMPS MP, 1988, ONCOGENE, V2, P305; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PELICCI G, 1995, IN PRESS ONCOGENE; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS RM, 1994, NEURON, V12, P1; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	50	120	124	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675449				2022-12-28	WOS:A1995RU79800011
J	WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR				WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR			INVOLVEMENT OF RB-1, P53, P16(INK4) AND TELOMERASE IN IMMORTALIZATION OF HUMAN-CELLS	ONCOGENE			English	Article						SENESCENCE; IMMORTALIZATION; RB-1; P53; P16(INK4); TELOMERASE	RETINOBLASTOMA PROTEIN; MONOCLONAL-ANTIBODY; LIFE-SPAN; WILD-TYPE; LINES; IDENTIFICATION; MUTATIONS; CYCLINS; PHOSPHORYLATION; EXPRESSION	Involvement of the retinoblastoma susceptibility (RB-1), p16(INK4), p53 and telomerase genes in immortalisation was examined by determining their status in 15 human cell lines representing four immortalisation complementation groups, No abnormalities of RB-1, p53 and p16(INK4) were detected in cell lines containing DNA tumour virus proteins known to bind to the protein products of the RB-1 and p53 genes, In contrast, in all other cell lines from each of the four groups either RB-1 was mutant or p16(INK4) protein was undetectable and there were cell lines containing p53 mutations in three of Telomerase activity was detected in 12/15 lines, including some of the virally immortalised lines and in some lines from each group, Since none of these changes correlated with complementation group, other genetic changes must be required for immortalisation.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,SYDNEY,NSW 2010,AUSTRALIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Children's Medical Research Institute - Australia; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Australian National University; John Curtin School of Medical Research			Bryan, Tracy M/B-8468-2014; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1992, EXP GERONTOL, V256, P271; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEHMAN TA, 1991, CANCER RES, V51, P4090; MILNER J, 1987, ONCOGENE, V1, P453; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REDDEL RR, 1995, INT J CANCER, V61, P199; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; XU HJ, 1989, ONCOGENE, V4, P807	41	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					971	976						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675456				2022-12-28	WOS:A1995RU79800018
J	AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J				AMFO, K; NEYNS, B; TEUGELS, E; LISSENS, W; BOURGAIN, C; DESUTTER, P; VANDAMME, B; VAMOS, E; DEGREVE, J			FREQUENT DELETION OF CHROMOSOME-19 AND A RARE REARRANGEMENT OF 19P13.3 INVOLVING THE INSULIN-RECEPTOR GENE IN HUMAN OVARIAN-CANCER	ONCOGENE			English	Article						OVARIAN CANCER; LOSS OF HETEROZYGOSITY; REARRANGEMENT; INSULIN RECEPTOR; CHROMOSOME 19	RIBONUCLEIC-ACID; P53 GENE; C-JUN; DNA; HETEROZYGOSITY; CARCINOMAS; LOSSES; POLYMORPHISM; ABERRATIONS; ALLELOTYPE	Human ovarian cancer cells usually have multiple specific chromosomal deletions which can be detected by cytogenetic analysis or molecular techniques. Tumour suppressor genes might be located in these deleted chromosomal segments. The importance of these different loci is usually estimated from the frequency with which they are deleted. Here we report a 59% loss of heterozygosity for chromosome 19 in the DNA of human invasive epithelial ovarian cancer from a series of 37 patients. In all cases informative on both chromosomal arms a subchromosomal loss is observed, Analysis of the same tumours for chromosome 17p and 11p loss suggests that loss of chromosome 19p/q is less important than 17p loss, but more important than lip loss. The deletion of chromosome 19q seems to be associated with distant, hematogeneous metastasis (stage TV), In two patients with high grade tumours, the deletion involves a rearrangement of the insulin receptor locus (19p13.3), This suggests that some of the previously described frequent cytogenetic 19p(+) markers and 19p13.3 breaks observed in high grade ovarian cancers, might actually occur in the insulin receptor gene.	FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED ONCOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT MED ONCOL & HEMATOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,EXPTL PATHOL LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,DEPT GYNAECOL ONCOL,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,CYTOGENET LAB,B-1090 JETTE,BELGIUM; FREE UNIV BRUSSELS,AKAD ZIEKENHUIS,HOP BRUGMANN,MED GENET LAB,B-1090 JETTE,BELGIUM	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel			Neyns, Bart/ABG-3145-2021; De Greve, Jacques/J-4939-2012; Lissens, Willy/B-2892-2013; Neyns, Bart/AAA-8267-2021	Neyns, Bart/0000-0003-0658-5903; De Greve, Jacques/0000-0002-2389-0742; Lissens, Willy/0000-0003-3875-9955; Teugels, Erik/0000-0002-7828-4555; De Sutter, Philippe/0000-0002-3064-3344				AMAN P, 1994, INT J ONCOL, V5, P177; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BARKER D, 1987, CYTOGENET CELL GENET, V46, P576; Battey, 1986, BASIC METHODS MOL BI; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; BERCHUCK A, 1992, AM J OBSTET GYNECOL, V166, P674; BOYD P, 1986, HUM GENET, V73, P171, DOI 10.1007/BF00291609; BRYSCH W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P401; CHEVENIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIBY W, 1993, CANCER RES, V53, P2393; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELLEIN SC, 1986, P NATL ACAD SCI USA, V83, P5223; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FROSSARD PM, 1987, GENE, V51, P103, DOI 10.1016/0378-1119(87)90480-X; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; HOPPENER JWM, 1988, FEBS LETT, V233, P57, DOI 10.1016/0014-5793(88)81355-3; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KORNELUK RG, 1991, NUCLEIC ACIDS RES, V19, P1157, DOI 10.1093/nar/19.5.1157; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE JH, 1990, CANCER RES, V50, P2724; MAEDA N, 1983, P NATL ACAD SCI-BIOL, V80, P5012, DOI 10.1073/pnas.80.16.5012; MARKS JR, 1991, CANCER RES, V51, P2979; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; OKAMOTO A, 1991, CANCER RES, V51, P5171; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SNDBERG AA, 1990, CHROMOSOMES HUMAN CA, P839; SOUTHERN EM, 1975, J MOL BIOL, V938, P503; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; TSAO SW, 1991, ANTICANCER RES, V11, P1975; VANDAMME B, 1992, CANCER RES, V52, P6646; VONDEIMLING A, 1992, CANCER RES, V52, P4277; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226; ZHENG JP, 1991, CANCER RES, V51, P4045	45	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					351	358						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624149				2022-12-28	WOS:A1995RK95700015
J	NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS				NISHINO, H; KNOLL, A; BUETTNER, VL; FRISK, CS; MARUTA, Y; HAAVIK, J; SOMMER, SS			P53 WILD-TYPE AND P53 NULLIZYGOUS BIG-BLUE TRANSGENIC MICE HAVE SIMILAR FREQUENCIES AND PATTERNS OF OBSERVED MUTATION IN LIVER, SPLEEN AND BRAIN	ONCOGENE			English	Article						P53; LACI TRANSGENIC MICE; MUTATION FREQUENCY	P53-DEFICIENT MICE; IONIZING-RADIATION; GENE AMPLIFICATION; SOMATIC MUTATION; MAMMALIAN-CELLS; SHUTTLE VECTOR; SKIN TUMORS; MOUSE MODEL; LACI GENE; HA-RAS	Transgenic mouse mutation detection systems offer a powerful tool for analysis of spontaneous and induced mutations in vivo. Mice doubly transgenic for a null mutation of the p53 tumor suppressor gene and a lambda shuttle vector harboring the lacI gene were utilized to examine the rate and pattern of spontaneous somatic mutation of the lad transgene in vivo. Three somatic tissues were examined: liver, spleen and brain, At 6 weeks of age, three p53 wild type (+/+) and three p53 nullizygous (-/-), lad (+/-) male mice were analysed, The mutation frequencies in the two genotypes were similar. The mutant frequencies for wild type (+/+) and nullizygous (-/-) p53 genotypes were, respectively, 4.2x10(-5) and 3.6x10(-5) in the liver, 4.3x10(-5) and 3.4 x 10(-5) in the spleen and 2.8 x 10(-5) and 3.0 x 10(-5) in the brain. When the data from the three tissues were combined, the mutant frequency was 3.7x10(-5) for the (+/+) genotype and 3.3 x 10(5) for the (-/-) genotype. By sequencing both strands in the DNA-binding region of the lad gene, 91 mutations were found. When recurrent mutations in the same mouse were excluded, a total of 67 definitely independent mutations were found. No statistically significant differences were found in the mutational spectra between the two genotypes when the three tissues were analysed individually or combined (P = 0.58). These findings suggest a need to reconsider the general form of hypothesis that the p53 gene serves as the 'guardian of the genome'.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic				Haavik, Jan/0000-0001-7865-2808; Knoll, Antje/0000-0002-1294-6923				BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CALLAHAN JD, 1995, MUTAT RES-FUND MOL M, V327, P201, DOI 10.1016/0027-5107(94)00191-7; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cooper D. N., 1993, HUMAN GENE MUTATION; DAMARUN KM, 1994, SCIENCE, V265, P1582; DIX D, 1989, J GERONTOL, V4, P10; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULDS L, 1958, J Chronic Dis, V8, P2, DOI 10.1016/0021-9681(58)90039-0; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GOSSEN J, 1993, TRENDS GENET, V9, P27, DOI 10.1016/0168-9525(93)90069-T; GOSSEN JA, 1991, MUTAT RES, V250, P423, DOI 10.1016/0027-5107(91)90198-W; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HENDERSON BE, 1988, CANCER RES, V48, P246; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KNOLL A, 1994, MUTAT RES-FUND MOL M, V311, P57, DOI 10.1016/0027-5107(94)90073-6; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, NUCLEIC ACIDS RES, V18, P3007, DOI 10.1093/nar/18.10.3007; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE AT, 1994, FASEB J, V8, P545, DOI 10.1096/fasebj.8.8.8181674; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1989, CANCER RES, V49, P5489; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, ANNU REV GENET, V28, P433; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEHTA CR, 1993, J AM STAT ASSOC, V78, P427; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONROE TJ, 1993, CANCER RES, V53, P5690; MYHR BC, 1991, ENVIRON MOL MUTAGEN, V18, P308, DOI 10.1002/em.2850180420; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; PIEGORSCH WW, 1994, ENVIRON MOL MUTAGEN, V23, P17, DOI 10.1002/em.2850230105; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; PROVOST GS, 1994, P NATL ACAD SCI USA, V91, P6564, DOI 10.1073/pnas.91.14.6564; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SISK SC, 1994, CARCINOGENESIS, V15, P471, DOI 10.1093/carcin/15.3.471; SOMMER SS, 1994, MUTAT RES, V307, P517; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	65	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					263	270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624143				2022-12-28	WOS:A1995RK95700007
J	RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F				RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F			DNA-BINDING SPECIFICITIES OF SPI-1/PU.1 AND SPI-B TRANSCRIPTION FACTORS AND IDENTIFICATION OF A SPI-1/SPI-B BINDING-SITE IN THE C-FES/C-FPS PROMOTER	ONCOGENE			English	Article						SPI-1/PU.1 AND SPI-B; DNA BINDING SITE SELECTION; C-FES/C-FPS	PU.1 REGULATES EXPRESSION; ETS-DOMAIN; PUTATIVE ONCOGENE; ESCHERICHIA-COLI; GENE; PROTEIN; PROTOONCOGENE; ACTIVATION; FAMILY; CELLS	Spi-1/PU.1 and Spi-B encode hematopoietic-specific transcription factors that are the most distantly related members of the Ets family. The Ets proteins share a conserved 85 amino acids DNA binding domain, the Ets domain and recognize various DNA target sites around a common core 5'-GGAA/T-3'. The DNA binding specificities of Spi-1 and Spi-B were investigated by using the method of polymerase chain reaction (PCR)-mediated random site selection. The deduced Spi-1 and Spi-B consensus binding sites are very similar suggesting that the functional activities of Spi-1 and Spi-B cannot be distinguished on the basis of their DNA binding specificities. We identified a putative Spi-1/Spi-B binding site in the promoter region of the c-fes/c-fps protooncogene which encodes a tyrosine kinase expressed predominantly in myeloid cells. In vitro translated Spi-1 and Spi-B proteins were capable to bind this site similarly and to activate the c-fes promoter in HeLa transfected cells. We showed that Spi-1 binds the Spi-1/Spi-B binding site of c-fes in HL-60 cells suggesting that Spi-1 may be involved in the regulation of c-fes transcription in myeloid cells. Intriguingly, we detected only Spi-l binding to this site in the Raji cell line which express both Spi-1 and Spi-B proteins. This suggests that Spi-1 and Spi-B exhibit different DNA binding activities in vivo although they share similar DNA binding specificities in vitro.	FAC MED LARIBOISIERE, INSERM, U248, 10 AVE VERDUN, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019					ALCALAY M, 1990, ONCOGENE, V5, P267; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DELGADO MD, 1994, ONCOGENE, V9, P1723; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORMAN CM, 1982, VIROLOGY, V52, P456; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUCKER M, 1992, ONCOGENE, V7, P943; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAO XH, 1994, J BIOL CHEM, V269, P18216; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PFAFF SL, 1985, VIROLOGY, V146, P307, DOI 10.1016/0042-6822(85)90014-5; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	61	105	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					303	313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624145				2022-12-28	WOS:A1995RK95700011
J	AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E				AHN, MJ; NASONBURCHENAL, K; MOASSER, MM; DMITROVSKY, E			GROWTH SUPPRESSION OF ACUTE PROMYELOCYTIC LEUKEMIA-CELLS HAVING INCREASED EXPRESSION OF THE NONREARRANGED ALLELES - RAR-ALPHA OR PML	ONCOGENE			English	Article						RETINOIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; RAR-ALPHA; PML	TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; T(15-17) TRANSLOCATION; RIBONUCLEIC-ACID; THYROID-HORMONE; X-RECEPTOR; LINE; SEQUENCES; SURVIVAL; CLONING	The balanced t(15;17) rearrangement found in acute promyelocytic leukemia (APL) cells fuses PML on chromosome 15 to the retinoic acid receptor alpha (RAR alpha) on chromosome 17, PML/RAR alpha is expressed in APL cells with the non-rearranged alleles, PML and RAR alpha, Clinical remissions induced by all-trans-retinoic acid (RA) treatment of APL patients are linked to expression of PML/ RAR alpha, a transcription factor with reported dominant negative functions, The roles of PML and RAR alpha in the RA response of APL have not yet been fully explored, This study examines these roles by individually transfecting RAR alpha and PML into NB4 APL cells. NB4 is the sole APL cell Line containing the t(15;17), RA treatment represses NB4 cell growth and induces a myeloid phentoype, Full length cDNAs for RAR alpha and PML were individually cloned into a CMV-driven expression vector containing the neomycin resistance gene, Surprisingly, none of the obtained stable transfectants expressed exogenous RAR alpha or PML mRNAs even when reverse transcription polymerase chain reaction (RT-PCR) detection assays were used. All clones expressed the neomycin resistance gene and were similar to parental NB4 cells in their growth and differentiation properties, An explanation explored for this lack of gene expression was that increased levels of RAR alpha or PML might suppress APL cell growth, To examine this possibility, transfection experiments were repeated using an episomal vector-based expression system containing an SV40 driven RAR alpha or PML cDNA and the hygromycin B resistance gene, A new selection strategy augmented expression of the desired cDNAs, A control episomal vector lacked a cDNA insert, Following electroporation and selection, exogenous RAR alpha expression was obtained. Compared to controls, the growth of these transfectants was markedly inhibited before and after RA-treatment and these cells more prominently induced myeloid maturation markers, In contrast, exogenous PML expression was transient since these transfectants did not appear to propagate in culture, These findings indicate: (1) a growth disadvantage for NB4 cells having increased expression of RAR alpha or PML and (2) increased RAR alpha expression augmented RA-mediated maturation of NB4 cells, This implicates a role for RAR alpha or PML in regulating the growth or differentiation of APL cells, It is hypothesized this occurs through antagonism of PML/RAR alpha actions in these leukemic cells.	MEM HOSP,DEPT MED,GENITOURINARY ONCOL SERV,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [K12CA001712, F32CA061646, R01CA062275] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA61646-01A1, 1R01 CA62275-01, CA01712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DALTON WT, 1988, BLOOD, V71, P242; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KURIE JM, 1994, BBA-MOL CELL RES, V1222, P88, DOI 10.1016/0167-4889(94)90028-0; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MILLER WH, 1990, ONCOGENE, V5, P511; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PACE U, 1994, CANCER RES, V54, P6365; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	31	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784078				2022-12-28	WOS:A1995RE54300005
J	LIN, JY; TERESKY, AK; LEVINE, AJ				LIN, JY; TERESKY, AK; LEVINE, AJ			2 CRITICAL HYDROPHOBIC AMINO-ACIDS IN THE N-TERMINAL DOMAIN OF THE P53 PROTEIN ARE REQUIRED FOR THE GAIN OF FUNCTION PHENOTYPES OF HUMAN P53 MUTANTS	ONCOGENE			English	Note						MUTANT P53; TRANSACTIVATION; TUMORIGENICITY; GAIN OF FUNCTION PHENOTYPES	LARGE-T-ANTIGEN; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; CELLS; DNA; GENE; RAS; IMMORTALIZATION; MODULATION	Some mutant forms of the p53 protein have been shown to gain new functions that are not shared by the wildtype p53 protein; (1) mutant p53 proteins can transcriptionally transactivate the multi-drug resistance gene-1 (MDR-1) and (2) when expressed in nontumorigenic cells with no endogenous p53 protein, mutant p53 proteins can enhance the tumorigenic potential of these cells (Dittmer et at, 1993). It has recently been shown (Lin et al., 1994b) that the transcriptional activator domain of the p53 protein contains two amino acids, leu-22 and trp-23, which are required by the wild-type p53 protein for transcriptional activity. To determine whether these same amino acid residues are utilized by mutant p53 proteins for their gain of function phenotype, the triple mutant p53 protein (at residues 22 and 23 in the transactivation domain and residue 281 in the DNA binding domain-a gain of function mutant) was made. While the p53-281 mutant transcriptionally activates the MDR-1 gene and enhances the tumorigenic potential of cells it is expressed in, the 22, 23, 281 triple mutant failed to carry out either of these functions.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University			Lin, Jiayuh/E-3515-2011					BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIN J, 1994, IN PRESS COLD SPG HB, V59; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, ONCOGENE, V6, P2055; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	30	118	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2387	2390						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784087				2022-12-28	WOS:A1995RE54300014
J	DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E				DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E			CYCLIN D1 MESSENGER-RNA OVEREXPRESSION AS A MARKER FOR MANTLE CELL LYMPHOMA	ONCOGENE			English	Article						MANTLE CELL LYMPHOMA; 11Q13; BCL-1; PRAD1; CCND1; NHL	GENOMIC ORGANIZATION; CENTROCYTIC LYMPHOMA; GENE REARRANGEMENT; CHROMOSOME 11Q13; EXPRESSION; TRANSLOCATION; BREAKPOINTS; LEUKEMIA; CLONING; LINES	In mantle cell lymphoma (MCL) a recurrent chromosomal rearrangement, t(11;14)(q13;q32), has been described. Most breakpoints have been detected within the 120 kb BCL-1 region, upstream of the cyclin D1 gene. To evaluate the association between BCL-1 rearrangement and expression of cyclin D1 in lymphoproliferative disorders, we analysed a series of 24 MCL, 56 other B-cell non-Hodgkin's lymphomas (NHL), 28 chronic B-cell leukemias, 18 hematopoietic cell lines and 10 normal lymphoid tissues at the RNA level. Hematopoietic cell lines with a known 11q13 translocation showed high expression of the 4.5 kb cyclin D1 transcript. Three B-cell lines without known 11q13 breakpoint showed low expression. We detected high expression in all (11/11) MCL with and in 11 out of 13 cases of MCL without detectable t(11;14) rearrangement. In three cases with a rearrangement at the 3' end of cyclin D1, two showed overexpression of the 1.5 kb transcript and one expression of an aberrant (3.0 kb) transcript. In other lymphoproliferative disorders, only 5/15 hairy cell leukemias, all without detectable t(11;14), and 5/8 B-cell leukemias suspected to be MCL in leukemic phase showed expression levels comparable to MCL, whereas no or only low expression were observed in 56 cases of other NHL, seven chronic B-cell leukemias and all (10/10) normal lymphoid tissues. Cell sorting experiments on fresh tonsils showed that this low expression was present in normal B-cells and not in T-cells. In contrast to other studies, our data indicate that cyclin D1 is expressed in many lymphoproliferative disorders and normal tissues, albeit at low levels. High levels of expression of cyclin D1 however is restricted to MCL and some hairy cell leukemias. We therefore propose that overexpression of cyclin D1 is a reliable marker for the classification of MCL.	LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			Kluin-Nelemans, Johanna C/F-8658-2018; van Krieken, Joannes H J M/D-4138-2009	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BATES S, 1994, ONCOGENE, V9, P1633; BONTROP RE, 1986, TISSUE ANTIGENS, V27, P22; BOSCH F, 1994, BLOOD, V84, P2726; BOSCH ML, 1987, HUM IMMUNOL, V19, P91, DOI 10.1016/0198-8859(87)90097-8; DEBOER CJ, 1993, CANCER RES, V53, P4148; DEKROON JFE, 1992, BLOOD S1, V80, pA436; FALKENBURG JHF, 1986, EXP HEMATOL, V14, P101; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JADAYEL D, 1994, BLOOD, V83, P3664; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KLUINNELEMANS JC, 1994, LEUKEMIA, V8, P2095; KLUINNELEMANS JC, 1994, BLOOD, V84, P3134; KOEFFLER HP, 1980, BLOOD, V56, P344; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANGE B, 1987, BLOOD, V70, P192; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; OKA K, 1994, BRIT J HAEMATOL, V86, P786, DOI 10.1111/j.1365-2141.1994.tb04830.x; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHUURING E, 1995, IN PRESS GENE; SETO M, 1992, ONCOGENE, V7, P1401; TAM SW, 1994, ONCOGENE, V9, P2663; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZUCCA E, 1994, ANN ONCOL, V5, P507, DOI 10.1093/oxfordjournals.annonc.a058904; ZUCCA E, 1994, LEUKEMIA LYMPHOMA, V13, P105, DOI 10.3109/10428199409051659	43	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1833	1840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753558				2022-12-28	WOS:A1995QX46900016
J	JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB				JIANG, HP; LIN, J; SU, ZZ; HERLYN, M; KERBEL, RS; WEISSMAN, BE; WELCH, DR; FISHER, PB			THE MELANOMA DIFFERENTIATION-ASSOCIATED GENE MDA-6, WHICH ENCODES THE CYCLIN-DEPENDENT KINASE INHIBITOR P21, IS DIFFERENTIALLY EXPRESSED DURING GROWTH, DIFFERENTIATION AND PROGRESSION IN HUMAN-MELANOMA CELLS	ONCOGENE			English	Article						TERMINAL CELL DIFFERENTIATION; GROWTH CONTROL; MATRIGEL-ASSISTED PROGRESSION; METASTASIS SUPPRESSION	HUMAN-MALIGNANT MELANOMA; GLIOBLASTOMA-MULTIFORME CELLS; RECOMBINANT HUMAN FIBROBLAST; POLYMERASE CHAIN-REACTION; WILD-TYPE P53; ANTIGENIC PHENOTYPE; TRANSFORMED PHENOTYPE; IMMUNE INTERFERON; MESSENGER-RNA; SUPPRESSION	The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) induces terminal differentiation with an irreversible loss of proliferative capacity in human melanoma cells, Using subtraction hybridization, cDNAs were identified that display enhanced expression in terminally differentiated and growth arrested human melanoma cells (Jiang and Fisher, 1993; Jiang et al., 1994a), A specific melanoma differentiation-associated (mda) cDNA, mda-6, is described whose expression inversely correlates with melanoma progression and growth, mda-6 is identical to WAF1/CIP1/SDI1 that encodes the M-r 21 000 protein (p21) that is an inhibitor of cyclin-dependent kinases, Actively growing normal melanocyte, SV40-immortalized human melanocyte and dysplastic nevus cell. lines synthesize elevated levels of mda-6 mRNA; whereas, actively proliferating radial and early vertical growth phase primary melanomas as well as metastatic human melanoma cells produce reduced levels of mda-6 mRNA, Treatment of primary and metastatic human melanoma cells with IFN-beta+MEZ results in growth inhibition and an increase in mda-6 expression, mda-6 expression also increases when human melanoma cells are grown to high saturation densities or when grown in serum-free medium, Using anti-p53 and anti-p21 antibodies, an inverse correlation is found between p53 and p21 protein levels during growth arrest and differentiation, Induction of growth arrest and terminal differentiation in H0-1 human melanoma cells by IFN-beta+MEZ results in a temporal decrease in wildtype p53 protein levels with a corresponding increase in p21 levels, In the Matrigel-assisted melanoma progression model, mda-6 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice, In metastatic human melanoma cells displaying a loss of metastatic potential resulting from introduction of a normal human chromosome 6, mda-6 mRNA levels increase, Taken together, these studies indicate that mda-6 (p21) may function as a negative regulator of melanoma growth, progression and metastasis.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT PATHOL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES,DEPT UROL, CTR COMPREHENS CANC, NEW YORK, NY 10027 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; SUNNYBROOK HLTH SCI CTR, DIV CANC RES, TORONTO, ON M4N 3M5, CANADA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; PENN STATE UNIV, COLL MED,MILTON S HERSHEY MED CTR,DEPT PATHOL, DIV EXPTL PATHOL, HERSHEY, PA 17033 USA	Columbia University; Columbia University; The Wistar Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA43208, CA35675, CA25874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043208, P01CA025874, R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1986, ANTICANCER RES, V6, P765; FISHER PB, 1991, STATUS DIFFERENTIATI, V2, P201; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; HARPER JW, 1993, CELL, V75, P805; HAYES TE, 1991, NEW BIOL, V3, P259; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; KOBAYASHI H, 1994, AM J PATHOL, V144, P776; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI Y, 1994, ONCOGENE, V9, P2261; LIN J, 1994, INT J ONCOL, V5, P5; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loganzo Frank Jr., 1994, Molecular and Cellular Differentiation, V2, P23; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOTAN R, 1993, RETINOIDS ONCOLOGY, P43; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; MELBER K, 1989, CANCER RES, V49, P3650; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLIKIN D, 1991, CANCER RES, V51, P5449; MONTANO X, 1994, ONCOGENE, V9, P1455; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; RICHON VM, 1989, ONCOGENE, V4, P165; RON D, 1994, P NATL ACAD SCI USA, V91, P1985, DOI 10.1073/pnas.91.6.1985; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SHOBAT O, 1987, ONCOGENE, V1, P277; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	73	181	192	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753561				2022-12-28	WOS:A1995QX46900019
J	MOASSER, MM; REUTER, VE; DMITROVSKY, E				MOASSER, MM; REUTER, VE; DMITROVSKY, E			OVEREXPRESSION OF THE RETINOIC ACID RECEPTOR-GAMMA DIRECTLY INDUCES TERMINAL DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article						RETINOIC ACID; DIFFERENTIATION; EMBRYONAL CARCINOMA; EPISOMAL VECTOR; RAR-GAMMA	ACUTE PROMYELOCYTIC LEUKEMIA; TERATOCARCINOMA STEM-CELLS; EPSTEIN-BARR VIRUS; GRANULOCYTIC DIFFERENTIATION; NUCLEAR RECEPTORS; EXPRESSION; ALPHA; GENE; MOUSE; ISOFORMS	All-trans retinoic acid (RA) exerts profound effects on the growth and differentiation of normal, embryonic, and malignant cells. The effects of RA are mediated through multiple members of the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of nuclear transcription factors, The RARs and RXRs exhibit specific patterns of expression during development and in adult tissues suggesting tissue or cell-type specific functions. Using NTera2/clone D1 (NT2/D1) human embryonal carcinoma cells as a model, we report that the RA induced terminal differentiation of these cells into a neuronal phenotype is characterized by an increase in expression of RAR alpha, RAR beta, RAR gamma, and a slight induction of RXR alpha. TO study the role of these receptors in the differentiation process we individually overexpressed RAR alpha, beta, gamma and RXR alpha in NT2/D1 cells by cDNA transfection. Using induced cDNA expression by episomal vector amplification we show that RAR gamma overexpression causes the terminal mesenchymal differentiation of these cells,while over-expresssion of RAR alpha, beta and RXR alpha has no observed maturation or growth inhibitory effects. Over-expression of these receptors in the derived RA resistant subclone NT2/D1-R1 showed phenotypic changes characteristic of RA response in RAR gamma transfectants. These studies indicate that of the retinoid receptors expressed in RA-treated NT2/D1 cells, it is the upregulation of RAR gamma that specifically induces the terminal differentiation of these cells.	MEM HOSP,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MOLEC PHARMACOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-03, T32-CA-09512-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009512, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1987, J CELL BIOCHEM, V35, P321, DOI 10.1002/jcb.240350407; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANIATIS T, 1989, COLD SPRING HARBOR L; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1994, ONCOGENE, V9, P833; MOON RC, 1983, CANCER RES, V43, P24696; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	41	49	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1537	1543						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731708				2022-12-28	WOS:A1995QU68100009
J	COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP				COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP			ANDROGEN SUPPRESSED APOPTOSIS IS MODIFIED IN P53 DEFICIENT MICE	ONCOGENE			English	Article						APOPTOSIS; GENE, P53; PROSTATE, GLAND; CELL CYCLE; CASTRATION EFFECT; DNA FRAGMENTATION	WILD-TYPE P53; RAT PROSTATE; CELL-CYCLE; DNA; DEATH; INVOLUTION; INDUCTION; GLAND; GENE	Several in vitro studies have provided evidence that the tumor suppressor protein, p53, is involved in the cell death process referred to as apoptosis, The recent development of p53 knock-out mice has enabled further investigation into the function of p53 for apoptosis, in vivo. Radiation-induced apoptosis is suppressed in such mice, yet other forms of apoptosis do not seem to be significantly affected, In this report, we present evidence that such male p53 nullizygous mice have less apoptosis in the prostate glands associated,vith the first 4 days following castration, Ventral prostate glands were obtained from normal, heterozygous p53-null and p53 nullizygous mice at daily intervals after castration, These tissues were stained for apoptosis with the use of the irt situ end labeling method and apoptotic bodies were quantified by microscopy, Although labeled apoptotic bodies were observed in post-castrated tissues from all of these genetic variant mice, the onset of apoptosis was delayed and the occurrence of apoptosis was significantly reduced in the p53 nullizygous mice when compared to normal controls, Heterozygous p53-null mice were intermediate for these criteria, Examination of the internucleosomal DNA fragmentation pattern at 2 days of castration supports a significant diminution of prostate cell apoptosis in nullizygous p53 mice, Additionally, large nucleated and multinucleated cells were detected in the prostate epithelium of noncastrated p53 nullizygous mice and these abnormal cells were increased after castration, Flow cytometric analysis of these tissues confirmed a high number of 4C and 8C DNA content cells in the p53 nullizygous prostates and their frequency was increased by castration, In concordance with an earlier study, we conclude that functional p53 protein is not essential for prostate epithelial cells to undergo catration-induced apoptosis, However, wild-type p53 does appear to enhance this process, especially in the early period following castration, and this protein may regulate an aberrant prostate cell cycling activity that follows castration.	CNRS, URA 1337, PARIS, FRANCE; ECOLE NORMALE SUPER, F-75230 PARIS 05, FRANCE; COLUMBIA UNIV, PRESBYTERIAN HOSP, DEPT UROL, NEW YORK, NY 10032 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine	COLOMBEL, M (corresponding author), CHU HENRI MONDOR, SERV UROL, ETUD TUMEURS UROL GRP, F-94010 CRETEIL, FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; colombel, marc/0000-0002-0152-8021; Radvanyi, Francois/0000-0002-5696-6424				BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CASEY G, 1991, ONCOGENE, V6, P1791; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; KATZ AE, 1989, CANCER RES, V49, P5889; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KIPRIANOU N, 1990, CANCER RES, V50, P3748; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARIE D, 1993, BIOL CELL, V78, P41, DOI 10.1016/0248-4900(93)90113-S; MERRITT AJ, 1994, CANCER RES, V54, P614; RAMVQVIST T, 1993, ONCOGENE, V8, P1495; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XJ, 1994, BIOCHEM BIOPH RES CO, V198, P1189, DOI 10.1006/bbrc.1994.1168	21	55	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1269	1274						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731676				2022-12-28	WOS:A1995QR65100002
J	YANG, JJ; KANG, JS; KRAUSS, RS				YANG, JJ; KANG, JS; KRAUSS, RS			TRANSFORMATION-RESTORING FACTOR - A LOW-MOLECULAR-WEIGHT SECRETED FACTOR REQUIRED FOR ANCHORAGE-INDEPENDENT GROWTH OF ONCOGENE-RESISTANT MUTANT-CELL LINES	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; GENETIC REVERTANT; RAS ONCOGENE; GROWTH FACTORS; SIGNAL TRANSDUCTION	ACTIVATED PROTEIN-KINASE; H-RAS ONCOGENE; SIGNAL-TRANSDUCTION; MAP KINASES; NUDE MICE; PHOSPHORYLATION; TUMORIGENICITY; FIBROBLASTS; EXPRESSION; REVERTANTS	We have previously described two independent mutant rat fibroblast cell lines that fail to form colonies in soft agar when infected with a v-H-ras-expressing retrovirus, yet still undergo transformation-related morphological alterations in response to this oncogene, We report here that conditioned medium (CM) from non-transformed rat fibroblasts contains an activity that specifically corrects this defect in the mutant cell lines, rendering them capable of anchorage-independent growth in response to uas, The major activity in CM, designated transformation-restoring factor (TRF), is similar to 1300 molecular weight, lipid insoluble, and heat, protease, acid and base stable, Latent activity, distinct from TRF, is also present in CM; several lines of evidence indicate that transforming growth factor (TGF) beta is responsible for this activity, TRF, however, cannot substitute for TGF beta in the phenotypic transformation of NRK cells, TRF activity is decreased in CM of control cells transformed by uas and this response to ras is retained by the mutant cell lines, We propose that whereas wild-type cells transformed by ras may constitutively activate a TRF-regulated pathway, thus becoming independent of TRF for growth in soft agar, these mutants have acquired dependence on an exogenous supply of TRF for this aspect of the transformed phenotype, Cellular activities regulated, directly or indirectly, by TRF may be effecters of the anchorge-independent growth property that is a hallmark of transformed rodent fibroblasts.	MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA059474, R29CA059474] Funding Source: NIH RePORTER; NCI NIH HHS [CA59474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; ANZANO MA, 1982, CANCER RES, V42, P4776; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLBURN NH, 1978, CANCER RES, V38, P624; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EAGLE H, 1960, P NATL ACAD SCI USA, V46, P427, DOI 10.1073/pnas.46.4.427; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GWATKIN RB, 1960, NATURE, V186, P984, DOI 10.1038/186984a0; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PICKART L, 1973, NATURE-NEW BIOL, V243, P85; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHODELL M, 1973, NATURE-NEW BIOL, V243, P83; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	35	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1291	1299						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731679				2022-12-28	WOS:A1995QR65100005
J	DOBRZANSKI, P; RYSECK, RP; BRAVO, R				DOBRZANSKI, P; RYSECK, RP; BRAVO, R			SPECIFIC-INHIBITION OF RELB/P52 TRANSCRIPTIONAL ACTIVITY BY THE C-TERMINAL DOMAIN OF P100	ONCOGENE			English	Note						RELB-P52 COMPLEX; P100 C-TERMINUS; TRANSCRIPTIONAL INHIBITION	NF-KAPPA-B; REL-ASSOCIATED PP40; DNA-BINDING; ACTIVATION; PROTEIN; ALPHA; PHOSPHORYLATION; PRECURSOR; ENCODES; FAMILY	The Rel/NF-kappa B family transcriptional factors plays an important role in the regulation of immune and acute phase responses. The activity of Rel/NF-kappa B complexes is regulated by their interactions with members of the I kappa B family of inhibitors. We have previously shown that the RelB/p52 heterodimer is not effectively inhibited by any of the known I kappa B molecules: I kappa B alpha, I kappa B gamma and Bcl3. Here we report that the C-terminal domain of p100 (the putative I kappa B delta) functions as a strong inhibitor of RelB/p52 transcriptional activity. In vivo interaction with I kappa B delta leads to the cytoplasmic retention and decreased DNA binding activity of RelB/p52 complexes. Thus, I kappa B delta is the only I kappa B molecule able to efficiently modulate the activity of RelB/p52 heterodimer, In Daudi cells, a 46 kD protein, probably representing the C-terminal product of the proteolytic processing of p100, remains associated,vith Rel/NF-kappa B complexes and might have a transient regulatory function. Our results indicate a specific role for the putative I kappa B delta and suggest a possible mechanism of how the truncation of the ankyrin domain of p100, found in a number of lymphoid neoplasias, might contribute to tumorigenesis.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P343; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	44	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1003	1007						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898917				2022-12-28	WOS:A1995QL03800022
J	JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC				JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC			INDUCTION OF APOPTOSIS IN NIH3T3 CELLS AFTER SERUM DEPRIVATION BY OVEREXPRESSION OF RHO-P21, A GTPASE PROTEIN OF THE RAS SUPERFAMILY	ONCOGENE			English	Article						RHO; APOPTOSIS; TRANSFORMATION	SWISS 3T3 CELLS; BINDING PROTEIN; RHO P21; ADP-RIBOSYLATION; GENE-PRODUCT; EXPRESSION; EXCHANGE; GROWTH; ENDONUCLEASE; ACTIVATION	Oncogenes appear to influence apoptosis in two ways. Some activate cells from a growth-arrested state to one in which both apoptosis and entry to S-phase become possible, the choice between them being determined by a second signal, such as cytokine or growth factor. Cells in this state are often sensitive to apoptosis induced by a wide variety of agents, including several drugs used in cancer chemotherapy. Other oncogenes prevent activation of the apoptosis effector pathway, even in the presence of a death stimulus, the affected cells therefore being resistant to chemotherapeutic agents. In rodent fibroblasts, c-myc or the adenovirus oncogene E1A effect the first type of change, whereas bcl-2, v-abl, E1B or activated uas effect the second. Here we study in rodent fibroblast the effect of expression of rho genes, members of the ras superfamily which we have previously shown to be tumorigenic when highly expressed in this cell type. We show that expression of wild-type who from Aplysia californica stimulates apoptosis in cultured cell lines and that the apoptotic index in tumors generated by these cell lines is similar to those induced by E1A-transformed cells. In contrast, mutated rho, activated by Val(14) substitution in the GTP binding site, it less potent as a stimulator of apoptosis, generating a phenotype more similar to that obtained with activated vas. Thus, rho genes may play a critical role in the regulation of apoptosis.	CSIC, INST INVEST BIOMED, MADRID, SPAIN; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH, MIDLOTHIAN, SCOTLAND; CLIN PUERTA HIERRO, SERV ANAT PATOL, MADRID, SPAIN; UNIV AUTONOMA MADRID, DEPT BIOQUIM, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Edinburgh; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid			Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/AAY-4271-2021; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Lacal, Juan Carlos/N-9064-2015	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, NATO ADV SCI I A-LIF, V220, P237; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN WN, 1994, J BIOL CHEM, V269, P820; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LACAL JC, 1994, ONCOL REP, V1, P677; LANG P, 1992, J BIOL CHEM, V267, P11677; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MORII N, 1992, J BIOL CHEM, V267, P20921; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUGAI M, 1992, J BIOL CHEM, V267, P21297; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VICENT S, 1992, MOL CELL BIOL, V12, P3138; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG, 1994, J BIOL CHEM, V269, P2369; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					811	816						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898922				2022-12-28	WOS:A1995QL03800001
J	COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE				COMERFORD, SA; MAIKA, SD; LAIMINS, LA; MESSING, A; ELSASSER, HP; HAMMER, RE			E6 AND E7 EXPRESSION FROM THE HPV-18 LCR - DEVELOPMENT OF GENITAL HYPERPLASIA AND NEOPLASIA IN TRANSGENIC MICE	ONCOGENE			English	Article						HPV-18; CERVICAL NEOPLASIA; SEMINAL VESICLE; PREPUTIAL GLAND; TRANSGENIC MICE	HUMAN PAPILLOMAVIRUS TYPE-16; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; REGULATORY REGION; UTERINE CERVIX; STROMAL CELLS; GENE-PRODUCTS; T-CELL; PROTEIN	Human papillomavirus type 18 infection is highly associated with malignant tumors of the genital tract. To investigate the tissue specificity of the HPV long control region (LCR) and the transforming ability of the E6-E7 oncoproteins, an HPV-18 transgene containing the viral LCR and E6 and E7 genes was introduced into mice. Three founder males exhibited enlarged seminal vesicles and preputial glands by 50 weeks of age. A line of transgenic mice was established by in vitro fertilization, and subsequent generations of transgenic males and females were monitored for lesions. Approximately 80% of hemizygous transgenic males exhibited enlarged seminal vesicles and preputial glands as early as 12 weeks of age. Histological examination indicated that this enlargement was due to distension by fluid, along with polyploid hyperplasia of the lining secretory epithelium. E6 and E7 transcripts were limited to affected organs and kidney. Approximately 41% of transgenic females developed cervical neoplasms between 1-2 years of age. Histologically, tumors were mesenchymal rather than epithelial in origin. E6 and E7 transcripts were restricted to cervical tumor tissue and kidney. These findings suggest that the HPV-18 LCR has an element(s) which directs expression specifically to the urogenital tract in transgenic mice.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV WISCONSIN, SCH VET MED, DEPT PATHOBIOL SCI, MADISON, WI 53706 USA; UNIV MARBURG, DEPT CELL BIOL, D-35033 MARBURG, GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Philipps University Marburg				Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759				APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BEDELL MA, 1991, J VIROL, V65, P2254, DOI 10.1128/JVI.65.5.2254-2260.1991; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; CID A, 1993, J VIROL, V67, P6742, DOI 10.1128/JVI.67.11.6742-6752.1993; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; COMERFORD SA, 1991, J VIROL, V65, P4681, DOI 10.1128/JVI.65.9.4681-4690.1991; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIETRICH W, 1992, GENETICS, V131, P423; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1988, J VIROL, V62, P665, DOI 10.1128/JVI.62.3.665-672.1988; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JOCHMUSKUDIELKA I, 1989, J NATL CANCER I, V81, P1698, DOI 10.1093/jnci/81.22.1698; JONES MH, 1992, ONCOGENE, V7, P1631; KIRCHNER H, 1986, PROG MED VIROL, V33, P1; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; KREIDER JW, 1987, J VIROL, V61, P590, DOI 10.1128/JVI.61.2.590-593.1987; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; MCCANCE DJ, 1985, BIOCHIM BIOPHYS ACTA, V823, P195, DOI 10.1016/0304-419X(86)90002-8; MCLEAN CS, 1993, J GEN VIROL, V74, P239, DOI 10.1099/0022-1317-74-2-239; MENEGUZZI G, 1991, VIROLOGY, V181, P62, DOI 10.1016/0042-6822(91)90470-V; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; MITTAL R, 1993, OBSTET GYNECOL, V81, P5; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SANG BC, 1992, VIROLOGY, V189, P448, DOI 10.1016/0042-6822(92)90568-A; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; SAPPINO AP, 1989, VIRCHOWS ARCH A, V415, P551, DOI 10.1007/BF00718649; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SELVEY LA, 1990, J IMMUNOL, V145, P3105; SHEPHERD PS, 1992, J GEN VIROL, V73, P1269, DOI 10.1099/0022-1317-73-5-1269; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SPENCER ES, 1970, BRIT MED J, V3, P251, DOI 10.1136/bmj.3.5717.251; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; TINDLE RW, 1991, P NATL ACAD SCI USA, V88, P5887, DOI 10.1073/pnas.88.13.5887; TINSLEY JM, 1992, J GEN VIROL, V73, P1251, DOI 10.1099/0022-1317-73-5-1251; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WANK R, 1991, NATURE, V352, P723, DOI 10.1038/352723a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; YOKOTA J, 1989, CANCER RES, V49, P3598	68	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					587	597						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845684				2022-12-28	WOS:A1995QF64800020
J	HUEN, DS; HENDERSON, SA; CROOMCARTER, D; ROWE, M				HUEN, DS; HENDERSON, SA; CROOMCARTER, D; ROWE, M			THE EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 (LMP1) MEDIATES ACTIVATION OF NF-KAPPA-B AND CELL-SURFACE PHENOTYPE VIA 2 EFFECTOR REGIONS IN ITS CARBOXY-TERMINAL CYTOPLASMIC DOMAIN	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; LMP; NF-KB; CD40; CD54	NASOPHARYNGEAL CARCINOMA; BETA-GALACTOSIDASE; TRANSFORMED-CELLS; GENE-EXPRESSION; LYMPHOCYTES-B; INDUCTION; LINE; REPLICATION; DNA; HETEROGENEITY	The Epstein-Barr virus (EBV) encoded latent membrane protein, LMP1, is oncogenic in rodent fibroblasts and is an essential effector protein in EBV-induced growth-transformation of human B lymphocytes. Previous structure-function studies with LMP1 have relied largely on rodent fibroblast transformation as a functional readout, with apparently conflicting results. We have now analysed several LMP1 mutants in various human cell types, including B cells, T cells and epithelial cells, using two independent functional assays; (i) activation of NF-KB, and (ii) induction of two cell surface activation markers, CD54 and CD40. The results suggest that the cytosolic N-terminus is not essential for LMP1 function in any cell type studied. The third and fourth transmembrane helices and the intracytosolic loops are dispensable for activation of NF-KB, but they do influence the induction of CD54 and CD40. The major effector domain appears to be the cytosolic C-terminus in which were identified two 'C-terminal activating regions', CTAR-1 (residues 194-232) and CTAR-2 (residues 351-386). Whilst the exact results depended upon the host cell line, CTAR-2 was generally more important for activation of NF-KB, and both CTAR-1 and CTAR-2 were required for optimal induction of CD54 and CD40. Analysis of NF-kappa B activation by LMP1 in Rat-1 fibroblasts indicated that many mutations that were functional in human cells were poorly tolerated in the rodent cells; a result that is in broad agreement with published Rat-1 transformation data.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	University of Birmingham			Rowe, Martin/B-2880-2009; Huen, David/F-3676-2014	Rowe, Martin/0000-0003-4139-7326; Huen, David/0000-0002-9900-2297; Hope, Sheila/0000-0002-3608-4379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARENZANASEISDEDOS, 1993, J VIROL, V67, P6596; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIMALDI JC, 1991, J IMMUNOL, V149, P3921; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1993, ONCOGENE, V8, P1575; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KIEFF E, 1990, P1889; KIEFF E, 1994, 51ST S SOC GEN MICR, P123; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MASUCCI MG, 1989, J VIROL, V63, P3135, DOI 10.1128/JVI.63.7.3135-3141.1989; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MILLER G, 1990, P1921; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; PENG M, 1992, ONCOGENE, V7, P1775; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PILON M, 1990, J IMMUNOL, V146, P1047; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SCHWARTZ O, 1990, GENE, V88, P197, DOI 10.1016/0378-1119(90)90032-M; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	56	432	445	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					549	560						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845680				2022-12-28	WOS:A1995QF64800016
J	KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF				KNECHT, H; BACHMANN, E; BROUSSET, P; ROTHENBERGER, S; EINSELE, H; LESTOU, VS; DELSOL, G; BACHMANN, F; AMBROS, PF; ODERMATT, BF			MUTATIONAL HOT-SPOTS WITHIN THE CARBOXY-TERMINAL REGION OF THE LMP1 ONCOGENE OF EPSTEIN-BARR-VIRUS ARE FREQUENT IN LYMPHOPROLIFERATIVE DISORDERS	ONCOGENE			English	Article						EPSTEIN-BARR VIRUS; ONCOGENE; LMP1; MUTATIONAL HOTSPOTS; LYMPHOMA; TRANSLOCATIONS	MEMBRANE-PROTEIN LMP-1; REED-STERNBERG CELLS; LATENT GENE-PRODUCTS; HODGKINS-DISEASE; NASOPHARYNGEAL CARCINOMA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; B-CELLS; EXPRESSION; INFECTION; LYMPHOMAS	We have recently identified in Epstein-Barr virus (EBV) positive Hodgkin's disease (HD) a variant of the latent membrane protein 1 (LMP1) oncogene characterized by four point mutations and a 30 base pair deletion. These findings led us to test whether such mutants were also present in other lymphoproliferative disorders (LPD). We analysed 98 EBV DNA positive cases (67 LPD, 15 benign conditions, 16 lymphoblastoid cell lines) by PCR for deletions within the LMP1 gene. DNA sequencing of the region coding for the carboxy terminal protein domain was performed on 24 cases. In 13 cases the same combination of 4 point mutations at positions 168 320, 168 308, 168 295 and 168 225 was identified. Of these cases, 12 had an additional point mutation at position 168 357 and eight at position 168 355, and nine had a 30 base pair deletion including nucleotides 168 285 to 168 256. These deletion mutants were identified in HD, angioimmunoblastic lymphadenopathy, B-immunoblastic lymphoma, peripheral T-cell lymphoma, and two lymphoblastoid cell lines. Our findings reveal a high frequency of non-random point mutations at preferential sites within the 3' (carboxy terminal) region of the LMP1 oncogene. The association of these mutational hot spots with LPD suggests that they are involved in EBV related lymphomagenesis and that they define a clinically relevant EBV strain.	CHU VAUDOIS,DEPT INTERNAL MED,CH-1011 LAUSANNE,SWITZERLAND; CHU PURPAN,ANAT PATHOL LAB,TOULOUSE,FRANCE; UNIV TUBINGEN HOSP,MED CLIN,TUBINGEN,GERMANY; ST ANNA CHILDRENS HOSP,CCRI,VIENNA,AUSTRIA; UNIV ZURICH HOSP,INST PATHOL,CH-8091 ZURICH,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Toulouse; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Saint Anna Children's Hospital; University of Zurich; University Zurich Hospital			Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Rothenberger, Sylvia/0000-0001-8633-2994				ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; BROUSSET P, 1993, BLOOD, V82, P872; CARBONE A, 1993, J CLIN ONCOL, V11, P1674, DOI 10.1200/JCO.1993.11.9.1674; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; HERBST H, 1991, BLOOD, V78, P2666; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HU LF, 1993, ONCOGENE, V8, P1575; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; KIEFF E, 1990, FUNDAMENTAL VIROLOGY, P897; KNAPP S, 1994, ONCOGENE, V9, P1501; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, LEUKEMIA, V7, P580; KNECHT H, 1994, ACTA HAEMATOL, V90, P167; KORBJUHN P, 1993, BLOOD, V82, P217, DOI 10.1182/blood.V82.1.217.bloodjournal821217; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LESTOU VS, 1993, GENE CHROMOSOME CANC, V8, P38, DOI 10.1002/gcc.2870080108; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; RAABTRAUB N, 1991, J VIROL, V65, P7032, DOI 10.1128/JVI.65.12.7032-7036.1991; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THORLEYLAWSON DA, 1987, P NATL ACAD SCI USA, V88, P5384; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; VASSALLO J, 1993, APPL IMMUNOHISTO M M, V1, P213; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1992, BLOOD, V79, P1789; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	49	87	89	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845677				2022-12-28	WOS:A1995QF64800013
J	POLUHA, W; POLUHA, DK; ROSS, AH				POLUHA, W; POLUHA, DK; ROSS, AH			TRKA NEUROGENIC RECEPTOR REGULATES DIFFERENTIATION OF NEUROBLASTOMA-CELLS	ONCOGENE			English	Note						APHIDICOLIN; TERMINAL DIFFERENTIATION; TYROSINE KINASE; NERVE GROWTH FACTOR; NGF RECEPTOR; C-MYC	NERVE GROWTH-FACTOR; DEVELOPING SENSORY NEURONS; PROTOONCOGENE; EXPRESSION; BLASTOMA; LINES; PROTEIN; ENCODES; TUMORS	We examined events associated with neuronal differentiation of neuroblastoma cell line SH-SY5Y, Treatment with nerve growth factor (NGF) and aphidicolin, an inhibitor of DNA polymerases alpha and delta, induces terminal differentiation of SH-SY5Y cells, Following 3-4 days of treatment with NGF+aphidicolin, the cells irreversibly ceased proliferation and differentiated. There was a succession of events preceding differentiation, Downregulation of c-myc was an early event occurring after less than 1 day of treatment with NGF+aphidicolin. Upregulation of the trkA and low-affinity NGF receptors (LNGFR) occurred after 3 days of NGF+aphidicolin treatment and required treatment with both NGF and aphidicolin, To test the role of TrkA in neuroblastic differentiation, we transfected SH-SY5Y cells with a TrkA-expression plasmid, In response to NGF in the absence of aphidicolin, the TrkA-transformant line ceased proliferation and irreversibly differentiated. SH-SY5Y cells bearing a control plasmid displayed only modest, reversible differentiation and did not cease cell proliferation in response to NGF, Hence, expression of NGF receptors is upregulated during differentiation of SH-SY5Y cells, and overexpression of TrkA enhances NGF-induced differentiation.	WORCESTER FDN EXPTL BIOL INC,SHREWSBURY,MA 01545	Worcester Foundation for Biomedical Research					NICHD NIH HHS [HD-07312] Funding Source: Medline; NINDS NIH HHS [NS-21716, NS-28760] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716, R01NS028760] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; DONOVAN MJ, 1993, AM J PATHOL, V143, P1560; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JENSEN LM, 1987, DEV BIOL, V120, P56, DOI 10.1016/0012-1606(87)90103-5; JENSEN LM, 1992, J BIOL CHEM, V267, P19325; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KOGNER P, 1993, CANCER RES, V53, P2044; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; ROSS AH, 1985, ARCH BIOCHEM BIOPHYS, V242, P540, DOI 10.1016/0003-9861(85)90241-3; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WRIGHT EM, 1992, NEURON, V9, P139, DOI 10.1016/0896-6273(92)90229-7; WYATT S, 1993, DEVELOPMENT, V119, P635; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	26	60	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					185	189						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824271				2022-12-28	WOS:A1995QA98000021
J	HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T				HAMAGUCHI, I; IWAMA, A; YAMAGUCHI, N; SAKANO, S; MATSUDA, Y; SUDA, T			CHARACTERIZATION OF MOUSE NONRECEPTOR TYROSINE KINASE GENE, HYL	ONCOGENE			English	Note							RAT-BRAIN; PROTEIN; MICE; FYN; LOCALIZATION; FAMILY; CSK	We previously reported a novel human non-receptor tyrosine kinase gene, HYL (hematopoietic consensus tyrosine-lacking kinase) (Sakano et al., 1994), which consists of each of the SH2 (src homology 2), SH3 and tyrosine kinase catalytic domains. HYL has unique structural features shared with CSK (C-terminal Src kinase). Recently it has also been reported that matk (Bennett et al., 1994) and Ctk (Klages et al., 1994) are isolated as novel kinases with structural similarity to CSK. Comparisons of cDNA sequence indicate the HYL, matk and Ctk are the same gene. We further characterized the mouse HYL genomic structure and HYL mRNA expression in mouse brain. The mouse HYL gene is distributed over 5.8 kb and is composed of 12 exons; The exon-intron organization is almost identical with that of human CSK. The mouse HYL gene was assigned to the R-positive C1 band of chromosome 10 by fluorescent in situ hybridization. RNA in situ hybridization demonstrated the broad distribution of HYL mRNA expression in various neuronal cells. Especially, strong signals were detected in Purkinje cells, pyramidal cells in the hippocampus, granule cells in the dentate gyrus, and mitral cells in the olfactory bulb, indicating that mRNA expression of HYL in brain is very similar to that of SRC-family kinases. These findings establish close relationship between the HYL and CSK genes and also suggest that HYL may play an important role in signal transduction through SRC-family kinases in the central nervous system.	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI 416,SHIZUOKA,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 263,JAPAN	Kumamoto University; National Institutes for Quantum Science & Technology			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771				BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; COOKE M P, 1989, New Biologist, V1, P66; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SAKANO S, 1994, ONCOGENE, V9, P1115; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SOMSSICH IE, 1989, GENETIC VARIANTS STR, P580; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAGI T, 1993, ONCOGENE, V8, P3343; ZHAO YH, 1991, ONCOGENE, V6, P1725	25	16	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3371	3374						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936664				2022-12-28	WOS:A1994PM65800033
J	SUZUKI, T; HIRAI, H; YOSHIDA, M				SUZUKI, T; HIRAI, H; YOSHIDA, M			TAX PROTEIN OF HTLV-1 INTERACTS WITH THE REL HOMOLOGY DOMAIN OF NF-KAPPA-B P65 AND C-REL PROTEINS BOUND TO THE NF-KAPPA-B BINDING-SITE AND ACTIVATES TRANSCRIPTION	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; TRANSACTIVATOR; ENHANCER; PROMOTER; P40X	Tax protein of human T cell leukemia virus type 1 (HTLV-1) enhances transcription of several cellular genes through activation of a specific enhancer, the NF-kappa B binding site. We found previously that Tax binds to NF-kappa B p50, which is a member of the Rel/NF-kappa B family proteins, and associates with the DNA sequence of the NF-kappa B binding site. In the present study, we tested other NF-kappa B family proteins and found that NF-kappa B p65 and c-Rel proteins also bind to Tax and that their complexes with Tax bind to the DNA sequence of the NF-kappa B binding site. The Tax binding site on NF-kappa B p50 is the Rel homology domain, which is conserved in the Rel/NF-kappa B family proteins. The formations of these complexes by Tax mutants were well correlated with their transactivating capacities. In F9 embryonic carcinoma cells, Tax enhanced transcription synergistically with NF-kappa B p65 or c-Rel. Thus Tax interacts with the Rel homology domain of Rel/NF-kappa B family proteins which bind to the NF-kappa B binding site and activates transcription.	UNIV TOKYO,INST MED SCI,DEPT CELL & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BAUERLE PA, 1988, CELL, V53, P211; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GESSAIN A, 1985, LANCET, V2, P407; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KIYOKAWA T, 1984, JPN J CANCER RES, V75, P747; LANOIX J, 1994, ONCOGENE, V9, P841; Leonardo MJ, 1998, CELL, V58, P227; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	36	92	95	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3099	3105						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936632				2022-12-28	WOS:A1994PM65800001
J	GALIEN, R; EMANOILRAVIER, R; MERCIER, G				GALIEN, R; EMANOILRAVIER, R; MERCIER, G			DIFFERENTIAL-EFFECTS OF C-JUN AND CREB ON CAMP RESPONSE ELEMENT ACTIVATION BY HA-RAS	ONCOGENE			English	Article							LEUCINE ZIPPER STRUCTURE; DNA-BINDING PROTEIN; ATF CDNA CLONES; CYCLIC-AMP; TRANSCRIPTION FACTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; GENE-TRANSCRIPTION; CROSS-TALK; FOS-JUN	We have previously shown that a Long Terminal Repeat (LTR) of the Intracisternal A-type Particle (IAP) element was activated by ras oncogenes. Here we show that, like the somatostatin CRE (som CRE) and the collagenase TPA Response Element (coll TRE), the IAP CRE is activated by c-jun and that Val 12 Ha-ras cooperates with c-jun to activate these motifs. Neither jun-B nor jun-D activated the IAP CRE, although they were able to act on the som CRE and the coll TRE and to synergize with ras. The CREB factor activated both CREs and modestly inhibited the coll TRE, but diminished the effect of ras on the coll TRE. Finally, forskolin was shown to cooperate with Ha-ras to activate the CRE and the coll TRE. Taken together, these results show that CREB is not involved in ras activation of the CRE and suggest that c-jun is at least one of the elements implicated in this phenomenon.	HOP ST LOUIS,RETROVIRUS & RETROTRANSPOSONS VERTEBRES LAB,CNRS,UPR 0043,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1992, ONCOGENE, V7, P2271; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DEGROOT RP, 1992, ONCOGENE, V7, P841; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALIEN R, 1991, ONCOGENE, V6, P849; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTAL A, 1989, CELL, V54, P325; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU YL, 1990, J BIOL CHEM, V265, P20285; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	83	17	17	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1101	1108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7907782				2022-12-28	WOS:A1994NC04800012
J	MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN				MANO, H; MANO, K; TANG, B; KOEHLER, M; YI, T; GILBERT, DJ; JENKINS, NA; COPELAND, NG; IHLE, JN			EXPRESSION OF A NOVEL FORM OF TEC KINASE IN HEMATOPOIETIC-CELLS AND MAPPING OF THE GENE TO CHROMOSOME-5 NEAR KIT	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; AMINO-TERMINAL DOMAIN; SENSITIVE V-ABL; SIGNAL TRANSDUCTION; C-ABL; DEVELOPMENTAL EXPRESSION; CYTOPLASMIC DOMAINS; ANTIGEN RECEPTOR; MESSENGER-RNA; MYELOID CELLS	The Tec kinase was initially identified as a novel cytoplasmic protein tyrosine kinase that is preferentially expressed in the liver and is highly homologous to the Drosophila Dsrc28C src-related tyrosine kinase. In screening of interleukin 3 (IL-3)-dependent myeloid leukemia cells for protein tyrosine kinases, we observed that all cell lines examined expressed high levels of Tec transcripts. However, characterization of Tec cDNAs indicated that they differed significantly from the published sequence. Most strikingly, an insertion of 41 bp in the 5' region affects the initiation codon and results in replacing the published 13 amino acid amino-terminal sequences with 94 amino acids. Using polymerase chain reaction (PCR) analysis, only the form containing the insertion was detected in hematopoietic cells. In addition, we found an in-frame insertion of 66 bp that introduces an additional 22 amino acids into the SH3 domain. This insertion restores conserved SH3 sequences that are found in the src gene family and in the Dsrc28C gene. By PCR analysis, approximately equal levels of Tec transcripts containing the intact SH3 domain and containing the 22 amino acid deletion were found in hematopoietic cells. Lastly, by interspecies backcross analysis, we show that the Tec gene is tightly linked to the c-Kit gene on mouse chromosome 5.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA	St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101, P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARDS A, 1988, ONCOGENE, V2, P297; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEGIORGI L, 1981, NATURE, V292, P545, DOI 10.1038/292545a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Green EL, 1981, GENETICS PROBABILITY, P77; Green MC., 1989, GENETIC VARIANTS STR, P12; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1990, PEPTIDE GROWTH FACTO; ISFORT R, 1988, J BIOL CHEM, V263, P19203; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KANAKURA Y, 1990, BLOOD, V76, P706; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MANO H, 1990, ONCOGENE, V5, P1781; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WADSWORTH SC, 1990, DEV BIOL, V138, P296, DOI 10.1016/0012-1606(90)90198-R; WILKS AF, 1988, ONCOGENE, V3, P289; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	63	161	168	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					417	424						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678927				2022-12-28	WOS:A1993KN00600021
J	MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM				MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM			GENE STRUCTURE AND DIFFERENTIAL EXPRESSION OF ACIDIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA - IDENTIFICATION AND DISTRIBUTION OF 4 DIFFERENT TRANSCRIPTS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-II GENE; FACTOR FAMILY; HUMAN GLIOMAS; TISSUES; MENINGIOMAS; PROMOTERS; SEQUENCE; CULTURE; CLASS-1	We have isolated four cDNA clones coding for human acidic fibroblast growth factor (aFGF) containing alternative 5' untranslated exons. Using RNAase protection analyses, we demonstrated the presence of at least four upstream, untranslated exons that are alternatively spliced to the first protein-coding exon. We designate these four untranslated exons, - 1A, - 1B, - 1C and - 1D. Splicing of these exons to the first coding exon will generate mRNA 1.A, 1.B, 1.C and 1.D respectively. Expression of these transcripts is regulated in a tissue-specific manner, as the major aFGF transcript in human brain frontal cortex differs from that in kidney. Furthermore, the pattern of aFGF transcripts in several glioblastoma cell fines tested is different from that in normal brain tissue. We isolated nine overlapping genomic clones containing these four upstream, untranslated exons. These four exons were localized on these clones by Southern hybridization and nucleotide sequence analysis. The overlapping clones are shown to be contiguous with our previously isolated genomic clones that contain the three aFGF-coding exons. The sizes of the four introns are 82.9, 71.1, 29.3 and 6.9 kbp. The transcriptional start sites of the two most upstream exons (- 1A and - 1B) have been mapped using RNAase protection and primer extension analyses. The sequences upstream of the start sites for aFGF 1.B mRNA do not contain a consensus TATA box. In contrast, the canonical CCAAT and TATA sequences are located at the proper distances from the transcription start site of aFGF 1.A mRNA.	OHIO STATE UNIV, DEPT INTERNAL MED, DAVIS MED RES CTR, 480 W 9TH AVE, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Los Alamos National Laboratory			Chiu, Ing-Ming/B-1534-2008; Chotani, Maqsood/E-2891-2011		NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058, R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058, T32 CA09338, R01 CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALTERIO J, 1990, BIOCHEM BIOPH RES CO, V166, P1205, DOI 10.1016/0006-291X(90)90994-X; Ausubel FM, 1988, MOL REPROD DEV; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; CHIU IM, 1989, MOL CHEM NEUROPATHOL, V10, P37, DOI 10.1007/BF02969485; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; DEPAGTERHOLTHUIZEN P, 1987, FEBS LETT, V214, P259, DOI 10.1016/0014-5793(87)80066-2; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; HALL JA, 1990, J CELL BIOCHEM, V43, P17, DOI 10.1002/jcb.240430103; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARICS I, 1989, ONCOGENE, V4, P335; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUSSELL DS, 1963, PATHOLOGY NERVOUS SY, P93; Sambrook J, 1989, MOL CLONING LABORATO; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	56	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					341	349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678925				2022-12-28	WOS:A1993KN00600013
J	CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG				CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG			PATTERN OF RAS AND GSP ONCOGENE MUTATIONS IN RADIATION-ASSOCIATED HUMAN THYROID-TUMORS	ONCOGENE			English	Note						RADIATION-ASSOCIATED TUMORS; ONCOGENES; RAS; GSP; ACTIVATION	ACTIVATION; CANCER	The preferential activation of the Ki-ras oncogene in follicular radiation-associated human thyroid carcinomas, has been suggested by Wright et al. (1991). However, only 12 thyroid tumors were analysed in this study. In order to confirm if radiation favours, in human thyroid tumorigenesis, the appearance of a particular molecular lesion, we studied 33 benign and malignant human radiation-associated thyroid tumors. We used polymerase chain reaction (PCR) amplification and allele-specific hybridization with mutant-specific probes for the three ras genes and the gsp oncogene. Compared to 85 'spontaneous' human thyroid tumors, the radiation-associated cases: (1) show a similar overall frequency of uas and gsp mutations (about 30% and 6% respectively); (2) present a similar frequency of mutation of the three ras genes without any predominance in adenomas and papillary carcinomas and (3) all Ki-ras mutations were found in papillary carcinomas (4/15). ras and gsp genes were never found mutated simultaneously, suggesting an alternative role for both oncogenes in the thyroid tumorigenic radiation-associated process.	IFC HO1,MOLEC GENET GRP,F-94801 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT HISTOPATHOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT NUCL MED,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy			de Vathaire, Florent/L-2983-2016	de Vathaire, Florent/0000-0002-8374-9281				BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; DEVRIES MV, 1986, GENE, V50, P313; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, ONCOGENE, V3, P541; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; YASHIMOTO K, 1993, CANCER, V72, P1386	17	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					601	603						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630645				2022-12-28	WOS:A1995RN53000022
J	PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ				PELLEGATA, NS; CAJOT, JF; STANBRIDGE, EJ			THE BASIC CARBOXY-TERMINAL DOMAIN OF HUMAN P53 IS DISPENSABLE FOR BOTH TRANSCRIPTIONAL REGULATION AND INHIBITION OF TUMOR-CELL GROWTH	ONCOGENE			English	Article						P53; C-TERMINAL DOMAINS	WILD-TYPE P53; DNA-BINDING; PROTEIN COMPLEXES; OLIGOMERIZATION; SUPPRESSION; MUTATIONS; TRANSFORMATION; WILD-TYPE-P53; LOCALIZATION; DETERMINANT	To investigate the relevance of the C-terminal domains of the human p53 tumor suppressor gene to its growth suppressive and transcriptional regulatory properties deletion mutants were generated which eliminated 30 (53 Delta 363), 60 (p53 Delta 333) and 87 (p53 Delta 306) amino acids from the C-terminus of the p53 protein. p53 Delta 363 has lost the highly basic tail of the protein (residues 360-386). p53 Delta 333 and p53 Delta 306 lack the oligomerization domain (residues 320-360); p53 Delta 306 has also lost the major nuclear localization signal of p53 (NLSI, residues 316-325). These mutants were assayed for transactivation from two p53 consensus binding sites and for transcriptional repression of two promoter systems in Calu6 lung cancer cells (p53 null). Moreover, their ability to inhibit cell growth in tumor cell lines with a defined p53 status was analysed. Deletion of the oligomerization domain correlated with significant loss of: (a) transactivation from a genomic sequence; (b) transcriptional repression; (c) the ability to inhibit colony formation. An intact NLSI was not a prerequisite for transactivation. p53 Delta 363 behaved similarly to wt p53 in all the assays. We established an inducible expression system for p53 Delta 363 in a human fibrosarcoma cell line known to be growth-suppressed by wt p53. The induction of p53 Delta 363 expression also inhibited cell proliferation albeit to a lesser extent than wt p53. However, p53 Delta 363 could upregulate WAF1/CIP1, GADD45 and MDM2 genes. Thus, the basis tail of p53 appears not to be required for the biological functions of the protein assayed.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine			Pellegata, Natalia S/I-1256-2012	Pellegata, Natalia S/0000-0002-8000-7784	NATIONAL CANCER INSTITUTE [P30CA062203, R01CA019401, R37CA019401] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62203, CA 19401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAJOT JF, 1992, CANCER RES, V52, P6956; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1992, NATURE, V56, P215; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V252, P49; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1707; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	48	33	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					337	349						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624148				2022-12-28	WOS:A1995RK95700014
J	KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI				KUZMIN, I; DUH, FM; LATIF, F; GEIL, L; ZBAR, B; LERMAN, MI			IDENTIFICATION OF THE PROMOTER OF THE HUMAN VON HIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE	ONCOGENE			English	Article						VON HIPPEL-LINDAU DISEASE; PROMOTER; TUMOR SUPPRESSOR	HUMAN RETINOBLASTOMA GENE; TRANSCRIPTION FACTOR; SMALL REGION; CHROMOSOME-3; CARCINOMA; NRF-1; LOCUS; DNA	The von Hippel-Lindau (VHL) disease gene is a novel multiple tumor suppressor gene which plays a causal role in the origin of some common cancers including clear cell renal carcinomas and hemangioblastomas of the central nervous system. Here we report the identification of transcription start sites and the promoter of the human VHL gene. The promoter sequence does not contain TATA and CCAAT boxes. Transcription is initiated around a putative SP1 binding site about 60 bp upstream from the first AUG codon in the VHL mRNA. Several putative transcription factor binding sites, notably for nuclear respiratory factor 1 and PAX, were found upstream of the transcription start sites, Promoter-luciferase expression constructs demonstrate, that the promoter is functional when transfected into 293 cells (transformed primary human embryonal kidney cells) and UMRC 6 renal carcinoma cells. Activity is dependent on correct orientation of the promoter. A minimal promoter region of 106 bp was delineated, A set of VHL minigenes, containing the 5' flanking VHL genomic region, was constructed and transfected into UMRC 6 cells. In these cells the level of transcription from the minigenes driven by VHL promoter was comparable with endogenous VHL expression.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KUZMIN, I (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, IMMUNOBIOL LAB, FREDERICK, MD 21702 USA.							BERGER SL, 1987, ANAL BIOCHEM, V161, P272, DOI 10.1016/0003-2697(87)90451-9; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAUCH H, 1995, IN PRESS HUM GENET; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHANG ACY, 1988, FOCUS, V10, P66; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GLENN GM, 1991, HUM GENET, V87, P207, DOI 10.1007/BF00204184; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GROSSMAN HB, 1985, J SURG ONCOL, V28, P237; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANNO H, 1994, CANCER RES, V54, P4845; KUZMIN I, 1994, CANCER RES, V54, P2486; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P1145; PLACHOV D, 1990, DEVELOPMENT, V110, P643; RICHARDS FM, 1994, HUM MOL GENET, V3, P595, DOI 10.1093/hmg/3.4.595; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; SEIZINGER BR, 1991, P NATL ACAD SCI USA, V88, P2864, DOI 10.1073/pnas.88.7.2864; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHUIN T, 1994, CANCER RES, V54, P2852; TANG A, 1989, ONCOGENE, V4, P401; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WADA KN, 1992, NUCLEIC ACIDS RES, V20, P2111, DOI 10.1093/nar/20.suppl.2111; YAO M, 1993, HUM GENET, V92, P605, DOI 10.1007/BF00420947	43	70	73	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2185	2194						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784063				2022-12-28	WOS:A1995RB70300014
J	FELLER, SM; KNUDSEN, B; HANAFUSA, H				FELLER, SM; KNUDSEN, B; HANAFUSA, H			CELLULAR PROTEINS BINDING TO THE FIRST SRC HOMOLOGY-3 (SH3) DOMAIN OF THE PROTOONCOGENE PRODUCT C-CRK INDICATE CRK-SPECIFIC SIGNALING PATHWAYS	ONCOGENE			English	Article						CRK; SH3; SIGNAL TRANSDUCTION; CRKL; BLOT ASSAY	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; PHOSPHOTYROSINE-CONTAINING PROTEINS; ADAPTER PROTEIN; CYTOPLASMIC PROTEIN; SARCOMA-VIRUS; V-CRK; RAS; GRB2; IDENTIFICATION	The widely expressed c-Crk protein, composed of one SH2 and two SH3 domains, lacks an apparent catalytic domain, suggesting that it functions through the formation of specific complexes with other proteins. Bacterially expressed c-Crk formed in vitro highly stable complexes via the first SH3 domain [SH3(N)]. Most prominent were a 185 kDa protein of unknown identity (p185), Sos- immunoreactive bands of 170 kDa (p170) and 145 to 155 kDa bands, corresponding to the recently cloned C3G protein. p170 also bound to Ash/Grb2 and Nck while p185 and C3G bound only to Crk, Additional Crk binding proteins were found in hematopoietic cells, particularly the myeloid-monocytic lineage. The protein binding properties of Crk were subsequently compared to CRKL, the product of a homologous but distinct gene, and found to be very similar. The binding of two guanine nucleotide exchange factors, Sos and C3G, to Crk and CRKL indicates that Ras or related proteins likely play a role in signaling through Crk family proteins.			FELLER, SM (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, IN PRESS J BIOL CHEM; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1992, BIOCHEMISTRY-US, V31, P3044, DOI 10.1021/bi00127a003; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METH ENZYMO; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, STRUCT BIOL, V1, P221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SECHLER JMG, 1989, J IMMUNOL METHODS, V119, P277, DOI 10.1016/0022-1759(89)90407-9; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUDOL M, 1994, ONCOGENE, V9, P2145; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	111	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1465	1473						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731701				2022-12-28	WOS:A1995QU68100001
J	ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH				ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH			MUTATIONAL ANALYSIS OF THE CARBOXY-TERMINAL PORTION OF P53 USING BOTH YEAST AND MAMMALIAN-CELL ASSAYS IN-VIVO	ONCOGENE			English	Article						P53; CELL CYCLE ARREST; TUMOR SUPPRESSOR GENE	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; PROTEIN; APOPTOSIS; CANCER; LINE; TRANSFORMATION	Increasing evidence indicates that p53 is a transcriptional tuans-activator through its sequence-specific DNA binding domain. Tumor-derived p53 mutations disrupt the tuans-activation ability mainly due to loss of its sequence-specific DNA binding, Using both yeast and mammalian cell assays, the effect of p53 mutations in the carboxy terminal portion was investigated in order to address how p53 mutations outside of the DNA binding domain affect p53 function, The p53 cDNA in the carboxy-terminus was randomly mutagenized by error-prone polymerase chain reactions and the amplified cDNA was screened for the ability to trans-activate using a yeast assay, Four p53 mutations, including two missense and two nonsense mutations located in the carboxy-terminal oligomerization domain, were further analysed for trans-activation, cell cycle arrest and colony formation in a human osteosarcoma cell line, Saos-2. These functional properties of p53 were disrupted by the missense mutations. Surprisingly, one of the nonsense mutations disrupts the trans-activation function and the ability to G1 arrest but shows a strong inhibition of colony formation, These results confirm that mutations in the oligomerization domain can inactivate p53 function and also indicate that p53-mediated cell growth inhibition does not necessarily depend on the ability to arrest cell cycle.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CHILDRENS HOSP,DANA FARBER INST,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	ISHIOKA, C (corresponding author), TOHOKU UNIV,INST DEV AGING & CANC,DEPT CLIN ONCOL,SENDAI,MIYAGI 980,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NISHIDA N, 1993, CANCER RES, V53, P368; OKAMOTO A, 1991, CANCER RES, V51, P5632; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YAMADA Y, 1991, CANCER RES, V51, P5800; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1485	1492						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731702				2022-12-28	WOS:A1995QU68100003
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; THOMSON, CT; SACCHETTINI, JC; DEPINHO, RA			EVOLUTIONARY RELATIONSHIPS AND FUNCTIONAL CONSERVATION AMONG VERTEBRATE MAX-ASSOCIATED PROTEINS - THE ZEBRA FISH HOMOLOG OF MXI1	ONCOGENE			English	Article							C-MYC ONCOGENE; INDUCED TERMINAL DIFFERENTIATION; DNA-BINDING; LEUCINE ZIPPER; N-MYC; RAS COTRANSFORMATION; MUTATIONAL ANALYSIS; MESSENGER-RNAS; CELL-CYCLE; EXPRESSION	In mammals, current evidence supports the view that Myc-responsive activities are regulated in part through an intracellular balance between levels of transcriptionally-active Myc/Max heterodimers and those of transcriptionally-inert Max/Max, Mad/Max-and Mxil/Max complexes. To gain insight into the roles of Mad and Mxi1 in cellular growth and differentiation and to fortify key structure-function relationships from an evolutionary standpoint, low stringency hybridization screens were used to identify potential homologs of these Max-associated proteins in the zebra fish genome. A single class of cDNA clones that cross-hybridized both to human mad and mxi1 probes was shown to encode a putative protein with significantly greater homology to mammalian Mxi1 than to Mad, particularly in the basic and helix-loop-helix (bHLH) regions. The high degree of structural relatedness between vertebrate Mxi1 proteins apparent in molecular;modelling studies was consistent with the findings that the HLH/leucine zipper (LZ) region of zMxi1 exhibited the same profile of. dimerization specificities as its mammalian counterpart in the two-hybrid system and that zmxi1 could, like human mxi1 (Lahoz et al., 1994), suppress the oncogenic potential of mouse c-myc in a mammalian cell. Finally, a comparison of steady-state zc-myc and zmxi1 mRNA levels during zebra fish embryogenesis demonstrated (i) high levels of zc-myc relative to zmxi1 mRNA during initiation of organogenesis, a period characterized by intense growth and active differentiation and (ii) rising levels of zmxi1 mRNA during progression towards the terminally differentiated state. These contrasting patterns of developmental expression together with the capacity of zmxi1 to repress myc-induced transformation support a model for the regulation, by Max-associated proteins, of Myc functions in the control of normal cell development and neoplastic growth.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA09173-14] Funding Source: Medline; NIGMS NIH HHS [T32 GM07128, GM45859] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128, R01GM045859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HISAOKA K. KENNETH, 1960, JOUR MORPHOL, V107, P205, DOI 10.1002/jmor.1051070206; HISAOKA KENICHI KENNETH, 1958, J MORPH, V102, P311, DOI 10.1002/jmor.1051020205; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; KING MW, 1993, CELL GROWTH DIFFER, V4, P85; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARUYAMA K, 1987, ONCOGENE, V1, P361; Maxam A M, 1980, Methods Enzymol, V65, P499; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Nei M., 1987, MOL EVOLUT GENET, P293; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; REDDY CD, 1992, ONCOGENE, V7, P2085; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROSSANT J, 1992, GENE DEV, V6, P1, DOI 10.1101/gad.6.1.1; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	69	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3167	3177						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936639				2022-12-28	WOS:A1994PM65800008
J	TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F				TORTORA, G; PEPE, S; BIANCO, C; BALDASSARRE, G; BUDILLON, A; CLAIR, T; CHOCHUNG, YS; BIANCO, AR; CIARDIELLO, F			THE RI-ALPHA-SUBUNIT OF PROTEIN-KINASE-A CONTROLS SERUM DEPENDENCY AND ENTRY INTO CELL-CYCLE OF HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; AMP BINDING-PROTEINS; I REGULATORY SUBUNIT; AMINO-ACID SEQUENCE; C-HA-RAS; GROWTH-INHIBITION; MOLECULAR-CLONING; MAMMALIAN-CELLS; DOWN-REGULATION; HL-60 LEUKEMIA	MCP-10A, a nontransformed mammary epithelial cell line, requires a mixture of hormones and growth factors for optimal cell proliferation. In this report we show that when MCF-10A cells are cultured in serum free medium they become quiescent and accumulate in G(0)/G(1) phases of the cell cycle. Following addition of complete medium to quiescent cells, MCF-10A cells enter into the S phase within 15-18h and resume the cell cycle distribution of proliferating cells within 24 h. Measurement of RI alpha subunit of the cAMP-dependent protein kinase (PKA) shows a 10- to 15-fold increase in protein levels at 6 h following complete medium addition, thus preceding cell entry into the S phase. Retroviral vector-mediated overexpression of RI alpha, but not of RII beta or C alpha subunits of PKA, enables MCF-10A cells to grow in serum-free medium. In addition, RI alpha downregulation by specific antisense oligodeoxynucleotide treatment or following infection with a retroviral vector containing the RI alpha cDNA in antisense orientation determines growth arrest of proliferating MCF-10A cells and is able to partially block S phase entry of quiescent MCF-10A cells following complete medium addition. These results suggest that RI alpha/PKAI is involved in the control of cell cycle progression of mammary epithelial cells at a G(1) to S transition border, and that its overexpression is able to overcome serum and growth factors requirement for cell proliferation.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TORTORA, G (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CATTEDRA ONCOL MED,I-80131 NAPLES,ITALY.		Budillon, Alfredo/K-4763-2016; Baldassarre, Gustavo/K-1350-2016; Tortora, Giampaolo/AAA-1252-2019	Budillon, Alfredo/0000-0002-6330-6053; Baldassarre, Gustavo/0000-0002-9750-8825; Ciardiello, Fortunato/0000-0002-3369-4841; Tortora, Giampaolo/0000-0002-1378-4962				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BYUS CV, 1977, NATURE, V268, P63, DOI 10.1038/268063a0; CERESETO A, 1993, P AM ASSOC CANC RES, V34, P175; CHOCHUNG YS, 1991, PHARMACOL THERAPEUT, V50, P1, DOI 10.1016/0163-7258(91)90071-S; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CIARDIELLO F, 1990, J BIOL CHEM, V265, P1016; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1993, INT J CANCER, V53, P438, DOI 10.1002/ijc.2910530315; CIARDIELLO F, 1994, ONCOGENE, V9, P291; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MILLER WR, 1993, BREAST CANCER RES TR, V26, P89, DOI 10.1007/BF00682703; MILLER WR, 1990, BRIT J CANCER, V61, P263, DOI 10.1038/bjc.1990.48; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PEPE S, 1994, CYTOMETRY, V15, P73, DOI 10.1002/cyto.990150112; RIABOWOL KT, 1992, BIOCHEM CELL BIOL, V70, P1064, DOI 10.1139/o92-151; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SOULE HD, 1990, CANCER RES, V50, P6075; TAGLIAFERRI P, 1988, J BIOL CHEM, V263, P409; TAIT L, 1990, CANCER RES, V50, P6087; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TORTORA G, 1993, CELL GROWTH DIFFER, V4, P359; TORTORA G, 1991, P NATL ACAD SCI USA, V88, P2011, DOI 10.1073/pnas.88.5.2011; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	39	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3233	3240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936647				2022-12-28	WOS:A1994PM65800016
J	BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R				BOUGERET, C; ROTHHUT, B; JULLIEN, P; FISCHER, S; BENAROUS, R			RECOMBINANT CSK EXPRESSED IN ESCHERICHIA-COLI IS AUTOPHOSPHORYLATED ON TYROSINE RESIDUE(S)	ONCOGENE			English	Article							PROTEIN-KINASES; GENE-PRODUCT; PP60C-SRC; PHOSPHORYLATION; SITES; ACTIVATION; PP60V-SRC; MUTATION; INVITRO	The C-terminal src kinase (Csk) is responsible for the phosphorylation of the carboxy-terminal tyrosine of several tyrosine kinases of the Src family. This phosphorylation site has a negative regulatory function. Csk is unique among the members of the protein tyrosine kinase family because it lacks the conserved tyrosine autophosphorylation site and has been thought to be devoid of autophosphorylation activity. Using the glutathione S-transferase (GST) bacterial expression system, we have produced large amounts of a chimeric rat Csk protein. We have determined that the GST-Csk fusion protein isolated from bacteria is autophosphorylated on tyrosine residue(s). GST-Csk and purified Csk are capable of undergoing autophosphorylation on tyrosine residue(s) in vitro. The GST-Csk fusion protein also phosphorylates exogenous substrates, including the heteropolymer poly-Glu/Tyr and enolase. This is the first indication that Csk is autophosphorylated on tyrosine residue(s) both in vivo in bacteria expressing Csk cDNA and in vitro. These findings suggest that the autophosphorylation of Csk might play a role in the regulation of its kinase activity as well as its binding to other cellular proteins.	UNIV PARIS 05,INSERM,U332,INST COCHIN GENET MOLEC,22 RUE MECHAIN,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Rothhut, Bernard/0000-0001-6467-8134				BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHRISMAN TD, 1981, J BIOL CHEM, V256, P2981; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P937; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARIN O, 1991, J BIOL CHEM, V266, P17798; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PATANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; STERN DF, 1991, MOL CELL BIOL, V11, P937; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	27	43	44	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1241	1247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	7683130				2022-12-28	WOS:A1993KY32800015
J	MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA				MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA			PHOSPHORYLATION OF SRC MUTANTS AT TYR-527 IN FIBROBLASTS DOES NOT CORRELATE WITH INVITRO PHOSPHORYLATION BY CSK	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; REGULATORY DOMAIN; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING; TRANSFORMATION; P56LCK	In normal fibroblasts, the product of the cellular src gene, p60c-src or Src, is repressed by phosphorylation at its C-terminal tyrosine residue, Tyr 527. Mutations in Src that prevent phosphorylation cause enzymatic activation and malignant transformation. The tyrosine kinases that phosphorylate Src at Tyr 527 in vivo have not been identified, but a tyrosine kinase known as CSK is an excellent candidate. CSK has the unusual ability to phosphorylate Src in vitro only at Tyr 527. To examine whether CSK has the appropriate sequence specificy to explain the phosphorylation of Src at Tyr 527 in fibroblasts, we have made use of a set of C-terminal substitution mutants of Src. These mutants were previously characterized for their levels of Tyr 527 phosphorylation when expressed in Rat2 fibroblasts. The ability of CSK to phosphorylate selected mutants has now been tested, using both in vitro phosphorylation assays and co-expression of CSK with the Src mutants in a heterologous organism, Saccharomyces cerevisiae. We also tested whether the mutant Src molecules could autophosphorylate at Tyr 527, by examining the phosphorylation state of catalytically active forms expressed in the absence of CSK in yeast cells. The results show that CSK has strict sequence specificity for the normal Src sequence, although it can also phosphorylate the Lck sequence. The other mutant Src molecules tested were not phosphorylated by CSK, even though some of these mutants are highly phosphorylated at Tyr 527 in Rat 2 cells. All the mutants that are phosphorylated at Tyr 527 in Rat2 cells are also able to autophosphorylate at Tyr 527. The results suggest that CSK, autophosphorylation, and phosphorylation by kinases other than CSK, may all contribution to repressing Src catalytic activity in fibroblasts.	OSAKA UNIV,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Osaka University	COOPER, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA041072, R01CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4243; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARTANEN J, 1991, ONCOGENE, V6, P2013; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1988, ONCOGENE RES, V3, P207	39	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					117	124						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	7678701				2022-12-28	WOS:A1993KN00500014
J	CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M				CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M			IDENTIFICATION OF GUANINE EXCHANGE FACTOR KEY RESIDUES INVOLVED IN EXCHANGE ACTIVITY AND RAS INTERACTION	ONCOGENE			English	Article						RAS EXCHANGE FACTOR; HUMAN; SACCHAROMYCES CEREVISIAE; ALAMINE SCANNING; 2-HYBRID	SACCHAROMYCES-CEREVISIAE CDC25; NUCLEOTIDE-RELEASING FACTOR; GENE-PRODUCT; SCANNING MUTAGENESIS; SIGNAL TRANSDUCTION; PROTEIN-KINASE; YEAST; RECEPTOR; GRB2; DNA	We have carried out a functional analysis of the human HGRF55 exchange factor in the yeast Saccharomyces cerevisiae. Twelve residues conserved among most of all known guanine exchange factors (GEFs) have been independently changed to alanine. Taking advantage of the ability of Hgrf55p to replace the yeast Cdc25p exchange factor, and using the two-hybrid system with RAS2(ala22) allele, we have identified key residues for the interaction with Pas and/or its activation. Substitution of arginine 392 to alanine leads to a complete loss of interaction with Ras, though the protein remains stable. Substitution of Asp266 or Arg359 to alanine results in inactive proteins at 39 degrees C, still able however to interact with Ras. The other charged-to-alanine substitutions led to no detectable phenotype when present alone but most of them dramatically increased the temperature sensitive phenotype observed with [Asp266Ala] substitution. Surprisingly, the cysteine to alanine substitution in the highly conserved PCVPF/Y motif proved to be without effect, suggesting that the sulfhydryl group is not essential for stability or interaction with Ras.	UNIV PARIS 11, INST GENET & MICROBIOL,INFORMAT GENET & DEV LAB, CNRS,URA 1354, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Camus, Christelle/A-3141-2009	Camus, Christelle/0000-0001-6590-1713				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CAMUS C, 1994, MOL GEN GENET, V245, P167, DOI 10.1007/BF00283264; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1993, ONCOGENE, V8, P2583; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Miller J. H, 1972, EXPT MOL GENETICS; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; VANAELST L, 1990, EUR J BIOCHEM, V193, P675; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8	47	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					951	959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675454				2022-12-28	WOS:A1995RU79800016
J	SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M				SACHDEV, S; ROTTJAKOB, EM; DIEHL, JA; HANNINK, M			I-KAPPA-B-ALPHA-MEDIATED INHIBITION OF NUCLEAR TRANSPORT AND DNA-BINDING BY REL PROTEINS ARE SEPARABLE FUNCTIONS - PHOSPHORYLATION OF C-TERMINAL SERINE RESIDUES OF I-KAPPA-B-ALPHA IS SPECIFICALLY REQUIRED FOR INHIBITION OF DNA-BINDING	ONCOGENE			English	Article						I-KAPPA-B; NF-KAPPA-B; REL; TRANSCRIPTIONAL REGULATION; PHOSPHORYLATION	TRANSCRIPTION FACTORS; ACTIVATION; CELLS; GENE; TRANSFORMATION; EXPRESSION; MECHANISM; ONCOGENE; ENCODES; BETA	I kappa B-alpha inhibits both DNA-binding and nuclear translocation of dimeric Rel complexes that contain either the RelA or c-Rel proteins. These inhibitory functions of I kappa B-alpha proteins are regulated by both constitutive and inducible phosphorylation. We have mapped the constitutive phosphorylation sites of p40, the avian I kappa B-alpha protein, to a C-terminal acidic serine-rich region that contains four serine residues. Deletions or point mutations that significantly alter the overall negatively charged character of this region abolish association of p40 with Rel proteins in vitro. Serine-to-alanine amino acid substitutions in this region modulate the association of p40 with Rel proteins in vitro and abolish p40-mediated inhibition of DNA-binding by c-Rel. Substitution of aspartic acid residues for the phosphorylated serine residues has no effect on p40-mediated inhibition of DNA-binding. In contrast, the C-terminal acidic serine-rich region is not required for p40-mediated inhibition of nuclear translocation of Rel proteins. Our results demonstrate that p40-mediated inhibition of nuclear translocation and inhibition of DNA-binding by Rel proteins are separable functions. Our results suggest that the phosphorylation status of C-terminal serine residues of I kappa B-alpha proteins will be an important aspect of the autoregulatory feedback loop that enforces temporal control of Rel-regulated gene expression.	UNIV MISSOURI, DEPT BIOCHEM, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P21; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOONG AC, 1994, CANCER RES, V54, P1425; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LINK E, 1992, J BIOL CHEM, V267, P239; MOSIALOS G, 1994, MOL CELL BIOL, V91, P12740; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TZEN CY, 1994, EXP CELL RES, V211, P12, DOI 10.1006/excr.1994.1052; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					811	823						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675442				2022-12-28	WOS:A1995RU79800001
J	CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A				CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A			THE EXPRESSION OF THE HIGH-MOBILITY GROUP HMGI (Y) PROTEINS CORRELATES WITH THE MALIGNANT PHENOTYPE OF HUMAN THYROID NEOPLASIAS	ONCOGENE			English	Article						HMGI (Y) PROTEINS; THYROID; CARCINOMAS; TUMOR MARKER; IMMUNOHISTOCHEMISTRY	NUCLEAR PROTEINS; HISTONE H1; CELLS; BINDING; MOUSE; GENE; DNA; TRANSFORMATION; CARCINOMAS; SEQUENCE	High Mobility Group I(HMGI) proteins are nuclear proteins involved in the regulation of chromatin structure and function, Elevated expression of the HMGI proteins (HMGI, HMGY and HMGI-C) has been correlated with the presence of a highly malignant phenotype in epithelial and fibroblastic rat thyroid cells, and in several experimental carcinomas, Here, we demonstrate that HMGI and HMGY proteins are expressed in human thyroid carcinomas and thyroid carcinoma cell lines, but not in adenomas, goiters, normal thyroid tissues and cells, These results indicate a correlation between HMGI and HMGY expression and the malignant phenotype of thyroid neoplasias, suggesting that these proteins may be used as markers in thyroid cancer.	UNIV REGGIO CALABRIA, FAC MED & CHIRURG, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY; IST NAZL TUMORI, FDN SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV TRIESTE, DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC, I-34127 TRIESTE, ITALY; UNIV NAPLES, FAC MED & CHIRURG, CNR, CTR ENDOCRINOL ONCOL SPERIMENTALE, I-80131 NAPLES, ITALY; UNIV COMPLUTENSE MADRID, HOSP UNIV 12 OCTUBRE, DEPT PATHOL, E-28041 MADRID, SPAIN	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Complutense University of Madrid; Hospital Universitario 12 de Octubre			Visconti, Roberta/C-5299-2009	MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8573; SANTORO M, 1990, ONCOGENE, V5, P1595; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TAMIMI Y, 1993, CANCER RES, V53, P5512; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; [No title captured]	34	190	191	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1307	1314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731681				2022-12-28	WOS:A1995QR65100007
J	FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S				FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S			TRICHOSTATIN-A INHIBITS BOTH RAS-INDUCED NEURITE OUTGROWTH OF PC12 CELLS AND MORPHOLOGICAL TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article						ONCOGENES; RAS; PC12; TRICHOSTATIN A HEURITE DIFFERENTIATION	NERVE GROWTH-FACTOR; C-FOS INDUCTION; NEURONAL DIFFERENTIATION; HISTONE ACETYLATION; BINDING AFFINITIES; DNA-BINDING; JUN; SEQUENCES; LINE; MICROINJECTION	During screening for inhibitors of ras-mediated differentiation of PC12 cells, trichostatin A (TSA) was isolated from the metabolites of Streptomyces as a potent inhibitor, TSA blocked both oncogenic ras- and NGF-induced neurite outgrowth from PC12 cells, However, addition of TSA 1 h after NGF-stimulation did not inhibit neuronal differentiation, suggesting that TSA affects an early step in the NGF- signaling pathway mediated by ras, Northern blotting analysis showed that TSA prolonged the maximum expression period of c-fos mRNA triggered by NGF and delayed its return to the basal level, TSA reduced c-jun mRNA induction by NGF but greatly enhanced c-myc mRNA induced by NGF, Yoshida et al, (J. Biol. Chem., 265, 17174-17179, 1990) showed that TSA inhibits histone deacetylation, which might influence the gene expression involved in cellular differentiation, In this study, we also found that TSA prevents histone deacetylation in PC12 cells as well as other cell lines, suggesting that inhibition of histone deacetylation by TSA might affect the expression of early-response genes, We also demonstrated that TSA induced reversion of oncogenic ras-transformed NIH3T3 cells to a normal morphology, suggesting that inhibitors of ras-mediated differentiation of PC12 cells may be effective as anticancer agents,	BANYU TSUKUBA RES INST MERCK, ONCOGENE RES LAB, TSUKUBA, IBARAKI 30033, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	Merck & Company; University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Yoshigaki, Junko/AAE-6702-2020	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUJITAYOSHIGAKI J, 1992, ONCOGENE, V7, P2019; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IZAWA M, 1992, CANCER RES, V52, P1628; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHINDOOKADA N, 1990, BASIC LIFE SCI, V52, P309; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; SUGITA K, 1992, CANCER RES, V52, P168; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; WU BY, 1989, J BIOL CHEM, V264, P9000; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1988, CELL TECHNOL S, V4, P91	34	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1119	1123						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700637				2022-12-28	WOS:A1995QN35300012
J	WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF				WANG, ZY; QIU, QQ; GURRIERI, M; HUANG, J; DEUEL, TF			WT1, THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, REPRESSES TRANSCRIPTION THROUGH AN INTERACTIVE NUCLEAR-PROTEIN	ONCOGENE			English	Note						WT1; TUMOR SUPPRESSOR; TRANSCRIPTION; INTERACTIVE PROTEIN	FACTOR-A-CHAIN; KIDNEY DEVELOPMENT; UROGENITAL SYSTEM; EXPRESSION; GROWTH; CELLS; KRUPPEL; DOMAINS; LOCUS; DNA	The Wilms' tumor suppressor gene, wt1, encodes a transcription factor of the zinc finger family, Mutations in WT1 have been detected in subsets of Wilm's tumor and in patients,vith the Denys-Drash Syndrome, In order to determine how WT1 regulates transcription and perhaps the consequences that mutations in WT1 may have, we established that residues 85-124 and 181-250 of WT1 constitute domains that function independently with DNA binding domain to repress or activate transcription, respectively, and function equally effectively with heterologous promoters, suggesting the activator and repressor domains interact with nuclear components of general importance, To seek evidence for such components, increasing concentrations of WT1 repressor domain without a zinc finger DNA binding domain were co-transfected with fixed concentrations of wild-type (wt) WT1 and PDGF A-chain promoter/reporter gene constructs, As levels of the repressor domain were increased, a progressive loss of wt WT1 repressor activity and a progressive increase in its activation were observed, suggesting that the repressor domain of WT1 competes with wt WT1 for an interactive protein that is an essential component of the repressor activity of wt WT1, Because the most common mutation associated with Denys-Drash Syndrome disrupts the zinc finger domains of WT1, the results also suggest that the mutant WT1 may have aberrant DNA binding activity and perhaps function as a dominant negative effector	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital			Huang, Jeffrey/J-5248-2017; Huang, Jeffrey K./AAH-2418-2021	Huang, Jeffrey/0000-0003-0996-9451; Huang, Jeffrey K./0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL14147, HL31102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R37HL031102, R01HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, P5828; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	29	62	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1243	1247						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700651				2022-12-28	WOS:A1995QN35300028
J	FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA				FOX, GM; HOLST, PL; CHUTE, HT; LINDBERG, RA; JANSSEN, AM; BASU, R; WELCHER, AA			CDNA CLONING AND TISSUE DISTRIBUTION OF 5 HUMAN EPH-LIKE RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article						PROTEIN TYROSINE KINASES	MOLECULAR-CLONING; FAMILY; IDENTIFICATION; GENE; MEMBERS; EMBRYO; EXPRESSION; CHICKEN; BRAIN; HEK	We have isolated cDNA clones from a human fetal brain library that encode five members of the EPH sub-family of receptor protein tyrosine kinases (PTKs), Comparison of the DNA sequences of these receptors to the Genbank database reveals that two of our clones correspond to the previously identified HEK and ERK receptors, two are apparently human homologues of the mouse receptors Sek and Bsk and one is novel, With these additions, the number of known human EPH sub-family members is nine and the total in all vertebrate species is 13 making it the largest known sub-family of PTKs. Analysis of the expression pattern of EPH sub-family mRNAs reveals that some are expressed in a wide variety of adult tissues while others are quite restricted, Consistent with the amplification of these sequences from a fetal brain cDNA library, all five members which we have isolated are expressed in the brain. We have named these receptors HEK4, HEK5, HEK7, HEK8 and HEK11, following the nomenclature of Wicks et al. (1992) and the numbering convention set forth by Sajjadi et al. (1991), Analysis of these new EPH sub-family members will increase our understanding of the biology of this receptor family and their isolation will provide reagents for the identification of ligands for this large family of orphan receptors.			FOX, GM (corresponding author), AMGEN INC, AMGEN CTR, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA.							ANDRES AC, 1994, ONCOGENE, V9, P1461; BARBACID M, 1993, ONCOGENE, V8, P2033; BARTLEY M, 1994, NATURE, V368, P558; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; IWASE T, 1993, BIOCHEM BIOPH RES CO, V194, P698, DOI 10.1006/bbrc.1993.1878; KIYOKAWA E, 1994, CANCER RES, V54, P3645; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; Maniatis T., 1982, MOL CLONING LAB MANU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MARU Y, 1990, ONCOGENE RES, V5, P199; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	34	73	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					897	905						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898931				2022-12-28	WOS:A1995QL03800011
J	FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X				FUCHS, B; OCONNOR, D; FALLIS, L; SCHEIDTMANN, KH; LU, X			P53 PHOSPHORYLATION MUTANTS RETAIN TRANSCRIPTION ACTIVITY	ONCOGENE			English	Note						P53; PHOSPHORYLATION; TRANSCRIPTION GROWTH SUPPRESSION	CASEIN KINASE-II; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; NUCLEAR-LOCALIZATION; SEQUENCE; SITE; TRANSACTIVATION; EXPRESSION; MUTATION; P34CDC2	To investigate the effect of phosphorylation on the transcription activity of p53, ten phosphorylation mutants were constructed covering all the identified phosphorylation sites of rat p53. These included mutants of two casein kinase I sites (Ser6 and Ser9), two DNA-PK sites (Ser15 and Ser39), a p34cdc2 site(Ser313), the adjacent Ser312 and a casein kinase II site (Ser390). Two double phosphorylation mutants (Ser4, 6 and Ser15, 390) and one triple phosphorylation mutant (Ser4, 6 and 15) were also constructed. The transcription activity of all the p53 phosphorylation mutants was tested by transfection into two different types of cells, Saos-2 cells and p53(-/-) fibroblasts derived from p53 knock out mice, which both lack endogenouse p53. Surprisingly, all the p53 phosphorylation mutants retain transcription activity and the seven mutants tested can also suppress cell growth.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV BONN,INST GENET,MOLEK GENET ABT,D-53117 BONN,GERMANY	Imperial College London; Ludwig Institute for Cancer Research; University of Bonn				Lu, Xin/0000-0002-6587-1152				ADDISON C, 1990, ONCOGENE, V5, P423; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN JY, 1993, ONCOGENE, V8, P2159; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREBOURG T, 1992, CANCER RES, V52, P6976; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V289, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231	32	72	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					789	793						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862459				2022-12-28	WOS:A1995QH61200022
J	THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S				THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S			SUPPRESSION OF TUMORIGENICITY OF BREAST-CANCER CELLS BY TRANSFER OF HUMAN-CHROMOSOME-17 DOES NOT REQUIRE TRANSFERRED BRCA1 AND P53 GENES	ONCOGENE			English	Article						BREAST CANCER CELLS; HUMAN CHROMOSOME 17; CHROMOSOME TRANSFER; TUMOR SUPPRESSOR GENES	DENATURANT GEL-ELECTROPHORESIS; LINKAGE ANALYSIS; OVARIAN-CANCER; ALLELE LOSS; LINE; CARCINOMAS; DISTINCT; REGIONS; HYBRIDIZATION; POLYMORPHISMS	A number of candidate tumor suppressor genes located on the human chromosome 17 are thought to have a role to play in the development of breast cancer. In addition to the p53 gene on 17p13.1 and the BRCA1 gene mapped to 17q12-21, other chromosomal regions for tumor suppressor genes have been suggested to exist on 17p13.3 and both the central and the distal parts of 17q, although definitive functional proof of their involvement in breast cancer tumorigenesis is still lacking. In this report we show that microcell transfer of a human chromosome 17 into wild-type p53 breast cancer cells CAL51 results in loss of tumorigenicity and anchorage-independent growth, changes in cell morphology and a reduction of cell growth rates of the neo-selected microcell hybrids. In the hybrid cells, which express the p53 wild-type protein, only the p- and the distal parts of the q arm of donor chromosome 17 are transferred. Thus, our results provide functional evidence for the presence of one or more tumor suppressor gene(s) on chromosome 17, which are distinct from the p53 and the BRCA1 genes.	MAX DELBRUCK CTR MOLEK MED,FORSCH GRP MED ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ROBERT ROSSLE KLIN,BEREICH PATHOL,D-13122 BERLIN,GERMANY; UNIV KAISERSLAUTERN,HUMANBIOL & HUMANGENET ABT,D-67663 KAISERSLAUTERN,GERMANY; HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,TUMORVIROL ABT,D-20251 HAMBURG,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kaiserslautern; Heinrich Pette Institute	THEILE, M (corresponding author), MAX DELBRUCK CTR MOLEK MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; BAKER JM, 1993, ONCOGENE, V8, P497; BENCHEICKH M, 1992, INT J CANCER, V51, P542, DOI 10.1002/ijc.2910510407; BORG A, 1994, J NATL CANCER I, V86, P792, DOI 10.1093/jnci/86.10.792; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CHANG F, 1993, BRIT J CANCER, V68, P653, DOI 10.1038/bjc.1993.404; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOLDGAR DE, 1993, AM J HUM GENET, V52, P743; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1992, AM J HUM GENET, V50, P1235; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; KLEVER M, 1991, HUM GENET, V86, P484; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; LALLE P, 1994, ONCOGENE, V9, P437; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1991, SCIENCE, V250, P1233; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MERLO GR, 1992, AM J PATHOL, V140, P215; NAGAI MA, 1994, BRIT J CANCER, V69, P754, DOI 10.1038/bjc.1994.142; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1994, CANCER RES, V54, P1818; NEGRINI M, 1992, ONCOGENE, V7, P2013; NORMAND T, 1993, HUM MOL GENET, V2, P479, DOI 10.1093/hmg/2.4.479; OCONNELL P, 1994, AM J HUM GENET, V54, P526; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; SHIMIZU M, 1990, ONCOGENE, V5, P185; SMITH SA, 1994, GENE CHROMOSOME CANC, V10, P71, DOI 10.1002/gcc.2870100112; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; TAKITA K, 1992, CANCER RES, V52, P3914; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TRIPATHY D, 1993, ONCOGENES THMOR SUPP; VALERA A, 1994, HUM GENE THER, V5, P449, DOI 10.1089/hum.1994.5.4-449; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WATATANI M, 1993, BREAST CANCER RES TR, V28, P231, DOI 10.1007/BF00666584; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789	63	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					439	447						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845668				2022-12-28	WOS:A1995QF64800004
J	FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF				FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF			OVEREXPRESSION OF MOS ONCOGENE PRODUCT IN SWISS 3T3 CELLS INDUCES APOPTOSIS PREFERENTIALLY DURING S-PHASE	ONCOGENE			English	Article						APOPTOSIS; MOS ONCOGENE; CELL CYCLE; S-PHASE	MURINE SARCOMA-VIRUS; MEIOTIC MATURATION; XENOPUS-OOCYTES; MAP KINASE; PROTO-ONCOGENE; EARLY EVENT; DEATH; ENDONUCLEASE; INVITRO; FIBROBLASTS	When Swiss 3T3 cells are acutely infected with Moloney murine sarcoma virus containing the v-mos oncogene, 90% of the cells round up and detach from the monolayer (floating cells) and express high levels of v-Mos. The majority of the floating cells are generated between 30 and 70 h post infection when the cellular level of Mos reaches similar to 0.1% of the total protein. Seventy percent of the floating cells exclude trypan blue but are growth arrested with 2C or 4C DNA content, whereas the remaining floating cells with <2C DNA content, are dead or dying, and show characteristic apoptotic phenotypes. The apoptotic cells are most likely generated from cells in S-phase since these cells are absent from the viable floating cell population and the percentage of cells with <2C DNA approximated the expected S-phase fraction of logarithmically growing cells. In addition, 5'-bromo-2'-deoxyuridine-labeling studies showed that similar to 50% of the floating cells with typical apoptotic phenotypes were metabolically-labeled with the drug. These analyses show that cell populations in different stages of the cell cycle are differently affected by high levels of v-Mos expression and cells in S-phase appear to be uniquely sensitive and undergo apoptosis.	NCI, FREDERICK CANC RES & DEV CTR, ABL, BASIC RES PROGRAM, FREDERICK, MD 21702 USA; NCI, DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM, MATH BIOL LAB,MEMBRANE BIOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS SI, 1989, J IMMUNOL, V142, P1789; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KUNG AL, 1990, CANCER RES, V50, P7307; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOCK RB, 1990, CANCER RES, V50, P3761; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; UCKER DS, 1991, NEW BIOL, V3, P103; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					1	8						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824263				2022-12-28	WOS:A1995QA98000001
J	KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD				KO, TC; SHENG, HM; REISMAN, D; THOMPSON, EA; BEAUCHAMP, RD			TRANSFORMING GROWTH-FACTOR-BETA-1 INHIBITS CYCLIN D1 EXPRESSION IN INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article						TGF-BETA; CYCLIN; CELL CYCLE; EPITHELIAL CELL; CYCLIN-DEPENDENT KINASE; GENE EXPRESSION	SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT KINASE CDK4; RAT SMALL-INTESTINE; FACTOR-BETA; TGF-BETA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; GENE-EXPRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS	Transforming growth factor-beta 1 (TGF-beta 1) inhibits most epithelial cell types by blocking cell cycle progression during the G(1) phase. D cyclins are normally expressed during G(1) and are regulators of G(1) progression. One of the crucial functions of D cyclins is their ability to bind to a cyclin-dependent kinase (Cdk4). In mink lung epithelial cells, TGF-beta 1 inhibits Cdk4 expression. We have measured cell cycle progression and D cyclins and Cdk4 expression in non-transformed rat intestinal epithelial cell lines (IEC-6 and RIE-1) after TGF-beta 1 treatment. In exponentially growing cultures, TGF-beta 1 blocked DNA synthesis and suppressed cyclin D1 mRNA and protein expression, whereas the levels of cyclins D2, D3 and Cdk4 remained relatively unchanged. TGF-beta 1 was also added to Go-synchronized IEC-6 cells after serum stimulation. TGF-beta 1 prevention of G(1) progression was associated with an inhibition of cyclin D1 protein expression. Cyclin D3 levels were not affected by TGF-beta 1 during G(1) traverse. Our results suggest that cyclin D/Cdk4 is a crucial target of TGF-beta 1 and that regulation of this kinase is mediated through cyclin D1 in intestinal epithelial cells.	UNIV TEXAS, MED BRANCH, DEPT SURG, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [R37CA024347, R01CA024347] Funding Source: NIH RePORTER; NCI NIH HHS [CA 24347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Babyatsky M. W., 1991, TXB GASTROENTEROLOGY, P475; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLAY J, 1986, J CELL PHYSIOL, V129, P343, DOI 10.1002/jcp.1041290312; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRESLIN JS, 1993, AM J RESP CELL MOL, V9, P533, DOI 10.1165/ajrcmb/9.5.533; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNIE AB, 1965, EXP CELL RES, V39, P528, DOI 10.1016/0014-4827(65)90055-8; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FILMUS J, 1992, ONCOGENE, V7, P521; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GINTY DD, 1989, AM J PHYSIOL, V256, pG342, DOI 10.1152/ajpgi.1989.256.2.G342; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KO TC, 1993, SURGERY, V114, P147; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAEMMLI UK, 1983, NATURE, V303, P497; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1992, CANCER SURV, V12, P81; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGEE DW, 1991, CYTOKINE, V3, P543, DOI 10.1016/1043-4666(91)90480-2; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOLL T, 1993, PHILOS T ROY SOC B, V340, P351, DOI 10.1098/rstb.1993.0078; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; THOMPSON EA, 1980, J NATL CANCER I, V65, P477; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	73	142	146	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					177	184						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824270				2022-12-28	WOS:A1995QA98000020
J	SUBLETT, JE; JEON, IS; SHAPIRO, DN				SUBLETT, JE; JEON, IS; SHAPIRO, DN			THE ALVEOLAR RHABDOMYOSARCOMA PAX3/FKHR FUSION PROTEIN IS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article						RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; DNA BINDING; PAIRED BOX; HOMEOBOX	DNA-BINDING-DOMAIN; FORK HEAD DOMAIN; PAIRED BOX; MAMMALIAN-CELLS; GENE FUSION; PAX3; DROSOPHILA; FAMILY; IDENTIFICATION; TRANSLOCATION	Chimeric transcription factors, created by gene fusions as the result of chromosomal translocations, have been implicated in the pathogenesis of several pathologically disparate solid tumors. The PAX3/FKHR fusion gene, formed by a t(2;13)(q35;q14) in alveolar rhabdomyosarcoma, encodes a hybrid protein that contains both PAX3 DNA binding domains, the paired box and homeodomain, linked to the bisected DNA binding domain of FKHR, a member of the forkhead family of transcription factors: Here we report that PAX3 and PAX3/FKHR display similar, but not identical transactivation activities when tested with model Pax recognition sequences. No functional role could be ascribed solely to the residual FKHR binding domain present in the fusion protein, but FKHR was found to contribute a strong carboxyl terminal activation domain replacing the one located in the unrearranged PAX3 gene. We show that the native PAX3/FKHR protein present in tumor cells with this translocation has transcriptional characteristics similar to the in vitro expressed protein. The ability of the PAX3/FKHR hybrid protein to bind DNA in a sequence specific manner and to transactivate the expression of artificial reporter genes suggests that its aberrant expression could subvert the transcriptional programs that normally control the growth, differentiation, and survival of primitive myogenic precursors in vivo.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERSPERG N, 1969, JNCI-J NATL CANCER I, V43, P151; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOTH CF, 1993, AM J HUM GENET, V52, P455; KASTURY K, 1994, P NATL ACAD SCI USA, V91, P3616, DOI 10.1073/pnas.91.9.3616; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	44	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					545	552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630639				2022-12-28	WOS:A1995RN53000015
J	CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C				CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C			ROLE OF THE AUTOPHOSPHORYLATION SITE ON THE BIOLOGICAL FUNCTION OF PP56(LCK)	ONCOGENE			English	Article						AUTOPHOSPHORYLATION; KINASES; FUNCTION	CELL ANTIGEN RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE P56LCK; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; NUCLEAR FACTOR; EXPRESSION; GENE	Src-family tyrosine kinases act as signaling molecules in a aide array of cellular activation processes. The existence of the various src-family members reflects the requirement for different cell-surface receptors to transmit cell-type specific intracellular signals. The structural basis for the functional specificity of src-kinases is being actively investigated. In the present report we have analysed the contribution of the area surrounding the autophosphorylation site (located at subdomain VII of the catalytic domain) in determining src-kinases activity and functional specificity. To this end we analysed the kinase activities of the lymphoid src-kinase pp56(lck) and a mutant of pp56(lck) in which this region has been exchanged for the corresponding area of the serine/threonine kinase c-Raf. Our studies indicate that the change at subdomain VII affected the ability of pp56(lck) to phosphorylate physiological substrates. Furthermore, when analysed in T cells, the mutant at subdomain VII failed to induce interleukin-2 production, a specific biological function of pp56(lck). Thus, the area surrounding the autophosphorylation site of pp56(lck) plays a critical role in mediating its specific biological function.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	CARRERA, AC (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, CAMPUS CANTOBLANCO, E-28049 MADRID, SPAIN.		Gonzalez-Garcia, Ana/D-9736-2014	Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434	NCI NIH HHS [CA 43803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WOODROW MA, 1993, J IMMUNOL, V150, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784086				2022-12-28	WOS:A1995RE54300013
J	MARTEL, C; LALLEMAND, D; CREMISI, C				MARTEL, C; LALLEMAND, D; CREMISI, C			SPECIFIC C-MYC AND MAX REGULATION IN EPITHELIAL-CELLS	ONCOGENE			English	Article						C-MYC; MAX; C-FOS; EPITHELIAL CELLS	DENSITY-DEPENDENT REGULATION; MESSENGER-RNA; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; TRANSGENIC MICE; PROTO-ONCOGENE; DNA-BINDING; BSC-1 CELLS; 3T3 CELLS	We have investigated c-myc, max and c-fos mRNA and protein expression in proliferating, quiescent and stimulated immortalized, SV40 T antigen (LT) transformed and tumor-derived epithelial cells as well in human primary keratinocytes and have compared them to their expression in fibroblasts. In proliferating immortalized and tumor-derived epithelial cells, the levels of c-myc, max and c-fos expression were comparable and much higher than in transformed fibroblasts, c-myc and c-fos mRNA and protein levels remained high even during quiescence, when cells stopped dividing. In contrast, whereas max mRNA was constitutively expressed, max protein levels decreased in both fibroblasts and epithelial cells at high cell density. Changing the medium to serum-free medium of confluent epithelial cells induced a complete proliferative response which started with a transient increase in c-fos and c-myc mRNA, followed by the expression of max, Addition of serum to the medium did not induce additional effects. In fibroblasts, similar treatment induced the arrest of c-myc expression and growth, but max expression was also induced in these cells by serum. Our results therefore show that max expression is growth regulated in both immortalized and transformed epithelial as well as fibroblast cells, In contrast, in epithelial cells, c-myc displayed two contrasting behaviors.	INST PASTEUR, UNITE TECHNOL CELLULAIRE, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE VIRUS ONCOGENES, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CREMISI C, 1989, MECH B CELL NEOPLASI, P314; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, J BIOL CHEM, V261, P9161; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULBECCO R, 1970, NATURE, V227, P802, DOI 10.1038/227802a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLEY RW, 1977, P NATL ACAD SCI USA, V74, P5046, DOI 10.1073/pnas.74.11.5046; HOLLEY RW, 1978, P NATL ACAD SCI USA, V75, P339, DOI 10.1073/pnas.75.1.339; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MORELLO D, 1989, ONCOGENE, V4, P955; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ONCLERCQ R, 1989, NUCLEIC ACIDS RES, V17, P735, DOI 10.1093/nar/17.2.735; ONCLERCQ R, 1989, ONCOGENE RES, V4, P293; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SAMBROOK J, 1989, COLD SPR HARB LAB PR; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATERS CM, 1991, ONCOGENE, V6, P797; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2195	2205						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784064				2022-12-28	WOS:A1995RB70300015
J	SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ				SMARDOVA, J; WALKER, A; MORRISON, LE; KABRUN, N; ENRIETTO, PJ			THE ROLE OF THE CARBOXY-TERMINUS OF V-REL IN TRANSFORMATION AND ACTIVATION OF ENDOGENOUS GENE-EXPRESSION	ONCOGENE			English	Article						V-REL; ONCOGENES; GENE EXPRESSION; TRANSFORMATION	NF-KAPPA-B; CHICKEN SPLEEN-CELLS; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; ONCOGENIC TRANSFORMATION; TRANSCRIPTION FACTORS; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; CELLULAR PROTEINS; HOMOLOGY DOMAIN	Proteins within the Rel/NF-kappa B transcription factor family can be divided into two functional domains, a homologous amino terminal region, the Rel Homology Domain, and a divergent carboxy terminal domain. The amino terminal sequences specify DNA binding, nuclear localization, and interaction with the I kappa B family of inhibitory proteins. The carboxy terminus of each protein functions as a transcriptional activation domain, however, precise definition of sequence requirements has been difficult. To further define these sequences, small 100 bp deletions were constructed throughout the carboxy terminus of v-Rel. Each resulting mutant was assayed for DNA binding, localization, protein complex formation, activation of endogenous gene expression and ability to transform bone marrow cells and fibroblasts. Surprisingly, deletion within the carboxy terminus had marginal effects on transforming potential. However, three separate regions were required for full activation of gene expression. Taken together, these results suggest that the carboxy terminus of v-Rel contains multiple sequences that participate in the activation of gene expression.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1987, CURRENT PROCOLS MOL; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GARSON K, 1990, ONCOGENE, V5, P1431; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1991, TRENDS GENET, V7, P307; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J-I, 1991, P NATL ACAD SCI USA, V88, P3175; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1992, SEM DEV BIOL, V3, P15; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN J, 1992, ONCOGENE, V7, P1903; LEHN DA, 1993, DNA CELL BIOL, V12, P753, DOI 10.1089/dna.1993.12.753; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MACCABE JA, 1990, J EXPER ZOO, V257, P208; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; RUBEN SM, 1991, SCIENCE, V254, P11, DOI 10.1126/science.1925549; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992	60	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2017	2026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761102				2022-12-28	WOS:A1995QZ92600016
J	MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L				MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L			DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF C-MYC PROMOTER THROUGH THE SAME DNA-BINDING SITES TARGETED BY SP1-LIKE PROTEINS	ONCOGENE			English	Article						C-MYC TRANSCRIPTION; SP1; SP3	TRANS-ACTIVATION; FACTOR E2F; SP1; PRODUCT; DOMAINS; GENE; TRANSACTIVATION; ELEMENTS; COMPLEX; CLONING	Sp1 and Sp3 are closely related members of a gene family encoding proteins with very similar structural features. The zinc finger DNA binding domains of Sp1 and Sp3 are highly conserved and they bind to GC and GT box with comparable affinities. To begin to delineate the specific roles of these two members of the Sp1-like gene family, here we have analysed the DNA binding specificity and their effects on activation of human c-myc promoter. We found that both proteins bind to the same sites of c-myc promoter, upstream to both the P1 and P2 initiation sites. Cotransfection experiments, in mammalian and insect cells, indicated that Sp1 trans-activate c-myc promoter, whereas Sp3 did not. In addition, enforced expression of Sp3 repressed Spl-mediated activation of c-myc. Finally, we found that Sp1 and E2F-1/DP-1 cooperatively trans-activate c-myc promoter. In contrast enforced expression of Sp3 fails to repress EZF-1/DP-1-mediated activation.	UNIV NAPLES FEDERICO II, DIPARTIMENTO GENET BIOL GEN & MOLEC, I-80134 NAPLES, ITALY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	University of Naples Federico II; Philipps University Marburg			De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Suske, Guntram/0000-0002-4807-0513; Majello, Barbara/0000-0003-2789-3585				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG Y, 1991, ONCOGENE, V6, P1979; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMANTIA G, 1992, NUCLEIC ACIDS RES, V20, P4129, DOI 10.1093/nar/20.16.4129; LIPP M, 1989, ONCOGENE, V4, P535; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	33	120	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1841	1848						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753559				2022-12-28	WOS:A1995QX46900017
J	COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR				COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR			CONSISTENT LOSS OF THE WILD-TYPE ALLELE IN BREAST CANCERS FROM A FAMILY LINKED TO THE BRCA2 GENE ON CHROMOSOME 13Q12-13	ONCOGENE			English	Note						BREAST CANCER; GENETICS; LOSS OF HETEROZYGOSITY	RETINOBLASTOMA; HETEROZYGOSITY; CARCINOMA; REGION	A small proportion of breast cancer is attributable to the inheritance of dominant, high penetrance susceptibility genes. One of these genes, BRCA2, has recently been localised by genetic linkage analysis to chromosome 13q12-13, This is a region known to exhibit loss of heterozygosity in 20-40% sporadic breast cancers, In this study, we have examined cancers from a family showing strong evidence of linkage to BRCA2. LOH was seen in seven out of eight informative cancers, In all cases the allele lost was the wild type allele that does not segregate with the disease in the family. The data suggest that both alleles of BRCA2 are inactivated in cancers, the pattern expected of a recessive oncogene or tumour suppressor gene.	ROYAL MARSDEN HOSP,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; UNIV IRELAND TRINITY COLL,ST JAMES HOSP,SCH MED,DEPT MED,DUBLIN 8,IRELAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Trinity College Dublin; Trinity College Dublin			McManus, Ross/AAE-9236-2020; Lakhani, Sunil/I-1970-2018	McManus, Ross/0000-0002-0529-9617; Lakhani, Sunil/0000-0003-4067-2760				CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; GERSDORFSTEICHE.E, 1994, AM J HUM GENET, V55, P870; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; STRATTON MR, 1995, IN PRESS J PATHOL; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	14	217	219	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1673	1675						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731724				2022-12-28	WOS:A1995QU68100026
J	BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL				BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL			INHIBITION OF CD4/P56LCK SIGNALING BY A DOMINANT-NEGATIVE MUTANT OF THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						T-CELL ACTIVATION; RAS; TYROSINE PHOSPHORYLATION	T-CELL ACTIVATION; CYCLOSPORINE-A; TYROSINE KINASES; LYMPHOCYTES-T; RAS PROTEIN; RECEPTOR; ASSOCIATION; TRANSFORMATION; PROLIFERATION; TRANSDUCTION	T-cell antigen receptor stimulation results in phosphorylation of the SH2 containing She proteins and recruitment of the Grb2/mSos complex suggesting that She proteins are involved in transducing T-cell activating signals to Ras, We have measured the effects of the isolated Shc-SH2 domain and the dominant negative Ras(N17) protein on activation of the T-cell specific transcription factor NF-AT, The isolated Shc-SH2 domain was designed to compete with endogenous She binding to upstream tyrosine phosphorylated proteins and to interfere with coupling to regulators of Ras activation, We have demonstrated that both the Shc-SH2 domain and the Ras(N17) protein significantly inhibited NF-AT activation by the CD4 coreceptor and the CD4 associated tyrosine kinase p56(lcK). Tn contrast, only the Ras(N17) protein reduced NF-AT activation by the TCR/CD3 complex, Furthermore, tyrosine kinase activity and p56(lcK) protein were found in complexes immunoprecipitated with She specific antisera after CD4 triggering but not after CD3 triggering, These results indicate that both CD4 and CD3 signal to Ras and that this signaling is mediated by independent pathways of activation of the She adaptor protein.	IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY	University of Siena; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Telford, John Laird/ABG-8144-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; Baldari, Cosima/0000-0002-4414-6744				ALCALAY M, 1990, ONCOGENE, V5, P267; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; HAIGWOOD NL, 1990, VACCINES 90, P313; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PELICCI G, 1991, CELL, V70, P93; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J., 1989, MOL CLONING; SEFTON BM, 1991, ONCOGENE, V6, P683; Signoret N, 1993, Trends Microbiol, V1, P328, DOI 10.1016/0966-842X(93)90072-Y; STEIMER KS, 1988, VACCINES 88, P347; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS D, 1990, IMMUNOLOGY, V71, P10; WOODROW MA, 1993, J IMMUNOL, V9, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	31	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700640				2022-12-28	WOS:A1995QN35300015
J	TILBROOK, PA; PATERSON, HF; MARSHALL, CJ				TILBROOK, PA; PATERSON, HF; MARSHALL, CJ			REVERSION OF A HUMAN TUMOR-CELL LINE CONTAINING ONCOGENIC P21(RAS) IS ASSOCIATED WITH A DEFECT IN THE POSTTRANSLATIONAL PROCESSING OF THE RAS PROTEIN	ONCOGENE			English	Note						RAS; ISOPRENYLATION; POSTTRANSLATIONAL MODIFICATIONS; REVERTANT	P21RAS ONCOPROTEIN; PLASMA-MEMBRANE; TRANSFORMATION; PRODUCT; SIGNAL; KINASE; MOTIF; ACID; CAAX	Correct post-translational modifications of the ras proteins are essential for their membrane localisation and functioning. The flat revertant cell lines 1aCB and 8b, derived from the human bladder carcinoma cell line EJ, contain the transforming gene V12Ha-ras and are resistant to retransformation by vas protein or DNA, but still do require the presence of ras for proliferation. Both revertant cell lines demonstrated reduced levels of membrane associated p21(ras) when compared to their parental EJ cell lines. This reduced level in 1aCB was reflected by an increase in nuclear associated p21(ras), as seen by immunofluorescence of endogenous and introduced ras. In addition, 1aCB had a reduced ratio of ras in the detergent to aqueous phases after triton X114 partitioning, suggesting a defect in Step I processing of the p21(ras) in the cell line. This was not however due to defects in the Step I enzymes farnesyltransferase or carboxymethyltransferase whose activities were not reduced.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSS JL, 1988, MUTAT RES, V195, P255; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P1167; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HUANG S, 1991, ONCOGENE, V6, P1211; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; PATERSON HF, 1989, CIBA F S, V142, P135; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHULZ TF, 1988, IMMUNOLOGY, V64, P581; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	25	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					805	809						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862461				2022-12-28	WOS:A1995QH61200024
J	ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ				ENG, C; SMITH, DP; MULLIGAN, LM; HEALEY, CS; ZVELEBIL, MJ; STONEHOUSE, TJ; PONDER, MA; JACKSON, CE; WATERFIELD, MD; PONDER, BAJ			A NOVEL POINT MUTATION IN THE TYROSINE KINASE DOMAIN OF THE RET PROTOONCOGENE IN SPORADIC MEDULLARY-THYROID CARCINOMA AND IN A FAMILY WITH FMTC	ONCOGENE			English	Article						MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; RECEPTOR TYROSINE KINASE GENE	MULTIPLE ENDOCRINE NEOPLASIA; PROTOONCOGENE; FEATURES	Germline mutations within one of six codons of the RET proto-oncogene account for the majority of cases of multiple endocrine neoplasia (MEN) type 2A and type 2B and familial medullary thyroid carcinoma (FMTC). MEN 2A and FMTC mutations characterised thus far occur exclusively in the cysteine-rich domain of the extracellular region of RET. We now report a missense mutation in the intracellular tyrosine kinase domain of RET in the germline of a family with FMTC that does not have a cysteine codon mutation. In this family, the mutation, which alters GAG (GIu) to GAC (Asp) at codon 768, segregates with the FMTC phenotype. The same mutation was also detected in sporadic MTC but not in corresponding constitutional DNA, confirming that it is likely to be of pathological significance rather than a rare polymorphism.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DEPT MED, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PEDIAT, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON, ENGLAND	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada; Ludwig Institute for Cancer Research; Henry Ford Health System; Henry Ford Hospital; University of London; University College London				Zvelebil, Marketa/0000-0001-8018-5591; Eng, Charis/0000-0002-3693-5145				CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, IN PRESS GENES CHROM; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JACKSON C E, 1986, Materia Medica Polona, V18, P59; JACKSON CE, 1973, ANN INTERN MED, V78, P845, DOI 10.7326/0003-4819-78-6-845; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SUGAYA R, 1994, MECH DEVELOP, V45, P139, DOI 10.1016/0925-4773(94)90027-2; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901	22	253	257	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					509	513						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845675				2022-12-28	WOS:A1995QF64800011
J	THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L				THOMAS, M; MASSIMI, P; JENKINS, J; BANKS, L			HPV-18 E6 MEDIATED INHIBITION OF P53 DNA-BINDING ACTIVITY IS INDEPENDENT OF E6 INDUCED DEGRADATION	ONCOGENE			English	Article						P53; HPV18 E6; OLIGOMERIZATION; DNA BINDING	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; GENE-EXPRESSION; CELLULAR P53; PROTEIN; TRANSACTIVATION; CELLS; WILD-TYPE-P53	A key activity of the p53 protein during suppression of cell growth is its ability to stimulate transcription from promoters of cellular genes which contain a p53 responsive element. The E6 proteins from the oncogenic associated Human Papillomaviruses (HPVs) have been shown to inhibit specifically the p53 transcriptional activation and this has been proposed as a mechanism whereby the virus prevents the suppression of cell cycle progression and the induction of apoptosis. However, the mechanism by which E6 exercises this function is unknown, as is the ability of E6 to associate with different oligomeric forms of p53. In this study we demonstrate that E6 induces changes within the p53 protein which result both in inhibition of DNA binding and in dissociation of p53 protein previously bound to the DNA. These activities correlate exactly with the ability of E6 to inhibit p53 transcriptional activation and are independent of the ability of E6 to direct the degradation of the p53 protein. Further, we show that E6 labels wild type tetrameric and dimeric forms of p53 proteins for ubiquitin mediated degradation more readily than monomeric forms of the protein. However, in vivo analyses indicate that E6 is capable of inhibiting the transcriptional activation induced by the tetrameric, dimeric and monomeric forms of p53.	MARIE CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND		THOMAS, M (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1993, CANCER RES, V53, P4469; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1988, ONCOGENE HDB, P403; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V362, P857; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANG BC, 1994, ONCOGENE, V9, P853; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	74	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					261	268						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838526				2022-12-28	WOS:A1995QC62400005
J	SEETHARAM, L; GOTOH, N; MARU, Y; NEUFELD, G; YAMAGUCHI, S; SHIBUYA, M				SEETHARAM, L; GOTOH, N; MARU, Y; NEUFELD, G; YAMAGUCHI, S; SHIBUYA, M			A UNIQUE SIGNAL-TRANSDUCTION FROM FLT TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR VEGF	ONCOGENE			English	Article						ENDOTHELIAL GROWTH FACTOR; VEGF; ANGIOGENESIS; FIT TYROSINE KINASE; SIGNAL TRANSDUCTION	TRK PROTOONCOGENE PRODUCT; PERMEABILITY FACTOR; CELL GROWTH; BINDING-SITES; DEVELOPMENTAL EXPRESSION; SENSITIVE METHOD; AMINO-ACID; PROTEIN; ANGIOGENESIS; MITOGEN	Flt-1 (fms-like tyrosine kinase-1), a receptor-type tyrosine kinase of sharing similar features with two other flt-family encoded proteins KDR/Flk-1 and Flt-4, has been recently identified as a receptor for Vascular Endothelial Growth Factor (VEGF) known to induce the proliferation of vascular endothelial cells. In this study, we demonstrate that Flt-1 encodes for a 180 kDa glycoprotein, binds VEGF with high affinity, undergoes autophosphorylation but does not generate any mitogenic response in transfected NIH3T3 fibroblasts. Interestingly, the immediate early gene c-myc was not induced, whereas the c-fos was induced very weakly in Flt-1 expressing NIH3T3 cells. A comparative analysis of the Flt-1 signal cascade in the environment of endothelial cells with that of Flt-1 expressing NIH3T3 cells showed that VEGF induced phosphorylation of PLC gamma and GAP complex on tyrosine in both type of cells. However, a strong activation of MAP kinases was observed only in endothelial cells. Further, different from many other receptor tyrosine kinases, tyrosine phosphorylation of She protein, an important adaptor for signal transduction from many receptor kinases, was very weak in both Flt-1-NIH3T3 cells and endothelial cells. These results suggest that Flt-1 kinase utilizes a unique signal transduction system in endothelial cells, and the activation of the Flt-1 kinase is insufficient to trigger a mitogenic response in NIH3T3 fibroblasts.	UNIV TOKYO, INST MED SCI, DEPT GENET, TOKYO 108, JAPAN; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	University of Tokyo; Technion Israel Institute of Technology			GOTOH, Noriko/D-8430-2015; Neufeld, Gera/F-1524-2019					APRELIKOVA O, 1992, CANCER RES, V52, P746; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIER G, 1992, DEVELOPMENT, V114, P521; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COFFIN JD, 1988, DEVELOPMENT, V102, P735; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOTOH Y, 1990, EUR J BIOCHEM, V193, P611; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KLAGSBRUN M, 1987, ANGIOGENIS MECHANISM; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9627; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULER R, 1986, ONCOGENES GROWTH CON; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1986, P NATL ACAD SCI USA, V83, P3855, DOI 10.1073/pnas.83.11.3855; RISAU W, 1988, DEVELOPMENT, V102, P471; ROSNET O, 1993, ONCOGENE, V8, P173; Sambrook J, 1989, MOL CLONING LABORATO; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATOH H, 1987, JPN J CANCER RES, V78, P772; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHESSINGER J, 1992, NEURON, V9, P383; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1990, CANCER RES, V50, P1774; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WRANA JL, 1994, ANTURE, V370, P341; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAMANE A, 1994, ONCOGENE, V9, P2683; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	79	417	439	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					135	147						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824266				2022-12-28	WOS:A1995QA98000016
J	BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S				BRAUCHLE, M; ANGERMEYER, K; HUBNER, G; WERNER, S			LARGE INDUCTION OF KERATINOCYTE GROWTH-FACTOR EXPRESSION BY SERUM GROWTH-FACTORS AND PRO-INFLAMMATORY CYTOKINES IN CULTURED FIBROBLASTS	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS FACTOR-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; CELL GROWTH; MACROPHAGES; SECRETION; CLONING; FAMILY; PDGF	We have recently demonstrated a large induction of keratinocyte growth factor expression in dermal fibroblasts during wound healing. To identify possible mediators of KGF induction, we have now analysed the regulation of KGF expression in vitro in cultured murine and human fibroblasts. Here we demonstrate that KGF mRNA and protein expression is low in quiescent fibroblasts but is strongly induced upon serum stimulation. This induction can be mediated by at least two different intracellular pathways involving protein kinase C or cAMP-dependent kinases. Our finding that induction of KGF expression by serum is independent of de novo protein synthesis demonstrates, that KGF is the product of a primary response gene. The stimulatory effect of serum on KGF expression is likely to be a combinatorial effect of different mitogens, since several purified serum growth factors also stimulated KGF expression but to a lesser extent compared to serum. Furthermore, we also found a strong KGF induction by interleukin-1 beta, tumor necrosis factor-alpha and interleukin-6, cytokines which are released by polymorphonuclear leukocytes and activated macrophages during wound healing. These data suggest that serum which is released upon hemorrhage as well as pro-inflammatory cytokines might be responsible for the KGF induction in vivo during skin repair.	MAX PLANCK INST BIOCHEM,VIRUS FORSCH ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCO NA, 1990, BLOOD, V75, P2049; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; DINARELLO CA, 1991, CYTOKINE HDB, P47; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1991, SCIENCE, V251, P335; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WERNER S, 1991, ONCOGENE, V6, P2137; WERNER S, IN PRESS J INVEST DE; Wong H. L., 1989, HUMAN MONOCYTES, P383; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	30	191	193	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3199	3204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936642				2022-12-28	WOS:A1994PM65800011
J	HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T				HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T			ACCELERATED EXON SKIPPING OF IRF-1 MESSENGER-RNA IN HUMAN MYELODYSPLASIA/LEUKEMIA - A POSSIBLE MECHANISM OF TUMOR-SUPPRESSOR INACTIVATION	ONCOGENE			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; INTERFERON-INDUCIBLE GENES; POLYMERASE CHAIN-REACTION; CELL LUNG-CARCINOMA; PRE-MESSENGER-RNA; P53 GENE; IFN-BETA; RETINOBLASTOMA ANTIONCOGENE; TRANSCRIPTIONAL ACTIVATOR	The transcription factor IRF-1 has been shown to function as a tumor suppressor. Here we report that a significant proportion of the IRF-1 mRNA detected in normal human hematopoietic cells and cultured cell lines lacks exon 2 (containing the AUG initiation codon) and 3 as a result of exon skipping. Surprisingly, when we examined the bone marrow and peripheral mononuclear cells from patients with myelodysplastic syndrome (MDS) or leukemia secondary to MDS, we could still detect the exon-skipped form but little or none of the intact IRF-1 mRNA. This appears to be the result of accelerated exon skipping since we could find no mutations within the exons and splicing junctions from these patients. The exon-skipped form of IRF-1 lacking exons 2 and 3 displayed neither DNA binding nor tumor suppressive activities. Thus this accelerated exon skipping may cause the inactivation of IRF-1 and thereby contribute to the development of human hematopoietic malignancies.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo			Harada, Hisashi/H-2815-2019; Kondo, Takeshi/G-2103-2012	Harada, Hisashi/0000-0001-5993-1289; Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220; Kitagawa, Motoo/0000-0003-1036-840X				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHA Y, 1993, DNA CELL BIOL, V11, P605; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GALLAGHER R, 1979, BLOOD, V54, P713; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORI N, 1990, ONCOGENE, V5, P1713; NIMER SD, 1987, BLOOD, V70, P1705; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PEDERSEN B, 1991, LEUKEMIA, V5, P566; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUGIMOTO K, 1993, BLOOD, V81, P3022; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANAKA N, 1991, IN PRESS CANCER LETT; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	69	126	128	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3313	3320						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936656				2022-12-28	WOS:A1994PM65800025
J	WEIH, F; CARRASCO, D; BRAVO, R				WEIH, F; CARRASCO, D; BRAVO, R			CONSTITUTIVE AND INDUCIBLE REL NF-KAPPA-B ACTIVITIES IN MOUSE THYMUS AND SPLEEN	ONCOGENE			English	Article							DORSOVENTRAL PATTERN-FORMATION; C-REL; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; SIGNAL TRANSDUCTION; PROTEIN SUBUNITS; LYMPHOID-CELLS; P65 SUBUNIT; GENE; FAMILY	We have studied the expression of members of the rel family of transcription factors and ikba in mouse thymus and spleen by in situ hybridization. Our results show that the vel genes have different temporal and spatial patterns of expression suggesting distinct roles in these lymphoid tissues. The Rel/NF-kappa B proteins and I kappa B alpha in thymus and spleen were also analysed by Western blotting and electrophoretic mobility shift assays. Although RelB protein is present at significantly lower levels in thymus and spleen extracts when compared to RelA, in both tissues the predominant kappa B-binding activity consists of p50/RelB and p52/RelB heterodimers and only very little binding of RelA-containing complexes to kappa B sites was detected. Significant binding of c-Rel complexes was only found in spleen extracts. Treatment of thymus and spleen extracts with deoxycholate (DOC), however, results in a strong increase in binding to kappa B sites of both RelA and c-Rel complexes. In contrast, binding of RelB complexes is not induced after DOC treatment. Our results suggest a differential role of Rel/NF-kappa B complexes in mouse thymus and spleen with RelB heterodimers representing the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, IN PRESS DEVELOPMENT; CARRASCO D, 1994, CELL BIOL LABORATORY; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DOBRANSKI P, 1994, IN PRESS EMBO J; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; IP YT, 1992, J CELL SCI, P33; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METCALF D, 1971, FRONTIERS BIOL HEMAT, P172; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; RYSECK RP, 1994, IN PRESS IMMEDIATE E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	73	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3289	3297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936653				2022-12-28	WOS:A1994PM65800022
J	KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J				KOHNO, T; MORISHITA, K; TAKANO, H; SHAPIRO, DN; YOKOTA, J			HOMOZYGOUS DELETION AT CHROMOSOME 2Q33 IN HUMAN SMALL-CELL LUNG-CARCINOMA IDENTIFIED BY ARBITRARILY PRIMED PCR GENOMIC FINGERPRINTING	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; HUMAN DNA; CANCER; HETEROZYGOSITY; LINES; ADENOCARCINOMA; LOCALIZATION; EXPRESSION; SEQUENCES	We have searched for novel genetic alterations in human cancer cell lines by using the arbitrarily primed polymerase chain reaction (AP-PCR), which is a PCR-based genomic fingerprinting. A homozygous deletion was detected in a small-cell lung carcinoma (SCLC) cell line, NCI-H82. Since homozygous deletion is a critical genetic alteration for the inactivation of tumor suppressor gene, we defined the locus of homozygous deletion. Fluorescence in situ hybridization analysis revealed that the deletion was localized at chromosome 2q33. Allelic loss on chromosome 2q was detected in 29.4% (5/17) of SCLC and 37.5% (12/32) one non-SCLC by restriction fragment length polymorphism analysis. Considerably high incidence of allelic loss on chromosome 2q was also detected in colorectal carcinoma and neuroblastoma. These results suggest the presence of a novel tumor suppressor gene at 2q33, which is involved in the development of several human cancers. The size of the homozygous deletion in the NCI-H82 cell line was more than 20 kilobase pairs. Seven loci mapped to 2q32-qter were all retained in this cell line, suggesting the presence of submicroscopic interstitial deletion in this cell line. Homozygous deletion detected in this study should be an invaluable tool for positional cloning of the target tumor suppressor gene at 2q33.	NATL CANC CTR, RES INST, CHUO KU, TOKYO 104, JAPAN; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Cancer Center - Japan; St Jude Children's Research Hospital				takano, hirokuni/0000-0002-6465-7883	NCI NIH HHS [CA-21765, CA-23099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARNEY DN, 1985, CANCER RES, V45, P2913; DARIAVACH P, 1988, EUR J IMMUNOL, V18, P1901, DOI 10.1002/eji.1830181206; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EHRENBORG E, 1991, BIOCHEM BIOPH RES CO, V176, P1250, DOI 10.1016/0006-291X(91)90420-C; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KOHLER A, 1993, GENOMICS, V15, P233, DOI 10.1006/geno.1993.1045; KOHNO T, 1993, ONCOGENE, V8, P1825; KUBOTA Y, 1987, FEBS LETT, V212, P159, DOI 10.1016/0014-5793(87)81577-6; LEE KP, 1990, J IMMUNOL, V145, P344; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Maniatis T., 1982, MOL CLONING; MATSUMOTO T, 1991, JPN J CANCER RES, V82, P820, DOI 10.1111/j.1349-7006.1991.tb02708.x; MATSUMURA Y, 1992, CANCER RES, V52, P2174; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MORI N, 1989, CANCER RES, V49, P5130; MORISS SW, 1991, BLOOD, V78, P2013; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELSH J, 1991, NUCLEIC ACIDS RES, V19, P5275, DOI 10.1093/nar/19.19.5275; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YAMADA T, 1985, JPN J CANCER RES, V76, P967; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; 1991, CYTOGENET CELL GENET, V58, P1	44	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					103	108						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905618				2022-12-28	WOS:A1994MW24700013
J	GELMAN, IH; KHAN, S; HANAFUSA, H				GELMAN, IH; KHAN, S; HANAFUSA, H			MORPHOLOGICAL TRANSFORMATION, TUMORIGENICITY AND SRC-SPECIFIC CYTOTOXIC T-LYMPHOCYTE-MEDIATED TUMOR-IMMUNITY INDUCED BY MURINE 3T3 CELLS EXPRESSING SRC ONCOGENES ENCODING NOVEL NON-MYRISTYLATED N-TERMINAL DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; ANTI-PHOSPHOTYROSINE ANTIBODIES; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; REJECTION ANTIGEN; FIBRO-SARCOMA; PROTEINS; PP60SRC; P60SRC; RECEPTOR	We previously reported the development of a src-specific tumor regression system in chickens in which preinfection with rASV1702, a mutant of Rous sarcoma virus (RSV) encoding non-myristylated src product with a novel N-terminal domain, results in the immune suppression of challenge tumors induced by RSV. In order to adapt this sytem to the mouse, we have developed NIH3T3 and Balb/c3T3 (B3T3) cell lines that express 1702src, v-src, c-src, and other src variants, either by transfection or by infection with packaged recombinant Moloney virus (MLV) vectors. The sequence of the 1702 src cDNA, produced by reverse transcription-polymerase chain reaction (RT-PCR), confirmed the previously suggested 1702src N-terminal domain structure, fusing six amino acids from Pr76gag and 39 amino acids of env signal peptide sequence to Ala-76 of src. These cell lines were characterized for src expression and activity, cell compartmentalization of src product, tyrosine phosphorylation substrate specificity and transforming and tumorigenic potential. Based on these parameters, murine cell lines expressing 1702src were characteristically similar to chicken embryo fibroblasts (CEFs) infected with rASV1702. Finally, B3T3/1702src expressors, or membrane fractions of these cells, induced src-specific tumor protection in syngeneic mice against v-src-transformed tumor challenges. Splenic lymphocytes isolated from Balb/c mice inoculated with B3T3/1702src cells showed in vitro cytotoxicity against B3T3/v-src cells but not against untransformed B3T3 cells. Antibodies specific for Lyt2, mouse CD3 and H-2D(d) blocked this cytotoxicity, whereas those specific for L3T4 did not, suggesting MHC class I-restricted, CD8-mediated cell killing. These data indicate that Balb/c3T3-expressed 1702src induces a cellular anti-tumor immunity based on src-specific tumor rejection antigens.	ROCKEFELLER UNIV,DEPT MOLEC ONCOL,NEW YORK,NY 10021	Rockefeller University	GELMAN, IH (corresponding author), MT SINAI MED CTR,DEPT MICROBIOL,BOX 1124,1 GUSTAVE L LEVY PLAZA,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; GARBER EA, 1983, NATURE, V302, P161, DOI 10.1038/302161a0; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; GELMAN IH, 1993, CANCER RES, V53, P915; GELMAN IH, 1986, J MOL BIOL, V191, P395, DOI 10.1016/0022-2836(86)90135-X; GELMAN IH, 1989, J VIROL, V63, P2461, DOI 10.1128/JVI.63.6.2461-2468.1989; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1987, ONCOGENES CANCER, P233; HORIO K, 1991, JPN J CANCER RES, V82, P676, DOI 10.1111/j.1349-7006.1991.tb01903.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KREUGER JG, 1982, CELL, V28, P889; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KUZUMAKI N, 1988, J NCI, V12, P959; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SHIMIZU J, 1991, J IMMUNOL, V146, P1708; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SUDA T, 1989, JPN J CANCER RES, V80, P879, DOI 10.1111/j.1349-7006.1989.tb01730.x; SUDA T, 1988, JPN J CANCER RES, V79, P365, DOI 10.1111/j.1349-7006.1988.tb01600.x; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMITA Y, 1990, J IMMUNOL, V144, P2425; WANG LH, 1984, J VIROL, V49, P881, DOI 10.1128/JVI.49.3.881-891.1984; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	41	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2995	3004						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692370				2022-12-28	WOS:A1993MC09300013
J	GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL				GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL			P53 DEPENDENT GROWTH SUPPRESSION BY THE C-ABL NUCLEAR TYROSINE KINASE	ONCOGENE			English	Article						CELL CYCLE; GROWTH ARREST; ONCOGENE; TUMOR; SUPPRESSOR GENES	TATA-BINDING PROTEIN; CELL-CYCLE ARREST; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; P53-DEFICIENT MICE; ACTIVATION DOMAIN; GENE-PRODUCT; MUTATION; DNA; PHOSPHORYLATION	Growth suppression by the Rb and p53 tumor suppressor proteins is mediated through effects on cell cycle regulatory proteins at the G1/S transition. Because overexpression of c-Abl induces G1 arrest in fibroblasts, we reasoned that c-Abl may also affect cell cycle proteins which regulate G1. We used fibroblasts containing disruptions of the Rb or p53 genes to genetically test the role of these proteins in c-Abl growth suppression. We find that c-Abl requires p53 but not Rb to suppress growth, c-Abl binds p53 in vitro and enhances p53 dependent transcription from a promoter containing p53 DNA binding sites. An Abl mutant which no longer binds p53 does not enhance p53 transcriptional activity and fails to suppress growth. These findings provide a novel link between a growth inhibitory tyrosine kinase and the p53 tumor suppressor protein.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020; Sawyers, Charles/G-5327-2016					AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTIONI T, 1995, ONCOGENE, V10, P1325; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SERRANO M, 1993, NATURE, V16, P704; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSUKADA T, 1993, ONCOGENE, V8, P3313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	63	127	132	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651743				2022-12-28	WOS:A1995RQ46900023
J	LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R				LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-9, AND LOW INCIDENCE OF MUTATIONS OF CYCLIN-DEPENDENT KINASE INHIBITORS P15 (MTS2) AND P16 (MTS1) GENES IN GLIOMAS	ONCOGENE			English	Note						GLIOMAS; CKIS; P16 GENE; P15 GENE	DELETIONS; P21	Four cyclin-dependent kinase inhibitors called p15, p16, p21 and p27 have been identified in mammals. Because these proteins participate in the control of cell cycle, they are potential targets for somatic mutations during carcinogenesis. In order to document the prevalence of p15 and p16 alterations in gliomas, we looked for loss of heterozygosity of chromosome 9p where these genes are localized. Allelic losses were observed in 31 of 44 investigated cases. In all cases they involved the p15/ p16 locus. We then looked for mutations in the p16 and p15 genes in 46 gliomas. A total of three DNA variants were observed which were all present in the matched constitutional DNA. They may be unrelated to tumor development. A single somatic mutation was detected. It involved a C to G substitution in codon 93 of p16 and is predicted to change a threonine into an arginine. Taken together, these data indicate that inactivation by point mutation of these two cyclin-dependent kinase inhibitors is uncommon in glial tumor carcinogenesis, but that there may be a tumor suppressor gene on 9p in the vicinity of pld and p15 genes.	INST CURIE,INSERM,U434,F-75231 PARIS 05,FRANCE; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75013 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Hoang-Xuan, Khe/O-7527-2017					CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIANI C, 1994, CANCER RES, V54, P6338; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOANGXUAN K, 1994, INT J CANCER, V60, P478; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAMES CD, 1993, CANCER RES, V53, P3674; JEGO N, 1993, ONCOGENE, V8, P209; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, CANCER RES, V52, P2523; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHMIDT EE, 1994, CANCER RES, V54, P321; SERRANO M, 1994, NATURE, V366, P704; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	35	66	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					597	600						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630644				2022-12-28	WOS:A1995RN53000021
J	TRIVEDI, P; ZHANG, QJ; CHEN, F; MINAROVITS, J; EKMAN, M; BIBERFELD, P; KLEIN, G; WINBERG, G				TRIVEDI, P; ZHANG, QJ; CHEN, F; MINAROVITS, J; EKMAN, M; BIBERFELD, P; KLEIN, G; WINBERG, G			PARALLEL EXISTENCE OF EPSTEIN-BARR-VIRUS (EBV) POSITIVE AND NEGATIVE CELLS IN A SPORADIC CASE OF BURKITT-LYMPHOMA	ONCOGENE			English	Article						EBV; EBNA; BL; SPORADIC; VIRUS LOSS	LINES; DNA; MOLECULES; ANTIGENS; EXPRESSION; PATTERNS; GENOME; HLA	In the Burkitt lymphoma line Oma-BL1, EBV positive and negative cells coexist. We demonstrate that EBV positive and negative subclones are identical with respect to chromosome markers and HLA type and that the same c-myc rearrangement occurs in all the subclones. This shows that the tumor cells are derived from the same patient and are of monoclonal origin. In the positive subclones, the EBV genome was stably maintained in the episomal form. The EBV negative subclones could be derived from previously uncloned tumor cells in early passage, but not from the EBV positive subclones.			TRIVEDI, P (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL MTC,S-17177 STOCKHOLM,SWEDEN.		Winberg, Gosta/I-5686-2013	Winberg, Gosta/0000-0002-3371-4056	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2ROI CA 30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; CASPERSSON T, 1971, HEREDITAS-GENETISK A, V67, P89; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; DETHE G, 1985, BURKITTS LYMPHOMA HU, P165; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HURLEY EA, 1991, J VIROL, V65, P1245, DOI 10.1128/JVI.65.3.1245-1254.1991; JOSHI SS, 1991, INT J CANCER, V47, P643, DOI 10.1002/ijc.2910470502; KLEIN G, 1981, NATURE, V299, P313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir G. M., 1987, ADV VIRAL ONCOL, P173; Maniatis T., 1982, MOL CLONING; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MORGAN J, 1989, J VIROL, V63, P3190, DOI 10.1128/JVI.63.7.3190-3194.1989; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; PATARROYO M, 1988, INT J CANCER, V41, P901, DOI 10.1002/ijc.2910410623; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; REISMAN D, 1984, VIROLOGY, V137, P113, DOI 10.1016/0042-6822(84)90014-X; RONCELLA S, 1993, LEUKEMIA LYMPHOMA, V9, P157, DOI 10.3109/10428199309148520; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SEABRIGHT MA, 1987, LANCET, V2, P971; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; SUGDEN B, 1979, J VIROL, V31, P590, DOI 10.1128/JVI.31.3.590-595.1979; TEO CG, 1987, P NATL ACAD SCI USA, V84, P8473, DOI 10.1073/pnas.84.23.8473; TOWBIN H, 1976, P NATL ACAD SCI USA, V76, P4350; TRIVEDI P, 1993, J GEN VIROL, V74, P1393, DOI 10.1099/0022-1317-74-7-1393; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	29	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					505	510						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630634				2022-12-28	WOS:A1995RN53000010
J	DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P				DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P			HETERODIMERIZATION OF C-JUN WITH ATF-2 AND C-FOS IS REQUIRED FOR POSITIVE AND NEGATIVE REGULATION OF THE HUMAN UROKINASE ENHANCER	ONCOGENE			English	Article						C-JUN; ATF-2; HETERODIMERIZATION UROKINASE; ENHANCER	ELEMENT-BINDING PROTEIN; RESPONSE ELEMENT; PLASMINOGEN-ACTIVATOR; TRANSCRIPTION FACTORS; STROMELYSIN PROMOTER; LEUCINE ZIPPER; CYCLIC-AMP; AP-1; PHOSPHORYLATION; CRE-BP1	Dimerization plays a pivotal role in modulating the activity of the c-Jun proto-oncogene product. Heterodimerization with activating transcription factor-2 (ATF-2) alters the DNA-binding specificity of c-Jun, allowing its targeting to several cAMP responsive element (CRE)related sequences, which control a subset of AP-1-responsive genes, Here me show that a c-Jun/ATF-2 heterodimer binds to the AP-1 site (nPA 5'-TRE) essential for the activity of the human urokinase enhancer, conferring on this element several distinctive regulatory properties. The c-Jun/ATF-2 heterodimer was identified by binding competition assays, u.v. cross linking, and monospecific antibodies, In vitro binding studies revealed that the uPA 5'-TRE sequence is recognized by the cyclic AMP-unresponsive ATF-2 factor, but not by the cyclic AMP-inducible CREB, In addition, in vivo studies suggest that ATF-2 can mediate, at the same time, the activation of the c-Jun/ATF-2 site and the repression of the canonical. collagenase AP-1 site. We report that heterodimerization with c-Fos does not increase the binding of c-Jun to the uPA 5'-TRE, in contrast to the increased binding at a consensus AP-1 site. Our data further suggest that c-Fos can act as a repressor of the c-Jun/ATF-2 binding site, revealing an important functional difference, with respect to canonical AP-I elements.	INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; CU STRASBOURG,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN K,DENMARK	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Copenhagen								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; Blasi F, 1990, Semin Cancer Biol, V1, P117; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JS, 1994, J BIOL CHEM, V4, P2887; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY KJ, 1991, NUCLEIC ACIDS RES, V19, P6839; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	110	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					365	376						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624151				2022-12-28	WOS:A1995RK95700017
J	GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA				GUILLOUF, C; ROSSELLI, F; KRISHNARAJU, K; MOUSTACCHI, E; HOFFMAN, B; LIEBERMANN, DA			P53 INVOLVEMENT IN CONTROL OF G2 EXIT OF THE CELL-CYCLE - ROLE IN DNA DAMAGE-INDUCED APOPTOSIS	ONCOGENE			English	Article						P53; DNA DAMAGING AGENTS; APOPTOSIS; G2 CHECKPOINT	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; ERYTHROLEUKEMIA-CELLS; INDUCTION; AGENTS; RADIATION; CAFFEINE; PROTEIN; GROWTH; LINE	DNA damage in proliferating mammalian cells induces a complex cellular response comprising perturbation of the cell cycle and programmed cell death. The relationship between p53-dependent and p53-independent apoptotic cell death, as well as the cell cycle checkpoints induced by DNA damaging agents were explored in hematopoietic cells, using M1 myeloblastic leukemia cells, which are null for p53 expression, genetically engineered M1 variants, expressing p53(ts) and bcl-2 transgenes, as well as myeloblast enriched bone-marrow cells obtained from wild type p53 (wt p53) and p53-deficient mice. It is shown that gamma-irradiation of M1p53(ts) cells activated a function of the temperature sensitive mutant transgene p53 (p53(ts)), promoting increased apoptosis relative to parental, null p53 M1 cells. It is also shown that the kinetics of apoptotic cell death induced by gamma-irradiation correlated with the rapidity of exit from gamma-ray-induced G2 arrest for all the different hematopoietic cell types indicated above. Finally, data has been obtained to demonstrate that, in addition to a role in apoptosis and G1 arrest, wild-type p53 positively modulated the exit from the gamma-ray-induced G2 checkpoint. Taken together, these findings indicate that this new function for p53 is a component of the physiological pathway by which p53 exerts its role in apoptosis.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; INST CURIE,CNRS,UA 1292,F-75231 PARIS 05,FRANCE	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745	NCI NIH HHS [1RO1CA51162, 1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618, R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; FRITSCHE M, 1993, ONCOGENE, V8, P307; GUILLOUF C, 1995, IN PRESS BLOOD; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMAMURA J, 1994, BLOOD, V8, P2412; IMRAY FP, 1983, MUTAT RES, V112, P369; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NATARAJAN AT, 1980, HUM GENET, V54, P183, DOI 10.1007/BF00278969; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P203, DOI 10.1080/09553009414550241; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SELVAKUMARAN M, 1994, MOL CELL BIOL, V4, P2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEWART N, 1995, ONCOGENE, V10, P109; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	40	168	168	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784074				2022-12-28	WOS:A1995RB70300025
J	LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J				LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J			CYCLIN D2 IS A MODERATELY OSCILLATING NUCLEOPROTEIN REQUIRED FOR G1 PHASE PROGRESSION IN SPECIFIC CELL-TYPES	ONCOGENE			English	Article						CELL CYCLE; D-TYPE CYCLINS; ONCOGENE; G1 REGULATION	HUMAN BREAST-CANCER; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; NUCLEAR-PROTEIN; GROWTH-FACTOR; D1; CLONING; G(1); PHOSPHORYLATION; DIFFERENTIATION	To explore regulation and function of cyclin D2, a candidate cell cycle-regulatory proto-oncogene, we examined subcellular localisation, cell type- and cell cycle-dependent expression, and requirement of cyclin D2 protein for G1 progression, in a panel of 40 human normal and cancer cell types. Except for lymphoid cells and sarcoma cell lines, expression of cyclin D2 was considerably more restricted than that of cyclin D1, whereas both D-type cyclin proteins were low or undetectable in cells lacking functional retinoblastoma gene product. In G1 cells, the cyclin D2 protein was more resistant to extraction and localised predominantly to nuclei, whereas it became more soluble and distributed in both nuclei and cytoplasm from G1/S transition onwards. Centrifugal elutriation and multiparameter flow cytometry analyses of several cell types showed moderate cell cycle oscillation with maximum levels of the cyclin D2 protein reached in late G1. Microinjection and/or electroporation of antibodies to cyclin D2 during G1 arrested the cyclin D2-expressing lymphocytes, breast myoepithelium, and U-2-OS sarcoma cells in G1 phase, whereas cyclin D2-negative cell types were unaffected by such treatment. Consistent with the putative protooncogenic role of cyclin D2 in specific cell types, our data show that this G1 cyclin has properties closely resembling those of cyclin D1, including the essential positive role in regulation of G1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; UNIV COPENHAGEN, PANUM INST, INST MED ANAT A, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN N, DENMARK; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; MAX PLANCK GESELL, MAX DELBRUCK HAUS, D-13122 BERLIN, GERMANY	Danish Cancer Society; University of Copenhagen; Cancer Research UK; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Welcker, Markus/0000-0001-6723-4790; Petersen, Ole William/0000-0003-1691-749X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; HANNA Z, 1993, ONCOGENE, V8, P1661; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORK C, 1990, DIFFERENTIATION, V43, P146; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALMERO I, 1993, ONCOGENE, V8, P1049; PETERSEN OW, 1988, DIFFERENTIATION, V39, P197, DOI 10.1111/j.1432-0436.1988.tb00094.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TAM SW, 1994, ONCOGENE, V9, P2663; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	129	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2125	2134						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784057				2022-12-28	WOS:A1995RB70300007
J	STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH				STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH			IDENTIFICATION OF INTERLEUKIN-1 AND PLATELET-DERIVED GROWTH FACTOR-B AS MAJOR MITOGENS FOR THE SPINDLE CELLS OF KAPOSIS-SARCOMA - A COMBINED IN-VITRO AND IN-VIVO ANALYSIS	ONCOGENE			English	Article						KAPOSIS SARCOMA; PDGF; INTERLEUKIN ONCOSTATIN; IN SITU HYBRIDIZATION; GP130	IL-6 SIGNAL TRANSDUCER; YOUNG HOMOSEXUAL MEN; ONCOSTATIN-M; EXPRESSION; RECEPTOR; AUTOCRINE; CULTURE; INVITRO; GP130; HYBRIDIZATION	By means of a combined in vitro and in vivo analysis we provide evidence that IL-1 beta and PDGF-B, but not OSM (oncostatin M) or IL-6, are major mitogens for the spindle cells of Kaposi's sarcoma (KS) in vivo. PDGF-B and IL-1 beta stimulated proliferation of cultivated KS spindle cells in vitro. Analysis of gene expression in vivo revealed that both factors as well as the PDGF beta-receptor are present in KS lesions, By contrast, IL-6 had no effect and OSM inhibited proliferation of cultivated KS spindle cells. Again, the effect of these factors on cultivated KS spindle cells in vitro was reflected by the gene expression observed in KS lesions in vivo. Neither the expression of IL-6 receptor nor of OSM could be detected in KS lesions by in situ hybridization, Moreover, in situ hybridization revealed an identical pattern of gene expression in cultivated KS spindle cells and KS spindle cells in vivo with respect to the above-mentioned cytokines [PDGF-B, IL-1 beta, IL-1 alpha, IL-6, OSM] and their receptors [PDGF beta-receptor, gp130, IL-6 receptor, leukemia inhibitory factor (LII;) receptor]. This further supported the suitability of cultivated KS spindle cells as an in vitro model in order to determine which cytokines may activate proliferation of KS spindle cells in vivo.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; MAX PLANCK INST PSYCHIAT, NEUROMORPHOL ABT, D-82152 MARTINSRIED, GERMANY; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; UNIV ESSEN GESAMTHSCH KLIN, HAUTKLIN, ESSEN, GERMANY	University of Munich; Max Planck Society; University of Duisburg Essen	STURZL, M (corresponding author), MAX PLANCK INST BIOCHEM, VIRUSFORSCH ABT, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Stürzl, Michael/B-3019-2015; Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021	Stürzl, Michael/0000-0002-9276-2824; 				ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BOVI PD, 1986, CANCER RES, V46, P6333; CAI J, 1994, AM J PATHOL, V145, P74; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBEIL J, 1991, J IMMUNOL, V146, P2972; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HAMILTON AS, 1994, J ACQ IMMUN DEF SYND, V7, P410; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6; KAPOSI M, 1872, ARCH DERMATOL SYPHIL, V4, P742; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; REGEZI JA, 1993, AM J PATHOL, V143, P240; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTH WK, 1989, ONCOGENE, V4, P483; SCHIRREN CG, 1990, BRIT J DERMATOL, V123, P313, DOI 10.1111/j.1365-2133.1990.tb06290.x; SCHULZEOSTHOFF K, 1990, J INVEST DERMATOL, V95, P238, DOI 10.1111/1523-1747.ep12478105; SNOVER DC, 1985, CLIN BIOCH ANAL, P181; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; STURZL M, 1992, AIDS RES HUM RETROV, V8, P1753, DOI 10.1089/aid.1992.8.1753; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; XERRI L, 1991, AM J PATHOL, V138, P9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG J, 1994, J IMMUNOL, V152, P943	41	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2007	2016						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761101				2022-12-28	WOS:A1995QZ92600015
J	VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD				VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD			IDENTIFICATION OF FULL-LENGTH AND TRUNCATED FORMS OF EHK-3, A NOVEL MEMBER OF THE EPH RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH GENE FAMILY; EHK-3; NEURAL EXPRESSION	RAT TRKC; PROTEIN; GENE; ENCODES; NEUROTROPHIN-3; HINDBRAIN; MOUSE	Factors that bind and activate receptor tyrosine kinases are known to play key roles during development and in the adult, The Eph-related receptors constitute the largest known family of receptor tyrosine kinases, Members of the Eph family exhibit intriguing patterns of expression in the embryo, implicating them in a variety of developmental processes, and their expression is often restricted to particular subpopulations of postmitotic neurons in the adult, We describe the identification and characterization of a novel member of the Eph receptor family, which we have termed Ehk-3 for Eph Homologous Kinase 3, Ehk-3 displays all the major structural features shared by other members of the Eph family, including a cysteine-rich region and tandem fibronectin type-III domains in its extracellular portion, Ehk-3 is expressed in two forms in a developmentally-regulated fashion: a conventional full-length version containing the intracellular tyrosine kinase domain, as well as a truncated form that lacks this domain, Both forms of Ehk-3 are quite restricted to the nervous system in the adult, but Ehk-3 is more widely expressed in the embryo, suggesting that Ehk-3 mediates different functions during development and in the adult.			VALENZUELA, DM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FROHMAN MA, 1990, PCR PROTOCOLS; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NIETO MA, 1992, DEVELOPMENT, V116, P1137; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9	21	49	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1573	1580						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731712				2022-12-28	WOS:A1995QU68100013
J	EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD				EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD			ALTERED SUBCELLULAR LOCATION OF AN ACTIVATED AND TUMOR-ASSOCIATED EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Note						GLIO BLASTOMA; TYROSINE KINASE; ONCOGENE; ENDOPLASMIC RETICULUM; EGF-BINDING; CONFOCAL MICROSCOPY	AVIAN ERYTHROBLASTOSIS VIRUS; HUMAN-BRAIN-TUMORS; PROTEIN KINASE-C; B GENE-PRODUCT; EGF RECEPTOR; SIGNAL TRANSDUCTION; HUMAN GLIOBLASTOMAS; PLASMA-MEMBRANE; HUMAN GLIOMAS; CELL-SURFACE	The epidermal growth factor (EGF) receptor is a membrane bound tyrosine kinase whose activity is initiated by ligand binding, The malignant brain tumour glioblastoma frequently shows amplification and rearrangements of the EGF receptor gene that are associated with the synthesis of a constitutively activated tyrosine kinase, lacking amino acids 6-273 near the protein's N-terminus, When expressed in Chinese hamster ovary (CHO) cells, this mutant receptor (p140(EGFR)) displays ligand-independent tyrosine kinase activity, stimulates DNA synthesis, and promotes cell proliferation, Here, we investigate the subcellular location of p140(EGFR) in CHO cell transfectants as web as in human glioblastoma tumours, p140(EGFR) had an intracellular location that contrasted sharply with the plasma membrane location of the wild-type EGF receptor, Endoglycosidase H sensitivity analysis and the pattern of p140(EGFR) immunoreactivity suggested that the aberrant tyrosine kinase resided primarily in the endoplasmic reticulum, The half-life of p140(EGFR) in, the endoplasmic reticulum was extended several-fold over that of the ligand-activated wild-type receptor, The altered subcellular location of p140(EGFR) in combination with its prolonged half-life suggest that this activated tyrosine kinase may escape the regulatory mechanisms utilized for the attenuation of wild-type receptor signaling, Therefore, the previously reported growth stimulatory property of the ligand-independent p140(EGFR) may be attributed to a sustained tyrosine kinase activity resulting from an altered subcellular location.	EMORY UNIV, SCH MED, DEPT NEUROSURG, MOLEC NEUROONCOL LAB, ATLANTA, GA 30322 USA; KAROLINSKA HOSP, LUDWIG INST CANC RES, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; EMORY UNIV, SCH MED, DEPT PEDIAT, DIV MED GENET, ATLANTA, GA 30322 USA	Emory University; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska University Hospital; Emory University			James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOWEN S, 1991, J BIOL CHEM, V266, P1162; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FAURE R, 1992, J BIOL CHEM, V267, P11215; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISTER M, 1988, CANCER RES, V48, P3910; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	39	43	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1455	1460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731699				2022-12-28	WOS:A1995QR65100026
J	HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K				HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K			ETS-RELATED PROTEIN E1A-F CAN ACTIVATE 3 DIFFERENT MATRIX METALLOPROTEINASE GENE PROMOTERS	ONCOGENE			English	Note						ETS; MMP; INVASION; TRANSCRIPTION	COLLAGENASE GENE; MAMMALIAN-CELLS; ONCOGENE FAMILY; BINDING-SITES; EXPRESSION; PEA3; FOS; AP-1; TRANSCRIPTION; ELEMENTS	An Ets-related E1A-F has been characterized as an enhancer-binding protein for the adenovirus E1A gene, Here we show, in transient expression assays, that E1A-F can activate three different subclasses of the matrix metalloproteinase gene promoters, Expressions of the chloramphenicol acetyltransferase (CAT) reporter gene under the control of stromelysin, type I collagenase and 92 kD type IV collagenase promoters were increased approximately 10- to 20-fold by co-transfection with the E1A-F expression vector. Activation levels were as much high as those obtained by exogenous expression of AP-1 transcription factor. These results suggest that EIA-F positively regulates transcriptions from matrix metalloproteinase genes that are associated with invasion and metastasis of tumor cells.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOL MOLEC, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; OKAYAMA UNIV, FAC ENGN SCI, DEPT BIOTECHNOL, OKAYAMA 700, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN	Sapporo Medical University; Okayama University; Kanazawa University			Higashino, Fumihiro/F-8510-2012; Seiki, Motoharu/K-9443-2015					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1989, NATURE, V284, P67; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NERLOV C, 1991, ONCOGENE, V6, P1583; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POWELL WC, 1993, CANCER RES, V53, P417; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SATO H, 1993, ONCOGENE, V8, P395; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOSHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10015, DOI 10.1093/nar/17.23.10015	29	149	153	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1461	1463						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731700				2022-12-28	WOS:A1995QR65100027
J	KRAUT, N; FRAMPTON, J; GRAF, T				KRAUT, N; FRAMPTON, J; GRAF, T			REM-1, A PUTATIVE DIRECT TARGET GENE OF THE MYB-ETS FUSION ONCOPROTEIN IN HEMATOPOIETIC PROGENITORS, IS A MEMBER OF THE RECOVERIN FAMILY	ONCOGENE			English	Article						RETROVIRUS E26; ACUTE AVIAN LEUKEMIA VIRUS; HEMATOPOIETIC STEM CELLS; V-ETS; TARGET GENE	CALCIUM-BINDING PROTEIN; CHICKEN ERYTHROID-CELLS; V-MYB; TRANSCRIPTION FACTORS; MYELOMONOCYTIC CELLS; MOLECULAR-CLONING; NERVOUS-SYSTEM; C-ETS-1 LOCUS; ONCOGENE; DIFFERENTIATION	The Myb-Ets oncoprotein encoded by the E26 avian leukaemia virus represents a fusion of two transcription factors which cooperate in transforming multipotent haematopoietic progenitors (MEPs) in vitro and in vivo, Previous studies with a temperature sensitive mutant in ets (ts1.1 E26) have suggested that the Ets part of the Myb-Ets fusion protein blocks multilineage differentiation of transformed MEPs, by regulating specific target genes, Using this system in a differential screening approach we have now identified a new gene, called rem-1, as a target for the E26 virus, Following shift of ts1.1 mutant transformed cells to the nonpermissive temperature a decreased expression of rem-1 was observed which increased upon downshift, The finding that this reexpression did not require new protein synthesis suggests that the Ets component of the fusion protein directly regulates rem-1 transcription, Rem-1 is related to a family of EF-hand-containing calcium-binding proteins that are predominantly expressed in the brain and in retinal cells, This family includes recoverin and visinin, proteins that have been implicated in regulating photoreception, Rem-1 is likewise expressed in these tissues but in addition in haematopoietic cells and in the gut, Enforced expression of rem-1 in ts1.1-transformed MEP cells, using a retroviral vector, showed that this gene is not sufficient to block their differentiation, but that it may provide them with a growth advantage.	EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Graf, Thomas/B-4252-2015	Graf, Thomas/0000-0003-2774-4117				BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSL S, V1, P195; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAJIMOTO Y, 1993, J NEUROCHEM, V61, P1091, DOI 10.1111/j.1471-4159.1993.tb03624.x; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LENZ SE, 1992, MOL BRAIN RES, V15, P133, DOI 10.1016/0169-328X(92)90160-D; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; QUEVA C, 1993, ONCOGENE, V8, P2511; Sambrook J, 1989, MOL CLONING LABORATO; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; STOKER AW, 1992, MOL VIROLOGY PRACTIC; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; YAMAGATA K, 1990, NEURON, V2, P469; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	20	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1027	1036						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700627				2022-12-28	WOS:A1995QN35300001
J	BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J				BARTKOVA, J; LUKAS, J; STRAUSS, M; BARTEK, J			CYCLIN D1 ONCOPROTEIN ABERRANTLY ACCUMULATES IN MALIGNANCIES OF DIVERSE HISTOGENESIS	ONCOGENE			English	Note						CELL CYCLE; OVER-EXPRESSION OF CYCLIN D1; HUMAN TUMORS; ONCOGENE	ASSISTED IMAGE-ANALYSIS; BREAST-CANCER; RETINOBLASTOMA PROTEIN; SQUAMOUS-CELL; AMPLIFICATION; GENES; CARCINOMAS; EXPRESSION; ONCOGENE; BCL-1	Cyclin D1 is a cell cycle regulator essential for G1 phase progression and a candidate proto-oncogene whose deregulated expression has been implicated in pathogenesis of several types of cancer. We have examined expression of cyclin D1 in 212 primary tumours of five histogenetically distinct types by immunohistochemistry and found strong aberrant accumulation of the protein in 21%, and a moderate overabundance in further 25% of cases. While the abnormalities were more frequent in carcinomas of the breast, i.e. the cancer type known for cyclin D1 gene amplification, aberrant expression was also seen in significant subsets of colorectal cancers, soft tissue sarcomas, uterine carcinomas and malignant melanomas. Comparison of distinct stages of tumour progression showed concordant cyclin D1 patterns in the in situ vs invasive breast carcinoma components (n=37) and between primary and metastatic lesions (n=51) of several tumour types. The specificity of the immunohistochemical data was supported by immunoblotting analysis of tissue and tumour lysates, and the tumour-specific over-expression was confirmed by computer-assisted image analysis. These observations suggest that alterations of cyclin D1 expression represent a common feature of malignancies of diverse histogenesis and indicate that both the spectrum of tumour types and the frequency of cyclin D1 aberrations significantly exceed previous estimations based on genetic analyses.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK; MAX PLANCK GESELL,MAX DELBRUCK HANS,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BACUS S, 1988, AM J CLIN PATHOL, V90, P233, DOI 10.1093/ajcp/90.3.233; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BERENSON JR, 1989, ONCOGENE, V4, P1111; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CZERNIAK B, 1990, J HISTOCHEM CYTOCHEM, V38, P463, DOI 10.1177/38.4.1969431; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILLETT C, 1994, CANCER RES, V54, P1812; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEACH FS, 1993, CANCER RES, V53, P1986; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAM SW, 1994, ONCOGENE, V9, P2663; THEILLET C, 1990, ONCOGENE, V5, P147; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	39	201	203	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					775	778						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862456				2022-12-28	WOS:A1995QH61200019
J	FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ				FERNANDEZ, A; FOSDICK, LJ; MARIN, MC; DIAZ, C; MCDONNELL, TJ; ANANTHASWAMY, HN; MCCONKEY, DJ			DIFFERENTIAL REGULATION OF ENDOGENOUS ENDONUCLEASE ACTIVATION IN ISOLATED MURINE FIBROBLAST NUCLEI BY RAS AND BCL-2	ONCOGENE			English	Note						APOPTOSIS; RAS; BCL-2; NUCLEI	TUMOR NECROSIS FACTOR; FACTOR-MEDIATED CYTOTOXICITY; DNA FRAGMENTATION; MEMBRANE PROTEIN; CELL LINES; APOPTOSIS; EXPRESSION; THYMOCYTES; DEATH	Transfection of a murine fibroblast cell line with an activated form of the Harvey ras oncogene conferred sensitivity to apoptosis induced by various agents. This intrinsic sensitivity to apoptosis correlated with the expression of endogenous endonuclease activity in isolated nuclei that was undetectable in the untransfected parental cell line. Subsequent transfection with the human bcl-2 oncogene prevented the morphological and biochemical features of apoptosis in whole cells, although it failed to confer complete protection against cell death. Furthermore, transfection of the bcl-2 oncogene also inhibited the enhanced endonuclease activity in isolated nuclei. Our results indicate that some of the effects of Ha-ras and bcl-2 and potentially other oncogenes, are exerted on the biochemical machinery of apoptosis at the level of the nucleus.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA046523, R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09255-02, R01-CA-46523, R01-CA-62597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; DEJONG D, 1994, CANCER RES, V54, P256; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENNET T, 1993, CANCER RES, V53, P1456; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LASTER SM, 1988, J IMMUNOL, V141, P2629; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	25	44	44	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					769	774						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862455				2022-12-28	WOS:A1995QH61200018
J	PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S				PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S			KINASE-ACTIVITIES OF C-MOS AND V-MOS PROTEINS - A SINGLE AMINO-ACID EXCHANGE IS RESPONSIBLE FOR CONSTITUTIVE ACTIVATION OF THE 124-V-MOS KINASE	ONCOGENE			English	Article						PROTEIN KINASE ACTIVITY; C-MOS; V-MOS; MAP KINASE ACTIVATION; PHOSPHORYLATION; ONCOGENE; ATP BINDING MUTATION	MURINE SARCOMA-VIRUS; MAMMALIAN SOMATIC-CELLS; PROTO-ONCOGENE PRODUCT; XENOPUS OOCYTES; CYTOSTATIC FACTOR; MAP KINASE; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; CRYSTAL-STRUCTURE; FROG OOCYTES	The Mos protein kinase is a serine-/threonine-specific protein kinase with a crucial role in meiotic cell divisions in vertebrates. Several oncogenic derivatives of the c-Mos protein have been discovered in murine retroviruses. These proteins have acquired mutations and exhibit different degrees of protein kinase activity in vitro. In an attempt to understand the factors governing Mos protein kinase activity we have compared the kinase activities of the wild-type c-Mos protein and of two v-Mos proteins (strain HT1 and MSV124) after expression in insect cells. Only the 124 v-Mos protein showed kinase activity in vitro as measured by autophosphorylation, vimentin phosphorylation or by phosphorylation and activation of MAP kinase kinase. By domain swapping and site-directed mutagenesis we identified a single point mutation in the 124 v-Mos protein (Arg(145)-->Gly) which is responsible for its constitutive activity. This residue is located in the alpha-helix C of the kinase domain close to the ATP binding fold and is conserved in all known c-Mos proteins. Introduction of the corresponding mutation into HT1 v-Mos and into murine c-Mos activated bath proteins for autophosphorylation, vimentin phosphorylation and for signalling via MAP kinase kinase in vitro. We hypothesize that the Arg(145)-->Gly mutation found in 124 v-Mos mimicks a conformational change which might be an obligatory step in the activation of c-Mos in vivo.	MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY; UNIV VIENNA, BIOZENTRUM, INST BIOCHEM & MOLEK ZELLBIOL, A-1030 VIENNA, AUSTRIA	Max Planck Society; University of Vienna				Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLAIR DG, 1984, CANCER CELLS ONCOGEN, P281; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P58; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					623	630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862439				2022-12-28	WOS:A1995QH61200001
J	MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D				MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D			NDF HEREGULIN ACTIVATES MAP KINASE AND P70/P85 S6 KINASE DURING PROLIFERATION OR DIFFERENTIATION OF MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article						TYPE I RECEPTOR TYROSINE KINASES; HC11 CELLS; BREAST TUMOR CELLS; ERBB-2; PROTEIN KINASE C	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; HUMAN-BREAST-CANCER; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ERBB-2 RECEPTOR; NEU ONCOGENE; TYROSINE PHOSPHORYLATION; C-ERBB-2 PROTOONCOGENE; EXTRACELLULAR DOMAIN	Neu differentiation factors (NDF) are a novel family of polypeptide factors which activate sub-class I tyrosine kinase receptors. In all mammary epithelial cells analysed in this study, NDF activates the same signalling pathways while it induces different, cell-specific biological effects. In AU565 cells which are growth inhibited, as well as in T47D or HC11 cells which proliferate in response to NDF, the MAP kinase isoforms p44(ERK1) and p42(ERK2) and the p70/p85 S6 kinase are activated. NDF stimulates tyrosine phosphorylation and the in vitro kinase activity of ErbB-2. When PKC is activated by TPA, NDF is no longer able to activate ErbB-2 in T47D cells, leading to a blockage of cell proliferation. Activation of ErbB-2 by point mutation, or by monoclonal antibodies, also stimulates both the MAPK and the p70/p85 S6 kinase pathways. The same monoclonal antibodies can induce AU565 cell differentiation. In summary, during growth or differentiation of mammary epithelial cells, NDF stimulates several independent signalling pathways which can also be triggered by ErbB-2 stimulation alone. PKC activation blocks the biological effect induced by NDF through negative modulation of ErbB-2.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; CIBA GEIGY LTD,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis			taverna, daniela/J-8358-2016	taverna, daniela/0000-0002-6365-527X				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; BACUS SS, 1993, CANCER RES, V53, P5251; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CAO HN, 1991, ONCOGENE, V6, P705; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	59	123	124	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					167	175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824269				2022-12-28	WOS:A1995QA98000019
J	CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC				CHEN, XR; WRIGHT, KL; BERKOWITZ, EA; AZIZKHAN, JC; TING, JPY; LEE, DC			PROTEIN INTERACTIONS AT SP1-LIKE SITES IN THE TGF-ALPHA PROMOTER AS VISUALIZED BY IN-VIVO GENOMIC FOOTPRINTING	ONCOGENE			English	Article							GROWTH-FACTOR-ALPHA; LIVER EPITHELIAL-CELLS; CHEMICALLY TRANSFORMED INVITRO; HUMAN-BREAST-CANCER; MESSENGER-RNA; TRANSCRIPTION FACTOR; TRANSGENIC MICE; ANTERIOR-PITUITARY; DEVELOPMENTAL EXPRESSION; HUMAN KERATINOCYTES	Transcription from the rat TGP alpha promoter initiates at two predominant sites (-188 and -58) in a G+C-rich region that does not contain TATA or CAAT motifs. Previous studies using transfected reporter constructs implicated the transcription factor Sp1 in active expression from the promoter, particularly from the -58 site (Chen et al., 1992; Shin et al., 1992). In the present report we have examined the functionality of two adjacent clusters of Sp1-like recognition sites that are located in the upstream portion of the promoter from -300 to -273. A double-stranded oligonucleotide, which spanned this region and contained the putative Sp1 elements, demonstrated similar gel-mobility shifts in the presence of both crude HeLa cells nuclear extract and pure Sp1 protein. Mutations that simultaneously altered several of the overlapping Sp1 elements significantly reduced the gel-mobility shift activity of this oligonncleotide probe and, when introduced into the promoter templates, inhibited transcription in vitro from the proximal -188 start site. To confirm the binding of protein to these sites in cells, we carried out an in vivo genomic footprinting analysis of this portion of the TGF alpha promoter in normal and transformed rat liver epithelial cell lines that express the endogenous gene at varying levels. This analysis revealed clear evidence of protein/DNA interaction at Sp1-like sites in the -300 and -273 region in cells actively expressing the gene but not in a normal, parental cell. line that expressed very low levels of TGF alpha mRNA. Collectively, these results corroborate the functional importance of Sp1 binding elements in the -300 to -273 region, and together with previous findings, indicate that two clusters of Sp1 binding sites respectively determine levels of transcription from the -188 and -58 start sites. Our additional finding that Sp1 mRNA and protein were present at similar levels in normal and transformed cells that expressed the endogenous TGF alpha gene at markedly different levels, suggests that the activity of the TGF alpha promoter could be regulated via the accessibility of Sp1 protein.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA048185, R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48185, CA-43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BORGUNDVAAG B, 1992, ENDOCRINOLOGY, V130, P3453, DOI 10.1210/en.130.6.3453; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHEN XR, 1992, ONCOGENE, V7, P1805; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIU C, 1988, CANCER RES, V48, P850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKNIGHT GS, 1977, ANAL BIOCHEM, V78, P86, DOI 10.1016/0003-2697(77)90011-2; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER SG, 1991, MOL ENDOCRINOL, V5, P1439, DOI 10.1210/mend-5-10-1439; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; PAULI U, 1987, SCIENCE, V236, P1308, DOI 10.1126/science.3035717; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SEROOGY KB, 1993, J NEUROCHEM, V60, P1777, DOI 10.1111/j.1471-4159.1993.tb13403.x; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; TAKAGI H, 1993, CANCER RES, V53, P4329; TSAO MS, 1985, CANCER RES, V45, P5139; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1983, VIROLOGY, V124, P201, DOI 10.1016/0042-6822(83)90307-0; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZIPFEL PA, 1993, CELL GROWTH DIFFER, V4, P637; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	67	22	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3179	3187						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936640				2022-12-28	WOS:A1994PM65800009
J	MIGLIACCIO, A; PAGANO, M; AURICCHIO, F				MIGLIACCIO, A; PAGANO, M; AURICCHIO, F			IMMEDIATE AND TRANSIENT STIMULATION OF PROTEIN-TYROSINE PHOSPHORYLATION BY ESTRADIOL IN MCF-7 CELLS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; PHOSPHOTYROSINE-CONTAINING PROTEINS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; ESTROGEN-RECEPTOR; HORMONE BINDING; OWN RECEPTOR; STEROID-HORMONES; CELLULAR PROTEIN; ONCOGENE PRODUCT	Estradiol stimulates protein phosphorylation on tyrosine in human breast cancer MCF-7 cells under conditions of estradiol-stimulated cell growth. The stimulatory effect of estradiol has been observed by P-32-labeling of cells followed by purification of proteins using antiphosphotyrosine antibody coupled to agarose and confirmed by immunoblotting analysis with antiphosphotyrosine antibody. This stimulation is immediate (maximal in 10 s) and transient. In addition, it is receptor-mediated since estradiol stimulation is prevented by two well-known antiestrogens, OH-Tamoxifen and ICI 164 384. Estradiol fails to stimulate tyrosine protein phosphorylation of Cos cells which do not express the estradiol receptor. Two substrates of the estrogen stimulated phosphorylation on tyrosine with approximate mol wt of 55 and 60 kDa interact with a polyclonal antibody raised against amino acids 527-533 of pp60c-src (anti-cst.1 antibody). Tyrosine kinase activity of immunoprecipitates made using either anti cst.1 antibody or the monoclonal 327 antibody specific for pp60c-src shows that kinase(s) strongly related to pp60c-src are immediately and transiently stimulated by estradiol treatment of cells. The present findings provide the first demonstration that a steroid hormone rapidly stimulates tyrosine phosphorylation of target cells and induces functional modifications of substrates of this phosphorylation. These modifications might initiate the estradiol action on cell growth.	UNIV NAPOLI 2, FAC MED & CHIRURG,IST PATOL GEN & ONCOL, CATTEDRA PATOL GEN 2,VIA S ANDREA DAME 2, I-80138 NAPLES, ITALY	Universita della Campania Vanvitelli			Migliaccio, Antimo/AAB-3376-2019	Migliaccio, Antimo/0000-0002-4197-2055				AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; AURICCHIO F, 1987, EMBO J, V6, P2923, DOI 10.1002/j.1460-2075.1987.tb02596.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BISWAS R, 1987, CANCER RES, V47, P3509; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; EK B, 1982, J BIOL CHEM, V257, P486; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MULDOON TG, 1988, J STEROID BIOCHEM, V30, P23, DOI 10.1016/0022-4731(88)90072-6; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARIKH I, 1980, J BIOL CHEM, V255, P266; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PRATT WB, 1988, J BIOL CHEM, V263, P267; REDDY KB, 1992, CANCER RES, V52, P3636; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; STERN DF, 1991, METHOD ENZYMOL, V198, P494; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WONG TW, 1984, J BIOL CHEM, V259, P8505; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1983, J BIOL CHEM, V258, P3431	52	114	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2183	2191						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687761				2022-12-28	WOS:A1993LP17100019
J	ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R				ZAKUT, R; PERLIS, R; ELIYAHU, S; YARDEN, Y; GIVOL, D; LYMAN, SD; HALABAN, R			KIT-LIGAND (MAST-CELL GROWTH-FACTOR) INHIBITS THE GROWTH OF KIT-EXPRESSING MELANOMA-CELLS	ONCOGENE			English	Article							FACTOR RECEPTOR PROTOONCOGENE; TYROSINE KINASE RECEPTOR; ACTIVATED PROTEIN-KINASE; CYTOMETRIC DNA ANALYSIS; W-MUTANT MICE; C-KIT; SI-LOCUS; SIGNAL TRANSDUCTION; FUNCTION MUTATIONS; HUMAN MELANOCYTES	Previous studies in vivo and in vitro show that KIT kinase promotes normal melanocyte development and growth. However, the role of the KIT proto-oncogene in neoplastic melanocytes is not certain. We therefore examined KIT expression and function in human melanomas. Our results show that KIT mRNA was expressed in 12 of 28 melanoma cell lines (approximately 40%), mainly in those originating from pigmented tumors. Surprisingly, activation of KIT with mast cell growth factor (MGF) in melanoma cells produced biological responses opposite to those elicited in normal melanocytes. MGF inhibited rather than stimulated the growth of metastatic melanoma cell lines. The opposite effects may be due to aberrant signal transduction by KIT in melanoma cells in response to MGF. The in vitro inhibition of melanoma cells by MGF suggests that growth in vivo of this tumor is not promoted by KIT kinase activation, but rather that transformed melanocytes might regress when MGF is expressed in their immediate environment.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98103; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Yale University; Weizmann Institute of Science	ZAKUT, R (corresponding author), NCI,SURG BRANCH,BETHESDA,MD 20892, USA.		YARDEN, YOSEF/K-1467-2012		NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848] Funding Source: NIH RePORTER; NCI NIH HHS [5-R29-CA44542] Funding Source: Medline; NIAMS NIH HHS [1RO1-AR39848] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CARROW CE, 1991, BLOOD, V78, P2216; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; Coppock D L, 1991, Cancer Treat Res, V54, P67; Cowan J M, 1991, Cancer Treat Res, V54, P3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1992, ONCOGENE, V7, P2195; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; Kock A, 1991, Cancer Treat Res, V54, P41; Kriegler M., 1990, GENE TRANSFER EXPRES; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QUI F, 1988, EMBO J, V7, P1003; RATAJCZAK M, 1991, CLIN RES, V39, pA190; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sambrook J, 1989, MOL CLONING LABORATO; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; SZEBO KM, 1990, CELL, V63, P195; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3342; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	96	97	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2221	2229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687762				2022-12-28	WOS:A1993LP17100023
J	MAGGIRWAR, SB; HARHAJ, E; SUN, SC				MAGGIRWAR, SB; HARHAJ, E; SUN, SC			ACTIVATION OF NF-KAPPA-B/REL BY TAX INVOLVES DEGRADATION OF I-KAPPA-B-ALPHA AND IS BLOCKED BY A PROTEASOME INHIBITOR	ONCOGENE			English	Note						TAX; HTLV-I; NF-KAPPA-B; I-KAPPA-B-ALPHA; PROTEIN PHOSPHORYLATION; PROTEASOME INHIBITOR	T-CELL LEUKEMIA; VIRUS TYPE-I; RECEPTOR GENE-EXPRESSION; HTLV-I; TRANSCRIPTION FACTOR; NUCLEAR-LOCALIZATION; PRECURSOR P105; DNA-BINDING; C-REL; PROTEINS	The tax gene product of the human T-cell leukemia virus type I (HTLV-I) induces the nuclear expression and biological function of the NF-kappa B/Rel family of host transcription factors although the underlying mechanism remains unclear, In the present study, we demonstrate that Tax-mediated activation of NF-kappa B/Rel can be inhibited by a proteasome inhibitor, suggesting the involvement of proteolytic reactions in this Tax-specific activation pathway. Transient transfection and reporter gene assays have revealed that Tax overrides the inhibitory function of I kappa B alpha in both F9 embryonal cells and Jurkat T cells. Moreover, Tax-mediated inactivation of I kappa B alpha requires a 16 amino acid sequence element located at the N-terminal region (amino acid 21-36) of I kappa B alpha, which is also required for tumor necrosis factor alpha-induced degradation of this inhibitory protein. We further demonstrate that the proteasome inhibitor also blocks the degradation of I kappa B alpha observed in HTLV-I-infected T cells. Interestingly, inhibition of I kappa B alpha degradation in these cells led to the accumulation of a phosphorylated form of I kappa B alpha. Together, these studies suggest that Tax activation of NF-kappa B/Rel may involve induction of phosphorylation and subsequent proteasome-mediated degradation of the inhibitor I kappa B alpha.	PENN STATE UNIV,COLL MED,MILTON S HERSHEY MED CTR,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1986, SCIENCE, V241, P1652; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MUNOZ E, 1994, J VIROL, V68, P8035; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1046; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	57	49	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					993	998						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675460				2022-12-28	WOS:A1995RU79800022
J	FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E				FUKUDA, M; GOTOH, Y; TACHIBANA, T; DELL, K; HATTORI, S; YONEDA, Y; NISHIDA, E			INDUCTION OF NEURITE OUTGROWTH BY MAP KINASE IN PC12 CELLS	ONCOGENE			English	Article						PC12 CELL DIFFERENTIATION; THIOPHOSPHORYLATED MAP KINASE; CL100	NERVE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PHOSPHORYLATION; CASCADE; ACTIVATION; INVITRO; PATHWAY	Treatment of PC12 cells with nerve growth factor (NGF) results in neural differentiation of the cells, inducing neurite outgrowth. Ras protein has been shown to play an essential role in this process. To examine whether or not the MAP kinase (MAPK) cascade mediates the NGF- and Pas-induced neural differentiation process, we injected PC12 cells with constitutive active forms of each components of the MAPK cascade. When a moderately active mutant of Xenopus MAPK kinase (S222E-MAPKK) in which Ser 222 was changed into glutamic acid was injected, the neurite outgrowth of PC12 cells occurred to some extent. Injection of an N-terminal truncated STE11 protein (Delta N-STE11), a constitutively active form of STE11 which is a yeast MAPKK kinase, induced neurite outgrowth in PC12 cells. Furthermore, injection of thiophosphorylated MAPK, but not purified active MAPK, into PC12 cells resulted in neurite outgrowth. Thiophosphorylated MAPK was resistant to protein phosphatase 2A treatment, while purified active MAPK was inactivated by this treatment. All these results have suggested that sustained activation of MAPK is sufficient for PC12 cell differentiation. In accord with this, the Delta N-STE11- or S222E- MAPKK-induced neurite outgrowth was inhibited by coinjection of CL-100 protein, a dual-specificity phosphatase that is capable of inactivating MAPK.	KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & CELL BIOL,SUITA,OSAKA 565,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN	Kyoto University; University of Tokyo; Osaka University; National Center for Neurology & Psychiatry - Japan			Fukuda, Makoto/C-9745-2009	Fukuda, Makoto/0000-0003-0112-9925				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALLESSI DR, 1993, ONCOGENE, V8, P2015; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEBREDA AR, 1994, TRENDS BIOCHEM SCI, V19, P1, DOI 10.1016/0968-0004(94)90163-5; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAMMUELS ML, 1993, MOL CELL BIOL, V13, P6241; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIRAKABE K, 1992, J BIOL CHEM, V267, P16685; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; ZHENG CF, 1993, J BIOL CHEM, V268, P644	53	141	143	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					239	244						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624141				2022-12-28	WOS:A1995RK95700004
J	GANJU, P; WALLS, E; BRENNAN, J; REITH, AD				GANJU, P; WALLS, E; BRENNAN, J; REITH, AD			CLONING AND DEVELOPMENTAL EXPRESSION OF NSK2, A NOVEL RECEPTOR TYROSINE KINASE IMPLICATED IN SKELETAL MYOGENESIS	ONCOGENE			English	Article						NSK2; RECEPTOR TYROSINE KINASE; MYOGENESIS; EPITHELIA; MOUSE CHROMOSOME 13; DEVELOPMENT	HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; PROTEIN; DIFFERENTIATION; MUSCLE; CELLS; IDENTIFICATION; PROTEASES; MODULES; FAMILY	The protein superfamily of transmembrane receptor tyrosine kinases (RTKs) are essential components of intercellular signalling pathways necessary for normal cellular regulation, We report the cloning and developmental expression pattern of NskZ, a novel, structurally distinct mammalian RTK characterised by a putative extracellular region bearing four immunoglobulin-like domains. The Nsk2 locus was mapped to the distal region of mouse chromosome 13 and was found to be expressed preferentially in skeletal muscle amongst adult mouse tissues. Moreover, increased steady-state levels of Nsk2 transcripts were apparent on terminal differentiation of committed skeletal myoblast cell lines in vitro and multiple isoforms of the NskZ RTK were identified in skeletal myotube cultures. RNA in situ hybridisation studies of mouse embryos confirmed skeletal myogenesis to be a major site of Nsk2 expression during normal embryogenesis, and identified other likely sites of Nsk2 function in ganglia of the developing peripheral nervous system and various embryonic epithelia, including those of kidney, lung and gut, during fetal development. Taken together, our data suggest normal functions for Nsk2 RTKs in distinctive aspects of skeletal muscle development, neurogenesis and mesenchymal-epithelial interactions during organ formation.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research				Brennan, Jane/0000-0003-3222-5485				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBACID M, 1993, ONCOGENE, V8, P2033; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRKENMEIER EH, 1992, MAMM GENOME, V3, P537, DOI 10.1007/BF00350618; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; ELLIOTT RW, 1991, MAMM GENOME, V1, P118, DOI 10.1007/BF02443788; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FRANKEL WN, 1989, J VIROL, V63, P3810, DOI 10.1128/JVI.63.9.3810-3821.1989; GANJU P, 1994, ONCOGENE, V9, P1613; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARP SL, 1994, P NATL ACAD SCI USA, V91, P5286, DOI 10.1073/pnas.91.12.5286; LEUDERS KK, 1993, MAMM GENOME, V4, P69; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; OLSEN EN, 1992, DEV BIOL, V154, P261; OLSEN EN, 1994, GENE DEV, V8, P1; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; QU Z, 1990, NEURON, V2, P367; REITH AD, 1985, IN PRESS MAMM GENOME; REITH AD, 1991, GENOME ANAL, V3, P105; SAXEN L, 1992, CIBA F SYMP, V165, P183; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SZEBENYI G, 1991, J BIOL CHEM, V266, P5534; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	47	54	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624144				2022-12-28	WOS:A1995RK95700009
J	GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH				GUDAS, J; NGUYEN, H; LI, T; HILL, D; COWAN, KH			EFFECTS OF CELL-CYCLE, WILD-TYPE P53 AND DNA-DAMAGE ON P21(CIP1/WAF1) EXPRESSION IN HUMAN BREAST EPITHELIAL-CELLS	ONCOGENE			English	Article						P21(CIP1/WAF1); POST TRANSCRIPTIONAL REGULATING; WILD-TYPE P53; RADIATION EFFECTS; CELL CYCLE	HUMAN PAPILLOMAVIRUS TYPE-16; SYNTHASE MESSENGER-RNA; E6 ONCOPROTEIN; PROTEIN; CANCER; GROWTH; LINE; CDNA; TRANSFORMATION; TRANSCRIPTION	In this study we examine the relationship between p21(CIP1/Waf1) (CIP1), a 21 kDa protein that binds to and modulates the activity of several cyclin dependent kinases and expression of wild-type (WT) p53 in human breast epithelial cells. Basal CTP1 protein, but not CIP1 mRNA levels correlated well with expression of WT p53 in human breast epithelial cells. To obtain more direct evidence that WT p53 regulated the level of CTP1 protein, the Human Papilloma Virus (HPV) E6 protein was introduced into immortalized 184B5 breast cells, Residual WT p53 levels correlated well with CIP1 protein but not CIP1 mRNA levels in isolated clones of transfected cells. CIP1 protein mas increased at early times after growth factor arrested cells were stimulated to proliferate. The rise in CLP1 protein was due to a concomitant increase in CIP1 mRNA levels in MCF10, but not in normal mammary epithelial cells. DNA damage induced by ionizing radiation resulted in a transient increase in WT p53 levels but a prolonged induction of CIP1 protein. The sustained increase in CIP1 protein 24 h after radiation could not be attributed to a concomitant increase in CIP1 mRNA levels, Although the half-life of the CIP1 protein was not altered following irradiation, a fourfold increase in the amount of radioactivity incorporated into CIP1 protein was detected. When considered together these data suggest that wild-type p53 affects CIP1 protein accumulation at a posttranscriptional level in human breast epithelial cells under different physiologic and stress conditions.	ONCOGENE SCI, CAMBRIDGE, MA 02142 USA		GUDAS, J (corresponding author), NCI, MED BRANCH,DIV CANC TREATMENT, MED BREAST CANC SECT,BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BARTEK J, 1990, ONCOGENE, V5, P893; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; Dulcic V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; GUDAS JM, 1993, CELL GROWTH DIFFER, V4, P421; HALDAR S, 1994, CANCER RES, V54, P2095; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LI Y, 1994, ONCOGENE, V9, P2261; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MICHIELI P, 1994, CANCER RES, V54, P3391; MUNGER K, 1989, J VIROL, V63, P4417; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOULE HD, 1990, CANCER RES, V50, P6075; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	67	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					253	261						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624142				2022-12-28	WOS:A1995RK95700006
J	SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE				SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE			ALTERATIONS IN THE STRUCTURE OF THE EBV NUCLEAR ANTIGEN, EBNA1, IN EPITHELIAL-CELL TUMORS	ONCOGENE			English	Article						NASOPHARYNGEAL CARCINOMA; MUTATIONS; DNA BINDING; EPSTEIN-BARR VIRUS	EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; DNA-BINDING; BURKITT-LYMPHOMA; EXPRESSION; PROTEIN; REPLICATION; TRANSCRIPTION; SEQUENCE; PROMOTER	The EBV nuclear antigen, EBNA1, is the only viral protein consistently expressed in all virus-infected cells. It is required in trans for viral replication, maintenance of EBV extrachromosomal episomes, and transcriptional transactivation in latently-infected B-cells. It binds RNA suggestive of a regulatory role in post-transcriptional events and in transgenic mice, it is tumorigenic. In RNase protection studies relating to the EBV-associated tumour, nasopharyngeal carcinoma (NPC), we show that a C-terminal EBNA1 RNA probe from the prototype B95-8 marmoset strain can protect its own mRNA from enzymatic digestion, but does not fully protect EBNA1 mRNA from NPC cells. This finding is consistent with changes in the coding region for the antigen. We thus determined the sequences of EBNA1 genes derived from an NPC xenograft and numerous patient biopsies and identified a number of mutations in the gene in these human cells, relative to B95-8. Many of the nucleotide changes would lead to non-conservative amino acid alterations in apparently functionally significant regions of the protein. We show that although some of the mutations lie in regions designated as critical to DNA binding, they have negligible effect on this property of EBNA1. The basic regions in EBNA1 that may bind to RNA, at least in vitro, are exempt from mutation. Thus, unless the alterations are 'silent', which for such a critical viral function seems unlikely, they may relate to as yet unmapped viral activities, such as a role in tumorigenesis and the ability of EBNA1 to evade the cellular immune system, or be associated with the ability of the antigen to regulate gene transcription.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CHINESE UNIV HONG KONG,DEPT MICROBIOL,HONG KONG,HONG KONG; QUEEN MARYS HOSP,DEPT MICROBIOL,HONG KONG,HONG KONG	Imperial College London; Chinese University of Hong Kong								ABDELHAMID M, 1992, VIROLOGY, V190, P168, DOI 10.1016/0042-6822(92)91202-6; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEARING JC, 1985, VIROLOGY, V145, P105; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; INOUE N, 1991, VIROLOGY, V182, P84, DOI 10.1016/0042-6822(91)90651-Q; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFEMINA RL, 1989, VIROLOGY, V172, P584, DOI 10.1016/0042-6822(89)90201-8; LUNG ML, 1990, VIROLOGY, V177, P44, DOI 10.1016/0042-6822(90)90458-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; POLVINOBODNAR M, 1988, NUCLEIC ACIDS RES, V16, P3415, DOI 10.1093/nar/16.8.3415; POLVINOBODNAR M, 1992, VIROLOGY, V187, P591, DOI 10.1016/0042-6822(92)90461-W; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; SMITH PR, 1991, NUCLEIC ACIDS RES, V19, P2435, DOI 10.1093/nar/19.9.2435; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; SPECK SH, 1989, ADV VIRAL ONCOL, P133; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V318, P812; YATES JL, 1988, CANCER CELL, V6, P197; ZHANG CX, 1993, J GEN VIROL, V74, P509, DOI 10.1099/0022-1317-74-3-509	48	69	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1545	1552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731709				2022-12-28	WOS:A1995QU68100010
J	HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y				HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y			DETECTION OF K-RAS MUTATIONS IN DNAS ISOLATED FROM FECES OF PATIENTS WITH COLORECTAL TUMORS BY MUTANT-ALLELE-SPECIFIC AMPLIFICATION (MASA)	ONCOGENE			English	Article						FECES; COLORECTAL CANCER; GENETIC DIAGNOSIS; K-RAS; MASA (MUTATED ALLELE SPECIFIC AMPLIFICATION	POLYMERASE CHAIN-REACTION; CANCER	K-ras mutations are found in approximately half of all colorectal tumors examined, To explore the possibility of detecting mutated K-ras rapidly and efficiently in DNAs isolated from fecal material, we applied the mutant allele specific amplification (MASA)-PCR method to DNA from feces of patients with colorectal tumors, Among 55 colorectal adenocarcinomas or adenomas examined, 19 were found to carry K-ras mutations in codons 12 or 13, We were able to PCR-amplify DNAs isolated from feces of 15 of these 19 patients, but in only three of the fecal samples, we were able to detect the K-ras mutations corresponding to tumor DNA by MASA and ethidium-bromide staining of the gel, The carcinomas in these three cases were more than 40 mm x 40 mm in size and located in the sigmoid colon or rectum, However, we identified the K-ras mutations in fecal DNAs of additional seven patients by MASA when the gels were blotted and probed with a radio-labeled oligonncleotide; the tumors in those patients had arisen in the distal half of the colon and the smallest of these tumors was only 7 mm x 5 mm, No K-ras mutations were detectable in feces of the remaining five cases, whose tumors were relatively small and/or located in the proximal region, The results suggested that the MASA-PCR system has potential for development as a simple, rapid and noninvasive method for diagnosing the presence of colorectal tumors that carry mutant K-ras alleles, particularly tumors located in the distal colon.	JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT INTERNAL MED, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT SURG, TOSHIMA KU, TOKYO 170, JAPAN; EISAI & CO LTD, TSUKUBA RES LABS, IBARAKI, OSAKA, JAPAN; HAMAMATSU MED UNIV, DEPT SURG 2, SHIZUOKA, JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Eisai Co Ltd; Hamamatsu University School of Medicine								AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BOS JL, 1989, CANCER RES, V49, P4682; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; SATO T, 1990, CANCER RES, V50, P7184; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STORK P, 1991, ONCOGENE, V6, P857; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOBI M, 1994, J NATL CANCER I, V86, P1007; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	12	92	114	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1441	1445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731696				2022-12-28	WOS:A1995QR65100023
J	SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH				SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH			FUNCTIONAL DIVERSITY OF LIM PROTEINS - AMINO-TERMINAL ACTIVATION DOMAINS IN THE ONCOGENIC PROTEINS RBTN1 AND RBTN2	ONCOGENE			English	Article						LIM DOMAIN; LEUKEMIA; TRANSCRIPTION; ACTIVATION DOMAIN	EXPRESSION VECTOR; MAMMALIAN-CELLS; DNA-BINDING; GENE; MOTIF; YEAST; DIFFERENTIATION; HOMEODOMAIN; ENCODES; ELEGANS	The RBTN1 and RBTN2 genes are activated by distinct translocations involving chromosome 11 in some T cell acute leukaemias. The RBTN proteins belong to the LIM family which comprises proteins with one, two or three cysteine-rich LIM domains, sometimes together with homeodomains or protein kinase domains. The RBTN1 and RBTN2 proteins comprise only tandem LIM domains. We report that RBTN1 and RBTN2 proteins are capable of supporting transcriptional transactivation of specific reporter genes in transfection assays. The results, using intact proteins or fusions with the homeodomain of the heterologous protein Isl-1, show that this transcriptional activation ability resides in the NH2-terminal parts of both proteins. The use of yeast assays with RBTN2 shows that RBTN2 forms homodimers and that the NH2-terminal 27 amino acids are sufficient to facilitate transcriptional transactivation. These data expand the functional diversity of the LIM-domain protein family and they augment the previously defined relationship between chromosomal translocations and transcriptional activation.			SANCHEZGARCIA, I (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUTHON MA, 1993, BLOOD, V81, P647; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; Rose MD., 1990, METHODS YEAST GENETI; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	46	20	21	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1301	1306						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731680				2022-12-28	WOS:A1995QR65100006
J	CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M				CORVI, R; SAVELYEVA, L; BREIT, S; WENZEL, A; HANDGRETINGER, R; BARAK, J; OREN, M; AMLER, L; SCHWAB, M			NON-SYNTENIC AMPLIFICATION OF MDM2 AND MYCN IN HUMAN NEUROBLASTOMA	ONCOGENE			English	Article						ONCOGENES; REVERSE GENOMIC HYBRIDIZATION; TUMORIGENESIS; P53; PEDIATRIC CANCER	AMPLIFIED DNA-SEQUENCES; N-MYC; CELL-LINES; HUMAN SARCOMAS; P53 MUTATIONS; HUMAN CANCER; CDNA CLONES; C-MYC; GENE; TUMOR	Amplification of the MYCN gene is a well documented genetic alteration of aggressively growing human neuroblastomas. Through cytogenetic studies we have identified neuroblastoma cell lines which, in addition to amplified MYCN, carry amplified DNA not harbouring MYCN. In situ hybridization of biotinylated total genomic DNA to metaphase chromosomes of normal human lymphocytes by reverse genomic hybridization revealed the amplified DNA to be derived from chromosome 12 band q13-14, Subsequent filter analyses showed a 20- to 40-fold amplification of the MDM2 gene, located at 12q13-14, both in three cell lines and in an original tumor, in addition to amplified MYCN, As the apparent consequence of amplification abundant MDM2 protein was present, a part of which was complexed with p53.	GERMAN CANC RES CTR, DIV CYTOGENET, D-69120 HEIDELBERG, GERMANY; UNIV TUBINGEN, CHILDRENS CLIN, D-72070 TUBINGEN, GERMANY; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Weizmann Institute of Science								ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; Bertheir F., 1990, Computational Intelligence, II. Proceedings of the International Symposium `Computational Intelligence 89', P1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1981, J VIROL, V34, P752; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KHATIB ZA, 1993, CANCER RES, V53, P5535; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOMURO H, 1993, CANCER RES, V53, P5284; LADANYI M, 1993, CANCER RES, V53, P16; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LEACH FS, 1993, CANCER RES, V53, P2231; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIBERT LM, 1994, GENE CHROMOSOME CANC, V9, P261; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUDOLPH G, 1991, HUM GENET, V86, P562; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; VOGAN K, 1993, CANCER RES, V53, P5269; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	53	98	98	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1081	1086						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700632				2022-12-28	WOS:A1995QN35300007
J	FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E				FISCELLA, M; ZAMBRANO, N; ULLRICH, SJ; UNGER, T; LIN, D; CHO, B; MERCER, WE; ANDERSON, CW; APPELLA, E			THE CARBOXY-TERMINAL SERINE-392 PHOSPHORYLATION SITE OF HUMAN P53 IS NOT REQUIRED FOR WILD-TYPE ACTIVITIES	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; MUTANT P53; GENE AMPLIFICATION; GROWTH ARREST; BINDING-SITE; DNA; TRANSCRIPTION; EXPRESSION	Wild-type p53 functions in the G1 DNA damage checkpoint pathway by activating gene transcription and preventing cell cycle progression. Others reported that mutation of the serine 386 codon in mouse p53 abolished its ability to suppress growth. Serine 386 of murine p53 and the homologous residue of human p53, serine 392, are phosphorylated in vivo and can be phosphorylated in vitro by casein kinase II (CKII). We constructed mutants that changed serine 392 of human p53 to alanine (p53-S392A) or aspartic acid (p53S392D); cotransfection of both these mutants with a reporter gene carrying a p53-responsive element into the p53-null Saos-2 cell line activated transcription as well as did wild-type p53. Furthermore, both mutants blocked cell cycle progression after transient transfection in these cells. A stable derivative of the T98G human glioblastoma cell line was established that expressed p53-S392A in response to dexamethasone. Overexpression of this mutant activated transcription of the endogenous waf1 (also called cip1) and mdm2 genes to the same extent as wild-type p53 and also produced growth arrest. Finally, p53-S392A and p53-S392D suppressed foci formation by activated ras and adenovirus EIA oncogenes as efficiently as did wild-type p53. Thus, unlike mutants that altered the serine 15 phosphorylation site, elimination of the serine 392 phosphorylation site had no discernible effect on p53 function. We conclude that neither phosphorylation nor RNA attachment to serine 392 are required for human p53's ability to suppress cell growth or to activate transcription in vivo.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892; AMER RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); American Red Cross; Jefferson University; United States Department of Energy (DOE); Brookhaven National Laboratory			Zambrano, Nicola/B-9352-2014	Zambrano, Nicola/0000-0001-9395-3481	NATIONAL CANCER INSTITUTE [R01CA055541, R01CA054140] Funding Source: NIH RePORTER; NCI NIH HHS [CA55541, CA54140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FISCELLA M, 1993, ONCOGENE, V8, P1519; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARPER JW, 1993, CELL, V75, P805; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER P, 1994, INT J ONCOL, V4, P491; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	67	68	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3249	3257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936649				2022-12-28	WOS:A1994PM65800018
J	SCHUUR, ER; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; RABINOVICH, JM; BALUDA, MA			DISTRIBUTION OF ALTERNATIVELY SPLICED CHICKEN C-MYB EXON 9A AMONG HEMATOPOIETIC TISSUES	ONCOGENE			English	Note							AVIAN-MYELOBLASTOSIS VIRUS; DIFFERENTIAL EXPRESSION; CELLS; GENE; IDENTIFICATION; PROTOONCOGENE; TRANSCRIPTS; ONCOGENES	The role of the c-myb proto-oncogene in cellular differentiation may be regulated in part by alternative splicing of its mRNAs. Previously, two forms of alternative splicing of the chicken c-myb gene between exons 9 and 10 were described: one form utilizes the entire 360 base pair (bp) exon 9A while a second form utilizes exon 9A' which consists of the 3' 150 bp of exon 9A. In this study the distribution among chicken hematopoietic tissues of these two forms of alternative splicing was determined by Northern blot analysis using a probe specific for exon 9A. RNA species of 4.2 kilobases (kb) and 4.4 kb which contain exon 9A' or exon 9A, respectively, were detected in each tissue tested. Quantitative analysis of the major 4.0 kb c-myb species and the c-myb species containing exon 9A and exon 9A' revealed that cells from yolk sac contained both the highest absolute and the highest relative levels of alternatively spliced c-myb mRNA, presumably because of the preponderance of immature erythroid cells in these preparations.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHUUR, ER (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KIM WK, 1988, ONCOGENE RES, V3, P147; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; ROMANOFF AL, 1960, AVIAN EMBRYO, P575; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SCHUUR ER, 1991, ONCOGENE, V6, P1409; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	27	5	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3363	3365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936662				2022-12-28	WOS:A1994PM65800031
J	PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K			2 HUMAN FLT4 RECEPTOR TYROSINE KINASE ISOFORMS WITH DISTINCT CARBOXY-TERMINAL TAILS ARE PRODUCED BY ALTERNATIVE PROCESSING OF PRIMARY TRANSCRIPTS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; C-KIT; GENE; SPECIFICITY; ORGANIZATION; EXPRESSION; REGION	FLT4 is a recently cloned gene encoding a transmembrane tyrosine kinase related to the FLT1 and KDR/FLK1 vascular endothelial growth factor receptors. We have previously shown that FLT4 is expressed as transcripts of 4.5 and 5.8 kb in several human fetal and adult tissues. Here we show that these transcripts encode two polypeptides, FLT4s (short) and FLT41 (long), which are proteolytically processed in transfected cells and leukemia cells and which have different carboxy terminal tails. The 3' coding region of the 5.8 kb mRNA was found to be 65 codons longer than that of the the 4.5 kb mRNA. Analysis of the genomic structure of the region encoding the two carboxy termini revealed that the two transcripts are generated by alternative polyadenylation and subsequent alternative splicing during RNA processing. Our findings thus show regulation of FLT4 structure in the carboxy terminal tail considered important for receptor function. The significance of the two forms may relate to the role of additional potential autophosphorylation sites in the FLT4 long form.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	PAJUSOLA, K (corresponding author), UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, PL 21, SF-00014 HELSINKI, FINLAND.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1993, ONCOGENE, V8, P1233; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HAMPE A, 1989, ONCOGENE RES, V4, P9; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PAJUSOLA K, 1992, CANCER RES, V52, P5738; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIBUYA M, 1990, ONCOGENE, V5, P519; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P1829; TAHIRA T, 1990, ONCOGENE, V5, P97; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	23	81	104	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2931	2937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692369				2022-12-28	WOS:A1993MC09300006
J	GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR				GREENHALGH, DA; ROTHNAGEL, JA; WANG, XJ; QUINTANILLA, MI; ORENGO, CC; GAGNE, TA; BUNDMAN, DS; LONGLEY, MA; FISHER, C; ROOP, DR			HYPERPLASIA, HYPERKERATOSIS AND BENIGN-TUMOR PRODUCTION IN TRANSGENIC MICE BY A TARGETED V-FOS ONCOGENE SUGGEST A ROLE FOR FOS IN EPIDERMAL DIFFERENTIATION AND NEOPLASIA	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; MOUSE SKIN CARCINOGENESIS; TRANSCRIPTION FACTOR AP-1; KERATIN GENE-EXPRESSION; C-FOS; CHEMICAL CARCINOGENESIS; CELL-LINES; PROTEIN; JUN; ACTIVATION	A vector, derived from the human K1 keratin gene, has been employed to target v-fos expression exclusively in the epidermis of transgenic mice. Adult transgenic mice expressors (3-4 months) displayed hyperplasia and hyperkeratosis, initially in wounded (tagged) ears, which later became bilateral. This phenotype appeared at other epidermal sites, most notably in the axilla and inguinal areas. This indicates that a second promoting event, such as wounding or friction, is required to elicit these pathological changes. Highly keratotic benign ear lesions and benign squamous papillomas appeared after long latency at sites of phenotypic epidermis. These data suggest that v-fos may be interfering with c-fos function in normal keratinocyte differentiation, but by itself is insufficient to elicit overt benign lesions.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; UPJOHN CO,KALAMAZOO,MI 49001	Baylor College of Medicine; Pfizer			Rothnagel, Joe/A-4874-2010	Rothnagel, Joe/0000-0002-6710-3165	NCI NIH HHS [CA52607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALDAZ CM, 1988, CANCER RES, V48, P3253; ARGYRIS TS, 1982, CARCINOGENESIS COCAR, P43; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FISHER PA, 1983, METHOD ENZYMOL, V96, P589; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; GREENHALGH DA, 1990, P NATL ACAD SCI USA, V87, P643, DOI 10.1073/pnas.87.2.643; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; GREENHALGH DA, 1989, MOL CARCINOG, V3, P154; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOGAN B, 1986, MANIPULATING MOUSE E; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORRIS RJ, 1986, CANCER RES, V46, P3061; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROOP DR, 1988, CANCER RES, V48, P3245; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V95, pS59, DOI 10.1111/1523-1747.ep12505805; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYNECK RP, 1991, ONCOGENE, V6, P533; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STRICKLAND JE, 1988, CANCER RES, V48, P165; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	63	59	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2145	2157						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687760				2022-12-28	WOS:A1993LP17100015
J	HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE				HJERMSTAD, SJ; PETERS, KL; BRIGGS, SD; GLAZER, RI; SMITHGALL, TE			REGULATION OF THE HUMAN C-FES PROTEIN-TYROSINE KINASE (P93C-FES) BY ITS SRC HOMOLOGY-2 DOMAIN AND MAJOR AUTOPHOSPHORYLATION SITE (TYR-713)	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; FUJINAMI SARCOMA-VIRUS; CYTOPLASMIC SIGNALING PROTEINS; SH2 DOMAINS; V-FES; TRANSFORMING ACTIVITY; CATALYTIC DOMAINS; LEUKEMIA-CELLS; MYELOID CELLS; EXPRESSION	The c-fes proto-oncogene product is expressed predominantly in hematopoietic cells of the myeloid lineage and has been implicated in the regulation of myeloid differentiation. The c-fes locus encodes a 93-kDa protein tyrosine kinase (p93c-fes) that possesses several structural features characteristic of the cytoplasmic class of protein tyrosine kinases, including a consensus sequence for autophosphorylation surrounding Tyr-713 and a src homology 2 (SH2) domain. To assess the effect of each of these potential regulatory sites on p93c-fes protein tyrosine kinase activity, we specifically deleted the c-fes SH2 domain using the polymerase chain reaction and replaced Tyr-713 with phenylalanine by oligonucleotide-directed mutagenesis (Y713F mutant). The resulting mutants were expressed in Escherichia coli and assayed for changes in protein tyrosine kinase activity using an immune complex kinase assay. Both mutations produced a marked decrease in the rate and extent of autophosphorylation and phosphorylation of the model substrate, enolase. To test whether the c-fes SH2 domain could interact with the autophosphorylated kinase domain, the SH2 domain was expressed as a fusion protein with glutathione S-transferase and immobilized on glutathione-agarose. The recombinant c-fes SH2 domain precipitated p93c-fes as readily as a monoclonal antibody. Binding of the SH2 domain to p93c-fes was completely dependent upon autophosphorylation, as a kinase-defective mutant of p93c-fes was not precipitated by the SH2 domain. High-affinity binding was also observed with recombinant SH2 domains from v-src and v-fps, raising the possibility of protein-protein interactions between various members of the cytoplasmic PTK family. These results indicate that the c-fes SH2 domain and consensus autophosphorylation site (Tyr-713) play major roles in the positive regulation of p93c-fes tyrosine kinase activity, possibly through intramolecular interaction.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, 600 S 42ND ST, OMAHA, NE 68198 USA; UNIV NEBRASKA, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, CANC PHARMACOL SECT, WASHINGTON, DC 20007 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska System; University of Nebraska Medical Center; Georgetown University				Briggs, Scott D/0000-0003-2852-3594	NCI NIH HHS [NCI P30 CA36727-08, NCI CA 58667, NCI CA 54231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA054231, R01CA058667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOULET I, 1992, ONCOGENE, V7, P703; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1982, SCIENCE, V216, P1136, DOI 10.1126/science.6281890; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOEFFLER HP, 1981, CANCER RES, V41, P919; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1988, ONCOGENE, V3, P491; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VEILLETTE A, 1992, ONCOGENE, V7, P971; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WOOD ER, 1992, J BIOL CHEM, V267, P14138; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801	46	52	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2283	2292						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687763				2022-12-28	WOS:A1993LP17100031
J	HERZINGER, T; WOLF, DA; EICK, D; KIND, P				HERZINGER, T; WOLF, DA; EICK, D; KIND, P			THE PRB-RELATED PROTEIN P130 IS A POSSIBLE EFFECTOR OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED CELL-CYCLE ARREST IN KERATINOCYTES	ONCOGENE			English	Article						GROWTH CONTROL; TUMOR SUPPRESSOR GENES	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; HUMAN MYC PROMOTER; TGF-BETA; C-MYC; TRANS-ACTIVATION; DEPENDENT KINASE; DIRECT BINDING; INHIBITION; P107	Transforming growth factor beta 1 (TGF-beta 1) is known to inhibit epithelial cell growth by inducing a G1 cell cycle arrest. We have studied the effect of TGF-beta 1 on protein binding to a transcription factor E2F consensus element in extracts from early passage human keratinocytes (HFKs) and a permanent human keratinocyte cell line (HaCaT). Treatment of these cells with TGF-beta 1 resulted in the formation of a DNA binding complex between the pRb-related protein p130 and E2F. Formation of the E2F-p130 complex correlated with inhibition of cell cycle progression in G1 and suppression of the E2F-regulated cdc2 gene. While p130 mRNA and protein levels were not influenced by TGF-beta 1, the activity of cyclin-dependent kinase 2 (Cdk2) towards p130 in vitro was inhibited. The results identify p130 as a downstream target of TGF-beta 1 and a possible mediator of the G1 cell cycle arrest.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GIORDANO A, 1991, ONCOGENE, V6, P481; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MASSAGUE J, 1992, CANCER SURV, V12, P81; MAYOL X, 1993, ONCOGENE, V8, P2561; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; ONG G, 1991, ONCOGENE, V6, P761; PAGANO M, 1992, ONCOGENE, V7, P1681; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLF DA, 1995, ONCOGENE, V10, P2067; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	54	31	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2079	2084						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784052				2022-12-28	WOS:A1995RB70300002
J	LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K				LICHTNER, RB; KAUFMANN, AM; KITTMANN, A; ROHDESCHULZ, B; WALTER, J; WILLIAMS, L; ULLRICH, A; SCHIRRMACHER, V; KHAZAIE, K			LIGAND-MEDIATED ACTIVATION OF ECTOPIC EGF RECEPTOR PROMOTES MATRIX PROTEIN ADHESION AND LUNG COLONIZATION OF RAT MAMMARY ADENOCARCINOMA CELLS	ONCOGENE			English	Article						EGF RECEPTOR; METASTASIS; MATRIX	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; METASTATIC PROPERTIES; DUCTAL MORPHOGENESIS; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTORS; EXPRESSION	Increased expression of EGF receptor (EGFR) in metastases of human mammary carcinoma as compared to cells of the primary cancer suggests a contribution of EGFR to mammary carcinoma metastasis. To test for a positive causative link, we investigated 13762NF rat mammary adenocarcinoma cloned tumor cell lines of high (MTLn3) or low (MTC) metastatic potential, While MTC cells expressed barely detectable amounts of EGFR, MTLn3 cells expressed readily detectable levels of functional receptors. A full length cDNA of the human EGFR (HER) was introduced by infection with a retroviral vector into MTC cells, Expression of HER was stable and receptors were functional with respect to surface expression, ligand binding and EGF-stimulated phosphorylation, Independent clones of the transfectants were isolated and characterized. Ligand stimulation of MTC HER cells and derived clones led to enhanced adhesion of tells to extracellular matrix proteins. Implantation of cells intravenously into female nu/nu mice revealed ligand-dependent enhancement of lung colonizing potential of EGFR-expressing cells.	GERMAN CANC RES CTR, DIV CELLULAR IMMUNOL, D-69120 HEIDELBERG, GERMANY; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE, VIC 3050, AUSTRALIA; MAX PLANCK INST BIOCHEM, DEPT MOLEC BIOL, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Max Planck Society	LICHTNER, RB (corresponding author), SCHERING AG, RES LABS, MULLERSTR 170-178, D-13342 BERLIN, GERMANY.			Kaufmann, Andreas/0000-0001-7732-3009				ADELMANNGRILL BC, 1990, EUR J CELL BIOL, V51, P322; BARKER S, 1989, BRIT J CANCER, V60, P673, DOI 10.1038/bjc.1989.338; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BOYD D, 1989, CANCER RES, V49, P2427; CAMPOSGONZALEZ R, 1990, CELL MOTIL CYTOSKEL, V15, P34, DOI 10.1002/cm.970150106; CHAUDHRY A, 1994, CANCER RES, V54, P981; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DITTADI R, 1993, BRIT J CANCER, V67, P7, DOI 10.1038/bjc.1993.2; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; ENGSTROM W, 1986, J CELL SCI, V86, P47; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAIHO M, 1989, CANCER RES, V49, P2533; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEWIS S, 1990, J CLIN PATHOL, V43, P385, DOI 10.1136/jcp.43.5.385; LICHTNER RB, 1993, CLIN EXP METASTAS, V11, P113, DOI 10.1007/BF00880072; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NERI A, 1982, J NATL CANCER I, V68, P507; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NICOLSON G L, 1986, Cancer Reviews, V3, P25; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; NICOLSON GL, 1983, INT REV EXP PATHOL, V25, P77; NICOLSON GL, 1990, ONCOGENE, V5, P747; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; ROHDESCHULZ B, 1995, IN PRESS INVASION ME; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SCHIRRMACHER V, 1980, IMMUNOBIOLOGY, V157, P89, DOI 10.1016/S0171-2985(80)80091-X; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YU DH, 1994, CANCER RES, V54, P3260	63	53	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1823	1832						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753557				2022-12-28	WOS:A1995QX46900015
J	JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB				JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB			PROTOONCOGENIC PROPERTIES OF THE DP FAMILY OF PROTEINS	ONCOGENE			English	Article						DP/E2F; CELL CYCLE; TRANSCRIPTION; ONCOGENE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS-E1A PREVENTS; CELL-PROLIFERATION; COMPLEX-FORMATION; BINDING PROTEIN; CYCLIN-A; TRANSACTIVATION; P107; FIBROBLASTS	The cellular transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product, cyclins and cyclin-dependent kinases. DRTF1/E2F is a heterodimeric DNA binding activity which arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers, for example, DP-1 and E2F-1, Tn DRTF1/E2F the activity of DP-1 is under cell cycle control, possibly by phosphorylation, and in many types of cells it is a frequent, if not general DNA binding component of DRTF1/E2F. The expression of other DP proteins, such as DP-2, is tissue-restricted. Here, we show that DP-1 and DP-2 are integrated with another growth regulating pathway which involves signal transduction emanating from activated Ras protein. Thus, activated Ha-ras can co-operate with DP-1 or DP-2 in the transformation of rat embryo fibroblasts, establishing for the first time that DP proteins are endowed with proto-oncogenic activity. Moreover, an analysis of a dominant-negative and mutant DP-l proteins suggests that the primary target through which DP-1 mediates its oncogenic activity is unlikely to be due to the regulation of E2F site-transcription, suggesting an E2F-independent effector function for DP-1, These results therefore establish DP genes as proto-oncogenes and thus argue that deregulating the normal control of DP protein activity will be important in promoting aberrant cellular proliferation.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	MRC National Institute for Medical Research; Philipps University Marburg			Lam, Eric W-F/AAW-8566-2020; Müller, Rolf/L-4997-2016	Lam, Eric W-F/0000-0003-1274-3576; Müller, Rolf/0000-0003-3339-4248				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1992, J CELL SCI, P77; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kouzarides Tony, 1993, Trends in Cell Biology, V3, P211, DOI 10.1016/0962-8924(93)90113-F; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOVEC H, 1994, ONCOGENE, V9, P323; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TSAI LH, 1993, ONCOGENE, V8, P1593; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	41	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1529	1536						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731707				2022-12-28	WOS:A1995QU68100008
J	ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E				ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E			OVEREXPRESSION OF HUMAN CYCLIN-A ADVANCES ENTRY INTO S-PHASE	ONCOGENE			English	Article						CELL CYCLE; CYCLIN A; G1-S TRANSITION; S-PHASE CONTROL; SCANNING LASER CYTOMETRY	HUMAN CELL-CYCLE; SEA-URCHIN EGGS; DNA-REPLICATION; PROTEIN-KINASE; MESSENGER-RNA; MAMMALIAN FIBROBLASTS; TRANSCRIPTION FACTOR; VIRAL ONCOPROTEINS; RESTRICTION POINT; DEPENDENT KINASES	Cyclin A is a cell cycle regulatory protein that functions in mitotic and S-phase control in mammalian cells. Using a genomic construction corresponding to the human cyclin A gene under the control of its own promoter, we have established stable transfectants overexpressing cyclin A protein, Experiments assisted by laser scanning image cytometry showed that this overexpression begins from late G1 phase onwards and is therefore cell cycle-regulated in this model. We demonstrated that this overexpression advances entry into S phase, leading to a contraction of the overall cell generation time. These results provide evidence that cyclin A can be a rate-limiting factor with respect to the control of the transition to S phase in mammalian cells.	CHU NECKER ENFANTS MALAD, INSERM, U132, F-75743 PARIS 15, FRANCE; INST PASTEUR, CYTOMETRIE ANALYT & PREPARAT LAB, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	ROSENBERG, AR (corresponding author), INST NECKER, INSERM, U370, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE.		Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442; Rosenberg, Arielle/0000-0003-2085-8146				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATES S, 1994, ONCOGENE, V9, P71; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731704				2022-12-28	WOS:A1995QU68100005
J	PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE				PEEBLES, RS; MALISZEWSKI, CR; SATO, TA; HANLEYHYDE, J; MAROULAKOU, IG; HUNZIKER, R; SCHNECK, JP; GREEN, JE			ABNORMAL B-CELL FUNCTION IN HTLV-I-TAX TRANSGENIC MICE	ONCOGENE			English	Article						HTLV-I; GROWTH FACTORS; B-CELLS; TRANSGENIC MICE; LYMPHOPROLIFERATION; AUTOIMMUNE DISEASE	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; COLONY-STIMULATING FACTOR; PRIMARY SJOGRENS-SYNDROME; EPSTEIN-BARR-VIRUS; HEPATITIS-C VIRUS; INTERLEUKIN-2 RECEPTOR; MOUSE MODEL; ACTIVATION; GENE	Transgenic mice that carry the HTLV-I Tax gene develop an exocrinopathy with some similarities to Sjoegren's syndrome. Our experiments reveal that these mice have lymphadenopathy and splenomegaly composed primarily of B lymphocytes, as well as abnormal levels of secreted immunoglobulins. To gain insight into whether the lymphadenopathy manifested by these transgenic mice was the result of induction of cytokines by Tax, we utilized cell lines from these mice to study in vitro B-cell responses. Conditioned media (CM) derived from the cell lines caused B-cells to proliferate when a second signal, surface Ig cross-linking, was provided. The CM also caused a marked enhancement of IgM secretion by spleen cells or by purified B-cells treated with supplemental cytokines. The B-cell proliferative response and enhanced IgM secretion have not been attributed to a known cytokine. These results suggest that the CM from the cell lines contain a factor(s) involved in novel pathways of B-cell growth and differentiation that may participate in the pathologic development of autoimmune disease.	NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224; NCI,GENET LAB,BETHESDA,MD 20892; IMMUNEX CORP,DEPT CELLULAR IMMUNOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Immunex Corporation								ABBAS AK, 1991, CELLULAR MOL IMMUNOL, P186; BABOONIAN C, 1990, ARTHRITIS RHEUM, V33, P1749, DOI 10.1002/art.1780331122; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FLESCHER E, 1992, ARTHRITIS RHEUM, V35, P1068, DOI 10.1002/art.1780350912; FOX RI, 1993, J RHEUMATOL, V20, P764; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GARRY RF, 1990, SCIENCE, V250, P1127, DOI 10.1126/science.1701273; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1992, AM J PATHOL, V140, P1401; GREEN JE, 1991, MOL CELL BIOL, V11, P4635, DOI 10.1128/MCB.11.9.4635; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITESCU S, 1991, RHEUM DIS CLIN N AM, V17, P99; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KARAMERIS A, 1992, CLIN EXP RHEUMATOL, V10, P327; LAVOIE TB, 1992, J IMMUNOL, V1148, P503; LILENBAUM A, 1990, J VIROL, V64, P256; LINDAHL G, 1985, CLIN EXP IMMUNOL, V61, P475; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARIETTE X, 1993, ARTHRITIS RHEUM, V36, P280, DOI 10.1002/art.1780360225; MARKUSSE HM, 1993, CLIN IMMUNOL IMMUNOP, V66, P26, DOI 10.1006/clin.1993.1004; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OUTSCHOORN I, 1993, CLIN IMMUNOL IMMUNOP, V66, P59, DOI 10.1006/clin.1993.1008; PFLUGFELDER SC, 1993, AM J PATHOL, V143, P49; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROUSSEAU PG, 1989, MOL IMMUNOL, V26, P993, DOI 10.1016/0161-5890(89)90118-1; SHATTLES WG, 1991, CLIN EXP IMMUNOL, V89, P46; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TALAL N, 1990, CLIN EXP RHEUMATOL, V8, P23; TALAL N, 1991, B RHEUM DIS, V40, P6; TATEISHI M, 1993, ARTHRITIS RHEUM, V36, P827, DOI 10.1002/art.1780360614; YOUNG NS, 1972, J CLIN INVEST, V51, P1790, DOI 10.1172/JCI106980; YUAN D, 1992, INT IMMUNOL, V4, P1373, DOI 10.1093/intimm/4.12.1373	40	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1045	1051						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700628				2022-12-28	WOS:A1995QN35300003
J	UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K				UCHIDA, T; WADA, C; WANG, CX; ISHIDA, H; EGAWA, S; YOKOYAMA, E; OHTANI, H; KOSHIBA, K			MICROSATELLITE INSTABILITY IN PROSTATE-CANCER	ONCOGENE			English	Note						MICROSATELLITE INSTABILITY; PROSTATE CANCER	GENETIC INSTABILITY; ALLELIC LOSS; MUTATIONS; GROWTH; COLON	Assessment of the genetic instability of a microsatellite has indicated a new mechanism in human carcinogenesis. Examination was made to determine whether microsatellite instability is associated with the onset of prostate cancer. Twenty-nine DNA samples from 24 primary prostate cancer, two metastatic lymph-node and three benign prostatic hypertrophy patients were used. Differences in unrelated microsatellites for tumor and normal DNA were detected in nine of 24 (37.5%) cases. Seven of 11 (63.6%) with poorly differentiated adenocarcinomas and seven of 15 (46.7%) stage D metastatic patients showed somatic instability in a number of microsatellites. Statistically significant differences in well to moderately differentiated tumors and poorly differentiated cancer (P=0.015, Chi-square test), were detected but not for stages A-C and D (P=0.2311). Genetic alterations would thus appear to be rare in low grade and/or early prostate cancers but more common in high grade and/or advanced prostate cancers.	KITASATO UNIV,SCH MED,DEPT CLIN PATHOL,KANAGAWA 228,JAPAN	Kitasato University	UCHIDA, T (corresponding author), KITASATO UNIV,SCH MED,DEPT UROL,KANAGAWA 228,JAPAN.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOVA GS, 1993, CANCER RES, V53, P3869; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; RISINGER JI, 1993, CANCER RES, V53, P5100; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1990, CELL, V56, P917; UCHIDA T, 1994, CANCER RES, V54, P3682; UCHIDA T, 1993, BRIT J CANCER, V68, P751, DOI 10.1038/bjc.1993.423; WEBER JL, 1989, AM J HUM GENET, V144, P388; 1991, HTLH WELFARE STATIST, P417; 1992, GENERAL RULE CLIN PA	26	62	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1019	1022						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898920				2022-12-28	WOS:A1995QL03800025
J	BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A				BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A			WILD-TYPE P53 MODULATES APOPTOSIS OF NORMAL, IL-3 DEPRIVED, HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						P53; APOPTOSIS; IL-3-DEPENDENCE	DIFFERENTIATION; GROWTH; LINE; CYCLE; GENE; SUPPRESSION; EXPRESSION; INDUCTION; MUTANT; TRANSFORMATION	Apoptotic cell death is an active process which regulates the maintenance of the hematopoietic homeostasis. It has been reported that wild-type p53 (wt-p53) protein induces apoptosis in leukemia cells. To assess whether p53 is involved in the apoptotic process of normal hematopoietic cells, we introduced the temperature-sensitive p53Val(135) mutant into the murine myeloid precursor cell line 32Dcl3. These are diploid, non-tumorigenic cells whose survival and proliferation are dependent upon growth factor supply (IL-3 and serum). Overexpression of wt-p53 protein does not affect morphology and proliferation of 32D cells as long as they are maintained in the presence of IL-3. However, after IL-3 withdrawal, wt-p53 overexpression significantly accelerates apoptosis. This phenomenon is IL-3 specific since no differences in death rates induced by serum starvation are found between parental cells and p53-transfectants. When the latter experiments are carried out at 37 degrees C with p53 protein in mutant conformation, an extended survival of 32D cells is observed after IL-3 deprivation, but not after serum withdrawal. Taken together, these results show that wt-p53 actively mediates the apoptosis due to the absence of specific growth factors, such as IL-3, suggesting that p53 might be involved in the response of myeloid precursors to environmental cytokines for the maintenance of the hematopoietic homeostasis.	CRS,REGINA ELENA CANC INST,MOLEC ONCOGENESIS LAB,I-00158 ROME,ITALY				Crescenzi, Marco/J-3603-2018; Soddu, Silvia/ABH-6774-2020; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Soddu, Silvia/K-2467-2018	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Soddu, Silvia/0000-0001-8526-0044; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUKE RC, 1983, J IMMUNOL, V137, P1442; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEE JC, 1982, J IMMUNOL, V128, P2393; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; RIZZO MG, 1993, CLIN EXP METASTAS, V11, P368, DOI 10.1007/BF00132980; ROVERA G, 1987, ONCOGENE, V1, P29; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	34	64	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862450				2022-12-28	WOS:A1995QH61200013
J	DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS				DAWSON, CW; ELIOPOULOS, AG; DAWSON, J; YOUNG, LS			BHRF1, A VIRAL HOMOLOG OF THE BCL-2 ONCOGENE, DISTURBS EPITHELIAL-CELL DIFFERENTIATION	ONCOGENE			English	Article						BHRF1; BCL-2; EBV; APOPTOSIS; EPITHELIAL	EPSTEIN-BARR-VIRUS; ORAL HAIRY LEUKOPLAKIA; TERMINAL DIFFERENTIATION; HUMAN KERATINOCYTES; B-CELLS; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; INFECTED-CELLS; REPLICATION; PROTEIN	Epstein-Barr virus (EBV) is associated with tumours of both lymphoid and epithelial origin. Whilst a role for EBV latent genes in the development of these malignancies is accepted, it is also possible that viral proteins involved in EBV replication may influence the oncogenic process. BHRF1 is an immediate early protein which has homology with the Bcl-2 oncogene and can protect B cells from apoptosis. In vivo this protein is most abundantly expressed in the upper layers of oral 'hairy' leukoplakia (HL), a benign hyperparakeratotic tongue lesion which represents a focus EBV replication. We have transfected BHRF1 into the human squamous cell carcinoma line SCC12F which retains several features of normal keratinocytes behaviour in vitro. BHRF1 expression in these epithelial cells is associated with a delay in the commitment of cells to terminal differentiation, increased resistance to the DNA damaging drug, cis-platin and enhanced survival under conditions of serum deprivation. As the differentiation of epithelial cells is an apoptotic process, this data strongly suggests that BHRF1 expression delays the terminal differentiation of epithelial cells through the prevention of apoptosis. This effect of BHRF1, which may normally function to promote productive EBV infection, could contribute to the development of EBV-associated tumours.	UNIV BIRMINGHAM, SCH MED, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham			Young, Lawrence S/B-7213-2009; ELIOPOULOS, ARISTIDES/R-9449-2018; ELIOPOULOS, ARISTIDES/ABI-6632-2020	Young, Lawrence S/0000-0003-3919-4298; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COCHET C, 1993, VIROLOGY, V197, P358, DOI 10.1006/viro.1993.1597; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIGILEITNER O, 1986, DIFFERENTIATION, V31, P191, DOI 10.1111/j.1432-0436.1986.tb00400.x; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GUTSCH DE, 1994, MOL CELL BIOL, V14, P1939, DOI 10.1128/MCB.14.3.1939; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HICKISH T, 1994, CANCER RES, V54, P2808; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; LEE MA, 1992, J VIROL, V66, P1899, DOI 10.1128/JVI.66.4.1899-1906.1992; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MCCALL CA, 1991, J INVEST DERMATOL, V97, P111, DOI 10.1111/1523-1747.ep12478519; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; MILLER G, 1990, VIROLOGY, P1921; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIEDOBITEK G, 1991, J GEN VIROL, V72, P3035, DOI 10.1099/0022-1317-72-12-3035; OITVAI ZN, 1993, CELL, V74, P609; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, BLOOD, V78, P1162; PARKINSON FK, 1983, CARCINOGENESIS, V4, P857, DOI 10.1093/carcin/4.7.857; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; RHEINWALD JG, 1981, CANCER RES, V41, P1657; SANDVEJ K, 1992, HISTOPATHOLOGY, V20, P387, DOI 10.1111/j.1365-2559.1992.tb01008.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; THOMAS JA, 1991, AM J PATHOL, V139, P1369; THOMAS JA, 1991, ADV CANCER RES, V57, P329; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	47	54	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					69	77						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824280				2022-12-28	WOS:A1995QA98000009
J	MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H				MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H			THE DROSOPHILA TIS11-HOMOLOG ENCODES A DEVELOPMENTALLY CONTROLLED GENE	ONCOGENE			English	Article							TETRADECANOYL PHORBOL ACETATE; PRIMARY RESPONSE GENE; SWISS 3T3 CELLS; NUCLEOTIDE EXCHANGE; TYROSINE KINASE; SEQUENCE; PROTEIN; RECEPTOR; GRB2; RAS	We previously identified a murine primary response gene family containing three members; TIS11, TIS11B and TIS11D. Using degenerate oligonucleotides derived from conserved regions of the mouse TIS11 family cDNAs as primers and Drosophila genomic DNA as template for polymerase chain reaction amplification, we have identified a fly TIS11 homologue called DTIS11. The DTIS11 protein shares 90% sequence identity with the murine TIS11B and TIS11D proteins, over a 74 amino acid region that contains two CX(8)CX(5)CX(3)H repeated motifs separated by 18 amino acids. DTIS11 maps to region 11B(14-16) on the X-chromosome. Northern blot and in situ hybridization show that a maternal 3 kb message is present in embryos of early developmental stages. A 6 kb DTIS11 mRNA subsequently appears. In KC embryonal cells, both a strong 3 kb message and a less intense 6 kb message are present. The larger (6 kb) message is modestly induced in KC cells by both forskolin and tetradecanoyl phorbol acetate, and is stabilized by cycloheximide.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DOE,DEPT BIOL CHEM,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI WS, 1990, J BIOL CHEM, V265, P16556; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580	31	36	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3329	3334						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936658				2022-12-28	WOS:A1994PM65800027
J	HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S				HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S			SUSCEPTIBILITY AND RESISTANCE TO J3V1 RETROVIRUS-INDUCED MURINE PLASMACYTOMAGENESIS IN RECONSTITUTED SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article							MOUSE PLASMACYTOMAS; BALB/C MICE; B-CELLS; V-MYC; INDUCTION; GENETICS; LOCALIZATION; EXPRESSION; MACROPHAGE; MUTATION	To date much is known about the genetics of susceptibility and resistance to plasmacytoma induction in mice, however little is known about the cellular aspects of these phenotypes. The complexity of plasmacytomagenesis allows for susceptibility and resistance to reflect differences in B cells, T cells, accessory cells and/or stromal elements contributing to the disease process. Alternatively, these phenotypes may result from differential abilities to affect events critical to plasmacytomagenesis, such as myc deregulation. To address these possibilities, the v-myc-raf-containing retrovirus, J3V1, was used to induce plasmacytomas (PCTs) in severe combined immunodeficient (SCID) mice reconstituted with susceptible (Balb/c) and/or resistant (DBA/2) cells. The results demonstrate that Balb/c bone marrow (BM)-reconstituted SCID mice yielded PCTs of donor origin, while DBA/2 BM-reconstituted mice did not. Mice reconstituted with both DBA/2 BM and Balb/c peripheral lymphocytes, as well as those reconstituted with Balb/c peripheral lymphocytes alone, also yielded only Balb/c PCTs. These results indicate that: (1) a microenvironment supportive of plasmacytomagenesis is insufficient to allow PCT development among resistant cells; (2) DBA/ 2 BM-derived cells do not suppress plasmacytomagenesis by target cell elimination or microenvironment destruction; (3) resistance is not solely attributable to the inability of DBA/2 B cells to deregulate myc; and (4) potential PCT targets reside in a number of lymphoid tissues. Taken together, these results demonstrate that a major aspect of resistance/susceptibility to plasmacytomagenesis is dictated by the genotype of the target B cell.	NCI,FREDERICK CANC RES CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HILBERT, DM (corresponding author), NCI,GENET LAB,BETHESDA,MD 20892, USA.							ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; AUSTYN JM, 1981, EUR J IMMUNOL, V1, P801; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANCRO M, 1976, J EXP MED, V144, P1554, DOI 10.1084/jem.144.6.1554; CLYNES R, 1989, P NATL ACAD SCI USA, V85, P6067; Coffman R L, 1982, Immunol Rev, V69, P5; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; ECKHARDT L, 1989, IMMUNOGENETICS, V11, P275; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HO MK, 1982, J IMMUNOL, V128, P2281; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KURIE JM, 1990, ONCOGENE, V5, P577; LARGAESPADA D, 1990, CURR TOP MICROBIOL, V166, P91; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MERWIN RM, 1963, J NAT CANC, V31, P998; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; POTTER M, 1988, Genomics, V2, P257, DOI 10.1016/0888-7543(88)90010-9; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1975, J NATL CANCER I, V54, P1413, DOI 10.1093/jnci/54.6.1413; POTTER M, 1984, J EXP MED, V160, P435, DOI 10.1084/jem.160.2.435; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1984, CANCER SURV, V3, P247; POTTER M, 1981, J IMMUNOL, V127, P1591; POTTER M, 1960, J NATL CANCER I, V25, P847, DOI 10.1093/jnci/25.4.847; POTTER M, 1967, METHOD CANCER RES, V2, P105; POTTER M, 1982, CANCER COMPREHENSIVE, P139; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEVES RH, 1987, CYTOGENET CELL GENET, V44, P76, DOI 10.1159/000132347; SCHEID MP, 1979, IMMUNOGENETICS, V9, P423, DOI 10.1007/BF01570435; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRINGER TA, 1979, EUR J IMMUNOL, V9, P311; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENNSTROM B, 1981, J VIROL, V39, P625	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1993	2000						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	7685514				2022-12-28	WOS:A1993LG68200032
J	LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R				LUCIBELLO, FC; BRUSSELBACH, S; SEWING, A; MULLER, R			SUPPRESSION OF THE GROWTH FACTOR-MEDIATED INDUCTION OF C-FOS AND DOWN-MODULATION OF AP-1-BINDING ACTIVITY ARE NOT REQUIRED FOR CELLULAR SENESCENCE	ONCOGENE			English	Note							HUMAN-FIBROBLASTS; PROTO-ONCOGENE; GENE; JUN; CELLS; PHOSPHORYLATE; FAILURE; PRODUCT; RNA	It has been suggested that the impaired response of the c-fos gene to serum growth factors and the concomitant loss of AP-1 activity may be a crucial step in the process of cellular senescence. In the present study, we provide evidence arguing against such a conclusion. Data obtained in five independent experiments showed that both c-fos RNA and protein expression were similar in 'young' and in senescent serum-stimulated WI-38 cells, suggesting that the previously reported suppression of c-fos induction is not an obligatory event in the process of cellular senescence. Likewise, expression of fra-1, c-jun and junB continued to be high in serum-stimulated senescent cells, while induction of fosB was reduced approximately fivefold. Among all genes tested fosB thus seems to be the most suitable marker for the detection of senescent cells. Stimulated senescent cells showed only a approximately twofold reduction of AP-1-binding activity, and senescent cells continuously exposed to serum exhibited normal AP-1-binding activity. These observations support the conclusion that a down-modulation of AP-1 is not crucial for human fibroblasts to enter the senescent state.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PAULSSON Y, 1986, EMBO J, V5, P2157, DOI 10.1002/j.1460-2075.1986.tb04479.x; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	24	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684831				2022-12-28	WOS:A1993LE06400031
J	CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A				CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A			LOSS OF HETEROZYGOSITY OF IMPRINTED GENES IN SV40 T/T ANTIGEN-INDUCED HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Article						GENOMIC IMPRINTING; CHROMOSOME IMBALANCES; HEPATOCARCINOGENESIS	GROWTH-FACTOR-II; MOUSE CHROMOSOME-7; TRANSGENIC MICE; WILMS-TUMOR; CANCER; RAT; EXPRESSION; RNA; H19; HEPATOCARCINOGENESIS	Expression of the chromosomally linked Insulin-like Growth Factor II (IGF-II) and H19 genes is regulated by parental imprinting during development, since the maternally inherited IGF-II and the paternally inherited H19 alleles are inactive in fetal tissues. Here we show that expression of IGF-II and H19 genes is activated in transgenic mice during SV40 Tag-induced hepatocarcinogenesis and that imprinting of both genes is conserved in the liver tumors. Allelic imbalances of IGF-II and H19 genes and other chromosome 7 markers were detected in one third (13/39) of the hepatocellular carcinomas analysed. A strong bias on the allele retained in the neoplasms was observed, since underrepresentation or complete loss of maternal chromosome 7 was recognised in 12/13 cases. High levels of IGF-II mRNA were expressed by all carcinomas with relative excess of paternal chromosome 7 alleles and suppressed H19 expression was found in the neoplasms lacking the maternal alleles. Overall the results indicate that expression of imprinted genes is involved in progression of experimental liver tumors and suggest that the murine chromosome 7, whose loss may possibly cause the inactivation of a growth-inhibitory gene, is preferentially retained as paternal copy in the liver tumors because of parental imprinting of IGF-II gene.	UNIV NAPLES FEDERICO II,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST RIC BIOL MOLEC P ANGELETTI,DEPT GENET,I-00040 POMEZIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II			Casola, Stefano/O-3922-2014; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/A-4991-2015; Ciliberto, Gennaro/J-4131-2017; Zarrilli, Raffaele/F-5067-2012; Riccio, Andrea/AAY-7571-2020; Cerrato, Flavia/O-8315-2015	Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Ciliberto, Gennaro/0000-0003-2851-8605; Zarrilli, Raffaele/0000-0003-4191-9032; Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Pedone, Paolo Vincenzo/0000-0002-0828-5843				ALBRECHT S, 1994, CANCER RES, V54, P5041; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK G, 1980, STAINING PROCEDURES; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUJIMORI M, 1991, CANCER RES, V51, P89; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HELD WA, 1994, CANCER RES, V54, P6489; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOLDENER BC, 1993, MAMM GENOME, V4, pS110, DOI 10.1007/BF00360833; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V7, P1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J, 1989, MOL CLONING LABORATO; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCOTT J, 1985, NATURE, V317, P174; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	56	35	35	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					711	721						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651735				2022-12-28	WOS:A1995RQ46900013
J	TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE				TANIGUCHI, T; SCHOFIELD, AE; SCARLETT, JL; MORISON, IM; SULLIVAN, MJ; REEVE, AE			ALTERED SPECIFICITY OF IGF2 PROMOTER IMPRINTING DURING FETAL DEVELOPMENT AND ONSET OF WILMS-TUMOR	ONCOGENE			English	Article						IMPRINTING; IGF2; PROMOTER; FETAL TISSUE; WILMS TUMOR	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; FACTOR GENES; RELAXATION	The specificity of IGF2 promoter imprinting was examined in embryonal tissues and Wilms tumour. In several fetal tissues of approximately 12 weeks gestation, IGF2 was found to be monoallelically expressed from all IGF2 promoters i.e. P1, P2, P3 and P4. However, in tissues of slightly older gestation age (15-17 weeks) relaxation of imprinting at the P1 promoter was evident, although the P2-P4 promoters remained imprinted. These data indicate that early in embryogenesis a population of cells exists in which all IGF2 promoters are imprinted, but that as development proceeds the imprinting of the P1 promoter is relaxed. The pattern of IGF2 promoter imprinting was also analysed in Wilms tumour. In some tumours, the pattern of promoter imprinting was identical to that found in early fetal kidney, indicating that this tumour originates within early embryonic kidney tissue. In contrast, in tumours in which relaxation of imprinting had occurred, imprinting relaxation affected all IGF2 promoters. This aberrant pattern of promoter imprinting, which was not detected in fetal kidney, provides further evidence that pathological relaxation of IGF2 imprinting is involved in the genesis of Wilms tumour.	UNIV OTAGO,DEPT BIOCHEM,CANC GENET LAB,DUNEDIN,NEW ZEALAND	University of Otago			Sullivan, Michael/B-5459-2012; Morison, Ian M/A-1236-2008	Morison, Ian M/0000-0003-3616-0025; Sullivan, Michael/0000-0002-8606-5889				ADAMS SM, 1991, FOCUS, V13, P56; BELL GI, 1985, P NATL ACAD SCI USA, V82, P6450, DOI 10.1073/pnas.82.19.6450; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GLENN CC, 1993, HUM MOL GENET, V2, P2001, DOI 10.1093/hmg/2.12.2001; JANSEN M, 1985, FEBS LETT, V179, P243, DOI 10.1016/0014-5793(85)80527-5; Jansen M, 1990, GROWTH FACTORS GENES; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NIELSEN FC, 1990, J BIOL CHEM, V265, P13431; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P1; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; SCOTT J, 1985, NATURE, V317, P261; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sussenbach J S, 1989, Prog Growth Factor Res, V1, P33, DOI 10.1016/0955-2235(89)90040-9; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAGSTAFF J, 1993, AM J HUM GENET, V53, P105; WEKSBERG R, 1993, HUM MOL GENET, V2, P549, DOI 10.1093/hmg/2.5.549; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	28	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					751	756						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651739				2022-12-28	WOS:A1995RQ46900017
J	MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD				MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD			INCREASED RETINOIC ACID RECEPTOR-GAMMA EXPRESSION SUPPRESSES THE MALIGNANT PHENOTYPE AND ALTERS THE DIFFERENTIATION POTENTIAL OF HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article						DIFFERENTIATION; RETINOIC ACID RECEPTOR GAMMA; NEUROBLASTOMA; RETINOIC ACID	BINDING-PROTEINS; MOUSE; GENE; GROWTH; TRANSCRIPTION; PATTERN; CANCER	Human neuroblastoma (NB) tumor cell lines treated in vitro with the retinoid, all-trans-retinoic acid (aRA), form neurites and undergo growth arrest, Retinoids exert their diverse morphologic effects through a signalling pathway which involves the nuclear retinoid receptors, Defective retinoic acid receptor (RAR) function contributes to the malignant phenotype of several human and experimental tumors. Considerable evidence from gene disruption studies now suggests that one of the RARs, RAR gamma, may directly mediate some retinoid effects on embryonic and malignant cells. We, firstly, examined primary NE tumor tissue for a correlation between endogenous RAR gamma expression and clinical stage of the tumor and secondly, the effects of exogenous overexpression of the RAR gamma gene on a human NE tumor cell line. RAR gamma mRNA expression in 32 primary NE tumor tissue samples were significantly higher in clinically localised tumors compared with advanced or disseminated tumors. The human NE tumor cell line, BE(2)-C, was stably transfected with a mammalian expression (pREP4) over-expressing the human RAR gamma cDNA. Two selected clones over-expressing RAR gamma and 2) exhibited a reduced growth rate compared to control cells, Tumorigenicity was inhibited for BE/G1 cells and there was a delayed onset to tumor formation for BE/G2, cells. aRA caused growth inhibition but not neuritic differentiation of the BE/G clones, while 9-cis-retinoic acid caused both growth arrest and neuritic differentiation. Taken together these results suggest that reduced endogenous RAR gamma expression may contribute to the malignant phenotype of human NE. In NE cells the retinoid signalling pathway for neuritic differentiation may be distinct from that causing growth inhibition.	UNIV NEW S WALES,FAC MED,SCH PAEDIAT,KENSINGTON,NSW 2033,AUSTRALIA; UNIV TECHNOL SYDNEY,DEPT BIOCHEM & PHYSIOL,BROADWAY 2007,AUSTRALIA	University of New South Wales Sydney; University of Technology Sydney	MARSHALL, GM (corresponding author), PRINCE WALES CHILDRENS HOSP,CHILDRENS LEUKAEMIA & CANC RES CTR,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Greenwood, Kathryn/U-6965-2017	Greenwood, Kathryn/0000-0002-1556-0065; Norris, Murray/0000-0002-0632-4589; Cheung, Belamy/0000-0001-8784-860X; Haber, Michelle/0000-0003-2036-8817				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BASELGA J, 1993, ONCOGENE, V8, P3257; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BORDOW SB, 1994, CANCER RES, V54, P5036; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; Cushing H, 1927, AM J PATHOL, V3, P203; DAWSON MI, 1994, BLOOD, V84, P446; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI T, 1991, CANCER RES, V51, P3958; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MOASSER MM, 1994, ONCOGENE, V9, P833; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J., 1989, MOL CLONING LABOROAT; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; XU XC, 1994, CANCER RES, V54, P3580	42	35	36	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					485	491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630632				2022-12-28	WOS:A1995RN53000008
J	NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK				NEVILLE, EM; STEWART, M; MYSKOW, M; DONNELLY, RJ; FIELD, JK			LOSS OF HETEROZYGOSITY AT 9P23 DEFINES A NOVEL LOCUS IN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						LUNG CANCER; NONSMALL CELL; LOSS OF HETEROZYGOSITY; CHROMOSOME 9P; 9P23	REGION	Genetic studies have previously demonstrated cytogenetic deletions and allelic imbalance or loss of heterozygosity (LOH) on the p arm of chromosome 9, in a number of tumour types. We have analysed 45 Non-Small Cell Lung Cancers (NSCLC) with a panel of highly polymorphic microsatellite markers on chromosome 9. Our results indicate that loss on 9p is concentrated within the D9S156-D9S161 region with 44% (20/45) LOH, however the area with minimal loss in this set of lung tumours was found at D9S157 (9p23), with 30% LOH (10/33), whereas loss at the IFNA locus was only found in 6% (2/34) tumours. Five of the lung tumours in this study which demonstrated LOH at D9S157 retained heterozygosity at the adjacent informative markers lying centromeric and telomeric to D9S157. No correlations were found between any of the clinico-pathological parameters and LOH on 9p or at the D9S157 locus. The results of this study indicates the presence of a further putative tumour suppressor gene on 9p at the D9S157 locus (9p23) to be most likely involved in the pathogenesis of non-small cell lung cancer.	UNIV LIVERPOOL,DEPT CLIN DENT SCI,MOLEC GENET & ONCOL GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,DEPT PATHOL,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND; BROADGREEN HOSP,CTR CARDIOTHORAC,LIVERPOOL L14 3LB,MERSEYSIDE,ENGLAND	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust			Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				CAIRNS P, 1993, CANCER RES, V53, P1230; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HARMER EM, 1978, GENEVA UNION INT CAN, P41; HOLLAND EA, 1994, ONCOGENE, V9, P1361; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; MEAD LJ, 1994, CANCER RES, V54, P2307; MERLO A, 1994, CANCER RES, V54, P640; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; ORLOW I, 1994, CANCER RES, V54, P2848; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITEHOUSE JMA, 1994, MANAGEMENT LUNG CANC	20	45	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					581	585						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630642				2022-12-28	WOS:A1995RN53000019
J	EPSTEIN, RJ				EPSTEIN, RJ			PREFERENTIAL DETECTION OF CATALYTICALLY INACTIVE C-ERBB-2 BY ANTIBODIES TO UNPHOSPHORYLATED PEPTIDES MIMICKING RECEPTOR TYROSINE AUTOPHOSPHORYLATION SITES	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASES; ONCOGENES; NEOPLASMS; PHOSPHORYLATION; ANTIBODIES	GROWTH-FACTOR RECEPTOR; POSITIVE BREAST-CANCER; HER-2 NEU ONCOGENE; PROTEIN; AMPLIFICATION; EXPRESSION; CARCINOMA; CELLS; PHOSPHOTYROSINE; HER2/NEU	The c-evbB-2 tyrosine kinase is often overexpressed in human breast cancer, but correlations of receptor expression with tumour behaviour have proven elusive in patients without metastases at diagnosis. To address the possibility that receptor function may be more informative than expression, we previously developed function-specific cerbB-2 antibodies using synthetic tyrosine-phosphorylated peptide immunogens (Epstein et al., Proc, Natl. Acad. Sci. USA 1992; 89: 10435-10439). Here the converse approach has been taken to determine the functional status of c-erbB-2 receptors detected by antibodies to dephosphorylated (dep) autophosphorylation sequences. In contrast to antiphosphopeptide (apt) antibodies, dep antibodies to the Tyr(1248) autophosphorylation site exhibited preferential, but not exclusive, binding to tyrosine-dephosphorylated c-erbB-2, Consistent with this, catalytically active and inactive receptors could not be clearly distinguished by in vitro autophosphorylation experiments in which c-erbB-2 was immunoprecipitated using a monoclonal Tyr(1248) dep antibody, A dep antiserum recognizing autophosphorylation sites N-terminal to Tyr(1248) exclusively recognized tyrosine-dephosphorylated c-erbB-2 following antibody preabsorption with homologous phosphopeptides. Although indirect, these data are consistent with a model of sequential c-erbB-2 autophosphorylation in which Tyr(1Z48) iS the final residue modified, Moreover, since many studies of c-erbB-2 expression have used antibodies to dephosphorylated autophosphorylation sites, these results caution against automatically equating such receptor immunoreactivity with in vivo function or clinical significance.	CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND	Imperial College London	EPSTEIN, RJ (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DIV CELL MOLEC & ONCOL RES,LONDON W6 8RF,ENGLAND.							AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1988, CANCER RES, V48, P1238; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAO HN, 1991, ONCOGENE, V6, P705; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1992, CELL GROWTH DIFFER, V3, P157; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUANG SS, 1990, J BIOL CHEM, V265, P3340; IGLEHART JD, 1990, CANCER RES, V50, P6701; KURY F, 1990, EUR J CANCER, V26, P946, DOI 10.1016/0277-5379(90)90616-2; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OREILLY SM, 1990, EUR J CANCER, V26, P1035, DOI 10.1016/0277-5379(90)90045-U; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PERES R, 1987, CANCER RES, V47, P3425; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; RO J, 1989, ONCOGENE, V4, P351; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILDENHAIN Y, 1990, ONCOGENE, V5, P879; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158	47	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					315	323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624146				2022-12-28	WOS:A1995RK95700012
J	TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML				TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML			THE RAS SUPPRESSOR RSU-1 LOCALIZES TO 10P13 AND ITS EXPRESSION IN THE U251 GLIOBLASTOMA CELL-LINE CORRELATES WITH A DECREASE IN GROWTH-RATE AND TUMORIGENIC POTENTIAL	ONCOGENE			English	Note						RSU-1; GLIOBLASTOMA, TUMOR SUPPRESSOR	SACCHAROMYCES-CEREVISIAE; FACTOR RECEPTOR; TYPE-1 NEUROFIBROMATOSIS; ADENYLYL CYCLASE; HUMAN GLIOMAS; BRAIN-TUMORS; GENE; CHROMOSOME-10; HETEROZYGOSITY; MULTIFORME	Rsu-1, which was isolated based on its ability to suppress transformation by v-Ras, is a highly conserved gene which shares homology with yeast adenylyl cyclase in the region required for activation by Ras, Genomic DNA clones of human RSU-1 have been isolated and used as a probe for fluorescence in situ hybridization (FISH) to assign RSU-1 to 10p13, confirming the previous results of somatic cell hybrid mapping localizing RSU-1 to chromosome 10. Screening of more than 20 human tumor cell lines for RSU-1 expression revealed that most cell lines contained abundant RSU-1 RNA and protein. However, the p33 RSU-1 protein was undetectable in the U251 glioblastoma cell line and transfection of a rsu-1 expression vector into U251 cells yielded a cell line in which rsu-1 was under the control of a regulatable metallothionein promoter. Addition of Cd2+ to the U251-Rsu-1 transfectant resulted in transcription of rsu-1 RNA and the accumulation of p33 Rsu-1 protein. Appearance of the Rsu-1 protein correlated with a reduction in growth rate of the U251-Rsu-1 transfectant. In addition, reduction in anchorage independent growth and phenotypic alteration in U251-Rsu-1 transfectant agar colonies was observed. Two U251-Rsu-1 transfectant cell lines were non tumorigenic when injected subcutaneously into athymic nude mice. These results, in conjunction with the frequent deletions observed in chromosome 10 in glioblastomas, suggest that RSU-1 loss of function may play a role in the progression of this disease.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Masuelli, Laura/AGW-4259-2022; Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; MASUELLI, Laura/0000-0001-8174-8034				AMBROSE D, 1994, J CELL PHYSIOL, V159, P92, DOI 10.1002/jcp.1041590113; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; BIGNER SH, 1988, CANCER RES, V48, P405; CAVENEE WK, 1992, CANCER, V70, P1788, DOI 10.1002/1097-0142(19920915)70:4+<1788::AID-CNCR2820701621>3.0.CO;2-L; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1990, CANCER SURV, V9, P631; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; MARK J, 1977, HEREDITAS, V87, P243; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RESNICOFF M, 1994, CANCER RES, V54, P2218; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROJAN J, 1993, SCIENCE, V259, P9497; TSUDA T, 1993, GENOMICS, V18, P461, DOI 10.1006/geno.1993.1503; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YE Z, 1993, NEUROL RES, V15, P59, DOI 10.1080/01616412.1993.11740109	43	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624154				2022-12-28	WOS:A1995RK95700021
J	KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A				KINOSHITA, T; YOKOTA, T; ARAI, KI; MIYAJIMA, A			REGULATION OF BCL-2 EXPRESSION BY ONCOGENIC RAS PROTEIN IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						APOPTOSIS; INTERLEUKIN; COLONY-STIMULATING FACTOR; BCL-X; CELL SURVIVAL	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; C-MYC; SIGNAL-TRANSDUCTION; TYROSINE KINASE; BONE-MARROW; GM-CSF; APOPTOSIS; DEATH; INTERLEUKIN-3	Interleukin 3 (IL-3) and granulocyte-macrophage colony stimulating factor (GM-CSF) induce DNA synthesis and suppress apoptosis of hematopoietic cells. IL3/GM-CSF exert pleiotropic functions by activating multiple signaling cascades through distinct domains of the common receptor subunit. As we previously reported, the Ras signaling pathway plays a pivotal role in suppressing apoptotic death rather than stimulating DNA synthesis in IL-3 dependent hematopoietic cells. In order to clarify the molecular basis of Ras-induced cell survival, we investigated the effect of Ras activation on the expression of Bcl-2 and its related molecules. Activation of the Ras pathway by using an inducible oncogenic Ras resulted in the rapid up-regulation of bcl-2 and bcl-x(L), and the level of expression was nearly equivalent to that observed in growing cells. On the other hand, expression of bar, an antagonistic bcl-2 homologue, was not affected by oncogenic Ras or IL-3-deprivation. Thus, the Ras pathway regulates the expression of Bcl-2 and its related survival protein, and this appears to underlie the mechanism by which IL3/GM-CSF inhibit apoptosis through activation of the Ras pathway.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL BIOL,PALO ALTO,CA 94304; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BISCI,BUNKYO KU,TOKYO 113,JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Tokyo; University of Tokyo			Yokota, Takashi/J-8483-2015					ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; ITOH N, 1993, J IMMUNOL, V151, P621; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V14, P3602; OKUDA K, 1994, J BIOL CHEM, V269, P24602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REED JC, 1994, J CELL BIOL, V124, P537; SAKAMAKI, 1994, FEBS LETT, V353, P133; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIROUZU M, 1992, ONCOGENE, V7, P475; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TORIGOE T, 1992, BLOOD, V80, P617; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1057; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	156	158	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784065				2022-12-28	WOS:A1995RB70300016
J	GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR				GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR			EXCLUSION OF THE WILMS-TUMOR GENE (WT1) PROMOTER AS A SITE OF FREQUENT MUTATION IN WILMS-TUMOR	ONCOGENE			English	Note						WT1; PROMOTER; MUTATION; SCCP; WILMS TUMOR; TUMOR SUPPRESSOR GENE	DENYS-DRASH SYNDROME; DOMINANT NEGATIVE MUTATIONS; HUMAN RETINOBLASTOMA GENE; SUPPRESSOR GENE; GENITOURINARY DEVELOPMENT; EXPRESSION; KIDNEY; REGION; LOCUS; INACTIVATION	WT1 is a tumour suppressor gene expressed in a specific temporal and spatial pattern in the developing kidney. Up to 15% of Wilms tumours have point mutations in the WT1 gene coding sequence. We have now investigated whether mutations in the WT1 promoter could be associated with loss of control WT1 expression and subsequent Wilms tumour formation. Using single-strand conformational polymorphism (SSCP) analysis we analysed 39 sporadic Wilms tumours for WT1 promoter mutations. We found six linked common sequence polymorphisms and two unlinked less frequent polymorphisms which allowed us to identify four tumours with loss of heterozygosity but none with point mutations, small deletions, insertions or rearrangements. We therefore conclude that WT1 promoter mutations are unlikely to play an important role in Wilms tumorigenesis.	UNIV OTAGO, SCH MED, DEPT BIOCHEM, CANC GENET LAB, DUNEDIN, NEW ZEALAND; UNIV OTAGO, SCH MED, DEPT PATHOL, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago								ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Campbell C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P541; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1994, ONCOGENE, V9, P2059; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1992, CANCER SURV, V12, P105; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NORDENSKJOLD A, 1994, HUM GENET, V93, P115; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHNEIDER S, 1993, HUM GENET, V91, P599; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	45	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1677	1681						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731725				2022-12-28	WOS:A1995QU68100027
J	SMITH, ML; CHEN, IT; ZHAN, QM; OCONNOR, PM; FORNACE, AJ				SMITH, ML; CHEN, IT; ZHAN, QM; OCONNOR, PM; FORNACE, AJ			INVOLVEMENT OF THE P53 TUMOR-SUPPRESSOR IN REPAIR OF UV-TYPE DNA-DAMAGE	ONCOGENE			English	Article						P53; UV; DNA REPAIR; GADD45; HPV E6; CHECKPOINTS	EXCISION REPAIR; IONIZING-RADIATION; CELLULAR-RESPONSE; ESCHERICHIA-COLI; PROTEIN; GENE; ACTIVATION; CHECKPOINT; APOPTOSIS; AGENTS	The tumor suppressor p53 plays a central role in the cellular responses to genotoxic stress. Besides its well known role in activation of the G(1) checkpoint after exposure to agents like ionizing radiation and its role in apoptosis, the possibility exists that p53 may have additional roles, such as in DNA repair. For example, p53, is known to bind to single strand DNA such as would occur during repair events, and the proteins encoded by two p53-regulated genes have previously been found to bind to at least one protein involved in DNA damage processing including nucleotide excision repair (NER). NER is an important and versatile DNA repair mechanism, which is the major pathway for repair of u.v.-type lesions and damage by a variety of important carcinogens and mutagens. If components of the p53 pathway are involved in NER, then disruption of p53 function by mutations or expression of certain viral proteins could have important implications in carcinogenesis and cancer treatment. In the present study we show that disruption of normal p53 function in human colon carcinoma RKO cells with either the human papillomavirus E6 oncoprotein or a dominant-negative mutant p53 transgene results in reduced repair of u.v.-induced DNA damage. The E6 and mutant p53-containing cell lines demonstrated reduced repair of u.v.-induced DNA lesions in host cell reactivation experiments with reporter plasmids, and reduced repair in in vitro DNA repair assays. With this in vitro assay, extracts from the E6- and mutant p53-containing lines also showed loss of induced repair following cellular u.v.-irradiation. The reduced DNA repair activity of the transfected cell lines also correlated with reduced clonogenic survival following u.v.-irradiation. These results indicate that p53 and/or p53-regulated gene products function in the NER pathway and that this process is inducible by DNA damage.			SMITH, ML (corresponding author), NCI,DIV CANC TREATMENT,MOLEC PHARMACOL LAB,DEV THERAPEUT PROGRAM,BLDG 37,ROOM 5C09,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BOHR VA, 1989, LAB INVEST, V61, P143; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CROOK T, 1994, ONCOGENE, V9, P1225; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRIEDBERG EC, 1991, BIOESSAYS, V13, P295, DOI 10.1002/bies.950130607; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOY CA, 1984, MUTAT RES, V140, P199, DOI 10.1016/0165-7992(84)90077-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOVAL TM, 1988, RADIAT RES, V115, P413, DOI 10.2307/3577291; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRICE BD, 1994, CANCER RES, V54, P896; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; SMITH ML, 1995, IN PRESS CURR OPINIO; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG XW, 1994, P NATL ACAD SCI USA, V91, P230; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	64	379	381	1	18	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1053	1059						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700629				2022-12-28	WOS:A1995QN35300004
J	NIEWOLIK, D; VOJTESEK, B; KOVARIK, J				NIEWOLIK, D; VOJTESEK, B; KOVARIK, J			P53 DERIVED FROM HUMAN TUMOR-CELL LINES AND CONTAINING DISTINCT POINT MUTATIONS CAN BE ACTIVATED TO BIND ITS CONSENSUS TARGET SEQUENCE	ONCOGENE			English	Article						P53; PROTEIN-DNA INTERACTIONS; PROTEIN CONFORMATION	WILD-TYPE P53; DNA-BINDING; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; GENE-EXPRESSION; PROTEIN; CANCER	Mutation of the p53 gene is one of the most common genetic lesions observed in human cancer. The p53 protein functions as a transcription factor, however it is still unresolved to what extend this property is related to its tumour suppressor activity. Since there is evidence that protein modifications as well as protein-protein interactions may regulate p53 function, we have studied p53 protein-DNA complex formation in nuclear extracts prepared from human tumour cell lines. In 13 different cell lines PAb421-induced DNA binding activity was compared to the level and conformation of the endogenous p53 protein. Surprisingly, sequence-specific p53 DNA binding activity was detected not only in cell lines that express wild-type p53, but also in seven cell lines which contain only mutant protein. Oligonucleotide competition analyses with various p53 target sequences and methylation interference experiments establish that wild-type and mutant p53 differ significantly in their sequence-specific interactions. Our analysis also provides evidence that the PAb1620 conformation is neither sufficient nor essential for DNA binding of endogenous p53 and that the cellular environment in addition to the specific point mutation may influence p53 DNA binding activity.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC	Masaryk Memorial Cancer Institute								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MEEK DW, 1992, BIOCHEM J, V287, P1; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; OFVERSTEDT LG, 1984, BIOCHIM BIOPHYS ACTA, V782, P120, DOI 10.1016/0167-4781(84)90014-9; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIIO Y, 1993, ONCOGENE, V8, P2059; SOUSSI T, 1990, ONCOGENE, V5, P945; STRATTON MR, 1990, ONCOGENE, V5, P1297; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHANG W, 1993, ONCOGENE, V8, P2555	91	68	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					881	890						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898929				2022-12-28	WOS:A1995QL03800009
J	SCHWEIGHOFFER, F; FAURE, M; FATH, I; CHEVALLIERMULTON, MC; APIOU, F; DUTRILLAUX, B; STURANI, E; JACQUET, M; TOCQUE, B				SCHWEIGHOFFER, F; FAURE, M; FATH, I; CHEVALLIERMULTON, MC; APIOU, F; DUTRILLAUX, B; STURANI, E; JACQUET, M; TOCQUE, B			IDENTIFICATION OF A HUMAN GUANINE NUCLEOTIDE-RELEASING FACTOR (H-GRF55) SPECIFIC FOR RAS PROTEINS	ONCOGENE			English	Article							GTPASE ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MAMMALIAN-CELLS; CDC25 GENE; PRODUCT; DOMAIN; EXCHANGE; MUTANTS; SCD25	A critical step in the activation of cellular Ras is the release of bound GDP. Oligonucleotide primers derived from a mouse cDNA sequence homologous to the Sac-charomyces cerevisiae CDC25 gene product were used to screen a human brain cDNA library. The cloning led to the isolation of a 2.8-kb cDNA predicted to encode a protein of 488 amino acids. This protein was produced in Escherichia coli as a glutathione S-transferase fusion protein and functioned in vitro as a specific guanine nucleotide-releasing factor. Polyclonal antibodies raised against the last 281 amino acids of the protein allowed a protein in the molecular weight range of 55 kDa to be identified in human cortex homogenates. Analysis by Northern blotting led to the identification of a 5.5-kb mRNA in brain poly(A)+ RNA. The functionality of the encoded protein was evaluated after expression in different cells: (i) in Saccharomyces cerevisiae the effects of the cdc25.5 and RAS2 Ala-22 mutations were reversed; (ii) in chinese hamster ovary cells, a RAS-responsive element was transactivated as demonstrated by the expression of a CAT reporter gene under the control of the polyomavirus enhancer. Finally, in situ hybridization on of human chromosomes revealed a localization on band 15q2.4.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE; INST CURIE,BIOL SECT,F-75231 PARIS 05,FRANCE; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,SEZ BIOCHIM COMPARATA,I-20133 MILAN,ITALY	Sanofi-Aventis; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Milan								ADAMS JM, 1992, ONCOGENE, V7, P611; BARLAT I, 1993, ONCOGENE, V8, P215; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; REY I, 1991, ONCOGENE, V6, P347; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SHERMAN F, 1986, LABORATORY COURSE MA; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SKOLNIK EY, 1991, CELL, V65, P833; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SMITH DB, 1988, GENE, V67, P131; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952	34	45	47	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1477	1485						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684828				2022-12-28	WOS:A1993LE06400010
J	ZAUBERMAN, A; LUPO, A; OREN, M				ZAUBERMAN, A; LUPO, A; OREN, M			IDENTIFICATION OF P53 TARGET GENES THROUGH IMMUNE SELECTION OF GENOMIC DNA - THE CYCLIN-G GENE CONTAINS 2 DISTINCT P53 BINDING-SITES	ONCOGENE			English	Article						P53 TARGETS; CYCLINS; CELL CYCLE; TUMOR SUPPRESSOR; DNA BINDING	WILD-TYPE P53; PROTEIN; EXPRESSION; TRANSACTIVATION; P53-PROTEIN; INHIBITOR; KINASES; ELEMENT; MUTANT; P21	An immune-selection procedure was employed in order to isolate p53-binding sites from rat genomic DNA. One such site was found to reside within the first intron of the cyclin G gene. Cyclin G mRNA levels are strongly elevated upon induction of wild type p53 activity in cells carrying a temperature sensitive p53 mutant. The cyclin G gene also carries a second p53-binding motif upstream to its transcriptional start site. The presence of two high affinity p53-binding sites may confer upon the cyclin G gene the potential to be activated very efficiently by p53. These data raise the possibility that cyclin G may be a downstream mediator of at least some of the biological effects of p53.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1991, NATURE, V349, P802; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OTTO A, 1993, ONCOGENE, V8, P2591; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAMURA K, 1993, ONCOGENE, V8, P2113; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	33	152	155	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2361	2366						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784084				2022-12-28	WOS:A1995RE54300011
J	MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH				MADANI, A; SOULIER, J; SCHMID, M; PLICHTOVA, R; LERME, F; GATEAUROESCH, O; GARNIER, JP; PLA, M; SIGAUX, F; STERN, MH			THE 8-KD PRODUCT OF THE PUTATIVE ONCOGENE MTCP-1 IS A MITOCHONDRIAL PROTEIN	ONCOGENE			English	Note						MITOCHONDRIA; T-CELL PROLYMPHOCYTIC LEUKEMIA; (X-14) TRANSLOCATION; MTCP-1	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; TRANSLOCATION; CHROMOSOME; GENE; ABNORMALITIES; SEQUENCE; IMPORT	An unusually small (8 kD) protein (p8(MTCP-1)) is coded by the putative oncogene MTCP-1 (also called c6.1B), involved in the translocation t(X;14)(q28;q11) associated with some mature T-cell proliferations. Here, we show by subcellular fractionation and by confocal microscopy that this protein is located in the mitochondria. This localization orientates toward a role of p8(MTCP-1) in the mitochondrial metabolism which may be relevant for the oncogenic process.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75475 PARIS,FRANCE; HOP ST LOUIS,INST HEMATOL,SERV COMMUN IMAGERIE CELLULAIRE,F-75475 PARIS,FRANCE; HOP ST LOUIS,BIOCHIM LAB,F-75475 PARIS,FRANCE; FAC MED LYON SUD,INSERM,U189,F-69921 OULLINS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				BEATTY DW, 1986, S AFR MED J, V69, P115; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; GLICK B, 1991, ANNU REV GENET, V25, P21; GOYNS MH, 1993, LEUKEMIA, V7, P848; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; MACKAY IR, 1989, IMMUNOL TODAY, V10, P315, DOI 10.1016/0167-5699(89)90088-1; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	25	30	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2259	2262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784073				2022-12-28	WOS:A1995RB70300024
J	VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V				VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V			COREGULATED EXPRESSION OF DBL AND POLY(ADP-RIBOSE) POLYMERASE IN EWINGS-SARCOMA CELLS AND DBL-TRANSFORMED NIH3T3 FIBROBLASTS	ONCOGENE			English	Note						EWINGS SARCOMA; GENE EXPRESSION; DBL ONCOGENE; POLY(ADP-RIBOSE) POLYMERASE; NIH3T3 FIBROBLASTS	PROTO-ONCOGENE; DNA; PROTOONCOGENE; CLONING; PRODUCT; ORIGIN; CDNA; GENE	Poly(ADP-ribose) polymerase (PADPRP) is a ubiquitous enzyme constitutively expressed at low levels in the majority of eukaryotic cells, including most mammalian tumors and tumor-derived cell lines. Overexpression of PADPRP following the introduction of cDNA recombinant constructs into various cell types results in cell death. An exception to this effect are Ewing's sarcoma (ES) cells, which have been shown to contain elevated steady-state levels of PADPRP mRNA and high constitutive levels of protein and polymerase activity. In fact, this excess of PADPRP has been suggested to participate in the intrinsic radiosensitivity of Ewing's sarcomas, a highly malignant childhood bone tumor frequently curable with radiotherapy. It appears that ES cells might possess a hitherto unknown mechanism(s) by which PADPRP overexpression is controlled and made compatible with cell survival and proliferation. In order to investigate the contribution of other genetic alterations to PADPRP regulation in ES cells, we analysed the expression levels of PADPRP and of other genes, such as oncogenes and tumor suppressor genes, which may enhance the proliferative potential of ES cells. We have detected a positive correlation between the expression levels of the DNA-repair enzyme poly(ADP-ribose) polymerase and the dbl proto-oncogene in Ewing's sarcoma cells. The co-regulated expression of these genes has been established in NIH3T3 cells transformed by the human dbl oncogene or by overexpression of the dbl proto-oncogene. In both instances, the increase in dbl expression resulted in elevated levels of PADPRP mRNA and polymerase activity. The dbl oncogene was more efficient than the proto-oncogene in upregulating PADPRP expression. The inability of other oncogenes to upregulate PADPRP upon transformation of NIH3T3 cells demonstrated the specificity of the dbl in the process. Transfection of dbl-transformed NIH3T3 cells with retroviral PADPRP vectors resulted in the establishment of clones with PADPRP levels higher than those detectable in untransformed NIH3T3 cells transfected with the same retroviral constructs. These results suggest that dbl plays a role in the mechanism by which mammalian cells autoregulate their endogenous levels of PADPRP. Post-translational modification of the dbl or proto-dbl proteins by cytoplasmic PADPRP does not participate in the mechanism(s) underlying the observed PADPRP/dbl co-regulation.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Eva, Alessandra/J-8268-2016; /AAB-6461-2022	Eva, Alessandra/0000-0003-2949-078X; 	NATIONAL CANCER INSTITUTE [R01CA058986] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DEFRANCISCIS V, 1991, CANCER RES, V51, P4234; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GRAZIANI G, 1989, ONCOGENE, V4, P823; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; IKAI K, 1980, P NATL ACAD SCI-BIOL, V77, P3682, DOI 10.1073/pnas.77.6.3682; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; NOTARIO V, 1990, ONCOGENE, V5, P1425; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Prasad Sarada, 1994, Applied and Theoretical Electrophoresis, V4, P3; PRASAD SC, 1990, CANCER RES, V50, P38; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; THOMASSIN H, 1985, BIOCHEM BIOPH RES CO, V133, P654, DOI 10.1016/0006-291X(85)90955-6; VECCHIO G, 1989, ONCOGENE, V4, P897; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	25	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784072				2022-12-28	WOS:A1995RB70300023
J	LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD				LI, JJ; OBERLEY, LW; STCLAIR, DK; RIDNOUR, LA; OBERLEY, TD			PHENOTYPIC CHANGES INDUCED IN HUMAN BREAST-CANCER CELLS BY OVEREXPRESSION OF MANGANESE-CONTAINING SUPEROXIDE-DISMUTASE	ONCOGENE			English	Article						BREAST; CANCER; MNSOD; TRANSFECTION; SOFT AGAR; NUDE MICE	SYRIAN-HAMSTER TISSUES; GLUTATHIONE-PEROXIDASE; ANTIOXIDANT ENZYMES; IMMUNOHISTOCHEMICAL LOCALIZATION; KIDNEY DEVELOPMENT; TRANSFECTED CELLS; EXPRESSION VECTOR; TRANSGENIC MICE; MAMMALIAN-CELLS; DOWNS-SYNDROME	Human manganese containing superoxide dismutase (MnSOD) cDNA was transfected into a human breast cancer cell line (MCF-7) in order to examine the effect of increased functional MnSOD on the cellular phenotype. A MnSOD-overexpressing clone was compared to control vector-transfected cells and to wild type MCF-7 cells. Southern blotting indicated incorporation of MnSOD cDNA into genomic DNA in the MnSOD overexpressing cell line. The MnSOD overexpressing cell line showed a 5.7-fold increase in MnSOD activity compared to wild type MCF-7 cells. Similar increases in MnSOD immunoreactive protein and mRNA levels were observed by Western and Northern blotting as well as using RT-PCR, The plating efficiency of cells grown in different concentrations of serum (1 to 20%) was decreased in the MnSOD overexpressing cell line. The fraction in soft agar culture was also after MnSOD cDNA transfection. When inoculated in nude mice, tumor growth was markedly inhibited in MnSOD overexpressing cells compared to wild type MCF-7 cells or plasmid control cells, These results support the hypothesis that increased MnSOD expression suppresses the malignant phenotype of human breast cancer cells and suggests that the MnSOD gene is a tumor suppressor gene in human breast cancer.	UNIV IOWA, RADIAT RES LAB, MED LABS 14, IOWA CITY, IA 52242 USA; UNIV KENTUCKY, GRAD CTR TOXICOL, LEXINGTON, KY 40506 USA; WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL SERV, MADISON, WI 53705 USA	University of Iowa; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital				Li, Jian Jian/0000-0003-3694-9675; Ridnour, Lisa A./0000-0001-9446-8349	NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA041267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41267, CA 49797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN SC, 1985, CANCER RES, V45, P1611; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; AMSTAD P, 1994, J BIOL CHEM, V269, P1606; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; EMANUEL JR, 1991, NUCLEIC ACIDS RES, V19, P2790, DOI 10.1093/nar/19.10.2790; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V53, P205, DOI 10.1016/0165-4608(91)90097-E; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOVEN DP, 1984, INT J CANCER, V33, P783, DOI 10.1002/ijc.2910330612; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MINCGOLOMB D, 1991, EMBO J, V10, P2119, DOI 10.1002/j.1460-2075.1991.tb07745.x; NEGRINI M, 1994, CANCER RES, V54, P1331; NORRIS KH, 1990, MUTAT RES, V237, P95, DOI 10.1016/0921-8734(90)90015-J; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OBERLEY LW, 1994, DRUGS DIET DIS, P47; OBERLEY TD, 1991, AM J PATHOL, V139, P355; OBERLEY TD, 1990, AM J PATHOL, V137, P199; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI DOI 10.1074/jbc.RA117.001068; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; ROSENBERG CD, 1990, CANCER RES, V50, P1559; SAFFORD SE, 1994, CANCER RES, V54, P4261; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0	49	245	250	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1989	2000						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761099				2022-12-28	WOS:A1995QZ92600013
J	DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC				DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC			CLONING AND CHARACTERIZATION OF MN1, A GENE FROM CHROMOSOME 22Q11, WHICH IS DISRUPTED BY A BALANCED TRANSLOCATION IN A MENINGIOMA	ONCOGENE			English	Article						22Q11; BALANCED TRANSLOCATION; CAG REPEAT; MENINGIOMA; LEUKEMIA	TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS; HETEROZYGOSITY; IDENTIFICATION; CARCINOMAS; TYPE-2; BRAIN	We have isolated a gene, called MN1, which resides on chromosome 22 and which was found to be disrupted by a balanced translocation (4;22) in meningioma 32. The MN1 gene spans about 70 kb and consists of at least two large exons of approximately 4.7 kb and 2.8 kb, The MN1 cDNA codes for a protein of 1319 amino acids when the first methionine in the open reading frame is used. The MN1 cDNA contains two CAG repeats, one of which codes for a string of 28 glutamines, The t(4;22) disrupts the S-exon within the open reading frame, In meningioma 32 no expression of the MN1 mRNA is observed, These results suggest that inactivation of the MN1 gene in this tumour may contribute to its pathogenesis.	ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; UNIV CINCINNATI, MED CTR, DEPT MOLEC GENET, CINCINNATI, OH 45267 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC GENET & CELL BIOL, PRINCETON, NJ 08543 USA	Erasmus University Rotterdam; Erasmus University Rotterdam; Roswell Park Cancer Institute; University System of Ohio; University of Cincinnati; Bristol-Myers Squibb			Riegman, Peter/GLS-0041-2022; POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127				BIEGEL JA, 1990, J NEUROSURG, V73, P710, DOI 10.3171/jns.1990.73.5.0710; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1994, GENE CHROMOSOME CANC, V9, P24; DUMANSKI JP, 1990, CANCER RES, V50, P5863; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOYNS MH, 1984, LEUKEMIA RES, V8, P547, DOI 10.1016/0145-2126(84)90003-1; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PULST SM, 1993, NEUROLOGY, V43, P2096, DOI 10.1212/WNL.43.10.2096; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P452; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VANBIEZEN NA, 1993, GENOMICS, V15, P206, DOI 10.1006/geno.1993.1036; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VISKOCHIL D, 1990, CELL, V62, P87; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	35	127	129	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731706				2022-12-28	WOS:A1995QU68100007
J	LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP				LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP			N-TERMINAL-130 AMINO-ACIDS OF MDM2 ARE SUFFICIENT TO INHIBIT P53-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						MDM2; P53-MEDIATED TRANSACTIVATION	WILD-TYPE P53; GENE-EXPRESSION; BINDING-SITE; CELL-GROWTH; LUNG-CANCER; PROTEIN; MUTATIONS; ONCOGENE; FORMS; DNA	The human oncoprotein MDM2 binds with the tumor suppressor p53 and inhibits p53-directed transactivation. In this report we show that deletion of 336 amino acids from the C-terminus of human MDM2 does not decrease its efficiency to bind p53 in vivo and inhibit p53-directed transactivation. Even further deletion of MDM2 from the C-terminus up to amino acid 131 does not reduce its ability to inhibit p53-mediated transactivation. Since deletion up to amino acid 131 also deletes many antigenic sites of MDM2 and the truncated protein cannot be immunoprecipitated by the antibodies available to us, two internal deletions were made to define the p53-interaction domain. Internal deletion of four amino acids beginning at 110 residue (amino acids 110 to 113) did not reduce p53-binding or inhibition of p53-directed transactivation whereas internal deletion of amino acids 60 to 65 reduces but does not abolish these activities. Sequential deletion of amino acids from the N-terminus leads to sequential destruction of p53-binding and inhibition of transactivation capability of MDM2. Fourteen amino acids can be deleted from this end without any reduction of these activities. Deletion of 28 N-terminal amino acids residues drastically reduces, but does not abolish the p53-binding ability of the protein, as well as inhibition of p53-directed transactivation. Deletion of 58 amino acids from the N-terminus of the oncoprotein abolishes its ability to bind p53 in vivo and to inhibit p53-directed transactivation. These results locate the p53-binding domain of MDM2 within amino acids 14 to 154 and inhibition of transactivation domains of MDM2 within amino acid residues 14 to 130 suggesting possible p53-independent biological functions of the 491 amino acid long oncoprotein.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio				Leng, Roger/0000-0001-9652-4703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31498-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBS SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P49; LADANYI M, 1993, CANCER RES, V53, P16; LENG P, 1985, INT J ONCOL, V6, P251; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Sambrook J, 1989, MOL CLONING LABORATO; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	50	50	51	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1275	1282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731677				2022-12-28	WOS:A1995QR65100003
J	CARRASCO, D; BRAVO, R				CARRASCO, D; BRAVO, R			TISSUE-SPECIFIC EXPRESSION OF THE FOS-RELATED TRANSCRIPTION FACTOR FRA-2 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						FRA-2 EXPRESSION; DEVELOPMENT; JUN AND FOS EXPRESSION	C-JUN; DNA-BINDING; NEGATIVE REGULATOR; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTORS; NULL MUTATION; FACTOR AP-1; PROTEINS; COMPLEXES	The fra-2 gene is related to the proto-oncogene c-fos and encodes a member of the AP-1 transcription factor gene family. We have studied the expression of fra-2 during mouse embryonic development and compared it to the pattern of expression of other fos and jun family members. By in situ hybridization and immunohistochemical analysis we have shown fra-2 expression during late organogenesis. fra-2 transcripts are detected in several differentiating epithelia, developing cartilage and central nervous system. The pattern of fra-2 expression is distinct from that observed for other fos related genes, suggesting that fra-2 has a unique role in cellular differentiation during fetal development.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFDERHEIDE E, 1987, J CELL BIOL, V15, P599; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, CELL BIOL LABORATORY, P466; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P272; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARAKKAL PF, 1967, AM J ANAT, V121, P175, DOI 10.1002/aja.1001210202; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1988, NATURE, V334, P532; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SUZUKI T, 1992, NUCLEIC ACIDS RES, V19, P5537; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1069	1079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700631				2022-12-28	WOS:A1995QN35300006
J	JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO				JONES, TL; KARAVANOVA, I; MAENO, M; ONG, RC; KUNG, HF; DAAR, IO			EXPRESSION OF AN AMPHIBIAN HOMOLOG OF THE EPH FAMILY OF RECEPTOR TYROSINE KINASES IS DEVELOPMENTALLY-REGULATED	ONCOGENE			English	Article						EPH; TYROSINE KINASE; XENOPUS LAEVIS	XENOPUS-EMBRYOS; PROTEIN-KINASES; CDNA CLONING; W-LOCUS; GENE; MOUSE; DROSOPHILA; IDENTIFICATION; ENCODES; CHICKEN	In order to study the function of tyrosine kinase receptors during Xenopus development, we have isolated Xek (Xenopus Elk-like kinase), a tyrosine kinase receptor, which shows significant homology to rat Elk and chicken cek5, members of the Eph family. Xek exists as a maternally expressed mRNA which decreases in expression at the mid blastula transition and reappears at late neurulation in Xenopus, Xek mRNA is expressed at higher levels in the anterior and dorsal regions of embryonic stages 16, 24 and 37. In adult Xenopus tissues, Xek appears to be ubiquitously expressed with higher expression observed in brain and ovary, In situ hybridization analysis demonstrates localized mRNA expression in the brain, brachial arches, trigeminal facial ganglion, and the retina of the swimming tadpole stage of development. The similarities in sequence and expression pattern suggest that Xek is an amphibian member of the Eph family and may play a role in the development or function of the central nervous system.	NCI,FREDERICK CANC RES & DEV CTR,LEUKOCYTE BIOL LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,COMPARAT CARCINOGENESIS LAB,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Daar, Ira/0000-0003-2657-526X				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BASLER K, 1988, TRENDS GENET, V4, P74, DOI 10.1016/0168-9525(88)90044-3; BECKMANN M, 1994, ONCOGENE, V9, P3757; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BOHME B, 1993, ONCOGENE, V8, P2857; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FLETCHER FA, 1994, ONCOGENE, V9, P3241; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMPS MP, 1988, ONCOGENE, V2, P305; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEWTIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP PD, 1967, DAUDIN; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	48	29	32	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1111	1117						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700636				2022-12-28	WOS:A1995QN35300011
J	KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; OSADA, H; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			FREQUENT LOSS OF IMPRINTING OF THE H19 GENE IS OFTEN ASSOCIATED WITH ITS OVEREXPRESSION IN HUMAN LUNG CANCERS	ONCOGENE			English	Article						GENOMIC IMPRINTING; H19; IGF2; SNRPN; LUNG CANCER	SPORADIC WILMS-TUMOR; GROWTH FACTOR-II; DNA METHYLATION; EXPRESSION; RELAXATION; H19-GENE; ALLELES; RNA	Accumulating evidence suggests that deregulation of the insulin-like growth factor II (IGF2) and H19 genes at 11p15, due to loss of imprinting (LOI), plays a role in the oncogenesis of Wilms' tumors, We previously reported LOI of IGF2 in carcinomas of the lung, a common cancer of adults, We show here that LOI of H19 is also a frequent event in lung cancer development, and correlated with hypomethylation of the promoter region, Furthermore, the present study also revealed that overexpression of H19 is often associated with LOI of H19 in lung cancers retaining both parental alleles, showing a contrast to LOI in Wilms' tumors, Interestingly, in contrast to frequent LOI of the imprinted genes at 11p15, LOI was not observed for the remaining gene known to be imprinted in man, SNRPN at 15q12.	AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTOLOMEI MS, 1994, NAT GENET, V6, P220, DOI 10.1038/ng0394-220; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; JONES PA, 1986, CANCER RES, V46, P461; KONDO M, 1994, ONCOGENE, V9, P3063; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OWEN RD, 1993, CELL GROWTH DIFFER, V4, P1013; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TYCKO B, 1994, AM J PATHOL, V144, P431; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	32	207	211	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1193	1198						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700644				2022-12-28	WOS:A1995QN35300021
J	LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A				LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A			CDKN2 (MTS1) TUMOR-SUPPRESSOR GENE-MUTATIONS IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article						P16; TUMOR SUPPRESSOR; MELANOMA; LOH; MUTATION	ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYPOSIS-COLI GENE; P53 GENE; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; COLORECTAL CARCINOMAS; INTERFERON GENES; CRITICAL REGION; CHROMOSOME-9	Tumor suppressor gene CDKN2 (also called MTS1, CDK4I and p16(INK4)) is located in 9p21 and deleted homozygously in a high percentage of tumor cell lines. We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2. Overall, 18% (27/154) of the cell lines carried mutations in CDKN2. These mutations were found in cell lines derived from melanoma, bladder, lung and prostate cancers, as well as sarcomas of various origin. The spectrum of the CDKN2 mutations found in melanoma cell lines indicated a major role for ultraviolet light in generating the mutations, suggesting the mutations occurred in vivo. The frequency of loss of heterozygosity in 9p21 in this set of lines is only slightly higher than the background rate of aneuploidy, suggesting that a second 9p21 tumor suppressor gene, if it exists, must lie near CDKN2.	MYRIAD DIAGNOST SERV INC,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; LEIDEN UNIV,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT DERMATOL,2333 AA LEIDEN,NETHERLANDS; CROSS CANC INST,DEPT RADIAT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	Utah System of Higher Education; University of Utah; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); University of Alberta	LIU, Q (corresponding author), MYRIAD GENET INC,421 WAKARA WAY,SALT LAKE CITY,UT 84108, USA.			Gruis, Nelleke/0000-0002-5210-9150	NCI NIH HHS [CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1993, CANCER RES, V53, P4761; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P680; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUIS NA, 1994, IN PRESS J PATHOLOGY; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERLO A, 1994, CANCER RES, V54, P640; MIDDLETON PG, 1991, LEUKEMIA, V5, P680; MORI T, 1994, CANCER RES, V54, P3396; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563	43	132	139	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700630				2022-12-28	WOS:A1995QN35300005
J	ALEXANDER, WS; DUNN, AR				ALEXANDER, WS; DUNN, AR			STRUCTURE AND TRANSCRIPTION OF THE GENOMIC LOCUS ENCODING MURINE C-MPL, A RECEPTOR FOR THROMBOPOIETIN	ONCOGENE			English	Note						C-MPL; THROMBOPOIETIN; HEMATOPOIETIN RECEPTOR; ALTERNATIVE SPLICING; GENE STRUCTURE	GROWTH-HORMONE RECEPTOR; MOLECULAR-CLONING; SUPERFAMILY; EXPRESSION; MEMBER; BINDING; FAMILY; PROTOONCOGENE; INITIATOR; ONCOGENE	We have cloned and characterised the murine gene encoding c-Mpl, a receptor for thrombopoietin and member of the hematopoietin receptor superfamily. The gene encompasses 15 kb of the mouse genome and the organisation of its 12 exons conforms closely to the pattern observed for the genes of other hematopoietin receptor family members. A site for initiation of c-mpl transcription was identified 13 nucleotides upstream of the proposed translation initiation codon. The murine mpl promoter sequence lacks conventional TATA and CAAT motifs although the transcription initiation site shares homology with the initiator sequence that specifies transcription initiation in the terminal deoxynucleotidyl transferase gene. The promoter contains consensus binding sequences for several transcriptional regulators including Ets and GATA factors, which have been implicated in control of transcription in megakaryocytes, a cell type that expresses mpl. The generation of multiple transcripts is a feature of the mpl locus. Two distinct mpl transcripts differing by an in-frame insertion of 24 nucleotides were detected in mouse spleen cells. Genomic sequence analysis identified differential splicing of alternative exon 4 sequences as the likely basis for these transcripts, which are predicted to encode receptors which differ within the first Mpl hematopoietin receptor domain.			ALEXANDER, WS (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GORDON MS, 1992, BLOOD, V80, P302; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ORKIN SH, 1992, BLOOD, V80, P575; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	32	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862460				2022-12-28	WOS:A1995QH61200023
J	KOTANI, S; ENDO, T; KITAGAWA, M; HIGASHI, H; ONAYA, T				KOTANI, S; ENDO, T; KITAGAWA, M; HIGASHI, H; ONAYA, T			A VARIANT FORM OF CYCLIN-DEPENDENT KINASE-2 (CDK2) IN A MALIGNANTLY TRANSFORMED RAT-THYROID (FRTL-TC) CELL-LINE	ONCOGENE			English	Article						CDK2-BETA, FRTL-TC; CELL CYCLE; CYCLINS	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE; MAMMALIAN-CELLS; S-PHASE; EPITHELIAL-CELLS; G1 PHASE; CDC2; YEAST; PHOSPHORYLATION; ACID	Cyclin-dependent kinase 2 (Cdk2) controls the transition from the G1 to the S phase in the mammalian cell cycle. We found by immunoblotting that anti-Cdk2 antibodies recognize three Cdk2 proteins (of 33, 34 and 39 kDa) in FRTL-5 and FRTL-Tc cells (malignantly transformed FRTL cells). Although 33 kDa protein is a phosphorylated form of 34 kDa protein previously reported, the nature of 39 kDa protein is unknown. In order to determine the nature of this protein, we screened a FRTL-5 cDNA library. Two cDNA clones of the rat homologue (rat Cdk2-alpha and -beta) of human Cdk2 were isolated. The open reading frame of rat Cdk2-alpha cDNA encoded a protein with 428 amino acids and has a high degree of conservation with human Cdk2. The calculated molecular weight of Cdk2-alpha protein is 33892 Da. The rat Cdk2-beta cDNA was identical to Cdk2-alpha cDNA except that it had extra 144 bp; this coincided with insertion of 48 amino acids into Cdk2-alpha protein between Met 196 and Val 197. The calculated molecular weight of Cdk2-beta protein is 39087 Da. Northern blot analysis indicated that the sizes of rat Cdk2-alpha and -beta mRNAs are approximately 2.5 kb and 3.0 kb, respectively. Partial proteolytic mapping showed that Cdk2-beta gene product is 39 kDa Cdk2 in the immunoblotting. We also found that Cdk2-beta protein binds to cyclin A and suc1 proteins. During G1-S phase in FRTL-Tc cells, Cdk2-alpha protein level is constant, but is gradually phosphorylated. In contrast, the level of Cdk2-beta protein increases through the S phase and decreases at the early G2 phase. These results suggest that a variant form of Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells.	UNIV YAMANASHI, SCH MED, DEPT INTERNAL MED 3, YAMANASHI 40938, JAPAN; BANYU PHARMACEUT CO LTD, TSUKUBA RES INST, TSUKUBA 30033, IBARAKI, JAPAN	University of Yamanashi; Merck & Company; Novartis			Higashi, Hideaki/F-6872-2012					AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BANKS L, 1990, ONCOGENE, V5, P833; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENDO T, 1990, ENDOCRINOLOGY, V126, P1492; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANTIBODIES LABORATOR; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IKEDA M, 1991, ENDOCRINOLOGY, V128, P2540, DOI 10.1210/endo-128-5-2540; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; OHTA K, 1994, J MOL ENDOCRINOL, V12, P85, DOI 10.1677/jme.0.0120085; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; TAMURA K, 1993, ONCOGENE, V8, P2113; TSAI LH, 1993, ONCOGENE, V8, P1593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					663	669						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862443				2022-12-28	WOS:A1995QH61200005
J	JOOSS, KU; MULLER, R				JOOSS, KU; MULLER, R			DEREGULATION OF GENES ENCODING MICROFILAMENT-ASSOCIATED PROTEINS DURING FOS-INDUCED MORPHOLOGICAL TRANSFORMATION	ONCOGENE			English	Note						FOS; MORPHOLOGICAL TRANSFORMATION; CYTOSKELETON; TROPOMYOSINS; EZRIN; GENE EXPRESSION	GROWTH-FACTORS; JUN; CELLS; SUPPRESSION; EXPRESSION; INDUCTION; ONCOGENE; VIRUS; AP-1; CDNA	The mechanism of Fos-induced transformation is still poorly understood. In the present study, we have asked whether genes whose products play a role in determining cell morphology might become deregulated in the course of Fos-induced transformation. A clear up-regulation in Fos-transformed rat fibroblasts was seen with ezrin, as well as tropomyosin (TM) -3 and -5B, while TM-1 was down-regulated. Significantly, the same genes were deregulated in a very similar, but hormone-inducible may in cells expressing a Fos-estrogen receptor fusion protein. In agreement with these results, Fos-expressing cells showed decreased levels of two TM isoforms of 36 and 38 kDa, and showed an impaired TM network. The significance of these observations is strengthened by the fact that the deregulation of TM expression has been shown to contribute to morphological transformation in other experimental systems. Deregulation of the TM and ezrin genes precedes the induction of morphological transformation suggesting that this deregulation is not merely a consequence of transformation. On the other hand, deregulation follows the induction of direct Fos target genes. We therefore propose that a cascade of regulatory events is triggered by Fos oncoproteins which eventually leads to the deregulation of genes encoding cytoskeleton-associated proteins.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ALGRAIN M, 1993, CURR BIOL, V3, P451, DOI 10.1016/0960-9822(93)90354-Q; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BRASELMANN S, 1992, J CELL SCI, P97; BURGER C, 1994, J CELL SCI, V107, P241; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JOOSS KU, 1994, EMBO J, V13, P1467, DOI 10.1002/j.1460-2075.1994.tb06401.x; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NEUBERG M, 1991, ONCOGENE, V6, P1325; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SEWING A, 1993, J CELL SCI, V104, P545; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x	29	46	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					603	608						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845686				2022-12-28	WOS:A1995QF64800022
J	ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP				ROMANO, A; WONG, WT; SANTORO, M; WIRTH, PJ; THORGEIRSSON, SS; DIFIORE, PP			THE HIGH TRANSFORMING POTENCY OF ERBB-2 AND RET IS ASSOCIATED WITH PHOSPHORYLATION OF PAXILLIN AND A 23 KDA PROTEIN	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; DNA-BINDING PROTEINS; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; EGF RECEPTOR; INTERFERON-GAMMA; ADAPTER PROTEIN; RAS	Two-dimensional gel maps of proteins phosphorylated by the epidermal growth factor receptor (EGFR) and erbB-2 kinases were obtained, to investigate the molecular basis of the different biological properties of these two molecules. Several proteins were phosphorylated by EGFR or erbB-2 with different stoichiometry. Differences were either quantitative or qualitative. In NIH3T3 cells, erbB-2 is 100-fold more transforming than EGFR. In the same cell line several proteins were preferentially phosphorylated by erbB-2, as compared to EGFR. To identify which of these substrates might be directly involved in mitogenic signaling, we obtained two-dimensional maps of proteins phosphorylated on tyrosine by EGFR/ret and an EGFR/erbB-2(TK) chimeric receptors. Both these chimerae behaved indistinguishably from erbB-2 in a number of bioassays and potently transformed NIH3T3 cells. Paxillin and a 23 kDa substrate were invariably phosphorylated to higher stoichiometry whenever potent mitogenic and transforming signals were activated. We propose that paxillin and the 23 kDa substrate are important elements in the erbB-2 and ret-activated mitogenic and transforming signaling.	NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80125 NAPLES,ITALY; FAC MED & CHIRURG NAPLES,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC L CAL,NAPLES,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita degli Studi di Bari Aldo Moro			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MONTMINY M, 1993, SCIENCE, V261, P1694, DOI 10.1126/science.8397444; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SORKIN A, 1993, ONCOGENE, V8, P3021; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WIRTH PJ, 1991, ELECTROPHORESIS, V12, P931, DOI 10.1002/elps.1150121112	50	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2923	2933						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916147				2022-12-28	WOS:A1994PG82200018
J	DOUGALL, WC; QIAN, XL; PETERSON, NC; MILLER, MJ; SAMANTA, A; GREENE, MI				DOUGALL, WC; QIAN, XL; PETERSON, NC; MILLER, MJ; SAMANTA, A; GREENE, MI			THE NEU-ONCOGENE - SIGNAL-TRANSDUCTION PATHWAYS, TRANSFORMATION MECHANISMS AND EVOLVING THERAPIES	ONCOGENE			English	Review							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; BREAST-CARCINOMA CELLS; FACTOR RECEPTOR MUTANTS; PHOSPHOLIPASE-C-GAMMA; TUMOR EFFECTS INVIVO; NIH 3T3 CELLS; EGF-RECEPTOR; MONOCLONAL-ANTIBODIES; POINT MUTATION		UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania	DOUGALL, WC (corresponding author), UNIV PENN,SCH MED,CTR RECEPTOR BIOL,DIV IMMUNOL,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AASLAND R, 1988, BRIT J CANCER, V57, P358, DOI 10.1038/bjc.1988.82; AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALPER O, 1990, CELL GROWTH DIFFER, V1, P591; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BIRCHMEIER C, 1993, BIOESSAYS, V15, P185, DOI 10.1002/bies.950150307; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; BROWN VI, 1991, DNA CELL BIOL, V10, P399, DOI 10.1089/dna.1991.10.399; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CAO HN, 1991, ONCOGENE, V6, P705; CAO HN, 1992, J BIOL CHEM, V267, P20489; CHAZIN VR, 1992, ONCOGENE, V7, P1859; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; COHEN JA, 1989, ONCOGENE, V4, P81; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; DREBIN JA, 1982, B T CELL TUMORS, P221; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FLANAGAN JG, 1988, P NATL ACAD SCI USA, V85, P8057, DOI 10.1073/pnas.85.21.8057; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1992, J BIOL CHEM, V267, P13851; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HOPKINS N, 1981, P NATL ACAD SCI-BIOL, V78, P7555, DOI 10.1073/pnas.78.12.7555; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KASPRZYK PG, 1992, CANCER RES, V52, P2771; KATZEN AL, 1991, DEV BIOL, V145, P287, DOI 10.1016/0012-1606(91)90127-O; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KOSKINEN P, 1990, ONCOGENE, V5, P615; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANGTON BC, 1991, CANCER RES, V51, P2593; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHTOLA L, 1991, J CELL BIOCHEM, V45, P69, DOI 10.1002/jcb.240450114; LEITZEL K, 1992, J CLIN ONCOL, V10, P1436, DOI 10.1200/JCO.1992.10.9.1436; LEVEA CM, 1993, RECEPTOR, V3, P293; LIN YZJ, 1991, ONCOGENE, V6, P639; LIN YZJ, 1992, J CELL BIOCHEM, V49, P290, DOI 10.1002/jcb.240490312; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LONARDO F, 1990, New Biologist, V2, P992; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MAIER LA, 1991, CANCER RES, V51, P5361; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORI S, 1990, JPN J CANCER RES, V81, P489, DOI 10.1111/j.1349-7006.1990.tb02596.x; MORI S, 1987, VIRCHOWS ARCH B, V54, P8, DOI 10.1007/BF02899192; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MYERS JN, 1992, RECEPTOR, V2, P1; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRESS MF, 1990, ONCOGENE, V5, P953; PUPA SM, 1993, ONCOGENE, V8, P2917; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P1; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SEGATTO O, 1992, ONCOGENE, V7, P1339; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WADA T, 1989, ONCOGENE, V4, P489; WANG DP, 1993, CANCER, V72, P2628, DOI 10.1002/1097-0142(19931101)72:9<2628::AID-CNCR2820720918>3.0.CO;2-R; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1994, J CELL BIOCHEM, V18, P221; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	163	223	241	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2109	2123						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913542				2022-12-28	WOS:A1994NX62900001
J	VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K				VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K			DETERMINATION OF SEQUENCES RESPONSIBLE FOR THE DIFFERENTIAL REGULATION OF MYC FUNCTION BY DELTA-MAX AND MAX	ONCOGENE			English	Article						MYC; MAX; DELTA-MAX; TRANSFORMATION; TRANSACTIVATION	MAMMALIAN EXPRESSION VECTOR; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; PROTEIN; FORMS; COTRANSFORMATION; DIMERIZATION; DOMAINS; COMPLEX	The DNA-binding, transcriptional activation and transforming activities of the Myc protein require dimerization with Max. Max can form also homodimers which are able to bind the same DNA sequence as Myc/Max heterodimers and suppress Myc-induced transcription and transformation. We have recently identified naturally occurring truncated form of Max, Delta Max, which in a rat embryo fibroblast enhances transformation by Myc and Ras, Like Max, this Delta Max protein contains a b-HLH-Zip domain, except that the end of the leucine zipper is replaced by five Delta Max-specific amino acid residues. Delta Max also lacks the C-terminal sequences of Max including a nuclear localisation signal. Here we have dissected the regions responsible for the specific effects of Max and Delta Max in Ras-Myc cotransformation of rat embryo fibroblasts, Our results indicate that the suppressive activity of Max requires C-terminal acidic and basic regions and an intact leucine zipper. Replacement of the end of the leucine zipper with the Delta Max-specific sequence is responsible for the enhancement of transformation by Delta Max. Surprisingly, Delta Max does not require the DNA-binding basic region for enhancement of transformation and has no effect on Myc-induced transcription activation from Myc/Max-binding site-containing promoter construct.	UNIV HELSINKI,HAARTMAN INST,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND	University of Helsinki			makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009; Alitalo, Kari K/J-5013-2014; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Vastrik, Imre/0000-0001-6658-9311				ALITALO K, 1992, GENE AMPLIFICATION M, P371; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATAGIRI F, 1992, MOL CELL BIOL, V12, P809; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Sambrook J, 1989, MOL CLONING LABORATO; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; VASTRIK I, 1993, ONCOGENE, V8, P503; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	32	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					553	560						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630640				2022-12-28	WOS:A1995RN53000016
J	XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA				XIAO, S; LI, DZ; VIJG, J; SUGARBAKER, DJ; CORSON, JM; FLETCHER, JA			CODELETION OF P15 AND P16 IN PRIMARY MALIGNANT MESOTHELIOMA	ONCOGENE			English	Article						MESOTHELIOMA; IN SITU HYBRIDIZATION; CYCLINS; CYCLIN-DEPENDENT KINASES	DELETIONS; 9P	The p15 and p16 CDK4 inhibitor genes map within the chromosome band 9p21 region deleted frequently in malignant mesothelioma and other cancers, p16 has been implicated recently as a potential target of 9p21 deletions in mesothelioma, but the role of this gene is uncertain because deletions have been detected more often in established cell lines than in primary tumor specimens. We determined p15 and p16 copy number by fluorescence in situ hybridization with a P1 contig in 50 primary mesotheliomas. Codeletion of p15 and p16 was found in 72% of mesotheliomas, including all cases with spindle-cell components (n = 21) and total deletion of p15 and p16 was found in several mesotheliomas that lacked cytogenetic deletion of the chromosome 9 short arm. Point mutations were not found, however, in exon 2 of retained p15 and p16 alleles from seven mesotheliomas. These findings demonstrate that p15, p16 and/or a closely neighboring gene, are the targets of frequent chromosome 9p deletion in primary malignant mesothelioma.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DIV GERONTOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NCI NIH HHS [1K11CA01498-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CARINS P, 1994, SCIENCE, V265, P415; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; FUSCO V, 1993, ANTICANCER RES, V13, P683; GRANADOS R, 1994, ACTA CYTOL, V38, P711; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OELS HC, 1971, CHEST, V60, P564, DOI 10.1378/chest.60.6.564; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; POPESCU NC, 1988, CANCER RES, V48, P142; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAGUCHI T, 1993, CANCER RES, V53, P4349; WALKER DG, 1995, CANCER RES, V55, P20; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	27	146	148	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					511	515						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630635				2022-12-28	WOS:A1995RN53000011
J	LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D				LIU, L; LASSAM, NJ; SLINGERLAND, JM; BAILEY, D; COLE, D; JENKINS, R; HOGG, D			GERMLINE P16(INK4A) MUTATION AND PROTEIN DYSFUNCTION IN A FAMILY WITH INHERITED MELANOMA	ONCOGENE			English	Article						CDK INHIBITORS; P16(INK4A); MELANOMA	WILD-TYPE P53; GROWTH; SUPPRESSION; GENE; ONCOGENE; LOCUS; CELLS; MLM	The gene encoding the cell cycle inhibitor p16(INK4A) (also known as p16, MTS1, CDKN2 and INK4) has been mapped to human chromosome band 9p21, a region that also contains a putative melanoma susceptibility gene. Although germline mutations in the coding region of the p16(INK4A) gene have been detected in some families with inherited melanoma, many other families show no evidence of such mutations and hence the role of p16(INK4A) in the development of this tumor is still unclear. In this report, we describe a family with inherited melanoma in which a novel mutation in exon 2 of the p16(INK4A) gene segregates with the disease. The mutant gene encodes a protein with an in-frame deletion of two amino acids (Asp96 and Leu97). We show that the mutant protein is functionally abnormal: it is unable to bind cdk4 in vitro and does not inhibit colony formation in tertiary passage rat embryo fibroblasts. Moreover, in a metastatic lesion from one patient the wild type p16(INK4A) allele was deleted and the mutant allele retained. We conclude that family members carrying this germline mutation in the p16(INK4A) gene are predisposed to melanoma. By extension, these findings implicate the p16(INK4A) gene in the development of some cases of familial melanoma.	TORONTO GEN HOSP,DIV ONCOL RES,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT PATHOL,TORONTO,ON M5G 2C4,CANADA; TORONTO GEN HOSP,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL,TORONTO,ON M4N 3M5,CANADA; TORONTO SUNNYBROOK REG CANC CTR,DIV CANC BIOL RES,TORONTO,ON M4N 3M5,CANADA; MAYO CLIN & MAYO FDN,DIV LAB GENET,ROCHESTER,MN 55905	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Mayo Clinic								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTUTTA D, 1994, LANCET, V344, P1607, DOI 10.1016/S0140-6736(94)90408-1; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P6041; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COLEMAN A, 1994, CANCER RES, V54, P344; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUIS NA, 1995, IN PRESS AM J PATH, V146; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KAUFMAN DK, 1993, NEUROLOGY, V43, P1728, DOI 10.1212/WNL.43.9.1728; LIU L, 1995, IN PRESS ONCOGENE; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MYERSON M, 1994, MOL CELL BIOL, V14, P2077; NANCARROW DJ, 1992, GENOMICS, V12, P18, DOI 10.1016/0888-7543(92)90401-D; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTA M, 1994, CANCER RES, V54, P5269; PENG HQ, 1993, CANCER RES, V53, P3574; ROVINSKI B, 1988, ONCOGENE, V2, P445; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V265, P183; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WALKER GJ, 1994, ONCOGENE, V9, P819; XU L, 1994, CANCER RES, V54, P5262	42	97	99	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					405	412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624155				2022-12-28	WOS:A1995RK95700022
J	FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC				FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC			EFFECTS OF P53 MUTANTS ON WILD-TYPE P53-MEDIATED TRANSACTIVATION ARE CELL-TYPE DEPENDENT	ONCOGENE			English	Article						P53; P53 MUTANTS; TRANSACTIVATION; CELL TYPE SPECIFICITY	TRANSCRIPTIONAL ACTIVITY; GENE AMPLIFICATION; PROTEIN COMPLEXES; RAS MUTATIONS; CYCLE CONTROL; BINDING-SITE; DNA-DAMAGE; LINES; CANCER; EXPRESSION	The spectrum of p53 mutations differs among human cancer types. We have hypothesized that the p53 mutational spectrum observed in particular tumor types reflects the functional ability of different p53 mutants to modulate wild-type (WT) p53-dependent gene transcription. Missense p53 mutants representing several mutational hotspot codons were cotransfected with WT p53 and analysed for their effects on p53-dependent transactivation of a reporter construct containing a specific p53 binding sequence (PG(13)-CAT) in human tumor cell lines lacking endogenous p53. Our results show that the ability of p53 mutants to inhibit WT p53-mediated transactivation is cell type dependent. In cell lines derived from a lung adenocarcinoma and mesothelioma, the transactivation function of WT p53 was strongly inhibited by all p53 mutants examined. However, in cell lines derived from a prostate carcinoma and an osteosarcoma, the mutants examined generally had only minimal dominant negative effects. In cell lines derived from a hepatocellular carcinoma and an ovarian carcinoma, two mutants (248(trp) and 273(his)) enhanced WT p53 mediated-transactivation of the reporter construct. Additional mutants retained the ability to inhibit WT p53-mediated transactivation in these cell lines. In addition, in a series of four breast tumor cell lines, the p53 mutants examined had similar effects on WT p53 transactivation ability including enhanced transactivation activity in the 273(his) cotransfectants. The p53 mutants were incapable of transactivating the PG(13)-CAT reporter in the absence of WT p53 expression. Therefore, the dominant negative effects of p53 mutants on WT p53 function may vary depending on the particular cell type. In addition, mutants with stronger inhibitory capabilities may confer a selective advantage during the tumorigenic process.	NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; TUFTS UNIV NEW ENGLAND MED CTR,DEPT RADIOL ONCOL & BIOCHEM,BOSTON,MA 02111	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts Medical Center			Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1990, CANCER RES, V50, P7351; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V55, P4855; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; METCALF RA, 1992, CANCER RES, V52, P2610; MILLER CW, 1993, ONCOGENE, V8, P1815; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PONCHEL F, 1994, CANCER RES, V54, P2064; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIBBETTS LM, 1984, P AM ASSOC CANC RES, V25, P45; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1993, CANCER RES, V53, P4772	69	105	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2103	2111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784055				2022-12-28	WOS:A1995RB70300005
J	HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR				HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR			EFFECTS OF HETEROZYGOSITY FOR THE RB-1(T19NEO) ALLELE IN THE MOUSE	ONCOGENE			English	Article						RB-1; TRANSGENIC; MOUSE; PITUITARY; TUMORIGENESIS; NESIDIOBLASTOSIS	RETINOBLASTOMA GENE-PRODUCT; HUMAN-BREAST-CARCINOMA; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; PROTEIN; PHOSPHORYLATION; MUTATION; BINDING	We describe the pathology of a cohort of 80 mice heterozygous for an inactive allele of the Rb-1 tumour suppressor gene. The majority of these mice developed locally invasive tumours, arising from the pituitary gland. The time of onset of overt signs of disease in mice known to have inherited their mutant allele paternally shows a small but statistically significant shift to the lower end of the spectrum, suggesting that tumorigenesis is influenced by gametic imprinting. In situ hybridisation analysis demonstrates the presence in the tumours of proopiomelanocortin mRNA, which is normally found both in corticotroph and melanotroph cells. Mice within this cohort also develop systemic defects. Most notably, there is increased siderosis in the spleen indicating the possibility of an abnormality in red blood cell turnover, This is consistent with the abnormalities of erythropoiesis described previously in homozygous R6-1-deficient mice. In addition, a proportion of mice developed liver steatosis, probably representing the end organ effects of hormonal imbalance as a direct consequence of tumour presence. A significant proportion showed C cell hyperplasia in the thyroid. The spectrum of pathology in mice differs from that in the human but does provide a useful model of site-specific tumour predisposition.			HARRISON, DJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Armstrong, Jane/0000-0002-0524-0260				BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOWMAKER JK, 1991, VISION VISUAL DYSFUN, V2, P63; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANEE WK, 1983, NATURE, V305, P779; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V362, P849; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARQUHARSON MA, 1992, J CLIN PATHOL, V45, P999, DOI 10.1136/jcp.45.11.999; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOOPER ML, 1995, IN PRESS J CELL SC S, V18; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JACKS T, 1992, NATURE, V359, P285; KATO J, 1993, GENE DEV, V7, P331; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAINS RE, 1979, J BIOL CHEM, V254, P7885; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER RG, 1981, SURVIVAL ANAL, pCH4; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PURDIE CA, 1994, ONCOGENE, V9, P603; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; ROBERTS JL, 1980, BIOCHEM, V17, P3609; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1993, ONCOGENE, V8, P279; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	44	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1615	1620						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731716				2022-12-28	WOS:A1995QU68100018
J	ANDO, K; GRIFFIN, JD				ANDO, K; GRIFFIN, JD			CDK4 INTEGRATES GROWTH-STIMULATORY AND INHIBITORY SIGNALS DURING G1 PHASE OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						HEMATOPOIESIS; CYCLINS; CELL CYCLE, INTERLEUKIN-3; CDK4; TGF-BETA-1; RETINOBLASTOMA	RETINOBLASTOMA-SUSCEPTIBILITY GENE; D-TYPE CYCLINS; TGF-BETA; PROTEIN-KINASES; PRODUCT; EXPRESSION; PROGRESSION; SUBUNIT; ENTRY	Proliferation of hematopoietic cells is controlled by both growth stimulatory and inhibitory cytokines acting primarily in G1, but the mechanism which integrate these disparate signals are unknown. In a myeloid cell line dependent on interleukin-3 (IL-3) for proliferation, expression of the cyclin dependent kinase Cdk4 and D-type cyclin partners, D2 and D3, in mid G1 was found to be directly related to the concentration of IL-3. TGF beta 1, which induces cell cycle arrest in mid-G1, blocked IL-3-induced expression of Cdk4, but had no effect on expression of cyclins D2 or D3. Sublines made to constitutively express Cdk4, but not lines constitutively expressing cyclins D2 or D3, were hyper responsive to IL-3 and resistant to TGF beta 1. Using an in vitro kinase assay with recombinant retinoblastoma protein (Rb) as a substrate, cyclin D2-associated kinase activity was shown to be induced in G1 by IL-3 and inhibited by TGF beta 1. Constitutive expression of Cdk4, but not cyclin D2 or D3, increased cyclin D2-associated Rb kinase activity and this activity could no longer be inhibited by TGF beta 1. Also, in vivo phosphorylation of Rb was inhibited by TGF beta 1 in wild type but not in Cdk4 lines. Cdk2 kinase activity was also decreased by TGF beta 1, and restored by overexpression of Cdk4. These results implicate Cdk4 activity as a mid G1 checkpoint sensitive to both growth stimulatory and inhibitory cytokines.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATUSHIME H, 1991, CELL, V65, P701; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	31	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					751	755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862452				2022-12-28	WOS:A1995QH61200015
J	KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP				KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP			LIGANDS FOR THE RECEPTOR TYROSINE KINASES HEK AND ELK - ISOLATION OF CDNAS ENCODING A FAMILY OF PROTEINS	ONCOGENE			English	Article						LIGANDS; ELK; HEK; RECEPTOR TYROSINE KINASES	TUMOR-NECROSIS-FACTOR; PROTO-ONCOGENE; IL-1 RECEPTOR; GENE; EXPRESSION; SEQUENCE; CLONING; CELLS; IDENTIFICATION; STIMULATION	Hek is a member of the eph subfamily of receptor tyrosine kinases whose members include elk, hek2, sek, eph and eck among others. Using a soluble form of hek consisting of the extracellular region of the receptor fused to the Fc domain of human IgG1 and an expression cloning strategy, we have isolated two different but related cDNAs from the human T-lymphoma line HSB-2 that encode ligands for hek. The cDNAs encode proteins of 238 and 201 amino acids (44% amino acid identity) that are anchored to the membrane by glycosyl-phosphatidylinositol (GPI)-linkage. The proteins encoded by these cDNAs are bound by hek with affinity constants of 2 x 10(8) m(-1). These proteins also bind the elk tyrosine kinase receptor. These cDNAs are related to other cDNAs that we have recently isolated from a human placental library that encode ligands for both hek and elk and define an emerging family of ligands for eph-related kinases (LERKs).	IMMUNEX RES & DEV CORP,DEPT GENE EXPRESS,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC GENET,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC IMMUNOL,SEATTLE,WA 98101									ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCGREW JT, 1991, CELL IMMUNOL, V137, P118, DOI 10.1016/0008-8749(91)90062-G; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILLIAMS D E, 1991, Progress in Growth Factor Research, V3, P235, DOI 10.1016/0955-2235(91)90002-L; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	82	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838529				2022-12-28	WOS:A1995QC62400009
J	SHAO, ZH; ROBBINS, PD				SHAO, ZH; ROBBINS, PD			DIFFERENTIAL REGULATION OF E2F AND SP1-MEDIATED TRANSCRIPTION BY G1 CYCLINS	ONCOGENE			English	Article						RETINOBLASTOMA PROTEIN; CYCLINS; SP1; E2F	RETINOBLASTOMA GENE-PRODUCT; PROTEIN-KINASE-C; HUMAN CELL-CYCLE; RB PROTEIN; BINDING-ACTIVITY; RNA-POLYMERASE; CDC2 KINASE; PHOSPHORYLATION; EXPRESSION; PHASE	Cyclins have been demonstrated to mediate phosphorylation of the retinoblastoma tumor suppressor gene product (Rb) and/or to bind directly to Rb. Since Rb is a regulator of E2F and Sp1-mediated transcription, we have examined the effect of overexpression of cyclins on transcription mediated by E2F-dependent adenovirus E2 promoter and by Sp1 in a cotransfection assay in 3T3 cells. All the G1 cyclins tested, C, D1, D2, D3 and E, as well as cyclin A were able to stimulate E2 promoter activity to various levels with D3 showing the strongest stimulation. For stimulation of the E2 promoter by cyclins A, E and D-type cyclins was dependent upon the presence of functional E2F and ATF binding sites. Cyclin C, however, was able to stimulate both E2F and ATF-dependent transcription to the same level as the wild type E2 promoter. In addition, cyclin C was able to stimulate transcription mediated by Sp1, GAL4-Sp1 and GAL4-VP16, suggesting that cyclin C affects a general pathway of transcriptional activation. In contrast, cyclin D1 was able to repress specifically Sp1-mediated transcription through an Rb-independent pathway, These results suggest that cyclins can regulate transcription mediated by specific transcription factors in both positive and negative manners. Furthermore, the results demonstrate clear functional differences between the G1 cyclins, in particular, functional differences between the related D-type cyclins.	UNIV PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA55227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, ONCOGENE, V6, P2179; ADNANE S, 1995, IN PRESS ONCOGENE; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO J, 1993, GENE DEV, V7, P331; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; UDVADIA AJ, 1992, CELL GROWTH DIFFER, V3, P597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	50	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					221	228						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838522				2022-12-28	WOS:A1995QC62400001
J	ELDER, PA; BELL, SM; KNOWLES, MA				ELDER, PA; BELL, SM; KNOWLES, MA			DELETION OF 2 REGIONS ON CHROMOSOME-4 IN BLADDER-CARCINOMA - DEFINITION OF A CRITICAL 750-KB REGION AT 4P16.3	ONCOGENE			English	Article							HUNTINGTON DISEASE REGION; HEPATOCELLULAR-CARCINOMA; INDEFINITE DIVISION; GENETIC-ANALYSIS; HUMAN-CELLS; HETEROZYGOSITY; CANCER; ALLELOTYPE	Loss of heterozygosity (LOH) of chromosome 4 has been identified in several human tumours including carcinomas of colorectum, ovary, liver and head and neck. LOH at loci on chromosome 4p has previously been identified in 22% of primary bladder tumours. We have assessed LOH in 178 bladder tumours using a panel of six microsatellite markers. Thirty-four tumours (19%) showed LOH at one or more loci. Twenty-three deletions involved restricted regions of 4p and could be used to define two common regions of deletion. A very small common region between D4S43 and D4S127 (estimated to be similar to 750 kB) was involved in 14/23 (61%) of 4p deletions. A second common region centromeric to D4S174 was deleted in 7/23 (30%) of tumours with deletions. Two tumours (9%) had deletions involving both regions independently. Previous functional studies have demonstrated both a senescence function and a suppressor of tumorigenicity on human chromosome 4. Localisation of the common regions of deletion in bladder tumours provides a starting point for positional cloning of the gene(s) concerned and for more precise comparative functional studies.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657; Bell, Sandra/0000-0002-3022-9864				BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1991, ONCOGENE, V6, P2305; CAIRNS P, 1993, CANCER RES, V53, P1230; FUJIMOTO Y, 1994, CANCER RES, V54, P281; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; KIRKNESS EF, 1991, GENOMICS, V10, P985, DOI 10.1016/0888-7543(91)90189-L; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LOCKE PA, 1993, SOMAT CELL MOLEC GEN, V19, P95, DOI 10.1007/BF01233958; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OLUMI AF, 1990, CANCER RES, V50, P7081; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pershouse M. A., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P539; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SATO T, 1991, CANCER RES, V51, P5118; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WALKER GJ, 1991, CANCER RES, V51, P4367; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889; 1978, TNM CLASSIFICATION M, P113; 1973, WHO INT CLASSIFICATI, V10	24	42	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3433	3436						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970702				2022-12-28	WOS:A1994PT39200004
J	RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G				RIMESSI, P; GUALANDI, F; MORELLI, C; TRABANELLI, C; WU, Q; POSSATI, L; MONTESI, M; BARRETT, JC; BARBANTIBRODANO, G			TRANSFER OF HUMAN-CHROMOSOME-3 TO AN OVARIAN-CARCINOMA CELL-LINE IDENTIFIES 3 REGIONS ON 3P INVOLVED IN OVARIAN-CANCER	ONCOGENE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; YEAST ARTIFICIAL CHROMOSOME; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; LUNG-CANCER; SHORT ARM; BREAST-CANCER; GROWTH-FACTOR; LOW-GRADE; HETEROZYGOSITY	The molecular pathogenesis of ovarian carcinoma involves altered expression of growth factors, activation of oncogenes and loss of tumor suppressor genes. Loss of heterozygosity on chromosomes 3p, 6q, 11p, 17 and 18q was reported as a significant alteration in ovarian cancer. However, no functional proof has been provided of tumor suppressor activity located in these chromosomal regions. We therefore introduced normal human chromosomes 3 and 11 into an ovarian carcinoma cell line by microcell mediated chromosome transfer. Transfer of chromosome 3 induced senescence acid growth arrest as well as suppression of tumorigenicity. Tumors induced by chromosome 3 monochromosomic hybrids consistently lost three small regions on 3p, two of which located in 3p23-24.2 and one located in 3p21.1-21.2, suggesting that these chromosomal regions are important for suppression of tumorigenicity of ovarian carcinoma cells. Transfer of chromosome 11 reduced the in vitro growth properties of ovarian cancer cells but did not significantly affect tumorigenicity. These results provide functional evidence for chromosome 3 tumor suppressor activity in ovarian cancer and define the chromosomal regions on 3p involved in the pathogenesis of this tumor. This experimental system, based on functional effects, may be useful for further delimitation and isolation of critical regions on 3p involved in tumor suppression.	UNIV FERRARA, SCH MED, INST MICROBIOL, I-44100 FERRARA, ITALY; UNIV FERRARA, SCH MED, INTERDEPT CTR BIOTECHNOL, I-44100 FERRARA, ITALY; UNIV ANCONA, INST BIOMED SCI, I-60131 ANCONA, ITALY; NIEHS, MOLEC CARCINOGENESIS LAB, RES TRIANGLE PK, NC 27709 USA	University of Ferrara; University of Ferrara; Marche Polytechnic University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Gualandi, Francesca/K-7513-2016	Gualandi, Francesca/0000-0001-9551-057X; Trabanelli, Cecilia/0000-0001-7107-0338				BARRETT JC, 1994, APOPTOSIS, V2, P253; BASSAM BJ, 1993, APPL BIOCHEM BIOTECH, V42, P181, DOI 10.1007/BF02788051; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BAST RC, 1992, J NATL CANCER I, V84, P556, DOI 10.1093/jnci/84.8.556; BERCHUCK A, 1991, AM J OBSTET GYNECOL, V164, P669, DOI 10.1016/S0002-9378(11)80044-X; BERCHUCK A, 1990, CANCER RES, V50, P4087; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUICK RN, 1985, CANCER RES, V45, P3668; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DODSON MK, 1993, CANCER RES, V53, P4456; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HIBI K, 1992, ONCOGENE, V7, P445; JACOBS IJ, 1993, CANCER RES, V53, P1218; JAKOBOVITS A, 1993, NATURE, V362, P255, DOI 10.1038/362255a0; JENKINS RB, 1993, CANCER GENET CYTOGEN, V71, P76, DOI 10.1016/0165-4608(93)90205-Z; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KIECHLESCHWARZ M, 1993, CANCER, V72, P2423, DOI 10.1002/1097-0142(19931015)72:8<2423::AID-CNCR2820720821>3.0.CO;2-P; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; KOHNO T, 1993, ONCOGENE, V8, P1825; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1991, CANCER GENET CYTOGEN, V53, P143, DOI 10.1016/0165-4608(91)90093-A; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROCHE J, 1994, HUM MOL GENET, V3, P215, DOI 10.1093/hmg/3.1.215; ROQUE L, 1993, GENE CHROMOSOME CANC, V8, P199, DOI 10.1002/gcc.2870080311; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMIZU M, 1990, ONCOGENE, V5, P185; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; STROMBERG K, 1992, CANCER RES, V52, P341; TANAKA K, 1992, CANCER GENET CYTOGEN, V61, P42, DOI 10.1016/0165-4608(92)90368-I; TAVASSOLI M, 1993, GENE CHROMOSOME CANC, V8, P195, DOI 10.1002/gcc.2870080310; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHENG JP, 1991, CANCER RES, V51, P4045	65	69	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3467	3474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970706				2022-12-28	WOS:A1994PT39200008
J	ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; SOUDANT, N; FERREIRA, E; DHORDAIN, P; DEWITTE, F; BEGUE, A; FLOURENS, A; STEHELIN, D; LEPRINCE, D			A MODEL FOR GENE EVOLUTION OF THE ETS-1 ETS-2 TRANSCRIPTION FACTORS BASED ON STRUCTURAL AND FUNCTIONAL HOMOLOGIES	ONCOGENE			English	Article							PU.1 REGULATES EXPRESSION; ETS PROTO-ONCOGENE; DNA-BINDING; ACTIVATION DOMAINS; V-ETS; C-ETS-1 LOCUS; PROTEINS; FAMILY; PROMOTER; CELLS	The chicken c-ets-l locus encodes two transcription factors, p54(c-ets-1) and p68(c-ets-1) that differ in their N-termini, encoded respectively by the I-54 and alpha beta exons. p68(c-ets-1) equivalents are only found in birds and reptiles while p54(c-ets-1) is widely conserved in vertebrates, from amphibians to mammals. Thus, the classical view concerning the evolution of the c-ets-1 gene has been to consider that I-54 is of ancient origin whereas alpha and beta, which provide an additional activating domain in p68(c-ets-1), would have been acquired much more recently. Sequencing the alpha and beta exons in various species pinpointed a highly conserved region of 13 amino acids which is rich in acidic and hydrophobic residues, a feature of some other transactivating domains. Strikingly, this subdomain is also present in the otherwise unrelated N-terminal activating region of p58(c-ets-2) and was thus named BEC for Ets-1-Beta/Ets-2-Conserved sequence. Moreover, the two N-termini share the BEC sequence at a homologous position in their highly similar genomic organization indicating a common origin. This structural homology underlies a functional similarity since fusion of the heterologous GAL4 DNA-binding domain with either of the two isolated domains demonstrates that BEC is essential in both cases for the transactivating activity. The function of the alpha beta domain in the context of p68(c-ets-1) also strictly depends on the presence of the BEC sequence. Finally, the whole N-terminus of p58(c-ets-2) can functionally substitute for its counterpart in p68(c-ets-1) further demonstrating that p68(c-ets-1) and p58(c-ets-2) are structurally and functionally more closely related than previously thought. Besides, we also found BEC in the N-terminus of the Drosophila pointed gene which may be considered as closely related to the uncommitted 'ets1/2' common ancestor. These data demonstrate that the alpha and beta exons are not a recent and specific acquisition but stem, like the p58(c-ets-2) N-terminus, from the invertebrate unduplicated 'ets 1/2' gene. This work unravels a new model for the ets-1/ets-2 gene's evolution, based for the first time on both structural and functional evidences. Accordingly, p68(c-ets-1) and p58(c-ets-2) are the direct descendants of the ancestral 'ets1/2' gene whereas I-54 may have been acquired as a second promoter in the c-ets-1 gene after the duplication. Indeed, I-54 is not found in the Drosophila pointed gene. The high degree of similarity, and hence of functional redundancy, between p68(c-ets-1) and p58(c-ets-2) may have led to the rapid divergence (and even loss in mammals) of alpha and beta during evolution whereas I-54, which provided a novel function unique to c-ets-1, was maintained within the presently widespread p54(c-ets-1) version.	INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Leprince, Dominique/0000-0002-1999-0775				ALBAGLI O, 1992, ONCOGENE, V7, P1435; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; Crepieux Pascale, 1993, Gene Expression, V3, P215; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JAWORSKI CJ, 1989, NATURE, V337, P752, DOI 10.1038/337752a0; JENNINGS CGB, 1992, DEV BIOL, V150, P121, DOI 10.1016/0012-1606(92)90012-6; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LI X, 1993, NATURE, V367, P83; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PAHL HL, 1993, J BIOL CHEM, V268, P5014; QUEVA C, 1993, ONCOGENE, V8, P2511; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAO VN, 1993, ONCOGENE, V8, P2167; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VENKATESH LK, 1993, J VIROL, V67, P3868, DOI 10.1128/JVI.67.7.3868-3876.1993; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	59	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3259	3271						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936650				2022-12-28	WOS:A1994PM65800019
J	STEINMAN, RA; HOFFMAN, B; IRO, A; GUILLOUF, C; LIEBERMANN, DA; ELHOUSEINI, ME				STEINMAN, RA; HOFFMAN, B; IRO, A; GUILLOUF, C; LIEBERMANN, DA; ELHOUSEINI, ME			INDUCTION OF P21 (WAF-1/CIP1) DURING DIFFERENTIATION	ONCOGENE			English	Article							LEUKEMIA-CELL LINE; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; C-MYC; TERMINAL DIFFERENTIATION; SODIUM-BUTYRATE; DOWN-REGULATION; HL-60 CELLS; P53 PROTEIN; EXPRESSION	The recently cloned protein, p21 (WAF1/CIP1) is a downstream effector of p53, and mediates growth arrest by inhibiting the action of G1 cyclin-dependent kinases. Since cellular differentiation is frequently characterized by G1 arrest, we examined whether p21 upregulation occurs in differentiation. We show that p21 expression is triggered by multiple differentiation-inducing agents in hematopoietic and hepatoma cells through a p53-independent pathway. The dramatic rise in p21 levels occurs as an immediate early response to differentiation inducers. The induction of p21 is coupled to the expression of early differentiation markers, and is uncoupled from apoptosis. Finally, evidence is presented that p21 expression is uncoupled from G1 arrest in the presence of deregulated c-myc.	UNIV PITTSBURGH,SCH MED,PITTSBURGH CANC INST,PITTSBURGH,PA 15213; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	STEINMAN, RA (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213, USA.			El-Houseini, Motawa/0000-0003-4873-8429	NATIONAL CANCER INSTITUTE [R01CA051162, R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [IRO1CA51162, IRO1CA43618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTOUN GR, 1991, LEUKEMIA RES, V15, P1029, DOI 10.1016/0145-2126(91)90108-6; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHANG KS, 1991, LEUKEMIA, V5, P205; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; FISCHKOFF SA, 1990, LEUKEMIA, V4, P302; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HARPER JW, 1993, CELL, V75, P805; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MEIER RW, 1991, BIOCHEM BIOPH RES CO, V176, P1345, DOI 10.1016/0006-291X(91)90434-9; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLLINEDO F, 1993, BIOCHEM J, V294, P137, DOI 10.1042/bj2940137; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NEVINS JR, 1992, SCIENCE, V258, P424; OBERG F, 1993, J IMMUNOL, V150, P3487; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SEN S, 1993, LEUKEMIA RES, V17, P639, DOI 10.1016/0145-2126(93)90068-V; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SILVENNOINEN O, 1990, BIOCHEM BIOPH RES CO, V168, P959, DOI 10.1016/0006-291X(90)91122-9; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; STEINMAN RA, 1994, BLOOD, V83, P119; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TKATCH LS, 1994, UNPUB J LEUK BIOL; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEN A, 1992, P SOC EXP BIOL MED, V199, P291; YEN A, 1992, EUR J CELL BIOL, V57, P210; YEN A, 1993, CANCER RES, V53, P3085	49	611	619	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3389	3396						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936667				2022-12-28	WOS:A1994PM65800036
J	ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J				ZHENG, DQ; VAYSSIERE, JL; PETIT, PX; LECOEUR, H; SPATZ, A; MIGNOTTE, B; FEUNTEUN, J			APOPTOSIS IS ANTAGONIZED BY LARGE T-ANTIGENS IN THE PATHWAY TO IMMORTALIZATION BY POLYOMAVIRUSES	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; SIMIAN VIRUS-40; EMBRYO FIBROBLASTS; HAMSTER POLYOMAVIRUS; THYMOCYTE APOPTOSIS; GROWTH ARREST; PROTEIN; TRANSFORMATION; BINDING	The viability of rat embryo cells immortalized by thermosensitive mutants of SV40 or polyoma Large T antigen is impaired at the non-permissive temperature thus demonstrating that the immortal phenotype is dominantly maintained by Large T antigens. We have observed that exposing these cells to the restrictive temperature not only induces growth arrest but also causes apoptotic cell death. We present evidence supporting the model that polyomaviruses may indeed establish immortality by antagonizing the lethal effects of tumor suppressor genes via physical interactions between their products and Large T antigens. In the case of SV40-immortalized cells REtsAF, shift-up to 39.5 degrees C dissociates Large T antigen/p53 complexes releasing wild-type p53 molecules capable of inducing apoptotic cell death. In polyomavirus-immortalized cells, apoptosis may result from an alternative pathway mediated by other unidentified negatively acting molecules.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INST PASTEUR,UNITE ONCOL VIRALE,F-75015 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			SPATZ, ALAN/B-8645-2009; Feunteun, Jean/AAZ-1267-2020; Petit, Patrice X./A-3692-2009; Petit, patrice/AAF-6774-2020; PETIT, Patrice/A-4453-2008; Mignotte, Bernard/A-3499-2009	SPATZ, ALAN/0000-0003-3020-1420; Petit, Patrice X./0000-0002-5038-9101; Mignotte, Bernard/0000-0002-8512-8518; Feunteun, Jean/0000-0003-1212-9189				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOUTEBROZE L, 1993, ONCOGENE, V8, P685; GOUTEBROZE L, 1992, J VIROL, V66, P2495, DOI 10.1128/JVI.66.4.2495-2504.1992; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JONKER RR, 1993, NATO ASI SERIES H, V67, P355; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEREM BS, 1983, NATURE, V304, P88, DOI 10.1038/304088a0; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAYSSOERE JL, 1994, UNPUB COMMITMENT APO; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHU J, 1981, J VIROL, V65, P6872; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	44	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3345	3351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936660				2022-12-28	WOS:A1994PM65800029
J	PIETRAS, RJ; ARBOLEDA, J; REESE, DM; WONGVIPAT, N; PEGRAM, MD; RAMOS, L; GORMAN, CM; PARKER, MG; SLIWKOWSKI, MX; SLAMON, DJ				PIETRAS, RJ; ARBOLEDA, J; REESE, DM; WONGVIPAT, N; PEGRAM, MD; RAMOS, L; GORMAN, CM; PARKER, MG; SLIWKOWSKI, MX; SLAMON, DJ			HER-3 TYROSINE KINASE PATHWAY TARGETS ESTROGEN-RECEPTOR AND PROMOTES HORMONE-INDEPENDENT GROWTH IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						HER-2/NEU; ESTROGEN RECEPTOR; HEREGULIN; TYROSINE PHOSPHORYLATION; BREAST CANCER	MESSENGER-RIBONUCLEIC-ACID; DOWN-REGULATION; PROTO-ONCOGENE; MCF-7 CELLS; PHOSPHORYLATION; NEU; AMPLIFICATION; TRANSCRIPTION; PROTOONCOGENE; ACTIVATION	Growth of human breast cells is closely regulated by steroid hormone as well as peptide hormone receptors. Members of both receptor classes are important prognostic factors in human breast cancer. Clinical data indicate that overexpression of the HER-2 gene is associated with an estrogen receptor-negative phenotype. In this study, we demonstrate that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor, results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen. Moreover, activation of the HER-2 receptor in breast cancer cells by the peptide growth factor, heregulin, leads to direct and rapid phosphorylation of ER on tyrosine residues, This is followed by interaction between ER and the estrogen-response elements in the nucleus and production of an estrogen-induced protein, progesterone receptor. In addition, overexpression of HER-2 receptor in estrogen-dependent tumor cells promotes ligand-independent down-regulation of ER and a delayed autoregulatory suppression of ER transcripts. These data demonstrate a direct link between these two receptor pathways and suggest one mechanism for development of endocrine resistance in human breast cancers.	GENENTECH INC,SAN FRANCISCO,CA 94080; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MEGABIOS CORP,BURLINGAME,CA 94010	Roche Holding; Genentech; Cancer Research UK	PIETRAS, RJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095, USA.		Jansen, Heiko T./A-5770-2008; McKenzie, Katherine/AAY-4144-2020	Jansen, Heiko T./0000-0003-0178-396X; Pietras, Richard/0000-0002-2846-3192	NCI NIH HHS [R01 CA36827, R29 CA60835, P01 CA32737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060835, P01CA032737, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1989, ONCOGENE, V4, P1389; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BELLINGHAM DL, 1992, MOL ENDOCRINOL, V6, P2090, DOI 10.1210/me.6.12.2090; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHAZIN VR, 1992, ONCOGENE, V7, P1859; DEMAIO A, 1990, BIOCHIM BIOPHYS ACTA, V1087, P303, DOI 10.1016/0167-4781(90)90003-K; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DENTON RR, 1992, J BIOL CHEM, V267, P7263; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; ERNST M, 1991, MOL ENDOCRINOL, V5, P1597, DOI 10.1210/mend-5-11-1597; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORIGOME T, 1987, ENDOCRINOLOGY, V121, P2099; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; KOFFMAN B, 1991, J STEROID BIOCHEM, V38, P135, DOI 10.1016/0960-0760(91)90118-O; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; KUNG W, 1994, BIOCHEM BIOPH RES CO, V202, P1357, DOI 10.1006/bbrc.1994.2080; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; OSBORNE CK, 1994, BREAST CANCER RES TR, V32, P49, DOI 10.1007/BF00666205; PARKER MG, 1993, BREAST CANCER RES TR, V26, P131, DOI 10.1007/BF00689686; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1984, BIOCHEM BIOPH RES CO, V123, P84, DOI 10.1016/0006-291X(84)90383-8; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POWER RF, 1991, SCIENCE, V213, P1636; PRESS MF, 1993, CANCER RES, V53, P4960; READ LD, 1989, MOL ENDOCRINOL, V3, P295, DOI 10.1210/mend-3-2-295; READ LD, 1990, CANCER RES, V50, P3947; REDDY KD, 1992, CANCER RES, V3, P401; REE AH, 1989, ENDOCRINOLOGY, V124, P2577, DOI 10.1210/endo-124-5-2577; RUSSELL KS, 1992, CANCER RES, V52, P6624; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; STEBLER A, 1994, BREAST CANCER RES TR, V31, P175; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WAKELING AE, 1993, J STEROID BIOCHEM, V47, P107, DOI 10.1016/0960-0760(93)90063-3; WANG BC, 1992, CANCER RES, V52, P4102; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; ZEILLINGER R, 1989, ONCOGENE, V4, P109	59	529	544	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2435	2446						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784095				2022-12-28	WOS:A1995RE54300022
J	CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V				CARBONI, JM; YAN, N; COX, AD; BUSTELO, X; GRAHAM, SM; LYNCH, MJ; WEINMANN, R; SEIZINGER, BR; DER, CJ; BARBACID, M; MANNE, V			FARNESYLTRANSFERASE INHIBITORS ARE INHIBITORS OF RAS BUT NOT R-RAS2/TC21, TRANSFORMATION	ONCOGENE			English	Article						R-RAS2/TC21; P21 RAS; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE I; BISUBSTRATE ANALOGS; FARNESYLATION	GTP-BINDING PROTEINS; GERANYLGERANYL TRANSFERASE; PRENYLATION; ISOPRENYLATION; GROWTH; CELLS; FARNESYLATION; REQUIREMENT; SPECIFICITY; SEQUENCE	Recent results from several laboratories including ours strongly suggest that farnesyltransferase (FT) inhibitors belonging to distinct chemical classes block growth of oncogenic Ras transformed cells at concentrations that do not affect the growth and viability of normal cells, This is despite blocking the farnesylation and thus the membrane association of Ras in both cell types. This is a paradox given the requirement for Ras function in normal cell growth. Recent evidence that R-Ras2/TC21 utilizes components of Ras signal transduction pathways to trigger cellular transformation (Graham et al., MCB 14, 4108-4115, 1994) prompted us to consider the possibility that R-Ras2/TC21 is involved in some aspects of the growth regulation of normal cells. If so, R-Ras2/TC21 may be compensating for Ras function in untransformed cells treated with FT inhibitors. In this study, we demonstrated that a cell active bisubstrate analog FT inhibitor, BMS-186511, completely blocked the function of oncogenic Ras, but did not affect the function of oncogenic R-Ras2/TC21, as determined by several criteria including inhibition of anchorage dependent and independent growth, reversal of transformed morphology and restoration of actin cytoskeleton. While it is known that TC21 protein becomes prenylated, it is not known whether it is farnesylated or geranylgeranylated. Our in vitro prenylation experiments indicate that R-Ras2/TC21 protein serves as a good substrate for FT as well as geranylgeranyltransferase I (GGTI) and thus provide the apparent molecular basis for these differences. Overall, these results, coupled with the ubiquitous expression of R-Ras2/TC21 in many cells including untransformed NIH3T3 cells, are consistent with the possibility that R-Ras2/TC21 may be one of the factors that render normal cells insensitive to the growth inhibitory action of FT inhibitors.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; manne, veeraswamy/B-1954-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COX AD, 1993, J BIOL CHEM, V268, P11548; COX AD, 1994, ONCOGENE, V9, P3281; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOBERTY G, 1993, FEBS LETT, V330, P323, DOI 10.1016/0014-5793(93)80897-4; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1995, IN PRESS ONCOGENE; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SELF AJ, 1993, ONCOGENE, V8, P655; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	54	59	61	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1905	1913						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761092				2022-12-28	WOS:A1995QZ92600004
J	STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR				STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR			UV-HYPERMUTABILITY OF XERODERMA-PIGMENTOSUM CELLS DEMONSTRATED WITH A DNA-BASED MUTATION SYSTEM	ONCOGENE			English	Article						MUTATIONS; POLYMERASE CHAIN REACTION; RESTRICTION SITE; ULTRAVIOLET; XERODERMA PIGMENTOSUM	POLYMERASE CHAIN-REACTION; NITROSOUREA-INDUCED MUTATIONS; LYMPHOCYTES-T; COMPLEMENTATION GROUP; MAMMALIAN-CELLS; CIRCULATING LYMPHOCYTES; STRAND SPECIFICITY; GENOTYPIC ANALYSIS; MOLECULAR ANALYSIS; REPAIR-PROFICIENT	We have developed a DNA-based system, to detect mutations at restriction sites without any selection in culture. DNA is exhaustively digested with a restriction enzyme. Primers Ranking a chosen site for this enzyme are used in the polymerase chain reaction (PCR). Only DNA molecules mutated at the chosen site are resistant to digestion and can serve as templates for the PCR. We have initially used this system to demonstrate the generation of mutations by ethyl methanesulphonate (EMS) at a TaqI site in the aprt gene of Chinese hamster cells, and by u.v.-C irradiation at a TaqI site in the hprt gene of human fibroblasts, In repair-deficient xeroderma pigmentosum (XP) cells the u.v.-induced mutant frequency was greatly enhanced. We have been able to detect and analyse mutations in XP cells at TaqI sites in three different genes, hprt, p53 and c-Ha-ras1. Both u.v.-C and u.v.-B irradiation have been used as mutagenic agents with both lymphoblastoid and fibroblast cells from XP patients from complementation group G. The mutant DNA molecules have been sequenced. Following u.v.-C-irradiation, the majority of mutations analysed were GC-->AT transitions, but several double and tandem mutations were also found.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALBERTINI RJ, 1985, MUTAT RES, V150, P411, DOI 10.1016/0027-5107(85)90138-1; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; ARLETT CF, 1993, CANCER RES, V53, P609; ARLETT CF, 1983, INDUCED MUTAGENESIS, P249; BIGBEE WL, 1990, MUTAT RES, V240, P165, DOI 10.1016/0165-1218(90)90056-8; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BRIDGES BA, 1990, MUTAGENESIS, V5, P523, DOI 10.1093/mutage/5.6.523; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; COLE J, 1994, MUTAT RES, V304, P33, DOI 10.1016/0027-5107(94)90320-4; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HENDERSON L, 1986, MUTAGENESIS, V1, P195, DOI 10.1093/mutage/1.3.195; HOU SM, 1993, MUTAGENESIS, V8, P43, DOI 10.1093/mutage/8.1.43; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; HUSSAIN SP, 1994, ONCOGENE, V9, P13; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KOVALIC D, 1991, NUCLEIC ACIDS RES, V19, P4560, DOI 10.1093/nar/19.16.4560; MADZAK C, 1991, J MOL BIOL, V218, P667, DOI 10.1016/0022-2836(91)90252-2; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; MEUTH M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P1, DOI 10.1016/0304-419X(90)90009-P; MYERS B, 1994, MUTAGENESIS, V9, P175, DOI 10.1093/mutage/9.3.175; NALBANTOGLU J, 1983, J MOL BIOL, V167, P575, DOI 10.1016/S0022-2836(83)80099-0; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; PALOMBO F, 1992, NUCLEIC ACIDS RES, V20, P1349, DOI 10.1093/nar/20.6.1349; PARRY JM, 1990, MUTAGENESIS, V5, P209, DOI 10.1093/mutage/5.3.209; POURZAND C, 1993, MUTAT RES, V288, P113, DOI 10.1016/0027-5107(93)90213-Y; ROSSI AM, 1990, MUTAT RES, V244, P353, DOI 10.1016/0165-7992(90)90084-W; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; STEINGRIMSDOTTIR H, 1993, MUTAT RES, V294, P29, DOI 10.1016/0921-8777(93)90055-L; STRAUSS GH, 1979, MUTAT RES, V61, P353, DOI 10.1016/0027-5107(79)90140-4; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YAGI T, 1991, CANCER RES, V51, P3177; ZIJLSTRA J, 1990, MUTAGENS CARCINOGENS, P187	43	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2057	2066						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761106				2022-12-28	WOS:A1995QZ92600020
J	GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV				GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV			SOMATIC APC AND K-RAS CODON-12 MUTATIONS IN PERIAMPULLARY ADENOMAS AND CARCINOMAS FROM FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS	ONCOGENE			English	Note						AMPULLARY CANCER; FAP; APC; K-RAS; DUODENAL CANCER	DUODENAL ADENOMAS; GENE-MUTATIONS; COLI GENE; IDENTIFICATION; CANCER; TUMORS; VATER; FAP	Periampullary adenomas in the duodenum of Familial Adenomatous Polyposis (FAP) patients are among the most frequent and clinically important extracolonic neoplasms in FAP. The purpose of this study was to characterize the frequency and nature of somatic adenomatous polyposis coli (APC) gene and K-ras codon 12 mutations in periampullary adenomas and carcinomas in FAP. These molecular changes have been shown to be important during the early stages of colorectal carcinogenesis. DNA was prepared from endoscopic periampullary biopsies and paraffin blocks from 49 FAP patients. Of 143 samples, 77 were histologically normal, 29 were biopsies from small periampullary adenomas, 29 biopsies were from 19 large adenomas and eight samples were from periampullary cancers. APC mutations in the mutation cluster region and K-ras codon 12 mutations were detected by polymerase chain reaction based techniques. Somatic APC mutations consisting of deletions at codons 1464 and 1465 were detected in one small and two large periampullary adenomas. Loss of heterozygosity was seen in one periampullary carcinoma, K-ras codon 12 mutations were detected in seven of 19 large periampullary adenomas and in one of eight periampullary carcinomas. These data suggest that K-ras codon 12 mutations may be important during periampullary tumorigenesis in FAP but somatic APC mutations in the mutation cluster region are infrequent. Local environmental factors in the duodenum may contribute to differences in the molecular changes which occur during the adenoma-to-carcinoma sequence in periampullary compared to colonic tumorigenesis.	UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT PATHOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	GALLINGER, S (corresponding author), UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT SURG,TORONTO,ON M5G 1X5,CANADA.		Gallinger, Steven/E-4575-2013; Bapat, Bharati/B-5839-2014					BACZAKO K, 1985, HUM PATHOL, V16, P305, DOI 10.1016/S0046-8177(85)80018-6; BAPAT B, 1993, HUM MOL GENET, V2, P1957, DOI 10.1093/hmg/2.11.1957; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH JM, 1992, DIS COLON RECTUM, V35, P1170, DOI 10.1007/BF02251971; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAYES DH, 1987, ANN SURG, V206, P572; HORII A, 1992, CANCER RES, V52, P3231; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAGELMAN DG, 1988, LANCET, V1, P1149; JOHAN G, 1992, GASTROENTEROLOGY, V102, P1980; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1993, CANCER RES, V53, P5079; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; ODZE RD, 1993, HUM PATHOL, V24, P442, DOI 10.1016/0046-8177(93)90095-X; PENNA C, 1993, BRIT J SURG, V80, P1027, DOI 10.1002/bjs.1800800833; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RHODES M, 1992, GUT, V33, P125, DOI 10.1136/gut.33.1.125; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	25	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753564				2022-12-28	WOS:A1995QX46900022
J	GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J				GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J			REPRESSION OF THE RETINOIC ACID RECEPTOR-ALPHA GENE BY THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, WT1	ONCOGENE			English	Article						WILMS TUMOR; RETINOIC ACID RECEPTOR; WT1; CANCER GENETICS	ACUTE PROMYELOCYTIC LEUKEMIA; FACTOR-A-CHAIN; PROMOTER ACTIVITY; GROWTH; LOCUS; TRANSCRIPTION; EXPRESSION; BINDING; INDUCTION; DELETION	The Wilms' tumor (WT) suppressor gene, WT1, encodes a zinc finger DNA binding protein (wt1) which functions as a transcriptional regulator. Germline WT1 mutations predispose to WTs and in many cases are associated with urogenital anomalies. Identification of wt1 downstream targets is essential to understanding regulatory processes involved in development of this system. In this study, we demonstrate that wt1 can repress transcription of the retinoic acid receptor-alpha 1 (RAR-alpha 1) promoter. Transient transfection, deletion mutagenesis, and mobility shift assays suggest that wt1 mediates repression of the human RAR-alpha 1 promoter through a GC-rich DNA binding motif (5'-GCGGGGGCG-3'), at positions -111 to -120 bp (relative to the transcription initiation site). In contrast, the murine RAR-alpha 1 promoter contains a cryptic binding motif and is not responsive to wt1. These results indicate that some wt1-regulatory pathways are not conserved across species, suggesting a molecular basis for differences in phenotypes between humans and mice harboring WT1 lesions.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL CHILDRENS HOSP,DEPT EXPTL MED,MONTREAL,PQ H3H 1P3,CANADA	McGill University; McGill University; McGill University								BORROW J, 1990, SCIENCE, V249, P1557; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HONG WK, 1994, RETINOIDS BIOL CHEM; KRIEDBERG JA, 1993, CELL, V74, P679; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MORIYA N, 1993, DEV GROWTH DIFFER, V35, P123; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SHENEFELT RE, 1972, TERATOLOGY, V5, P5103; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANGWUU S, 1990, CANCER RES, V50, P2786; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	34	102	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1125	1129						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700638				2022-12-28	WOS:A1995QN35300013
J	KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M				KRAUTWALD, S; BUSCHER, D; DENT, P; RUTHENBERG, K; BACCARINI, M			SUPPRESSION OF GROWTH FACTOR-MEDIATED MAP KINASE ACTIVATION BY V-RAF IN MACROPHAGES - A PUTATIVE ROLE FOR THE MKP-1 PHOSPHATASE	ONCOGENE			English	Article						V-RAF; MAP KINASES; PHOSPHATASES; MKP-1	IMMEDIATE-EARLY GENE; SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; IN-VITRO; SACCHAROMYCES-CEREVISIAE; COMPLEX-FORMATION; XENOPUS-OOCYTES; FACTOR P62TCF; C-MYC	Many tyrosine kinase growth factor receptors activate the MAP Kinase (MAPK) pathway by stimulating the activity of the RAF kinase. In some, but not all cell types, the expression of activated RAF is sufficient to induce constitutive MAPK activation. In BAC-1.2F5 macrophages the expression of virally activated RAF does not correlate with constitutive MAPK activation; on the contrary, growth factor-mediated stimulation of MAPK activity is suppressed in these cells. Suppression correlates with v-RAF expression, as MAPK activation is normal in a revertant cell Line that stopped expressing v-RAF. Inhibition of MAPK activation is associated,vith lack of ERK-2 tyrosine phosphorylation, and is not due to the suppression of CSF-l-mediated MEK activation. Pretreatment with vanadate restores growth factor-stimulated activation and tyrosine phosphorylation of MAPK in v-RAF-expressing macrophages, indicating the involvement of a tyrosine phosphatase. Interestingly, v-RAF-expressing macrophages contain low constitutive levels of MKP-1 mRNA, an immediate early gene that encodes a MAPK-specific phosphatase and is induced in the parental cell line by CSF-1 treatment. The restoration of MAPK activation by vanadate pretreatment and the presence of MKP-1 mRNA in V-RAF-expressing macrophages raise the intriguing possibility that in macrophages RAF may be feeding back on the MAPK pathway by participating in the control of MKP-1 expression.	FRAUNHOFER INST TOXICOL & MOLEC BIOL,DEPT IMMUNOBIOL,D-30625 HANNOVER,GERMANY; UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Fraunhofer Gesellschaft; University of Virginia; University of Virginia			Baccarini, Manuela/B-6481-2014; Krautwald, Stefan/J-9984-2016	Baccarini, Manuela/0000-0002-3033-391X; Krautwald, Stefan/0000-0001-7768-2132				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Baccarini M, 1991, Receptor, V1, P243; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUSCHER D, 1993, ONCOGENE, V8, P3323; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KEYSE SM, 1992, NATURE, V59, P644; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; STANLEY ER, 1985, METHOD ENZYMOL, V116, P565; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P56; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1187	1192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700643				2022-12-28	WOS:A1995QN35300020
J	TAHARA, H; SATO, E; NODA, A; IDE, T				TAHARA, H; SATO, E; NODA, A; IDE, T			INCREASE IN EXPRESSION LEVEL OF P21(SDI1/CIP1/WAF1) WITH INCREASING DIVISION AGE IN BOTH NORMAL AND SV40-TRANSFORMED HUMAN FIBROBLASTS	ONCOGENE			English	Article						P21/SDI1/CIP1/WAF1; CELLULAR SENESCENCE; P53; T-ANTIGEN; HUMAN FIBROBLAST	CYCLIN-DEPENDENT KINASES; DNA-SYNTHESIS; T-ANTIGEN; CELLS; INHIBITOR; MUTANT; P21	p21(sdil/cip1/waf1) gene, whose product inhibits Cyclin/Cdk kinase and blocks cell proliferation, is known to be upregulated by p53 and to be expressed at high levels in senescent human fibroblasts. The present paper reports that p21 expression level was much lower in SV40ts T-antigen transformed cells than in normal cells and that after inactivation of ts T-antigen it recovered to that of normal cells. However, cell division age-dependent increase in expression level of p21 occurred not only in normal human fibroblasts but also in SV40ts T-antigen transformed fibroblasts with active T-antigen. These results suggest that cell age-dependent increase in p21 occurs independently upon the function of T-antigen binding proteins including p53, while the basal expression level of p21 is up-regulated by p53 as previously reported.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; MEIJI CELL TECHNOL CTR,RES DIV CELLULAR REGULAT,ODAWARA 250,JAPAN	Hiroshima University; Meiji Holdings Co., Ltd.				Noda, Asao/0000-0002-9029-9813				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGUCHI N, 1975, J VIROL, V15, P1297, DOI 10.1128/JVI.15.6.1297-1301.1975; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6	19	117	117	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					835	840						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898925				2022-12-28	WOS:A1995QL03800004
J	KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A				KRANENBURG, O; DEGROOT, RP; VANDEREB, AJ; ZANTEMA, A			DIFFERENTIATION OF P19 EC CELLS LEADS TO DIFFERENTIAL MODULATION OF CYCLIN-DEPENDENT KINASE-ACTIVITIES AND TO CHANGES IN THE CELL-CYCLE PROFILE	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASES; PIG CELLS; DIFFERENTIATION; CELL CYCLE CONTROL; RETINOBLASTOMA GENE PRODUCT	EMBRYONAL CARCINOMA-CELLS; SUSCEPTIBILITY GENE-PRODUCT; SV40 LARGE-T; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-REPLICATION; EXPRESSION; FAMILY; E2F; PHASE	The retinoblastoma gene product (pRb) is essential for normal embryonic development, Phosphorylation of pRb by cyclin dependent kinases (cdk's) is believed to be crucial for the regulation of its function, In this report we have studied the regulation of pRb and cdk's during in vitro differentiation of P19 embryonal carcinoma (EC) cells, as a model for early developmental processes, During EC cell differentiation, the synthesis of pRb is strongly induced, In addition, the phosphorylation state of induced pRb is modulated, yielding mainly underphosphorylated pRb, Concomitantly, the pRb kinases cdk2 and cdk4 are differentially regulated: cdk2 kinase activity is impaired, whereas cdk4 kinase activity is stimulated, due to an induction of cyclins D1 and D2. Furthermore, the DNA binding activity of E2F transcription factors is strongly impaired during differentiation and the number of cells in G1 is increased. Thus, P19 EC cell differentiation is accompanied by changes in cdk-activities, pRb regulation and E2F DNA-binding, resulting in the generation of cell types with an altered cell cycle profile.	UNIV UTRECHT HOSP,DEPT PULM DIS,3508 GA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University Medical Center	KRANENBURG, O (corresponding author), LEIDEN UNIV,DEPT MOLEC CARCINOGENESIS,SYLVIUS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.		Kranenburg, Onno/K-4115-2015	Kranenburg, Onno/0000-0002-2112-4390				AJCHENBAUM F, 1993, J BIOL CHEM, V25, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATA JY, 1993, GENE DEV, V7, P331; KITAGAWA M, 1992, ONCOGENE, V7, P1067; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; MUMMERY CL, 1987, CELL DIFFER DEV, V20, P153, DOI 10.1016/0045-6039(87)90429-5; MURRAY EJ, 1991, MOL CELL BIOL, V11, P5534, DOI 10.1128/MCB.11.11.5534; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALERMO L, 1993, ONCOGENES, V8, P1049; PINES J, 1993, BIOCHEM SOC T, V21, P921, DOI 10.1042/bst0210921; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	51	55	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					87	95						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824282				2022-12-28	WOS:A1995QA98000011
J	FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR				FOLETTA, VC; SONOBE, MH; SUZUKI, T; ENDO, T; IBA, H; COHEN, DR			CLONING AND CHARACTERIZATION OF THE MOUSE FRA-2 GENE	ONCOGENE			English	Article							C-FOS; MESSENGER-RNAS; JUN COMPLEXES; TRANSCRIPTION; PROTEINS; AP-1; EXPRESSION; FAMILY; SERUM; DNA	Transcription factor AP-1 is comprised of multiple protein complexes that include members of a family of genes related to the proto-oncogene c-fos. In this report, we have extended the analysis of one member of this family, fos-related antigen-2 (fra-2), by isolating and characterising genomic and cDNA clones encoding:the mouse fra-2 homolog. The overall gene structure (number and positions of introns) was similar to that of both the chicken fra-2 gene and other members of the fos family, and the relative positions of putative enhancers in the 5' regulatory region were well conserved between the mouse and chicken fra-2 genes. High levels of fra-2 mRNA were detected in ovary, stomach, small and large intestine, brain, lung and heart. The mouse Fra-2 protein showed 94% and 87.5% conservation with human and chicken Fra-2, respectively, and mouse Fra-2, like the chicken homolog, induced transformation of chicken embryo fibroblasts. The characterisation of the mouse fra-2 gene provides a basis for analysis of Fra-2 function in the whole animal.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO,JAPAN	Australian National University; John Curtin School of Medical Research; University of Tokyo			Sonobe, Martha/I-2877-2015	Cohen, Donna/0000-0002-0419-9542				ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FUJIWARA K, 1987, J VIROL, V61, P4021; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HADMAN M, 1993, ONCOGENE, V8, P1895; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MATSUI M, 1990, ONCOGENE, V5, P249; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MOLDERS H, 1987, ONCOGENE, V1, P377; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; THOMPSON JA, 1979, J VIROL, V31, P437, DOI 10.1128/JVI.31.2.437-446.1979; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715	38	45	48	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3305	3311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936655				2022-12-28	WOS:A1994PM65800024
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			A CONSERVED REGION ADJACENT TO THE BASIC DOMAIN IS REQUIRED FOR RECOGNITION OF AN EXTENDED DNA-BINDING SITE BY MAF/NRL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; FOS-JUN; MAF ONCOGENE; TRANSCRIPTION; GENE; ACTIVATION; COMPLEX; EXPRESSION; ENHANCER; PROMOTER	The c-maf proto-oncogene and the neural retina specific gene nul encode members of a subfamily of bZIP proteins that form heterodimers with Fos and Jun. We have determined the DNA binding specificities of various homo- and heterodimeric combinations among Nrl, Maf, Fos and Jun. Fos-Jun heterodimers and Jun homodimers bound to a palindromic TGAC(G)TCA recognition sequence as previously demonstrated. Maf and Nrl homodimers also bound to palindromic recognition sites with the consensus sequence TGC(N)(6-7)GCA. Fos-Nrl, Jun-Nrl and Fos-Maf heterodimers bound to nonpalindromic recognition sequences with the consensus sequence TGAC(N)(3-4)GCA. These results indicate that Nrl and Maf have a DNA binding specificity distinct from that of Fos and Jun, and that each subunit in the dimer independently recognizes one half of the recognition sequence. This allows combinatorial determination of target gene specificity. Specific recognition of the extended DNA binding sequence by Maf requires an ancillary DNA binding region on the amino terminal side of the basic domain that is conserved among Maf/Nrl family members. Thus, heterodimer formation among distantly related bZIP family members can generate novel DNA binding specificities and the addition of an auxiliary DNA binding domain to the simple bZIP motif can facilitate the recognition of extended binding sites.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Kerppola, Tom/AFK-6155-2022; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008; Kerppola, Tom/AAG-4457-2022; Curran, Tom/F-5234-2018	Kerppola, Tom/0000-0002-0611-9446; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CURRAN T, 1988, CELL, V55, P305; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	36	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3149	3158						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936637				2022-12-28	WOS:A1994PM65800006
J	ANAND, R; WILKINSON, JM; KELLIE, S				ANAND, R; WILKINSON, JM; KELLIE, S			LOCALIZATION OF PP60(C-SRC) TO THE SURFACE-MEMBRANE OF HUMAN PLATELETS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; EXPRESS HIGH-LEVELS; INTRACELLULAR MEMBRANES; GLYCOPROTEIN-IIB; ARACHIDONIC-ACID; PHORBOL ESTERS; SRC PROTEIN; PP60C-SRC; PHOSPHORYLATION; LOCALIZATION	In platelets, pp60c-src has been variously localised to cytosol, dense bodies, or plasma membrane and surface-connected canalicular membranes. We have investigated the localisation of pp60c-src in highly purified human platelet subcellular fractions isolated using density gradient centrifugation and continuous flow electrophoresis followed by quantitative immunoblotting. We have obtained fractions enriched in surface membranes and alpha granule membranes as assessed by the presence of the marker proteins gpIb, gpIIb, thrombospondin, fibrinogen and fibronectin. Quantitative immunoblotting demonstrated that most of the cellular pp60c-src co-purified with markers for surface membrane components and that unlike the situation in fibroblasts, platelet pp60c-src did not associate with non-granule intracellular membranes such as Golgi, endoplasmic reticulum and endosomes. A small subpopulation of the total cellular pp60c-src co-purified with granule components or dense body markers, however this occurred in proportion to the presence of surface membrane markers. Our results demonstrate that the majority of platelet pp60c-src is located on the cytoplasmic face of the plasma membrane in human platelets.	LITTLEMORE HOSP,YAMANOUCHI RES INST,OXFORD OX4 4XN,ENGLAND; ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,DEPT BIOCHEM PHARMACOL,LONDON EC1,ENGLAND				Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474				AAKHUS AM, 1992, THROMB HAEMOSTASIS, V67, P252; AUTHI KS, 1985, BIOCHEM J, V230, P274; Brass L F, 1991, Prog Hemost Thromb, V10, P127; CALVETE JJ, 1989, BIOCHEM J, V261, P551, DOI 10.1042/bj2610551; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DHAR A, 1991, J BIOL CHEM, V266, P18797; ELMORE MA, 1990, FEBS LETT, V269, P283, DOI 10.1016/0014-5793(90)81177-P; FEDER D, 1991, J BIOL CHEM, V266, P19040; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOGSTAD GO, 1981, BIOCHIM BIOPHYS ACTA, V670, P150, DOI 10.1016/0005-2795(81)90003-9; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HACK N, 1984, BIOCHEM J, V222, P235, DOI 10.1042/bj2220235; HACK N, 1986, BIOCHEM J, V233, P661, DOI 10.1042/bj2330661; HALENDA SP, 1985, J BIOL CHEM, V260, P2484; HORAK ID, 1990, ONCOGENE, V5, P597; HORNBY EJ, 1991, BRIT J HAEMATOL, V79, P277, DOI 10.1111/j.1365-2141.1991.tb04533.x; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KELLIE S, 1987, FEBS LETT, V213, P428, DOI 10.1016/0014-5793(87)81536-3; KNIGHT DE, 1980, THROMB RES, V20, P437, DOI 10.1016/0049-3848(80)90282-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENASHI S, 1981, J BIOL CHEM, V256, P4095; MURPHY CT, 1991, BIOCHIM BIOPHYS ACTA, V1133, P46, DOI 10.1016/0167-4889(91)90240-X; MURPHY CT, 1991, BIOCHEM J, V278, P255, DOI 10.1042/bj2780255; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; POLL C, 1986, BIOCHIM BIOPHYS ACTA, V886, P434, DOI 10.1016/0167-4889(86)90179-5; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RENDU F, 1989, BLOOD, V73, P1545; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988	39	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3013	3020						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692371				2022-12-28	WOS:A1993MC09300015
J	COBB, BS; PARSONS, JT				COBB, BS; PARSONS, JT			REGULATION OF THE CELLULAR SRC PROTEIN-TYROSINE KINASE - INTERACTIONS OF THE CARBOXYL-TERMINAL SEQUENCES RESIDING BETWEEN THE KINASE DOMAIN AND TYROSINE-527	ONCOGENE			English	Article							SH3 DOMAINS; MONOCLONAL-ANTIBODIES; TRANSFORMING PROTEIN; STABLE ASSOCIATION; PP60C-SRC; PHOSPHORYLATION; PP60SRC; BINDING; SITES; GENE	Negative regulation of the cellular Src tyrosine kinase (pp60c-src) is mediated through the phosphorylation of a C-terminal tyrosine residue, Tyr-527. Current models predict that inhibition of c-Src kinase activity results from an interaction of phosphorylated Tyr-527 with the amino terminal SH2 domain. Tyr-527 is located 11 residues C-terminal from the end of the kinase domain. Insertion or deletion of residues within these 11 residues of pp60c-src activates kinase activity and induces morphological transformation. The resultant variant Src proteins also exhibit a reduced level of phosphorylation of Tyr-527. We have used antibodies to phosphotyrosine, susceptibility to tyrosine phosphatases and binding of mutant Src proteins to peptides mimicking the tyrosine phosphorylated C-terminus of pp60c-src to investigate the tyrosine phosphorylated and unphosphorylated forms of such insertion/deletion variants. The reactivity of variant proteins with phosphotyrosine antibodies and the susceptibility of phosphorylated Tyr-527 to tyrosine phosphatases were similar to that of wild type pp60c-src. In addition, the results of binding experiments performed with a C-terminal peptide containing phosphorylated Tyr-527 indicated that only dephosphorylated forms of variant Src proteins bound phospho-peptide. These data suggest that insertion or deletion mutations within the C-terminal region of pp60c-src do not substantially alter the interaction of phosphorylated Tyr-527 with the SH2 domain. Rather, the data are consistent with the hypothesis that the reduction of phosphorylation of Tyr-527 and the accompanying activation of these variants may be due to the action of a tyrosine phosphatase and the ineffecient phosphorylation of Tyr-527 by a regulatory kinase.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MCCARLEY DJ, 1987, J VIROL, V61, P1927, DOI 10.1128/JVI.61.6.1927-1937.1987; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARTANEN J, 1991, ONCOGENE, V6, P2013; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH JL, 1983, J CLIN NEURO-OPHTHAL, V3, P3; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1993	8	11					2897	2903						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692368				2022-12-28	WOS:A1993MC09300002
J	ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC				ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC			SELECTIVE ASSOCIATION OF THE P59(FYN) TYROSINE KINASE WITH MURINE T-LYMPHOMA MEMBRANE PHOSPHOPROTEINS	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; SRC-FAMILY; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; HUMAN-LYMPHOCYTES; MICE LACKING; PHOSPHORYLATION; PHOSPHOTYROSINE	The p59fyn oncogene product, a tyrosine kinase of the src family, is a key enzyme in T-lymphocyte transmembrane signalling that is not known to bind with high stoichiometry to any surface receptor protein. By contrast, the p56lck, another important T-cell tyrosine kinase, is directly linked to CD4 or CD8 surface glycoproteins with high stoichiometry. To document the mode of p59fyn interaction with proteins of the plasma membrane, proteins co-precipitating with the kinase in extracts of purified membranes were phosphorylated in vitro. resolved by two-dimensional electrophoresis and compared with those co-precipitating with the p56lck kinase. The p59fyn, but not the p56lck kinase, associates with three phosphotvrosyl-proteins among which a 95- to 100-kDa component also binds to the src-homology 2 (SH2) domain of the v-crk oncoprotein. This p95-100 phosphoprotein is not the p95Vav product of the Vav proto-oncogene; it is recovered much more effectively from P-32i-metabolically labelled cells after treatment with the tyrosine phosphatase inhibitor phenylarsenoxide, suggesting that its phosphorylation state is controlled by tyrosine phosphatases. The p59fyn may be integrated into the plasma membrane by specific phosphotyrosylproteins and so differ from the p56lck tyrosine kinase, which binds preferentially to the CD4 and CD8 transmembrane adhesion glycoproteins.	CTR MED UNIV GENEVA,FAC MED,DEPT PATHOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva				Arni, Stephan/0000-0001-5497-8256				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOESSLI DC, 1990, EUR J IMMUNOL, V20, P1497, DOI 10.1002/eji.1830200714; HOESSLI DC, 1983, P NATL ACAD SCI USA, V83, P439; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	44	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2485	2491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689723				2022-12-28	WOS:A1993LT36800020
J	BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE				BOUKAMP, P; PETER, W; PASCHEBERG, U; ALTMEIER, S; FASCHING, C; STANBRIDGE, EJ; FUSENIG, NE			STEP-WISE PROGRESSION IN HUMAN SKIN CARCINOGENESIS IN-VITRO INVOLVES MUTATIONAL INACTIVATION OF P53, RAS(H) ONCOGENE ACTIVATION AND ADDITIONAL CHROMOSOME LOSS	ONCOGENE			English	Article						RAS-ONCOGENE; HUMAN KERATINOCYTES; MALIGNANT TRANSFORMATION; P53 MUTATION; CHROMOSOME 15	SQUAMOUS-CELL CARCINOMAS; NEOPLASTIC TRANSFORMATION; HUMAN KERATINOCYTES; VIRAL INTEGRATION; FRAGILE SITES; GENE; CANCER; EXPRESSION; LINE; HYBRIDIZATION	Two mechanisms relevant for skin carcinogenesis in man are mutational inactivation of p53 and oncogenic activation of c-ras(H) gene. Previously, we transfected c-ras(H) oncogene into human skin keratinocytes (HaCaT) with u.v.-typic mutations in both p53 alleles, which produced benign and malignant tumorigenic clones, expressing similar amounts of mutant Pas protein, Here we show that neither the ras integration site nor the karyotypic changes affects the formation of the benign or malignant tumorigenic phenotype, From the original malignant HaCaT-ras clone we took single human chromosomes, carrying the c-ras(H) oncogene and transferred them by microcell mediated chromosome transfer into genetically different untransfected nontumorigenic HaCaT cells, This novel approach identified the genetic background of the recipient cell as a critical determinant for the resulting tumor phenotype, Exhibiting similar oncogene expression, microcell hybrids from early passage cells remained nontumorigenic or formed benign tumors, while those with more cytogenetic aberrations (later passages) and loss of >1 copy of chromosome 15 became malignant. Since aberrations in chromosome 15 were also detected in three of five human skin carcinoma lines this study provides evidence that p53 and c-ras(H) mutations are early events of human skin carcinogenesis, while loss of gene(s) on chromosome 15 is a late event.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine	BOUKAMP, P (corresponding author), GERMAN CANC RES CTR,DIV CARCINOGENESIS & DIFFERENTIAT,NEUENHEIMER FELD 280,D-69009 HEIDELBERG,GERMANY.		Pascheberg, Ulrich/GON-9981-2022		NCI NIH HHS [CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA019401, R01CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMBROS PF, 1986, CHROMOSOMA, V94, P11, DOI 10.1007/BF00293525; ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; BOS JL, 1989, CANCER RES, V49, P4682; BOUKAMP P, 1982, JNCI-J NATL CANCER I, V68, P415; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1994, KERATINOCYTE HDB, P485; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRISSETTE JL, 1993, MOL CARCINOGEN, V7, P21, DOI 10.1002/mc.2940070105; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P4322; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FRIEND KK, 1976, SOMAT CELL GENET, V2, P183, DOI 10.1007/BF01542631; FUSENIG NE, 1991, ORAL CANC, P218; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GANTT R, 1987, CANCER RES, V47, P1390; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGENT JE, 1985, J HISTOCHEM CYTOCHEM, V33, P1241, DOI 10.1177/33.12.2415575; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1903, CARCINOGENESIS, V14, P833; MCKENNA WG, 1988, SCIENCE, V241, P1325, DOI 10.1126/science.3045971; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PARSHAD R, 1994, CARCINOGENESIS, V88, P524; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POPESCU NC, 1990, HUM GENET, V84, P383; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TILGEN W, 1983, CANCER RES, V43, P5995; VANDERRIET P, 1994, CANCER RES, V54, P25; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	47	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					961	969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675455				2022-12-28	WOS:A1995RU79800017
J	NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT				NGUYEN, H; MUSTAFA, A; HISCOTT, J; LIN, RT			TRANSCRIPTION FACTOR IRF-2 EXERTS ITS ONCOGENIC PHENOTYPE THROUGH THE DNA-BINDING TRANSCRIPTION REGRESSION DOMAIN	ONCOGENE			English	Article						INTERFERON; TRANSCRIPTION; ONCOGENESIS; INTERFERON REGULATORY FACTORS	GENE REGULATORY ELEMENTS; IFN-INDUCIBLE GENES; PROTEIN-KINASE; BETA; INDUCTION; CHROMOSOME-2P21-P22; EXPRESSION; ACTIVATION; CELLS; PRKR	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) play a transcriptional role in the regulation of the IFN-beta gene as well as other immunoregulatory genes. IRF-1 serves as a transcriptional activator whereas IRF-2 acts as an antagonistic transcriptional repressor. IRF-1 and IRF-2 also play opposing functional roles in cell growth regulation, and are implicated as a potential antioncogene and oncogene, respectively. To analyse the relationship between DNA binding/transcriptional repression and oncogenic transformation, NIH3T3 cells expressing C-terminal deletions of IRF-2 were established and assayed for transformation by saturation density analysis, anchorage independent growth in soft agar and tumor formation in nude mice. Cells expressing an IRF-2 protein of at least 160 N-terminal amino acids were transformed in vitro and tumorigenic in vivo, thus mapping IRF-2 oncogenic activity to its DNA binding/ transcriptional repression domain, Overexpression of wild-type and truncated IRF-2 proteins resulted in reduced IFN-beta mRNA levels following induction by dsRNA. However, there was no effect of IRF-2 on IFN-beta inducibility by Sendai virus infection, suggesting the involvement of multiple IFN-beta induction pathways. In DNA binding assays, recombinant IRF-2 was found to preferentially bind to the IFN-beta PRDI site compared to IRF-1. These studies indicate that the transformed phenotype resulting from overexpression of IRF-2 may be due to constitutive engagement of the IRF-E recognition site, thus preventing DNA binding and transactivation of putative tumor suppressor genes by the IRF-1 anti-oncogene.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				BARBER GN, 1993, GENOMICS, V16, P765, DOI 10.1006/geno.1993.1262; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COHEN L, 1992, VIROLOGY, V191, P589, DOI 10.1016/0042-6822(92)90234-G; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; DADDARIO M, 1992, J IMMUNOL, V148, P1222; DADDARIO M, 1990, J VIROL, V64, P6080, DOI 10.1128/JVI.64.12.6080-6089.1990; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; HANASH SM, 1995, GENES CHROM CANC, V8, P34; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1983, SCIENCE, V259, P971; HISCOTT J, 1995, IN PRESS SEMINARS VI, V6; KAMIJO R, 1994, CELL, V263, P1612; KIRCHOFF S, 1995, IN PRESS ONCOGENE; KOROMILAS AE, 1992, SCIENCE, V257, P1865; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SQUIRE J, 1993, GENOMICS, V16, P768, DOI 10.1006/geno.1993.1263; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1994, J BIOL CHEM, V269, P27059; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; [No title captured]	34	50	50	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					537	544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630638				2022-12-28	WOS:A1995RN53000014
J	KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S				KEANE, MM; RIVEROLEZCANO, OM; MITCHELL, JA; ROBBINS, KC; LIPKOWITZ, S			CLONING AND CHARACTERIZATION OF CBL-B - A SH3 BINDING-PROTEIN WITH HOMOLOGY TO THE C-CBL PROTOONCOGENE	ONCOGENE			English	Article						CBL-B; SK3 PROTEIN INTERACTIONS; MAMMARY CELLS; DIFFERENTIATION	ACUTE PROMYELOCYTIC LEUKEMIA; MESSENGER-RNA; DNA-BINDING; ZINC FINGER; V-CBL; SACCHAROMYCES-CEREVISIAE; POINT MUTATIONS; RAR-ALPHA; GENE; SEQUENCE	We have cloned a new gene, cbl-b, with homology to the c-cbl proto-oncogene. A large protein is predicted (approx, MW 108 000) that has a proline rich domain, a nuclear localization signal, a C3HC4 zinc finger and a putative leucine zipper. There is striking nucleotide and amino acid homology to the c-cbl proto-oncogene most notably in the structural motifs described above. Cbl-b is expressed in normal and malignant mammary epithelial cells, in a variety of normal tissues, and in hematopoietic tissue and cell lines. Cbl-b expressions is up-regulated with macrophage/monocyte differentiation of the HL60 and U937 cell lines, There is direct association of the cbl-b protein with the Src Homology 3 domains of several proteins including signaling, cytoskeletal and adaptor proteins. Our data suggest that cbl-b encodes a protein which can interact with signal transduction proteins to regulate their function or to be regulated by them, Together, cbl-b and c-cbl are members of a novel family of proto-oncogenes involved in signal transduction.	USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20889; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Rivero-Lezcano, Octavio Miguel/J-9089-2015	Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Battey, 1986, BASIC METHODS MOL BI; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LAWRENCE JB, 1988, CELL, V52, P51; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILUSZ J, 1989, NUCLEIC ACIDS RES, V17, P3899, DOI 10.1093/nar/17.10.3899; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	182	189	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2367	2377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784085				2022-12-28	WOS:A1995RE54300012
J	BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J				BRONDELLO, JM; MCKENZIE, FR; SUN, H; TONKS, NK; POUYSSEGUR, J			CONSTITUTIVE MAP KINASE PHOSPHATASE (MKP-1) EXPRESSION BLOCKS G1 SPECIFIC GENE-TRANSCRIPTION AND S-PHASE ENTRY IN FIBROBLASTS	ONCOGENE			English	Article						CELL CYCLE ENTRY; GENE TRANSCRIPTION; GROWTH CONTROL; MAP KINASE CASCADE; PHOSPHATASES	PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; C-FOS; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; COMPLEX-FORMATION; ENCODED PROTEIN; 3T3 CELLS	MAP kinase (mitogen activated protein kinase) represents a ubiquitously expressed family of kinases whose long term activation via phosphorylation is essential for the mitogenic response in fibroblasts. Two family members, p42 and p44 MAP kinase are cytosolic proteins in quiescent cells, but become nuclear following mitogenic stimulation, Inactivation of MAP kinases occurs via a specific phosphatase, MKP-1. Hence, we examined the localisation of this phosphatase, to determine the cellular site of MAP kinase inactivation, Transient transfection of CCL39 fibroblasts with epitope-tagged MKP-1 showed the protein to be entirely nuclear in both quiescent and mitogen stimulated cells, whereas a catalytically inactive mutant in which the essential cysteine was mutated to serine (MKP-1CS) was predominately cytoplasmic and again serum stimulation failed to alter the protein's localisation. Expression of either wild type or inactive MKP-1 did not alter the cytosolic localisation of p44 MAP kinase in quiescent cells nor the ability of MAP kinase to translocate to the nucleus following mitogen stimulation, Expression of wild type MKP-1 inhibited serum stimulated early (c-fos promoter) and late (dhfr promoter) transcriptional events as web as entry into S-phase. This inhibition was reversed by the co-expression of an active MAP kinase. We conclude that in the continual expression of MKP-1, the cellular localisation of MAP kinase is unaffected and that inactivation of MAP kinase by MKP-1 is a nuclear process leading to the inhibition of cell division.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Cold Spring Harbor Laboratory			Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945				AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; EGAN SE, 1993, NATURE, V363, P35; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KWAK SP, 1993, J BIOL CHEM, V269, P3596; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MELOCHE S, 1992, MOL ENDOCRINOL, V63, P845; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARNE PH, 1993, NATURE, V364, P1031; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	58	154	159	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1895	1904						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761091				2022-12-28	WOS:A1995QZ92600003
J	ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC				ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC			HER-2/NEU-TARGETING CANCER-THERAPY VIA ADENOVIRUS-MEDIATED E1A DELIVERY IN AN ANIMAL-MODEL	ONCOGENE			English	Article						HER-2/NEU; GENE THERAPY; E1A; ADENOVIRAL VECTOR	NEGATIVE BREAST-CANCER; GROWTH-FACTOR RECEPTOR; NECROSIS-FACTOR-ALPHA; HUMAN TUMOR-CELLS; OVARIAN-CANCER; NEU ONCOGENE; GENE-PRODUCTS; RECURRENT DISEASE; INCREASED RISK; POOR SURVIVAL	Overexpression of HER-2/neu has been demonstrated in human ovarian cancer and correlated with poor prognosis. We previously found that the adenovirus type 5 early region 1A (EIA) gene product can repress overexpression and suppress the tumorigenic potential of the HER-2/neu-overexpressing cancer cells. To develop an efficient HER-2/neu-targeting gene therapy with EIA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce the HER-2/neu-overexpressing human ovarian cancer cell line SK-OV3.ip1. Tumor cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction. To test therapeutic efficacy in vivo, tumor-bearing mice were established by i.p. injection with ovarian cancer cells and treated by i.p. injection of 10(8) PFU viral solution containing either replication-deficient Ad.E1A(+); control virus Ad.E1A(-) which is the same adenovirus as Ad.E1A(+) except for E1A deletion, or just PBS. Ad.E1A(+) significantly prolonged survival in treated mice for 1 year (80%) whereas in control groups, ah mice died of cancer within 4.5 months. Immunohistochemistry analysis indicated that Ad.E1A protein was expressed in tumor tissue and expression of HER-2/neu p185 protein was suppressed in vivo. As a control, another ovarian cancer cell Une 2774, in which HER-2/neu is expressed at a basal level, was also inoculated i.p. following the same therapeutic procedure. Ad.E1A(+) could not prolong survival of 2774 cells, indicating that Ad.E1A(+) specifically targeted HER-2/neu-overexpressing tumor cells and functioned as an antitumor agent.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KERN JA, 1990, CANCER RES, V50, P5284; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MITRA AB, 1994, CANCER RES, V54, P637; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PARK JB, 1989, CANCER RES, V49, P6605; PATERSON MC, 1991, CANCER RES, V51, P556; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWADA Y, 1986, J EXP MED, V163, P563, DOI 10.1084/jem.163.3.563; SAWADA Y, 1994, INT J CANCER, V57, P598, DOI 10.1002/ijc.2910570426; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V23, P177; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	55	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1947	1954						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761095				2022-12-28	WOS:A1995QZ92600008
J	MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR				MANNE, V; YAN, N; CARBONI, JM; TUOMARI, AV; RICCA, CS; BROWN, JG; ANDAHAZY, ML; SCHMIDT, RJ; PATEL, D; ZAHLER, R; WEINMANN, R; DER, CJ; COX, AD; HUNT, JT; GORDON, EM; BARBACID, M; SEIZINGER, BR			BISUBSTRATE INHIBITORS OF FARNESYLTRANSFERASE - A NOVEL CLASS OF SPECIFIC INHIBITORS OF RAS TRANSFORMED-CELLS	ONCOGENE			English	Article						P21 RAS PROTEINS; TRANSFORMATION; POSTTRANSLATIONAL MODIFICATIONS; MEVALONATE; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLTRANSFERASE	FARNESYL-PROTEIN TRANSFERASE; GERANYLGERANYL TRANSFERASE; SELECTIVE-INHIBITION; CDNA CLONING; POSTTRANSLATIONAL MODIFICATION; PRENYLATED PROTEINS; ALPHA-SUBUNIT; BETA-SUBUNIT; GTP-BINDING; P21RAS	We describe the biological properties of a new class of potent farnesyltransferase (FT) inhibitors designed as bisubstrate analog inhibitors. These inhibitors incorporate the structural motifs of both farnesyl pyrophosphate and the CAAX tetrapeptide, the two substrates of the reaction catalyzed by FT. Both the phosphinate inhibitor, EMS-185878, and the phosphonate inhibitor, BMS-184467, exhibited higher in vitro FT selectivity than some of the previously reported CVFM peptidomimentics and benzodiazepine analogs. Xenopus oocyte maturation induced by microinjected oncogenic Ras proteins was blocked by coinjected EMS-184467 and EMS-185878. However, both inhibitors showed poor cell activity presumably because of the doubly charged nature of the compounds. Thus, masking the charge on the carboxylate ion markedly improved the cell permeability of EMS-185878, leading to EMS-186511, the methyl carboxyl ester prodrug. EMS-186511 inhibited FT activity in whole cells as determined by inhibition of p21 Ras protein processing, inhibition of farnesylation of proteins including Ras and the accumulation of unfarnesylated Ras proteins in the cytosolic fraction. While the cellular effects of these bisubstrate analog inhibitors had no significant effect on growth of untransformed NIH3T3 cells, they produced pronounced inhibition of Ras transformed cell growth. Both the anchorage dependent and independent growth of ras transformed cells were severely curtailed by micromolar concentrations of EMS-186511, We also found that both H-ras and K-pas transformed cells are affected by this bisubstrate inhibitor. However, K-ras transformed cells appear to be less sensitive. The inhibition of FT activity in cells and the ensuing inhibition of ras transformed cell growth is further manifested in distinct morphological changes in cells. Cells flattened, became less refractile and grew in contact inhibited monolayer. Moreover, the highly diffused character of the actin cytoskeleton in the ras transformed cells was dramatically reverted to an organized network of stress cables crisscrossing the entire cells upon treatment with EMS-186511. All of these effects of EMS-186511 are limited to ras transformed cells that utilize farnesylated Ras, but are not seen in transformed cells that use geranylgeranyl Ras or myristoyl Ras. Significantly, these FT inhibitors did not produce any signs of gross cytotoxicity in untransformed, ras transformed cells or other oncogene transformed cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DIV DISCOVERY CHEM,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT BIOL MOLEC,PRINCETON,NJ 08543; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599	Bristol-Myers Squibb; Bristol-Myers Squibb; University of North Carolina; University of North Carolina Chapel Hill	MANNE, V (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,ONCOL DRUG DISCOVERY,PRINCETON,NJ 08543, USA.		manne, veeraswamy/B-1954-2010	Der, Channing/0000-0002-7751-2747; Cox, Adrienne D./0000-0002-4901-2454; Hunt, John/0000-0001-6389-1021; manne, veeraswamy/0000-0002-1179-5529				AARONSON SA, 1971, J GEN VIROL, V13, P245, DOI 10.1099/0022-1317-13-2-245; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1992, J LIPID RES, V33, P1731; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GEORGES RN, 1993, CANCER RES, V53, P1743; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; GRAY GD, 1993, CANCER RES, V53, P577; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P14182; KASHANISABET M, 1994, CANCER RES, V54, P900; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOIZUMI M, 1993, BIOL PHARM BULL, V16, P879; KOTHAPALLI R, 1993, LIPIDS, V28, P969, DOI 10.1007/BF02537116; LEFTHERIS K, 1994, BIOORG MED CHEM LETT, V4, P887, DOI 10.1016/S0960-894X(01)80257-2; LIU WC, 1992, J ANTIBIOT, V45, P454, DOI 10.7164/antibiotics.45.454; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MANNE V, 1991, MOL BASIS CANCER, P27; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SINENSKY M, 1992, BIOESSAYS, V14, P25, DOI 10.1002/bies.950140106; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; WALLACE RA, 1973, J EXP ZOOL, V18, P321; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	82	137	141	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1763	1779						17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753553				2022-12-28	WOS:A1995QX46900010
J	SEIMIYA, H; SAWABE, T; INAZAWA, J; TSURUO, T				SEIMIYA, H; SAWABE, T; INAZAWA, J; TSURUO, T			CLONING, EXPRESSION AND CHROMOSOMAL LOCALIZATION OF A NOVEL GENE FOR PROTEIN-TYROSINE-PHOSPHATASE (PTP-U2) INDUCED BY VARIOUS DIFFERENTIATION-INDUCING AGENTS	ONCOGENE			English	Article						PTPASE; LEUKEMIA; DIFFERENTIATION	POLYMERASE CHAIN-REACTION; LEUKOCYTE-COMMON ANTIGEN; HL-60 LEUKEMIA-CELLS; C-JUN EXPRESSION; IMMUNOGLOBULIN SUPERFAMILY; CYTOGENETIC ANALYSIS; OKADAIC ACID; SINGLE GENE; RECEPTOR; AMPLIFICATION	Previously, we cloned two gene fragments encoding novel protein tyrosine phosphatases, termed PTP-U1 and PTP-U2. Here, we report the full-length sequence, expression, and chromosomal localization of the PTP-U2 gene. The cDNA for PTP-U2, which was obtained from a human normal kidney library, predicts a protein of 1216 amino acids, -140 kDa, that contains a single transmembrane domain and a single intracellular catalytic domain. The extracellular domain of PTP-U2 contains 14 putative N-glycosylation sites and eight repeats of fibronectin type III-like motif, These data suggest that PTP-U2 is structurally similar to HPTP beta and DPTP10D, which have been reported previously. Northern blot analysis revealed that there were two different transcripts for PTP-U2. In kidney and brain, gene expression of PTP-U2 was detected as a 5.4 kb mRNA and in lung and placenta as 3.5 kb. The 3.5 kb transcript was also detected in human leukemia cell lines (eg., U937), Interestingly, its gene expression was enhanced by various differentiation-inducing agents, such as phorbol ester, dihydroxy vitamin D-3, retinoic acid, and dimethyl sulfoxide. The bacterially expressed PTP-U2 fusion protein exhibited intrinsic tyrosine phosphatase activity. The PTP-U2 gene was assigned to chromosome 12p13.2-p13.3.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Kyoto Prefectural University of Medicine; Japanese Foundation for Cancer Research				Seimiya, Hiroyuki/0000-0003-3314-9736				ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BUTLER TM, 1990, CANCER RES, V50, P6323; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1987, BLOOD, V70, P1233; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANK DA, 1988, CANCER RES, V48, P4299; FRANK DA, 1988, CANCER RES, V48, P52; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KELLY AP, 1991, NATURE, V353, P571, DOI 10.1038/353571a0; KHARBANDA S, 1992, CELL GROWTH DIFFER, V3, P391; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SAYA H, 1993, FEBS LETT, V327, P224, DOI 10.1016/0014-5793(93)80174-S; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; SEIMIYA H, 1993, J BIOCHEM-TOKYO, V113, P687, DOI 10.1093/oxfordjournals.jbchem.a124104; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P46, DOI 10.1016/0167-4889(91)90043-W; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YI TL, 1991, BLOOD, V78, P2222	56	43	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1731	1738						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753550				2022-12-28	WOS:A1995QX46900006
J	SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; MURAKAMI, T; YOSHIDA, M			TAX PROTEIN OF HTLV-1 DESTABILIZES THE COMPLEXES OF NF-KAPPA-B AND I-KAPPA-B-ALPHA AND INDUCES NUCLEAR TRANSLOCATION OF NF-KAPPA-B FOR TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						HTLV-1; I-KAPPA-B; TRANSCRIPTIONAL-ACTIVATION; NF-KAPPA-B	T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEATS; TUMOR-NECROSIS-FACTOR; TRANSACTIVATOR TAX; TRANS-ACTIVATION; GENE-EXPRESSION; PRECURSOR P105; DNA-BINDING; ENHANCER	Tax protein of HTLV-1 stimulates transcription of specific cellular genes through the NF-kappa B binding site. We previously showed that Tax binds to the ankyrin motifs of I kappa B-gamma, and dissociates the I kappa B-gamma/NF-kappa B complexes, resulting in nuclear translocation of NF-kappa B proteins. We herein report the effects of Tax on I kappa B-alpha, another member of I kappa B family proteins expressed in human T cells. Tax binds to I kappa B-alpha and partially dissociates the NF-kappa B/I kappa B-alpha complex in vitro. In Tax-expressing cells, Tax/I kappa B-alpha complex was detected only at low level, but NF-kappa B/I kappa B-alpha complex was mostly dissociated and NF-kappa B was translocated into the nucleus. Furthermore, Tax induced reduction of I kappa B-alpha protein. I kappa B-alpha a protein was stabilized by NF-kappa B protein through forming NF-kappa B/I kappa B-alpha complex, but Tax expression cancelled this stabilization effect on I kappa B-alpha. These findings suggest that Tax induces dissociation of and/or inhibits the formation of NF-kappa B/I kappa B-alpha complexes, resulting in release of NF-kappa B and destabilization of I kappa B-alpha. Consistently, transcription of NF-kappa B directed gene was activated. These Tax effects counteract the negative feedback control of NF-kappa B by I kappa B-alpha and contribute to constitutive activation of NF-kappa B in Tax-transfected and HTLV-1-infected cells.	UNIV TOKYO,INST MED SCI,DEPT CELLULAR & MOLEC BIOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEURLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P68; BAIL OL, 1993, EMBO J, V12, P5043; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CRENON I, 1993, ONCOGENE, V8, P867; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GESSAIN A, 1985, LANCET, V2, P407; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MARUYAMA M, 1987, CELL, V48, P493; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	54	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1199	1207						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700645				2022-12-28	WOS:A1995QN35300022
J	YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC				YATES, KE; LYNCH, MR; WONG, SG; SLAMON, DJ; GASSON, JC			HUMAN C-FES IS A NUCLEAR TYROSINE KINASE	ONCOGENE			English	Note						C-FES; TYROSINE KINASE; NUCLEAR LOCALIZATION; HEMATOPOIESIS	SIGNAL-TRANSDUCTION; GROWTH-HORMONE; GENE-PRODUCT; FPS-GENE; PROTEIN; PHOSPHORYLATION; JAK2; DNA; ERYTHROPOIETIN; LOCALIZATION	FES is a non-receptor protein tyrosine kinase expressed in hematopoietic progenitors and differentiated myeloid cells. It has recently been implicated in granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3) and erythropoietin signal transduction. To better understand the role played by FES in normal and neoplastic hematopoiesis, we used cell fractionation techniques to examine the subcellular localization of FES in myeloid cells and cell lines. FES was observed in the nuclear, granular and plasma membrane fractions of primary human neutrophils and the myeloid leukemia cell line, HL-60. The nuclear localization was confirmed by immunocytochemistry of neutrophils.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL CANCER INSTITUTE [R01CA040163] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA40163, CA09056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CARE A, 1994, ONCOGENE, V9, P739; DHUT S, 1991, ONCOGENE, V6, P1459; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAO QL, 1991, MOL CELL BIOL, V11, P1180, DOI 10.1128/MCB.11.2.1180; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LANFRANCONE L, 1989, INT J CANCER, P35; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Warren L, 1974, Methods Enzymol, V31, P156; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	37	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1239	1242						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700650				2022-12-28	WOS:A1995QN35300027
J	HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB				HAN, EKH; SGAMBATO, A; JIANG, W; ZHANG, YJ; SANTELLA, RM; DOKI, Y; CACACE, AM; SCHIEREN, I; WEINSTEIN, IB			STABLE OVEREXPRESSION OF CYCLIN D1 IN A HUMAN MAMMARY EPITHELIAL-CELL LINE PROLONGS THE S-PHASE AND INHIBITS GROWTH	ONCOGENE			English	Article						CYCLINS; CELL CYCLE; BREAST CANCER	PROTEIN-KINASE-C; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; RAT FIBROBLASTS; DEPENDENT KINASES; CHROMOSOME 11Q13; MAMMALIAN-CELLS; SQUAMOUS-CELL; BREAST-CANCER; EXPRESSION	Amplification and/or increased expression of cyclin D1 occurs in an appreciable fraction of primary human breast carcinomas and several other types of human cancer. In addition, overexpression of cyclin D1 in rodent fibroblasts enhances growth and malignant transformation. The present study demonstrates that the extent of amplification and expression of cyclin D1 varies widely amongst a series of cell lines established from normal human mammary epithelium or human breast carcinomas, The HBL-100;mammary epithelial cell line did not display amplification or increased expression of cyclin D1. We used retrovirus-mediated transduction to obtain derivatives of this cell line that stably expressed relatively high levels of an exogenous cyclin D1 cDNA. These derivatives displayed an increased doubling time, decreased saturation density, decreased cloning efficiency, decreased anchorage-independent growth, an increased fraction of cells in the S-phase, and decreased tumorigenicity. Thus, increased expression of cyclin D1 in this cell line markedly inhibits rather than enhances growth, which may be due to the prolongation of S-phase.	COLUMBIA UNIV,COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CANC RES INST,NEW YORK,NY 10032	Columbia University; Columbia University			; Sgambato, Alessandro/K-7266-2016	Jiang, Wei/0000-0002-2309-9571; Sgambato, Alessandro/0000-0002-9487-4563				BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BERENSON JR, 1990, ONCOGENE, V5, P1343; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1993, CANCER SURV, V18, P77; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; GAFFNEY EV, 1982, CELL TISSUE RES, V227, P563, DOI 10.1007/BF00204786; GILLETT C, 1994, CANCER RES, V54, P1812; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P440; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, GENE DEV, V8, P9; PROCTOR AJ, 1991, ONCOGENE, V6, P789; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAINTRUF C, 1988, EXP CELL RES, V176, P60, DOI 10.1016/0014-4827(88)90120-6; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; TAM SW, 1994, ONCOGENE, V9, P2663; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	76	99	103	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898937				2022-12-28	WOS:A1995QL03800017
J	KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J				KANEKO, Y; NONOGUCHI, K; FUKUYAMA, H; TAKANO, S; HIGASHITSUJI, H; NISHIYAMA, H; TAKENAWA, J; NAKAYAMA, H; FUJITA, J			PRESENCE OF ALTERNATIVE 5'-UNTRANSLATED SEQUENCES AND IDENTIFICATION OF CELLS EXPRESSING CTK TRANSCRIPTS IN THE BRAIN AND TESTIS	ONCOGENE			English	Article						CTK; PROTEIN TYROSINE KINASE; BRAIN; TESTIS; ALTERNATIVE SPLICING; MALE GERM CELLS	PROTEIN-TYROSINE KINASES; RAT-BRAIN; C-SRC; MOUSE; FAMILY; GENE; CSK; LOCALIZATION; ACTIVATION; PP60C-SRC	From a mouse brain cDNA library, two species of the Csk-type tyrosine kinase (ctk) gene containing different 5' untranslated sequences were cloned, Using the common as well as specific nucleotide sequences of the two clones as probes, we examined the expression of ctk in various mouse tissues by Northern blot analysis, The results indicated that both species of ctk were expressed in the brain, testis and bone marrow, By in sits histochemistry of the brain, ctk transcript was detected in neurons throughout the entire brain, especially those of the cortex, the hippocampus and the cerebellum. This distribution pattern is similar to that of the Src family kinases including Yes, Src, Fyn and Lyn. In the testis, the major transcript (0.7 kb) was shorter than that expressed in the brain and the bone marrow (2.0 kb), A subsequent Northern blot analysis of fractionated germ cell populations and in situ histochemistry revealed that the short and long transcripts were expressed in germ cells and somatic cells, respectively, and that the expression level was quantitatively regulated during germ cell development. These results suggest that Ctk is involved in the regulation of neural function and differentiation of male germ cells through interactions with member(s) of the Src family kinases.	KYOTO UNIV, FAC MED, DEPT CLIN MOLEC BIOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT NEUROSCI, SAKYO KU, KYOTO 606, JAPAN; NIIGATA UNIV, FAC SCI, DEPT BIOL, NIIGATA 95021, JAPAN	Kyoto University; Kyoto University; Niigata University								BARE DJ, 1993, ONCOGENE, V8, P1429; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DUGGAL RN, 1987, ANN NY ACAD SCI, V513, P112, DOI 10.1111/j.1749-6632.1987.tb25002.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANEKO Y, 1993, BIOCHEM BIOPH RES CO, V197, P625, DOI 10.1006/bbrc.1993.2525; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MISKIMINS K, 1990, IRON TRANSPORT STORA, P119; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKANO S, 1994, ONCOGENE, V9, P1155; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZHAO YH, 1991, ONCOGENE, V6, P1725	35	15	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					945	952						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898936				2022-12-28	WOS:A1995QL03800016
J	DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A				DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A			INDUCTION OF THE MITOGEN-ACTIVATED P70 S6 KINASE BY ADENOVIRUS E1A	ONCOGENE			English	Article						E1A; ONCOGENE; TRANSCRIPTION; P70 S6 KINASE; PHOSPHORYLATION; TRANSFORMATION	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; CELL-CYCLE; PROTEIN-KINASE; MAP KINASES; C-JUN; PHOSPHORYLATION; GROWTH; TRANSFORMATION	Adenovirus E1A proteins can transform primary cells in culture in conjunction with other oncogenes, such as E1B or activated ras. The modulation of various cell cycle regulators by E1A is thought to be involved in this transformation process. In this paper we show that E1A enhances the expression of the mitogen-inducible p70 S6 kinase (70(s6k)), a kinase which is essential for G1 progression. p70(s6k) mRNA and protein levels are enhanced 3-4-fold in various E1A-expressing cell lines. Similarly, the activity of p70(s6k) is enhanced in E1A-expressing cells in a manner partially independent of enhanced expression of p70(s6k) The induction of p70(s6k) correlates with the presence of conserved region 1 (CR1) of E1A and with morphological transformation by E1A. These results suggest that induction of p70(s6k) by E1A might be involved in transformation by E1A.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,LEIDEN,NETHERLANDS; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Leiden University; Leiden University - Excl LUMC; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANNERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1991, ONCOGENE, V6, P2357; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MORAN E, 1986, MOL CELL BIOL, V7, P3470; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845679				2022-12-28	WOS:A1995QF64800015
J	LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK				LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK			MTS-1 (CDKN2) TUMOR-SUPPRESSOR GENE DELETIONS ARE A FREQUENT EVENT IN ESOPHAGUS SQUAMOUS CANCER AND PANCREATIC ADENOCARCINOMA CELL-LINES	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; ESOPHAGUS CANCER; PANCREAS CANCER	BLADDER-CANCER; CHROMOSOME-9; EXPRESSION; RETINOBLASTOMA; MUTATION; RECEPTOR; REGION	MTS-1 is a candidate tumor suppressor gene on chromosome 9p21-22, a region frequently observed to have loss of heterozygosity in esophagus squamous cell carcinomas and pancreatic ductal adenocarcinomas. In order to determine whether MTS-1 sequences are deleted or mutated in cell lines derived from these cancers, we performed PCR amplification of MTS-1 exons 1 and 2. In this fashion, we found that 67% of esophagus squamous cancer cell lines have deletions of both exons 1 and 2, and 50% of pancreatic cancer cell lines have similar deletions. Furthermore, an additional 30% of pancreatic cancer cell lines harbored point mutations or microdeletions based on DNA sequencing. MTS-1 encodes p16, an inhibitor of cyclin-dependent kinase 4 (cdk4) which complexes with cyclin D1. Our data suggest that MTS-1 deletions and mutations may play an important role in the molecular pathogenesis of esophagus squamous cell and pancreatic cancers.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Myriad Genetics, Inc								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; CAIRNS P, 1993, CANCER RES, V53, P1230; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HOHNE MW, 1992, CANCER RES, V52, P2616; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JAMES CD, 1993, CANCER RES, V53, P3674; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; REDSTON MS, 1994, CANCER RES, V54, P3025; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; RUPPERT JM, 1993, CANCER RES, V53, P5093; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; VANDERRIET P, 1994, CANCER RES, V54, P1156	26	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					619	622						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845688				2022-12-28	WOS:A1995QF64800024
J	VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M				VANDEL, L; PFARR, CM; HUGUIER, S; LOISEAU, L; SERGEANT, A; CASTELLAZZI, M			INCREASED TRANSFORMING ACTIVITY OF JUNB AND JUND BY INTRODUCTION OF AN HETEROLOGOUS HOMODIMERIZATION DOMAIN	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; JUN; DIMERIZATION; BZIP TRANSCRIPTION FACTOR; AP1	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING PROTEIN; C-JUN; LEUCINE ZIPPER; ONCOGENE JUN; TRANSCRIPTIONAL ACTIVATION; CELLULAR-TRANSFORMATION; SARCOMA VIRUS; FOS PROTEINS; GENE FAMILY	The closely-related proteins c-Jun, JunB and JunD form a family of transcription factors which require dimerization for DNA-binding and transcriptional activity. Dimerization is mediated by a conserved amphipathic a-helix located adjacent to a highly charged DNA-binding domain. The Jun proteins can form both homo and heterodimers within the Jun family and can-also cross-dimerize with the Fos proteins. When expressed at high levels in primary chicken cells, each mouse Jun displays distinct transforming capacities: c-Jun transforms efficiently, JunB transforms poorly, and JunD does not transform at all, The composition of the transforming dimers; however, is unknown. To study the activity of Jun-Jun homodimers we constructed artificial derivatives, denoted Jun(eb1), the naturally occurring dimerization been replaced by an heterologous homodimerization domain from the Epstein-Barr virus transcription factor EB1. These derivatives were introduced into chicken cells and assayed for their ability to affect growth. Unexpectedly, all three Jun(eb1) proteins conferred a transformed phenotype to primary cultures, promoting sustained growth in low-serum medium and colony formation from single cells in agar. These data demonstrate that when forced to accumulate as homodimers, both JunB and JunD can transform cells. They also suggest that the poor transforming activity of JunB and the absence of transforming activity of JunD may be due to their inability to accumulate to high levels as homodimers.	ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,URA 1644,UNITE VIRUS ONCOGENES,F-75724 PARIS,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pfarr, Curt/HHD-1410-2022	Vandel, Laurence/0000-0002-3692-2942				ANDERSON DD, 1981, J VIROL, V37, P445, DOI 10.1128/JVI.37.1.445-458.1981; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BERGER I, 1991, ONCOGENE, V6, P561; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3241; CHIU R, 1989, CELL, V54, P541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARRISON SC, 1991, NATURE, V363, P715; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HARTL M, 1991, ONCOGENE, V6, P1623; HARTL M, 1992, CELL GROWTH DIFFER, V3, P909; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVISTA N, 1994, ONCOL REP, V1, P185; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; METIVIER C, 1993, ONCOGENE, V8, P2311; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIMURA T, 1988, ONCOGENE, V3, P659; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	64	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					495	507						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845674				2022-12-28	WOS:A1995QF64800010
J	PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S				PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S			C-MYB ACTS AS TRANSCRIPTIONAL ACTIVATOR OF THE QUAIL PAX6 (PAX-QNR) PROMOTER THROUGH 2 DIFFERENT MECHANISMS	ONCOGENE			English	Article						C-MYB; PAX-6-REGULATION; NEURORETINA	HOMEOBOX-CONTAINING GENE; DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; MIM-1 GENE; B-MYB; SYNERGISTIC ACTIVATION; FUNCTIONAL DOMAINS; PROTEIN TRUNCATION; ESTROGEN-RECEPTOR	To understand the regulation of the Pax-6 gene, which plays an important role in eye development, we have characterized the promoter region of the quail Pax-6(Pax-QNR) gene. In addition to TATA and CAAT boxes, sequence analysis revealed several putative cis-regulatory elements among which three myb-responsive elements (MRE). C-myb encodes a nuclear, DNA-binding phosphoprotein that functions as transcriptional regulator. Co-transfection in quail embryo cells of the Pax-QNRlpax-6 promoter with a vector expressing the 75 kDa c-myb protein resulted in an increase in Pax-QNR promoter activity. By footprinting experiments we identified multiple binding sites for the myb protein within the promoter region. Protein containing the myb DNA-binding domain fused to the VP16-transactivation domain was fully efficient in Pax-QNR promoter transactivation, demonstrating that myb can transactivate through a direct binding on DNA. However, a myb truncated protein devoid of DNA-binding domain was also able to transactivate the Pax-QNR promoter. These results show that this promoter can be transactivated by the myb protein directly as well as indirectly. Finally we show by in situ hybridization that c-myb is strongly expressed in the developing neuroretina, simultaneously with Pax-QNR. These observations suggest that the c-myb protein may be a regulator of Pax-QNR/pax-6.	INST PASTEUR,DIFFERENCIAT CELLULAIRE & MOLEC LAB,CNRS,EP56,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014; plaza, serge/F-5290-2015					AKAM M, 1987, DEVELOPMENT, V101, P1; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; Crepieux Pascale, 1993, Gene Expression, V3, P215; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1185; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARTIN P, 1992, ONCOGENE, V7, P1721; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MOELLING K, 1984, CELL, V40, P983; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; QUEVA C, 1992, DEVELOPMENT, V114, P125; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	60	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					329	340						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838532				2022-12-28	WOS:A1995QC62400012
J	BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF				BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF			CELL PROLIFERATION AND CELL-CYCLE PROGRESSION ARE NOT IMPAIRED IN FIBROBLASTS AND ES CELLS LACKING C-FOS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; CELL CYCLE; ES CELLS; FIBROBLASTS	EMBRYONIC STEM-CELLS; TRANSGENIC MICE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; NERVOUS-SYSTEM; ANTISENSE RNA; NULL MUTATION; AP-1 ACTIVITY; DNA-SYNTHESIS; JUN	The transcription factor AP-1 is thought to play an important role in the control of cell proliferation, but the function of individual Fos and Jun family members is a largely unresolved issue. To directly analyse the function of c-Fos in the control of cell proliferation we have used embryonic stem (ES) cells and fibroblasts lacking c-Fos due to a disruption of the c-fos gene by homologous recombination, Our results demonstrate that proliferation of normally cycling cells and reentry of quiescent cells into the cell cycle following serum stimulation are not c-Fos-dependent and occur with similar efficiency in c-fos-/- and control cells. We also show that there is no compensatory overexpression or activation of other known Pos or Jun family members. On the contrary, the c-fos-/- cells showed a reduced induction of fra-1 after serum stimulation which is in agreement with the previous identification of fra-1 as a c-Fos target gene. Comparison of the AP-1 binding and transactivation activities in c-fos-/- and +/+ fibroblasts by electrophoretic mobility antibody supershift and CAT assays suggests that c-Fos is not a major component of AP-1 complexes in these cells. It is therefore conceivable that the lack of any detectable effect on cell proliferation in c-fos-/- cells might be due to a functional redundancy among the different AP-1 family members.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Müller, Rolf/L-4997-2016; Martin, Schreiber/F-2175-2013	Müller, Rolf/0000-0003-3339-4248; Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BRASELMANN S, 1992, J CELL SCI S, V16, P97; BURKERT U, 1991, NEW BIOL, V3, P698; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GORMAN CM, 1982, P NATL ACAD SCI USA, V79, P433; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Grigoriadis Agamemnon E., 1993, P497; HILBERG F, 1992, ONCOGENE, V7, P2371; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OKUNO H, 1991, ONCOGENE, V6, P1491; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859	46	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824281				2022-12-28	WOS:A1995QA98000010
J	ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E				ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E			P53-DEPENDENT PATHWAY OF RADIO-INDUCED APOPTOSIS IS ALTERED IN FANCONI-ANEMIA	ONCOGENE			English	Article						P53; APOPTOSIS; FANCONI ANEMIA; RADIATIONS	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; CELL-CYCLE CONTROL; ATAXIA-TELANGIECTASIA; GROWTH-ARREST; GENE AMPLIFICATION; MICE DEFICIENT; LEUKEMIC-CELLS; G2 PHASE	Fanconi anemia belongs to a group of human genetic diseases characterized by chromosomal instability, sensitivity to genotoxic agents associated to impaired processing of DNA lesions, cell cycle anomalies and cancer predisposition. We recently added to this list of distinctive features reduced production of interleukin 6 and overproduction of tumor necrosis factor alpha. Since growth factor deprivation, TNF alpha treatment or DNA damage can trigger apoptosis, we monitored the apoptotic response of FA cell lines. We show here that, although the spontaneous rate of apoptosis is slightly more elevated in FA than in normal cell cultures, the apoptosis induced by gamma-irradiation is drastically reduced in FA. Since the induction of apoptosis by radiation is a p53-dependent mechanism, the induction of this protein in FA cells was also examined. We found that the p53 protein is not radio-induced in FA cells belonging to the two genetic complementation groups examined (C and D), in contrast to normal cells. Moreover, the same impairment in p53 induction is observed after exposure to mitomycin C, a chemical agent for which FA cells demonstrate a specific cellular and chromosomal hypersensitivity, as well as after u.v.-B irradiation, an agent known to cause oxidative stress. These observations are in line with recent reports showing that at least certain cell lines from other chromosome breakage syndromes, such as ataxia telangiectasia and Bloom syndrome, may be also defective for radiation-induced increase of p53 protein. As the p53 tumor suppressor gene encodes a transcriptional activator whose targets include genes that regulate genomic stability, cellular response to DNA damage and cell cycle progression, we suggest that altered expression of p53 may be relevant to the FA phenotype.	INST GENET MOLEC, INSERM, U301, F-75010 PARIS, FRANCE; INST CURIE, DEPT RADIOTHERAPIE, MED SECT, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROSSELLI, F (corresponding author), INST CURIE, CNRS, URA 1292, 26 RUE ULM, F-75231 PARIS 05, FRANCE.		Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; soussi, thierry/0000-0001-8184-3293				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; BAGNARA GP, 1993, STEM CELLS, V11, P137; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BEUTLER B, 1990, Critical Reviews in Oncogenesis, V2, P9; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GLUCKMAN E, 1990, RADIOTHER ONCOL S, V1, P88; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; JENSEN PO, 1994, CYTOMETRY, V15, P154, DOI 10.1002/cyto.990150209; JONVEAUX P, 1991, NOUV REV FR HEMATOL, V33, P343; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, ONCOGENE, V5, P973; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; PARSHAD R, 1983, P NATL ACAD SCI-BIOL, V80, P5612, DOI 10.1073/pnas.80.18.5612; PERDAHL EB, 1994, BLOOD, V83, P645; ROSSELLI F, 1994, BLOOD, V83, P1216; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; STRATHDEE CA, 1992, AM J PEDIAT HEMATOL, V14, P177; VANLAAR T, 1994, ONCOGENE, V9, P981; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGNER RD, 1991, ADV MUTAGENESIS RES, V3, P81; WEICHSELBAUM RR, 1980, CANCER RES, V40, P920; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEKSBERG R, 1979, J CELL PHYSIOL, V101, P311, DOI 10.1002/jcp.1041010211; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	65	65	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824283				2022-12-28	WOS:A1995QA98000002
J	FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP				FLETCHER, FA; CARPENTER, MK; SHILLING, H; BAUM, P; ZIEGLER, SF; GIMPEL, S; HOLLINGSWORTH, T; BOS, TV; JAMES, L; HJERRILD, K; DAVISON, BL; LYMAN, SD; BECKMANN, MP			LERK-2, A BINDING-PROTEIN FOR THE RECEPTOR-TYROSINE KINASE ELK, IS EVOLUTIONARILY CONSERVED AND EXPRESSED IN A DEVELOPMENTALLY-REGULATED PATTERN	ONCOGENE			English	Article							GROWTH-FACTOR; FAMILY; GENE; PHOSPHORYLATION; MEMBERS; CLONING; CELLS; SITES	We have isolated and characterized cDNA clones that encode the rat homologue of a binding protein, LERK-2, for the receptor tyrosine kinase, elk. The cDNAs contain an open reading frame of 1527 nucleotides capable of encoding a protein 345 amino acid residues in length. The nucleotide sequence of the present clones is >90% identical to the previously identified human LERK-2 cDNA, and the predicted proteins encoded by the rat and human clones are identical at 95% of amino acid residues. Recombinant proteins expressed from the rat cDNAs bind to elk with high affinity, similar to recombinant human LERK-2 and an endogenously-expressed rat elk-binding protein. Expression of the rat LERK-2 mRNA was detected in embryonic brain, kidney, lung, skeletal muscle, thymus, liver, and heart, and diminished in the early post-natal period. Significant LERK-2 mRNA expression in the young adult rat was restricted to the lung, kidney, heart and testes.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101									BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, IN PRESS EMBO J; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAN J, 1991, ONCOGENE, V6, P1057; COOPER JA, 1984, J BIOL CHEM, V259, P7835; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	29	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3241	3247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936648				2022-12-28	WOS:A1994PM65800017
J	LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP				LOGANZO, F; DOSIK, JS; ZHAO, Y; VIDAL, MJ; NANUS, DM; SUDOL, M; ALBINO, AP			ELEVATED EXPRESSION OF PROTEIN-TYROSINE KINASE C-YES, BUT NOT C-SRC, IN HUMAN-MALIGNANT MELANOMA	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN MELANOCYTES; POINT MUTATIONS; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CUTANEOUS MELANOMA; SURFACE-ANTIGENS; CELLULAR-YES; HUMAN DNA; DIFFERENTIATION	The c-yes proto-oncogene encodes a protein tyrosine kinase, p62c-yes (c-Yes) that belongs to the Src family of non-receptor type protein tyrosine kinases. We compared the levels of c-Yes kinase activity and protein by immune complex kinase assays and immune blot analysis in 20 human melanoma and 10 human melanocyte cell tines. Results show that the average kinase activity of c-Yes in most melanoma cell lines is 5-10-fold higher than that in melanocyte cell lines. The protein level of c-Yes in these melanoma cell lines is correspondingly higher than that in melanocytes. The increase in c-Yes kinase activity is most likely attributable to the elevated protein level because single-strand conformational polymorphism of all structural and functional domains detected no mutations in any of the c-yes coding regions. Subcellular fractionation analysis indicated that c-Yes localizes to the plasma membrane, perinuclear and cytosolic compartments while c-Src predominantly associates with plasma membranes. In melanoma cells in which an elevated level of c-Yes is observed, a protein of 39 kD is heavily phosphorylated on tyrosine. This protein is only observed in melanoma cells and not in melanocytes, suggesting a perturbed signaling pathway in melanoma cells that results in abnormal tyrosine phosphorylation of cellular proteins. These data suggest that derangement of expression of the c-Yes tyrosine kinase may have a role in the malignant progression of the human melanocyte.	MEM SLOAN KETTERING CANC CTR,MAMMALIAN CELL TRANSFORMAT LAB,1275 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Rockefeller University					NATIONAL CANCER INSTITUTE [R01CA037907] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37907, CA-01605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ALBINO AP, 1991, CANCER RES, V51, P4815; ALBINO AP, 1993, IN PRESS CANCER TREA; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DANENBERG PV, 1992, NUCLEIC ACIDS RES, V20, P573, DOI 10.1093/nar/20.3.573; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P5847, DOI 10.1073/pnas.78.9.5847; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOLDEN A, 1988, ONCOGENE HDB, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; HALABAN R, 1991, Critical Reviews in Oncogenesis, V2, P247; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; Houghton A N, 1988, Prog Clin Biol Res, V256, P333; HOUGHTON AN, 1988, J EXP MED, V167, P197, DOI 10.1084/jem.167.1.197; HOUGHTON AN, 1982, J EXP MED, V156, P1755, DOI 10.1084/jem.156.6.1755; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KOPF AW, 1984, J AM ACAD DERMATOL, V11, P674, DOI 10.1016/S0190-9622(84)70225-8; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRUEGER J, 1991, ONCOGENE, V6, P933; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LONGSTRETH J, 1988, CANCER METAST REV, V7, P321, DOI 10.1007/BF00051373; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MCCLAY EF, 1991, CRIT REV ONCOL HEMAT, V11, P299, DOI 10.1016/1040-8428(91)90030-G; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PESCE A, 1964, J BIOL CHEM, V239, P1753; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROWLEY JD, 1990, CANCER RES, V50, P3816; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEMBA K, 1992, GENES CANCER, P74; SOBER AJ, 1991, DERMATOL CLIN, V9, P617; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUDOL M, 1992, MOL BASIS HUMAN CANC; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; VEILLETTE A, 1989, ONCOGENES, P121; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	65	55	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2637	2644						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690926				2022-12-28	WOS:A1993LX34300004
J	PARK, JS; MEISLER, AI; CARTWRIGHT, CA				PARK, JS; MEISLER, AI; CARTWRIGHT, CA			C-YES TYROSINE KINASE-ACTIVITY IN HUMAN COLON-CARCINOMA	ONCOGENE			English	Article								To examine the role of Src-related proteins in human colon carcinoma we measured the tyrosine kinase activity of pp60c-src (Src), p62c-yes (Yes), p56lck (Lck), p59fyn (Fyn), p59hck (Hck), p56lyn (Lyn) and p55c-fgr (Fgr) from colonic cells. Yes activity, similar to that of Src, was 10-20 fold higher in three of five colon carcinoma cell lines and fivefold higher in 10 of 21 primary colon cancers than that in normal colonic cells. Lck activity was present in COLO 205 cells, otherwise Lck, Fyn, Hck, Lyn and Fgr activities were not detected in any of the carcinoma cell lines or cancers tested. Increased Yes activity, like that of Src, was due mostly to increased protein levels and not to an apparent decrease in phosphorylation of Tyr 537, the major mechanisms known to deregulate enzymatic activity. Only those colon carcinoma cell lines with elevated Src and/or Yes tyrosine kinase activity as measured in vitro had elevated levels of three tyrosine-phosphorylated proteins as measured in vivo. Thus, colon carcinoma cells contain active tyrosine kinases and/or inactive tyrosine phosphatases not present in normal colonic cells, and Src and Yes appear to be active kinases in the carcinoma cells. These data, together with those demonstrating decreased Src activity in fully differentiated enterocytes, suggest that down regulation of Src-related tyrosine kinases is important for differentiation, and/or deregulation of the kinases is important for growth and transformation of intestinal epithelial cells.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,MED SCH LAB SURGE BLDG, P304, STANFORD, CA 94305 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15240 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIDDK NIH HHS [R29 DK43743, P30-DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043743, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BUCKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAY R, 1992, CATALOGUE CELL LINES, P119; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLEY TR, 1989, ONCOGENE, V4, P265; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629	69	116	117	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2627	2635						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690925				2022-12-28	WOS:A1993LX34300003
J	CORBEIL, HB; WHYTE, P; BRANTON, PE				CORBEIL, HB; WHYTE, P; BRANTON, PE			CHARACTERIZATION OF TRANSCRIPTION FACTOR E2F COMPLEXES DURING MUSCLE AND NEURONAL DIFFERENTIATION	ONCOGENE			English	Article						CELL CYCLE; DIFFERENTIATION E2F; TRANSCRIPTION FACTOR RETINOBLASTOMA	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; DNA-BINDING ACTIVITY; NERVE GROWTH-FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; VIRAL ONCOPROTEINS; PC12 CELLS; P107; FAMILY	The activities of E2F transcription factors are inhibited by interactions with members of the retinoblastoma (RE) tumor suppressor family, p105(RB), p107 and p130, In cycling cells p107 and p130 also interact with heterodimers comprised of Cdk2 and either A or E cyclins. We characterized E2F complexes present in C2C12 and P19 mouse cells induced to differentiate into muscle and neuronal cells, respectively. In both undifferentiated C2C12 and P19 cells, in addition to free species, E2F was found in complexes containing p107 or p130 and Cdk2. No E2F-pRB complexes were detected by electrophoretic mobility shift assays even though such cells were shown to contain pRB and E2F species capable of interacting in vitro. These results suggested that although present, pRB was unable to interact with E2F. Following differentiation of C2C12 cells into myotubes, E2F was present in at least two complexes which contained p130, but not in those containing p107 or Cdk2. Low levels of E2F-pRB complexes were also detected in fully differentiated C2C12 myotubes and in freshly isolated skeletal muscle. In the case of differentiated P19 neuronal cells, E2F was found in complexes containing pRB, p107 and p130. However, such cells may not be representative of fully differentiated neurons, as studies with rodent brain extracts indicated that only pRB-E2F complexes and those recognized by a p130-specific serum were present. These results suggested that in both muscle and neurons, pRB and p130 may play specific roles in the development or maintenance of terminal differentiation.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8S 4K1,CANADA	McGill University; McGill University; McMaster University								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V353, P249; BARBEAU D, 1994, ONCOGENE, V9, P359; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P128; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1994, J VIROL, V68, P6697, DOI 10.1128/JVI.68.10.6697-6709.1994; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1994, FASEB J, V7, P846; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYOL X, 1993, ONCOGENE, V8, P2561; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V55, P1144; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLACK RS, 1993, ONCOGENE, V8, P1585; SMITH DB, 1988, GENE, V657, P31; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIMAN KG, 1994, FASEB J, V7, P841; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	71	91	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					909	920						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675450				2022-12-28	WOS:A1995RU79800012
J	JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP				JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP			MOLECULAR-CLONING AND EXPRESSION PATTERN OF GENES FROM A 470 KB REGION NEAR BRCA1 LOCUS ON CHROMOSOME-17Q21	ONCOGENE			English	Note						CDNA; HYBRIDIZATION SELECTION; BRCA1 LOCUS; EXPRESSED SEQUENCES	FAMILIAL BREAST; OVARIAN-CANCER; POLYMORPHISMS; LOCALIZATION; FRAGMENTS; SELECTION; SEQUENCES; LINKAGE; CDNA	We have used direct cDNA selection to isolate expressed sequences from a set of four overlapping YACs, spanning approximately 470 kb of the chromosomal interval 17q21 centromeric to BRCA1 gene. Thirty-eight nonoverlapping unique cDNA fragments were identified in this region. Twenty-two of the selected cDNAs showed complete identity with known genes and expressed sequence tags. Two of these cDNAs shared sequence homology with genes known to encode potential DNA binding motifs and hence could function in transcriptional regulation. The remaining 16 unique cDNA fragments showed no significant similarity to sequences in the databases and could potentially encode novel genes. Northern analysis of the novel cDNAs showed differential expression in various tissues, supporting the transcribed nature of these sequences. Our results place the gene for a G-protein coupled receptor (GPR2) previously mapped to 17q within a 400 kb region on 17q21.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yale University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC001682] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC-01682] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRODY LC, 1995, GENOMICS, V25, P238, DOI 10.1016/0888-7543(95)80131-5; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1993, HUM MOL GENET, V2, P821, DOI 10.1093/hmg/2.6.821; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL AP, 1994, SCIENCE, V266, P120; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KRIZMAN DB, 1993, FOCUS, V15, P106; LANDSMAN D, 1989, NUCLEIC ACIDS RES, V17, P2301, DOI 10.1093/nar/17.6.2301; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; OSBORNELAWRENCE S, 1995, GENOMICS, V25, P248, DOI 10.1016/0888-7543(95)80132-6; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATEL K, 1991, NUCLEIC ACIDS RES, V19, P4371, DOI 10.1093/nar/19.16.4371; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P6565; PELTOKETO H, 1992, EUR J BIOCHEM, V209, P459, DOI 10.1111/j.1432-1033.1992.tb17310.x; Sambrook J, 1989, MOL CLONING LABORATO; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SULTSON J, 1992, NATURE, V356, P37; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; Zhao H. G., 1994, American Journal of Human Genetics, V55, pA252; ZHENG Y, 1991, CELL, V655, P817	35	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					981	986						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675458				2022-12-28	WOS:A1995RU79800020
J	SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA				SHAO, ZM; DAWSON, MI; LI, XS; RISHI, AK; SHEIKH, MS; HAN, QX; ORDONEZ, JV; SHROOT, B; FONTANA, JA			P53 INDEPENDENT G(0)/G(1) ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						RETINOIDS; BREAST CANCER; APOPTOSIS	ACID RECEPTOR-GAMMA; D-TYPE CYCLINS; X-RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; GROWTH; DEATH; GENE; IDENTIFICATION	The biological activity of a novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) was investigated in human breast carcinoma (HBC) cells. Although capable of selective binding to the RAR gamma nuclear receptor, AHPN inhibited the growth of a number of HBC cell lines via RAR- or RXR-independent pathways. AHPN also inhibited the growth of the human leukemia cell line HL-60R which does not possess functional RARs. RA significantly inhibited AP-1 mediated gene activation in MCF-7 cells while AHPN displayed no such anti-AP-1 activity. Retinoids normally are cytostatic in their inhibition of breast carcinoma growth and permit cell proliferation upon their removal, whereas AHPN induced G(0)/G(1) arrest within 6 h followed by apoptosis. In MCF-7 cells that harbor wild type p53, AHPN-induced G(0)/G(1) arrest and apoptosis was accompanied by p53-independent regulation of WAF1/CIP1 as well as bar mRNA levels while bcl-2 mRNA levels were decreased. In MDA-MB-231 cells which possess a mutant p53, AHPN-mediated G(0)/G(1) arrest and apoptosis was also associated with a concomitant up regulation of WAF1/CIP1 mRNA while these cells did not express bar or bcl-2 messages. Thus, AHPN represents a novel retinoid that induces G(0)/G(1) arrest and apoptosis via a unique pathway which appears to involve activation of known downstream effecters of p53 in a p53-independent manner.	UNIV MARYLAND, CTR CANC, DEPT MED, DIV HEMATOL & MED ONCOL, BALTIMORE, MD 21201 USA; DEPT VET AFFAIRS MED CTR, BALTIMORE, MD 21201 USA; SRI INT, DIV LIFE SCI, MENLO PK, CA 94025 USA; CTR INT RECH DERMATOL GALDERMA, VALBONNE, FRANCE	University System of Maryland; University of Maryland Baltimore; SRI International; Galderma R&D SNC				Fontana, Joseph/0000-0003-3829-3358	NCI NIH HHS [CA 63335, CA 51993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993, R01CA063335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLENBY G, 1994, J BIOL CHEM, V269, P16689; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BUSAM KJ, 1992, J BIOL CHEM, V267, P19971; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; DAVIES PJA, 1993, MAR AM ASS CANC RES; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1992, RETINOIDS NEW TRENDS, P205; DAWSON MI, UNPUB; DHRIKH MD, 1993, ANTICANCER RES, V13, P1387; DOMINIANNI SJ, 1977, J ORG CHEM, V42, P344, DOI 10.1021/jo00422a037; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HALDAR S, 1994, CANCER RES, V54, P2095; HERMANN T, 1993, ONCOGENE, V8, P55; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; JAFFEY P, 1992, CANCER RES, V52, P2384; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG W, 1993, ONCOGENE, V8, P3447; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1992, CELL SCI S, V16, P69; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MADER S, 1993, J BIOL CHEM, V268, P591; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOASSER MM, 1994, ONCOGENE, V9, P833; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; ROBERTSON KA, 1992, BLOOD, V80, P1885; ROMAN SD, 1993, CANCER RES, V53, P5940; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V183, P1003, DOI 10.1016/S0006-291X(05)80290-6; SHROOT B, 1990, Patent No. 4940696; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPORN MB, 1991, MOL ENDOCRINOL, V5, P3, DOI 10.1210/mend-5-1-3; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	86	232	250	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					493	504						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630633				2022-12-28	WOS:A1995RN53000009
J	ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB				ZHOU, P; JIANG, W; ZHANG, YJ; KAHN, SM; SCHIEREN, I; SANTELLA, RM; WEINSTEIN, IB			ANTISENSE TO CYCLIN D1 INHIBITS GROWTH AND REVERSES THE TRANSFORMED PHENOTYPE OF HUMAN ESOPHAGEAL CANCER-CELLS	ONCOGENE			English	Article						ANTISENSE; CYCLIN D1; ESOPHAGEAL CANCER; TUMORIGENICITY	RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; AMPLIFICATION; GENE; OVEREXPRESSION; EXPRESSION; FIBROBLASTS; CARCINOMAS; 11Q13; PHASE	The cyclin D1 gene is amplified and overexpressed in a significant fraction of human esophageal tumors, and several other types of human cancer, but the functional significance of this overexpression has not been established. To further address the roles of cyclin D1 in growth control and tumorigenesis, we have overexpressed an antisense cyclin D1 cDNA construct, either constitutively or inducibly, in the HCE7 human esophageal cancer cell line in which cyclin D1 is amplified and expressed at high levels. The expression of antisense cyclin D1 led to decreased expression of cyclin D1 at both the mRNA and protein levels, and this was associated with a marked inhibition of cell proliferation. Antisense cyclin D1 expressing cells displayed a decreased plating efficiency, increased doubling time, decreased saturation density, increased cell size, decreased cyclin D1-associated in vitro kinase activity, decreased anchorage-independent growth, and a loss of tumorigenicity in nude mice. These findings provide direct evidence that the overexpression of cyclin D1 in certain tumor cells contributes to their abnormal growth and tumorigenicity. The ability to revert the transformed phenotype of these cells with antisense cyclin D1 suggests that cyclin D1 may be a useful target in cancer therapy.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,INST CANC RES,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute				Jiang, Wei/0000-0002-2309-9571				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BONHAM L, 1991, ONCOGENE, V6, P1073; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GILLETT C, 1994, CANCER RES, V54, P1812; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; OSWALD F, 1994, ONCOGENE, V9, P2029; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHUURING E, 1992, ONCOGENE, V7, P355; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; TOOSHIMA H, 1994, CELL, V78, P67; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	56	155	168	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					571	580						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630641				2022-12-28	WOS:A1995RN53000018
J	HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS				HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS			CHARACTERIZATION OF THE INTERACTION BETWEEN PCNA AND GADD45	ONCOGENE			English	Article						GADD45; PCNA; 2-YBRID; CYCLINS; P21(CIP1)	CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; AUXILIARY PROTEIN; ESCHERICHIA-COLI; CYCLIN PCNA; REPAIR; P53; INHIBITOR; SUBUNIT; KINASES	We have examined the interaction between the DNA replication and repair protein PCNA, and the growth arrest and DNA damage induced protein Gadd45. An anti-Gadd45 polyclonal antibody co-immunoprecipitates PCNA but in reciprocal experiments, an anti-C terminal anti-PCNA antibody failed to co-immunoprecipitate Gadd45, We used a yeast two hybrid assay to demonstrate that human Gadd45 interacts with both human and S. pombe PCNA, We have determined that the N-terminal 94 amino acids of Gadd45 bind to PCNA, and using a series of N-terminal and C-terminal deletions of human PCNA we have mapped two potential Gadd45 binding sites, Deletion of the last 6 amino acids of PCNA ablated interaction, suggesting a role in Gadd45 binding, This explains the inability of an anti-C terminal PCNA antibody to co-immunoprecipitate Gadd45, Using a peptide ELISA approach, we showed that Gadd45 protein binds strongly to three regions of PCNA (residues 1-20, 61-80, and 196-215) and weakly to residues 121-170, The crystal structure of PCNA provides insight into our genetic and immunochemical data, Our results confirm an interaction between PCNA and Gadd45, define regions of both molecules involved in this interaction, and are consistent with a potential stoichiometry of 2 Gadd45 molecules to each PCNA monomer. These data provide support for the notion that PCNA-Gadd45 interactions co-ordinate cell cycle and DNA repair.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee	HALL, PA (corresponding author), UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND.		Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008; Cox, Lynne/AAT-2047-2021	Coates, Philip J/0000-0003-1518-6306; Cox, Lynne/0000-0002-5306-285X				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CANMAN CE, 1994, CANCER RES, V54, P5054; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COX LS, 1995, UNPUB; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V12, P2001; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRICE BD, 1992, CANCER RES, V52, P3814; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH M, 1994, SCIENCE, V226, P1376; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VANLAAR T, 1994, ONCOGENE, V9, P981; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1990, J CELL SCI, V96, P121; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	42	122	125	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2427	2433						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784094				2022-12-28	WOS:A1995RE54300021
J	MOLINARI, M; MILNER, J				MOLINARI, M; MILNER, J			P53 IN COMPLEX WITH DNA IS RESISTANT TO UBIQUITIN-DEPENDENT PROTEOLYSIS IN THE PRESENCE OF HPV-16 E6	ONCOGENE			English	Article						P53-DNA; UBIQUITIN-DEPENDENT PROTEOLYSIS; HPV-16 E6	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; CELL-CYCLE; GENE AMPLIFICATION; PROTEIN; CONFORMATION; BINDING; DEGRADATION; ONCOPROTEIN; PHOSPHORYLATION	The tumour suppressor p53 is a transcription factor with high affinity for specific DNA target sequences. Wild type p53 has a very short half life in normal cells but the protein shows transient accumulation in response to DNA damage, accompanied by up-regulation of target genes such as p21 and induction of growth arrest in G1 of the cell cycle. The rapid turnover of p53 may involve the ubiquitin-dependent proteolytic pathway. In order to investigate p53 turnover we have employed an in vitro system with rabbit reticulocyte lysate, in which ubiquitin-dependent degradation of p53 is mediated by the oncoprotein E6 of human papilloma virus type 16 (HPV-16). Using this system we have previously shown that E6-mediated degradation is preferential for p53 in the 1620(+) conformation (reactive with the monoclonal antibody PAb1620). p53-1620(+) is a pre-requisite for specific DNA binding and we have now asked if p53 in complex with DNA remains susceptible to ubiquitin-dependent proteolysis in the presence of E6. Our results indicate that p53-DNA complexes are resistant to degradation, whereas the 'free' protein is completely degraded within 20 min. Moreover, E6 did not complex with p53-DNA, possibly due to masking of sites recognised either by E6 or by the E6-associated protein (E6-AP) which facilitates E6-p53 interaction. Preincubation with E6 inhibited the DNA binding capacity of p53 and this effect could be explained, at least in part, by ubiquitination of the p53 protein.	UNIV YORK,DEPT BIOL,YORKSHIRE CANC RES CAMPAIGAN P53 GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								ANDERSON C, 1994, IN PRESS SEMINARS CA; BLUMENFELD N, 1994, J BIOL CHEM, V13, P9574; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1994, J BIOL CHEM, V13, P9582; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GU ZM, 1994, ONCOGENE, V9, P629; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARPER JW, 1993, CELL, V75, P805; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIM D, 1994, ONCOGENE, V9, P1869; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; RIVAS CI, 1992, BLOOD, V79, P1982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SRINIVASAN R, 1993, CANCER RES, V53, P5361; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1992, ONCOGENE, V7, P1646	53	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1849	1854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753560				2022-12-28	WOS:A1995QX46900018
J	HABETS, GGM; VANDERKAMMEN, RA; STAM, JC; MICHIELS, F; COLLARD, JG				HABETS, GGM; VANDERKAMMEN, RA; STAM, JC; MICHIELS, F; COLLARD, JG			SEQUENCE OF THE HUMAN INVASION-INDUCING TIAM1 GENE, ITS CONSERVATION IN EVOLUTION AND ITS EXPRESSION IN TUMOR-CELL LINES OF DIFFERENT TISSUE ORIGIN	ONCOGENE			English	Article						TIAM1; HUMAN SEQUENCE; GENE EXPRESSION; INVASION METASTASIS; GDS-PROTEINS; RHO-LIKE GTPASES; SIGNAL TRANSDUCTION	VAV PROTOONCOGENE; ANTIGEN EXPRESSION; PROTEINS; ONCOGENE; LEUKEMIA; RAS; BCR	By means of proviral tagging in combination with in vitro selection for invasive T-lymphoma variants, we have previously identified the murine invasion- and metastasis-inducing Tiam1 gene. Tiam1 encodes a novel protein which shares a Dbl-homology (DH) domain with GDP dissociation stimulator-(GDS) proteins that activate Rho-like GTPases, We have cloned the human TIAM1 coding sequence and studied its evolutionary conservation and expression pattern, TIAM1 is highly conserved among vertebrates, The close similarity between human T1AM1 and the mouse homologue is indicated by 88% and 95% identity of nucleotides and predicted sequences, respectively, The murine gene is highly expressed in brain and testis and at low or moderate levels in almost all other normal tissues, Interestingly, Tiam1 transcripts were found in virtually all analysed tumor cell lines of human and rodent origin including B- and T-lymphomas, neuroblastomas, melanomas and carcinomas, The evolutionary conservation as well as the broad expression pattern of Tiam1 in most normal tissues, suggests a general function in cellular signaling processes presumably by activation of a Rho-like GTPase that regulates the cytoskeletal organization.	NETHERLANDS CANC INST, ANTONI VAN LEEUWENHOEKHUIS, DIV CELL BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								ADAMS JM, 1992, ONCOGENE, V7, P611; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BORST J, 1989, EUR J IMMUNOL, V19, P1559, DOI 10.1002/eji.1830190907; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; CHAN AML, 1994, ONCOGENE, V9, P1057; COLLARD JG, 1987, CANCER RES, V47, P754; DEFRANCISCIS V, 1991, CANCER RES, V51, P4234; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, IN PRESS CYTOGENET C; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOOLENAAR CEC, 1992, INT J CANCER, V51, P238, DOI 10.1002/ijc.2910510212; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V80, P389; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1076; Schrier P I, 1991, Semin Cancer Biol, V2, P73; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; VANNOESEL CJM, 1992, J EXP MED, V175, P1511, DOI 10.1084/jem.175.6.1511; VECCHIO G, 1989, ONCOGENE, V4, P879; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	35	71	89	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1371	1376						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731688				2022-12-28	WOS:A1995QR65100014
J	HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M				HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M			K-RAS GENE-MUTATIONS IN EARLY COLORECTAL-CANCER ... FLAT ELEVATED VS POLYP-FORMING CANCER	ONCOGENE			English	Article						K-RAS; EARLY COLORECTAL CANCER; FLAT ELEVATED; POLYP-FORMING ADENOMA-CARCINOMA SEQUENCE	POLYMERASE CHAIN-REACTION; CONFORMATION POLYMORPHISM ANALYSIS; CHROMOSOME-5Q21; IDENTIFICATION; CARCINOMAS; COLON; ONCOGENES; ADENOMAS; DNA; FAP	K-ras gene mutations in early colorectal cancer were detected by two-step sensitive polymerase chain reaction (PCR) and enzyme digestion method. Early colorectal cancer was classified into fiat elevated cancer or polyp-forming cancer according to morphology and presence of adenomatous components. A total of 60 paraffin-embedded tissue specimens from patients with early colorectal cancer were analysed. K-ras codon 12 mutations were detected in 23.3% (7/30) of flat elevated cancer and 63.3% (19/30) of polyp-farming cancer. The incidence of K-ras codon 12 mutations in flat elevated cancer was significantly lower than in polyp-forming cancer (P < 0.01). These data suggested that K-ras gene mutations may be correlated with morphology or clinical features in flat elevated cancer, and that flat elevated cancer may originate from a pathway different from adenoma-carcinoma sequence.	KEIO UNIV, SCH MED, DEPT SURG, SHINJUKU KU, TOKYO 160, JAPAN; KEIO UNIV, SCH MED, DEPT PATHOL, SHINJUKU KU, TOKYO 160, JAPAN	Keio University; Keio University								ANDO M, 1991, JPN J CANCER RES, V82, P245, DOI 10.1111/j.1349-7006.1991.tb01836.x; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1989, CANCER RES, V49, P2141; CRAWFORD BE, 1983, CANCER, V51, P1760, DOI 10.1002/1097-0142(19830501)51:9<1760::AID-CNCR2820510933>3.0.CO;2-N; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KITAGAWA Y, 1991, CANCER RES, V51, P1504; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1990, CANCER RES, V50, P7166; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; SUGANO K, 1993, LAB INVEST, V68, P361; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOLBER RA, 1991, HUM PATHOL, V22, P70, DOI 10.1016/0046-8177(91)90064-V; YAMAGATA S, 1994, JPN J CANCER RES, V85, P147, DOI 10.1111/j.1349-7006.1994.tb02075.x; 1994, GENERAL RULES CLIN P	23	64	66	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1413	1416						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731692				2022-12-28	WOS:A1995QR65100019
J	HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A				HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A			THE ROLE OF IMMUNOGLOBULIN-KAPPA ELEMENTS IN C-MYC ACTIVATION	ONCOGENE			English	Article						BURKITTS LYMPHOMA; C-MYC; IMMUNOGLOBULIN KAPPA GENE REGULATORY ELEMENTS; MATRIX ATTACHMENT REGION; TRANSCRIPT ELONGATION	BURKITTS-LYMPHOMA CELLS; HEAVY-CHAIN GENE; DOWN-REGULATION; PROMOTER SHIFT; 1ST EXON; NUCLEOTIDE-SEQUENCE; CHROMATIN STRUCTURE; LOCATED DOWNSTREAM; STABLE INTEGRATION; INTRONIC MAR	Burkitt's lymphoma cells are characterized by chromosomal translocations involving the proto-oncogene c-myc on chromosome 8 and one of the immunoglobulin gene loci on chromosomes 2, 14 or 22, The translocated c-myc allele is transcriptionally activated, shows a preferential usage of promoter P1 over P2 (promoter shift) and lacks the ability to retain the transcription complex at the P2 promoter. In order to define the elements of the immunoglobulin kappa gene involved in deregulation of c-myc in a t(2;8) translocation, we designed constructs consisting of c-myc and different parts of the immunoglobulin kappa gene locus. Chromatin analysis of these stably transfected constructs revealed DNase I hypersensitive sites within the c-myc 5' region characteristic for an actively transcribed c-myc gene and three sites within the immunoglobulin kappa locus corresponding to the matrix attachment region, the intron and 3' enhancers, respectively. These three regulatory elements were necessary and sufficient for maximal c-myc activation and formation of the promoter shift. Kinetic nuclear run on experiments were performed to study the distribution of transcription complexes on c-myc exon 1 on constructs with and without the immunoglobulin kappa regulatory elements. The absence of a pausing polymerase complex at the c-myc P2 promoter could be demonstrated for constructs consisting of c-myc and the two kappa enhancers. Therefore the two enhancers are sufficient to relief the elongational block at the P2 promoter, however, the matrix attachment region is additionally required for maximal c-myc activation observed in Burkitt's lymphoma cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT, INST KLIN MOLEK BIOL, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862; Wolf, Dieter/0000-0002-3761-1070				ALLEN RW, 1987, J BIOL CHEM, V262, P649; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1994, ANAL BIOCHEM, V218, P347, DOI 10.1006/abio.1994.1190; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1994, CURR TOP MICROBIOL I, V194, P415; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; Sambrook J, 1989, MOL CLONING LABORATO; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; STROBL UZ, 1993, EMBO J, V12, P167; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; WHITEHURST C, 1992, NUCLEIC ACIDS RES, V20, P4929, DOI 10.1093/nar/20.18.4929; XU M, 1989, J BIOL CHEM, V264, P21190; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIRBEL RM, 1994, CHROMOSOME RES, V11, P93	62	37	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1393	1401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731690				2022-12-28	WOS:A1995QR65100017
J	KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H				KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H			THE PML GROWTH-SUPPRESSOR HAS AN ALTERED EXPRESSION IN HUMAN ONCOGENESIS	ONCOGENE			English	Article						ANTIONCOGENE; NUCLEAR BODIES; INTERFERON; STROMA; NEOANGIOGENESIS	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DNA-BINDING PROTEIN; ZINC FINGER; NUCLEAR-BODIES; TRANSCRIPTION FACTOR; TUMOR-CELLS; RAR-ALPHA; GENE; DIFFERENTIATION	Altered sub-nuclear localisation of the nuclear body-associated PML protein in acute promyelocytic leukaemia, has been proposed to contribute to leukaemogenesis. We have recently shown that PML is a primary target gene of interferons. Here, it is shown that PML has growth suppressive properties and displays an altered expression pattern during human oncogenesis. PML is widely expressed in cell-lines and is cell-cycle regulated. Overexpression of the protein induces a sharp reduction in growth rates in vitro and in vivo. In contrast with cell-lines, in normal tissues (including those that rapidly proliferate) only a few cells have detectable PML levels. However, these can be upregulated by soluble factors (e.g. IFN, estrogens.). Human epithelial tumors show a gradual increase of PML levels as the lesion progresses from benign dysplasia to carcinoma. A similar induction is found in the surrounding stroma and vessels, which likely results from paracrine interactions, Strikingly, when malignant cells turn invasive, they loose PML expression, while expression is conserved in the stromal compartment. These observations point to the existence of a consistent deregulation in the expression of the PML growth-suppressor during human oncogenesis.	HOP ST LOUIS, CTR HAYEM, CNRS, UPR 43, F-75475 PARIS 10, FRANCE; HOP ST LOUIS, IGM, PHARMACOL EXPTL LAB, PARIS, FRANCE; INST RECH SCI CANC, CNRS, UPR 272, VILLEJUIF, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U370, PARIS, FRANCE; UNIV UPPSALA HOSP, DEPT DERMATOL, S-75014 UPPSALA 14, SWEDEN; HOP ST LOUIS, SERV CLIN MALAD SANG, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Uppsala University; Uppsala University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			koken, marcel/J-8154-2012; koken, marcel/N-1349-2019; Quignon, Frédérique/P-4249-2017	koken, marcel/0000-0002-0839-0125; calvo, fabien/0000-0002-0298-7633; Sobczak, Joelle/0000-0001-7180-2789				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ashihara T, 1979, Methods Enzymol, V58, P248; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; DANIEL MT, 1993, BLOOD, V82, P1858; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FUSCONI M, 1991, CLIN EXP IMMUNOL, V83, P291; GAKEN J, 1992, BIOTECHNIQUES, V13, P32; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HUMBERT C, 1992, J CELL SCI, V103, P97; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SATO H, 1993, ONCOGENE, V8, P395; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119	46	231	240	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1315	1324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731682				2022-12-28	WOS:A1995QR65100008
J	ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U				ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U			THE TTG-2/RBTN2 T-CELL ONCOGENE ENCODES 2 ALTERNATIVE TRANSCRIPTS FROM 2 PROMOTERS - THE DISTAL PROMOTER IS REMOVED BY MOST 11P13 TRANSLOCATIONS IN ACUTE T-CELL LEUKEMIAS (T-ALL)	ONCOGENE			English	Article						T-CELL ONCOGENE; ALTERNATIVE TRANSCRIPTS; DISRUPTION BY TRANSLOCATIONS	ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; T(11-14)(P13-Q11) TRANSLOCATION; TRANSGENIC MICE; GENE; PROTEIN; DOMAIN; MOTIF; LINE	The TTG-2 gene has been identified at the site of chromosomal translocations in acute T-cell leukemia's (T-ALL). These breakpoints map to a region between 2 and 30 kb upstream of TTG-2 in chromosome 11p13. To establish the role of these translocation breakpoints in the deregulation of TTG-2 in T-ALL we have determined the complete structure of this gene. Isolation of new TTG-2 cDNA clones from fetal liver identified an alternative transcript (TTG-2a) containing two new noncoding 5' exons, Analysis of exon/intron boundaries, identified 6 exons spread over 35 kb in 11p13. The gene encodes two alternative transcripts initiating from two promoters. TTG-2a, from promoter 1 (P1) and TTG-2b, from promoter 2 (P2) differ in the length of the 5' untranslated region, but encode the same protein. A high level of TTG-2a was present in fetal liver and spleen, whereas in adult kidney a low level of TTG-2a and a high level of TTG-2b was found. The transcription start site for TTG-2a was identified by RNase protection experiments and it displayed sequence homology to an initiator element (inr). P1 lacks a TATA box, but binding sites for SP1 and GATA-1 are present. This new genomic organisation revealed that all known chromosomal translocations map upstream of P2, removing P1 and putative upstream regulatory sequences leaving P2 intact. These results show that chromosomal translocations disrupt the TTG-2 gene itself, further confirming its role in the development of T-ALL.			ROYERPOKORA, B (corresponding author), UNIV HEIDELBERG, INST HUMAN GENET, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEUG H, 1982, J CELL PHYSIOL, P195; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHAMPAGNE E, 1989, BLOOD, V73, P1672; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CLEARY ML, 1992, CANCER SURV, V15, P89; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FISCH P, 1992, ONCOGENE, V7, P2389; FITZGERALD TJ, 1992, BLOOD, V80, P3189; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YOFFE G, 1989, BLOOD, V74, P374	42	40	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1353	1360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731686				2022-12-28	WOS:A1995QR65100012
J	WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK				WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK			CELL-TYPE-SPECIFIC ACTIVITY OF THE N-MYC PROMOTER IN HUMAN NEUROBLASTOMA-CELLS IS MEDIATED BY A DOWNSTREAM SILENCER	ONCOGENE			English	Article						N-MYC; DOWNSTREAM SILENCER; NEUROBLASTOMA	HUMAN NEURO-BLASTOMA; EMBRYONAL CARCINOMA-CELLS; C-MYC; TRANSCRIPTIONAL REGULATION; DEPENDENT SILENCER; ENHANCER ELEMENT; GENE-EXPRESSION; RETINOIC ACID; AMPLIFICATION; DIFFERENTIATION	The N-myc oncogene is actively transcribed in many neuroblastoma tumors, but is not expressed in mature, normal tissue of any type. Chloramphenicol acetyl transferase (CAT) assays of constructs containing N-myc sequence transfected into N-myc expressing LA-N-5 neuroblastoma cells or non-expressing HeLa carcinoma cells have revealed a 201 base pair (bp) regulatory region mediating the cell type-specific activity of the promoter. While located downstream from 5' mRNA cap sites, the region appears to function by preventing transcriptional initiation. This downstream region is capable of suppressing promoter activity independently of position, and contains an element having 100% homology with the 9 bp consensus sequence of a transcriptional silencer found in the upstream region of the lysozyme gene. DNA gel retardation assays have shown that this sequence is involved in a specific DNA-protein interaction with nuclear extract from HeLa cells that is distinct from that occurring with extract from LA-NB cells. These results suggest that the N-myc promoter's cell type-specific activity is regulated by a downstream silencer, and that differential binding of regulatory protein from that present in non-expressing cells may result in the constitutive N-myc expression seen in neuroblastoma.	UNIV CALIF LOS ANGELES, SCH MED,JONSSON COMPREHENS CANC CTR,DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, GWYNNE HAZEN CHERRY MEM LABS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [P01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; COHN SL, 1990, ONCOGENE, V5, P1821; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EICK D, 1987, ONCOGENE, V2, P61; GRADY EF, 1987, CANCER RES, V47, P2931; HARA E, 1993, ONCOGENE, V8, P1023; HEN R, 1983, NUCLEIC ACIDS RES, V11, P8747, DOI 10.1093/nar/11.24.8747; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; REYNOLDS CP, 1990, PROG CLIN BIOL RES, V366, P203; ROSEN N, 1986, CANCER RES, V46, P4139; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; TOURMENTE S, 1993, INSECT BIOCHEM MOLEC, V23, P137, DOI 10.1016/0965-1748(93)90092-7; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WADA RK, 1992, ONCOGENE, V7, P711; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P1152; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	53	17	17	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1335	1341						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731684				2022-12-28	WOS:A1995QR65100010
J	JEON, IS; DAVIS, JN; BRAUN, BS; SUBLETT, JE; ROUSSEL, MF; DENNY, CT; SHAPIRO, DN				JEON, IS; DAVIS, JN; BRAUN, BS; SUBLETT, JE; ROUSSEL, MF; DENNY, CT; SHAPIRO, DN			A VARIANT EWINGS-SARCOMA TRANSLOCATION (7-22) FUSES THE EWS GENE TO THE ETS GENE ETV1	ONCOGENE			English	Article							NEUROECTODERMAL TUMOR; TRANSCRIPTION FACTORS; BINDING-PROTEIN; ONCOGENE FAMILY; FUSION; CHROMOSOME; DOMAIN; MEMBER; SPECIFICITIES; LIPOSARCOMA	Most Ewing's sarcomas or related primitive neuroectodermal tumors have the (11;22)(q24;q12) or less frequently the (21;22)(q22;q12) translocation. These rearrangements fuse the EWS gene on chromosome 22q12 to either the FLI1 or ERG genes, both members of the ETS family of transcription factors. Simple variant chromosomal translocations have been occasionally described in these tumors. We have identified a third Ewing's sarcoma translocation, the t(7;22)(q22;q12), that fuses EWS to the human homologue of the murine ETS gene ER81, This gene, designated ETV1 (for ETS Translocation Variant), is located on chromosome band 7p22. Identical EWS nucleotide sequences found in the majority of EWS-FLI1 and EWS-ERG chimeric transcripts are fused to a portion of ETV1 encoding an ETS domain with sequence specific DNA-binding activity. These findings confirm that the fusion of EWS to different ETS family members can result in a similar tumor phenotype.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tennessee System; University of Tennessee Health Science Center			Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NATIONAL CANCER INSTITUTE [P30CA021765, R01CA056819, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56819, CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DOUGLASS EC, 1986, J NATL CANCER I, V77, P1211; DOWNING JR, 1993, AM J PATHOL, V143, P1294; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KAWAMOTO EH, 1987, CANCER, V59, P1791, DOI 10.1002/1097-0142(19870515)59:10<1791::AID-CNCR2820591018>3.0.CO;2-#; LADANYI M, 1994, CANCER RES, V54, P2837; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTE D, 1994, ONCOGENE, V9, P1397; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SHAPIRO DN, 1993, GENOMICS, V17, P767, DOI 10.1006/geno.1993.1404; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SOUKUP S, 1986, American Journal of Human Genetics, V39, pA43; SQUIRE J, 1993, GENE CHROMOSOME CANC, V8, P190, DOI 10.1002/gcc.2870080309; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; TURCCUREL C, 1983, NEW ENGL J MED, V309, P492; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	37	422	445	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1229	1234						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700648				2022-12-28	WOS:A1995QN35300025
J	OKAZAKI, K; SAGATA, N				OKAZAKI, K; SAGATA, N			MAP KINASE ACTIVATION IS ESSENTIAL FOR ONCOGENIC TRANSFORMATION OF NIH3T3 CELLS BY MOS	ONCOGENE			English	Article						MAP KINASE; MOS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFORMATION	SIGNAL-REGULATED KINASE; MAMMALIAN SOMATIC-CELLS; NERVE GROWTH-FACTOR; PROTEIN-KINASE; XENOPUS-OOCYTES; IN-VITRO; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; SARCOMA-VIRUS; FROG OOCYTES	The c-mos proto-oncogene product, Mos, is a serine/threonine protein kinase that controls the meiotic cell cycle in vertebrate oocytes. Both;in vivo and in vitro, Mos can activate mitogen-activated protein kinase (MAPK) most probably by direct phosphorylation of MAPK kinase (MAPKK). In many cell types transformed by diverse oncogene products such as Raf, MAPK is constitutively activated, suggesting that the MAPK pathway may mediate oncogenic signalling by many oncogene products. Using mouse NIH3T3 cells, we examined whether oncogenic transformation by Mos is mediated by MAPK activation. Coexpression of a kinase-defective (dominant-negative) mutant of Mek1, one of the MAPKK isoforms, completely suppressed transformation by Mos. By contrast, coexpression of wild-type Mek1 markedly enhanced the transforming efficiency of Mos. Moreover, overexpression of the dominant-negative Mek1 reverted the transformation phenotype of Mos-transformed cells. These results indicate that in NIH3T3,cells the Mek1/MAPK pathway is necessary and sufficient for transformation (and its maintenance) by Mos. Transformation of NIH3T3 cells by Raf or Ras was also suppressed by the dominant-negative Mek1, but significantly less efficiently than that by Mos, suggesting the existence of multiple signalling pathways for Raf and Ras oncoproteins.			OKAZAKI, K (corresponding author), KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,2432-3 AIKAWA,KURUME,FUKUOKA 830,JAPAN.		Okazaki, Kenji/H-4393-2012					ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GOTOH Y, 1994, ONCOGENE, V9, P1891; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sambrook J., 1989, MOL CLONING; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	74	67	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1149	1157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700641				2022-12-28	WOS:A1995QN35300016
J	LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM				LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM			OVEREXPRESSED MAX IS NOT ONCOGENIC AND ATTENUATES MYC-INDUCED LYMPHOPROLIFERATION AND LYMPHOMAGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						MAX; MYC; TRANSGENIC MICE; LYMPHOMA; LYMPHOID DEVELOPMENT	C-MYC; DNA-BINDING; PROTEIN; GENE; COTRANSFORMATION; TRANSCRIPTION; DIMERIZATION; ACTIVATION; EXPRESSION; LEUKEMIA	The cellular growth promoting function of the Myc oncoprotein requires its heterodimerization with the Max protein, but Max can also form complexes that inhibit Myc action. To determine whether man overexpression in vivo is oncogenic and whether it can modulate the action of Myc, we generated transgenic mice in which the max gene was directed to express in lymphoid cells by a linked immunoglobulin heavy chain enhancer (E mu). Expression of the transgene at substantially higher levels than the endogenous max gene did not perturb lymphoid homeostasis in adult animals nor predispose to lymphomagenesis. The numbers of B-lymphoid cells in very young animals were reduced. Moreover, analysis of bi-transgenic E mu-myc/E mu-max mice revealed that man overexpression attenuated the premalignant B-lymphoproliferative state induced by an Ep-myr: transgene and reduced the rate of lymphoma onset. These results suggest that elevation of Max expression in vivo inhibits the function of Myc.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Fred Hutchinson Cancer Center			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628; Lindeman, Geoffrey/0000-0001-9386-2416	NCI NIH HHS [CA57138, CA20525, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R01CA057138, R37CA057138, R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; EVANS RJ, 1992, J APPROX THEORY, V69, P1, DOI 10.1016/0021-9045(92)90045-P; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; LINDEMAN GJ, 1994, IMMUNITY, V1, P517, DOI 10.1016/1074-7613(94)90094-9; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	35	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1013	1017						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898919				2022-12-28	WOS:A1995QL03800024
J	WHITE, DW; ROY, A; GILMORE, TD				WHITE, DW; ROY, A; GILMORE, TD			THE V-REL ONCOPROTEIN BLOCKS APOPTOSIS AND PROTEOLYSIS OF I-KAPPA-B-ALPHA IN TRANSFORMED CHICKEN SPLEEN-CELLS	ONCOGENE			English	Article						V-REL; I-KAPPA-B; APOPTOSIS; TEMPERATURE-SENSITIVE MUTANTS	DEATH GENE CED-3; C-REL; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PROTEIN; FIBROBLASTS; EXPRESSION; ENCODES	The v-Rel oncoprotein of the avian Rev-T retrovirus malignantly transforms chicken spleen cells in vivo and in vitro. We previously described two temperature-sensitive (ts) mutants of v-Rel (v-G37E and v-R273H) that show a ts ability to transform chicken spleen cells and to bind to DNA in vitro. We now show that spleen cell lines transformed by ts v-Rel proteins at the permissive temperature undergo apoptosis when cells are shifted to the nonpermissive temperature. The levels of most proteins (including v-Rel, p53, c-Myc, Rb and Bcl-2) do not change in these cells even at advanced stages of apoptosis, However, the chicken I kappa B-alpha protein (also called p40), which is in a complex with v-Rel in transformed cells, is degraded when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. In v-R273H-transformed cells, p40 is degraded without the appearance of proteolytic intermediates. In contrast, in v-G37E-transformed cells, p40 is cleaved to an intermediate species that is missing approximately 3-4 kDa from its amino terminus, This truncated form of p40 is found in a detergent-insoluble fraction and can also be detected in wild-type v-Rel-transformed cells that are induced to undergo apoptosis by treatment with cycloheximide, Both ts v-Rel proteins are ts for interaction with p40 in vitro. The results reported here indicate that v-Rel blocks a normal pathway of programmed cell death and that I kappa B-alpha can undergo multiple degradative pathways, which can be induced by alterations in the structure of the Rel protein to which it is bound.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215; W VIRGINIA UNIV,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	Boston University; West Virginia University					NCI NIH HHS [CAY1450, CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HRDLICKOVA R, 1995, IN PRESS J VIROL, V69; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5858; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P1322; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	68	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					857	868						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898928				2022-12-28	WOS:A1995QL03800007
J	HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS				HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS			P53 GENE-MUTATIONS INSIDE AND OUTSIDE OF EXONS-5-8 - THE PATTERNS DIFFER IN BREAST AND OTHER CANCERS	ONCOGENE			English	Article						P53 GENE; MUTATIONAL PATTERN; GENETIC EPIDEMIOLOGY	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; MOLECULAR EPIDEMIOLOGY; BINDING-SITE; MUTANT P53; CELL-LINES; T-ANTIGEN; PROTEIN; INVITRO; DNA	Most studies of mutations in the p53 tumor suppressor gene in tumors have examined only exons 5-8. Our laboratory previously round 64 mutations in exons 5-8 of the p53 gene in 194 primary breast cancers. Herein, we report 18 additional mutations found outside of exons 5-8. Mutations are present in exons 4, 9 and 10, and flanking splice junctions, but not in the promotor region or in exons 1, 2, 3 and 11. No missense mutations are found outside of exons 5-8, is predominance of frameshift mutations lesser numbers of nonsense and splice site mutations. In contrast, the majority of mutations in exons 5-8 in this sample are missense changes and all of these are at amino acids that are identical in the 11 known p53 sequences that represent about 1.6 billion years of evolutionary divergence. The difference in mutational pattern between these two regions of the p53 gene is due to a lack of missense mutations and inframe microdeletions outside of exons 5-8, A review of our database of p53 mutations (De Vries et al., in preparation) shows that the patterns of mutation inside and outside of exons 5-8 differ in other types of cancers as well. The paucity of missense mutations in exons 2-4 and 9-11 in breast and other cancers (even at amino acids identical throughout p53 gene evolution) suggest that at least some missense mutations result in a phenotype other than malignant transformation. These data also illustrate the importance of examining identical exons when comparing the pattern of p53 gene mutations in different populations.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NCI NIH HHS [R01 CA56881-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA HG, 1990, ONCOGENE, V5, P1409; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BLASZYK H, 1994, HUM MUTAT, V4, P158, DOI 10.1002/humu.1380040212; BLASZYK H, 1994, IN PRESS BIOTECHNIQU; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COLES C, 1992, CANCER RES, V52, P5291; DAMICO D, 1992, ONCOGENE, V7, P339; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V56, P215; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JONES PA, 1991, CANCER RES, V51, P3617; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIDA N, 1993, CANCER RES, V53, P368; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PURDIE CA, 1994, ONCOGENE, V9, P603; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSUDA H, 1993, JPN J CANCER RES, V84, P393; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; 1991, STATXACT VER 2 0	64	121	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					681	688						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862445				2022-12-28	WOS:A1995QH61200007
J	YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR				YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR			THE MICROPHTHALMIA GENE-PRODUCT INTERACTS WITH THE RETINOBLASTOMA PROTEIN IN-VITRO AND IS A TARGET FOR DEREGULATION OF MELANOCYTE-SPECIFIC TRANSCRIPTION	ONCOGENE			English	Article						MICROPHTHALMIA RETINOBLASTOMA; MELANOCYTE-SPECIFIC TRANSCRIPTION; E1A; TRANSCRIPTION REPRESSION; BASIC HELIX-LOOP-HELIX FACTOR	ADENOVIRUS E1A PROTEINS; TYROSINASE-RELATED PROTEIN; OCTAMER-BINDING-PROTEIN; HEAVY-CHAIN ENHANCER; DNA-SYNTHESIS; REGULATORY FUNCTIONS; INDIVIDUAL PRODUCTS; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; CELLULAR PROTEIN	Little is known of the molecular mechanisms underlying the differentiation of the melanocyte from the melanoblast or the progression from the melanocyte to a malignant melanoma. Since the adenovirus E1A products have proved a useful tool for understanding control of differentiation in other systems, we explored the possibility of using E1A as a probe for factors controlling melanocyte-specific gene expression and differentiation. The results obtained show that the adenovirus E1A 13S, but not the 12S, product can transform the highly pigmented and TPA-dependent melanocyte cell line melan-a, Transformation is characterised by a morphological change, loss of TPA-dependence, the ability to grow in soft agar and strikingly, loss of pigmentation which correlates with loss of expression of the melanocyte-specific TRP-1 and tyrosinase genes, Cotransfection assays demonstrated that repression of TRP-1 by E1A correlated with E1A binding to p105Rb and p300, with the target in the TRP-1 promoter being the M-box, an 11 bp basic-Helix-loop-Helix (bHLH) factor-binding motif conserved between melanocyte-specific promoters, Consistent with the M-box acting as a target for E1a-mediated transcription repression, we also show that the basic-helix-loop-helix-leucine zipper (bHLH-LZ) protein (Mi) encoded by the microphthalmia gene (mi), which is required for pigment cell differentiation, is a positive acting transcription factor which can interact with the retinoblastoma product in vitro and activate the TRP-1 promoter, Moreover, expression of the mi gene was reduced around 50-fold in the non-pigmented E1a-transformed melan-a cells compared to the nontransformed melan-a cell line, with ectopic expression of Mi able to prevent repression of the tyrosinase and TRP-1 promoters in the presence of E1A, Mi therefore appears to play a crucial role in melanocyte-specific gene expression. The parallels between repression of myogenesis and muscle cell bHLH factors, and Mi and melanocyte differentiation are discussed.	MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND				Vachtenheim, Jiri/I-6232-2017; Yavuzer, Ugur/C-1599-2016	Vachtenheim, Jiri/0000-0002-4923-9296; Goding, Colin/0000-0002-1614-3909				BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; BENTLEY NJ, 1994, IN PRESS MOL CELL BI; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ST, 1992, J VIROL, V66, P7452, DOI 10.1128/JVI.66.12.7452-7460.1992; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; DERY CV, 1987, ONCOGENE, V2, P15; DOOLEY TP, 1988, ONCOGENE, V3, P531; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEFF T, 1986, MOL CELL BIOL, V6, P201, DOI 10.1128/MCB.6.1.201; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PORTER SD, 1994, DEVELOPMENT, V120, P2103; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TANAKA S, 1990, DEVELOPMENT, V108, P223; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUKAMOTO K, 1992, PIGM CELL RES, P181; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	86	126	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					123	134						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824265				2022-12-28	WOS:A1995QA98000015
J	CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G				CASSARMALEK, I; MARCHAL, S; ALTABEF, M; WRUTNIAK, C; SAMARUT, J; CABELLO, G			V-ERBA STIMULATES QUAIL MYOBLAST DIFFERENTIATION IN A T3 INDEPENDENT, CELL-SPECIFIC MANNER	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; C-ERBA; GENE-EXPRESSION; ERYTHROID-DIFFERENTIATION; SKI ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION	The v-erbA oncoprotein represents a mutated version of a thyroid hormone receptor, responsible for the induction of a differentiation arrest in chicken erythroid cells. We have studied the influence of v-erbA on proliferation and differentiation of avian myoblasts. Secondary quail myoblast cultures were infected either with an avian retrovirus carrying the v-erbA oncogene in association with the neomycin resistance gene, or with a control deleted v-erbA/neo(R) retrovirus. We report here that v-erbA expression led to an increase in myoblast proliferation and to a surprising stimulation of quail myoblast terminal differentiation. In addition, these effects occurred in the presence or absence of T3, and v-erbA did not suppress T3 influence on myoblasts. Transient transfection assays demonstrated that, in contrast to its action in HeLa cells, v-erbA was unable to repress the transcriptional activation of a TRE-CAT reporter gene by liganded c-erbA alpha receptors in quail myoblasts. We also observed that the AP-1/c-erbA/v-erbA interactions are not functional in quail myoblasts. These data suggest that, in these cells, v-erbA action does not interfere with T3 induced mechanisms. They also demonstrate a cell specificity for the v-erbA pathway. Lastly, expression of c-erbA/v-erbA chimeric proteins and of the S61G v-erbA mutant indicates that the DNA binding domain of v-erbA, and more specifically serine 61, is directly involved in the enhancement of myoblast differentiation by the oncoprotein.	INRA, DIFFERENCIAT CELLULAIRE & CROISSANCE LAB, UNITE ENDOCRINOL CELLULAIRE, F-34060 MONTPELLIER 01, FRANCE; ECOLE NORMALE SUPER LYON, INRA, BIOL CELLULAIRE & MOLEC LAB, CNRS, UMR40, F-69364 LYON 07, FRANCE	INRAE; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408				ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CARNAC G, 1992, MOL ENDOCRINOL, V6, P1185, DOI 10.1210/me.6.8.1185; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1990, CIBA F SYMP, V150, P250; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1980, CELL, V22, P683, DOI 10.1016/0092-8674(80)90544-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GROSSI M, 1991, ONCOGENE, V6, P1767; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HERMANN T, 1993, ONCOGENE, V8, P55; KHAZAIE K, 1991, ONCOGENE, V6, P21; KING DB, 1987, J EXP ZOOL, P291; LARSEN J, 1992, ONCOGENE, V7, P1903; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUSCAT GEO, 1994, NUCLEIC ACIDS RES, V22, P583, DOI 10.1093/nar/22.4.583; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PAIN B, 1990, New Biologist, V2, P284; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCOW RO, 1951, ENDOCRINOLOGY, V49, P641, DOI 10.1210/endo-49-5-641; SHAINBERG A, 1984, J ENDOCRINOL, V101, P141, DOI 10.1677/joe.0.1010141; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; SMITMCBRIDE Z, 1993, ONCOGENE, V8, P1465; SNEDECOR GW, 1961, STATISTICAL METHODS; STOCKDALE FE, 1977, REGULATION CELL PROL, P165; SU HY, 1991, ONCOGENE, V6, P1759; SUTRAVE P, 1991, ONCOGENE, V6, P353; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2197	2206						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7913543				2022-12-28	WOS:A1994NX62900011
J	TAKAHASHI, H; IKEDA, T				TAKAHASHI, H; IKEDA, T			MOLECULAR-CLONING AND EXPRESSION OF RAT AND MOUSE B61 GENE - IMPLICATIONS ON ORGANOGENESIS	ONCOGENE			English	Article						B61; ECK; IN SITU HYBRIDIZATION; ORGANOGENESIS	RECEPTOR TYROSINE KINASES; PROTEIN; FAMILY	ECK is a member of EPH receptor protein-tyrosine kinase subfamily and human B61 has been identified as the ligand for ECK recently, In order to better understand the roles of B61-ECK signalling pathway in mammalian development, me have cloned rat and mouse B61 cDNA and examined the expression pattern during rat development, Sequence analysis has revealed that there is a considerable degree of identity among rat, mouse and human B61 (98.0% between rat and mouse, 86.3% between rat and human in amino acid level), Examination of B61 mRNA expression by in situ hybridization analysis revealed tight association of B61 with endothelial cells at an early stage and epithelial cells in various tissues including lung, kidney, intestine, skin at later stage of organogenesis. In the developing skeletal system, B61 is expressed in periosteum, perichondrium and hypertrophic chondrocytes and osteoblasts, In the developing nervous system, expression of B61 is restricted in the neurons of dorsal root ganglia, These expression profiles of B61 in epithelial cells of various organs, developing skeletal system and dorsal. root ganglia match those of ECK, Our data suggest that B61 plays pivotal roles in organogenesis, especially vasculogenesis/angiogenesis and epithelial cell proliferation/differentiation.	SHOWA UNIV,SCH DENT,DEPT ORAL PATHOL,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University	TAKAHASHI, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,HISTOCHEM LAB,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; GANJU P, 1994, ONCOGENE, V9, P1613; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IKEDA T, 1992, J CLIN INVEST, V92, P2814; KARPERIEN M, 1994, MECH DEVELOP, V47, P29, DOI 10.1016/0925-4773(94)90093-0; KORHONEN J, 1994, ONCOGENE, V9, P395; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957	15	17	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					879	883						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675446				2022-12-28	WOS:A1995RU79800008
J	PREVOSTEL, C; ALVARO, V; DEBOISVILLIERS, F; MARTIN, A; JAFFIOL, C; JOUBERT, D				PREVOSTEL, C; ALVARO, V; DEBOISVILLIERS, F; MARTIN, A; JAFFIOL, C; JOUBERT, D			THE NATURAL PROTEIN-KINASE C-ALPHA MUTANT IS PRESENT IN HUMAN THYROID NEOPLASMS	ONCOGENE			English	Article						TUMORIGENESIS; PROTEIN KINASE C; THYROID; ONCOGENE	H-RAS ONCOGENE; P53 MUTATIONS; FIBROBLASTS; OVEREXPRESSION; CARCINOMAS; GROWTH; CELLS; TUMORS; EXPRESSION; EPSILON	An altered protein expression of Ca2+-dependent protein kinase C (PKC) isoforms and a point mutation in the PKC alpha cDNA (position 908 of the nucleotide sequence, position 294 of the amino acid sequence, substitution of an aspartic acid by a glycine) have been previously described in a subpopulation of human pituitary tumors. In this work, we screened 16 thyroid tissue samples (four follicular adenomas, five colloid adenomas, three papillary carcinomas, one follicular carcinoma and three normal tissues adjacent to the tumors) for the presence of the PKC alpha point mutation and for PKC alpha, beta 1, beta 2, epsilon and delta protein expression. Screening for the presence of the PKC alpha mutant was performed by a subcloning technic. The polymerase chain reaction products were generated using reverse-transcribed cDNAs, subcloned and sequenced (10 clones were routinely sequenced). The PKC alpha point mutation at position 908 of the cDNA sequence was found in four out of the nine adenomas and in the follicular carcinoma. It was neither detected in the papillary carcinomas nor in the adjacent normal tissues (one was the adjacent normal tissue of the follicular carcinoma; in this sample, genomic DNA and cDNA were used to look for the presence of the mutant), demonstrating the somatic nature of this mutant. Western blot analysis of PKC isoforms showed that the expression of all isoforms was higher in the thyroid neoplasms as compared with their adjacent normal tissue (n=3). It was also higher in the samples containing the PKC mutant (two follicular adenomas, two colloid adenomas and the follicular carcinoma) as compared with the tumors where it was not detected (three papillary carcinomas and five adenomas). Samples could be ordered according to their increasing PKC expression as follows: normal adjacent tissue < follicular adenomas without PKC alpha mutant less than or equal to papillary carcinoma < follicular adenomas with PKC mutant < follicular carcinoma with PKC mutant. In conclusion, the discovery of the PKC alpha mutant in thyroid neoplasms demonstrates that this mutant is not particular to human pituitary tumors where it was originally detected. It is a somatic mutation and its presence is concomitant with high levels of all of the PKC isoforms analysed. The presence of the PKC mutant in thyroid neoplasms raises the question of its importance in thyroid tumorigenesis.	INSERM, U401, F-34094 MONTPELLIER 05, FRANCE; COLUMBIA UNIV, CTR COMPREHENS CANC, NEW YORK, NY USA; COLUMBIA UNIV, INST CANC RES, NEW YORK, NY USA; HOP LAPEYRONIE, F-34295 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Columbia University; Columbia University; Universite de Montpellier; CHU de Montpellier			Prevostel, Corinne/AAO-1433-2020	PREVOSTEL, Corinne/0000-0002-7553-087X				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOCKHORNDWORNICZAK B, 1990, VERH DEUT G, V74, P415; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; FAGIN JA, 1994, ANNU REV MED, V45, P45; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GORETZKI PE, 1992, WORLD J SURG, V16, P576, DOI 10.1007/BF02067325; HAGIWARA M, 1990, CANCER RES, V50, P5515; HATADA T, 1992, CANCER, V70, P2918, DOI 10.1002/1097-0142(19921215)70:12<2918::AID-CNCR2820701231>3.0.CO;2-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; ITO T, 1992, CANCER RES, V52, P1369; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; KOPP P, 1994, J CLIN ENDOCR METAB, V79, P134, DOI 10.1210/jc.79.1.134; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LEVY L, 1994, EUR J PHARM-MOLEC PH, V268, P327, DOI 10.1016/0922-4106(94)90057-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAPELLI E, 1994, INT J CANCER, V57, P281, DOI 10.1002/ijc.2910570225; MATSUO K, 1993, J CLIN ENDOCR METAB, V77, P991, DOI 10.1210/jc.77.4.991; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; POWIS G, 1994, TUMORI J, V80, P69, DOI 10.1177/030089169408000201; SHI YF, 1991, CANCER RES, V51, P2690; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STRINGER BM, 1989, EXPERIENTIA, V45, P372, DOI 10.1007/BF01957483; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; ZOU MJ, 1993, J CLIN ENDOCR METAB, V77, P1054, DOI 10.1210/jc.77.4.1054	44	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					669	674						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651730				2022-12-28	WOS:A1995RQ46900008
J	LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M				LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M			GENOMIC STABILITY AND WILD-TYPE P53 FUNCTION OF LYMPHOBLASTOID-CELLS WITH GERM-LINE P53 MUTATION	ONCOGENE			English	Article						P53; LI-FRAUMENI SYNDROME; EPSTEIN-BARR VIRUS; LYMPHOBLASTOID CELLS; GENOMIC STABILITY	DINUCLEOTIDE REPEAT POLYMORPHISM; TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; FRAUMENI SYNDROME; BREAST-CANCER; CHROMOSOMAL-ABNORMALITIES; CYCLE ARREST; FIBROBLASTS; APOPTOSIS; PROTEIN	Increased cancer risk associated with germ-line p53 mutation was linked to a deficit in the ability to maintain genomic stability. Accordingly, normal fibroblasts from cancer-prone individuals accumulate genomic aberrations with concomitant loss of mild-type p53 allele during in vitro culture. We tested whether such changes also occur in EBV-immortalized lymphoblastoid cells. Both normal and p53 germ-line mutant lymphoblastoid cells maintained functional p53 and genomic stability during long term in vitro culture. These unexpected differences between fibroblastic and lymphoblastic cells suggest that phenotypic expression of p53 deficiency is cell type specific. This could contribute to selective tissular localization of tumours observed in patients with Li-Fraumeni syndrome despite the presence of a mutant p53 allele in all cells.	CTR LEON BERARD, INSERM, CJF 9302, ONCOL MOLEC LAB, F-69373 LYON 08, FRANCE; HOP EDOUARD HERRIOT, INSERM, CJF 9307, CENT HEMATOL & CYTOGENET LAB, F-69437 LYON, FRANCE; INST GUSTAVE ROUSSY, DIAGNOST MOLEC LAB, F-94805 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			OZTURK, MEHMET/AAS-7241-2021; Moyret-Lalle, Caroline/G-2742-2013; LALLE, Philippe/G-7734-2018; ozturk, mehmet/G-3330-2014; Paillerets, Brigitte Bressac-de/D-8954-2018	OZTURK, MEHMET/0000-0002-6092-9706; Moyret-Lalle, Caroline/0000-0002-8359-2018; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BOND JA, 1994, ONCOGENE, V9, P1885; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DELDEIRY WS, 1994, CANCER RES, V54, P1169; DUTHU A, 1992, ONCOGENE, V7, P2161; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARDNEN DG, 1985, ISCN INT SYSTEM HUMA; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MAGAUD JP, 1985, HUM GENET, V69, P238, DOI 10.1007/BF00293032; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Sambrook J, 1989, MOL CLONING LABORATO; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEEL CM, 1977, NATURE, V270, P349, DOI 10.1038/270349a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILLIAMS WR, 1985, FAM CANCER, P151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	66	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2447	2454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784096				2022-12-28	WOS:A1995RE54300023
J	TORNALETTI, S; PFEIFER, GP				TORNALETTI, S; PFEIFER, GP			COMPLETE AND TISSUE-INDEPENDENT METHYLATION OF CPG SITES IN THE P53 GENE - IMPLICATIONS FOR MUTATIONS IN HUMAN CANCERS	ONCOGENE			English	Article						METHYLATION; P53; MUTATION	TUMOR SUPPRESSOR GENE; LIGATION-MEDIATED PCR; UV PHOTOPRODUCTS; DNA METHYLATION; SKIN-CANCER; CELLS; MUTAGENESIS; PROTEIN	CpG dinucleotides are the target of about one third of transition mutations found in human genetic diseases and tumors. Methylation at these sites is thought to be the cause of these genetic changes through spontaneous deamination of 5-methylcytosine. In order to define the contribution of 5-methylcytosine to the spectrum of p53 mutations in human cancers, we have determined the complete DNA methylation pattern along exons 5-8 of the human p53 gene by ligation-mediated polymerase chain reaction genomic sequencing. The study was conducted with nine different types of normal human tissue and cell lines, including skin fibroblasts, keratinocytes, lung epithelial cells, mammary epithelial cells and colonic mucosa cells. We found that the p53 sequences along exons 5-8 are completely methylated at every CpG site, including 46 different sites on both DNA strands. This methylation pattern is tissue-independent suggesting that tissue-specific methylation does not contribute to the differential mutation patterns seen in tumors, The occurrence of mutational hotspots at specific CpG sites is not related to selective methylation of only a subset of CpGs but may rather depend on a selection bias for particular amino acid changes. Our results are not inconsistent with theories that mutations in tumors with high CpG mutation rates, like colon cancer, are caused by spontaneous deamination of 5-methylcytosine and mutations in tumors with a lack of CpG involvement reflect superimposed fingerprints from exogenous carcinogens. However, given the lack of tissue specificity of methylation, alternative explanations (eg targeting of methylated CpG sites by tissue-selective carcinogens) should be considered to explain the high percentage of CPG mutations in some tumor types.	BECKMAN RES INST CITY HOPE,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BENTIVEGNA SS, 1994, CANCER RES, V54, P327; BIGGS PJ, 1993, MUTAGENESIS, V4, P275; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOCHANEK S, 1991, P NATL ACAD SCI USA, V88, P5759, DOI 10.1073/pnas.88.13.5759; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; ORY K, 1994, EMBO J, V15, P3496; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUGGERI B, 1993, P NATL ACAD SCI USA, V88, P10657; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wiebauer K., 1993, DNA METHYLATION MOL, P510; WIEBAUER K, 1989, NATURE, V399, P234; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	42	222	231	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731703				2022-12-28	WOS:A1995QU68100004
J	Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M				Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M			Identification of the sites of interaction between c-Raf-1 and Ras-GTP	ONCOGENE			English	Article						Oncogenes; RAS; RAF; Protein Interactions	KINASE SIGNALING PATHWAY; HA-RAS; RAF-1; ACTIVATION; BINDING; DOMAIN; ASSOCIATION; INHIBITION; PROTEINS; REGION	Specific sites of protein-protein interaction were identified in the 51-149 region of c-Raf-1 using contact epitope scanning and site-directed mutagenesis. Nineteen overlapping peptides based upon the primary sequence of the Ras binding domain of c-Raf-1 were tested for the ability to competitively inhibit complex formation between Ras-GTP and the c-Raf-1 N-terminus, A peptide containing c-Raf-1 residues 91-105 as well as five overlapping peptides covering a region extending from residues 118 to 143 interfered with Ras association, defining these sites as potential contact surfaces with Ras, Alanine scanning mutagenesis was used as a second probe for sites of Ras interaction with the c-Raf-1 N-terminus, Raf residues 64-67 and 80-103 were demonstrated as important for association with Ras-GTP with residues 66, 67, 84, 87, 89 and 91 identified as the most critical individual points of contact with the Ras protein, Alanine substitution of residues between 118-143 suggested only one potentially weak site of interaction defined by residues 120-125, The combined results of both peptide and mutagenic analyses suggest that the primary site of c-Raf-1 interaction,vith Ras maps to Raf residues 80-103, with secondary interactions occurring with residues 66 and 67 and possibly 120-125, Contact epitope scanning of the Ras effector region found maximum inhibition of Ras/Raf association with a peptide corresponding to Ras amino acids 37-51, A model is proposed for the GTP-dependent association of Ras and Raf.	Indiana Univ, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Dept Med, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Med Serv, Boston, MA 02129 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK07519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE ML, 1992, SYNTHETIC PEPTIDES, P58; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	53	55	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731678				2022-12-28	WOS:A1995QR65100004
J	LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP				LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP			MULTIPLE MESSENGER-RNA ISOFORMS OF THE HUMAN RET PROTOONCOGENE GENERATED BY ALTERNATE SPLICING	ONCOGENE			English	Article						RET; RECEPTOR TYROSINE KINASE; ALTERNATE SPLICING	TYROSINE KINASE; TRANSFORMING GENE; SOLUBLE RECEPTOR; II ONCOGENE; CELL-LINE; PROTOONCOGENE; SEQUENCE; CLONING; RNA; CARCINOMAS	The RET proto-oncogene encodes a receptor tyrosine kinase. We and others have recently shown that distinct germline mutations of the BET proto-oncogene account for the majority of cases of the dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes, and can cause a dominantly inherited form of Hirschsprung disease, a disorder of development of the autonomic innervation of the gut. RET is also oncogenically activated in some sporadic thyroid and adrenal tumours. Here we report the characterisation of multiple mRNA isoforms of RET generated by alternate splicing. Two isoforms are predicted to encode membrane-spanning receptors with a truncated extracellular ligand-binding domain. A third isoform is predicted to encode a soluble, secreted form of the receptor, These mRNA isoforms are expressed in both normal and tumour tissues.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PAEDIAT, KINGSTON, ON K7L 3N6, CANADA	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada				Lorenzo, Maria Jesus/0000-0003-4416-0615; Eng, Charis/0000-0002-3693-5145				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENGG C, 1995, IN PRESS GENES CHROM; Favaloro J, 1980, Methods Enzymol, V65, P718; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMABE T, 1992, ONCOGENE, V7, P627; KWOK JBJ, 1983, ONCOGENE, V8, P2575; LANZI C, 1992, ONCOGENE, V7, P2189; Leong S, 1981, ADV THYROID NEOPLASI, P95; Maniatis T., 1982, MOL CLONING; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P1007, DOI 10.1093/hmg/3.6.1007; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404	42	45	46	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1377	1383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731689				2022-12-28	WOS:A1995QR65100015
J	JANKNECHT, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ERNST, WH; NORDHEIM, A			SAP1A IS A NUCLEAR TARGET OF SIGNALING CASCADES INVOLVING ERKS	ONCOGENE			English	Article						C-FOS; ETS PROTEIN SAP1A; PHOSPHORYLATION; TRANSCRIPTION	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR; MAP KINASES; RAF; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; COMPLEX; ELK-1; TRANSDUCTION	The Ets protein SAP1a has been shown to interact with the c-fos serum response element upon recruitment by the serum response factor. We demonstrate that SAP1a is a nuclear protein stimulating transcription via the c-fos serum response element, and additionally via an Ets binding site independently of the serum response factor. However, transactivation has only been observed under conditions leading to the activation of extracellular signal-regulated protein kinases (ERKs). The transcriptional activation domain of SAP1a resides within the C-terminal region, the function of which may be impeded by the N-terminus. Several potential ERK consensus sites within the C-terminal region of SAP1a can modulate its transactivation efficacy, implicating that SAP1a is a direct target of ERKs. Since ERKs are activated by a broad range of signals, SAP1a may play an important role in the transformation of extracellular stimuli into a nuclear response.			JANKNECHT, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEUNG S, 1993, ONCOGENE, V8, P989; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	87	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1209	1216						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700646				2022-12-28	WOS:A1995QN35300023
J	BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR				BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR			EXPRESSION PATTERNS OF THE NOVEL RECEPTOR-LIKE TYROSINE KINASE, DDR, IN HUMAN BREAST-TUMORS	ONCOGENE			English	Article						DDR (DISCOIDIN DOMAIN RECEPTOR); PROTEIN TYROSINE KINASE; BREAST TUMOR; IN SITU HYBRIDIZATION	GROWTH-FACTOR RECEPTORS; HUMAN INSULIN-RECEPTOR; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; DISCOIDIN-I; CANCER; ONCOGENE; FAMILY; AMPLIFICATION; DISEASE	Using a reverse transcriptase-polymerase chain reaction based differential screening procedure, Rie have identified the discoidin domain receptor as a protein tyrosine kinase that is expressed in lymph nodes containing breast tumour metastases. By Northern blotting and in situ hybridisation we have demonstrated the expression of the discoidin domain receptor in human primary breast tumour samples, metastasis-containing lymph nodes and a numb;er of normal tissues. Direct comparison of malignant breast and adjacent normal epithelial tissue revealed over expression in the tumour cells.	INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories			Mitchell, Philip J/F-6393-2013; Dale, Trevor C/D-3749-2009; gusterson, barry a/D-3752-2009	Dale, Trevor C/0000-0002-4880-9963; 				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASPARINI G, 1994, BREAST CANCER RES TR, V29, P59, DOI 10.1007/BF00666182; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENNIPMAN A, 1989, CANCER RES, V49, P516; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; LAI C, 1994, ONCOGENE, V9, P877; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LATHE R, 1989, IN SITU HYBRIDISATIO, P71; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARSHALL E, 1993, SCIENCE, V259, P618, DOI 10.1126/science.8430308; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YIE Y, 1993, NUCLEIC ACIDS RES, V21, P361, DOI 10.1093/nar/21.2.361; ZERLIN M, 1993, ONCOGENE, V8, P2731	48	84	92	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					569	575						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845682				2022-12-28	WOS:A1995QF64800018
J	LI, NX; SCHLESSINGER, J; MARGOLIS, B				LI, NX; SCHLESSINGER, J; MARGOLIS, B			AUTOPHOSPHORYLATION MUTANTS OF THE EGF-RECEPTOR SIGNAL THROUGH AUXILIARY MECHANISMS INVOLVING SH2 DOMAIN PROTEINS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE-C-GAMMA; MOTH-EATEN MICE; POINT MUTATION; BINDING-SITE; HEMATOPOIETIC-CELLS; MITOGENIC SIGNAL; PHOSPHORYLATION	Many growth factors bind and activate receptors with intrinsic protein tyrosine kinase activity. Once activated these receptors undergo autophosphorylation allowing them to bind src homology 2 (SH2) domain proteins. We mutated or deleted all known autophosphorylation sites of the Epidermal Growth Factor-Receptor (EGF-receptor) and examined the effects of these mutations on gene expression, MAP kinase activation and mitogenesis. We find that the mutant receptors, although unable to bind SH2 domain proteins, are fully competent to activate all these signaling pathways. Our data indicates that these mutant receptors utilize several different compensatory mechanisms to overcome the lack of autophosphorylation sites. One mechanism is the use of tyrosine phosphorylated cellular proteins as surrogates for binding SH2 domain proteins. We find that all these mutant receptors can induce tyrosine phosphorylation of She which then acts as a binding site for the Grb2/Sos signaling complex. This data indicates that even though autophosphorylation mutants of the EGF-receptor cannot directly bind SH2 domain proteins, they are able to use auxiliary signals that result in activation of SH2 domain proteins crucial for mitogenesis.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University								BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSIAO WLW, 1992, MOL CARCINOGEN, V5, P140, DOI 10.1002/mc.2940050210; JIANG W, 1992, CANCER RES, V52, P2980; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOLER C, 1993, J BIOL CHEM, V268, P22010; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SURMACZ E, 1992, CANCER RES, V52, P4522; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1994, J BIOL CHEM, V269, P1; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	52	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3457	3465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970705				2022-12-28	WOS:A1994PT39200007
J	JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M				JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M			TRANSFECTION OF TISSUE TRANSGLUTAMINASE INTO A HIGHLY MALIGNANT HAMSTER FIBROSARCOMA LEADS TO A REDUCED INCIDENCE OF PRIMARY TUMOR-GROWTH	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; RAT-LIVER; HUMAN LEUKEMIA; APOPTOSIS; EXPRESSION; METASTASIS; ACTIVATION; RECEPTOR; ADHESION; IDENTIFICATION	Reduced expression of the tissue transglutaminase in both murine and human tumours has been consistently associated with tumour growth and progression. To investigate the functional effects of transglutaminase expression are have transfected a constitutive human tissue transglutaminase expression construct into a highly malignant hamster fibrosarcoma cell line Met B. - Met B clones expressing the exogenous tissue transglutaminase exhibited a reduced incidence of primary tumour formation and an increased adherence to tissue culture plastic and fibronectin coated surfaces when compared to transfected and non transfected control cells. Transglutaminase transfected clones exhibited no significant differences in their growth rates measured in vitro, cell morphology or levels of spontaneous apoptosis measured by the determination of detergent insoluble apoptotic envelopes. The data demonstrates a suppressive effect of tissue transglutaminase on tumour growth and confirms its importance in the phenotypic changes associated with the cancer process.	NOTTINGHAM POLYTECH,DEPT LIFE SCI,NOTTINGHAM NG11 8NS,ENGLAND; UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,HOUSTON,TX; UNIV SHEFFIELD,SCH MED,INST CANC STUDIES,SHEFFIELD S10 2RX,ENGLAND	Nottingham Trent University; University of Texas System; University of Texas Health Science Center Houston; University of Sheffield			Gentile, Vittorio/N-1685-2019; Gentile, Vittorio/A-3045-2008	Gentile, Vittorio/0000-0001-7792-8294; Gentile, Vittorio/0000-0001-7792-8294; MIAN, SYED SHARIQ/0000-0001-7563-5121; Griffin, Martin/0000-0003-3824-306X				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARNES RN, 1985, CARCINOGENESIS, V6, P459, DOI 10.1093/carcin/6.3.459; BIRKBICHLER PJ, 1977, CANCER RES, V37, P1340; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DE LUCA LM, 1990, METHOD ENZYMOL, V190, P81; DELCROS JG, 1986, FEBS LETT, V196, P325, DOI 10.1016/0014-5793(86)80272-1; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1981, MOL IMMUNOL, V18, P633, DOI 10.1016/0161-5890(81)90034-1; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FUKUDA K, 1993, HEPATOLOGY, V17, P118, DOI 10.1002/hep.1840170121; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRIFFIN M, 1989, BIOCHEM SOC T, V17, P714, DOI 10.1042/bst0170714; GRIFFIN M, 1982, ANAL BIOCHEM, V124, P406, DOI 10.1016/0003-2697(82)90057-4; HAND D, 1987, BIOCHIM BIOPHYS ACTA, V930, P432, DOI 10.1016/0167-4889(87)90016-4; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HAND D, 1989, BIOCHIM BIOPHYS ACTA, V970, P137; HAND D, 1986, BIOSCIENCE REP, V5, P1079; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KNIGHT CRL, 1993, IMMUNOLOGY, V79, P535; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; KNIGHT CRL, 1990, BIOCHIM BIOPHYS ACTA, V1053, P13, DOI 10.1016/0167-4889(90)90019-A; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1972, ANN ACAD SCI, V206, P6; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; ROCH AM, 1991, INT J CANCER, V48, P215, DOI 10.1002/ijc.2910480211; SCHMIDT R, 1985, FEBS LETT, V186, P201, DOI 10.1016/0014-5793(85)80708-0; TEALE DM, 1987, INVAS METAST, V7, P129; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIRVI KA, 1991, CANCER LETT, V60, P85, DOI 10.1016/0304-3835(91)90052-J	46	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2935	2942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916148				2022-12-28	WOS:A1994PG82200019
J	VINCENT, S; MARTY, L; LEGALLIC, L; JEANTEUR, P; FORT, P				VINCENT, S; MARTY, L; LEGALLIC, L; JEANTEUR, P; FORT, P			CHARACTERIZATION OF LATE RESPONSE GENES SEQUENTIALLY EXPRESSED DURING RENEWED GROWTH OF FIBROBLASTIC CELLS	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; CULTURED MOUSE CELLS; MESSENGER-RNA LEVELS; RAT FIBROBLASTS; 3T3 CELLS; C-FOS; MONOCLONAL-ANTIBODY; HAMSTER FIBROBLASTS; MOLECULAR-CLONING; MAMMALIAN-CELLS	Many proto-oncogenes are rapidly and transiently activated during the early stages of the cellular transition from a resting G0 state to the DNA synthesis (S) phase. To get better understanding of the gene complexity involved at later stages, we isolated, by cDNA cloning, and identified 17 genes that are activated sequentially during the period of time from proto-oncogene expression to the onset of DNA synthesis in the hamster CCL39 fibroblastic cell line. When protein synthesis is inhibited, induced expression of these genes is unaffected for 10 of them, enhanced for four, in a fashion similar to the immediate-early response genes, and inhibited for three, as observed for delayed early-response genes. In addition to rhoG, a new member of the ras homolog gene family (Vincent et al., 1992), cDNA sequencing indicated that six of them correspond to cytoskeletal proteins (alpha-tubulin, vascular alpha-actin and skeletal gamma-actin), extracellular matrix protein (thrombospondin), secreted protease (plasminogen activator inhibitor-1) and energy-linked transporter (mitochondrial proton/phosphate symporter). This overall survey shows that numerous differentially regulated gene activations are associated with the cell cycle progression, and suggests that proteins involved in cellular reshaping participate actively in the control of cellular growth.	INST GENET MOLEC MONTPELLIER,BP 5051,ROUTE MENDE,F-34033 MONTPELLIER 1,FRANCE				Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Le Gallic, Lionel/0000-0001-7147-9846				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CICCARELLI P, 1989, SCIENCE, V10, P1525; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIECKMANN D, 1991, NATURE, V351, P400; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; ELLIOTT EM, 1986, MOL CELL BIOL, V6, P906, DOI 10.1128/MCB.6.3.906; FERREIRA GC, 1989, J BIOL CHEM, V264, P15628; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GLAICHENHAUS N, 1987, CELL, V50, P1081, DOI 10.1016/0092-8674(87)90174-7; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MIN BH, 1990, J BIOL CHEM, V265, P16667; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOKUNAGA K, 1988, MOL CELL BIOL, V8, P3929, DOI 10.1128/MCB.8.9.3929; VANOBBERGHEMSCH.E, 1983, EMBO J, V4, P2927; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YANG HC, 1986, J CELL PHYSIOL, V127, P410, DOI 10.1002/jcp.1041270309; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	50	18	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1603	1610						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684829				2022-12-28	WOS:A1993LE06400024
